index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
0,14-3-3,protein,homodimer,ywha,uniprot,p62258,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,interactions,,,,,human,['1043'],nan,nan,"the crystal structures of 14-3-3 proteins are all homodimers (19). previous reports on dimerization equilibria studies showed ε, τ and γ isoforms are dimeric, while β was found to be in monomer-dimer equilibrium (27). ε has a higher preference to form heterodimers. each monomer of 14-3-3 consists of a bundle of nine α-helices. circular dichroism (cd) was used to monitor the thermal unfolding of the helices at 222 nm (figure 1a). the isoforms exhibited a narrow stability range with melting temperatures (tm) ranging from 57°c to 64°c. σ was the most stable of the isoforms studied, with an apparent tm of 64.4°c, while β had the lowest tm of 57.8°c. of the five isoforms studied, only the σ isoform exhibited reversible folding behaviour and showed isosbestic point indicative of two-state folding (figure 1b). we also used differential scanning calorimetry (dsc) to measure the melting temperature of different 14-3-3 isoforms (figure 1c). a systematic increase in the tm was observed in dsc as compared to cd, and this is probably due to the oligomeric state of 14-3-3. oligomeric proteins exhibit concentration dependent tm shifts in dsc. the 14-3-3 isoforms showed a similar trend in melting temperatures as measured by both cd and dsc. table 1 lists the tm values of the 14-3-3 isoforms measured using cd and dsc. the results confirmed that the 14-3-3 isoforms are stable enough for in vitro p53/14-3-3 interactions studies to be carried out.",pmc2817464,1,100,40,1,140
411,ep2,protein,,,uniprot,p34995,,,src,protein,,,uniprot,p12931,,,positive,d,forms a complex,,,,,,['2149'],nan,nan,"overexpression of ep2 increased phosphorylation and activity of src (fig. 5a) and ep2 formed a complex with src. some gpcrs such as angii type 1 receptor (at1r) (yin et al., 2003) and β-adrenergic receptors (β2-ar) (ma and huang, 2002) can activate src. among the ep receptors, ep4 has been shown to recruit src through β-arrestin and result in egfr activation (buchanan et al., 2006). β-arrestin is important in gpcr signaling and binds to activated gpcr, preventing further interaction of gpcr with its effector molecules (hanyaloglu and zastrow, 2008) or linking gpcr to other signaling molecules (lefkowitz and whalen, 2004; shenoy and lefkowitz, 2005). we have shown that β-arrestin cooperated with ep2 for p38 phosphorylation and the result from sequential co-immunoprecipitation experiment indicates that β-arrestin may be the part of ep2-src complex, although we were not able to show if endogenous ep2 can bind to src and β-arrestin because of the lack of reliable ep2 antibody.",pmc4624070,1,100,40,1,140
482,foxo3a,protein,,foxo3,uniprot,o43524,nucleus,go:0005634,pten,protein,phosphatase,pten,uniprot,p60484,cytoplasm,go:0005737,positive,d,binds,promoter,"hct116, sw480 crc",epithelial,colon,human,['3572'],nan,nan,"in our experiments, we unexpectedly found that selenite-induced foxo3a also binds to the promoter of the pten gene (figure 4a) in hct116 and sw480 crc cells, a finding also mentioned by chiacchiera et al.23 further experiments indicated that foxo3a directly facilitated pten transcription rather than blocking its degradation, as an mrna synthesis inhibitor clearly inhibited the increase in pten mrna after selenite treatment (figure 4b). moreover, the expression of pten also increased in a time-dependent manner after selenite treatment (figure 4c). pten activity in selenite-treated cells was also enhanced in both cell lines (figure 4d). to clarify whether upregulation of pten could indeed affect the akt/foxo3a signaling pathway, we knocked down pten expression or transfected cells with a phosphatase-dead (c124s) mutant. as shown in figures 4e and f, pten knockdown reversed the changes elicited by selenite in both cell lines. in addition, the inhibition of pten by sf167024 abrogated the changes in the akt/foxo3a/bim pathway induced by upregulated pten (figure 4g). from these results, we concluded that selenite-induced inhibition of akt and the activation of foxo3a/bim as well as apoptosis were critically regulated by increased levels of pten.",pmc3734838,1,100,40,1,140
476,foxo family proteins,protein,foxo3a,foxo,uniprot,o43524,cell nucleus,go:0005634,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,inhibition,,crc cells,colon cancer,colon,human,['3577'],nan,nan,"foxo family proteins have emerged as master regulators that control a plethora of cellular activities through the orchestration of different patterns of gene expression in response to diverse stimuli.28 notably, studies by the group of david t scadden revealed a role for foxo3a in maintaining a differentiation blockade in aml cells,29 which is in contrast to its canonical tumor suppressor role. furthermore, these cells could be regulated by many upstream factors such as akt, erk, ikkβ and jnk under different contexts.30, 31, 32, 33 in the present study, we focused on the effect of akt on foxo3a and its downstream targets because akt was shown to be aberrantly expressed in multiple malignant tumors, particularly in crc. thus, exploring the molecular mechanisms of drugs targeting akt could be of great significance for treating cancer, particularly for tumors harboring aberrantly upregulated akt activity. first, we found that selenite inhibited akt and its canonical upstream regulator pi3k and pdk1. we demonstrated that akt inhibition directly activated foxo3a in response to selenite, an event crucial for selenite-induced apoptosis. the akt/foxo3a signaling hub has also been shown to be regulated by many other chemotherapy drugs, such as 18β-glycyrrhetinic acid, isoflavone and paclitaxel.34, 35, 36 foxo3a is phosphorylated by akt at thr32, ser256 and ser319, and phosphorylation of these amino acids provides binding sites for 14-3-3 proteins, resulting in the retention of foxo3a by 14-3-3 in the cytoplasm. accordingly, selenite treatment drastically decreased 14-3-3 binding sites on foxo3a proteins, indicating that foxo3a was retained in the nucleus (supplementary figure s2d). furthermore, inhibition of akt by selenite was shown to be directly related to the reduced phosphorylation of foxo3a (figures 2a and b), which resulted in foxo3a accumulation in the nucleus. this prompted us to further investigate the role of foxo3a in the nucleus following treatment with selenite in crc cells.",pmc3734838,1,100,40,1,140
475,fkbp12,protein,,fkbp1a,uniprot,p62942,,,mtor,protein,,mtor,uniprot,p42345,,,positive,d,binds,frb domain,,,,,['777'],nan,nan,"a schematic of mtor structure. some of the proteins interacting with mtor domains are highlighted. the frb domain is where the fkbp12 and rapamycin/rapalog complex binds, which is within the region that binds fkbp38.",pmc3837323,1,100,40,1,140
471,fas,protein,,,uniprot,p25445,plasma membrane,go:0005886,procaspase-9,protein,,,uniprot,p55211,cytoplasm,go:0005737,positive,d,processing,,,keratinocytes,skin,mouse,['2706'],nan,nan,"in their earlier study implicating fas and mitochondrial apoptotic pathways in sm injury, rosenthal et al.114 investigated fas apoptotic signaling. sm induced the upregulation of fas and fasl in keratinocytes as well as processing of procaspase-3, −7, −8 and −9. sm-induced apoptosis and caspase-3 activity was also diminished by fas-blocking antibody. the observation of caspase-8 and −9 activation suggests that both death receptor and mitochondrial apoptotic pathways are involved in sm-induced cell death. also in this study, they further investigated the role of fas using keratinocytes from fas knockout mouse pups and keratinocytes transformed by hpv-16 e6/e7 that stably expressed a dominant-negative, fas-activated death domain (fadd-dn). fadd-dn suppressed sm-induced dna fragmentation as well as caspase-3, −6, and −8 processing and/or activity. fadd-dn was also shown to partially diminish sm-induced vesication of grafts on nude mice. keratinocytes from fas knockout pups showed a reduction in sm-induced caspase-3 activation and dna strand breaks relative to controls. rosenthal et al. noted that markers of apoptosis were only diminished by fadd-dn and fas knockout, consistent with the involvement of other pathways (mitochondrial pathways) in sm-induced apoptosis.",pmc2206000,1,100,40,1,140
470,fas,protein,,fas,uniprot,p25445,plasma membrane,go:0005886,fadd,protein,,fadd,uniprot,q13158,cytosol,go:0005829,positive,d,recruitment,,,b-cell,,human,['1617'],nan,nan,"cytochrome c release from mitochondria represents an important control point during apoptosis, although the mechanisms causing cytochrome c release remain unclear (green and reed 1998). it has been proposed that at least two different mechanisms exist for cytochrome c release from mitochondria, one that is caspase dependent and the other that is caspase independent. in fas-induced apoptosis, oligomerization of the fas receptor leads to recruitment of fadd and subsequent caspase-8 activation (nagata 1997). activated caspase-8 cleaves bid, a bh3 domain-only proapoptotic member of the bcl-2 family. the cleaved p15 bid fragment translocates to mitochondria, where it causes release of cytochrome c, probably by changing the conformation of bax (li et al. 1998; luo et al. 1998; desagher et al. 1999). bid-deficient hepatocytes do not release cytochrome c in response to agonistic anti–fas antibody, which confirms the importance for cleaved bid to induce cytochrome c release in this model (yin et al. 1999). in our study, c2-ceramide–induced cytochrome c release appears to be caspase independent since a broad caspase inhibitor, zvad-fmk, inhibits caspase activation but not cytochrome c translocation. the mechanism for caspase-independent release of cytochrome c remains unclear. a recent study (kennedy et al. 1999) indicates that akt inhibits the release of cytochrome c from mitochondria after uv irradiation, which may involve activation of cell-surface fas receptor (rehemtulla et al. 1997; aragane et al. 1998). in contrast, our data indicate that akt fails to inhibit cytochrome c release induced by ceramide via a caspase-independent mechanism. therefore, the function for akt to regulate cytochrome c release may vary in response to different apoptotic stimuli or within a different cellular context.",pmc2185587,1,100,40,1,140
457,erα,protein,,esr1,uniprot,p03372,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,ser473,,,,human,['1871'],nan,nan,"western blotting was performed as described previously.19, 50 after determining the protein content of the cell lysates, the protein extracts were separated by 10% sds-page, transferred to a pvdf membrane and incubated with primary antibody (erα, akt, p-akt ser473, p-gsk-3β ser9, phb and vdac antibodies were from santa cruz biotechnology, santa cruz, ca, usa, and tubulin and histone h1 antibodies were from abcam, cambridge, ma, usa). the signal was detected by ecl detection system (ge healthcare, buckinghamshire, uk).",pmc4669803,1,100,40,1,140
414,ep2,protein,,ptger2,uniprot,p43116,,,p38,protein,,mapk14,uniprot,q16539,,,positive,i,phosphorylation,,,,,,['2140'],nan,nan,overexpression of ep2-induced p38 phosphorylation is not dependent on the activation of heterotrimeric g protein,pmc4624070,1,100,40,1,140
413,ep2,protein,,ptger2,uniprot,p43116,,,p38,protein,,mapk14,uniprot,q16539,,,positive,d,phosphorylation,,hek 293,,,,['2132'],nan,nan,ep2 induces p38 phosphorylation via the activation of src in hek 293 cells,pmc4624070,1,100,40,1,140
412,ep2,protein,,ptger2,uniprot,p43116,cell membrane,go:0005886,p38,protein,,mapk14,uniprot,q16539,cytoplasm,go:0005737,positive,d,phosphorylation,,,epithelial,,human,['2150'],nan,nan,"in summary, our results indicate that the increased level of ep2 allows the binding with src and β-arrestin and induces p38 phosphorylation/activation. our studies provide the insights on additional level of ep2 signaling and a possible link between ep2 signaling and inflammation via p38. in addition, our finding suggests that the regulation of ep2 expression is important in controlling the p38 inflammatory pathway independent of pge2 levels. thus, agents or drugs that down-regulate the expression of ep2 could have anti-inflammatory responses and ep2 could be a new target for the development of anti-inflammatory drugs without the adverse side effects of selective cox-2 inhibitors.",pmc4624070,1,100,40,1,140
410,enac,protein,sodium channel,scnn1,uniprot,p37088,plasma membrane,go:0005886,egf,protein,growth factor,egf,uniprot,p01133,extracellular,go:0005576,negative,i,inhibition,extracellular,mdck,epithelial,kidney,mouse,['1770'],nan,nan,"the epithelial sodium channel (enac) is expressed in a variety of tissues, including the renal collecting duct, where it constitutes the rate-limiting step for sodium reabsorption. liddle's syndrome is caused by gain-of-function mutations in the β and γ subunits of enac, resulting in enhanced na reabsorption and hypertension. epidermal growth factor (egf) causes acute inhibition of na absorption in collecting duct principal cells via an extracellular signal–regulated kinase (erk)–dependent mechanism. in experiments with primary cultures of collecting duct cells derived from a mouse model of liddle's disease (β-enac truncation), it was found that egf inhibited short-circuit current (isc) by 24 ± 5% in wild-type cells but only by 6 ± 3% in homozygous mutant cells. in order to elucidate the role of specific regions of the β-enac c terminus, madin-darby canine kidney (mdck) cell lines that express β-enac with mutation of the py motif (p616l), the erk phosphorylation site (t613a), and c terminus truncation (r564stop) were created using the phoenix retroviral system. all three mutants exhibited significant attenuation of the egf-induced inhibition of sodium current. in mdck cells with wild-type β-enac, egf-induced inhibition of isc (<30 min) was fully reversed by exposure to an erk kinase inhibitor and occurred with no change in enac surface expression, indicative of an effect on channel open probability (po). at later times (>30 min), egf-induced inhibition of isc was not reversed by an erk kinase inhibitor and was accompanied by a decrease in enac surface expression. our results are consistent with an erk-mediated decrease in enac open probability and enhanced retrieval of sodium channels from the apical membrane.",pmc2151644,1,100,40,1,140
362,cyclin d3,protein,,ccnd3,uniprot,p30281,cytoplasm,go:0005737,p21,protein,,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,d,association,,hct116,colon,,human,['1087'],nan,nan,"in co-immunoprecipitations using antibodies against cyclin d1 and cyclin d3, we noticed a marked increase in the association of p21 in response to sustained cdk7 inhibition. this increase was not paralleled by a similar increase of cdk4 and cdk6 associations (lanes 3 and 5 in figure 1c). interestingly, the increased association of p21 was already observed at the 5 h time point, when the total p21 level had not yet increased in response to cdk7 inhibition (figure 1b, 1c). because in serum-stimulated hct116 cells in g1 (which express relatively higher p21 levels than other cells) most of cdk4 and cdk6 complexes are stabilized by p21 and hence contain it, the increased p21 binding in response to cdk7 inhibition indicated an increased stoichiometry (and/or stability) of p21 binding to cyclin d complexes. binding of more than one p21 molecule is known to preclude the activity of cyclin d-cdk4-p21 complexes [3], [6], [10]. therefore, we designed experiments to evaluate the extent to which this increased association of p21 could contribute to inhibition of the activation of cdk4/6 caused by cdk7 inhibition.",pmc3667761,1,100,40,1,140
408,elk-1,protein,,,uniprot,p19419,nucleus,go:0005634,erk,protein,,,uniprot,p28482,cytoplasm,go:0005737,positive,i,recruitment,sre,,,,human,['1234'],nan,nan,"elk-1 recruitment of erk to sre in vitro is dependent on d domain. (a) the sre promoter template was incubated with recombinant coresrf alone (lanes 1–3), coresrf and relk-1 (lanes 4–6) or neither (lanes 7 and 8) along with inactive rerk (lanes 2, 5 and 7) or active rerk (lanes 3, 6 and 8). complexes were isolated on magnetic beads and analysed by immunoblotting. the arrows indicate erk2 (upper panel) and elk-1 (lower). (b) representation of elk-1 including dna-binding domain (ets), srf interaction domain (b), suppressor domain (s), docking (d) domain, trans-activation domain (c) and fxfp motif (f). sites of deletion/mutation are indicated in the corresponding mutants. (c) sds–page analysis of recombinant proteins used in this study, as indicated. full-length proteins and coresrf are identified by arrowheads. (d) recombinant elk-1 and the deletions represented in (b) were incubated with active rerk2 for the times indicated and phosphorylation of ser383 was analysed by sds–page and immunoblotting with a phospho-specific antibody (upper panel). elk-1 substrates were controlled with an antibody against elk-1 (lower panel). n.b. phosphorylation of elk-1 results in electrophoretic separation of isoforms that increases the signal on the membrane. relative amounts of elk-1 proteins in the assay are apparent in lanes 1, 4, 7 and 10. (e) the sre promoter template was incubated with recombinant coresrf alone (lanes 1 and 2), with coresrf and relk-1 (lanes 3 and 4), relk-δd (lanes 5 and 6), relk-fxla (lanes 7 and 8), relk-dbl (lanes 9 and 10) or without (lanes 11 and 12) along with inactive rerk2 (lanes 1, 3, 5, 7, 9 and 11) or active rerk2 (lanes 2, 4, 6, 8, 10 and 12). complexes were isolated on magnetic beads and analysed by immunoblotting with antibodies against erk (upper panel) and elk-1 (lower panel).",pmc2377423,1,100,40,1,140
407,elk-1,protein,,elk1,uniprot,p19419,nucleus,go:0005634,erk,protein,,mapk1,uniprot,p28482,nucleus,go:0005634,positive,d,phosphorylation,multiple sites,,,,,['1230'],nan,nan,"transcriptional activation by elk-1 in response to mitogens is contingent upon its phosphorylation on multiple sites by erk and the consequent recruitment of co-activators such as p300 to sres (12–14). although active erk is known to accumulate in the nuclei of mitogen-stimulated cells (53,54) the underlying mechanism is incompletely understood. however, several reports of mapks associating with gene promoters have appeared recently (22–27).",pmc2377423,1,100,40,1,140
406,elk-1,protein,,elf1,uniprot,p19419,,,erk,protein,,mapk1,uniprot,p28482,,,positive,d,recruitment,d-domain/kim,,,,,['1246'],nan,nan,"in this study, we have examined pics associated with promoters that contain a mitogen-responsive sre. we found that erk and msk are recruited to these complexes in a mitogen-dependent fashion in vitro, that the ternary complex factor elk-1 recruits erk directly via its d-domain/kim in vitro and is required for recruitment of both erk and msk to the c-fos promoter in vivo.",pmc2377423,1,100,40,1,140
405,eif4e-binding proteins-1 (4e-bp1),protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,tor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,regulates,,,,,human,['3598'],nan,nan,"signaling networks that promote cell growth are frequently dysregulated in cancer. one regulatory network, which converges on effectors such as eif4e-binding proteins-1 (4e-bp1) and p70(s6k), leads to growth by promoting protein synthesis [215]. in particular, a tumor suppressor complex whose function is lost in tuberous sclerosis patients regulates the nutrient signal carried by the critical signaling protein tor to the effectors 4e-bp1 and p70(s6k) [215].",pmc2652403,1,100,40,1,140
372,dna-pk,protein,kinase,,uniprot,p78527,nucleus,go:0005634,akt,protein,kinase,,uniprot,p31749,nucleus,go:0005634,positive,d,phosphorylation,dna double-strand breaks,hepg2,epithelial,liver,human,['14'],nan,nan,"it has been proposed that dna-pk (dna-dependent protein kinase) is also involved in akt activation in response to dna damage such as ir and doxorubicin [92]. this pathway is specific for dna damage as dna-pk is dispensable for akt ser473 phosphorylation upon insulin or growth-factor stimulation [92]. interestingly, phosphorylated akt forms nuclear foci and colocalizes with dna-pk at double-strand dna breaks and the interaction between akt and dna-pk is dna damagedependent [92]. akt1 knockout mice resemble the dna-pk deficiency radiosensitivity phenotype, with attenuated p21cip1 expression and increased apoptosis in response to dna damage, supporting the notion that dna-pk/akt1 pathway has a marked impact on cell survival after dna damage due to transcriptional regulation of p21cip1 [92]. beside akt1, akt2 and dna-pk are also required for the stabilization of p53 in response to ir, which is mediated by the inactivation of gsk-3 [96]. the above results suggest a novel mechanism through which dna-pk phosphorylates and activates akt at the site of dna double-strand breaks. this process triggers the induction of a transcriptional program that promotes cell survival in response to dna damage. whether dna-pk directly phosphorylates akt itself or acts through pdk1 and whether dna-pk and akt interact directly remain unclear [97, 98].",pmc3317191,1,100,40,1,140
371,ddb2,protein,,ddb2,uniprot,q92466,,,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,ubiquitination,,,,,,['2201'],nan,nan,"it is noteworthy that ddb2 is also known as a p53 target gene (32–34). genotoxic stress causes the transcriptional activation of the p53 target genes including ddb2, which mediates the ubiquitination of cabin1 and finally boosts p53 activity by eliminating the repressor. we assume that this is a very efficient mechanism for positive regulation of p53 activity upon dna damage.",pmc3575827,1,100,40,1,140
368,cytochrome c,protein,,,uniprot,p99999,mitochondria,go:0005739,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,positive,d,substrates,,,,,human,['1600'],nan,nan,cell extracts were incubated in the presence or absence of cytochrome c and datp at 37°c for 15 min as described above. then the lysates were incubated with caspase-9 colorimetric substrate (lehd-pna) to measure caspase-9 activity according to the protocol suggested by the manufacturer. the cleavage of the peptide was quantitated spectrophotometrically at a wavelength of 405 nm. the results are expressed as fold increase in caspase-9 activity of apoptotic reactions (cytochrome c and datp added) compared with that of control reactions (bsa and datp added).,pmc2185587,1,100,40,1,140
367,cytochrome c,protein,,cycs,uniprot,p99999,mitochondria,go:0005739,procaspase-3,protein,,casp3,uniprot,p42574,cytosol,go:0005829,positive,i,cleaves,,,neuronal,brain,mouse,['1595'],nan,nan,"recent biochemical studies have revealed that caspase activation during apoptosis is a tightly regulated process (salvesen and dixit 1997; thornberry and lazebnik 1998; budihardjo et al. 1999). apoptotic stimuli such as activation of cell surface receptors or environmental stress can induce cytochrome c release from mitochondria (green and reed 1998). once in the cytosol, cytochrome c binds to apaf-1 and induces its oligomerization. oligomerization of apaf-1 recruits procaspase-9 and results in subsequent caspase-9 activation (srinivasula et al. 1998; zou et al. 1999). active caspase-9 cleaves procaspase-3 and generates active caspase-3. active caspase-3 cleaves a number of important cellular proteins to execute cell death and activate additional downstream caspases (slee et al. 1999). phenotypes of caspase-3–, caspase-9–, or apaf-1–deficient mice are very similar to each other in that all these mice manifest brain overgrowth due to reduced apoptosis during brain development (cecconi et al. 1998; hakem et al. 1998; kuida et al. 1998; yoshida et al. 1998). on the other hand, caspase-1–, caspase-2–, caspase-8–, caspase-11–, bid-, or fadd-deficient mice do not show obvious defects in brain development (los et al. 1999; yin et al. 1999). these genetic studies confirm the critical roles for apaf-1, caspase-9, and caspase-3 in regulating neuronal apoptosis.",pmc2185587,1,100,40,1,140
365,cytochrome c,protein,,cycs,uniprot,p99999,mitochondria,go:0005739,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,protects,,,neural cells,,human,['1619'],nan,nan,"recently, cytochrome c was implicated in the pathogenesis of parkinson's disease since purified cytochrome c stimulates α-synuclein aggregation in vitro and cytochrome c colocalizes with α-synuclein in lewy bodies of patients with parkinson's disease (hashimoto et al. 1999). our findings here indicate that akt protects neural cells from acute apoptosis caused by cytochrome c release and may allow cytosolic cytochrome c to participate in other cellular process such as α-synuclein aggregation. interestingly, expressing active akt or treatment with zvad-fmk inhibited chromatin condensation after cytochrome c injection, yet many rescued cells still shrank, suggesting that cytochrome c may cause cell shrinkage independent of caspase activation. it should be possible to examine additional roles of cytochrome c independent of its effects on apopsome complex formation in apaf-1 or caspase-9–deficient neurons.",pmc2185587,1,100,40,1,140
484,foxo3a,protein,transcription factor,foxo3,uniprot,o43524,nucleus,go:0005634,pten,protein,phosphatase,pten,uniprot,p60484,cytoplasm,go:0005737,positive,i,upregulated,,,,,human,['3571'],nan,nan,foxo3a-upregulated pten expression is involved in regulating selenite-induced changes in the akt/foxo3a/bim signaling pathway,pmc3734838,1,100,40,1,140
486,gab1,protein,,gab1,uniprot,q13480,,,pi3k,protein,,pik3ca,uniprot,p42336,,,positive,d,binding,,hek293,,,,['2687'],nan,nan,"quantitative data on the dynamics of protein–protein complexes can further validate the model and provide insight into mechanisms of integrative cellular responses to insulin–egf co-stimulation. as the data (figure 3d and supplementary figure s8) suggest that gab1 is one of the key mediators of insulin–egf crosstalk, we determined gab1 interactions with other network nodes. although it is not immediately obvious, the simulations predict that following co-stimulation with insulin and egf, the amount of gab1-bound pi3k will increase (compared with egf stimulation) only on a short time scale (figure 4a, blue dashed lines versus green dotted lines), whereas the post-peak concentration of gab1-bound pi3k will decrease owing to dephosphorylation of gab1 phosphotyrosines by gab1-bound shp2 and the competitive recruitment of pi3k by phosphorylated irs. to test this prediction, the binding of pi3k and shp2 to gab1 and of pi3k to irs4 (the major irs protein in these cells (fantin et al, 1998)) was measured by immunoprecipitation analysis following stimulation of hek293 cells with egf, insulin and their combination. the data confirm that insulin–egf co-stimulation increased the pi3k–gab1 complex concentration at 30 s and 1.5 min, whereas the post-peak levels were decreased compared with egf only stimulation, in agreement with in silico predictions (figure 4a, right panel). at 3 min of stimulation with insulin and egf, the data show robust pi3k–irs binding response and decreased pi3k–gab1 binding, compared with egf alone (figure 4b). the predicted increase in gab1-bound grb2 (figure 4a, solid versus dash–dotted lines) and shp2 (figure 4c) correlates with an increase in the total level of gab1 tyrosine phosphorylation (figures 3d and 4e) and is supported by the data shown in figure 4d for 1.5-min stimulation (quantitation of the blots shown in figure 4b, d and e is presented in supplementary figure s11a–c).",pmc2683723,1,100,40,1,140
492,glycogen synthase kinase-3β (gsk-3β),protein,,gsk3b,uniprot,p49841,nucleus,go:0005634,ribosomal protein s6 (s6rp),protein,,rps6,uniprot,p62753,cytoplasm,go:0005737,positive,d,regulates,,,,kidney,human,['3368'],nan,nan,"the phosphoinositide 3-kinase (pi3k)/akt/mammalian target of rapamycin 1 (mtorc1) signaling pathway is aberrantly activated in renal cell carcinoma (rcc). we previously demonstrated glycogen synthase kinase-3β (gsk-3β) positively regulated rcc proliferation. the aim of this study was to evaluate the role of gsk-3 in the pi3k/akt/mtorc1 pathway and regulation of the downstream substrates, eukaryotic translation initiation factor 4e-binding protein 1 (4ebp1), ribosomal protein s6 kinase (s6k), and ribosomal protein s6 (s6rp).",pmc4936323,1,100,40,1,140
496,gsk-3,protein,kinase,gsk3a,uniprot,p49841,cytoplasm,go:0005737,c-myc,protein,transcription factor,myc,uniprot,p01106,nucleus,go:0005634,negative,d,phosphorylation,,,,,human,['2046'],nan,nan,"gsk-3 inhibitors may be appropriate for the treatment of certain diseases including: diabetes, obesity, ischemia, cancer, sepsis, colitis and neurological disorders. however, the evaluation of gsk-3 inhibitors in clinical trials has been hampered by the fear that inhibition of gsk-3 may stimulate or aid in malignant transformation as gsk-3 can phosphorylate such pro-oncogenic factors as beta-catenin, c-jun and c-myc which targets them for degradation [28]. however, no studies have been reported suggesting that treatment of mice with gsk-3 inhibitors resulted in an increase in cancer incidence. in contrast, studies in prostate, pancreatic, ovarian, thyroid, melanoma, brain, pheochromocytoma, paraganglioma, colorectal, and hematopoietic cancers have indicated that gsk-3 inhibitors could suppress proliferation [298]. in fact, many patients with bi-polar disorder have been treated with lithium for prolonged periods of time. there does not appear to be any evidence that these patients have increased incidences of cancer. in the studies by wang et al, treatment on mice with mixed-lineage leukemia (mll) like leukemia (see below) with lithium actually increased the survival of the mice approximately 50%.",pmc4102778,1,100,40,1,140
551,gsk3,protein,,gsk3,uniprot,p49841,,,smad4,protein,,smad4,uniprot,q13485,,,positive,d,phosphorylation,linker region,,fibroblast,,human,['69'],nan,nan,"we recently reported that smad4 activity and stability are directly regulated through gsk3 phosphorylations in the linker region of smad4 that are primed by the mitogen-activated protein kinase (mapk) extracellular signal-regulated kinase (erk).19 we found that fibroblast growth factor (fgf)/epidermal growth factor (egf) stimulation leads to smad4 phosphorylation by erk of the canonical mapk site (pxtp) located at threonine 277. phosphorylation of this site recruits transcriptional co-activators, most likely p300, allowing smad4 to reach peak transcriptional activity.19,20 however, mapk also primes smad4 for 3 subsequent gsk3-mediated phosphorylations that cause transcriptional inhibition and generate a phosphodegron that is used as a docking site by β-trcp, leading to protein polyubiquitination and proteasomal degradation.19 wnt signaling inhibits gsk3 activity22,23 and therefore potentiates smad4 activity, particularly at low concentrations of tgf-β.19 thus, the linker domain of smad4 contains a growth factor-regulated transcription activation domain that integrates wnt, fgf/egf, and tgf-β signaling. this convergence of signaling pathways via smad4 plays an important role during early xenopus development, where it regulates cell competence to mesoderm induction on the dorsal side of the embryo.19",pmc4845174,1,100,40,1,140
1,14-3-3,protein,,,uniprot,p62258,,,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,transcriptional regulation,,h1299,epithelial-like,lung,human,['1050'],nan,nan,"we next investigated whether the 14-3-3/p53 interactions plays any role in regulating the transcriptional activity of p53. luciferase assays were carried out in a h1299 cell line with a stably integrated p21-luciferase reporter gene. cells were co-transfected with 14-3-3 and p53, followed by cpt treatment. non-drug treated cells showed only a marginal increase in transcriptional activity, which is probably due to the basal phosphorylation status of p53 (supplementary figure s2). but, upon drug treatment, the transcriptional activity of p53 is increased ∼2.5-fold compared with mock-transfected cells. transfection with each of the 14-3-3 isoform resulted in a significant increase in p53 activity as compared with in the absence of 14-3-3 (p < 0.05). we also co-transfected the p53 mutants s378a, s366a, t387a and 3a mutant with 14-3-3 isoforms in separate experiments. the four isoforms exhibited a similar increase in the transcriptional activity of p53 s366a, s378a and t387a mutants. when compared with wt p53, the difference in transcriptional activity of these mutants was negligible, suggesting that the influence of 14-3-3 in p53 activity was not affected by individual mutations. however, with the 3a mutant, γ and ε had a decreased level of transcriptional activity closer to that of wt p53 in the absence of 14-3-3 (p < 0.05), indicating that these phosphorylation sites are essential for p53 up-regulation by these isoforms. τ and σ had no distinguishable change in the activity level with the 3a mutant, indicating that phosphorylation at these sites may not be necessary for these isoforms to activate p53 (figure 4a). control experiments, transfecting with empty vectors, were carried out throughout the study. cells co-transfected with p53, p53 mutants and empty vector (14-3-3 insert is absent) showed that the proteins are over-expressed. control experiment carried out in the absence of 14-3-3 showed that the differences in transcriptional activity of wt p53 and the p53 mutants were statistically negligible (figure 4c). this experiment confirmed that the mutations introduced had little effect on the activity of p53. overall, the results demonstrated that the presence of 14-3-3 isoforms enhanced the transcriptional activity of p53. phosphorylation at either of the sites s366, s378 or t387 is necessary and sufficient for γ and ε to activate p53, but is dispensable for τ and σ.",pmc2817464,1,100,40,1,140
545,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,smad4,protein,,smad4,uniprot,q13485,nucleus,go:0005634,positive,i,phosphorylation,linker region,,,,human,['80'],nan,nan,"gsk3 phosphorylation can be induced by mapk/erk activation, or by tgf-β via an erk- and wnt-independent mechanism. (a) western blot showing that gsk3 phosphorylation of the smad4 linker region can be induced by egf through an erk-dependent mechanism or by tgf-β through a different erk-independent mechanism. these results show that tgf-β can induce linker phosphorylation of smad4 but that in this case erk is not the priming kinase. (b) gsk3 linker phosphorylations of smad4 were inhibited by wnt3a when induced by fgf, whereas the tgf-β induced linker phosphorylations were unaffected by wnt3a.",pmc4845174,1,100,40,1,140
544,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,smad4,protein,,smad4,uniprot,q13485,nucleus,go:0005634,positive,d,phosphorylation,,,fibroblast,,human,['74'],nan,nan,"enhanced phosphorylation of smad4 pro130ser and smad4 asn351his. (a) western blot analysis showing that smad4 proteins harboring point mutations are less stable than their wild-type counterparts. mutations pro130ser and asn351his increase phosphorylation by gsk3 marked by a custom-made psmad4gsk3 antibody. cells were preincubated with licl for 5 h. the gel shown is a representative experiment that was replicated in 2 independent experiments. (a’) quantification of protein stability, normalized for gapdh levels, from the western blot above. (a”) quantification of protein phosphorylation by gsk3 (normalized for total flag-smad4 protein in each lane) of the same western blot. note that licl treatment blocks gsk3 phosphorylation while increasing protein stability. (b) inhibition of β-trcp using transfected dn-β-trcp showing that smad4m130 and m351 are more highly phosphorylated than wild-type smad4 and that their rapid degradation requires β-trcp. this experiment was independently replicated twice. (b’) quantification of flag-smad4 protein (normalized for gapdh) from western blot above. (b”) quantification of phospho-smad4gsk3, normalized for total flag-smad4, from the same western blot. note that in these experiments fgf addition was not required because 10% serum provided a basal level of mapk activation.",pmc4845174,1,100,40,1,140
543,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,mediates activation,,,,,,['507'],nan,nan,gsk3 mediates activation of p53 in response to pi-3 kinase inhibition,pmc3481126,1,100,40,1,140
542,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,acetylation,,,,,human,['511'],nan,nan,"these results indicated that activation of gsk3 following inhibition of pi 3-kinase led to activation of p53 via acetylation. we therefore sought to determine whether inhibition of gsk3 blocked transcriptional activation of p53 target genes following pi 3-kinase inhibition (figure 7). treatment with the gsk3 inhibitor sb-216763 interfered with the induction of most of the p53-target genes, including cdkn1a, confirming the role of gsk3 in p53 activation. however, the induction of some genes that were dependent on p53 (flcn, hoxc5, loc688916 and txnip) (figure 2a) was not significantly reduced by inhibition of gsk3, consistent with the induction of these genes by other transcription factors or with the possibility that inhibition of pi-3 kinase can also activate p53 independently of gsk3 activity.",pmc3481126,1,100,40,1,140
540,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,htert,protein,,tert,uniprot,o14746,nucleus,go:0005634,positive,d,activates expression,,,cancer,,human,['2294'],nan,nan,"our results indicate that gsk3 activates htert expression in cancer cells and contributes to telomere length homeostasis. gsk3 inhibition is a clinical strategy for several chronic diseases. these results imply that it may also be useful in cancer therapy. however, the complex network effects we show here have implications for either setting.",pmc2714081,1,100,40,1,140
539,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,htert,protein,,tert,uniprot,o14727,nucleus,go:0005634,negative,d,suppression,htert promoter,"5637, c33a, a549, hct116",epithelial,,human,['2301'],nan,nan,"to extend the observation that diverse gsk3 inhibitors suppress htert promoter activity, we performed htert reporter assays and parallel mtt assays, titrating the selective inhibitors ar-a014418 (benzyl-thiazolyl urea substructure), tws119 (pyrollopyrimidine core), and 6-bromoindirubin-3′-oxime (bio, indirubin core) alongside the gsk3-inactive bio derivative 1-methyl-bio (mebio) [10]. structures of all gsk3 inhibitors used in this study are available in supporting figure s1. all supporting figure and file legends are given in supporting file s4. active inhibitors of different chemotypes, but not mebio, suppressed htert promoter activity at sub-toxic concentrations (figure 1b). at optimal doses of 10 µm (ar-a01448) and 5 µm (tws119 and bio) promoter activities were 62%, 67% and 55% of control. bio and mebio were also titrated against the htert reporter in 5637, c33a, a549 and hct116 cells (figure 1c). bio, but not mebio, suppressed the htert promoter in all cells with ic50s in the range 5.4 µm-8.2 µm. similarly, bio, but not mebio activated topflash reporter activity in all cells, indicative of specific gsk3β inhibition (supporting figure s2).",pmc2714081,1,100,40,1,140
532,gsk3,protein,kinase,gsk3,uniprot,p49841,cytoplasm,go:0005737,tgf-β,protein,growth factor,tgfb1,uniprot,p01137,extracellular region,go:0005615,positive,i,inhibition,,caco-2,epithelial,colon,human,['85'],nan,nan,"we next investigated whether gsk3 inhibition could restore tgf-β signaling in a human cancer cell line carrying a point mutation in smad4. we used the colon cancer cell line caco-2, which has lost one allele of smad4 while the other allele harbors the asn351his smad4 point mutation (smad4−/n315h).31 caco-2 cells were transfected with the tgf-β–specific reporter caga12-luciferase (and pcs2-renilla for normalization), incubated with or without licl, and treated for 8 h with different amounts of tgf-β1 ligand (fig. 5). in the absence of licl, caco-2 cells showed no significant transcriptional response to tgf-β ligand stimulation (fig. 5, blue bars). however, preincubation of the cells with licl allowed tgf-β1 to induce the caga-12 reporter in a dose-dependent manner (fig. 5, red bars). these results demonstrate that gsk3 chemical inhibition can reactivate tgf-β signaling in cells harboring a point mutation (asn351his) in the endogenous tumor suppressor smad4.",pmc4845174,1,100,40,1,140
531,gsk3,protein,kinase,gsk3,uniprot,p49841,cytoplasm,go:0005737,tgf-β,protein,cytokine,tgfb1,uniprot,p01137,extracellular,go:0005576,positive,d,inhibition,,caco-2,epithelial,colon,human,['86'],nan,nan,"inhibition of gsk3 restores dose-dependent tgf-β signaling to caco-2 smad4−/n351h cells. the gsk3 inhibitor licl restores tgf-β responsiveness to the colon carcinoma caco-2 cell line, which endogenously expresses the smad4n351h mutant. cells were treated with 30 mm licl for 2 h before addition of the indicated amounts of tgf-β1. note that caco-2 cells are unresponsive to tgf-β1, yet in the presence of gsk3 inhibitors dose-dependent signaling is reactivated.",pmc4845174,1,100,40,1,140
528,gsk3,protein,kinase,gsk3,uniprot,p49841,cytoplasm,go:0005737,mtor kinase,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,impact,,,cancer,,human,['1561'],nan,nan,"our recent study has demonstrated that maintaining gsk3 activity is critical for mtor kinase inhibitors to exert their anticancer activity [16]. the current study has focused on determining whether gsk3 activity also impacts the anticancer efficacies of rapalogs and on understanding the underlying mechanisms. out results have shown that gsk3 is also an important determinant for cancer cells to respond to rapalogs. in addition to cyclin d1, rapalogs induce gsk3-dependent degradation of other oncogenic proteins such as c-myc and mcl-1; these effects should be tightly associated with rapalogs’ cancer therapeutic efficacies.",pmc4496196,1,100,40,1,140
527,gsk3,kinase,protein,gsk3a,uniprot,p49841,cytoplasm,go:0005737,dp,protein,,,uniprot,q16555,plasma membrane,go:0005886,positive,d,interaction,,hek 293,epithelial,,human,['1700'],nan,nan,"ac mutation alters dp phosphorylation by gsk3. (a) gsk3 interactions with r2834h and wt dp s-tag (dp ct) in hek 293 cells were examined following s-tag pulldown analyses where ripa lysates (input) and pull-down products were analyzed by immunoblotting. (a′) densitometry quantification of gsk3 interactions with wt and r2834h dp s-tag (dp ct). *, p < 0.03. error bars indicate sem. (b) pla of wt, r2834h, or s2849g dp-gfp cells incubated with primary antibody pairs of gfp-gsk3. nuclei were stained with dapi (blue). (b′) pla fluorescence intensity divided by number of nuclei was performed for each cell line using primary antibody pairs of gfp-gsk3 and with controls gsk3-rigg or gfp-migg. data quantification was analyzed from three separate experiments (>500 nuclei per experiment). *, p < 0.05. error bars indicate sem. (c) control or cagsk3-transfected and licl- or ly-294,002 (gsk3 act.)–treated dp-gfp cell lines, assessed by immunofluorescence. bars, 10 µm. (d and d′) r2834h dp s-tag (dp ct) cells were treated with nacl or licl or transfected with cagsk3, assessed by immunoblotting. densitometry quantification of three independent experiments. *, p < 0.001. error bars indicate sem.",pmc4347645,1,100,40,1,140
516,gsk-3beta,protein,,,uniprot,p49841,,,nf-kappab,protein,,nfkb,uniprot,q04206,,,positive,d,activation,,,hepatocytes,,mouse,['1985'],nan,nan,"gsk-3alpha and gsk-3beta are structurally similar, however, they are not functionally identical and they have some different substrate specificities. these gsk-3beta knock-out mice die around embryonic day 16 due to liver degeneration caused by hepatocyte apoptosis [27]. furthermore, gsk-3beta activity was essential for tnf-alpha-induced nf-kappab activation in hepatocytes. in contrast gsk-3alpha knockout mice are viable but exhibited enhanced glucose and insulin sensitivity and reduced fat mass. gsk-3alpha knock-out mice elicited metabolic and neuronal developmental abnormalities [31,32]. gsk-3alpha and gsk-3beta have different substrate preferences in the brain [33] and likely other tissues. thus, gsk-3 isoforms exhibit tissue-specific physiologically important functions which are may not be overlapping and sometimes may be different. these and other studies indicate that there are rationales for the specific targeting of gsk-3alpha or gsk-3beta in certain diseases.",pmc4102778,1,100,40,1,140
514,gsk-3beta,protein,,gsk3b,uniprot,p49841,,,cyclin d1,protein,,ccnd1,uniprot,p24385,,,positive,i,turnover regulation,,,breast cancer,breast,human,['2000'],nan,nan,cyclin d1 was detected at high levels in approximately 50% of breast cancer patients examined. however only 15-20% of these patient samples had amplification of cyclin d1 [131-133]. beta-catenin transactivation has been associated with cyclin d1 overexpression in breast cancer [134]. aberrant gsk-3beta expression may lead to increased beta-catenin transcription which increases cyclin d1 expression. cyclin d1 expression is increased in certain breast cancer patients as gsk-3beta regulates cyclin d1 turnover.,pmc4102778,1,100,40,1,140
513,gsk-3beta,protein,,gsk3b,uniprot,p49841,,,akt,protein,,akt1,uniprot,p31749,,,negative,d,phosphorylation,s9,,,,,['2004'],nan,nan,"the pi3k/pten/akt/mtor pathway and gsk-3 can cross-regulate each other at various points. some of the interactions between gsk-3 and the pi3k/pten/akt/mtor pathway are presented in figure 3. as stated previously, gsk-3beta is negatively by akt when it is phosphorylated on s9. gsk-3beta is then inactive.",pmc4102778,1,100,40,1,140
512,gsk-3beta,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,vascular endothelial growth factor (vegf),protein,,vegfa,uniprot,p15692,extracellular region,go:0005576,negative,i,inhibition,,pancreatic cancer cells,epithelial,pancreas,human,['1997'],nan,nan,suppression of gsk-3beta expression inhibited pancreatic cancer growth and angiogenesis [125]. decreased levels of bcl-2 and vascular endothelial growth factor (vegf) were detected in cells which had gsk-3beta knocked-down. gsk-3 inhibitors may be appropriate for treatment of these types of tumors exhibiting gsk-3 overexpression in which gsk-3 is acting as a tumor promoter.,pmc4102778,1,100,40,1,140
510,gsk-3beta,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,htert,protein,reverse transcriptase,tert,uniprot,o14727,nucleus,go:0005634,negative,d,inhibition,,,cancer,,human,['2035'],nan,nan,"inhibition of gsk-3beta activity with the gsk3beta inhibitors sb-216763 and ar-a014418 controled cancer cell survival and proliferation, in a manner unrelated to wnt/beta-catenin signaling and akt activation, through decreasing telomerase reverse transcriptase (htert) expression and telomerase activity [256]. gsk-3beta inhibitors, lithium and sb-415286, have been also reported to overcome the inherent resistance of human hepatoma cells towards trail-induced apoptosis. the inhibitors exerted their anticancer activity through a complex mechanism which involved the promotion of apoptotic signals (caspase-8, caspase-3 and tp53 activation) and of protective signals (jnk activation) [257].",pmc4102778,1,100,40,1,140
505,gsk-3,protein,serine/threonine kinase,gsk3,uniprot,p49841,cytoplasm,go:0005737,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,i,phosphorylation,,,,,human,['1983'],nan,nan,"the serine/threonine kinase glycogen synthase kinase-3 (gsk-3) was initially identified and studied in the regulation of glycogen synthesis. gsk-3 functions in a wide range of cellular processes. aberrant activity of gsk-3 has been implicated in many human pathologies including: bipolar depression, alzheimer's disease, parkinson's disease, cancer, non-insulin-dependent diabetes mellitus (niddm) and others. in some cases, suppression of gsk-3 activity by phosphorylation by akt and other kinases has been associated with cancer progression. in these cases, gsk-3 has tumor suppressor functions. in other cases, gsk-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. in these situations, gsk-3 has oncogenic properties. while many inhibitors to gsk-3 have been developed, their use remains controversial because of the ambiguous role of gsk-3 in cancer development. in this review, we will focus on the diverse roles that gsk-3 plays in various human cancers, in particular in solid tumors. recently, gsk-3 has also been implicated in the generation of cancer stem cells in various cell types. we will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: pi3k/pten/akt/mtorc1, ras/raf/mek/erk, wnt/beta-catenin, hedgehog, notch and others.",pmc4102778,1,100,40,1,140
504,gsk-3,protein,,,uniprot,p49841,,,s6rp,protein,,rps6,uniprot,p62753,,,positive,i,downstream signaling cascade,,human renal proximal tubular epithelial cell (hrptepc) and rcc cells,"epithelial cell line, kidney tissue",kidney,human,['3382'],nan,nan,"pharmacological and genetic inhibition of gsk-3 suppresses 4ebp1, s6k, and s6rp phosphorylation in the mtorc1 downstream signaling cascade aberrantly activated in rcc cell lines. a the human rcc cell lines achn, caki1, and a498 cells were treated with ar-a014418 (25 μm or 50 μm) for 24 h or 48 h, respectively. b achn cells were treated with sb-216763 (25 μm or 50 μm), and with tdzd8 (5 μm or 10 μm) for 24 h or 48 h, respectively. c achn cells were transfected with non-specific control sirna (50 nm) as negative control (nc), gsk-3β-targeting (sigsk3β) sirnas (25 nm or 50 nm) and gsk-3α-targeting (sigsk3α) sirnas (50nm) for 48 h after seeding. d human renal proximal tubular epithelial cell (hrptepc) and normal kidney tissues had slight expression of gsk-3 and the mtorc1 downstream substances (p4ebp1, ps6k and ps6rp). in contrast, gsk-3 and the mtorc1 downstream signaling pathway were strongly activated in rcc cells. in a–d, immunoblot analysis was performed after cell lysis. data are representative of at least three separate experiments",pmc4936323,1,100,40,1,140
363,cyclin d3,protein,,ccnd3,uniprot,p30281,,,p21,protein,,cdkn1a,uniprot,p38936,,,positive,d,phosphorylation,,cho,epithelial-like,,human,['1141'],nan,nan,"(related to figure 3b, 3c). identification of the phosphorylated forms of p21. cho cells were transfected with plasmids encoding wild-type p21 (wt) or the indicated mutants of p21, alone (a) or together with plasmids encoding cyclin d3 and cdk4-ha (b). cell lysates were immunoprecipitated (ip) with anti-cyclin d3 (d3) (b) or anti-p21 antibodies (a) and incubated with the indicated recombinant kinases and atp. the proteins were separated by 2d gel electrophoresis followed by p21 immunodetection. right panel in (b), superimposition of 2d gel profiles of wt p21 (colorized in green) and the indicated mutants of p21 (colorized in red) after phosphorylation by cyclin a-cdk2. arrows indicate the main phosphorylated forms of p21.",pmc3667761,1,100,40,1,140
355,creb,protein,,creb1,uniprot,p16220,nucleus,go:0005634,noxa,protein,,bbc3,uniprot,o43521,nucleus,go:0005634,positive,d,transcriptional activation,noxa promoter,mel-rm and me4405,melanoma,skin,human,['3505'],nan,nan,"a number of transcription factors, including p53, e2f1 and creb, are involved in transcriptional activation of noxa in a cell type- and context-dependent manner [27, 36-38]. to examine the mechanism responsible for transcriptional upregulation of noxa by mek/erk signaling, we introduced luciferase reporter constructs of the noxa promoter with deletions of the known binding site for p53, e2f1, or creb into brafwt mel-rm and me4405 cells (figure 3a and supplementary figure s2). deletion of the creb binding site, but not deletion of the binding site for p53 or e2f1, markedly inhibited the transcriptional activity of the noxa promoter in mel-rm and me4405 cells with or without co-introduction of brafv600e (figure 3b). similarly, deletion of the creb binding site, but not deletion of the binding site for p53 or e2f1, inhibited the increase in the transcriptional activity in response to plx4720 (figure 3c). moreover, deletion of creb binding site did not cause any further reduction in the transcriptional activity of the noxa promoter in brafv600e igr3 and brafwt mel-rm cells treated with u0126 (figure 3d). of note, deletion of the p53 binding site attenuated upregulation of noxa by the dna-damaging drug etoposide, consistent the role of p53 in dna damage-mediated induction of noxa (figure 3e) [27]. taken together, these results suggest that transcriptional upregulation of noxa by mek/erk signaling is primarily mediated by creb. in support, knockdown of creb abolished upregulation of endogenous noxa by ectopic expression of brafv600e in mel-rm cells (figure 3f).",pmc4294377,1,100,40,1,140
560,gsk3,protein,,,uniprot,p49841,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,inhibition,,rat-1,fibroblast,,rat,['516'],nan,nan,"inhibition of gsk3 also reduced, but did not completely block, apoptosis resulting from inhibition of pi 3-kinase in both wild-type rat-1 cells and cells expressing dominant-negative p53. the reduction in apoptosis due to inhibition of gsk3 in both cell types suggests that p53 is one of several proapoptotic targets of gsk3, consistent with the identification of other gsk3 targets including mitf and usf1,18, 47, 48, 49 mcl-17 and eif2b.12 the finding that gsk3 reduced but did not eliminate apoptosis is also consistent with the direct effects of akt on other proapoptotic effectors, including foxo19, 20 and bad.8, 9 p53 is thus one component of the network of transcription factors that contributes to changes in gene expression and cell death following inhibition of pi 3-kinase and akt, with resulting activation of gsk3.",pmc3481126,1,100,40,1,140
243,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,mdm2,protein,e3 ubiquitin-protein ligase,mdm2,uniprot,q00987,nucleus,go:0005634,negative,d,knockdown,,,,,human,['1010'],nan,nan,"because these cell lines, like wd/ddls tumors, retain the characteristic amplification of chromosomal region 12q13-15 encoding the oncogenes cdk4 and mdm2 [30] we looked at whether the expression of mdm2 was different in the responder and non-responder cells. responder cells expressed higher levels of mdm2 than non-responders (figure 3a). however, it decreased approximately three-fold in the pd0332991 treated responder cells (ls8817, ls0082, ls141). on the other hand, it was relatively unchanged in the non-responders (ls8107, ls7785-1, ls7785-10, ls8313) (figure 3a and data not shown). furthermore, in responder cells, but not the non-responder cells, the level of mdm2 was reduced by cdk4 knockdown (figure 3a). mdm2 levels were also decreased in the responder cells that underwent senescence induced by expression of psm-rb (figure 2c), but not in the non-responder cell that underwent quiescence. this suggested that changes in mdm2 level, and not the absolute amount of mdm2, might be linked to the ability of cdk4 inhibitors to induce senescence.",pmc4480747,1,100,40,1,140
254,cdk4,protein,,cdk4,uniprot,p11802,,,p21,protein,,cdkn1a,uniprot,p38936,,,positive,d,binding,,hct116,,,,['1112'],nan,nan,"the requirement for cdk7 activity is dependent on cdk4 binding to p21, demonstrating the existence of cdk4-activating kinase(s) other than cdk7 in hct116 cells",pmc3667761,1,100,40,1,140
253,cdk4,protein,,cdk4,uniprot,p11802,,,mdm2,protein,,mdm2,uniprot,q00987,,,negative,d,protein expression regulation,,ls8817,,,human,['1012'],nan,nan,"(a) top, proteins were extracted from untreated cells or cells treated with 1 μm pd0332991 for two days and the expression of mdm2 determined by immunoblot. bottom, proteins were extracted from cells in which cdk4 levels were reduced with shrna vectors. cells transduced with vectors expressing a scrambled shrna were used as a control. tubulin is a loading control. this experiment was repeated at least three times and representative images are shown. (b) ls8817 cells were transduced with a lentivirus engineered to express mdm2 and selected for five days. cells transduced with a lentivirus expressing rfp were used as a control. after five days of selection the remaining cells were treated with pd0332991 for two days and protein accumulation measured by immunoblot. (c) as described in the legend to panel b, the cells were labeled during the last two hours with brdu prior to fixation. brdu incorporation was measured as described in the legend to figure 1b. (d) ls8817 cells were transduced with lentiviruses expressing the indicated mutants as described in the legend to panel b. top, a diagram representing the domains of mdm2 and corresponding point mutations (*) or deletions (δ) are indicated. bottom, the accumulation of sa-β-gal was determined seven days after drug treatment as described in the legend to figure 1c. the expression of mdm2 was measured by immunoblot after 48 hours.",pmc4480747,1,100,40,1,140
251,cdk4,protein,,cdk4,uniprot,p11802,cytoplasm,go:0005737,rb,protein,,rb1,uniprot,p06400,nucleus,go:0005634,negative,d,inhibition,,liposarcoma,,rb-positive,human,['1002'],nan,nan,cdk4 inhibition can induce senescence in a subset of rb-positive liposarcoma cell lines,pmc4480747,1,100,40,1,140
249,cdk4,protein,,cdk4,uniprot,p11802,cytoplasm,go:0005737,c-jun,protein,,jun,uniprot,p05412,nucleus,go:0005634,negative,d,abrogating,,,,,,['173'],nan,nan,"was inhibited by abrogating cdk4. surprisingly, the regulation of c-jun",pmc3084876,1,100,40,1,140
248,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,retinoblastoma protein,protein,transcription factor,rb1,uniprot,p06400,nucleus,go:0005634,positive,d,phosphorylation,ser 780,,,,human,['232'],nan,nan,phosphorylation of the cdk4 specific target ser 780 of retinoblastoma protein,pmc3084876,1,100,40,1,140
247,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,rb,protein,transcription factor,rb1,uniprot,p06400,nucleus,go:0005634,negative,i,inhibition,atp-binding site,breast cancer cell lines,epithelial,breast,human,['2515'],nan,nan,"compound 1 is a 2-aminopyrimidine analog identified as an atp-non competitive inhibitor of cdk4 in a high throughput screen, which was further found to inhibit rb phosphorylation in breast cancer cell lines, thereby offering promising perspectives for development of derivatives targeting this kinase [382].",pmc4381256,1,100,40,1,140
246,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,rb,protein,transcription factor,rb1,uniprot,p06400,nucleus,go:0005634,negative,d,inhibition,unphosphorylated rb,,,,human,['1008'],nan,nan,accumulation of unphosphorylated rb is sufficient to recapitulate the effect of cdk4 inhibition,pmc4480747,1,100,40,1,140
245,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,p16ink4a,protein,tumor suppressor,cdkn2a,uniprot,p42771,nucleus,go:0005634,positive,d,prevents fixation,,,cancerous,,human,['2486'],nan,nan,"cdk/cyclins and cancer. (a) schematic representation of normal cell growth and division regulated by cyclin-dependent kinases. hyperactivation of these kinases contributes to development of cancer cell proliferation; (b) cdk4/cyclin d in cancers: among all the cdk/cyclins, the complex cdk4/cyclin d is the one which presents most aberrations in cancers. hyperactive cdk4/cyclin d is found in several human cancers associated with the r24c mutation of cdk4 which prevents the fixation of the endogenous inhibitor p16ink4a, mutation of p16ink4a itself or cdk4 or cyclin d amplification; (c) cdk5/p25 in cancers.",pmc4381256,1,100,40,1,140
244,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,mdm2,protein,ligase,mdm2,uniprot,q00987,nucleus,go:0005634,positive,d,turnover,,,,various,human,['999'],nan,nan,"cdk4 inhibitors (cdk4i) earned breakthrough therapy designation from the fda last year and are entering phase iii clinical trials in several cancers. however, not all tumors respond favorably to these drugs. cdk4 activity is critical for progression through g1 phase and into the mitotic cell cycle. inhibiting this kinase induces rb-positive cells to exit the cell cycle into either a quiescent or senescent state. in this report, using well-differentiated and dedifferentiated liposarcoma (wd/ddls) cell lines, we show that the proteolytic turnover of mdm2 is required for cdk4i-induced senescence. failure to reduce mdm2 does not prevent cdk4i-induced withdrawal from the cell cycle but the cells remain in a reversible quiescent state. reducing mdm2 in these cells drives them into the more stable senescent state. cdk4i-induced senescence associated with loss of mdm2 is also observed in some breast cancer, lung cancer and glioma cell lines indicating that this is not limited to wd/ddls cells in which mdm2 is overexpressed or in cells that contain wild type p53. mdm2 turnover depends on its e3 ligase activity and expression of atrx. interestingly, in seven patients the changes in mdm2 expression were correlated with outcome. these insights identify mdm2 and atrx as new regulators controlling geroconversion, the process by which quiescent cells become senescent, and this insight may be exploited to improve the activity of cdk4i in cancer therapy.",pmc4480747,1,100,40,1,140
241,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,c-jun,protein,transcription factor,jun,uniprot,p05412,nucleus,go:0005634,positive,d,phosphorylation,nucleus,b lymphocytes,b-cell,,,['183'],nan,nan,here we demonstrate that cdk4 directly phosphorylates c-jun in b lymphocytes and,pmc3084876,1,100,40,1,140
298,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,p21,protein,,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,i,association,cyclin d-cdk4 complexes,,,,human,['1121'],nan,nan,"the action of cdk7 on cdk4 activation is two-pronged. in addition to having an initial acute effect on t172 phosphorylation of cdk4, cdk7 inhibition induced an increased association of p21 to cyclin d-cdk4 complexes, which might have been caused by reduction of the main phosphorylation of p21 at s130. as shown by the impairment of cdk4 phosphorylation by the s130a mutation of p21, the inhibition of s130 phosphorylation likely explains in part the inhibition of the activation of p21-bound cdk4 complexes and the refractoriness of cyclin d3-cdk4 complexes from cdk7-inhibited cells to in vitro activation by cak/cdk7. as reported by others [61], [62], the inhibition of s130 phosphorylation should also explain the subsequent augmentation of overall p21 levels.",pmc3667761,1,100,40,1,140
240,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,c-jun,protein,transcription factor,jun,uniprot,p05412,nucleus,go:0005634,positive,d,phosphorylation,,,b-cell,,human,['238'],nan,nan,its ability to phosphorylate a c-jun -gst fusion protein. the cdk4/cyclin d,pmc3084876,1,100,40,1,140
239,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,c-jun,protein,transcription factor,jun,uniprot,p05412,nucleus,go:0005634,positive,d,phosphorylation,c-jun,,,proliferation,,['208'],nan,nan,"proliferation, and tested the role of cdk4 in c-jun phosphorylation using more",pmc3084876,1,100,40,1,140
236,cdk4,protein,kinase,cdk4,uniprot,p11802,,,p21,protein,cyclin-dependent kinase inhibitor,cdkn1a,uniprot,p38936,,,negative,d,association,,,,,human,['1086'],nan,nan,cdk4 complexes from cdk7-inhibited cells are more strongly associated with p21 and are refractory to in vitro activation by cak,pmc3667761,1,100,40,1,140
234,cdk4,protein,complex,cdk4,uniprot,p11802,nucleus,go:0005634,p21,protein,,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,i,feedback,,,various,various,various,['1131'],nan,nan,"our data suggest that, depending on their activities during cell cycle progression, either cdk4 or cdk2 complexes can exert positive feedbacks to reduce the negative impact of p21 on cdk4 activation (figure 9). this could further amplify cdk4 activation and subsequently lead to increased degradation of p21, which in turn facilitates cdk2 activation. our data indicate that p21 inhibitory activity can be deactivated inside the inhibited cyclin d-cdk4 complex by other active cdk4 complexes. if this can be verified, theoretical conditions would be met to generate a bistable biochemical system (see e.g. [83] for a mathematical discussion of the analogous deactivation of p27 by cyclin e-cdk2). in such a switch-like biochemical module, binary (all-or-none) activation of cdk4 could occur, and sustain its permissiveness to activation despite reduced mitogenic stimulation, once the threshold barrier imposed by the p21 inhibitory potential has been overcome [84]. the positive “reverse” feedback pathways from cdk4 and cdk2 to cdk4 activation proposed here for the first time would introduce the notion that not only the prb-e2f switch [5], but also its trigger, might be endowed with bistable properties that would contribute to explaining the irreversibility of the cell cycle commitment at the r point. this mechanism (or similar ones in p21-independent cdk4 activation as observed in camp-dependent cell cycle of thyrocytes [39], [85]) can explain the exceptional robustness of the correlation between cdk4 t172 phosphorylation, prb phosphorylation and subsequent s-phase entry that we have observed in all the cell models and regulations we studied.",pmc3667761,1,100,40,1,140
233,cdk3,protein,kinase,cdk3,uniprot,o75969,nucleus,go:0005634,c-jun,protein,transcription factor,jun,uniprot,p05412,nucleus,go:0005634,positive,d,phosphorylation,c-jun,,,,human,['243'],nan,nan,et. al. indicating that c-jun is a target for cdk3 and therefore a regulator of ap-1,pmc3084876,1,100,40,1,140
231,cdk2,protein,,cdk2,uniprot,p24941,cytoplasm,go:0005737,p21,protein,,cdkn1a,uniprot,p38936,cytoplasm,go:0005737,negative,d,phosphorylation,s130,k7as hct116,epithelial,colon,human,['1100'],nan,nan,"previous reports have indicated that s130 phosphorylation of p21 can be catalyzed by cdk2 to form a phosphodegron recognized by the scf/skp2 ubiquitin ligase complex and to signal the proteasomal degradation of cyclin/cdk-bound p21, which is required for s-phase entry [61]–[63]. to evaluate whether inhibition of proteasomal degradation of p21 could indeed affect cdk4 phosphorylation, k7as hct116 cells were stimulated by serum in the presence or absence of the proteasome inhibitor mg132 (figure s7). mg132 increased p21 levels (figure s7a) and strongly inhibited the prb-kinase activity associated with cyclin d1 and p21 (figure s7b). here also, both the t172 phosphorylation of cdk4 and the s130 phosphorylation of p21 were inhibited by mg132 (figure s7c).",pmc3667761,1,100,40,1,140
230,cdk2,protein,kinase,cdk2,uniprot,p24941,nucleus,go:0005634,p21,protein,inhibitor,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,d,phosphorylation,s130,,,,cell,['1108'],nan,nan,activities of both cdk4/6 and cdk2 are required for s130 phosphorylation of p21 and activation of p21-bound cdk4.,pmc3667761,1,100,40,1,140
229,cdk2,protein,kinase,cdk2,uniprot,p24941,nucleus,go:0005634,p21,protein,cyclin-dependent kinase inhibitor,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,d,phosphorylation,s130,,,,human,['1126'],nan,nan,"the s130 phosphorylation site of p21 is not conserved in p27 and p57. nevertheless, s130 phosphorylation of p21 has been proposed [62] as the functional homologue of t187 phosphorylation of p27 [12], [77] and t310 phosphorylation of p57 [78]. s130 phosphorylation of p21 has been reported to be similarly catalyzed by cdk2 to form a phosphodegron recognized by the scf/skp2 ubiquitin ligase complex and to signal the proteasomal degradation of cyclin/cdk-bound p21 required for s-phase entry [61]–[63]. it was also found to be essential for release of a p21-imposed g1 arrest [79]. here we show for the first time that this phosphorylation is abundant in total and cdk4-bound p21 during g1 phase, indicating that it does not rapidly lead to p21 degradation at this stage, possibly because skp2 levels are kept low in g1 by proteasomal degradation initiated by apccdh1",pmc3667761,1,100,40,1,140
226,cdk1,protein,,cdk1,uniprot,p06493,cell,go:0005623,retinoblastoma,protein,,rb1,uniprot,p06400,nucleus,go:0005634,positive,d,phosphorylation,,,cell,,human,['2472'],nan,nan,"cdk1, cdk2, cdk4 and cdk6 and their associated cyclins a, b, d, e can be considered bona fide cell cycle regulators. whilst these cdks are widely, ubiquitously and constantly expressed throughout the cell cycle, their cyclin partners are periodically expressed and degraded at specific phases of the cell cycle, or in specific cells or tissues. hence, the spatio-temporal expression profiles of cyclins regulate activities of cdks in an orderly fashion, thereby ensuring timely cell cycle progression [17,18] (figure 1b). when quiescent cells (g0 phase) are stimulated to enter the cycle by mitogenic growth factors, notably via ras signaling pathway, expression of d-type cyclins promotes progression through g1 phase, through association and activation of cdk4 and cdk6, thereby promoting phosphorylation of retinoblastoma pocket protein family members (p107, p130, prb) [19]. phosphorylation of rb members partially inactivates their function as transcriptional repressors [20], leading to derepression of e2f transcription factors and consequent expression of genes which are required for g1/s transition, including cyclin e in late g1 (figure 2a). this in turn enables activation of cdk2/cyclin e, which further phosphorylates rb, thereby promoting complete release of e2f factors, inducing their maximal action as transcriptional activators and facilitating progression through g1 [21,22].",pmc4381256,1,100,40,1,140
255,cdk4,protein,,cdk4,uniprot,p11802,,,p21,protein,,cdkn1a,uniprot,p38936,,,positive,d,phosphorylation,s130,,,,,['1090'],nan,nan,"cdk4 activation correlates with s130 phosphorylation of p21, which is prevented by cdk7 inhibition",pmc3667761,1,100,40,1,140
256,cdk4,protein,,cdk4,uniprot,p11802,,,p21,protein,,cdkn1a,uniprot,p38936,,,positive,d,phosphorylation,s130 residue,,,,,['1132'],nan,nan,"a future challenge will be to identify the mechanisms that engage the positive feedback amplifying system that we suggest here for the activation of cdk4 complexes stabilized by p21, which represent the bulk of cdk4 complexes in g1 phase. mitogenic signal transduction kinases might directly phosphorylate the p21 s130 residue [86]. however, this possibility is not supported by the disappearance of s130 phosphorylation associated with cdk inhibition. alternatively, less stable but very active cyclin d-cdk4 complexes exist without binding to p21 or p27 [31], [58]–[60], the activation of which would depend on yet unknown non-cdk7 activating kinases as suggested here. our in vitro experiments (figure s6) raise the interesting possibility that a minimal amount of such hyperactive p21/p27-unbound cdk4 complexes might initiate the autocatalytic activation of a significant proportion of p21-bound cdk4 complexes through s130 phosphorylation (acting as kindling to ignite the pyre) (figure 9).",pmc3667761,1,100,40,1,140
257,cdk4,protein,,cdk4,uniprot,p11802,,,p21,protein,,cdkn1a,uniprot,p38936,,,positive,d,phosphorylation,t172,,,,human,['1070'],nan,nan,"in the cell cycle, duplication of all the cellular components and subsequent cell division are governed by a family of protein kinases associated with cyclins (cdks). related cdk4 and cdk6 bound to cyclins d are the first cdks to be activated in response to cell proliferation signals. they thus play a central role in the cell multiplication decision, especially in most cancer cells in which cdk4 activity is highly deregulated. we have identified the activating t172 phosphorylation instead of cyclin d expression as the highly regulated step determining cdk4 activation. this finding contrasts with the prevalent view that the only identified metazoan cdk-activating kinase, cdk7, is constitutively active. by using human cells genetically engineered for specific chemical inhibition of cdk7, we found that cdk7 activity was indeed required for cdk4 activation. however, this dependence was conditioned by cdk4 binding to the cdk inhibitory protein p21, which increased in response to cdk7 inhibition. further investigation revealed that cdk7 inhibition affects a major phosphorylation of p21, which we found to be required for cdk4 activation and performed by cdk4 itself and cdk2. thus, depending on cdk7 activity, cdk4 and cdk2 facilitate cdk4 activation, generating novel positive feedbacks involved in the cell cycle decision.",pmc3667761,1,100,40,1,140
259,cdk4,protein,,cdk4,uniprot,p11802,,,rb,protein,,,uniprot,p06400,nucleus,go:0005634,positive,d,phosphorylation,,,adenocarcinoma,lung,,['2357'],nan,nan,"in summary, our preclinical study demonstrated that genetic knockdown or pharmacological inhibition of cdk4 reduced the population of phosphorylated rb and induced g1 arrest. we also found the cdk4/6 inhibitor cink4 promotes apoptotic induction through the downregulation of rb and cyclin d1. in addition, cyclin d1 and bcl-2 play critical roles in synergistic anti-tumor efficacy with significant apoptotic induction by combined treatment with cink4 and paclitaxel in adenocarcinoma cells harboring kras mutations. we suggest cdk4 inhibition combined with taxane therapy may be a clinically useful strategy for kras mutant lung cancers.",pmc3742489,1,100,40,1,140
297,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,p21,protein,,cdkn1a,uniprot,p38936,nucleus,go:0005634,negative,d,inhibition,inactive,,,isolated cells,,['1092'],nan,nan,"specific inhibition of cdk7 by 1-nmpp1 prevents the main phosphorylation of p21, which is performed in vitro by both cdk4 and cdk2.",pmc3667761,1,100,40,1,140
296,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,p21,protein,,cdkn1a,uniprot,p38936,cytoplasm,go:0005737,negative,i,increase,whole-cell lysates,hct116 k7as,colorectal,,human,['1143'],nan,nan,"proteasomal inhibition increases p21 levels and mimics the effects of cdk7 inhibition on phosphorylations of prb and cdk2 (a), prb kinase activity (b), and t172 phosphorylation of cdk4 and s130 phosphorylation of p21 (c). hct116 k7as cells were restimulated or not restimulated with fetal bovine serum (+/− fbs) during 5 or 16 h in the continuous absence (−) or presence (+) of mg132. (a) western blotting analysis was performed with the indicated antibodies from whole-cell lysates. (b,c) lysates from cells treated for 5 h were immunoprecipitated (ip) with anti-p21 or anti-cyclin d1 (d1) antibodies and assayed for their prb-kinase activity, separated by sds-page and immunoblotted with the indicated antibodies (b), or were separated by 2d gel electrophoresis followed by cdk4 and p21 immunodetection (c).",pmc3667761,1,100,40,1,140
289,cdk7,protein,,cdk7,uniprot,p50613,,,prb,protein,,rb1,uniprot,p06400,,,negative,d,inhibition,,hct116,epithelial-like,,human,['1137'],nan,nan,"(related to figure 1). specific inhibition of cdk7 by 1-nmpp1 prevents t826 phosphorylation of prb and t160 phosphorylation of cdk2 while increasing p21 accumulation (a). specific inhibition of cdk7 also prevents the activating phosphorylation (b) and prb-kinase activity of cdk6 (c). wt (a) and k7as (a–c) hct116 cells were stimulated (+) or not stimulated (−) with fetal bovine serum (fbs) for the indicated times in the absence (−) or presence (+) of 1-nmpp1. (a) western blotting analysis with the indicated antibodies from whole-cell lysates. (b,c) cell lysates (analyzed in figure 1b–1d) were immunoprecipitated (ip) with anti-cyclin d1 (d1) or anti-cyclin d3 (d3) and separated by 2d gel electrophoresis followed by cdk6 immunodetection (b), or were immunoprecipitated with anti-cdk6 antibody, assayed for prb-kinase activity, separated by sds-page, and immunoblotted with the indicated antibodies (c). arrows, position of the t177-phosphorylated form of cdk6.",pmc3667761,1,100,40,1,140
288,cdk7,protein,,cdk7,uniprot,p50613,,,prb,protein,,rb1,uniprot,p06400,,,negative,d,inhibition,,hct116,epithelial,colon,human,['1080'],nan,nan,"specific inhibition of cdk7 by 1-nmpp1 prevents dna synthesis (a), prb phosphorylation (b), cdk4/6 prb-kinase activity (c) and cdk4 activating phosphorylation (d). hct116 wt or k7as (k7as/as) cells were stimulated (+) or not stimulated (−) with fbs for the indicated times in the absence (−) or presence (+) of 1-nmpp1. (a) dna synthesis was evaluated from duplicate dishes by counting the percentage of cells having incorporated brdu during the last 30 min of stimulation. (b) western blotting analysis with the indicated antibodies from whole-cell lysates. (c) cell lysates were immunoprecipitated (ip) with anti-cyclin d1 (d1), anti-cyclin d3 (d3) or anti-p21 (p21) antibodies and were assayed for their prb-kinase activity, separated by sds-page and immunoblotted with the indicated antibodies (c). (d) the same immunoprecipitates were separated by 2d gel electrophoresis followed by immunodetection using antibodies directed against cdk4 or t172-phosphorylated cdk4. arrows, t172-phosphorylated form of cdk4.",pmc3667761,1,100,40,1,140
287,cdk7,protein,,cdk7,uniprot,p50613,,,p21,protein,,cdkn1a,uniprot,p38936,,,positive,d,phosphorylation,s130,,,,,['1119'],nan,nan,"cdk7 inhibition reveals novel positive feedbacks mediated by s130 phosphorylation of p21, which is catalyzed by active cdk4 and cdk2 to permit t172 phosphorylation and activation of cdk4 complexes stabilized by p21 binding. s130 phosphorylation of p21 thus amplifies cdk4 activation and subsequently leads to increased degradation of p21, which in turn facilitates cdk2 activation. those retrocontrols of cdk4 activation should contribute to explaining the irreversibility of the cell cycle commitment at the r point. green/red colors indicate a final positive/negative influence on r point passage. 1, 2, two different levels of cdk7 action demonstrated by the present observations. cdk4 ak?, hypothetical cdk4-activating kinase(s) phosphorylating p21-unbound cdk4 and s178p cdk6 during cdk7 inhibition.",pmc3667761,1,100,40,1,140
279,cdk7,protein,kinase,cdk7,uniprot,p50613,cell nucleus,go:0005634,p21,protein,,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,d,phosphorylation,s/t-p motifs,cho,epithelial-like,,human,['1094'],nan,nan,"we next wanted to identify the phosphorylation sites of p21 in k7as cells. different phosphorylated forms of a protein present characteristic reproducible migrations in 2d gel separations, which allows them to be monitored once they are identified [41]. as the phosphorylations of p21 depended on cdk7 activity, we hypothesize that they could have been catalyzed by cdks, which phosphorylate s/t-p motifs. p21 contains three such motifs (t57, s98, s130). so we produced human p21 and its t57a, s98a and s130a mutants in cho cells, and compared their 2d gel separation patterns after in vitro phosphorylation by active recombinant cdk complexes. in the same experiments, p21 was also produced as a complex with cyclin d3 and cdk4 (immunoprecipitated by the dcs-28 cyclin d3 antibody) to evaluate how the accessibility of p21 phosphorylation sites might have been affected. as analyzed in figure 3b and figure s5, cyclin e1-cdk2 and cyclin d3-cdk4 phosphorylated unbound p21 at both s130 and s98 but not at t57 (the patterns were not affected by the t57a mutation), whereas only s130 was phosphorylated by cyclin a2-cdk2. in p21 complexed with cyclin d3 and cdk4, phosphorylation of s130 by cyclin e1-cdk2 and cyclin d3-cdk4 was more complete, while s98 phosphorylation was much reduced. by contrast, after incubation with cyclin a2-cdk2, cyclin d3/cdk4-bound p21 was more completely phosphorylated and several multi-phosphorylated forms appeared. the s130a mutation affected all the phosphorylated forms (figure s5b). the multi-phosphorylated forms were similarly affected by the s98a mutation, whereas the t57a mutation had no effect (figure s5b). therefore, after phosphorylation by cyclin a2-cdk2, all phosphorylated forms of cyclin d3/cdk4-bound p21 contained the s130 phosphorylation, and its most abundant forms resulted from a combination of s130 and s98 phosphorylations associated with one or two unidentified phosphorylations (but not on t57) (figure 3b; figure s5). in similar in vitro experiments, the association of p21 with cyclin d1-cdk4 was also required for its complete s130 phosphorylation by cyclin d1-cdk4 and cyclin d1-cdk6 (figure s6). overall, these observations suggest that interaction of p21 with cyclin d-cdk4 increases the accessibility of the s130 residue to the five recombinant active cdks we tested, and the accessibility of s98 to cyclin a2-cdk2 only, while impairing s98 accessibility to cyclin e1-cdk2 and cyclin d1/d3-cdk4. cdk4 was not phosphorylated by recombinant cdk2 and cdk4 complexes in these experiments (not shown).",pmc3667761,1,100,40,1,140
278,cdk5,protein,member of cdk family,cdk5,uniprot,q00535,cytoplasm,go:0005737,retinoblastoma protein (prb),protein,,rb1,uniprot,p06400,nucleus,go:0005634,positive,d,phosphorylation,,,neuron,central nervous system,human,['2478'],nan,nan,"cdk5 is an unconventional member of the cdk family which is ubiquitously expressed, but mainly active in post-mitotic neurons, where it is activated by neuron-specific activators p35/p25 and p39 rather than by cyclins [73,74]. initially identified through structural homology with cdk2 [75,76], and independently isolated as a proline-directed histone h1 kinase from bovine brain, cdk5/p35 was found to phosphorylate histone h1 and retinoblastoma protein (prb) [77,78,79]. however, this kinase is not involved in coordination of cell cycle progression, and instead exerts its functions mainly in the central nervous system, where it promotes neurite extension, neuronal migration, synapse formation during brain development, synaptic plasticity and synaptic activities in mature neurons, axonal guidance, neuronal development and differentiation, and further participates in regulation of autophagy [43,44,45,80,81,82,83,84]. moreover several extraneuronal functions of cdk5 have been reported including apoptosis in nonneuronal model systems and insulin secretion in pancreatic cells [46,85,86].",pmc4381256,1,100,40,1,140
277,cdk4,protein,,,uniprot,p11802,nucleus,go:0005634,p21,protein,,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,i,inhibition,cdk4 phosphorylation,,,,human,['1133'],nan,nan,"the corollary of the central position of t172-phosphorylation of cdk4 in the cell cycle decision module is its responsiveness to various drugs or treatments used or envisaged in cancer therapy. cdk4 phosphorylation is a central node integrating oncogenic signaling cascades, as its abrogation requires combined inhibition of the ras/mek/erk and mtor pathways [37]. but amazingly, it is also inhibited by various cdk inhibitors that were not suspected to affect cdk4 activity, including roscovitine (seliciclib), and drugs that increase p21 levels, including proteasome inhibitors, such as bortezomib. in p53-proficient cells, genotoxic therapeutic drugs and treatments, which induce large amounts of p21, are thus also expected to inhibit cdk4 phosphorylation. the resulting inhibition of cdk4 activity may halt cell proliferation in prb-proficient tumors. on the other hand, p21-dependent inhibition of cdk4 activation might also explain the stronger resistance of prb-proficient cells to the apoptotic effect of these different treatments, which might be exploited to protect normal cells and hence allow more aggressive treatments of prb-deficient tumors [29], [87]. finally, the novel positive feedback pathways identified here from cdk4 and cdk2 to facilitate cdk4 activation may explain the relative resistance to receptor or cell signaling kinase inhibitory drugs of cancer cells that have intrinsically strong cdk4 activity (e.g. due to frequent cdkn2a deletion or cdk4 amplification) and/or cdk2 activity (e.g. due to deregulation of cyclin e). this would provide a rationale for treatments that combine inhibitory drugs targeting oncogenic signaling pathways and cdks, as suggested recently [88].",pmc3667761,1,100,40,1,140
273,cdk4,protein,,,uniprot,p11802,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,inhibition,,wd/ddls,mesenchymal,soft tissue sarcoma,,['1019'],nan,nan,"cdk4 inhibition leads to a loss of p53 protein in wd/ddls cell lines (supplementary figure 4) but mdm2 knockdown does not (figure 4a). thus, we wanted to ask if mdm2 knockdown could also induce senescence in a p53-independent manner. to accomplish this, we first treated non-responder ls8107 cells with pd0332991 to insure that they exited the cell cycle with reduced amounts of p53, and subsequently we infected these cells with a lentivirus vector expressing an shrna to mdm2. in one experiment we removed pd0332991 two days after infection, and in the other we left the cells in pd0332991 for the duration of the experiment. the results were similar: p53 levels did not increase under either condition, and sa-β-gal positive cells accumulate after mdm2 knockdown (figure 4d). furthermore, knocking down p53 in ls8817 cells did not disrupt either cdk4 inhibitor induced down-regulation of mdm2 or accumulation of sa-β-gal (or sahf, not shown), nor did it prevent mdm2 knockdown induced senescence (supplementary figure 5).",pmc4480747,1,100,40,1,140
272,cdk4,protein,,cdk4,uniprot,p11802,unknown,unknown,mdm2,protein,,mdm2,uniprot,q00987,unknown,unknown,negative,i,down-regulation,,unknown,unknown,wd/ddls,unknown,['1033'],nan,nan,"our data is consistent with an association of favorable clinical outcome with cdk4 inhibitors and the drug-induced down-regulation of mdm2 in wd/ddls. we hypothesize that geroconversion underlies the efficacy of cdk4 inhibitors in the clinic. although cdk4 inhibitors are somewhat effective alone in wd/ddls [24, 25], we suspect that their activity can be improved in combination with other agents; however, what agents to select is not obvious.",pmc4480747,1,100,40,1,140
271,cdk4,protein,,cdk4,uniprot,p11802,plasma membrane,go:0005886,prb,protein,,rb1,uniprot,p06400,nucleus,go:0005634,positive,d,phosphorylation,t826,hct116 k7as,epithelial,colon,human,['1136'],nan,nan,"(related to figure 1). characterization of dna synthesis (a), cell cycle protein levels (b) and cdk4 phosphorylation during cell cycle progression in hct116 k7as cells. hct116 wt (a) or k7as (a–c) cells were synchronized by serum deprivation for two days and re-stimulated with 10% fetal bovine serum (fbs) for different times. (a) dna synthesis was evaluated from duplicate dishes by counting the percentage of cells having incorporated brdu during the last 30 min of stimulation. (b) western blotting analysis was performed with the indicated antibodies from whole-cell lysates. *, prb hypophosphorylated band; **, prb hyperphosphorylated bands. (c) cell lysates were immunoprecipitated (ip) with anti-cyclin d1 (d1) or anti-cyclin d3 (d3) antibodies and separated by 2d gel electrophoresis followed by cdk4 detection. arrows, t172-phosphorylated form of cdk4. different exposures are shown for the different time points to better visualize the proportion of the cdk4 phosphorylated form irrespective of the relative amount of cyclin d-cdk4 complexes. in k7as hct116 (k7as), dna synthesis started to increase between 6 and 8 h after stimulation and peaked at 12–16 h (figure s1a). as readout of cdk4 and cdk6 activity, t826 phosphorylation of prb was first observed to increase at 3 h and peaked at 16 h (figure s1b). cyclin d1 and cyclin d3 expression was first seen to increase at 2 h. whereas cyclin d1 accumulation peaked at 6 h, cyclin d3 continued to accumulate during s and g2 phases until 24 h. cdk4 and cdk6 expression was much less modulated (figure s1b). interestingly, the phosphorylation of cyclin d1-bound cdk4 appeared at 2–3 h into g1 phase, whereas the phosphorylation of cyclin d3-bound cdk4 was already detected in serum-deprived cells and further increased much later at 12 h and subsequent time points, when most cells were in s-g2 phases (figure s1c). this suggests that cdk4 complexed to cyclin d1 and cyclin d3 might have partially different roles in the different cell cycle phases. the activating t160 phosphorylation of cdk2 was observed to increase at 4–6 h, along with an increased accumulation of cyclin e and a migration shift of this protein (likely associated with its cdk2-dependent phosphorylation [90]). this coincided with the partial disappearance of p21 and p27, which reappeared at later time points (20–24 h) (figure s1b).",pmc3667761,1,100,40,1,140
270,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,rb,protein,,rb1,uniprot,p06400,nucleus,go:0005634,negative,d,phosphorylation,,rat insulinoma ins-1 cells,pancreatic,pancreas,rat,['3153'],nan,nan,"rat insulinoma ins-1 cells were cultured in rpmi-1640 medium (invitrogen), supplemented with 10% heat inactivated fetal bovine serum (hyclone/thermo fisher scientific), 1 mm sodium pyruvate, 2 mm l-glutamate, 0.05 mm 2-mercaptoethanol, 10 mm hepes and penicillin/streptomycin. cells were transfected with smart pool cdk2 sirna or cdk4 sirna or control dsrna (dharmacon/thermo fisher scientific), using the rnaimax lipofection reagent (gibco/invitrogen). for stimulation of cell cycle progression, cells at 48 h posttransfection were incubated in the medium with low (0.1 mm) glucose for 48 h, followed by incubation in the medium with high (11 mm) glucose. at various times after stimulation with high glucose, cells were harvested for immunoblotting and flow cytometry. at 30 min before each harvesting point, bromodeoxyuridine (brdu, sigma/aldrich) was added to the medium. immunoblotting and flow cytometry were performed as described previously 14. anti-brdu antibody for flow cytometry was obtained from pharmingen/bd biosciences. antibodies against cdk2, cdk4, cdk6, cyclin d1, cyclin d3, cyclin e and actin were purchased from santa cruz biotechnology. anti-total rb antibody was from pharmingen/bd biosciences, and the phospho-specific antibodies against rb and p130 were from cell signaling technology.",pmc4135037,1,100,40,1,140
269,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,prb,protein,,rb1,uniprot,p06400,nucleus,go:0005634,positive,d,phosphorylation,,t98g glioma cells,epithelial-like,brain,human,['1515'],nan,nan,"the activation of cdk4 is a peculiarly complex process requiring different successive steps, which are distinguished by their independent regulations. this allows to better understand how cdk4 can function at the restriction point as a master integrator of various mitogenic and antimitogenic controls of the cell cycle. a few models, including the physiologically relevant example of the thyroid primary culture system, have allowed to dissociate the regulated assembly of d-type cyclin-cdk4 complexes from the accumulation of their individual partners, the nuclear import of these complexes from their assembly, and the activating phosphorylation of cdk4 from the formation and nuclear accumulation of the d-type cyclin-cdk4-p27/p21 holoenzyme (figure 1). we have identified this last step as an ultimate regulatory target determining cdk4 activity, prb phosphorylation and the passage through the g1 phase restriction point. some evidence is emerging that the activation process of the six possible cyclin d1/2/3-cdk4/6 complexes could be subject to partly different regulatory mechanisms. cyclin d3-cdk6 complexes appears to be especially resistant to inhibition by p16 [196] and p27 [197]. in t98g glioma cells, serum stimulates the phosphorylation of cyclin d3-bound cdk4 but not cyclin d3-bound cdk6 [82]. in thyrocytes, the distinct mitogenic pathways of growth factors or tsh appear to be channeled to preferentially activate and utilize cdk4 complexed to either cyclin d1 or cyclin d3 [45,70,100] (figure 1). this leads to partly different phosphorylations of prb, which might differentially impact prb function in the transcriptional regulation of genes involved in cell cycle or differentiation [45,100].",pmc1647274,1,100,40,1,140
267,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,p21,protein,,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,d,phosphorylation,,k7as hct116,colon,colon,human,['1107'],nan,nan,"we observed that cdk4 and cdk6, associated with cyclin d3 and cyclin d1, also phosphorylated p21 complexed with d-type cyclins and cdk4 in vitro (figure 3b; figure s6). so we evaluated the effect of pd0332991 on s130 phosphorylation and cdk4 activation in k7as hct116 cells (figure 7). pd0332991 is a specific inhibitor of cdk4 and cdk6 and does not inhibit cdk2 and the proliferation of prb-negative cells [27], [70]. pd0332991 (250 nm) inhibited the t826 phosphorylation of prb (not shown) and partially the s130 phosphorylation of p21, but apparently not the s98 phosphorylation (figure 7b). treatment of the cells with pd0332991 did inhibit the phosphorylation and consequently in vitro activity of p21-bound cdk4 (figure 7a, 7b). this indicates that this drug inhibited not only the activity of cdk4 but also its activation by phosphorylation, which might be related to the inhibition of p21 phosphorylation. curiously, and at variance with all the inhibitory treatments we used, such inhibitory effects of pd0332991 cell treatment on cdk4 activation were not observed for cdk4 precipitated by antibodies against cyclin d1 (figure 7a, 7b) and cyclin d3 (not shown). this puzzling and very reproducible discrepancy necessarily implies that in pd0332991-treated cells the active phosphorylated cyclin d1/3-bound cdk4 was no longer associated with p21. we speculate that high-affinity binding of this atp-competing drug to cdk4 in cells had somehow impaired p21 binding to cdk4, e.g. by competing with the insertion of the 310 helix of p21 in the catalytic cleft of cdk4 or by altering the folding of cdk4. regardless of the reason, these observations show that the effect of pd0332991 on cdk4 activation depended on the binding of cdk4 to p21. they thus suggest that cdk4 (and/or cdk6) might contribute to the activation of p21-bound cdk4 complexes by phosphorylating p21.",pmc3667761,1,100,40,1,140
266,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,p-c-jun,protein,,,uniprot,p05412,nucleus,go:0005634,positive,d,normalization,,,,,,['229'],nan,nan,100%. the level of p-c-jun in cdk4 deficient cells was normalized,pmc3084876,1,100,40,1,140
264,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,c-jun,protein,transcription factor,jun,uniprot,p05412,nucleus,go:0005634,positive,d,phosphorylation,c-jun,,,,human,['252'],nan,nan,"our results focus on cdk4's ability to phosphorylate c-jun, but other cdk family",pmc3084876,1,100,40,1,140
263,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,c-jun,protein,,jun,uniprot,p05412,nucleus,go:0005634,positive,d,regulates,c-jun,,,,,['219'],nan,nan,proliferation. to further explore the possibility that cdk4 regulates c-jun,pmc3084876,1,100,40,1,140
261,cdk4,protein,,cdk4,uniprot,p11802,,,rb protein,protein,,rb1,uniprot,p06400,,,positive,d,amplification,,,,,,['1027'],nan,nan,"seven patients with measurable advanced wd/ddls confirmed positive for cdk4 amplification and rb protein expression, and whom had progressed on at least one systemic therapy prior to enrollment (clinicaltrials.gov identifier nct01209598), consented to pre-treatment biopsies taken prior to therapy and post-treatment biopsies taken after receiving one dose of oral pd0332991 (125mg daily for 21 days). tumor response was assessed with ct scan by a reference radiologist every 6 weeks for 36 weeks, and every 12 weeks thereafter. patients were followed up until march 2014. three patients (red bars) did not derive clinical benefit and stopped treatment within 84 days. two of these patients (#2 and #3, triangles) died on study and are indicated with a triangle. the third patient, #8, came off study as their disease progressed. four patients (blue bars) had demonstrable clinical benefit, remaining on treatment for more than 84 days. two of these progressed after 168 (#8) and 376 (#7) days respectively, while two remained on treatment with ongoing benefit (arrows), one achieving a complete response (star). (inset) extracts were prepared from pre- and post-treatment biopsies of protein expression measured by immunoblot. gapdh was a loading control.",pmc4480747,1,100,40,1,140
260,cdk4,protein,,cdk4,uniprot,p11802,,,rb,protein,,rb1,uniprot,p06400,,,negative,d,depletion,,,insulinoma cells,,human,['3148'],nan,nan,cdk4 depletion inhibits cell cycle progression of insulinoma cells with suppressed rb phosphorylation,pmc4135037,1,100,40,1,140
552,gsk3,protein,,gsk3,uniprot,p49841,,,smad4,protein,,smad4,uniprot,q13485,nucleus,go:0005634,positive,i,phosphorylation,gsk3 phosphorylates smad4,,,,,['83'],nan,nan,"the gsk3 linker phosphorylations induced by tgf-β differ from those induced by fgf. indeed, we found that psmad4gsk3 phosphorylations are greatly inhibited by wnt3a but only when primed by fgf; when the psmad4gsk3 phosphorylation was triggered by tgf-β, wnt3a treatment had no effect (fig. 4b, compare lanes 2 to 3 and 6 to 7). this suggests that the 2 signaling pathways use different cellular mechanisms to trigger the phosphorylation of smad4 by gsk3. one possible explanation for this observation is that the fgf-induced gsk3 phosphorylations of smad4 take place in the cytoplasm, whereas tgf-β induced gsk3 phosphorylation of smad4 occurs in the nucleus while smad4 is engaged in transcription and would be independent of the wnt-destruction complex. this hypothesis would be consistent with the proposed cycle of activation for r-smad proteins,29,30 and with our previous results showing that the regulation of smad4 activity by wnt is entirely dependent on an fgf-triggered mapk/erk priming mechanism.18 we conclude from the results in fig. 4 that a second pathway exists for phosphorylation of smad4 gsk3 sites that is triggered by tgf-β but not regulated by wnt, as is the case when primed by fgf/egf.",pmc4845174,1,100,40,1,140
564,gsk3,proteinkinase,,gsk3,uniprot,p49841,cytoplasm,go:0005737,smad4,protein,,smad4,uniprot,q13485,nucleus,go:0005634,negative,i,phosphorylation,gsk3 phosphorylation sites,,,,human,['81'],nan,nan,"we conclude that the gsk3 phosphorylation sites of smad4 mediate the loss-of-function of the pro130ser and asn351his smad4 mutations by promoting their degradation via linker phosphorylations. remarkably, gsk3 inhibitors can restore the transcriptional function of these mutations, suggesting novel therapeutic possibilities.",pmc4845174,1,100,40,1,140
220,cd40,protein,,cd40,uniprot,p25942,plasma membrane,go:0005886,cjun,protein,,jun,uniprot,p05412,nucleus,go:0005634,negative,d,phosphorylation,cjun,,,,,['263'],nan,nan,stimulated via cd40 did not respond with easily detectable cjun phosphorylation,pmc3084876,1,100,40,1,140
966,rig-i,protein,,ddx58,uniprot,o95786,cytoplasm,go:0005737,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,negative,d,competitive binding,,,myeloid progenitor,pancreas,human,['2593'],nan,nan,"recent studies have established that rig-i restrains myeloid progenitor proliferation through competitive binding with active src4. the recognition between rig-i and src acts through a cooperative interaction involving rig-i recruitment domains (cards) and the src sh1 domain. in inactive src, the sh1 domain faces inward and is inaccessible to outside factors; therefore, the rig-i cards preferentially associates with activated src with an exposed sh1 domain. c-terminal to the rig-i cards there is a classic pxxp motif. the pxxp motif can combine with the src sh3 domain to prevent activated src from inducing proliferation. consistent with this finding,our results suggested that rig-i could bind active src competitively to inhibit pancreatic β cells proliferation elicited by igf-src signals (figs 4 and 8).",pmc4923948,1,100,40,1,140
979,runx3,protein,,runx3,uniprot,q13761,,,src,protein,,src,uniprot,p12931,,,positive,d,binding,,,,,,['813'],nan,nan,"the physical interaction between runx3 and src was further examined by ip and ib experiments following cotransfections with full-length runx3 and full-length (wt) or truncated versions of src (sh2, sh3, and tyrk). wt src and the kinase domain of src (tyrk) were capable of binding runx3. in contrast, the sh2 and sh3 domains of src did not interact with runx3 (fig. 3c). these results demonstrate that the kinase domain of src is essential for its physical binding to runx3. notably, tyrosine phosphorylation of runx3 was detected in cells that were cotransfected with either the full-length src or the kinase domain construct (tyrk). however, complete phosphorylation of runx3 only occurred in cells transfected with full-length src, suggesting that the sh2 or sh3 domain may also play a role in fully phosphorylating runx3 (fig. 3c, bottom panel).",pmc2843174,1,100,40,1,140
977,runx3,protein,,runx3,uniprot,q13761,cytoplasm,go:0005737,src,protein,,src,uniprot,p12931,unknown,unknown,positive,i,incorporation,unknown,unknown,cancer,unknown,unknown,['824'],nan,nan,"cell fractionation followed by immunoblotting analyses indicated that most of the tyrosine-phosphorylated runx3 was detected in the cytoplasm, although substantial levels of nonphosphorylated runx3 were detected in the nuclear fractions of src-activated cancer cell lines (fig. 4d). on the other hand, immunocytochemical staining with the same antibody detected runx3 mainly in the cytoplasm (fig. 5a). this discrepancy may be explained by epitope masking following the incorporation of runx3 into macromolecular transcriptional complexes that are nuclear matrix-associated (51).",pmc2843174,1,100,40,1,140
976,runx3,protein,,,uniprot,q13761,cytoplasm,go:0005737,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,positive,d,activation,cytoplasm,"mkn45, snu16, bt20, mb468","gastric cancer, breast cancer",,human,['818'],nan,nan,"it has been reported previously that runx3 is localized in the cytoplasm in the mkn45 and snu16 gastric cancer cell lines (28), and this was confirmed in our study (fig. 5a). notably, bt20 and mb468 breast cancer cell lines, which contain activated src, also showed cytoplasmic localization of runx3 (fig. 5a).",pmc2843174,1,100,40,1,140
975,runx3,protein,,,fplx,runx3,cytoplasm,go:0005737,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,negative,d,phosphorylation,cytoplasm,,"gastric cancer, breast cancer",,human,['823'],nan,nan,"we previously reported that runx3 is stabilized as an inactive form and localized in the cytoplasm after phosphorylation by the pim1 serine/threonine kinase (46), which is often hyper-activated in hematopoietic malignancies and prostate carcinomas (50). our finding that src inactivates runx3 by cytoplasmic sequestration in gastric cancer and breast cancer suggests that the inactivation of runx3 may be a key function of oncogenic kinases. further studies are needed to understand the physiological conditions under which this runx3 inactivation occurs and the biological meaning of runx3 inactivation by the src and pim1 oncogenic kinases.",pmc2843174,1,100,40,1,140
974,runx2,protein,transcription factor,runx2,uniprot,q13950,nucleus,go:0005634,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,upregulates,transcriptional and protein level,"mouse osteoblast and chondrocyte differentiation, amkl cell line meg-01",,,"mouse, meg-01 cells",['3260'],nan,nan,"the regulation of pi3k and akt protein levels by runx2 was initially demonstrated in the context of mouse osteoblast and chondrocyte differentiation. this work shows that runx2 upregulates pi3k subunits p85 and pik3cb (p110β) and the kinase akt. p110β is mainly regulated at the transcriptional level, while p85 and akt are regulated at both transcriptional and protein levels [47]. a similar mechanism is described in the megakaryocytic leukemia (amkl) cell line meg-01. runx1 directly binds to the runx1 binding sites of the pi3kcd (p110delta) promoter and the pi3kcd gene is a direct transcriptional target of runx1 in the meg-01 cells [59].",pmc4513933,1,100,40,1,140
972,runx2,protein,,,uniprot,q13950,,,akt,protein,,akt1,uniprot,p31749,,,positive,i,regulation,,prostate and breast cancer cells,,,,['3261'],nan,nan,"the indirect regulation of runx2 on the pi3k/akt signaling pathway has been documented in prostate and breast cancer cells. in androgen-independent prostate cancer cell lines, knocking down or overexpressing runx2 leads to a decreased or increased level of phosphorylated akt at serine 473 (pakts473) respectively by mechanisms yet to be defined [60]. a novel mechanism to activate akt activity is demonstrated in invasive breast cancer cells. endogenous runx2 is required to maintain high levels of pakts473 in invasive cancer cells, but not in non-invasive breast cancer cells or normal cells. runx2 knockdown in the invasive cancer cells results in the decrease of mrna and proteins levels of both mtor and rictor, two major components of the mtorc2 complex involved in phosphorylating akt on serine 473. the effect on mtor expression is mediated through direct binding of runx2 to the mtor promoter region (-2420 to -2441) containing two highly conserved runx binding elements at -2420 and -2430 bp. therefore, runx2 up regulates components of the mtorc2 complex, which directly phosphorylates akt [61].",pmc4513933,1,100,40,1,140
969,rig-i,protein,,,uniprot,p78310,cytoplasm,go:0005737,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,positive,d,induction,,,,pancreas,human,['2583'],nan,nan,"insulin-like growth factor i (igf-1) was reported to induce cell proliferation, and is closely associated with src activity31. to explore the role of rig-i in src signalling and cell proliferation in pancreatic β cells, we performed a series of experiments using igf-1 treatment. ra, a rig-i specific agonist, was used in the experiment at different concentrations (0, 1, 5, 10, 20, 50 and 100 μm) for different times (6, 12 and 24 h) with igf-1 (10 nm)28 to investigate the role of rig-i in the pancreatic β cell line. mtt assays indicated that ra at more than 5 μm inhibited the viability of min6 cells in a dose-dependent manner (fig. 4a). we then investigated whether rig-i could inhibit the proliferation of pancreatic β cells. min6 cells were subjected to starvation for 24 h in medium depleted of amino acids and serum, followed by igf-i treatment in serum-free medium28, and then treated with ra (10 μm) or transfected with plasmid rig-i. the percentage of edu-positive β cells increased in the cells treated with igf-1 only, while the percentage of edu-positive β cells decreased in the cells treated with igf-1 and ra or in those transfected with plasmid rig-i (fig. 4b, p < 0.05). flow cytometric assays after pi labelling showed that the percentage of min6 cells increased in the g1 phase (fig. 4c, p < 0.05), but decreased in the s phase in response to ra treatment or rig-i plasmid transfection (fig. 4d, p < 0.05). to explore whether rig-i affects the proliferation of β cells, we used a small interfering rna, si-rig-i rna, to transfect min6 cells. the percentage of edu-positive cells increased in cells transfected by si-rig-i rna and treated with ra compared with cells transfected with a scrambled sirna (fig. 4e, p < 0.05). these results suggested that rig-i contributes to the inhibition of proliferation elicited by igf/src signalling in min6 cells.",pmc4923948,1,100,40,1,140
968,rig-i,protein,,ddx58,uniprot,o95786,cytoplasm,go:0005737,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,negative,d,competes,pxxp motif,,pancreatic beta cell,pancreas,human,['2598'],nan,nan,"in summary, rig-i is significantly activated by glucolipotoxicity and metaflammation, and is implicated in β cell mass loss through proliferation inhibition, leading to body decompensation in the course of t2dm. via its pxxp motif, elevated rig-i competes with stat3 for activated src and then blocks the src/stat3/skp2 pathway to accumulate p27 function in pancreatic β cells, leading to cell cycle arrest at the g1 phase. these data provide a new insight into the pathogenesis of t2dm and suggest rig-i as a novel drug target.",pmc4923948,1,100,40,1,140
967,rig-i,protein,,ddx58,uniprot,o95786,cytoplasm,go:0005737,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,positive,i,proliferation,,,pancreatic β cell,pancreas,human,['2592'],nan,nan,"before exploring the potential association between rig-i and src-induced proliferation in pancreatic β cells, we obtained insights into the effect of rig-i on β cell growth. previous reports suggested that rig-i mediated β cell lesions42; we showed that elevated rig-i decreased β cell viability and abrogated igf-stimulated proliferation through cycle arrest at the g1 phase. by contrast, knockdown of rig-i could alleviate ra-mediated proliferation inhibition (fig. 4). the results revealed that rig-i is involved in inhibition of β-cells proliferation elicited by igf-src signals.",pmc4923948,1,100,40,1,140
964,rhoa,protein,,rhod,uniprot,p61586,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,binds,rhoa d-site,,,,human,['1537'],nan,nan,"we showed above that the interaction between rhoa and erk is mediated by rhoa d-site (fig 1e). we next examined whether the phosphorylation status of rhoa affects its interaction with erk. by using gst pull down assays, we showed that all of the rhoa single mutants including gst-rhoa s88a, s88e, t100a, and t100e bind to erk similarly as wild type rhoa (fig 4a). however, the double rhoa mutants, including both the alanine mutant that are unable to be phosphorylated by erk (gst-rhoa s88a/t100a) and phosphomimetic rhoa mutant (gst-rhoa s88e/t100e), bind to erk at a much lower level than the wild type rhoa (fig 4a). these data indicated that rhoa and erk interaction is mediated mostly by rhoa d-site, but is also affected by the erk phosphorylation sites s88 and t100.",pmc4729484,1,100,40,1,140
899,pras40,protein,,aktip,uniprot,o95267,,,mtor,protein,,mtor,uniprot,p42345,,,negative,d,dissociation,,,,,,['461'],nan,nan,"following rapamycin treatment, pras40 dissociated from mtor (figure 1a). however, released pras40 remained bound to raptor which, as reported previously [41], is also released from mtor upon rapamycin treatment. furthermore, pras40 binding to mtor was strongly reduced when raptor was knocked down (figure 2a). these findings indicate that pras40 binds mtorc1 via raptor. we also observed that pras40 associated less well with a kinase dead version of mtor (figure 2b), suggesting that mtorc1-mediated phosphorylation of pras40 (see below) may affect the pras40- mtorc1 interaction. our findings are in agreement with recent pras40 studies showing that pras40 binds preferentially to raptor [38], and that the mtor kinase domain is also involved in pras40 binding [39].",pmc2075366,1,100,40,1,140
963,rhoa,protein,,rhoc,uniprot,p08134,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,,cos-7,fibroblast,kidney,human,['1539'],nan,nan,"(a) the effects of rhoa phosphorylation on its interaction with erk. cos-7 cells were serum starved and treated with egf (50 ng/ml) for 15 min. the cell lysates were incubated with gst-fused wild type and mutant rhoa proteins bound to glutathione-sepharose beads. erk pulldowns were analyzed by immunoblotting with antibodies to erk. gst fusion protein loading was verified by amido black staining of the nitrocellulose membrane. (b) the effects of rhoa phosphorylation on egf-induced erk phosphorylation. cos-7 cells were transfected with expression constructs encoding gfp-tagged wild type and mutant rhoa proteins and these proteins were overexpressed. after serum starvation, cells were stimulated with egf for 15 min. erk phosphorylation and activation was determined by immunoblotting cell lysates with antibodies to p-erk and p-elk1, respectively. the expression of gfp-rhoa wild type and mutant proteins was determined by immunoblotting with antibodies to gfp.",pmc4729484,1,100,40,1,140
962,rhoa,protein,,rhob,uniprot,p61586,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,mediated,erk docking site,,,,,['1525'],nan,nan,the direct interaction between rhoa and erk is mediated by the erk docking site in the c-terminus of rhoa,pmc4729484,1,100,40,1,140
961,rhoa,protein,,,uniprot,p61586,plasma membrane,go:0005886,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,positive,d,co-ip,,"cos-7, skbr-3",,breast cancer cells,human,['1528'],nan,nan,"we next examined whether endogenous rhoa and erk interact with each other and whether this association also exists in breast cancer cell lines. we examined the expression level of rhoa in cos-7 cells and various breast cancer cells including bt-20, mcf-7, mda-mb-453, and skbr-3 cells. as shown in fig 1c, rhoa was well expressed in all of these cells. except for mcf-7 cells, the expression level of rhoa was notably higher in the rest of the breast cancer cells than in cos-7 cells, with highest expression level in skbr-3 cells (fig 1c). the interaction between endogenous rhoa and erk was examined by co-ip experiments in cos-7 and skbr-3 cells (fig 1d). following the ip with antibodies to rhoa, the immunoprecipitates were immunoblotted with antibodies to erk. we showed that erk co-iped with endogenous rhoa with or without egf stimulation in both cos-7 and skbr-3 cells (fig 1d).",pmc4729484,1,100,40,1,140
960,rhoa,protein,,,uniprot,p61586,,,rac1,protein,,,uniprot,p63000,,,positive,i,regulate subcellular localization,,,,,,['1557'],nan,nan,"we also examined the relative importance of the pbr and erk-induced phosphorylation on the subcellular localization of rhoa and rac1. our data indicate that the pbr is the determining factor for the subcellular localization of both rhoa and rac1. rac1 pbr domain is able to target significant amount of rhoa to the nucleus regardless the phosphorylation status of rhoa (fig 9). on the other hand, rhoa pbr is able to significantly reduce the nuclear localization of rac1 regardless of the phosphorylation status of rac1 (fig 9). egf-induced nuclear translocation of rac1 is dependent on erk-induced rac1 t108 phosphorylation, as we have reportedly previously [21]. however, egf-induced nuclear translocation of rac1 also requires the presence of rac1 pbr, as egf fails to stimulate the nuclear translocation of gfp-rac1rhoa-pbr (fig 9). it has been shown that switching of the pbrs between rac1 and rhoa alters their nuclear accumulation [42].",pmc4729484,1,100,40,1,140
957,rhoa,protein,gtpase,rh,uniprot,p61586,cytoplasm,go:0005737,erk,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,"erk (88s, 100t)",,,,,['1538'],nan,nan,the effects of rhoa phosphorylation (88s and 100t) on rhoa interaction with erk and on egf-induced erk phosphorylation.,pmc4729484,1,100,40,1,140
956,rheb,protein,,rheb,uniprot,q15382,specific regions of living cells,,mtor,protein,,mtor,uniprot,p42345,specific regions of living cells,,positive,d,interaction,specific regions of living cells,,,,cell-by-cell basis,['3329'],nan,nan,"this study is the first to show a direct interaction between rheb and mtor in specific regions of living cells. although previous studies have suggested an interaction using pull-down approaches [11], the ability to be able to study localization and interaction on a (live) cell-by-cell basis is important when studying a signalling complex which may play differing roles simultaneously in different parts of the cell, as appears to be the case with the mtorc1 complex. the fret-flim approach offered two other advantages. it was able to show a direct interaction of both rheb and raptor with mtor, also different conformations of the interacting components could be distinguished by this technique, such information being unavailable using a pull-down assay approach.",pmc3549280,1,100,40,1,140
955,rheb,protein,,rheb,uniprot,q15382,"golgi, er","go:0005794, go:0005783",mtor,protein,,,uniprot,p42345,nucleolus,go:0005730,positive,d,interact,cellular nucleus,,,,not specified,['3330'],nan,nan,"both egfp- and dsred-tagged rheb appeared to locate in perinuclear regions in the golgi and er, with no difference in the expression levels in transfected cells. previous studies of gfp-tagged rheb have also shown such perinuclear accumulation [28-30]. the insensitive nature of confocal image acquisition (i.e., because of analogue signal thresholding) can make it difficult to set the threshold of standard confocal photomultiplier tubes without losing weaker signals. consequently, gain and background levels can lead to either signal loss or oversampling. the use of highly sensitive time-correlated single photon counting, such as tcspc, allows fluorescence photons to be detected above any background level as well as the ability to quantify the number of photons detected. thus, in this current study using tcspc, we report persistent and observable egfp-rheb presence within both cytoplasmic and also the sub-cellular nuclear regions, although the signal from the nucleus is somewhat weak and it may possibly be due to the fact that it is over-expressed. however, regarding a nuclear rheb presence it is important to note (i) it has been suggested that mtor shuttles between the nuclear region and cytoplasm [25-27], and (ii) that mtorc1 plays a key role in ribosome biogenesis, a process which occurs in the nucleolus [1]. the presence of rheb within the cellular nucleus suggests it might interact with mtor in that compartment. although the role for rheb within the cell nucleus is unclear and whether it simply resides there or can indeed shuttle in and out is not known, however, it is likely to have a role in directing mtor localization and therefore downstream signalling within the nucleus. the interaction between rheb and mtor observed is unlikely to be due to mis-localization since randomly distributed protein molecules will be sufficiently far apart (>>10 nm) to limit direct stable interaction.",pmc3549280,1,100,40,1,140
954,rheb,protein,,,uniprot,q15382,endomembrane,go:0012505,mtor,protein,,mtor,uniprot,p42345,,,positive,d,activation,c-terminal caax motif,,,,,['3333'],nan,nan,"rheb undergoes post-translational lipid modification by farnesylation at its c-terminal caax motif. farnesylation is important for rheb localization to endomembrane and activation of the mtor pathway. thus, to avoid any changes at the c-terminus of rheb, egfp and dsred were located at the n-terminus of rheb. in our current studies, the rather large and difficult mtor has been successfully tagged with egfp at either terminus and discussed below.",pmc3549280,1,100,40,1,140
950,rb,gene,tumor suppressor,rb1,uniprot,p06400,nucleus,go:0005634,e2f1,protein,transcription factor,e2f1,uniprot,o75330,nucleus,go:0005634,positive,d,release,,,cancer cells,gastric cancer,human,['329'],nan,nan,"the rb tumor suppressor gene is inactivated in many cancers, including gastric cancer.30, 31 rb affects tumor progression by regulating the cell cycle, differentiation, and apoptosis. these functions are mediated by the interaction of rb with other cellular proteins, especially the e2f transcription factors.27, 32 when galectin-3 hyperphosphorylates rb through the cyclin d1/cdk4 complex, e2f1 is released from rb and initiates its transcriptional functions. the direct interaction of galectin-3 with e2f1, a transcription factor of skp2,15 is not supported by our data. a direct interaction between rb and galectin-3 activated e2f1 to generate skp2.",pmc4211374,1,100,40,1,140
995,shp2,protein,,ptpn11,uniprot,q06124,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,i,inhibition,,,,,,['2692'],nan,nan,"at the same time, the model predicts that the influence of shp2 activity inhibition on erk phosphorylation will be pronounced after 5 or more minutes following the onset of stimulation (supplementary figure s13d), whereas the experimental data show that this effect is already substantial at 1.5 min after stimulation (supplementary figure s13b). this shows the limitations of the minimal model, which should be improved in the future studies.",pmc2683723,1,100,40,1,140
1012,snail1,protein,,snai1,uniprot,o95863,nucleus,go:0005634,erk2,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,i,increase,,,epithelial,,human,['995'],nan,nan,"existence of feed-back loops has been described previously, and they seem to be particularly relevant in cell pathways implicated in embryo development (31). this mechanism provides the possibility of buffering, allowing corrections of the cell system when it is perturbed. in the case of snail1, it is also possible that this negative feed-back loop may contribute to the oscillatory pattern of expression of this gene during somitogenesis that has been recently described (32). our rna interference experiments also indicate that the existence of this self-repression is significant for controlling snail1 expression in epithelial cells, avoiding that transient increases in erk2 and pi3k induce a sustained activation of snail1 protein and the subsequent phenotypic changes. therefore, this loop would be responsible for controlling the stability of snail1 expression.",pmc1440880,1,100,40,1,140
1078,tfeb,protein,,,uniprot,o14974,nucleus,go:0005634,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,positive,i,regulation,,hela and mcf7,epithelial-like,cervix and breast,human,['2847'],nan,nan,"abnormalities in autophagic processes can lead to neurodegenerative diseases and cancer [10]. moreover, recent studies have identified tfeb and other family members as key players for metabolic reprogramming in pancreatic cancer [11, 12]. thus, tfeb presents an attractive target for manipulating the cellular autophagic capacity in disease treatment. to date, studies on tfeb have primarily focused on the role of mtor-mediated regulation of nuclear-cytoplasmic tfeb shuttling. intriguingly, transcription of tfeb-controlled autophagosomal and lysosomal genes is increased in cells overexpressing tfeb [1, 2, 6] and overall cellular tfeb protein levels are reduced following tfeb activation via long-term (15 hours) chloroquine-induced lysosomal stress [7], suggesting tfeb concentration changes may contribute to the regulation of tfeb signaling. however, the relationship between mtor activity states and temporal changes in tfeb subcellular localization and concentration has not been elucidated. to that end, we performed time course analysis over 15 hours of tfeb levels and localization by quantitative western blotting and imaging cytometry. we activated mtor by fresh addition of fully-supplemented medium (fm), or inhibited mtor by torin1 treatment [13] or nutrient deprivation [14]. we report that overall cellular tfeb levels transiently decrease in response to small increases in mtor activation, and transiently increase in response to mtor inhibition. both western blot and population-averaged imaging results displayed high variability, suggesting that heterogeneous tfeb responses within the cell population may cache important information on these complex dynamics. we therefore analyzed single-cell imaging cytometry data using spanning-tree progression analysis of density-normalized events (spade) agglomerative clustering [15], as a basis for unbiased and quantitative detection of spatial and temporal dynamics of subpopulations. using unsupervised clustering, we identified three tfeb phenotype subpopulations, with low, medium and high nuclear tfeb concentrations. we found that total cellular tfeb levels and subcellular localization are directly under control of a short-term rheostat controlled by mtor. mtor inhibition rapidly activates tfeb in a fraction of cells, for a limited duration, with distinct tfeb subpopulation re-inactivation dynamics in response to torin1 vs. nutrient deprivation. moreover, time course subpopulation analysis identified a correlation between tfeb protein levels and nuclear localization, and revealed differences between hela and mcf7 cells in the sensitivity of tfeb to mtor regulation. finally, subpopulation analysis revealed that in response to mtor inhibition, maximal nuclear localization of tfeb is negatively regulated by the proteasome, independently of tfeb concentration.",pmc4896000,1,100,40,1,140
1083,tfeb,protein,transcription factor,tfeb,uniprot,q6uuv9,nucleus,go:0005634,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,response to modulation,,,,,human,['2853'],nan,nan,mean population time course quantification of tfeb response to modulations in mtor activity by multispectral imaging cytometry,pmc4896000,1,100,40,1,140
1155,β-enac,protein,,scnn1b,uniprot,p51168,plasma membrane,go:0005886,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,putative erk phosphorylation site,,renal,kidney,,['1799'],nan,nan,point mutation of the py motif and the putative erk phosphorylation site in β-enac,pmc2151644,1,100,40,1,140
1143,β-catenin,protein,,ctnnb1,uniprot,p35222,cell membrane,go:0005886,c-myc,protein,,myc,uniprot,p01106,,,positive,d,recognize,,,,,,['2933'],nan,nan,"the antibodies against β-catenin, c-myc, phosphorylated c-jun (serine-63), anti-ha, fra1 and total erk1/2 were from santa cruz biotechnologies (santa cruz, ca, usa). antibodies recognizing phosphorylated erk1/2, lrp6 (serine-1490) and β-catenin (serine-552) as well as total lrp6 and tcf4 were obtained from cell signalling (danvers, ma, usa). antibodies against e-cadherin and β-catenin were from bd pharmingen (mississauga, on, usa). antibodies recognizing β-actin, phosphorylated lrp6 (threonine-1572) and β-catenin (tyrosine-142) were purchased from millipore (billerica, ma, usa). antibodies recognizing phosphorylated β-catenin (tyrosines-86 and -654) were purchased from abcam (toronto, on, canada). the mek inhibitor u0126 was purchased from lc laboratories (woburn, ma, usa) and icg-001 was purchased from abmole biosciences (kowloon, hong kong, china). dkk-1 was purchased from r&d systems (minneapolis, mn, usa). lgk974 was purchased from adooq bioscience (irvine, ca, usa). the specific erk inhibitor sch7729846 and mek inhibitor pd184352 were provided by pfizer inc. (groton, ct, usa). for immunofluorescence, goat anti-rabbit alexafluoro488 fluorescein isothiocyanate-labeled or goat anti-mouse alexafluoro568-labeled secondary antibodies were from molecular probes (life technologies, grand island, ny, usa). horseradish peroxidase antibodies were purchased from amersham biosciences (pittsburg, pa, usa), whereas alkaline phosphatase-conjugated antibodies were purchased from promega (madison, wi, usa).",pmc4687460,1,100,40,1,140
1142,α2-adrenergic receptor,protein,receptor,adra2c,uniprot,p18825,plasma membrane,go:0005886,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,transactivation,y845,,astrocyte,mature brain,human,['1408'],nan,nan,"in her2-overexpressing breast cancer cells, sk-br-3, endothelin-induced transactivation of egfr via phosphorylation of y845 has been demonstrated, and dual targeting of the endothelin and egfr systems, using atrasentan and trastuzumab, respectively, was shown to be effective in reducing cell proliferation and invasion [110]. in sk-br-3 cells, it was also shown that macrophage inhibitory cytokine-1, a member of the tgf superfamily, transactivates egfr and induces y845 phosphorylation via src activation [111]. transactivation of egfr by β2-adrenergic receptor signaling requires the phosphorylation of y845 by src to exert the full range of egfr activation that is comparable to egf-induced egfr activation. in this particular case of transactivation, the priming of the egfr activity via either the ligand stimulation or the overexpression of the receptor protein is also necessary [112]. isoproterenol-induced transactivation of egfr in astrocytes was also shown to involve src-dependent y845 phosphorylation; in this case, nanomolar concentrations, but not micromolar concentrations, of isoproterenol activation of β2-adrenergic receptor signaling are the trigger for this functional interaction, the astrocytic consequences of which are morphological differentiation and an increase in glial fibrillary acidic protein [113]. transactivation of egfr by α2-adrenergic receptor signaling in astrocytes in mature brain also involves y845 phosphorylation [114].",pmc3709701,1,100,40,1,140
1140,yes,protein,src family ptk,,uniprot,p07947,cytoplasm,go:0005737,egfr,protein,receptor,egfr,uniprot,p00533,cell membrane,go:0005886,positive,d,phosphorylation,y845,,hepatocyte,liver,human,['1418'],nan,nan,"there are some reported examples of the pro-apoptotic function of egfr y845 phosphorylation. reinehr et al. [150] described that, in hydrophobic bile salt-induced apoptosis of hepatocytes, yes, a src family ptk, associates with and phosphorylates egfr on y845, and contributes to activation of the cd95/fas/apo-1-dependent death pathway. in this system, the association of yes with egfr can be prevented by the inhibition of camp-dependent protein kinase/protein kinase a (pka), suggesting that the camp-pka pathway acts as anti-apoptotic machinery. further characterization of this hepatocyte apoptosis system has revealed that death ligand (e.g., cd95 ligand)-induced apoptosis involves the production of ros, a direct activator of yes, by a signaling pathway that includes sphingomyelinase, ceramide, pkcζ, and p47phox[151]. in primary hepatocytes, prothrombin induces apoptotic cell death that is accompanied by the prothrombin-dependent degradation of integrin α5. in this system, it has been shown that prothrombin promotes the interaction between integrin α5 and egfr, which in turn leads to tyrosine phosphorylation of both proteins including y845 phosphorylation, and activation of c-jun n-terminal kinase that is thought to be directly involved in the thrombin-induced apoptosis of hepatocytes [152].",pmc3709701,1,100,40,1,140
1135,wip1,protein,,ppm1d,uniprot,p78560,nucleus,go:0005634,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,positive,i,required for activation,,u2os,bone,,human,['1161'],nan,nan,"wip1 has many substrates, all involved in the regulation of apoptosis in response to dna damage or cellular stresses. to determine whether chk2 is required for the activation of caspase that occurs when smrt is down-regulated, we co-transfected u2os cells with sirnas for smrt and chk2. indeed, co-transfection with chk2 sirna attenuated the caspase activation caused by smrt knock-down, after treatment with doxorubicin (figure 4d, compare lanes 6 and 2).",pmc3656868,1,100,40,1,140
1133,wip1,protein,,ppm1d,uniprot,o15297,nucleus,go:0005634,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,positive,d,binding,nucleus,"mcf7, a549, hct15",epithelial,"breast, lung, colon",human,['1674'],nan,nan,"wip1 and chk2 were found to bind in the nucleus and binding was dependent upon the chk2 sq/tq domain, kinase activity, and nuclear localization signal and the wip1 n-terminal domain [128,129]. endogenous wip1 and chk2 could bind in mcf7 cells, which have a higher expression level of wip1 and in a549 cells [128,129]. using gst-wip1 in a gst pull down assay with lysates of hct15 cells stably expressing ha-chk2, wip1 was seen to bind to chk2 only after ir, suggesting that chk2 phosphorylation is important for the interaction [130]. in vitro, wip1 could dephosphorylate chk2 at multiple sites including t68 and this significantly reduced chk2 kinase activity [129,130]. overexpression of wip1 inhibited chk2 kinase activity in vitro, and in vivo, decreased t68 phosphorylation, caused a delay in chk2 activation following ir, and caused a delay in g2/m arrest [129,130]. knockdown of wip1 resulted in sustained chk2 t68 phosphorylation and kinase activity following ir, as well as an increase in apoptosis [129]. in the acute promyelocytic leukemia cell line nb4, arsenic trioxide could induce chk2 t68 phosphorylation through the inhibition of wip1 [131]. finally, in stomach adenocarcinoma tumors, high wip1 expression correlated with low chk2 phosphorylation [132].",pmc2954851,1,100,40,1,140
1132,wip1,protein,,,uniprot,p31946,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,dephosphorylation,s15,,fibroblast,,mouse,['1677'],nan,nan,"importantly, wip1 was induced in response to ir in a p53-dependent manner as a part of a negative feedback mechanism [140,141]. wip1-/- mefs exhibited a slight increase in p53 phosphorylation at s15 and an increase in the levels of p53 target p21 [140]. in an in vitro assay, wip1 could dephosphorylate p53 on s15 but not s46 [106]. after ir, wip1-/- mefs had an increase in protein levels and s15 phosphorylation whereas knockdown of wip1 with sirna resulted in increased p53 protein levels and s15 phosphorylation. in this system, wip1 did not have an effect on atm or atr after ir or uv, respectively, therefore the effect on p53 seems to be direct [106].",pmc2954851,1,100,40,1,140
1131,wip1,protein,,,uniprot,o15294,,,chk2,protein,,chek2,uniprot,o96017,,,positive,i,feedback,chk2 activation,u2os,osteosarcoma,,human,['1162'],nan,nan,"because the wip1-dependent feedback has been reported to cause oscillatory behavior in chk2 activation [24], [59], and because in genetic oscillators the intensity of the feedback loop dictates the oscillatory behavior of the system [60]–[62], we sought to examine the possibility that the smrt-dependent repression of wip1 might be responsible for influencing the dynamics of chk2 activation after dna damage. u2os cells were treated with doxorubicin at 10′ intervals for 2 hours, comparing cells transfected with scramble sirna or sirna against smrt. in control conditions, an oscillatory pattern of chk2 phosphorylation was observed, with two discrete peaks at 40′ and 80′. sirna against smrt altered this pattern, resulting in only one, more persistent phospho-chk2 peak (figure 4e). interestingly, when the cells transfected with the smrt sirna were also treated with a wip1 inhibitor, the single peak of chk2 activation (figure 4f, upper panel) was replaced by two peaks of activation after doxorubicin treatment, one at 40′–50′ and one at 70′ (figure 4f, lower panel). even if the peaks are not perfectly overlapping with the original oscillation observed in the wild type cells, this result suggests that the lack of inhibition of wip1 might play a role in the altered dynamics observed in the smrt knock-down.",pmc3656868,1,100,40,1,140
1129,wdr62,protein,scaffold,,uniprot,q6nsg0,,,jnk,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,positive,d,potentiate,,hek-293t,epithelial-like,kidney,human,['3216'],nan,nan,"the fact that wdr62 may play a role as a scaffold protein for the jnk tier prompted us to examine the ability of wdr62 to potentiate jnk kinase activity in the absence of a signal. myc-wdr62 was cotransfected into hek-293t cells at increasing amounts together with constant levels of either ha-jnk1 or ha-jnk2. cotransfection of either vehicle control or gfp was used as control for the basal jnk activity. the ha-jnks were precipitated with anti-ha antibodies, and the kinase activity was determined using bacterially purified gst-cjun (1-79) using in vitro kinase assay (katz et al., 2001). both ha-jnk1 and ha-jnk2 kinase activity measured in the presence of myc-wdr62 was augmented with the increasing amounts of wdr62 used in the transfection (figure 5, a and b). no change in jnk kinase activity was observed with the gfp control lysate.",pmc2801705,1,100,40,1,140
1128,wdr62,protein,,wdr62,uniprot,o43379,cytoplasm,go:0005737,jnk,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,positive,d,coimmunoprecipitation,,hek-293t,epithelial-like,kidney,human,['3214'],nan,nan,"to examine the physical association between wdr62 and jnk, we used coimmunoprecipitation of cell lysate derived from transiently transfected hek-293t cells. expression plasmid encoding hemagglutinin (ha) epitope–tagged jnk2, was used in combination with an expression plasmid encoding the myc epitope–tagged wdr62 fragment corresponding to jbp5 (c-terminal 505 amino acids). western blot analysis with total cell lysate derived from the transfected cells revealed high level of expression of the tagged-proteins encoded by the corresponding transfected plasmids (figure 4a). coimmunoprecipitation of cell lysate was performed with anti-ha mab (12ca5) followed by extensive washes. eluted proteins were resolved by sds-page, followed by western blotting and probed sequentially with anti-ha and anti-myc monoclonal antibodies. control transfected cell lysates lacking either myc-jbp5 or ha-jnk2 failed to detect any cross-reactive protein with the anti-myc antibodies (figure 4a, left panel, lanes 5, 6, and 8). in contrast, myc-jbp5 was efficiently precipitated by the anti-ha antibody only in the presence of ha-jnk2 (figure 4a, left panel, lane 7). conversely, coimmunoprecipitation with anti-myc antibody was able to detect ha-jnk2 only in cell lysate derived from cells transfected with plasmids encoding both ha-jnk2 and myc-jbp5 (figure 4a, right panel, lane 3).",pmc2801705,1,100,40,1,140
1119,uvrag,protein,,uvrag,uniprot,q9p2y5,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,i,phosphorylation,s550,,,,human,['2547'],nan,nan,"we were also able to detect s550 phosphorylation on endogenous uvrag in cell lysates (fig4f). satisfyingly, the phospho-s550 kinetics closely matched the uvrag band shift as well as that of the known mtor substrates 4e-bp1 and p70s6k, showing that uvrag behaves as a conventional mtor substrate.",pmc4585463,1,100,40,1,140
1118,uvrag,protein,,uvrag,uniprot,q9p2y5,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,inhibition,"s550, s571",stable cell line,unknown,unknown,unknown,['2546'],nan,nan,"to confirm that uvrag is phosphorylated at s550 and s571 in cells, we generated phospho-specific antibodies to these sites. ip of stably expressed gfp-uvrag from cells under control conditions produced immunoreactivity with both the phospho-specific s550 and the phospho-specific s571 antibodies. importantly, this signal was lost when cells were incubated with ebss to inhibit mtor activity (fig4e). as a control, cells expressing gfp-uvrag dbla at a similar level to wt gfp-uvrag failed to produce any reactivity with the phospho-specific antibodies under any condition. importantly, wt gfp-uvrag displayed the same electrophoretic mobility shift as endogenous uvrag upon mtor inhibition while the dbla mutant did not, indicating that the uvrag band shift represents dephosphorylation at the s550 and s571 residues.",pmc4585463,1,100,40,1,140
1116,twist1,protein,,twist1,uniprot,q15672,nucleus,go:0005634,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,i,inhibition,ampk-activated,,nsclc,lung,human,['1474'],nan,nan,silencing of twist1 sensitizes nsclc cells to cisplatin via ampk-activated mtor inhibition,pmc3388235,1,100,40,1,140
1115,twist1,protein,,twist1,uniprot,q15672,nucleus,go:0005634,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,knockdown,,,,,,['1484'],nan,nan,"knockdown of twist1 leads to inhibition of mtor activity, which has an important role in mcl-1 downregulation",pmc3388235,1,100,40,1,140
1114,twist1,protein,,twist1,uniprot,q15672,nucleus,go:0005634,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,activation,amp-activated protein kinase (ampk),,,,,['1485'],nan,nan,knockdown of twist1 leads to inhibition of mtor activity through amp-activated protein kinase (ampk) activation,pmc3388235,1,100,40,1,140
1112,twist1,protein,,,uniprot,q15672,,,mtor,protein,,,uniprot,p42345,,,negative,d,phosphorylation,,,lung cancer,,,['1490'],nan,nan,"in this regard, we determined whether mtor and its downstream factors are involved in sensitization to cisplatin induced by twist1 knockdown. unexpectedly, knockdown of twist1 led to reduced phosphorylation levels of mtor and s6k1, an mtor downstream effecter. downregulation of mtor and s6k1 with sirna sensitized cells to cisplatin, consistent with the previous finding that transfection of cisplatin-resistant lung cancer cells with sirna directed against mtor restores sensitivity.25 importantly, we showed that knockdown of mtor or s6k1 downregulates the mcl-1 protein level, which is increased in cisplatin-resistant cells.26 these results indicate that mcl-1 is a downstream target of mtor and s6k1. furthermore, mcl-1 may be regulated at the translational level, because the main function of mtor is to control translation via direct regulation of s6k1 and 4e-bp. this assumption is supported by several lines of evidence showing that mcl-1 is a potential downstream target of eif4e that specifically contains a g+c-rich (>70%) 5′ untranslated region among the antiapoptotic bcl-2 members.19, 27, 28 in addition, inhibition of mtor with rapamycin blocked mcl-1 protein synthesis, but not that of bcl-2 or bcl-xl.19",pmc3388235,1,100,40,1,140
1094,trf1,protein,,terf1,uniprot,q15554,nucleus,go:0005634,p21,protein,,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,d,unknown,g1-g2,,,,mouse,['558'],nan,nan,"trf1−/− mice (fig. 2c,d). of note, p53/p21 levels were still significantly higher in g1-g2 chk2−/−",pmc4331747,1,100,40,1,140
1088,thrombospondin-1 (tsp-1),protein,anti-angiogenic factor,thbs1,uniprot,p07996,extracellular space,go:0005615,myc,protein,transcription factor,myc,uniprot,p01106,nucleus,go:0005634,positive,d,phosphorylation,,,"mammary epithelial cells, kidney cells","mammary tissue, kidney tissue",human,['3608'],nan,nan,"tumor angiogenesis is postulated to be regulated by the balance between pro- and anti-angiogenic factors. it was demonstrated that the critical step in establishing the angiogenic capability of human cells is the repression of the critical anti-angiogenic factor, thrombospondin-1 (tsp-1) [263]. this repression is essential for tumor formation by mammary epithelial cells and kidney cells engineered to express sv40 early region proteins, htert, and h-rasv12. it was demonstrated that ras induces the sequential activation of pi3k, rho, and rock, leading to activation of myc through phosphorylation [263]. phosphorylation of myc via this mechanism enables it to repress tsp-1 expression [263]. thus a novel mechanism by which the cooperative activity of the oncogenes, ras and myc, leads directly to angiogenesis and tumor formation was described [263].",pmc2652403,1,100,40,1,140
1085,tgf-β,growthfactor,multifunctional,,uniprot,p01137,extracellular,,rb,protein,,rb1,uniprot,p06400,nucleus,go:0005634,positive,d,phosphorylation,serine 780,arpe-19,retinal pigment epithelial,eye,human,['1759'],nan,nan,"tgf-β is a multifunctional growth factor that regulates cell fate, including emt and apoptosis. we previously reported that tgf-β1 induces cytoskeletal actin rearrangement in human rpe cells via rho gtpase-dependent pathways that modulate the activities of lim kinase and cofilin.13 we also showed that tgf-β1 strongly induces the smad3 pathway, and that rhoa is not required downstream for tgf-β1-induced smad3 activation but acts as downstream of smad3 via net1.23 in the present study, we report that tgf-β1 signaling upregulates survivin to inhibit apoptosis during emt. tgf-β1 led to both emt and cell cycle progression, but not apoptosis, in arpe-19 cells (figures1 and 2). treatment of arpe-19 cells with tgf-β1 increased the level of hyperphosphorylated rb, which indicates that rb was inactivated following tgf-β1 treatment (figure 2c). moreover, the level of rb phosphorylated at serine 780 and the level of cyclin d1 were increased following tgf-β1 treatment (figure 2c). cyclin d is the first cyclin produced during the cell cycle in response to extracellular signals. cyclin d binds to cdk4, forming the active cyclin d–cdk4 complex, the cyclin d–cdk4 complex phosphorylates and inactivates the rb. hyperphosphorylated rb dissociates from the e2f/dp1/rb complex, leading to e2f activation. the activation of e2f results in the transcription of various genes, including cyclin e, cyclin a, dna polymerase, and thymidine kinase. rb is at least partly phosphorylated by cdk2. for cdk2 to be activated, it must bind a cyclin. cyclin e binds cdk2, forming the cyclin e–cdk2 complex, which then promotes progression from g1 to s phase. in this study, we showed that tgf-β1 increased the active form of cdk2 and the level of cdc25a (figure 2c). cdc25 phosphatases promote cell cycle progression by dephosphorylating and activating cdks. as a result, we prove that tgf-β1 induces cell cycle progression by regulating the activity and expression of several cell cycle regulators in this study.",pmc3730417,1,100,40,1,140
922,pyk2,protein,,,uniprot,q14289,tumors,,c-myc,protein,,myc,uniprot,p01106,nucleus,go:0005634,positive,d,phosphorylation,gsk3,,,tumors,mouse,['2756'],nan,nan,"a prior study (carothers et al., 2006) and our new data (figure 5c, right panel) showed that drastic elevation of pyk2 occurred in tumors in apcmin/+ mice, indicating that pyk2 is upregulated during the process of intestinal tumorigenesis. fak induction, although further enhanced in tumors, however, is triggered by apc mutation – the initiating event for tumorigenesis in the apc-mutant mice, through activated wnt pathway target c-myc (ashton et al., 2010). therefore fak induction by apc mutation should occur earlier than pyk2 elevation. if so, it explains why inhibition of fak by intestinal deletion of fak was sufficient to suppress tumor development. it also explains why pf562271 treatment inhibited pyk2 elevation in apcmin/+ mice (figure 5c, left panel). by phosphorylating gsk3 to promote the wnt pathway, elevated pyk2 in tumors further enhances wnt-dependent tumorigenesis – a positive feedback loop that reinforces the tumor development process (as suggested in carothers et al., 2006). in the revised manuscript, corresponding changes have been made to the discussion.",pmc4558782,1,100,40,1,140
891,pparγ,protein,,pparg,uniprot,p37231,nucleus,go:0005634,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,negative,i,inhibition,,h2106 nsclc,epithelial-like,lung,human,['2265'],nan,nan,"h2106 nsclc cells (104 cells/well) were cultured with the selective pparγ antagonist gw9662 (20 μm) for 1 hour, or transfected with tsc2 sirna (100 nm) for 48 hours before exposing the cells to rosiglitazone (10 μm) followed by incubation with 1 μci/ml [methyl-3h] thymidine (amersham, specific activity 250 ci/mmol) for up to 48 hours. the medium was removed and the attached cells were washed with 1x pbs. afterwards, the attached cells were treated with ice-cold 6% trichloroacetic acid (tca) at 4°c for 20 minutes and washed once with 6% tca. the cells were then solubilized with 0.1 n naoh and counted in a liquid scintillation counter in 4 ml of scintillation fluid.",pmc1892639,1,100,40,1,140
565,gsk3,proteinkinase,,,uniprot,p49841,cytoplasm,go:0005737,htert,protein,,tert,uniprot,o14727,nucleus,go:0005634,negative,d,inhibition,promoter,a2780,epithelial,ovary,human,['2299'],nan,nan,"in a focused screen of 79 well characterised kinase inhibitors, a2780 cells were transfected with htert reporter construct and 32 h post transfection were exposed to 10 µm each inhibitor for 16 h. six compounds suppressed promoter activity by at least 2-fold (figure 1a). compounds 38 (ro-31-8220, bis indole maleimide family; 4.6-fold), 69 (indirubin-3′-monoxime, indirubin core; 2.2-fold) and 79 (kenpaullone, indolo benazepinone core; 11.1-fold) are all reported to inhibit gsk3 [10]. the other hit compounds were: 26, tyrphostin ag 1295 (inhibitor of pdgfr [11]); 50, 5-iodotubercidin (inhibitor of adenosine kinase [12]); and 55, su4312 (inhibitor of pdgfr and fgfr [13]).",pmc2714081,1,100,40,1,140
594,insulin,hormone,,ins,uniprot,p01308,extracellular,go:0005576,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,phosphorylation,,l6 myotubes,muscle,muscle,human,['919'],nan,nan,lysates from l6 myotubes treated with kinase inhibitors and stimulated with insulin were analyzed by western blotting. quantitation of pakt and ptsc2 relative to the insulin control (lane 2) is show below these blots.,pmc2637922,1,100,40,1,140
770,npm,protein,,npm1,uniprot,p06748,,,p53mut,protein,p53 mutant,tp53,uniprot,p04629,,,positive,d,regulates,,,,,,['381'],nan,nan,"in order to confirm that npm oligomerisation was regulating p53mut stability we reasoned that direct perturbation of npm oligomers should therefore regulate p53mut stability in an analogous manner to phosphorylation by akt. nsc348884 is a compound that directly prevents formation of npm oligomers [60] and treatment with this compound abrogated the effects of akt inhibition or sirna mediated knockdown of akt on p53mut levels (fig. 5d and 5e). moreover, the stability of p53 was reduced by siarf and promoted by the mdm2 inhibitor nutlin3a independently of nsc34884 (fig. 5e). conversely, npm−/−:p53−/− mefs transfected with npm-wt and p53r248h display increased stability of p53 upon expression myr-akt1 (fig. s5d). on the other hand, basal p53r248h levels appear more stable in the context of npm-s48a, and importantly are not sensitive to myr-akt (fig. s5d). these findings suggest that disruption of npm quaternary structure is sufficient to stabilize p53mut and functions upstream of both arf and mdm2.",pmc4171619,1,100,40,1,140
767,notch,protein,,notch1,uniprot,p46531,membrane,go:0016020,pi3k,protein,,pik3r1,uniprot,p27986,cytoplasm,go:0005737,positive,d,signalling,,,t cell,,human,['2793'],nan,nan,reciprocal signalling between the notch and pi3k pathways in t cells,pmc1403772,1,100,40,1,140
766,notch,protein,,,uniprot,p46531,plasma membrane,go:0005886,pi3k,protein,,,uniprot,p42336,cytoplasm,go:0005737,positive,d,potentiation,,,ontologically-distinct,stem cell,,['2798'],nan,nan,"our data demonstrates that the potentiation of notch signalling by pi3k is conserved in ontologically-distinct cell types, leading us to suggest that it represents a general mechanism of signal integration linking two evolutionarily-conserved pathways together. this apparently simple observation has far-reaching implications regarding the mechanisms by which stem cell self-renewal and differentiation proceeds. it will be interesting to assess the relevance of this finding in other signalling contexts, such as tumour formation, where notch and pi3k have important roles.",pmc1403772,1,100,40,1,140
762,na/k-atpase,protein,,atp1a1,uniprot,p05023,plasma membrane,go:0005886,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,positive,d,interaction,,llc-pk1,epithelial-like,kidney,unspecified,['2052'],nan,nan,"na/k-atpase is a ubiquitously expressed membrane protein that transports na+ and k+ ions in and out of the cells at the expense of atp hydrolysis. it contains two major subunits–a α subunit which is responsible for transporting ions and a β subunit which is responsible for targeting of the protein to the plasma membrane [12, 13]. we have previously reported the discovery of a na/k-atpase/src receptor complex that could allow cardiotonic steroids such as ouabain to activate protein kinase cascades such as the ras/raf/erk [14, 15]. we have further demonstrated a direct interaction between the n domain of α1 subunit of na/k-atpase and src kinase domain [16, 17]. in accordance, we have mapped the src kinase domain binding motif in the α1 n domain and developed a 20 amino acid residue peptide called pnaktide that specifically inhibits na/k-atpase-associated src signaling [18]. our in vitro gst-pull down assay also revealed a potential interaction between the second cytosolic domain (cd2) of α1 subunit of na/k-atpase and src sh2 domain [14, 16]. as the first step to study this interaction in live cells, we made an yfp-cd2 expression vector based on our in vitro gst-pull down assay data [14], transfected it into llc-pk1 cells, and generated several stable cell lines. this allowed us to look at the possible functional interaction between cd2 and src in live cells without the interference from the interaction between src kinase domain and α1 n domain [18, 19]. the new findings are consistent with the notion that cd2 could interact with src directly and affects src-mediated signal transduction like a sh2 ligand.",pmc4638348,1,100,40,1,140
760,myosin ii atpase,protein,atpase,myh9,uniprot,p35579,cytoplasm,go:0005737,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,i,regulating,,,mesenchymal stem cells,,human,['1900'],nan,nan,"next we determined the effects of gradually inhibiting myosin ii atpase activity. immunofluorescence analysis showed that following exposure to 5 μm of blebbistatin, mscs became more flattened and rounded in shape (supporting information fig. s3a, s3b). immunoblot analysis demonstrated that exposure to 5 μm of blebbistatin increased oct4 and nanog expression and increased the level of stat3 (y705) (supporting information fig. s3c). thus myosin atpase ii activity may play an important role in regulating nanog expression.",pmc3537888,1,100,40,1,140
671,mtor,kinase,,,uniprot,p42345,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,i,phosphorylation,hydrophobic motif,,,,human,['929'],nan,nan,"we have shown through the use of these inhibitors that the inhibition of mtor kinase activity is sufficient to prevent the phosphorylation of akt at s473, providing further evidence that mtorc2 is the kinase responsible for akt hydrophobic motif phosphorylation upon insulin stimulation. we also find that phosphorylation at t308 is linked to phosphorylation at s473, as had been observed in experiments where mtorc2 was disabled by rnai and long-term rapamycin, but not homologous recombination. surprisingly however, inhibition of mtorc2 does not result in a complete block of akt signaling, as t308p is partially maintained and akt substrate phosphorylation is only modestly affected when s473 is not phosphorylated.",pmc2637922,1,100,40,1,140
668,mig6,protein,,,uniprot,q9haz2,cytoplasm,go:0005737,erk1/2,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,i,depletion,,"wm1366, wm1346, wm1361a",melanoma,skin,human,['159'],nan,nan,"conversely, depletion of mig6 in wm1366 cells led to an increase in egf-induced phosphorylation of egfr, akt and erk1/2 that was most evident 30 to 120 min following stimulation (figure 3c–d). mig6 depletion also slightly increased baseline erk1/2 phosphorylation. mig6 depletion in wm1346 and wm1361a cells enhanced egf-stimulation of egfr and erk1/2 phosphorylation but this effect did not transmit into increased levels of phospho-akt (figure s3c–f). despite the effects on egfr signaling, the addition of egf did not modulate growth inhibition or apoptosis induced by trametinib (figure 3e–f). together, these data show that mig6 levels negatively regulate egf-induced egfr phosphorylation and downstream signaling in mutant nras melanoma.",pmc4789776,1,100,40,1,140
642,mdc1,protein,,,uniprot,q14676,nucleus,go:0005634,chk1,protein,,chek1,uniprot,o14757,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['1650'],nan,nan,"mdc1 is phosphorylated in an atm- and chk2-dependent manner, and its brct domain directly recognizes the phosphoserine 139 in the carboxy end of γ-h2ax (table 1) [42,56]. recruitment of mdc1 to γ-h2ax foci is required for the formation of mrn, brca1, and 53bp1 foci [39,42,57]. thus, mdc1 functions as a molecular scaffold to mediate parts of the ddr downstream of foci formation [58]. claspin is a major regulator of the activity of chk1 and binds dna with high affinity. after dna damage or replication stress claspin is phosphorylated by chk1, an event that is required for a claspin-chk1 interaction and subsequent full activation of chk1 by atr, in another example of the network nature of the ddr [59-63].",pmc2954851,1,100,40,1,140
631,lc3-і /ii,protein,,,uniprot,o94817,cytosol,go:0005829,p-akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,mouse,['1834'],nan,nan,"platycodin-d (pd) (mw: 1224.58, hplc ≥ 98%) was purchased from shanghai yuanye biotechnology co. ltd. (shanghai, china). the chemicals used were rapamycin, ly294002, u0126, sp600125 and sb203580 (cell signaling technology, usa), insulin, gimesa (sigma, usa), trizol reagent (invitrogen, usa), real-time pcr master mix (toyobo, japan). mouse- or rabbit-polyclonal antibodies specific for lc3-і /ii, beclin-1, atg-5 and atg-7, p-akt (ser473), p-p70s6k (thr389), p-4ebp1 (thr37/46), akt, p70s6k, 4ebp1, p-erk1/2, p-jnk, p-p38 mapk, β-actin and secondary antibodies (goat anti-mouse or anti-rabbit igg-conjugated horseradish peroxidase (hrp)) were all purchased from cell signaling technology (beverly, usa).",pmc4466411,1,100,40,1,140
593,ing1,protein,,,uniprot,q9uk53,nucleus,go:0005634,src,protein,,,uniprot,p12931,plasma membrane,go:0005886,positive,d,physically interact,,hek293,epithelial,,human,['3545'],nan,nan,"to ask if ing1 might serve as a substrate for src, we performed immunoprecipitation-western assays to determine whether or not src could physically interact with ing1. as shown in figure 1a, when ing1 was expressed ectopically in hek293 cells, ing1 was recovered in src immunoprecipitates. paradoxically, when ing1 was co-expressed with either wt, activated (y530f) or kinase-dead (k295m) versions of src, the levels of ing1 associated with src were reduced dramatically. in addition, expression of src also reduced the total amount of ing1 in cells. however, the reduction of ing1 that occurred with kinase-dead src was less than the reduction observed with wt or activated forms of src. these results suggested that increases in levels of src could result in a decrease in total ing1 and in src-associated ing1, in a manner that was partially, but not entirely src kinase dependent.",pmc3621671,1,100,40,1,140
890,pp5,protein,,ppp5c,uniprot,p53041,,,atm,protein,,atm,uniprot,q13315,,,positive,d,binding,,,,,,['1662'],nan,nan,"in contrast to pp2a and wip1 which suppress atm activation, pp5 plays an important role in the activation of the ddr through atm. cells with decreased pp5 protein or activity exhibited a decrease in atm autophosphorylation at s1981, a decrease in atm kinase activity, and a phenotype of radio-resistant dna synthesis after dna damage, which is consistent with the phenotype of cells lacking atm [107]. pp5-deficient mefs displayed a defect in the g2/m checkpoint after ir, a decrease in atm activity, and less phosphorylation of the atm targets chk2 and nbs1 after dna damage [108]. interestingly, pp5 was found to bind to atm, and this binding was increased after treatment with ir or neocarzinostatin (which causes dsb) [107].",pmc2954851,1,100,40,1,140
592,ing1,protein,,,uniprot,q9uk53,,,src tyrosine kinase,protein,,src,uniprot,p12931,,,positive,d,phosphorylation,,,,,,['3556'],nan,nan,"ing1 is a type ii tumor suppressor whose activity affects many different pathways, including growth regulation, apoptosis, dna repair, chromatin remodeling, and gene expression [6], [7], [12], [13]. in this study we have shown that ing1 physically associates with, and is a target substrate of the src tyrosine kinase in vitro and in vivo, that src contributes to reducing levels of ing1 by phosphorylation-dependent and phosphorylation-independent mechanisms, and that such reduction blocks the ability of ing1 to induce apoptosis. this suggests that src may contribute to regulating ing1 levels and thus act to alter cell susceptibility to undergoing apoptosis since ing1 has been reported by many groups to enhance apoptosis [9]–[11], [41]–[47].",pmc3621671,1,100,40,1,140
591,ing1,protein,,ing1,uniprot,q9uk53,nucleus,go:0005634,src,protein,kinase,src,uniprot,p12931,plasma membrane,go:0005886,negative,d,block,y530f,mda-mb-468,breast cancer,,human,['3553'],nan,nan,"mda-mb-468 breast cancer cell line that we have shown is sensitive to ing1-induced apoptosis [40]. as shown in figure 7, transfection with a gfp expression construct resulted in 20% of transfected cells undergoing apoptosis while gfp plus ing1 expression induced apoptosis in 80% of the cell population. coexpression of wild-type src with ing1 blocked the ability of ing1 to induce apoptosis. coexpression of activated src with ing1 also blocked ing1-induced apoptosis, even though the levels of y530f protein expressed are considerably lower as noted in figures 1 and 3. although it was less effective than kinase active src, even the kinase dead mutant of src was able to block the majority of ing-induced apoptosis, consistent with it also reducing levels of ing1.",pmc3621671,1,100,40,1,140
580,hsp27,protein,,hspb1,uniprot,p04792,cytoplasm,go:0005737,p38 kinase,protein,kinase,mapk14,uniprot,q16539,cytoplasm,go:0005737,positive,d,phosphorylation,ser82,hek 293,epithelial-like,,human,['2139'],nan,nan,"studies have shown that hsp27 is a substrate of the p38 kinase and that the activation of p38 results in hsp27 phosphorylation at ser82, leading to changes in its intracellular distribution and interaction with other proteins (rouse et al., 1994; chang and karin, 2001; williams, 2001; yuan and rozengurt, 2008). as shown in fig. 1f, incubation of hsp27-transfected cells with sb203580, a widely used p38-specific inhibitor, reduced the basal level of hsp27 phosphorylation at ser82 (lane 2) compared to that in untreated cells (lane 1). moreover, co-transfection of hek 293 cells with ep2 and hsp27 increased hsp27 phosphorylation (lane 3) while sb203580 abolished ep2-induced hsp27 phosphorylation at ser82 (lane 4). this result suggests that overexpression of ep2 is associated with the increased p38 activity.",pmc4624070,1,100,40,1,140
578,h1.2,protein,,,uniprot,p16403,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,phosphorylation,t146,,any,any,any,['3317'],nan,nan,"of particular interest in our study is the observation that etoposide treatment of cells produces h1.2 t146 phosphorylation prior to p53 acetylation. whether these sequential modifications of h1.2 and p53 truly reflect the early programming of p53 response genes or a delayed unmasking of acetylated p53 remains unclear. however, we would suggest that dna damage-induced phosphorylation of h1.2 may enhance the accessibility of promoter-bound p53. in this way p300 may be properly targeted to gene promoters through interaction with p53 in damaged cells. thus, it is likely that h1.2 phosphorylation is critical in regulating the initial stage of dna damage-facilitated, p53-mediated transactivation. further studies will be required to determine the extent to which the preferred order of h1.2 phosphorylation and p53 acetylation described here pertains to other p53 target genes.",pmc3330162,1,100,40,1,140
576,h1.2,protein,,,uniprot,p16403,,,p53,protein,,tp53,uniprot,p04637,,,negative,i,transrepression,t146,h1299,lung carcinoma,lung,human,['3309'],nan,nan,"we next attempted to investigate the functional importance of h1.2 phosphorylation by performing luciferase reporter gene assays in h1299 cells. consistent with our previous results (kim et al 2008), h1.2 alone had no effect on p53-mediated transcription of reporter gene, but cooperated with purα and yb1 to inhibit p53 transcriptional activity (figure 3d, assay 4 versus assay 5). when h1.2 t146 was substituted to glutamic acid to mimic phosphorylation, the repressive effect of the h1.2 core complex was lost, and p53 transcriptional activity was fully recovered (assay 9). on the contrary, the mutant h1.2 bearing a threonine-to-alanine exchange at t146 still retained its ability to repress p53 transactivation (assay 7), thereby excluding a possible effect of mutation itself on h1.2 competency. these results, together with the results from the in vitro transcription and binding assays, strongly suggest that transrepression activity of h1.2 is strictly regulated by t146 phosphorylation. to further confirm that dna-pk kinase activity is essential for h1.2 phosphorylation and p53 transactivation, we carried out reporter gene assays in h1299 cells treated with the dna-pk inhibitor nu7026. as anticipated, nu7026 treatment markedly impaired dna damage-induced p53 activation in h1299 cells expressing the wild type h1.2 core complex (figure 3e, h1.2 wt core com). however, in repeated assays using cells transfected with h1.2 t146e mutant mimicking constitutive phosphorylation, the loss of h1.2 effects and thus no change in the level of p53 transactivation were evident (h1.2 t146e core com). when h1.2 t146a mutant blocking phosphorylation was transfected into the cells, the repressive effect of h1.2 was retained regardless of nu7026 treatment (h1.2 t146a core com). these results emphasize the essential role of dna-pk in the control of h1.2-p53 interaction and thus h1.2 activity in p53-mediated transcription.",pmc3330162,1,100,40,1,140
575,h1.2,protein,,,uniprot,p10412,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,phosphorylation,t146,,,,,['3308'],nan,nan,"knowing that h1.2 is specifically phosphorylated at t146 by dna-pk, we sought to determine the effects of this modification on transrepressive activities of the h1.2 core complex. toward this end, in vitro transcription assays were carried out by pre-phosphorylating the h1.2 core complex with dna-pk and adding it into the reactions after p53 but before p300 (figure 3a). when h1.2 was pre-modified by dna-pk, the h1.2 core complex lost its ability to repress p53-dependent, p300-mediated transcription from nucleosome arrays (figure 3b, lane 4 versus lane 5). the transcription stimulatory effect of dna-pk, however, was largely compromised upon mutation of h1.2 t146 to alanine (lane 5 versus lane 10). these results suggest that t146 phosphorylation by dna-pk is the major cause of the observed impairment of h1.2-induced repression. to further evaluate the relationship between h1.2 phosphorylation and p53 transcriptional activity, we performed in vitro binding experiments using gst-p53 290-393 and wild type or t146-mutated h1.2. both wild type and mutant h1.2 showed a comparable interaction with p53 290-393, as determined by western blot analysis of the binding reactions (figure 3c, lanes 3 and 7). the interaction between h1.2 and p53 was markedly diminished following h1.2 phosphorylation by dna-pk (lane 4 versus lane 3). in stark contrast, however, dna-pk was no longer capable of negatively regulating h1.2-p53 interaction, when h1.2 t146a mutant was used in the binding study (lane 8 versus lane 7).",pmc3330162,1,100,40,1,140
574,h1.2,protein,histone,hist1h1c,uniprot,p16403,nucleus,go:0005634,p53,protein,transcription factor,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,binding,,,,,,['3315'],nan,nan,"a flurry of recent studies about linker histone h1 proteins has offered the new emerging aspect that this family of proteins might be linked to regulation of specific genes, in addition to their well-known roles as a structural component of the nucleosome. in further support of h1 function in gene specific transcriptional regulation, we recently showed that the binding of the h1.2 core complex consisting of h1.2, yb1 and purα to p53 causes an impairment of p53-mediated transcription. although our studies uncovered a previously unrecognized role for the h1.2 complex in suppressing p53 transcriptional activity, it was not clear how h1.2 dissociates from p53 to initiate p53 transactivation in response to dna damage. in this study, we demonstrate the functional crosstalk between p53 acetylation and h1.2 phosphorylation in triggering h1.2 release from p53 as well as in stimulating p53 transcriptional network (see figure 6b).",pmc3330162,1,100,40,1,140
573,gsk3β,protein,,gsk3b,uniprot,p49841,nucleus,go:0005634,cyclin d1,protein,,ccnd1,uniprot,p24385,nucleus,go:0005634,negative,d,phosphorylation,t286,,hepatocyte,liver,mouse,['1294'],nan,nan,"gsk3β, active during fasting and inactive during refeeding due to its phosphorylation by insulin-akt signaling, negatively regulates cyclin d1 through phosphorylation of t286, causing nuclear exclusion of cyclin d1 and proteasomal degradation19,22. we hypothesized that insulin stimulation and subsequent inactivation of gsk3β allow cyclin d1 to form an active complex with cdk4, promoting pgc-1α acetylation. insulin or two gsk3β inhibitors increased nuclear cyclin d1 protein when tested in an overexpressed or endogenous manner (fig. 3f, extended data fig. 5k). this increase correlated with elevated pgc-1α acetylation and significant reduction of gluconeogenic genes (fig. 3g, extended data fig. 5l). in accordance, insulin increased cdk4-mediated gcn5 phosphorylation (fig. 3h). interestingly, we found that amino acids, but not insulin, increased cyclin d1 mrna expression in primary hepatocytes (extended data fig. 5m, 5n, 5o). to test if amino acids could be dietary components promoting cyclin d1 mrna in liver, mice were fed with empty calorie, glucose only or glucose and amino acids diets for 4 hr. a significant cyclin d1 mrna induction was observed only when amino acids were added to the diet (fig. 3i). these results indicate that amino acids contribute to the fed response along with insulin signaling to enhance cyclin d1 levels during refeeding.",pmc4076706,1,100,40,1,140
571,gsk3β,protein,,gsk3b,uniprot,p49841,,,c-jun,protein,,jun,uniprot,p05412,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['2733'],nan,nan,"phosphorylation of gsk3βy216 has been shown to be required for gsk3β's full kinase activity measured by in vitro phosphorylation of c-jun (hughes et al., 1993); however, mutation of y216 did not impair gsk3β's ability to phosphorylate tau (buescher and phiel, 2010). the reason for the discrepancy is not clear, but it might be explained by the fact that different substrates were used in these studies. the current study indicates that phosphorylation of gsk3βy216 per se does not affect gsk3β activity towards β-catenin, thus ruling out the possibility that gsk3βy216 regulates the wnt/β-catenin pathway through modulating gsk3β kinase activity.",pmc4558782,1,100,40,1,140
771,npm,protein,,npm1,uniprot,p06748,nucleolus,go:0005730,arf,protein,,cdkn2a,uniprot,p42771,nucleolus,go:0005730,positive,d,oligomerisation,,,tumor,,human,['395'],nan,nan,"the data presented in this report describes how the stability and localization of arf is regulated by npm quaternary structure. previous reports have demonstrated that the inhibition of npm oligomerisation using small molecule inhibitors [60] or rna aptameres [78] promotes the nucleoplasmic localization of npm and arf with accompanying activation of p53, but the physiological context was not known. we have found that akt limits npm oligomerisation (fig. 1), which in turn restricts npm nucleolar localization and accumulation of arf at the nucleolus (fig. 2 & 3). in tumor cells with constitutive activation of akt and mutation of p53, the promotion of nucleoplasmic arf/npm leads to the subsequent stabilization of p53mut through inhibition of mdm2 (fig. 4 & 5).",pmc4171619,1,100,40,1,140
772,npm,protein,,npm1,uniprot,p06748,nucleolus,go:0005730,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,bind,,,,,,['397'],nan,nan,"npm has also been reported to bind and stabilize p53 directly [82] and in addition, promote p53 stability by binding mdm2 [83]. kurki et al. reported that following uv or viral stress, npm re-localizes to the nucleoplasm from the nucleolus and is associated with mdm2, in an analogous manner to the increased formation of arf/mdm2 complex [45]. in agreement, failure to re-localize npm to the nucleoplasm prevents npm mediated inhibition of mdm2 [84]. our results suggest that inhibition of mdm2 by npm and arf are not independent and respond to cellular stress via disruption of npm oligomerization.",pmc4171619,1,100,40,1,140
773,npm,protein,,npm1,uniprot,p06748,nucleus,go:0005634,p14arf,protein,,cdkn2a,uniprot,p42771,nucleus,go:0005634,positive,d,binds,,,,,mouse,['389'],nan,nan,"(a) psn1 xenografts (psn1 cells co-injected with ltc-14 stellate cells) established in the flank of athymic nude mice were treated with mk-2206 (60 mg/kg-320 mg/kg) as indicated or β-cyclo-dextrin (1.5 mg/ml) carrier. xenograft tumors were lysed and lysates probed by western blot with the indicated antibodies. (b-d) sections of psn1 xenografts treated with three consecutive doses of mk-2206 (60 mg/kg). (b) sections of psn1 xenografts and in-vitro psn1 cells fixed and stained with anti-npm (red) and anti-p14arf (green). (c) psn1 xenografts treated with mk-2206 or carrier were stained with dapi, anti-p53 (do1) or p53mut (op29 clone) (d) psn1 xenografts treated with mk-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-ps473-akt, anti-phospho-s48-npm (ps48-npm) or p53. (e) psn1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of mk-2206 (60 mg/kg) or carrier. mice were subsequently treated with a single dose of ir (6 gy) and tumor volumes measured regularly with callipers. dash lines indicate tumor growth differential at 250 mm3.",pmc4171619,1,100,40,1,140
774,npm,protein,,npm1,uniprot,p06748,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,phosphorylation,cytoplasmic,,pancreatic ductal adenocarcinomas,,human,['393'],nan,nan,"interestingly, the ‘rxxs’ motif incorporating npm-ser48 lies within a characterized nuclear export sequence [55] (fig. 1b) and a proportion of phospho-s48-npm is cytoplasmic (fig. 2a, fig. s2c & s8d). we next restricted scoring to cytoplasmic positivity, solely within pancreatic ductal adenocarcinomas and scored for elevated p53 staining indicative of p53mut. of the total 122 tumors, 81 scored positive for p53 and the degree of p53 staining correlated with the levels of phospho-s48-npmcyto (<p=0.001) (fig. 8c). as the ink4a/arf locus can be deleted, methylated or transcriptionally repressed, we obtained mrna from a subset of tumors for which material was available (40 tumors). we determined that 26/40 pancreatic tumors were positive for arf mrna and observed a significant correlation between phospho-s48-npm and p53 staining intensity in tumors where arf was expressed (fig. s8e).",pmc4171619,1,100,40,1,140
883,pp1,enzyme,,,uniprot,p62136,cellular,go:0005623,p53,protein,,tp53,uniprot,p04637,nuclear,go:0005634,negative,d,dephosphorylation,"s15, s37",rabbit lens epithelial cells,epithelial,lens,rabbit,['1676'],nan,nan,"inhibition of pp1, but not pp2a, with okadaic acid induced the p53 target bax and, consequently, apoptosis in rabbit lens epithelial cells [138]. inhibition of pp1 only slightly increased p53 levels but dramatically increased p53 phosphorylation at s15 and s37 which enhanced regulation of p53 targets bcl2 and bax. pp1 dephosphorylated p53 at s15 and s37 in vitro and in vivo and this decreased its transcriptional activity and attenuated apoptosis [139].",pmc2954851,1,100,40,1,140
864,pi3k,enzyme,,,uniprot,p42336,plasma membrane,go:0005886,akt,protein,,akt1,uniprot,o75385,plasma membrane,go:0005886,positive,i,phosphorylation,,,,,human,['3591'],nan,nan,"pharmacological inhibitors of pi3k were instrumental in elucidating the role of the enzyme in cellular signaling events. these inhibitors include quercetin analogs, the most widely used being ly294002 [116], as well as the microbial product wortmannin [117-119]. in addition to their effects on pi3k isoforms, ly294002 and wortmannin also inhibit the activity of the related kinases such as mtor [120], atm and dna-pk [121]. studies with wortmannin and ly294002 uncovered a role for pi3k in activation of p70(s6k) by insulin and pdgf [122-125], as well as in the inactivation of glycogen synthase kinase-3 (gsk-3) [126]. subsequently, pi3k was shown to be essential in the activation of the proto-oncogene akt (or protein kinase b (pkb)) by pdgf [127] and other growth factors [128, 129]. these results were confirmed by the observation that transfection of membrane-targeted p110 was sufficient to trigger downstream responses characteristic of growth factor action, including the stimulation of p70(s6k) and akt [130, 131]. the phospholipids products of pi3k, initially pi(3,4)p2, were shown to directly activate akt by binding to its pleckstrin homology (ph) domain [132, 133]. ph domains were recognized to be modular domains with the ability to specifically bind to the lipid products of pi3k, including pip3 [134]. pi3k activity was also required for phosphorylation of both thr308 and ser473 activation sites of akt [135]. the kinase that phosphorylates akt was then purified, cloned and shown to phosphorylate akt1 at thr308 and increase its activity [136-138]. it was found that only pi(3,4,5)p3 or pi(3,4)p2 were effective in potently activating the kinase, which was termed pi(3,4,5)p3-dependent protein kinase-1 (pdk1) [136]. pdk1 is the protein kinase that mediates the activation of akt/pkb by insulin and growth factors [139]. pdk1 therefore plays a key role in mediating many of the actions of the second messengers produced by pi3k. in response to pdgf, binding of pi(3,4,5)p3 and/or pi(3,4)p2 to the ph domain of pdk-1 causes its translocation to the plasma membrane where it co-localises with akt/pkb, significantly contributing to the scale of akt/pkb activation [139, 140] (fig. 1). the identification of the kinase that phosphorylates the akt ser473 was achieved only in the last few years [141]. the complex of the mammalian target of rapamycin (mtor) and rictor was shown to be essential for this crucial phosphorylation step in akt by several groups [141, 142].",pmc2652403,1,100,40,1,140
860,phosphatidylinositol 3-kinase (pi3k),enzyme,,pik3ca,uniprot,p42336,,,akt,protein,,akt1,uniprot,p31749,,,positive,i,activation,,,,,human,['3338'],nan,nan,"the phosphatidylinositol 3-kinase (pi3k)/akt and ras oncogenic signalling modules are frequently mutated in sporadic human cancer. although each of these pathways has been shown to play critical roles in driving tumour growth and proliferation, their activation in normal human cells can also promote cell senescence. although the mechanisms mediating ras-induced senescence have been well characterised, those controlling pi3k/akt-induced senescence are poorly understood. here we show that pi3k/akt pathway activation in response to phosphatase and tensin homolog (pten) knockdown, mutant pi3k, catalytic, α polypeptide (pik3ca) or activated akt expression, promotes accumulation of p53 and p21, increases cell size and induces senescence-associated β-galactosidase activity. we demonstrate that akt-induced senescence is p53-dependent and is characterised by mtorc1-dependent regulation of p53 translation and stabilisation of p53 protein following nucleolar localisation and inactivation of mdm2. the underlying mechanisms of ras and akt-induced senescence appear to be distinct, demonstrating that different mediators of senescence may be deregulated during transformation by specific oncogenes. unlike ras, akt promotes rapid proliferative arrest in the absence of a hyperproliferative phase or dna damage, indicating that inactivation of the senescence response is critical at the early stages of pi3k/akt-driven tumourigenesis. furthermore, our data imply that chronic activation of akt signalling provides selective pressure for the loss of p53 function, consistent with observations that pten or pik3ca mutations are significantly associated with p53 mutation in a number of human tumour types. importantly, the demonstration that mtorc1 is an essential mediator of akt-induced senescence raises the possibility that targeting mtorc1 in tumours with activated pi3k/akt signalling may exert unexpected detrimental effects due to inactivation of a senescence brake on potential cancer-initiating cells.",pmc3325598,1,100,40,1,140
857,phb,protein,,phb,uniprot,p35232,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,t258,bc cell lines,,,,['1864'],nan,nan,"based on the importance of phb and akt in bc cell proliferation, we hypothesized that phosphorylation of phb by akt is necessary for the proliferation effects of phb. the overexpression of wild-type phb, mutant phb t258a, constitutively activated phb t258d and akt inhibitors were used to treat the bc cell lines. wild-type phb alone had an obvious effect on proliferation, whereas the mutant phb t258a and the akt inhibitor had a remarkable effect on inhibition of cell proliferation (figure 7d). in contrast, constitutively activated phb t258d significantly induced profileration and even removed the barrier of proliferation inhibition conferred by the akt inhibitors (figure 7d). these findings demonstrate that phosphorylation of phb is required for bc cell proliferation.",pmc4669803,1,100,40,1,140
856,phb,protein,,phb,uniprot,p35232,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,phosphorylation,,,bc cells,,human,['1861'],nan,nan,"it was interesting to examine whether the two proteins interacted with each other in different compartments of the bc cells. nuclear, mitochondrial and cytoplasmic (without mitochondrion) extracts were prepared from control t24 cells or t24 cells treated with akt inhibitor mk-2206 for 12 h. western blotting showed that active phospho-akt was present in the cell nuclear, mitochondrial and cytoplasmic extracts (without mitochondrion) (figure 6c). but the interaction between phb and akt were only detected in the cytoplasmic (without mitochondrion) extract of control cells (figure 6d) but not in the nuclear or mitochondrial extracts (data not shown). these experiments confirm that phb is being phosphorylated by akt in the cytoplasm.",pmc4669803,1,100,40,1,140
855,phb,protein,,,uniprot,p35232,mitochondria,go:0005739,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,phosphorylation,thr258,hek-293t,cancer,,human,['1866'],nan,nan,"the subcellular localization of phb has been shown to affect cell fate.19, 43 phosphorylation is also a fundamental posttranslational modification that is used to regulate phb function, localization and binding specificity of the proteins.25, 44 phb has been reported to interact with akt and to have a modulatory role in the pi3k/akt pathway. a recent study has shown that overexpressed akt phosphorylates phb on thr258 in vitro and that it is also capable of doing so in vitro on overexpressed phb in hek-293t cancer cells.25 our group is particularly interested in understanding the functional significance of akt-induced phosphorylation on phb and its downstream effects on bc cells. our data suggest the phosphorylation of phb by akt promotes cell proliferation, in contrast to much evidence suggesting the inhibitory effectors of phb on cancer. until now, there is no clear mechanism that explains these two disparate conclusions. in the present study, we found that endogenous akt directly regulates the phosphorylation thr258 of phb. furthermore, constitutively activated phb t258d significantly induce proliferation and removed the inhibition conferred by suppressing akt. we demonstrate here for the first time that phb through phosphorylate at thr258 to acquire the proliferation activity in pi3k/akt-dependent pathway.",pmc4669803,1,100,40,1,140
849,pdgfrβ,protein,,,uniprot,p09619,,,stat3,protein,,stat3,uniprot,p40763,,,positive,d,activates,,,,,,['1890'],nan,nan,"cytokine receptors, tyrosine kinase receptors including pdgfrβ and egfr, as well as nonreceptor tyrosine kinases, including cabl, are known to activate stat3 signaling [28, 29], which plays a pivotal role in inducing pluripotency [30]. to determine whether stat3 signaling was involved in mediating pdgfr inhibitor-iv-induced oct4 and nanog expression, the effect of increasing inhibition of stat3 in the presence of pdgfr inhibitor-iv was examined. immunoblot analysis demonstrated that an increasing dose of stat3 inhibitor produced a proportional decrease in pdgfr inhibitor-iv-induced oct4 and a marked reduction in nanog expression (fig. 4b). the same analysis confirmed the effectiveness of the stat3 inhibitor in decreasing stat3 (y705) phosphorylation (fig. 4b). thus, stat3 signaling is essential for pdgfr inhibitor-iv-induced oct4 and nanog expression.",pmc3537888,1,100,40,1,140
846,pdgfr,protein,,pdgfra,uniprot,p16234,plasma membrane,go:0005886,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,d,inhibition,nucleus,,mesenchymal stem cell,,human,['1889'],nan,nan,"pdgfr inhibition regulated stat3 signaling and nuclear translocation. (a): quantitative rt-pcr analysis examining oct4a and nanog transcript levels relative to gapdh and normalized to untreated controls, following 24-hour exposure to 20 μm mek, 5 μm pi3k, 10 μm stat3, or 10 nm gsk-3 inhibitors. *, p < .001 compared with untreated controls, using paired t test; n > 3 separate experiments, error bars represent sd. (b): immunoblot analysis of oct4 and nanog with β-actin as loading controls, and stat3 (y705) and total stat3 expression levels, following exposure to 0.1 μm pdgfr inhibitor-iv and an increasing dose of stat3 inhibitor (0–15 μm) for 24 hours. (c): immunoblot analysis examining nuclear and cytoplasm expression of pstat3 (y705), oct4, and nanog, with total stat3 and β-actin as corresponding loading controls, and nuclear membrane marker lamin b1, following 24 hours exposure to 0.1 μm pdgfr inhibitor-iv or untreated controls. (d): relative protein expression levels in nuclear extracts, normalized to untreated controls. *, p < .001 for (iv) treatment or (iv+egfr) treatment compared with untreated controls, using paired t test; n > 3 separate experiments; error bars represent sd. (e): immunoblot analysis examining nuclear and cytoplasm expression of pstat3 (y705), oct4, and nanog, with total stat3 and β-actin as corresponding loading controls, and nuclear membrane marker lamin b1, following 24 hours exposure to 0.1 μm pdgfr inhibitor-iv alone or in the presence of 2 nm egfr (egfr inhibitor). (f): representative bright-field images of control mesenchymal stem cell morphology and following 24-hour exposure to 2 nm egfr, 0.1 μm pdgfr inhibitor-iv, or 0.1 μm pdgfr inhibitor-iv with 2 nm egfr. scale bar = 100 μm. abbreviations: egfr, epidermal growth factor receptor; gapdh, glyceraldehyde 3-phosphate dehydrogenase; gsk, glycogen synthase kinase; mek, mapk kinase; pdgfr, platelet-derived growth factor receptor; pi3k, phosphoinositide 3-kinase; rt-pcr, reverse transcription polymerase chain reaction; stat, signal transducer and activator of transcription.",pmc3537888,1,100,40,1,140
836,p68,protein,rna helicase,ddx5,uniprot,o00571,nucleus,go:0005634,p53,protein,tumor suppressor,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,co-activation,,,,,human,['2521'],nan,nan,"the rna helicase p68 (ddx5) is an established co-activator of the p53 tumour suppressor that itself plays a pivotal role in orchestrating the cellular response to dna damage. although several factors influence the biological outcome of p53 activation, the mechanisms governing the choice between cell cycle arrest and apoptosis remain to be elucidated. in the present study we show that, while p68 is critical for p53-mediated transactivation of the cell cycle arrest gene p21waf1/cip1, it is dispensable for induction of several pro-apoptotic genes in response to dna damage. moreover, p68 depletion results in a striking inhibition of recruitment of p53 and rna pol ii to the p21 promoter but not to the bax or puma promoters, providing an explanation for the selective effect on p21 induction. importantly, these findings are mirrored in a novel inducible p68 knockout mouse model in which p68 depletion results in a selective inhibition of p21 induction in several tissues. moreover, in bone marrow, p68 depletion results in an increased sensitivity to γ-irradiation, consistent with an increased level of apoptosis. these data highlight a novel function of p68 as a modulator of the decision between p53-mediated growth arrest and apoptosis in vitro and in vivo.",pmc3556166,1,100,40,1,140
835,p68,protein,rna helicase,ddx5,uniprot,o00571,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,required for,,,,,human,['2520'],nan,nan,the rna helicase p68 (ddx5) is selectively required for the induction of p53-dependent p21 expression and cell cycle arrest after dna damage,pmc3556166,1,100,40,1,140
834,p68,protein,,ddx5,uniprot,o00571,nucleus,go:0005634,p53,protein,transcription factor,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,co-activation,promoter,,,,human,['2522'],nan,nan,"p68 (ddx5) is a prototypic member of the dead box family of rna helicases that can unwind rna in an atp-dependent manner (4). p68 is a multi-functional protein known to be involved in several cellular processes requiring manipulation of rna structures, including processing of pre-mrna, rrna, and mirna, and has been shown to be aberrantly expressed/modified in a range of cancers (5). studies from several groups, including our own, have demonstrated that p68 also plays an important, and apparently rna helicase-independent, role as a co-activator of several transcription factors that are critical to cancer development, including estrogen receptor alpha (6), androgen receptor (7), and the tumour suppressor p53 (8). p68 is recruited to the promoters of responsive genes under conditions in which these transcription factors are activated, consistent with a role in transcription initiation (9).",pmc3556166,1,100,40,1,140
796,p300,protein,,,uniprot,q09472,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,acetylation,p53 c-terminal basic region,,,,human,['3316'],nan,nan,"a key finding from our initial study is that p300-induced acetylation of the p53 c-terminal basic region attenuates p53-h1.2 interaction, which is necessary for enhancing p53 transcriptional activity and recruiting coactivators at p53 target promoters. supporting these biochemical data, cellular studies also demonstrate the inverse correlation between p53 acetylation and h1.2 transrepression. these observations strongly suggest that p53 acetylation is a key determinant for h1.2 dissociation from p53 and contributes to the fine tuning of p53 function in response to dna damage. in this study, we also establish another modification pathway in which dna-pk attenuates the repressive action of h1.2 against p53-mediated transactivation. we found that dna-pk specifically phosphorylates h1.2 at t146, thereby disrupting p53-h1.2 interaction and leading to the enhancement of p53 acetylation and the activation of p53 target genes. cellular studies using mutant h1.2 further demonstrate that h1.2 phosphorylation at t146 is responsible for the observed activation and consequently for timely cell growth arrest and apoptosis. our results implicating a primary function of h1.2 t146 phosphorylation in transcription and dna damage response seem to contrast with a recent report showing that h1.2 t146 is phosphorylated exclusively during mitosis (zheng et al 2010). however, we speculate that mitosis-coupled phosphorylation of h1.2 does not require dna-pk and may be mediated by cell cycle-regulated kinases, such as cyclin-dependent kinases. these results also suggest that h1.2 phosphorylation may play a broader role in cell signaling than previously expected. additional experiments will be necessary to uncover the relative importance and regulatory mechanisms of h1.2 phosphorylation that occurs during various cellular processes.",pmc3330162,1,100,40,1,140
795,p27,protein,,,uniprot,p46527,,,s6,protein,,rps6,uniprot,p62753,,,positive,d,phosphorylation,,,,,,['449'],nan,nan,"although a variety of research studies has shown that p27 performs cyclin-cdk-independent functions such as mediation of apoptosis, cytoskeleton rearrangements and transcriptional regulation,23, 24, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 the effect of p27 on modulation of protein translation remains largely untouched up to now. protein translation is a temporally and spatially well-recognized cellular event, and the deregulation of this process contributes greatly to tumor development.48 in our current studies, we investigated the role of p27 in arsenite-induced protein translation and its biological significance, as well as the underlying mechanisms. our findings clearly showed that the depletion of p27 expression by knockdown and knockout approaches resulted in an obvious elevation of s6 phosphorylation, indicating that loss of p27 leads to abnormal activation of the key molecule involved in the specific protein translation, such as hif-1α.",pmc4260754,1,100,40,1,140
794,p27,protein,,cdkn1b,uniprot,q13309,nucleus,go:0005634,hif-1α,protein,,hif1a,uniprot,q16665,nucleus,go:0005634,positive,i,translation,s6,,,,,['435'],nan,nan,p27 regulating cell transformation via s6-mediated hif-1 α  protein translation,pmc4260754,1,100,40,1,140
793,p27,protein,,cdkn1b,uniprot,q13309,,,hif-1α,protein,,,uniprot,q16665,,,positive,d,translational inhibition,,,,,human,['447'],nan,nan,"to investigate whether arsenite could affect hif-1α protein translation and whether inhibition of raf/erk/s6 pathway by p27 would attenuate it, we first checked hif-1α induction by arsenite in p27+/+ and p27−/−(δ51) cells. as shown in figure 7a, compared with the mild induction of hif-1α in p27+/+ cells, a remarked accumulation of hif-1α protein was observed in p27−/−(δ51) cells. the inhibition of hif-1α induction by p27 was further extended in p27−/−(fl) and p27+/+ cells (figure 7b). in addition, the transcription of vegf, a well-defined downstream target of hif-1α, was also found upregulated in p27−/−(δ51) cells in response to arsenite treatment (figure 7c). while the real-time pcr result clearly indicated that the mrna level of hif-1α was not upregulated in p27−/−(δ51) cells (figure 7d), suggesting that p27 might regulate hif-1α induction by arsenite through a translational or posttranslational mechanism. considering our previous work showing that arsenite was involved in prevention of hif-1α protein degradation, we checked the protein turnover rate of hif-1α using cycloheximide (chx), a protein synthesis inhibitor, to block the de novo production of proteins. as shown in figure 7e, hif-1α protein was firstly accumulated by treatment of 20 μm arsenite plus 10 μm mg132 for 6 h in both p27+/+ and p27−/−(δ51) cells. after removal of arsenite and mg132, hif-1α protein began to degrade in the presence of chx at a comparable rate in these two cell lines (figure 7e), suggesting that p27 did not alter the protein turnover process of hif-1α. subsequently, we used rapamycin to interfere with mtorc1 activity and found that it reduced hif-1α induction in p27−/−(δ51) cells (figure 7f), indicating that p27 inhibited hif-1α translation. to this end, short-term pulse-labeling assay was used to examine hif-1α protein translational process in both p27+/+ and p27−/−(δ51) cells. as shown in figure 7g, the incorporation of 35s-methionine/cysteine into newly synthesized hif-1α protein was gradually increased along with the isotope incubation time in both p27+/+ and p27−/−(δ51) cells. by normalizing over the global protein synthesis rate, the hif-1α protein synthesis rate was much higher in p27−/−(δ51) cells than that in p27+/+ cells, indicating that p27 interfered with hif-1α protein translation upon arsenite exposure. we further knocked down s6 expression by two sets of shrnas in p27−/−(δ51) cells (figure 7h), and found that hif-1α protein induction by arsenite was reduced accordingly (figure 7i). considering the fact that s6, unlike its phosphorylation, is a critical protein for functional ribosomes so that its complete absence or the lack of even just one allele leads to early embryonic lethality34 or to blockage of t-cell proliferation,17 knockdown of s6 may only suggest that hif-1α synthesis is highly sensitive to the compromised ribosome activity. to show explicitly the role of s6 phosphorylation in hif-1α protein translation under the control of the p27 signaling in arsenite response, we introduced s6 s235/236a double mutant, which specifically abolished phosphorylation of ser235/236 in endogenous s6.18 as shown in figure 7j, ectopic expression of ha-s6 s235/236a in p27−/− (δ51) cells efficiently attenuated arsenite-induced hif-1α upregulation. in line with this, hif-1α protein synthesis detected by pulse-labeling assay was markedly repressed by the introduction of ha-s6 s235/236a in p27−/−(δ51) cells (figure 7k), suggesting that p27 inhibited hif-1α translation in an s6-phosphorylation-dependent manner in arsenite response.",pmc4260754,1,100,40,1,140
791,p27,protein,,cdkn1b,uniprot,p46527,cytoplasm,go:0005737,hif-1 alpha,protein,,hif1a,uniprot,q16665,nucleus,go:0005634,negative,i,inhibits,ribosomal protein s6,,,,,['434'],nan,nan,the n-terminal region of p27 inhibits hif-1 α  protein translation in ribosomal protein s6-dependent manner by regulating phlpp-ras-erk-p90rsk axis,pmc4260754,1,100,40,1,140
778,p-p70s6k,protein,,,uniprot,q15418,cytoplasm,go:0005737,s6,protein,,rps6,uniprot,p62753,cytoplasm,go:0005737,negative,d,phosphorylation,,,"lung cancer cells (a549, sk-mes-1, nci-h460)",lung,humans,['3016'],nan,nan,"the expression levels of p-p70s6k and the downstream effector s6 were significantly reduced by pf-4708671. diametrically opposite, the downstream protein levels of bad, caspase3 and erk had increased after treatment with pf-4708671. in addition, pf-4708671 drastically inhibited cell proliferation and invasion ability in a549, sk-mes-1 and nci-h460 cells in vitro, causing cell cycle arrest in g0-g1 phase. limited effects of pf-4708671 were observed on apoptosis in the three nsclc cell lines assessed. importantly, pf-4708671 could inhibit tumorigenesis in nude mice in vivo.",pmc4714881,1,100,40,1,140
776,nucleophosmin (npm),protein,,npm1,uniprot,p06748,nucleoplasm,go:0005654,arf,protein,,cdkn2a,uniprot,p42771,nucleoplasm,go:0005654,negative,d,association,nucleoplasm,,,,human,['357'],nan,nan,"nucleophosmin (npm) is known to regulate arf subcellular localization and mdm2 activity in response to oncogenic stress, though the precise mechanism has remained elusive. here we describe how npm and arf associate in the nucleoplasm to form a mdm2 inhibitory complex. we find that oligomerization of npm drives nucleolar accumulation of arf. moreover, the formation of npm and arf oligomers antagonizes mdm2 association with the inhibitory complex, leading to activation of mdm2 e3-ligase activity and targeting of p53. we find that akt phosphorylation of npm-ser48 prevents oligomerization that results in nucleoplasmic localization of arf, constitutive mdm2 inhibition and stabilization of p53. we also show that arf promotes p53 mutant stability in tumors and suppresses p73 mediated p21 expression and senescence. we demonstrate that akt and pi3k inhibitors may be effective in treatment of therapeutically resistant tumors with elevated akt and carrying gain of function mutations in p53. our results show that the clinical candidate akt inhibitor mk-2206 promotes arf nucleolar localization, reduced p53mut stability and increased sensitivity to ionizing radiation in a xenograft model of pancreatic cancer. analysis of human tumors indicates that phospho-s48-npm may be a useful biomarker for monitoring akt activity and in vivo efficacy of akt inhibitor treatment. critically, we propose that combination therapy involving pi3k-akt inhibitors would benefit from a patient stratification rationale based on arf and p53mut status.",pmc4171619,1,100,40,1,140
775,npm,protein,,npm1,uniprot,p06748,nucleus,go:0005634,p53mut,protein,mutant,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,stabilization,,,tumor,pancreatic,human,['401'],nan,nan,"our data indicates that in tumors where npm is unable to oligomerize, retention of arf expression contributes to the stabilization of p53mut cells. in these cases, treatment with akt or pi-3k inhibitors reduces p53mut stability and sensitizes tumor cells to therapies that engage p73. mdm2 activity is absolutely required for this phenomenon as the mdm2 inhibitor nutlin3a blocks p53mut turnover which is induced following inhibition of akt (fig. 5e). furthermore, in our cohort of pancreatic tumors that retained arf expression, the level of phospho-s48-npm significantly correlated with elevated detection of p53mut indicating than in certain tumors akt and arf contribute to the stabilization of p53mut (fig. 8, table s2).",pmc4171619,1,100,40,1,140
223,cdc42,protein,small gtpase,cdc42,uniprot,p60953,cytoplasm,go:0005737,stat3,protein,transcription factor,stat3,uniprot,p40763,nucleus,go:0005634,positive,d,phosphorylation,y705,,,,human,['1894'],nan,nan,"cytoskeletal actin filaments that modulate cell morphology are regulated by the rho family of small gtpases: rhoa, rac1, and cdc42 [32]. more recently, active rhoa, rac1, and cdc42 have all been shown to regulate stat3 phosphorylation and nuclear translocation [33], while stat3 can also regulate rac1 activity, actin reorganization, and actomyosin contractility [34]. we therefore investigated the involvement of jak-stat3 signaling in regulating the msc shape. while jak inhibition effectively blocked stat3 (y705) (supporting information fig. s2d), there was no detectable effect on msc morphology (fig. 5a). however, jak inhibition changed the distinctive pdgfr inhibitor-iv-induced rounded msc shape to a more elongated morphology (fig. 5a).",pmc3537888,1,100,40,1,140
546,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,tgf-β,protein,,tgfb1,uniprot,p01137,extracellular region,go:0005576,positive,i,inhibition,,,,,,['76'],nan,nan,inhibition of gsk3 activity restores tgf-β signaling in cells expressing smad4m130 and smad4m351,pmc4845174,1,100,40,1,140
191,bi-functional redox factor 1 (ref-1),protein,,,uniprot,o43707,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,enhances,,,,,human,['1067'],nan,nan,"previous reports have also made similar observations on the influence of tetramerization in activating the sequence-specific dna binding of p53. deppert and co-workers (45) showed that bi-functional redox factor 1 (ref-1) enhances the specific dna binding of p53 by promoting association of dimers into tetramers and de-stacking of higher order oligomers into the tetrameric form. acetylation of p53 activates sequence-specific dna binding of p53 and is mediated by promoting tetramerization (46). in addition, p53β isoform hetero-tetramerize with wild-type p53 and stimulates it for bax expression but not p21 (47). bccip (brca2 and cdkn1a-interacting protein) enhances transactivation of p53-target genes by facilitating stable tetramer formation (48). in an elegant study, c-abl tyrosine kinase was shown to interact with p53 ctd and activate dna binding by decreasing the dissociation rate of p53–dna complex. this activation is independent of its kinase activity. interestingly, the interaction of c-abl with p53 stabilized the tetrameric conformation of p53, leading to selective stimulation and transactivation of p53 to p21 but not bax response element (49). while in the present study, p21 response element was used to study the effect of 14-3-3 on p53, both in vivo and in vitro, it might be interesting to see if 14-3-3 can exert promoter selectivity for activation of specific p53 target genes involved in either growth arrest or apoptosis, similar to c-abl.",pmc2817464,1,100,40,1,140
179,bad,protein,,bcl2l1,uniprot,q92934,cytoplasm,go:0005737,erk/p90rsk-1,protein,,erk1/2,uniprot,p27361,cytoplasm,go:0005737,negative,d,phosphorylation,"s136, s112",hela,epithelial-like,,human,['294'],nan,nan,"we next examined bad phosphorylation at s112 and s136 in hela cells treated with test compounds. compounds 76.3 and 76.4 appeared the most potent inhibitors and reduced egf-induced s112 phosphorylation by ~75-80% (figure 4c). in contrast, s136 phosphorylation in the presence of these compounds was inhibited by ~40%, which supports a selective inhibition of the erk/p90rsk-1 over akt signaling. as controls, the mek1/2 inhibitor, u0126, inhibited phosphorylation of s112 but not s136, whereas the pi3k inhibitor, ly294002, inhibited phosphorylation of both s112 and s136 (figure 4c) consistent with studies suggesting that phosphorylation of s136 induces a conformational change in bad to promotes access to kinases that phosphorylate other sites [37].",pmc3025971,1,100,40,1,140
7,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,mtor,protein,,frap1,uniprot,p42345,cytoplasm,go:0005737,positive,d,phosphorylation,s2448,,cancer cell,,human,['1185'],nan,nan,"the fact that 4ebp1 is a direct target of mtor and that 4ebp1 is hyperphosphorylated at all the 4 sites suggests that mtor is more activated in pc3 in comparison to pc3bm and hela. increased phosphorylation of mtor at s2448 correlates with enhanced phosphorylation of s6k (t421) and 4ebp1 (figure 2). activation of p70 s6k1 depends on its level of phosphorylation state at eight sites: t229 (catalytic domain), s371, t389 and s404 (linker domain) and s411, s418, t421, and s424 (autoinhibitory domain) [63], [64]. t229 (phosphorylated by pdk1) plays a key role in modulating s6k1 activity. s6k1 activation may be achieved by sequential phosphorylation of these sites by mapk pathways and pi3k [63], [64]. s6k1 activation up-regulates ribosome biosynthesis, and enhances cell translational capacity through phosphorylation of the 40s ribosomal protein s6 (rps6) and upregulation of translation of mrnas having 5′-terminal oligopyrimidine tracts (5′top), but in an mtor-dependent, rapamycin–sensitive manner [36], [37], [65]. however, the low level phosphorylation of p70s6k at s371 and t389 in pc3 in comparison to pc3bm and hela does not correlate with the translation up-regulation in pc3 (figure 2). it is possible that p70s6k could also be directly activated by pld2-generated pa in pc3 [59].",pmc3010991,1,100,40,1,140
183,bax,protein,pro-apoptotic,bax,uniprot,q07817,cytosol,go:0005829,caspase-9,protein,,casp9,uniprot,p55211,mitochondria,go:0005739,positive,i,induction of apoptosis,mitochondria,hek 293t,kidney,,human,['1316'],nan,nan,"bax is a pro-apoptotic member of the bcl-2 family that resides in the cytosol and translocates to mitochondria upon induction of apoptosis [52]. it has been demonstrated that ectopically expressed bax in human embryonic kidney cells (293t cells) induced cytochrome c release and caspase activation [53]. however, overexpression of bax did not influence the apoptosis rate or expression of bcl-2 and bcl-xl in human pancreatic cancer cells transduced with a retroviral expression vector [54]. but bax significantly increased the sensitivity to chemotherapeutic drugs like gemcitabine and 5-fu when transduced to pancreatic cancer cell line aspc-1 cells [54]. although bax failed to substantially increase susceptibility of the pancreatic cell line colo357 towards gemcitabine in vitro, in vivo data from a scid mouse model suggest that pancreatic tumors overexpressing bax caused higher sensibility to gemcitabine and therefore stronger tumor regression [b. schniewind, unpublished data]. that indicates that overexpression of bax may have therapeutic application in enhancing the efficacy of chemotherapy in pancreatic cancer. a recent study revealed that a binary adenoviral vector system (ad/gt-bax + ad/htert-gv16) using the human telomerase reverse transcriptase (htert) promoter to induce bax gene expression was able to induce apoptosis in pancreatic cancer cell lines [55]. transduced cells not only showed bax overexpression but also an increased level of caspase-3. another study revealed that increased levels of bax and reduced expression of bcl-2 are involved in the growth-inhibitory effect of cisplatin in pancreatic cancer cells. [56].",pmc149420,1,100,40,1,140
3,14-3-3 γ,protein,,ywhag,uniprot,p27348,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,sequesters,,,,,human,['1066'],nan,nan,"in our previous study, we proposed a model whereby 14-3-3 γ sequesters dimeric p53 to the tetrameric active dna binding form (13). p53 exists in equilibrium between dimers and tetramers at low concentrations. binding of two dimers facilitates the sequence specific dna binding of p53 in a co-operative manner (44). cofactors like 14-3-3 stabilize the tetrameric form of p53 by shifting the dimer-tetramer equilibrium in favour of active tetrameric form, resulting in increased dna binding. to our knowledge, we were the first to demonstrate previously, using fluorescence aided-analytical ultracentrifugation, that 14-3-3 sequesters dimeric p53 to form tetramers, resulting in reduced co-operativitiy and increased dna binding (13). the increase in dna binding of p53 (from 44 to 22 nm) with a concomitant reduction in hill constant (from 2.1 to 1.1) observed here, in the presence of 14-3-3 γ and ε, results from stable tetramer formation of p53. in other words, the dissociation constant of p53 to dimers and tetramers is decreased in the presence of 14-3-3.",pmc2817464,1,100,40,1,140
6,4e-bp1,protein,,eif4ebp1,uniprot,q13541,,,raptor,protein,,rptor,uniprot,q8n122,,,positive,d,binding,,,,,,['1442'],nan,nan,"besides the eif4e binding motif, there are two other key regulatory motifs in 4e-bp1, a raip motif, named after its sequence arg-ala-ile-pro at the n-terminus, and an mtor signaling (tos) motif at the c-terminus (figure 5) [90, 91]. the tos motif is also present in s6k1 and pras40, the other substrates of mtorc1 [27], and this motif is required for the interaction of 4e-bp1 with raptor since the mutation of specific residues within this motif abrogates the binding of raptor to 4e-bp1 [91, 92]. the raip motif has been found to be unable to bind with raptor [91] although another study reported that raptor does not bind to a 4e-bp variant with disrupted raip motif [93]. this motif is necessary for phosphorylation of residues present in both the n-terminus and the c-terminus of 4e-bp1. on the other hand, the tos motif primarily affects the phosphorylation of s65 and t70, while the phosphorylation of the n-terminal t36/t47 residues is not affected by inactivation of the tos motif to a great extent [91]. also the phosphorylation of these sites is rather insensitive to rapamycin which could suggest that these phosphorylations are possibly mtor independent however since these phosphorylations are inhibited by amino acids starvation of cells and by mtor kinase inhibitors like wortmannin, activated by rheb (an mtor activator), and are decreased in mtor knockdown cells which suggests that the phosphorylation of these n-terminal residues is mediated by mtor but through a raptor independent mechanism [94]. recently it has been shown that, in addition to the yxxxxlφ motif, other conserved regions in the n- and c-termini of 4e-bp1 might also be involved in its binding to eif4e [95, 96].",pmc4258317,1,100,40,1,140
4,14-3-3 γ,protein,,ywhag,uniprot,p61981,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,specific dna binding,,,,,,['1064'],nan,nan,activation of specific dna binding of p53 by 14-3-3 γ and ε,pmc2817464,1,100,40,1,140
164,atrx,protein,,atrx,uniprot,p46100,nucleus,go:0005634,mdm2,protein,,mdm2,uniprot,q00987,nucleus,go:0005634,negative,d,loss,,,,,,['1024'],nan,nan,atrx is required for loss of mdm2 and for senescence induced by pd0332991,pmc4480747,1,100,40,1,140
215,cd2,protein,,,uniprot,p06729,plasma membrane,go:0005886,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,positive,d,activation,,,,,,['2061'],nan,nan,"to test whether cd2 could act as a src sh2 ligand, interacting and regulating src activity, we measured basal src activity in cd2-2 and the control yfp-1 cell lines. should cd2 interact with the src sh2, we would expect an increase in basal src activity because such an interaction could displace the intra-molecular sh2/py529 interaction, resulting in src activation as shown by other sh2 ligands [26, 27]. indeed, as depicted in fig 3b, the expression of yfp-cd2 increased basal src activity in cd2-2 cells as measured by western blot analyses of src tyrosine phosphorylation at y418 (py418). this was further confirmed in cd2-1 cells. when the phosphorylation of y529 was measured, there was no detectable difference in py529 between the control and cd2-2 cells (fig 3c), indicating that the increase in src activity by the expression of yfp-cd2 is not because of a decrease in y529 phosphorylation. because erks are known downstream effectors of src activation, we also measured erk activity in the cell lysates. an increase in erk activity was noted (fig 3d).",pmc4638348,1,100,40,1,140
216,cd2,protein,,,uniprot,p06729,plasma membrane,go:0005886,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,positive,d,co-immunoprecipitation,,"yfp-1, cd2-2",,,,['2059'],nan,nan,"to test whether cd2 interacts with src in live cells, we first conducted a co-immunoprecipitation analysis. cell lysates from both control yfp-1 and cd2-2 cells were immunoprecipitated by a monoclonal anti-src antibody. immunoprecipitates were then analyzed by western blot using anti-src and anti-gfp antibodies. as shown in fig 3a, anti-src antibody co-precipitated yfp-cd2, but not yfp, in the cell lysates, consistent with the previous in vitro gst-pull down assays (fig 1) [14, 16].",pmc4638348,1,100,40,1,140
197,brca1,protein,tumor suppressor,brca1,uniprot,p38398,nucleus,go:0005634,akt,protein,oncogenic,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,cytoplasmic retention,nucleus,,cancer,breast,human,['21'],nan,nan,"the tumor suppressor and breast cancer susceptibility gene 1 (brca1) has been shown to play an integral role in regulating dna repair, cell cycle checkpoints, transcription, and maintenance of genomic stability. as one of the key players regulating dsb repair, brca1 forms nuclear foci in response to dna damage where it colocalizes with rad51 and facilitates rad51 filament formation to initiate hr repair. it has been reported recently that oncogenic akt1 can repress hrr by inducing cytoplasmic retention of brca1 in human cancer cells [100, 121]. importantly, cytoplasmic retention of brca1 is strongly correlated with activated akt1 in biopsies from sporadic breast cancer patients [121]. although akt is able to phosphorylate thr509 of brca1 within the nuclear localization sequences (nls), there is no direct evidence that thr509 phosphorylation is required for cytoplasmic localization of brca1 [135–137]. one potential scenario could be that thr509 phosphorylation prevents brca1 interacting with other proteins that localize to dna damage foci. conversely, brca1 could also regulate akt pathway in a negative manner. brca1 interacts with phospho-akt through brca1-brct domains leading to its ubiquitination and degradation, thereby downregulating akt signalling [138]. thus, elucidation of the precise molecular functions of brca1-akt pathway will be particularly important to understand tumorigenesis of hereditary and sporadic breast cancer.",pmc3317191,1,100,40,1,140
2,14-3-3,protein,,ywhab,uniprot,p31946,nucleus,go:0005634,p53,protein,wild-type,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,transcriptional activation,,h1299,lung carcinoma,lung,human,['1062'],nan,nan,"transcriptional activity of p53 is mainly regulated by two mechanisms: stabilization leading to increased p53 levels and activation of p53 for sequence-specific dna binding. hence, we investigated the mechanism behind 14-3-3-mediated transcriptional activation of p53. transcriptional assays were carried out in h1299 cell-lines that stably express wild-type p53 under the control of a tetracycline-regulated promoter. the results clearly demonstrated that σ and τ isoforms enhanced the transcriptional activity of p53, by increasing p53 levels, probably through stabilization. however, no increase in p53 levels was observed with γ and ε indicating the stabilization mechanism is isoform-specific.",pmc2817464,1,100,40,1,140
165,axin,gene,tumor suppressor,axin1,uniprot,o15169,nucleus,go:0005634,cyclin d1,protein,,ccnd1,uniprot,p24385,nucleus,go:0005634,negative,d,decreased expression,mammary epithelia,transgenic mice,epithelial,mammary,mouse,['2001'],nan,nan,"overexpression of the tumor suppressor axin gene in transgenic mice lead to decreased expression of cyclin d1 and increased apoptosis in mammary epithelia. in addition, impaired lymphoid development was observed in these [135]. ck2alpha overexpression in transgenic mice resulted in mammary tumorigenesis as under these circumstances ck2alpha promoted wnt signaling [136].",pmc4102778,1,100,40,1,140
218,cd24,protein,,cd24,uniprot,p25063,plasma membrane,go:0005886,ras,protein,oncogene,,uniprot,p01112,,,negative,d,inhibition,mek,nih/3t3,fibroblast,,mouse,['1713'],nan,nan,"cd24 is a dynamically regulated cell surface protein. high expression of cd24 leads to progression of lung, prostrate, colon, and pancreatic cancers, among others. in contrast, low expression of cd24 leads to cell proliferation and metastasis of breast cancer stem cells (bcscs). activating mutations in ras are found in 30% of all human cancers. oncogenic ras constitutively stimulates the raf, pi3k, and ral gds signaling pathways, leading to cellular transformation. previous studies have shown that expression of oncogenic ras in breast cancer cells generates cd24− cells from cd24+ cells. however, the molecular mechanisms involved in the generation of cd24− cells were not determined. here, we demonstrate that oncogenic ras (rasv12) expression suppresses cd24 mrna, protein, and promoter levels when expressed in nih/3t3 cells. furthermore, activation of only the raf pathway was sufficient to downregulate cd24 mrna and protein expression to levels similar to those seen in with rasv12 expression. in contrast, activation of the pi3k pathway downregulated mrna expression with a partial effect on protein expression whereas activation of the ralgds pathway only partially affected protein expression. surprisingly, inhibition of mek with u0126 only partially restored cd24 mrna expression but not surface protein expression. in contrast, inhibition of raf with sorafenib did not restore cd24 mrna expression but significantly increased the proportion of rasv12 cells expressing cd24. therefore, the raf pathway is the major repressor of cd24 mrna and protein expression, with pi3k also able to substantially inhibit cd24 expression. moreover, these data indicate that the levels of cd24 mrna and surface protein are independently regulated. although inhibition of raf by sorafenib only partially restored cd24 expression, sorafenib should still be considered as a potential therapeutic strategy to alter cd24 expression in cd24− cells, such as bcscs.",pmc4525067,1,100,40,1,140
193,braf,gene,,braf,hgnc,1097,,,mek2,protein,,map2k2,uniprot,p36507,,,positive,i,activation,,,iecs,colon,mouse,['2924'],nan,nan,"gain-of-function mutations in kras and braf genes are detected in up to 60% of colorectal tumors at a relatively early stage of the carcinogenic process.56 the nonoverlapping occurrence of braf and kras mutations suggests that aberrant braf downstream signaling is a critical mechanism for kras-mediated oncogenesis in crc.57 in this regard, expression of a constitutively active mutant of mek1 or mek2 in normal iecs is sufficient to induce morphological transformation, anchorage-independent growth and tumorigenicity in mice.23, 24, 25, 26 importantly, aberrant activation of kras/braf/mek signaling in these cells triggers emt characterized by the loss of epithelial polarity and expression of junctional proteins, particularly e-cadherin (figure 1).24, 29",pmc4687460,1,100,40,1,140
207,cabin1,protein,,dscr1,uniprot,q13573,chromatin,go:0000785,p53,protein,,tp53,uniprot,p04637,chromatin,go:0000785,negative,d,keeps in inactive state,chromatin,,,,,['2181'],nan,nan,"cabin1 acts as a negative regulator of p53 by keeping p53 in an inactive state on chromatin. genotoxic stress causes rapid dissociation of cabin1 and activation of p53. however, its molecular mechanism is still unknown. here, we reveal the phosphorylation- and ubiquitination-dependent degradation of cabin1 upon dna damage, releasing p53 for transcriptional activation. the dna-damage-signaling kinases, atm and chk2, phosphorylate cabin1 and increase the degradation of cabin1 protein. knockdown or overexpression of these kinases influences the stability of cabin1 protein showing that their activity is critical for degradation of cabin1. additionally, cabin1 was found to undergo ubiquitin-dependent proteasomal degradation mediated by the crl4ddb2 ubiquitin ligase complex. both phosphorylation and ubiquitination of cabin1 appear to be relevant for controlling the level of cabin1 protein upon genotoxic stress.",pmc3575827,1,100,40,1,140
219,cd4,protein,,,uniprot,p01730,plasma membrane,go:0005886,c-jun,protein,,jun,uniprot,p05412,nucleus,go:0005634,positive,i,regulate,,b lymphocytes,b-cell,,,['182'],nan,nan,"b lymphocytes, suggesting that other kinase(s) can regulate c-jun, and therefore",pmc3084876,1,100,40,1,140
190,bcr/abl kinase,protein,kinase,abl1,uniprot,p00519,cytoplasm,go:0005737,pi3k,protein,kinase,pik3ca,uniprot,p42336,cytoplasm,go:0005737,positive,d,inhibition,,,leukemia,bone marrow,human,['3652'],nan,nan,"sti571 (gleevec), an anti-leukemia drug targeting bcr/abl kinase can induce remissions of the ph(1)-positive leukemias (cml). the anti- ph(1)-leukemia effect of the combination of bcr/abl kinase inhibitor sti571 and pi3k inhibitors wortmannin or ly294002 was tested in [445]. it was shown that sti571 and wortmannin exerted a synergistic effect against the ph(1)-positive cell lines, but did not affect the growth of ph(1)-negative cell line [445]. moreover, the combinations of sti571 and wortmannin or sti571 and ly294002 were effective in the inhibition of clonogenic growth of cml-chronic phase and cml-blast crisis patient cells, while sparing normal bone marrow cells [445].",pmc2652403,1,100,40,1,140
696,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,chk1,protein,,chek1,uniprot,o14757,nucleus,go:0005634,negative,i,inhibition,,hek293,epithelial,kidney,human,"['3047', '3050']","nan,nan","nan,nan","it was evident from figure 3 (e and f) that mtor inhibition with pp242 or sirna caused a reduction in total chk1 protein and its phosphorylation, following etoposide-induced dna damage in hek293 cells. to dissect the mechanism of how mtor regulates chk1 we observed chk1 under various conditions and in different cell lines. first we assessed the status of phosphorylation residues and total chk1 level in hek293 cells following etoposide-induced dna damage from 15 minutes to 4hrs (figure 4c). following dna damage, chk1 is phosphorylated at ser345 and ser317 leading to autophosphorylation at ser296 and chk1 activation [32, 33]. as expected, etoposide-induced phosphorylation of these three residues of chk1 from 15 minutes to 4 hrs (figure 4c), all of which were inhibited in the presence of pp242 treatment (figure 4c). in addition, as previously observed in hek293 cells, pp242 also suppressed total chk1 level following etoposide-induced dna damage (figure 4c). however, when ultraviolet (uv) irradiation was used as the dna damaging agent, all three uv-induced chk1 phosphorylations were reduced by pp242 in hek293 cells without affecting total chk1 protein level (figure 4d). pp242 also prevented uv-induced chk1 phosphorylation (ser345) in mcf7 cells without affecting the total chk1 level (figure 4b). furthermore, in other breast cancer cell lines (hbl100, mda-mb-231 and hcc1937), pp242 (figure 4e) and mtor sirna treatment in hbl100 cells (figure 4f) inhibited all three chk1 phosphorylations induced by etoposide. interestingly, similar to hek293 cells, mtor inhibition caused a reduction in total chk1 level following etoposide treatment in hcc1937 cells but not in hbl100 and mda-mb-231 cell lines (figure 4e and f). collectively these results show that in all cell lines used in this study and by two different types of dna damage induction, and two different types of mtor inhibition, all three dna damage-induced phosphoryations of chk1 require mtor activity. in addition, the total level of chk1 also requires mtor but in a cell-specific manner and depending on the type of dna damage induction. taken together these results demonstrate that mtor is required for dna damage induced chk1 activity.,mtor inhibitors can either sensitize cells to chemotherapy or attenuate the ability of chemotherapeutics to induce apoptosis through multiple mechanisms which are not yet fully elucidated but seem to depend, at least in part, on the genetic context of cells. for example, the rapalog everolimus, sensitized lung carcinoma cells to cisplatin treatment [15], whereas in colon cancer and renal carcinoma cell lines, pharmacological inhibition of mtor kinase prevented chemotherapy-induced cell death [24, 39]. in hek293 cells, the inhibition of mtor activity using both pp242 and sirna led to an increase in etoposide-induced cell death, as evidenced from the increase in the sub g1 population (figure 3b and 3d). in breast cancer, the mtor signalling pathway is commonly dysregulated and is implicated in resistance to current treatment [40, 41]. we analysed a panel of breast cancer cell lines to assess cell viability following etoposide-induced dna damage (figure 7a). one cell line, hbl100, an immortalized epithelial cell line, displayed high sensitivity to etoposide as compared with three other breast cancer cell lines, mda-mb-231, mcf7 and hcc1937, which demonstrated varying degrees of resistance to etoposide (figure 7a). importantly, this resistance was overcome by the inhibition of mtor activity with pp242, which significantly decreased breast cancer cell viability following dna damage (figure 7a). consistent with our previous results, western blot analysis revealed that etoposide-induced chk1 phosphorylation was strikingly inhibited by pp242 in all breast cell lines tested (figure 7b). interestingly the total chk1 protein level was also reduced by pp242 following dna damage in these cells with the exception of hbl100 (figure 7b). the mtorc2-specific phosphorylation of akt at ser473 was also monitored by western blot to confirm that mtorc2 activity was sufficiently inhibited by pp242 in these cell lines. collectively, these results demonstrate that inhibition of mtor activity significantly potentiates etoposide-mediated cell death in breast cancer, suggesting that breast cancer cells may rely on the mtorc2-chk1 pathway for survival. in line with this, recent work has demonstrated that cisplatin-induced apoptosis was significantly increased by loss of rictor but not raptor in breast and ovarian cancer cells [40, 42].","pmc4381605,pmc4381605",2,10,38,1,58
731,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,b-raf,protein,,braf,uniprot,p15056,plasma membrane,go:0005886,positive,d,inhibition,,,,,human,['2465'],nan,nan,"new cancer treatments involve directly targeting enzymes essential for the growth and proliferation of cancer cells. the mtor pathway regulates cell growth, and the raf/mek/erk pathway is critical for cell proliferation. activating mutations in b-raf have been found in 60–70% of human melanomas, making b-raf a potential target for small molecule inhibitors as therapy [3,4,11,28]. indeed, new drugs such as bay43-9006 have been developed as selective inhibitors of b-raf and are currently in phase ii clinical trials [6]. inhibition of mtor by rapamycin has been standard treatment for immunosuppression following organ transplant [15], and the rapamycin derivative cci-779 is now being clinically tested as a cancer chemotherapy [18-20]. thus, b-raf and mtor are acknowledged targets for anti-proliferative therapy [29].",pmc1289294,1,10,38,1,48
429,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,phosphorylation,t125,,,,human,['295'],nan,nan,"erk phosphorylation of caspase-9 inhibits caspase-9 proteolytic activity and provides another mechanism by which activated erk proteins mediate cell survival [2]. the effects of test compounds on erk-mediated phosphorylation of caspase-9 on t125 were examined by immunoblotting lysates from cells where the erk pathway was stimulated with egf. apoptosis-inducing test compounds 76, 76.2, 76.3, and 76.4, inhibited caspase-9 phosphorylation by 50-60% in treated cells (figure 6a). next, active erk2 was incubated with caspase-9 protein in the absence or presence of test compounds and phosphorylation was examined using in vitro kinase assays. figure 6b shows that compounds 76, 76.2, 76.3, and 76.4 inhibited erk-mediated phosphorylation of caspase-9 in a dose dependent manner. while 76.3 appeared to be the more potent inhibitor of caspase-9 phosphorylation, there was no statistical difference between compounds at any of the doses.",pmc3025971,1,10,38,1,48
426,erk,protein,,erk,uniprot,p27361,cytoplasm,go:0005737,mek,protein,,mek,uniprot,q02750,cytoplasm,go:0005737,positive,d,phosphorylation,tyr/thr,vmm18 melanoma cells,melanoma,skin,human,['2464'],nan,nan,"in vmm18 melanoma cells, the dual phosphorylation (tyr/thr) of erk was 9-fold higher in cells grown in 5% serum relative to cells grown in the absence of serum (figure 5, lanes 2 versus 1). there also was an increased level in the dual phosphorylation (ser217/221) of mek (not shown). treatment of vmm18 melanoma cells with a 10 nm dose of bay 43-9006 produced a 75% decrease in the dual phosphorylation of erk (figure 5, lane 4) and reduced the phosphorylation of mek below detection levels (not shown). these results were consistent with the inhibition of b-raf by bay43-9006. on the other hand, when vmm18 melanoma cells were treated with a 10 nm dose of rapamycin, the dual phosphorylation of erk was reduced by about half (figure 5, lane 3). our interpretation of this result is that mtor activity is required to maintain the phosphorylation of erk in melanoma cells. combination treatment of a 10 nm dose of rapamycin plus a 10 nm dose of bay 43-9006 reduced the phosphorylation of erk to a level even below that seen in cells grown in the absence of serum (figure 5, lane 5). this inhibition of erk phosphorylation by combination of rapamycin and bay43-9006 was as effective as inhibition of mek by the u0126 compound (figure 5, compare lanes 5 and 6).",pmc1289294,1,10,38,1,48
438,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,prevent inactivation,,,,,,['298'],nan,nan,"our data support a mechanism by which the erk-targeted compounds prevent inactivation of caspase-9 and p90rsk-1 phosphorylation of bad (figures 4 and 6). both caspase-9 and p90rsk-1 contain d-domains that are thought to form contacts with the cd domain of erk proteins [1,24]; the region predicted to be targeted by the test compounds. structural studies underway are determining the site of interactions between the compounds and erk proteins to better understand the mechanisms of inhibition and identify chemical features that can be modified to improve inhibitor binding and efficacy. a region analogous to the cd domain of erk can be found on other map kinases family members including p38 and jnk [29,42]. the subtle differences between these regions are determinants of substrate selectivity between the map kinases. in addition, differences in the residues associated with the d-domains of map kinase interacting proteins can confer selectivity. for example, the differences in d-domains on map kinase kinase (mkk) proteins appear to be important for determining what map kinase the mkk isoform will target [43].",pmc3025971,1,10,38,1,48
420,erk,protein,docking domain,,uniprot,p27361,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,inhibition,docking domain,,,,,['277'],nan,nan,characterization of erk docking domain inhibitors that induce apoptosis by targeting rsk-1 and caspase-9,pmc3025971,1,10,38,1,48
430,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,cyclin d1,protein,,ccnd1,uniprot,p24385,nucleus,go:0005634,positive,d,regulation,transcription promoter binding sites,,lung adenocarcinoma,lung,human,['2352'],nan,nan,"an extensive list of signaling pathways regulate cyclin d1 and its transcription promoter binding sites.32 erk, a major downstream effector of ras, is strongly associated with cell cycle entry particularly for the induction of cyclin d1 expression via downregulation of p27kip1.33,34 conversely, cyclin d1 activity is independent of erk expression.34 in our experiment, cink4 reduced cyclin d1, but did not affect its upstream regulator, phosphorylated erk. these results suggest that the relationship between cyclind1 and erk is not a simple unidirectional linear one, at least in lung adenocarcinoma with kras mutations.",pmc3742489,1,10,38,1,48
893,pras40,protein,,akt1s1,uniprot,q96b36,cell,go:0005623,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,association,pras40-rpl11,,,,,['2285'],nan,nan,pras40 suppresses p53 accumulation and activity in a manner dependent upon pras40-rpl11 association,pmc4216640,1,10,38,1,48
700,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,chk1,protein,,chek1,uniprot,q13131,nucleus,go:0005634,positive,d,phosphorylation,,,breast cancer cells,breast,human,['3034'],nan,nan,"mtor signalling is commonly dysregulated in cancer. concordantly, mtor inhibitors have demonstrated efficacy in a subset of tumors and are in clinical trials as combination therapies. although mtor is associated with promoting cell survival after dna damage, the exact mechanisms are not well understood. moreover, since mtor exists as two complexes, mtorc1 and mtorc2, the role of mtorc2 in cancer and in the dna damage response is less well explored. here, we report that mtor protein levels and kinase activity are transiently increased by dna damage in an atm and atr-dependent manner. we show that inactivation of mtor with sirna or pharmacological inhibition of mtorc1/2 kinase prevents etoposide-induced s and g2/m cell cycle arrest. further results show that chk1, a key regulator of the cell cycle arrest, is important for this since ablation of mtor prevents dna damage-induced chk1 phosphorylation and decreases chk1 protein production. furthermore, mtorc2 was essential and mtorc1 dispensable, for this role. importantly, we show that mtorc1/2 inhibition sensitizes breast cancer cells to chemotherapy. taken together, these results suggest that breast cancer cells may rely on mtorc2-chk1 pathway for survival and provide evidence that mtor kinase inhibitors may overcome resistance to dna-damage based therapies in breast cancer.",pmc4381605,1,10,38,1,48
1061,src,protein,tyrosine kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,cysteine protease,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,phosphorylation,,,colon cancer,,human,['980'],nan,nan,"phosphorylation is an important post-transcriptional modification for various cellular proteins. phosphoryaltion of caspases by protein kinases has been widely studied. for example, caspase-9 phosphorylation by different kinases has been reported. interestingly, tyrosine phosphorylation can increase caspase-9 activity, whereas phosphorylation of various serine or threonine sites can decrease caspase-9 activity.35 the phosphorylation of caspase-8 and -3 has also been reported.12, 13 however, the modification and regulation of caspase-7 remains poorly understood. the function of caspase-7 was long assumed to be redundant with the function of caspase-3 because of their similar structure and common protein substrates. in our previous study, we found that phosphorylation of caspase-7 is important in chemotherapeutic drug-induced apoptosis of breast cancer cells.27 interestingly, pak2 is a serine/threonine kinase, which decreases caspase-7 activity by phosphorylation. in the present study, we showed that the src tyrosine kinase can directly phosphorylate and interact with caspase-7 (figure 4), resulting in increased caspase-7 activity (figure 6). our finding is similar to the story of caspase-9 phosphorylation.35 apparently, the effect of tyrosine phosphorylation is opposite to the effect of serine/threonine phosphorylation of caspase family members. we also showed that caspase-7 is important for 5-fu induction of apoptosis independent of caspase-3 (supplementary figure 1). the relation between src and caspase-7 might explain why cells with low levels of src are more resistant to 5-fu-induced apoptosis (figure 3). importantly, antioxidants, such as nac or catalase, decrease the apoptotic effect induced by 5-fu in colon cancer cells by regulating src-dependent caspase-7 phosphorylation. taken together, our results highlight the role of src in 5-fu-induced apoptosis and provide a novel explanation as to why 5-fu is not effective in combination with some antioxidants in colon cancer patients, which is important for clinical chemotherapy.",pmc4040661,1,10,38,1,48
698,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,chk1,protein,,chek1,uniprot,o14757,nucleus,go:0005634,positive,i,activation,,,breast cancer,,human,['3037'],nan,nan,"in this study we investigated how mtor signals to the cell machinery to promote cell survival following dna damage. we found that both mtorc1 and mtorc2 activities are transiently increased following dna damage. inactivation of mtor, with sirna or an mtorc1/2 kinase inhibitor, prevented dna damage induced s and g2/m cell cycle arrest as well as chk1 activation, demonstrating a requirement of mtor for cell survival by establishing efficient cell cycle arrest. furthermore, we show that ablation of mtorc2 prevents chk1 activation and augments dna damage-induced cell death, suggesting that breast cancer cells may rely on the mtorc2-chk1 pathway for survival.",pmc4381605,1,10,38,1,48
697,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,chk1,protein,,chek1,uniprot,o14757,nucleus,go:0005634,positive,d,phosphorylation,,mcf7,epithelial-like,breast,human,['3046'],nan,nan,"(a) pharmacological inhibition of mtor suppresses etoposide-induced chk1 activation not chk2. mcf7 cells were treated in the absence or presence of 400 nm pp242 for 1 hr before addition of 50 μm and 100 μm etoposide for 4 hrs. whole-cell lysates were analyzed by western blot for phosphorylated mtor (ser2448), chk1 (ser345), and chk2 (thr68) and total protein levels of chk1 and chk2. actin was used as a loading control. (b) pharmacological inhibition of mtor suppresses uv-induced chk1 activation not chk2. mcf7 cells were exposed to 10 and 20 joules of uv and left to recover in the presence of 400nm of pp242 for 4hrs. whole-cell lysates were analyzed by western blot for phosphorylated mtor (ser2448), chk1 and phosphorylated chk1 (ser345), chk2 and phosphorylated chk2 (thr68). actin was used as a loading control. (c) pp242 prevents etoposide-induced chk1 phosphorylations and chk1 protein level. hek293 cells were incubated with 50 μm of etoposide in the absence and presence of 200 nm of pp242 for the time points indicated. whole-cell lysates were assayed by western blot for chk1 and phosphorylated chk1 (ser345, ser296 and ser317), akt and phosphorylated akt (ser473). actin was used as loading control. (d) pp242 prevents uv-induced chk1 phosphorylations but not chk1 protein level. hek293 cells were exposed to 10 and 20 joules of uv and left to recover in the absence and presence of 400nm of pp242 for 2hrs. whole-cell lysates were assayed by western blot for phosphorylated mtor (ser2448), chk1 and phosphorylated chk1 (ser345, ser296 and ser317). actin was used as loading control. (e) pp242 prevents etoposide-induced chk1 phosphorylations in breast cancer cell lines. hbl100, mda-mb-231 and hcc1937 cells were treated in the absence or presence of 400 nm pp242 for 1 hr before addition of 50 μm etoposide for 4 hrs. whole-cell lysates were analysed by western blot for chk1 and phosphorylated chk1 (ser345, ser317 and ser296). actin was used as a loading control. (f) ablation of mtor with sirna inhibits etoposide-induced chk1 phosphorylations but not chk1 protein in hbl100 cells. hbl100 cells were transiently transfected with allstars control sirna duplexes or sirna to mtor for a total of 72 hr. 50 μm of etoposide was added 4 hr before the end of the 72 hrs period. whole-cell lysates were analysed by western blot for mtor, chk1 and phosphorylated chk1 (ser345, ser317 and ser296), akt and phosphorylated akt (ser473). actin was used as a loading control.",pmc4381605,1,10,38,1,48
456,erk2,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,inhibit,,hela,epithelial-like,,human,['296'],nan,nan,"test compounds inhibit erk-mediated phosphorylation of caspase-9 in cells and in in vitro kinase assays. (a) hela cells transfected with caspase-9 (c287a) were pre-treated for 1 hour with 50 um of indicated test compound, stimulated with egf (25 ng/ml), and immunoblotted for phosphorylated caspase-9 (pt125) or total caspase-9. graph shows the mean ± sem for relative phosphorylation as determined by densitometry scanning from 3 independent experiments. (b) in vitro kinase assays examining 32p incorporation into caspase-9 following incubation with active erk2 and γ-32p-atp for 60 min. in the absence or presence of 1-25 μm of the indicated test compound. relative phosphate incorporation was quantified by phosphoimager analysis. data show the mean ± sem of three independent experiments. * and # indicates statistical significance compared to egf-only treatment (a) or untreated controls (b), p ≤ 0.05 and p ≤ 0.01, respectively. c, untreated control; (-), egf treated control; u, u0126",pmc3025971,1,10,38,1,48
1056,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,erk1/2,protein,,,uniprot,p27361,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['2063'],nan,nan,"cell lysates were collected and analyzed for a) py418 src and total cellular src (c-src), b) phospho-erk1/2 and total erk1/2 c) phospho- akt and total akt. representative western blots are shown and quantitative data are mean± sem of at least three independent experiments. * p<0.05, compared with 0nm control, #, p<0.05, compared with different cell line. d) five hundred μg of total cell lysate was immunoprecipitated with 10μg of anti-src antibody and analyzed for co-precipitated na/k atpase α1. a representative western blot is shown. values are mean ± sem from at least three independent experiments. * p<0.05 compared with control.",pmc4638348,1,10,38,1,48
1055,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,erbb2,protein,,erbb2,uniprot,p04626,plasma membrane,go:0005886,positive,d,phosphorylation,tyrosine residue,"murine fibroblasts, human breast cancer cells",,breast,human,['1401'],nan,nan,"src also participates in cancer cell functions involving the other family member of the egfr and/or its phosphorylation on a tyrosine residue that is analogous to the egfr y845. in murine fibroblasts, c3h10t1/2, and human breast cancer cells, mda-mb-361, where high levels of expression of erbb2 (naturally overexpressed) and erbb3 (ectopically or naturally overexpressed) are evident, mutual interaction between erbb2 and erbb3 takes place. such erbb2-erbb3 interaction was shown to be responsible for the erbb3-dependent (i.e., the erbb3 ligand heregulin-dependent) anchorage-independent growth and cell motility in a src-dependent manner [78]. in mba-mb-361 cells, the heregulin-dependent cell functions involve the phosphorylation of erbb2 on y877, a tyrosine residue analogous to egfr y845 [78]. thus, src-dependent phosphorylation of a tyrosine residue that resides in the activation segment is a phenomenon that occurs commonly for at least two egfr family proteins, egfr and erbb2. the incidence of egfr-erbb2 interaction is also implicated as a prognostic parameter for high malignancy and drug resistance of breast cancer cells, and it is also associated with the occurrence of y845 phosphorylation [79].",pmc3709701,1,10,38,1,48
1054,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,physical and/or functional interactions,,,,,human,['1389'],nan,nan,"after the discovery of src and egfr, much work has focused on understanding how ptks and their substrates act as a trigger of cellular functions, including malignant cell transformation. these studies include analysis of physical and/or functional interactions, that is, crosstalk, between src and transmembrane receptor/ptks such as platelet-derived growth factor receptor [11], trk/nerve growth factor receptor [12], colony-stimulating factor receptor [13], erbb2/her2/neu [14], and egfr [15,16]. in particular, the interaction of src and egfr has raised much interest because both are ubiquitously expressed and their co-overexpression and/or mutations have often been found in cancer cells of humans and model animals.",pmc3709701,1,10,38,1,48
1053,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,phosphorylation,y845,,normal and cancerous,normal,human,['1428'],nan,nan,"for the past eighteen years or so, since the initial discovery of the src phosphorylation of egfr on y845, much progress has been made in the recognition that y845 phosphorylation takes place in a variety of cancerous and normal physiological cell contexts, as well as in the understanding that y845 phosphorylation plays pivotal roles in these cellular contexts (figure 2). because egfr and src are expressed in almost all normal cells and tissues, the possible impact of their molecular interactions that lead to y845 phosphorylation may not be limited to the known phenomena described in this review article, but rather spread more to other cellular functions that have not yet been documented. egfr and src are prototypical gene products, whose viral counterparts are oncogenic, and molecular and enzymatic functions are the transmembrane receptor ptk and the cytoplasmic non-receptor ptk, respectively. the co-overexpression of these proteins sometimes confers high malignancy for certain kinds of human cancer, and their continued study should provide more information of fundamental importance in the field of basic cell biology, as well as in cancer and other pathological areas of cell biology and medicine.",pmc3709701,1,10,38,1,48
1050,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,d,binds,sh2 domain corresponding sites,min6 cells,pancreatic β cells,pancreas,human,['2589'],nan,nan,"stat3 is the downstream substrate of src and binds to its sh2 domain corresponding sites. src induces stat3 dimerization and entry into the nucleus, resulting in the activation of the transcription and translation of target genes. to explore role of rig-i in its competitive binding with src and inhibition of src activity34, min6 cells were grown in serum-free dmem and treated with igf. western blotting was performed to detect binding of rig-i and stat3 with activated src after co-immunoprecipitation with specific p-src antibodies. after rig-i transfection or ra treatment, binding of active src with rig-i increased, while binding of active src with stat3 was attenuated (fig. 9a, p < 0.05). to investigate whether rig-i modulated the src and stat3 interaction, the si-rig-i plasmid was used in addition to ra treatment. binding of active src with stat3 was increased compared to ra use only (fig. 9b, p < 0.05). furthermore, the stat3 plasmid was also used to confirm these observations. binding of active src with rig-i was inhibited and binding of active src with stat3 was not decreased after transfection with the stat3 plasmid and treatment with ra compared with treatment with ra only (fig. 9c, p < 0.05). interestingly, the total src level was not altered in these three experiments. edu experiments were also carried out. transfection with plasmid stat3 could reverse the decrease in the percentage of edu-positive β cells induced by ra (fig. 9d, p < 0.05). these results suggested that rig-i inhibits the src/stat3 association via competitive binding with active src, leading to inhibition of pancreatic β cells proliferation.",pmc4923948,1,10,38,1,48
699,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,chk1,protein,,chek1,uniprot,o14757,nucleus,go:0005634,positive,i,activation,,,,,human,['3049'],nan,nan,"in mammalian cells, mtor forms two functionally distinct complexes, mtorc1 and mtorc2, which contain shared and distinct partners. while mtorc1 exclusively contains a scaffolding protein, raptor, required for its function [37] mtorc2 complex contains rictor, needed for its assembly [10]. pp242 inhibits both mtorc1 and mtorc2 complexes, therefore in order to dissect out the contribution of mtorc1 and/or mtorc2 to dna damage mediated chk1 regulation we used rapamycin, which predominantly inhibits mtorc1, as well as specific downregulation of raptor and rictor with sirna. rapamycin had no effect on early etoposide-induced chk1 phosphorylation and protein level as compared with pp242 (figure 6a), suggesting that mtorc1 activity was dispensable for dna damage mediated regulation of chk1. instead these data suggested a requirement of mtorc2 for etoposide-induced chk1 activation as sirna against raptor (selective downregulation of mtorc1) did not affect chk1, whereas sirna against rictor (selective downregulation of mtorc2) did prevent etoposide-induced chk1 phosphorylation and total chk1 protein level (figure 6b). these results are in line with recent work suggesting an increasing role of mtorc2 in cell cycle progression [38]. taken together, these results show that early etoposide-induced increase in chk1 phosphorylation and total chk1 protein was dependent on mtorc2.",pmc4381605,1,10,38,1,48
741,mtor,protein,,,uniprot,p42345,,,chk1,protein,,,uniprot,o14757,,,positive,d,activation,,hek293,,,,['3051'],nan,nan,"since its discovery as the target of rapamycin, mtor has been identified as a crucial mediator of protein synthesis, cell growth, and metabolism. mtorc1 is also important for relaying signals to the cell machinery in response to dna damage. a number of studies have demonstrated that mtorc1 is downregulated in response to dna damage in a p53 dependent manner [13, 14]. however, others have reported an increase in mtor kinase activity in response to dna damage [16, 19-21]. the mechanism by which mtor promotes cell survival under conditions of dna damage is poorly understood. here, we found an increase in both mtorc1 and mtorc2 activity induced by early dna damage. in addition, mtor protein levels were transiently increased by etoposide treatment in several cell lines. this observed increase was not due to increased protein synthesis, but likely due to a transient stabilization of mtor that was dependent on atm and atr and independent of p53. as mtor is a key regulator of cell cycle progression from g1 to s phase [27], we investigated whether mtor promotes cell survival following dna damage by regulating cell cycle arrest, which would consequently allow more time for dna repair. indeed, our results show that inhibition of mtor by both sirna and a specific inhibitor caused a striking inhibition of etoposide-induced s and g2/m cell cycle arrest. further analysis revealed that the activation of a key cell cycle arrest regulator chk1 was dependent on mtor, as mtor inhibition prevented etoposide-induced increase of chk1 phosphorylation and total protein level. mtor inhibition with sirna, against mtor or rictor, or with pp242 consistently caused a reduction in chk1 phosphorylation in all cell lines used in this study and by two different types of dna damage, thereby demonstrating a requirement for mtor in chk1 activation following dna damage. in addition, mtor inhibition caused a reduction in chk1 protein level under certain conditions, particularly in hek293 cells after etoposide-induced dna damage. since chk1 is degraded faster after dna damage and we found no change in mrna expression, mtor most likely regulates chk1 at translational level. the mechanism of how mtor regulates chk1 phosphorylation remains to be investigated. atr is known to directly phosphorylate and activate chk1, however we found atr to be upstream of mtor. it will be interesting in future studies to identify if mtor or one of its downstream targets are responsible for chk1 phosphorylation, or whether mtor is involved in the regulation of chk1 phosphatases [43].",pmc4381605,1,10,38,1,48
1062,src,protein,tyrosine kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,cysteine protease,casp7,uniprot,q14790,cytoplasm,go:0005737,positive,d,phosphorylation,"tyr58, tyr151, tyr229, tyr230",,,,human,['974'],nan,nan,"after confirming that src can phosphorylate caspase-7, the next step was to identify the site(s) of caspase-7 that can be phosphorylated by src. the potential tyrosine phosphorylation sites were predicted by the netphos 2.0 software program as previously described27 (figure 5a). nine peptides were designed and synthesized commercially (peptide 2.0, houston, tx, usa). the peptide array results indicated that tyr58, tyr151, tyr229 and tyr230 of caspase-7 are likely to be the most important sites to be phosphorylated by src (figure 5b). when all four sites were mutated to phenylalanine, the in vitro kinase assay results showed that phosphorylation of the mut-caspase-7 protein by src decreased dramatically compared with wt-caspase-7, suggesting that these four sites, tyr58, tyr151, tyr229 and tyr230, are the most important sites of caspase-7 to be phosphorylated by src (figure 5c).",pmc4040661,1,10,38,1,48
734,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,affect,,,,,,['1029'],nan,nan,"geroconversion describes the transition of a cell from quiescence to senescence [46, 51]. blagosklonny's group showed that mtor activity could affect the outcome of p53 dependent arrest [46, 51, 52]. here we report that the regulation of mdm2 and the expression of atrx can also affect whether transformed cells undergo quiescence or senescence, particularly in response to cdk4 inhibition. furthermore, we were able to correlate changes in mdm2 with patient outcome because seven patients enrolled in our palbociclib clinical trial (nct01209598) consented to providing pre- and post-treatment biopsies, suggesting that geroconversion might account for the clinical activity of this class of drugs. thus we accomplished what we set out to do—identify determinants that can distinguish whether cdk4 inhibition will induce quiescence or senescence, and in so doing we have unexpectedly identified two new molecular players (atrx and mdm2) and an event (mdm2 turnover) regulating geroconversion.",pmc4480747,1,10,38,1,48
353,class i pi3k,protein,,,uniprot,p42336,plasma membrane,go:0005886,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,control,,,,,,['3611'],nan,nan,"autophagy is a vacuolar, self-digesting mechanism responsible for the removal of long-lived proteins and damaged organelles by the lysosome [270, 271]. the discovery of the autophagy (atg) genes has provided key information about the formation of the autophagosome, and about the role of macroautophagy in allowing cells to survive during nutrient depletion and/or in the absence of growth factors [270, 271]. two connected signaling pathways encompassing class i pi3k and mtor play a central role in controlling macroautophagy in response to starvation [271]. however, a considerable body of literature reports that macroautophagy is also a cell death mechanism that can occur either in the absence of detectable signs of apoptosis (via autophagic cell death) or concomitantly with apoptosis [271]. macroautophagy is activated by signaling pathways that also control apoptosis [271].",pmc2652403,1,10,38,1,48
354,craf,protein,,craf,uniprot,p04049,,,akt,protein,,akt,uniprot,p31749,,,positive,d,phosphorylation,,,b-cell,,human,['2973'],nan,nan,"møcm induced early increases in craf, akt and gsk-3β phosphorylation, and erk1/2 phosphorylation peaked at 24 hrs (figure 9c, d). in both lm2 and jf32 cells, increased akt phosphorylation corresponded to more phosphorylation of the akt substrate, pgsk-3β (figure 9h and 9i). phospho-craf levels, another marker of akt activity, also increased in concert with heightened increased akt activity from 4-24 hrs; although p-craf abruptly dropped at 48 hrs, pakt and pgsk-3β levels remained highly elevated (figure 9f, h and 9i).",pmc3135566,1,10,38,1,48
356,cyclin d,protein,,ccnd1,uniprot,p24385,,,rb,protein,,rb1,uniprot,p06400,,,positive,d,phosphorylation,,arpe-19,epithelial,retinal pigment epithelium,human,['1749'],nan,nan,"cyclin d is the first cyclin produced during the cell cycle in response to extracellular signals. cyclin d binds to cdk4, forming the active cyclin d–cdk4 complex. the cyclin d–cdk4 complex phosphorylates and inactivates the retinoblastoma susceptibility protein (rb). hyperphosphorylated rb dissociates from the e2f/dp1/rb complex, leading to e2f activation. the activation of e2f results in the transcription of various genes, including cyclin e, cyclin a, dna polymerase, and thymidine kinase. cyclin e binds cdk2, forming the cyclin e–cdk2 complex, which then promotes progression from g1 to s phase. to further examine cyclin-cdk kinase activity and to determine whether the tgf-β1-induced proliferation of arpe-19 cells is mediated by rb, western analysis was performed using an antibody that specifically recognizes phosphorylated rb. treatment of arpe-19 cells with tgf-β1 increased the level of hyperphosphorylated rb, which indicates that rb was inactivated following tgf-β1 treatment (figure 2c). furthermore, the level of rb phosphorylated at serine 780 was increased following tgf-β1 treatment. this site is critical for the activation of rb and this result confirms that tgf-β1 inhibits rb. the level of cyclin d1 increased significantly in a time-dependent manner following tgf-β1 treatment (figure 2c). rb is at least partly phosphorylated by cdk2. for cdk2 to be activated, it must bind a cyclin. tgf-β1 increased the active form of cdk2 (figure 2c). phosphorylation at threonine 160 induces a shift in the electrophoretic mobility of cdk2.35 the tyrosine 15 and threonine 14 residues of cdk2 are dephosphorylated by the phosphatase cdc25a.36 cdc25 phosphatases promote cell cycle progression by dephosphorylating and activating cdks, which are the major driving force for cell cycle progression.37, 38 cdc25a activates cyclin e (a)-cdk2 during g1 and s phase, and also appears to be involved in the activation of cdk1 at the g2/m checkpoint.39, 40 the level of cdc25a increased following tgf-β1 treatment (figure 2c). cyclin e associates with and activates cdk2 in g1 phase. the increase in the levels of rb hyperphosphorylation and cyclin d1 was greater when cells were treated with tgf-β1 for 6 h than when they were treated for 48 h (data not shown). the levels of the other proteins discussed above were similar, regardless of whether the cells were treated with tgf-β1 for 24 or 48 h (data not shown). these data indicate that tgf-β1 induces cell cycle progression by regulating the activity and expression of several cell cycle regulators.",pmc3730417,1,10,38,1,48
162,atm kinase,protein,kinase,atm,uniprot,q13315,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,phosphorylation,"s313, s314, s366, t377, s378, t387",,,,human,['1037'],nan,nan,"the intrinsically unstructured p53 tad and p53 ctd are target sites for various post-translational modifications such as phosphorylation and acetylation (5,6). p53 ctd is acetylated at k370, k372, k381 and k382 by p300/cbp and these acetylations have been shown to decrease the non-specific dna binding of p53 ctd in vitro (7). phosphorylation of p53 at s15, t18, s20 upregulates its transcriptional activity by directly stabilizing it against mdm2-mediated degradation (8,9). several sites are also phosphorylated in the p53 ctd, particularly, s366, t377, s378, t387 and s392 (10,11). in response to dna damage, atm kinase, the gene mutated in ataxia telangiectasia, activates checkpoint kinases chk1 and chk2, which phosphorylate p53 at multiple sites, in particular, s313, s314, s366, t377, s378 and t387. mutation of these phosphorylation sites has differential effects on the acetylation of p53 (10). phosphorylation at s378 and dephosphorylation at s376 are important for 14-3-3 to activate human p53 (12). however, two additional sites, s366 and t387 have been identified on human p53 ctd in vitro that could be additional binding sites for 14-3-3 proteins (13).",pmc2817464,1,10,38,1,48
917,pten,protein,tumor suppressor,pten,uniprot,p60484,cytoplasm,go:0005737,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,phosphorylation,,,glioma,brain,human,['3651'],nan,nan,"further work provided the first evidence that the systemic administration of a pi3k inhibitor ly294002 has antitumor and antiangiogenic activity in vivo [442]. it was shown that pten reconstitution diminished phosphorylation of akt, induced the transactivation of p53 and increased the expression of p53 target genes in glioma cells [442]. pten and ly294002 induced p53 activity in human brain endothelial cells, suggesting that pten and pi3k pathways can suppress the progression of cancer through direct actions on tumor and endothelial cells [442]. ly294002 inhibited glioma tumor growth in vivo, induced tumor regression, decreased the incidence of brain tumors, and blocked the tumor-induced angiogenic response in vivo [442]. these data provided evidence that both pten and pi3k inhibitors regulate p53 function and display in vivo anti-angiogenic and anti-tumor activity [442]. these results provided evidence that the two tumor suppressor genes, pten and p53, act together to block tumor progression in vivo. ly294002 inhibited ascites formation in a mouse model of human ovarian cancer by inhibiting tumor and peritoneal neovascularization as well as vascular permeability [443]. ly294002 also directly inhibited vegf protein expression and release from ovarian carcinoma, suggesting that the inhibitor blocks the vegf signaling pathway involved in angiogenesis and vascular permeability [443].",pmc2652403,1,10,38,1,48
160,atm,protein,,,uniprot,p46531,,,p53,protein,,,uniprot,p04637,,,positive,d,phosphorylation,s15,,,,human,['2440'],nan,nan,"thus, according to our model, following dna damage atm phosphorylates p53-s15, dbc1-t454 and chk2-t68, inducing p53 stabilization, dbc1-sirt1 binding and chk2 activation and phosphorylation of regγ-ser247. these events enhance dbc1-regγ complex formation which, in turn, further increases its binding to and inhibition of sirt1, finally leading to p53-dependent apoptosis (figure 6).",pmc4245943,1,10,38,1,48
1073,stat3,protein,phosphorylated,stat3,uniprot,p40763,nucleus,go:0005634,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,positive,d,phosphorylation,,min6 cells,pancreatic beta-cell,pancreas,mouse,['2578'],nan,nan,ifa was used to observe visually the changes in localization and levels of phospho-stat3 or the level of src. min6 cells or isolated mouse islets were subjected to ifa after transfection and pharmaceutical treatment. fluorescein-labelled antibodies diluted in pbs-bsa [anti-insulin/cy3 antibody (1:50) and anti-phospho-stat3/tritc antibody (1:50) or anti-insulin/cy3 antibody (1:50) and anti-src/tritc antibody (1:50)] were added to min6 cells or mouse islets and incubated overnight at 4 °c. isolated mouse islets in suspension were centrifuged at 2000 × g for 5 min at 4 °c at each step2326.,pmc4923948,1,10,38,1,48
374,egf,protein,,egf,uniprot,p01133,cell membrane,go:0016020,erk,protein,,erk,uniprot,p27361,cytoplasm,go:0005737,positive,d,sustained signaling,erk signaling pathway,,,,human,['2693'],nan,nan,"our results suggest that co-stimulation with low, physiological egf doses and insulin endows the mitogenic egfr pathway with more sustained erk signaling. early observations showed that the duration of erk activation is crucial for cell fate decisions (marshall, 1995). in these classical experiments, pc12 cells proliferated after transient erk activation by egf, but differentiated after more sustained erk activation by the nerve growth factor. subsequent work revealed that the duration of erk activation is sensed by a network of immediate early genes, including the transcription factor c-fos (murphy et al, 2002), while the differential timing of erk signaling is explained by subtle alterations in signaling circuits, induced by distinct ligands (kholodenko, 2007).",pmc2683723,1,10,38,1,48
377,egf,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,,,,human,['2677'],nan,nan,"we have developed a computational model to describe in quantitative terms how cell stimulation by egf and insulin is linked to the activation of ras/erk and pi3k/akt pathways. the current model stems from our previously developed egfr network models that were based on in vitro and in vivo measurements of signaling kinetics. a number of egfr signaling model predictions were validated in our own studies (kholodenko et al, 1999; moehren et al, 2002; kiyatkin et al, 2006; birtwistle et al, 2007) and, in addition, tested by other groups (schoeberl et al, 2002; hatakeyama et al, 2003; resat et al, 2003; blinov et al, 2006). this paper extends our previous models to incorporate ir signaling and regulatory processes involved in egfr–ir crosstalk. however, we do not create a combinatorially complex in silico replica of all distinct biochemical species and interactions, which would be impractical (borisov et al, 2005; hlavacek et al, 2006; birtwistle et al, 2007). instead, we construct a basic, minimal model of the combined egfr and ir networks. the goal of this model is to provide an insight into the mechanisms of cellular responses to combined egf and insulin treatment that can account for our data.",pmc2683723,1,10,38,1,48
759,mutant kras,protein,,,uniprot,p01116,,,erk,protein,,mapk1,uniprot,p28482,,,positive,d,inhibition,,,nsclc,lung,human,['2632'],nan,nan,"the exact influence of statins on gefitinib resistance in human non-small cell lung cancer (nsclc) cells with kras mutation alone or kras/pik3ca and kras/pten comutations remains unclear. this work found that transfection of mutant kras plasmids significantly suppressed the gefitinib cytotoxicity in calu3 cells (wild-type kras). gefitinib disrupted the kras/pi3k and kras/raf complexes in calu3 cells, whereas not in calu3 kras mutant cells. these trends were corresponding to the expression of pakt and perk in gefitinib treatment. atorvastatin (1 μm) plus gefitinib treatment inhibited proliferation, promoted cell apoptosis, and reduced the akt activity in kras mutant nsclc cells compared with gefitinib alone. atorvastatin (5 μm) further enhanced the gefitinib cytotoxicity through concomitant inhibition of akt and erk activity. atorvastatin could interrupt kras/pi3k and kras/raf complexes, leading to suppression of akt and erk activity. similar results were also obtained in comutant kras/pten or kras/pik3ca nsclc cells. furthermore, mevalonate administration reversed the effects of atorvastatin on the kras/raf and kras/pi3k complexes, as well as akt and erk activity in both a549 and calu1 cells. the in vivo results were similar to those obtained in vitro. therefore, mutant kras-mediated gefitinib insensitivity is mainly derived from failure to disrupt the kras/raf and kras/pi3k complexes in kras mutant nsclc cells. atorvastatin overcomes gefitinib resistance in kras mutant nsclc cells irrespective of pik3ca and pten statuses through inhibition of hmg-coa reductase-dependent disruption of the kras/raf and kras/pi3k complexes.",pmc3789171,1,10,38,1,48
380,egf,protein,,,uniprot,p01133,extracellular region,go:0005615,erk1/2,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,,mdck,epithelial,kidney,human,['1776'],nan,nan,"egf-induced erk1/2 phosphorylation and p-erk1/2–dependent inhibition of ina in mdck cell lines. g525c, r564st, p616, and t613a mdck cell lines were grown to confluence on filters and bathed in im for 48 h. (a) individual monolayers were treated with vehicle (lane c; dmso, 10 μl, both sides, 45 min), egf (lane e; egf, 20 ng/ml, basolateral, 15 min), erk kinase inhibitor (u; u0126, 10 μm, both side, 45 min), or erk kinase inhibitor plus egf (u + e; u0126, 10 μm, both side, 30 then egf, 20 ng/ml, basolateral, 15 min). cells were then lysed, separated by sds-page, and probed for phosphorylated erk1/2 and total erk1/2. the blots are representative of three independent experiments. densitometry was performed on each blot and the ratio of perk1/2 to total erk1/2 was determined for each cell line under each condition and the data are summarized in b. (c) confluent monolayers of g525c, r564st, p616l, and t613a mdck cell lines were exposed to egf (20 ng/ml, 30 min, basolateral) with or without pretreatment with an erk kinase inhibitor (u0126; 10 μm, 15 min, bilateral). the inhibition of ina was calculated as previously described. n = 5. p < 0.05. *, significantly different compared with g525c control; **, significantly different compared with monolayers not treated with u0126.",pmc2151644,1,10,38,1,48
755,mtorc1,protein,,,uniprot,q13490,cytoplasm,go:0005737,cyclin d1,protein,,ccnd1,uniprot,p24385,nucleus,go:0005634,positive,i,degradation,,,,breast,human,['1584'],nan,nan,"several oncogenic proteins, such as cyclin d1, c-myc and mcl-1, are known to be regulated by mtorc1 signaling through cap-dependent translation [5, 32]. although rapamycin reduced the levels of these proteins, this study surprisingly failed to demonstrate that this occurs through mtorc1-mediated suppression of cap-dependent translation, since inhibition of gsk3 prevented reduction of these proteins without rescuing inhibition of phosphorylation of p70s6k, s6 and 4ebp1 and suppression of cap-binding by rapamycin (fig. 4). rather, we have demonstrated that rapamycin induces gsk3-dependent degradation of these proteins (figs. 4 and 5), revealing a novel mechanism by which rapalogs reduce the levels of these oncogenic proteins. our findings are in fact in agreement with a previous report that rapamycin induces gsk3-dependent degradation of cyclin d1 in human breast cancer cell lines [28]. in addition to these findings, we have further shown that the e3 ubiquitin ligases, fbx4 and fbxw7, mediate rapamycin-induced cyclin d1 degradation and c-myc and mcl-1 degradation, respectively (fig. 5).",pmc4496196,1,10,38,1,48
393,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,i,activation,,,cancer,ovarian,human,['1406'],nan,nan,"morgan et al. [105] showed that the combined use of the egfr inhibitor cetuximab or erlotinib with gemcitabine increases the efficacy of radiation of damaging pancreatic cancers. in this case, phosphorylation of y1173, but not y845, was shown to be effectively decreased, indicating that y1173, rather than y845, is a target of these egfr kinase inhibitors. in ovarian cancer cells that exhibit resistance to cisplatin therapy, ncx-4016, a nitro-derivative of aspirin, has been reported to inhibit effectively the egfr signaling involving y845 and y992 phosphorylation of the receptor, and the activation of akt and stat3 [106]. similar efficacy to egfr signaling was also shown with the use of a cyclooxygenase-2 inhibitor, celecoxib, and a cyclic gmp phosphodiesterase inhibitor, exisulind, in the wistar-unilever rat prostate cancer model [107].",pmc3709701,1,10,38,1,48
394,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,positive,i,activation,y845,a431,epithelial,skin,human,['1415'],nan,nan,"in some cell systems, y845 phosphorylation seems to promote growth arrest and/or inhibition of proliferation. in a431 epidermoid carcinoma cells, growth arrest induced by high concentrations of egf is accompanied by y845 phosphorylation and up-regulation of the stat3-p21waf1 pathway. in this case, sequestration of the phosphorylated y845 signal by the introduction into the cells of an antibody that binds to y845 attenuated these events [49]. a similar anti-proliferative function was also demonstrated in mb-231 breast cancer cells, in which angiocidin and egf promoted the y845 phosphorylation and activation of nfκb, which resulted in the induction of p21waf1 and cell cycle arrest [136]. activation of egfr signaling sometimes involves action of the extracellular signal that stimulates the shedding of the egfr ligand. liu et al. [137] have reported that thrombospondins, and their recombinant proteins containing egf-like repeats, are capable of inducing egfr activation (involving the phosphorylation of y845 and other tyrosine residues) and cell migration in a431 cells through the activation of matrix metalloprotease 9 (but not through direct binding to egfr). in a431 cells, in which egfr is overexpressed, depletion of cholesterol with methyl-β-cyclodextrin causes site-specific phosphorylation of egfr, including y845 [138]. further characterization of this event has revealed that cholesterol most likely affects the phosphorylation state of egfr by perturbing membrane properties to form membrane microdomains or “lipid rafts”, where src and other signaling proteins are enriched and constitute a platform for a variety of signal transductions [139–143]. lipid rafts in vascular smooth muscle cells [144] and bladder carcinoma cells [89,90] have also been reported to work as a scaffold for src-egfr signaling. in the case of bladder carcinoma cells, disruption of the membrane microdomains by methyl-β-cyclodextrin results in the interference with src-dependent signal transduction and the promotion of apoptosis under serum-deprived culture conditions [89,90], although its relationship to the phosphorylation state of egfr (i.e., y845) is unknown.",pmc3709701,1,10,38,1,48
752,mtorc1,protein,,,uniprot,p42345,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,accumulation,,normal human fibroblast,fibroblast,skin,human,['3342'],nan,nan,"to this end, we have analysed pi3k/akt pathway activation-induced senescence in a normal human fibroblast model. we show that this senescence requires mtorc1-dependent accumulation of p53 involving increased p53 synthesis and stabilisation mediated by inactivation of mdm2. we have identified important differences between senescence induced by the akt and ras oncogenic modules. activated pi3k/akt signalling rapidly induces senescence independent of the hyperproliferative phase required for the effect of h-rasv12. consistent with this finding, pi3k/akt-induced senescence is independent of the dna damage response that is required by h-rasv12.",pmc3325598,1,10,38,1,48
396,egfr,protein,,,uniprot,p00533,cell membrane,go:0005886,irs,protein,,,uniprot,p35568,cytoplasm,go:0005737,negative,d,phosphorylation,,hek293,,,human,['2679'],nan,nan,"the model also incorporates and analyzes complex feedback circuitry of the egfr and ir networks. for instance, pip3-dependent positive feedback circuits in the model involve gab1–pi3k and irs–pi3k interactions (rodrigues et al, 2000; johnston et al, 2003; mattoon et al, 2004). activated erk inhibits sos (dong et al, 1996; fucini et al, 1999), gab1 (lehr et al, 2004) and irs (de fea and roth, 1997) by direct phosphorylation. activated mtor mediates multiple modes of feedback, including positive feedback to akt and negative feedback loops to irs (gual et al, 2003; sarbassov et al, 2005). although akt-induced inhibitory phosphorylation of raf (zimmermann and moelling, 1999; wellbrock et al, 2004) is included in the model, we assume this inhibition to be weak in hek293 cells, as no noticeable mek or erk activation was detected experimentally, following inhibition of akt activity (see supplementary figure s4). the current model involves many parameters that have no analogs in our previously published models. we used the experimental data that are shown in figures 2 and 3 (excluding experiments with pi3k inhibitor) as a training data set to obtain reasonable fit between the model simulations and data by manually varying the parameter values (see supplementary table s1). however, when parameters were fitted, their upper and lower bounds were in agreement with experimental observations for similar reaction types. in addition, reaction rates were always constrained not to be faster than the diffusion limit.",pmc2683723,1,10,38,1,48
749,mtor,protein,serine/threonine protein kinase,,uniprot,q9y4h3,cytoplasm,go:0005737,amp kinase (ampk),protein,,prkaa1,uniprot,o43741,cytoplasm,go:0005737,positive,d,activation,cytoplasm,,,,,['2827'],nan,nan,"growth-regulating signals originating from within and outside the cells are integrated through serine/threonine protein kinase mammalian target of rapamycin (mtor) that has a key role in many aspects of cellular physiology. the mtor signaling network has been implicated in the regulation of many cell functions including protein synthesis, cell growth and cell survival (abraham, 1998; guertin & sabatini, 2005; huang & houghton, 2003; sabatini, 2006). there are several links between mtor signaling and human diseases such as cancer (wullschleger et al., 2006). a number of pathways converge to regulate the activity of mtor. these include amp kinase (ampk) that is activated by low atp levels and, therefore, nutritional status of the organism, receptor tyrosine kinases such as egfr and insulin receptor as well as wnt signaling pathway (hardie et al., 2006; inoki et al., 2006; kudo et al., 1996; tzatsos & kandror, 2006).",pmc2653860,1,10,38,1,48
157,atm,protein,,atm,uniprot,q13315,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,ser473,cos cells,epithelial-like,,human,['13'],nan,nan,"in vertebrates, atm is recruited to and activated primarily at dna double-strand breaks in conjunction with mrn (mre11 : rad50 : nbs1) complex. once activated, atm triggers the phosphorylation of multiple substrates at the site of damage, such as h2ax, chk2, and tumor suppressor p53, leading to cell cycle arrest, dna repair, or apoptosis. mutation of the atm-gene results in ataxia telangiectasia (at), a rare human disease characterized by growth retardation, severe immunodeficiency, insulin resistance, hypersensitivity to radiation, and predisposition to cancer [94]. interestingly, akt knockout mice show some similar phenotypic abnormalities to atm-deficient mice, such as growth retardation, insulin resistance, hypersensitivity to gamma-irradiation, and immunodeficiency [8, 11, 95], indicating that atm and akt may be involved in the same signalling transduction pathway. viniegra et al. provide clear evidence that atm acts as an upstream activator of akt in response to insulin or γ-radiation [91]. overexpression of exogenous atm and akt in cos cells promotes akt ser473 phosphorylation by insulin or ir and the phosphorylation depends on the pi3k-like catalytic domain of atm. although atm binds to akt directly, there is no apparent direct phosphorylation of akt ser473 by atm, suggesting that other intermediate proteins downstream of atm may be involved in direct phosphorylation of akt in response to insulin or ir. interestingly, another study by caporali et al. demonstrates that atr, but not atm, is required for akt phosphorylation at ser473 in response to temozolomide (tmz), a therapeutic methylating agent [93]. sirna-mediated knockdown of atr but not atm expression results in abrogation of tmz-induced phosphorylation of akt [93]. however, there is no clear evidence that atr phosphorylates akt directly in response to tmz. it is possible that atr mediates activation of another kinase to phosphorylate akt.",pmc3317191,1,10,38,1,48
155,atm,protein,kinase,atm,uniprot,q13315,nucleus,go:0005634,mtor,protein,kinase,frap1,uniprot,p42345,cytoplasm,go:0005737,positive,i,stabilization,,hct116,colorectal,colon,human,['3042'],nan,nan,"(a) etoposide induced increase in mtor is atm-dependent and p53-independent. hct116 p53+/+ cells and hct116 p53−/− cells were pre-treated in the absence or presence of 10 μm atm inhibitor (atmi) for 1 hr before incubation with 100 μm etoposide for 4 hrs. whole-cell lysates were assayed by western blot for mtor. actin was used as a loading control. (b) etoposide induced increase in mtor is atr-dependent. hek293 cells were transiently transfected with allstars sirna control duplexes or atr sirna for 72 hrs. 100 μm of etoposide was added at 4 hrs prior to the end of 72 hrs incubation period. whole-cell lysates were assayed by western blot for atr, mtor and phosphorylated mtor (ser2481), chk1 and phosphorylated chk1 (ser345). actin was used as loading control. (c) mtor accumulation induced by etoposide is stabilisation. hct116 p53+/+ cells (left panels) and hct116 p53−/− cells (right panels) were pre-treated in the absence or presence of 10 μm cycloheximide for 1 hr before incubation with either 10 μm of mg-132 or 100 μm of etoposide for a further 4 hrs. whole-cell lysates were assayed by western blot for mtor. actin was used as a loading control.",pmc4381605,1,10,38,1,48
682,mtor,protein,kinase,,uniprot,p42345,cytoplasm,go:0005737,p53,protein,transcription factor,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,regulation,,,,,human,['3045'],nan,nan,"key regulators of the dna damage-induced cell cycle arrest include chk1, chk2 and p53 proteins [29]. we therefore assessed whether mtor is required to activate these proteins by observing the status of the dna damage-induced phosphorylation and their total protein levels. western blot analysis revealed that etoposide-induced increase in phosphorylation and total protein level of chk1, and p53 were reduced by pharmacological inhibition of mtor kinase at 4 and 24 hrs. although chk2 phosphorylation was unaffected at 4hrs, it was reduced at 24 hrs (figure 3e). to confirm that the effects we observed were specific to mtor, we downregulated mtor with sirna and found that etoposide-induced phosphorylation of chk1 and chk2 were reduced as well as total chk1 level (figure 3f). overall, dna damage-induced phosphorylation of the histone protein, h2ax, a key indicator of the amount of damaged dna, did not appear to be affected by mtor inhibition (figure 3e and f). in conclusion, these results show that mtor is required for efficient dna damage-induced cell cycle arrest, and this is possibly mediated by regulation of key cell cycle proteins chk1, chk2 and p53. mtor-dependent induction of p53 after dna damage has previously been reported [16, 18, 24, 30] and as hek293 cells used here are known to have non-functional p53 [31], we further assessed mtor-dependent regulation of chk1 and chk2 after dna damage. we also extended our studies to include breast cancer cells as mtor is emerging as an important target for breast cancer treatment. pharmacological inhibition of mtor with pp242 inhibited early etoposide- and uv-induced chk1 phosphorylation in mcf7 cells, but not chk2 phosphorylation (figure 4a and 4b). in addition, sirna-mediated downregulation of mtor reduced total chk1 level and phosphorylation, but not chk2 phosphorylation, when a lower concentration of etoposide was used (supplementary figure 2). therefore we decided to focus primarily on how mtor is required for chk1 regulation following early dna damage.",pmc4381605,1,10,38,1,48
735,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,regulation,,,,,human,['3036'],nan,nan,"apart from regulating cell growth signalling, mtor also responds to numerous cell stresses including nutrient and energy availability, as well as genotoxic stress, in order to promote cell survival [1]. however, how mtor detects dna damage and signals this to the dna repair, cell cycle and cell death machineries is still poorly understood. while there is evidence that dna damage eventually leads to mtorc1 inhibition through p53-dependent mechanisms [13, 14], there are also an increasing number of reports demonstrating that mtorc1 positively regulates p53, [15-18] and that both mtorc1 and mtorc2 pathways are activated following dna damage [16, 19-21]. recently, two groups have identified that mtorc1 regulates the dna damage response through the upregulation of fancd2 gene expression, a key protein involved in the repair of dna double-strand breaks [22, 23].",pmc4381605,1,10,38,1,48
1047,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,noxa1,protein,,nox1,uniprot,q9y5s8,cytoplasm,go:0005737,positive,d,phosphorylation,tyr110,hek293,epithelial,kidney,human,['1363'],nan,nan,"src phosphorylates noxa1 on tyr110. (a and b) noxa1 is targeted by src-mediated phosphorylation. one representative experiment from three separate experiments is shown. (a) hek293 cells were transfected with flag-tagged noxa1 along with srcyf or srckm as indicated. after 24 h, cells were lysed and cell extract were resolved by sds-page using noxa1-specific antibody. (b) hek293 cells were transfected as indicated and cell extracts were treated or not with calf intestinal phosphatases (cip) as described in material and methods. proteins were resolved by sds-page and the presence of a phosphorylation doublet corresponding to noxa1 was detected using noxa1-specific antibody. (c) endogenous and ectopically-expressed noxa1 is tyr-phosphorylated by src in ht29 cells. ht29 cells were transfected with empty vector or with noxa1 expression vector and treated as indicated with pp2 or pp3. after 24 h, cells were lysed and ip was performed using noxa1-specific antibody. the levels of endogenous or ectopically-expressed noxa1, which was tyr-phosphorylated, were analyzed using anti-p-tyr antibody (lower panel), while the presence of noxa1 in cell lysates was verified by reblotting the membrane with noxa1-specific antibody (upper section). one representative experiment from three separate experiments is shown. (d) a schematic representation of the predicted phosphorylation sites on human noxa1 protein (accession number nm_006647) using bioinformatics tools available online (www.cbs.dtu.dk). the phosphorylation potential represents the likeness of a residue to be phosphorylated. its value is included between 0 (low phosphorylation potential) and 1 (high phosphorylation potential). phosphorylation potential (y axis) is plotted for each amino acid residue of noxa1 (x axis). the blue and the green lines indicate serine (ser) and threonine (thr) residues which could be targeted by ser/thr kinases. the red lines indicate tyrosine (tyr) residue which can be phosphoryalted by tyr-kinase. the black arrow indicates the tyr110 of noxa1 as the residue with the highest phosphorylation potential for tyr-kinase (=0.87). (e) src phosphorylates noxa1 on tyr110. hek293 cells were transfected as indicated with srcyf and with myc-tagged wild type noxa1, unphosphorylable noxa1 y110a and phosphomimetic noxa1 y110e. after 24 h, cells were lysed and ip was performed using noxa1-specific antibody. the levels of tyr-phosphorylated noxa1 were analyzed using anti-p-tyr antibody (lower panel), while comparable expression levels of transfected myc-tagged noxa1 mutants was verified by reblotting the membrane with myc antibody (upper section). one representative experiment from three separate experiments is shown. (f) src phosphorylates noxa1 directly. noxa1 wt and noxa1 y110a were transfected in hek293 cells and immunoprecipitated using noxa1 specific antibody. an in vitro kinase assay was performed using recombinant active src as in materials and methods. the levels of tyr-phosphorylated noxa1 were analyzed using anti-p-tyr antibody (upper panel), while immunoprecipitation efficiency was verified by reblotting the membrane with myc antibody (lower section).",pmc2993755,1,10,38,1,48
1018,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,enzyme,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['982'],nan,nan,"purified wt-caspase-7, mut-caspase-7, wt-caspase-3 and caspase-7 peptides were incubated with active src (upstate biotechnology, inc., boston, ma, usa) and 1 mci of [γ-32p] atp, 100 μm unlabeled atp and kinase buffer (50 mm tris-hcl ph 7.5, 10 mm mgcl2, 1 mm edta, 1 mm dtt and 0.01% brij 35; cell signaling technology, inc.). each reaction was incubated in a 32 °c water bath for 40 min and the reaction was stopped by adding 6 × sds loading buffer. the proteins were resolved by sds-page, and visualized by autoradiography.",pmc4040661,1,10,38,1,48
1041,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,phosphorylation,tyr845,hek293 cells,epithelial-like,kidney,human,['2144'],nan,nan,"src is known to be expressed in hek293 cells (abrahamsen et al., 2003; arinsburg et al., 2006). consistent with these studies, we found the expression of src in hek293 cells (fig. 4b). the phosphorylation of tyr416 in the activation loop of src protein is associated with the increased activity (hunter, 1987). when hek 293 cells were transfected with ep2, the levels of endogenous p-src were not significantly altered due to the low transfection efficiency with transient transfection (data not shown). therefore, we co-transfected hek293 cells with ep2 and src expression plasmids and the effect of ep2 on src phosphorylation was examined. because the previous results suggest that src is a potential upstream kinase for ep2-induced p38 phosphorylation, we anticipated that over-expression of ep2 would increase src activity. when hek 293 cells were co-transfected with expression vectors for ep2 and src, p-src (tyr416) levels were increased compared to those in vector and src-transfected cells (fig. 4b), indicating that ep2 overexpression induces the phosphorylation of src. then we examined if ep2 overexpression increases src activity. because tyr845 in egfr is a substrate for src and known to be phosphorylated by src (biscardi et al., 1999; tice et al., 1999), we hypothesized that ep2 would activate src, which in turn results in increase in egfr phosphorylation at tyr845. to test this, hek293 cells were co-transfected with expression vectors for ep2 and egfr and incubated with or without pp2. western blot analysis for phosphorylated tyr845 in egfr (fig. 4b) showed that the phosphorylation was increased by ep2 overexpression compared to vector and egfr-transfected cells. furthermore, ep2-induced increase in tyr845 phosphorylation was blocked by pp2 treatment, indicating that ep2 overexpression increases endogenous src activity. these results demonstrate that ep2 induces the phosphorylation and the activation of src.",pmc4624070,1,10,38,1,48
109,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,p53mut,protein,mutant,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,inhibition,,t24 and sq20b,,,human,['382'],nan,nan,"the data presented above suggests that inhibition of akt promotes increased turnover of p53mut. inhibiting p53mut function is of particular interest as mutations in p53 are attributed with gain of function phenotypes that accelerate tumor development, promote increased metastasis and resistance to therapy [24, 25]. mutations in p53 mediate resistance to dna damage induced by ionizing radiation (ir) [64] and therefore if our model is correct, akt inhibition should revert this effect. upon treatment with pi-103, the initial high levels of p53mut protein in t24 and sq20b cell lines are reduced concomitantly with decreased phospho-s48-npm and increased sensitivity to ir (fig. s6a and s6b) in line with previous reports [65]. moreover reduction of p53mut independently of akt inhibition, via sirna mediated silencing of p53, increases the sensitivity of t24 cells to ir (fig. s6c). inhibition of akt with mk-2206 mediates reduction in p53mut and clonogenic survival upon exposure to ir (fig. 6a), suggesting that the mechanistic regulation of npm dynamics and arf localization correlates with therapeutic resistance to dna damage. furthermore sirna mediated knockdown of arf expression similarly increased the sensitivity of t24 cells to ir, indicating that arf promotes resistance to ir in p53mut t24 cells (fig. 6b). nucleoplasmic arf is targeted for degradation by the e3-ligase ulf [57], therefore manipulation of ulf levels should have the opposite effect on sensitivity to ir. indeed, depletion of ulf resulted in elevated arf levels and enhanced resistance of t24 cells to ir in an arf dependent manner (fig. s6d). to confirm that phospho-s48-npm is responsible for ir resistance, we next ablated npm expression in t24 cells and expressed sirna resistant npm and npm-s48a mutants. in agreement with our model, overexpression of npm-s48a increases arf nucleolar foci (fig. 6c, bars) and decreases clonogenic survival (fig. 6c). these results suggest that akt mediated phosphorylation of npm-ser48 promotes cellular resistance to ir by promoting arf relocalization to the nucleoplasm and the stabilization of p53mut.",pmc4171619,1,10,38,1,48
980,s6,protein,active form,rps6,uniprot,p62753,cytoplasm,go:0005737,pten,protein,,pten,uniprot,p60484,nucleus,go:0005634,positive,d,activation,pten,,,,human,['901'],nan,nan,"a major challenge for the development of cancer therapy is the identification of predictive biomarkers of efficacy. there are no known predictive biomarkers for the efficacy or resistance in cancer of mtor inhibitors. activation of pi3k signalling, through akt activation, pten deletion, growth factor stimulation or aberrant growth factor receptor signalling, may indicate potential sensitivity of tumours to mtor inhibition [232]. thus, the differential expression of mtor pathway proteins (pten and active forms of akt and s6) may be possibly predictive markers for tumour response to mtor inhibition, as described in glioblastoma, prostate and breast cancer cell lines [233,234]. nevertheless, these predictors of response have been proposed based only on preclinical data and in specific types of cancer, and have not been clinically validated, with the exception of the loss of pten expression, that was used in clinical trials as a marker to evaluate glioblastoma sensitivity to rapamycin treatment [235]. moreover, there is a considerable variation in the therapeutic benefits detected in patients harbouring tumours predicted to be responders to mtor inhibition, because the genetic context in which the altered phenotype occurs may also be important for the patient response to therapy.",pmc3291999,1,10,38,1,48
613,jnk,protein,,jnk,uniprot,p45983,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,d,phosphorylation,ser-307,,,,,['953'],nan,nan,"α-tea, respectively, for 9, 15, and 24 h. α-tocopherol ether-linked acetic acid induced increased levels of pjnk2/1, increased levels of pirs-1 (ser-307), and reduced levels of total irs-1 in both cell lines (figure 4a). knockdown of jnk using a chemical inhibitor sp600125 (jnki) (figure 4b) or sirna (figure 4c) blocked the ability of α-tea to increase pirs-1 (ser-307) and decrease levels of total irs-1 protein, and suppressed the ability of α-tea to reduce pakt (ser-473), perk1/2, and pmtor (ser-2448). these data suggest that downregulation of irs-1 is involved in the ability of α-tea to suppress akt, erk, and mtor signalling and demonstrated that jnk is involved in this event via phosphorylation of irs-1 at ser-307, leading to its degradation.",pmc3039802,1,10,38,1,48
608,irs-1,protein,,irs1,uniprot,p35568,,,pkb,protein,,akt1,uniprot,p31749,,,positive,d,activation,,mefs,,,,['700'],nan,nan,"−/− mefs after overexpression of irs-1 or irs-2. we find that overexpression of either irs-1 or irs-2 results in an increase in pkb activation, which when combined with short-term inhibition of mtor/s6k signaling using rapamycin leads to a phenocopy of the effect of sustained (24 h) treatment with rapamycin (fig. 4 f).",pmc2172316,1,10,38,1,48
600,insulin receptor isoform-a,protein,,,uniprot,p06213,cell membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,cell membrane,go:0005886,positive,d,inhibition,"y845, y1068, y1173",,,,human,['1404'],nan,nan,"in colorectal cancer cells, sensitivity to an anti-egfr drug (i.e., gefitinib) can be improved by the pharmacological inhibition of insulin receptor isoform-a [97]. in this case, y845, y1068, and y1173 are employed as diagnostic markers for the active state of egfr. the anti-tumor effect of gefitinib and anastrozole has been investigated in estrogen-receptor-positive breast cancer cells, where the extent of y845 phosphorylation is used as one of the outcomes of the drug treatments [98]. the anti-cancer pro-apoptotic function of an indole compound, 3,3′-diindolylmethane, toward ovarian cancer cells also involves the suppression of the y845 phosphorylation of egfr and the subsequent erk/mapk signaling pathway [99]. specific inhibition of y845 phosphorylation by the src-specific inhibitor pp2 was also shown in cervical carcinoma cells hela and siha [100], and in ionizing irradiation-treated mda-mb-468 breast cancer cells [101]. x-radiation-induced dna synthesis in rat hepatocytes was additionally shown to involve y845 phosphorylation [102].",pmc3709701,1,10,38,1,48
116,akt,protein,,,uniprot,p31749,,,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,phosphorylation,s166-mdm2,,,,,['398'],nan,nan,"although we have focused on the akt mediated regulation of p53mut stability, the observation that regulation of npm oligomerisation governs arf localization may also be a direct mechanism which facilitates p53 stabilization following oncogene activation in the absence of dna damage [19]. in the absence of additional mutations, oncogene activation leads to p53 stabilization and the induction of cellular senescence. furthermore, growing evidence suggests that akt activity can mediate p53 stabilization and induction of senescence [85-87]. akt is known to directly phosphorylate s166-mdm2 leading to enhanced activity and reduced p53 levels, which in agreement with previous studies where observations were made in cells with ink4a/arf deletions [58, 59], we find akt inhibition increases p53 levels in arf null mcf7 cells (fig. s3g). importantly, we find that expression of arf stabilizes p53 but is now subject to npm mediated control and akt inhibition decreases p53 levels. this is in line with emerging evidence where constitutive activation of akt has been demonstrated to inhibit mdm2 activity [85]. moreover, we find that correlations exist between akt activity and p53 levels in breast and pancreatic cancer cohorts, and are dependent on cdkn2a expression levels (table s2). this is a relevant point for the administration of akt inhibitors in the clinic where efficacy is likely to rely on arf status as well as p53mut.",pmc4171619,1,10,38,1,48
115,akt,protein,,,uniprot,p31749,,,p16,protein,,cdkn2a,uniprot,q15631,,,negative,d,induce,,"bj-t, imr90",fibroblast,,,['3363'],nan,nan,"in addition, we demonstrate that, unlike ras, akt fails to induce high levels of p16 or sahfs in either bj-t or imr90 cells. although the levels of p16 have been shown to be an important determinant for ras-induced senescence (benanti and galloway, 2004), our data indicate that p16 is unlikely to play a role in akt-induced senescence. rapid induction of senescence without signs of dna damage, p16 accumulation or sahf formation has similarly been reported for the oncogenic fusion protein runx1-eto (wolyniec et al., 2009). the p16-dependent alterations to chromatin structure, detected as sahfs, are thought to promote the irreversibility of the cell cycle arrest due to stable silencing of pro-proliferative genes (narita et al., 2003). it is not clear as to how the absence of sahfs would affect the maintenance of the senescence phenotype of akt cells in vivo. however, here we demonstrate that both akt and ras induce a robust senescence-associated secretory phenotype, which may function to maintain senescence (freund et al., 2010). identification of these distinctly different mechanisms for p53-dependent senescence induction by active ras and akt reinforce the concept that specific oncogenic signalling modules may target distinct mediators of senescence.",pmc3325598,1,10,38,1,48
113,akt,protein,,,uniprot,p31749,,,caspase 9,protein,,,uniprot,p55211,,,negative,d,phosphorylation,ser-196,,,,human,['949'],nan,nan,"vehicle-treated hcc-1954 and mcf-7 cells express high levels of active akt (pakt) and phosphorylated downstream substrates gsk (pgsk), bad (pbad), and caspase 9 (pcaspase-9). treatment of hcc-1954 (20 μm) and mcf-7 cells (40 μm) with α-tea for 9, 15, and 24 h: (1) reduces levels of pakt (both ser-473 and ser-308) as well as its downstream substrates pgsk (α/β) (ser-21/9), pbad (ser-136), and pcaspase-9 (ser-196) and increases cleaved caspase 9 in a time-dependent manner (figure 2a), (2) downregulates perk1/2 and its substrates pp90sk (ser-380) and pbad (ser-112) (figure 2b), and (3) downregulates pmtor (ser-2448) and its substrates pp70s6k (thr-389) and p4e-bp1 (thr-37/46) (figure 2c). these data show that α-tea suppresses the active forms of akt, erk, mtor, and their downstream substrates, resulting in activation of proapoptotic mediators bad and caspase-9.",pmc3039802,1,10,38,1,48
96,akt,protein,,akt1,uniprot,p31749,,,pten,protein,,pten,uniprot,p60484,,,negative,d,inhibits,,pancreatic cancer panc-1,,,human,['1204'],nan,nan,"in most cancer cells, akt is constitutively active and enhances cell proliferation [105]. in order to understand a relationship between pten and akt in sfn-induced apoptosis, we measured the expression of pten and phosphorylation status of akt in cells treated with sfn (fig. 4a). sfn induces pten expression and inhibits akt phosphorylation in pancreatic cancer panc-1 cells. by comparison, sfn has no effect on total akt expression. these data suggest that sfn inhibits cell proliferation by regulating pi3k/akt pathway.",pmc2915986,1,10,38,1,48
110,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,pi3kca,protein,p110α catalytic subunit,pik3ca,uniprot,p42336,plasma membrane,go:0005886,positive,d,activation,,,cancer cells,various,human,['22'],nan,nan,"akt signaling is frequently activated in human cancers due to genetic and epigenetic alterations and has a role in neoplastic transformation [148–152]. although akt gene mutations are not widely reported, the amplification, overexpression, and activation of akt occurs at high frequency in a number of human cancers [148, 150]. alterations of akt signalling in human cancer also result from mutations of the upstream pi3k kinase and pten. pten is one of the most frequently mutated genes, second only to p53 in human cancers [30, 153]. inactivation of pten is strongly correlated with the activation of akt which in turn controls tumor cell proliferation. pten activity is lost by mutation, deletion, or promoter methylation silencing at high frequency in many primary and metastatic human cancers [154–156]. many activating mutations have also been described in pi3kca gene, upstream of akt, which encodes one of the p110α catalytic subunits of pi3k. pi3kca mutations (e542k, e545k, h1047r) are frequently observed in human colon, gastric, breast, and lung cancers and glioblastoma. they are able to constitutively activate akt and enhance its oncogenic activity [157–162].",pmc3317191,1,10,38,1,48
32,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,arf,protein,,cdkn2a,uniprot,p42771,nucleolus,go:0005730,positive,d,phosphorylation,ser48,,,,human,['373'],nan,nan,"the data presented above argues that phosphorylation of npm-ser48 by akt promotes the nucleoplasmic localization of arf. the major described function of arf in cells is as an inhibitor of the e3 ubiquitin ligase mdm2 and consequently leading to increased p53 stability [18, 21, 22]. the npm mediated sequestration of arf in the nucleolus has been proposed to increase mdm2 activity in the nucleoplasm[41] and furthermore, relocalization of arf from the nucleolus to the nucleoplasm is associated with the increased formation of arf/mdm2 complexes [45]. in t24 cells mdm2 is predominately detected in the nucleoplasm (fig. s3d & s3e), in agreement with previous reports [47]. although we observed an increase in arf nucleolar localization following akt inhibition, we did not detect any alteration in the cellular distribution of mdm2 (fig. s3e) suggesting that although npm and arf traffic to the nucleolus following inhibition of akt, mdm2 does not. mdm2 is known to be targeted to the nucleus in response to direct akt phosphorylation of ser166 and ser186, explaining the nuclear localization that we observe in the rasv12 mutant t24 cells (fig. s3d, s3e & s3f). however, expression of phospho-mimetic mdm2-s166d:s186d (mdm2-dd), that constitutively localizes in the nucleus of t24 cells, shows a similar mdm2 distribution and did not influence the nucleolar localization pattern of arf upon akt inhibition (fig. s3f). in line with previous studies, we observe mdm2 activity is positively regulated by akt but we find that this is influenced by the presence or absence of arf (fig. s3g). taken together this suggests that npm constitutively associates with arf and cycles between a heterodimer organization in the nucleus and an oligomeric state that associates with the nucleolus. we can also assume that akt promotes mdm2 nuclear localisation, but that its activity is controlled by the akt mediated npm-arf nucleoplasmic pool once there.",pmc4171619,1,10,38,1,48
1040,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,egfr,protein,,egfr,uniprot,p00533,cell membrane,go:0005886,negative,d,inhibition,,,colorectal cancer cells,colorectal cancer,human,['1405'],nan,nan,"lu et al. [103] have reported the mechanism of resistance to the anti-egfr monoclonal antibody cetuximab in colorectal cancer that had been made insensitive to this drug by exposure to subeffective doses of cetuximab over an extended period of time. in this system, the inhibition of src activity and y845 phosphorylation of egfr reverses the drug resistance. an alternative explanation for the cetuximab resistance in breast cancer cells was reported by li et al. [104], who showed that breast tumor kinase (btk)/protein-tyrosine kinase 6 (ptk6), a non-receptor, as well as a non-src family ptk, which was originally identified in human melanocytes, is highly expressed in most human breast cancers and that btk/ptk6 seems to be responsible for the y845 phosphorylation, the retention of which confers the resistance of cancer cells to an anti-egfr drug, cetuximab. this was the first report describing that a non-src family ptk can mediate y845 phosphorylation.",pmc3709701,1,10,38,1,48
33,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,bcl-2,protein,,bcl2,uniprot,p10415,mitochondria,go:0005739,negative,d,expression regulation,,hmn1,b-cell,,human,['1608'],nan,nan,"bcl-2 family proteins play an important role in regulating apoptosis and a growing number of signaling pathways are known to regulate apoptosis by modulating expression of bcl-2 family members (gross et al. 1999). we therefore explored the possibility that akt may inhibit apoptosis in hmn1 cells by regulating the expression levels of three key members of the bcl-2 family: bcl-2, bcl-x, and bax. western blots of vector-transfected cells and active myr-aktδ4-129–expressing cells indicated that stable expression of activated akt did not alter bcl-2, bcl-x, or bax expression to inhibit apoptosis (fig. 5).",pmc2185587,1,10,38,1,48
34,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,positive,d,substrate,,,,,,['774'],nan,nan,"around 40 substrates which mediate the pleiotropic akt functions have been identified, including caspase-9, murine double minute 2 (mdm2, a negative regulator of p53), bad, proline-rich akt substrate 40 (pras40), forkhead box class o (foxo) family of transcription factors, ikβ kinase α (ikkα), apoptosis signal-regulated kinase 1 [ask1, a negative regulator of pro-apoptotic c-jun n-terminal kinase (jnk)], raf, p27kip1, p21cip1, glycogen synthase kinase 3β (gsk3β), s-phase kinase-associated protein 2 (skp2), and camp response element-binding protein (creb). these substrates play key roles in the regulation of cell cycle progression, differentiation, and survival, either directly or through an intermediary [9,19,20].",pmc3837323,1,10,38,1,48
35,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,mitochondria,go:0005739,negative,d,phosphorylation,,,,,,['1620'],nan,nan,"a growing number of downstream targets of akt have been identified, including glycogen synthase kinase-3, bad, human caspase-9, and transcription factors such as creb, forkhead, and nfκb (pap and cooper 1998; khwaja 1999). while each of these has been implicated as an important target for akt to inhibit apoptosis, in the present case, caspase-9 appears to be the most likely candidate since akt phosphorylates human caspase-9 and inhibits its activity (cardone et al. 1998), which would provide a potential mechanism for akt to inhibit caspase activation at a postmitochondrial level. however, [32p]orthophosphate labeling of cells expressing active akt indicated that mouse caspase-9 is not phosphorylated by akt (data not shown). this may be explained by recent reports that the consensus akt phosphorylation sites on human caspase-9 are not conserved in caspase-9 from other species such as mouse caspase-9 in hmn1 cells (fujita et al. 1999; rodriguez et al. 2000). on the other hand, our data also suggest that there exists an additional, more general mechanism by which akt can suppress activation of caspases by cytochrome c at a postmitochondrial stage. when added into vector-cell extracts, immunoisolated active akt is sufficient to inhibit caspase activation induced by cytochrome c, suggesting that active akt has a direct effect on inhibiting cytochrome c–induced caspase activation. one such direct target for akt may be apaf-1, which forms a holoenzyme with caspase-9 and regulates caspase-9 activity (rodriguez and lazebnik 1999). akt phosphorylates apaf-1 in vitro (our unpublished observations); however, further studies are needed to determine whether cellular apaf-1 is a direct target of akt, and how the phosphorylation status of apaf-1 may regulate caspase-9 activation.",pmc2185587,1,10,38,1,48
587,igf-1,protein,,,uniprot,p05019,extracellular region,go:0005576,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,positive,d,regulates,,mefs,fibroblast,,human,['717'],nan,nan,−/− (white bars) mefs after 8 h in serum-free medium alone (−) or supplemented with 200 ng/ml igf-1 (+) in untreated mefs or mefs pretreated for 36 h with 20 nm rapamycin. the results are from four random 10× fields and are typical of experiments performed twice. (d) relative cell survival of tsc2,pmc2172316,1,10,38,1,48
36,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,activation,,,,,,['2667'],nan,nan,"elisa analysis both in vitro and in vivo using the elisa analysis kits (pakt: cat. no. 7160, cst; akt: cat. no. 7170, cst; perk: cat. no. 7315, cst; erk: cat. no. 7050, cst) according to the manufacturer's instructions. for analysis of akt and erk activation in vitro, cells were first treated with atorvastatin (1 or 5 μm), gefitinib (1 μm), or their combinations for 48 h. for analysis of akt and erk activation in vivo, tumor-bearing nu/nu mice were treated with atorvastatin 1 or 10 mg/kg, gefitinib 100 mg/kg and their combinations or control solvent for 1 week. tumors were snapped frozen and homogenized in cell lysis buffer (cst; cat. no. 9803). rations of pakt to total akt and perk to total erk were determined by specifc elisa assays.",pmc3789171,1,10,38,1,48
586,igf-1,protein,,igf1,uniprot,p05019,extracellular space,go:0005615,pkb,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,mefs,fibroblast,,human,['696'],nan,nan,"−/− (white bars) mefs after igf-1 stimulation in untreated cells or cells pretreated for 24 h with 20 nm rapamycin. results from triplicate determinations (means and sds) are shown normalized to control unstimulated samples and are representative of three independent experiments. (e) pkb activation after rnai-mediated inhibition of irs-1, irs-2, irs-1 plus irs-2, or a combination of scrambled irs-1 and irs-2 sirna (scrambled) in tsc2",pmc2172316,1,10,38,1,48
585,igf-1,protein,,igf1,uniprot,p05019,extracellular space,go:0005615,cyclin d1,protein,,ccnd1,uniprot,p24385,nucleus,go:0005634,positive,d,stimulates,,,cancer,breast,human,['2976'],nan,nan,"igf-1 stimulates erk and akt activities and elevates cyclin d1 expression. a-b: (a) lm2 or (b) jf32 cells were cultured in serum-free media, with or without 2 ng/ml migf-1 or megf, and cell homogenates were probed for protein expression. c-e: densitometry from western blot replicates from lm2 and jf32 cell lines was combined, and presented as fold change (mean ± sem) from untreated vehicle control lanes at each time point. * p < 0.05, ** p < 0.01 and *** p < 0.001 versus control (veh -) cells at each time point by 2-way anova.",pmc3135566,1,10,38,1,48
584,igf-1,protein,,igf1,uniprot,p05019,extracellular,,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,positive,d,survival factor,,,,,,['719'],nan,nan,"next, we tested the ability of igf-1 to act as a survival factor for tsc2",pmc2172316,1,10,38,1,48
583,igf-1,protein,,igf1,uniprot,p05019,extracellular,go:0005615,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,positive,d,stimulated chemotaxis,,mefs,,,,['716'],nan,nan,−/− (white bars) mefs. the results are expressed as a percentage of that of igf-1–stimulated chemotaxis of tsc2,pmc2172316,1,10,38,1,48
615,jnk,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,pi3k,protein,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,negative,d,downregulation,,mcf-7 and hcc-1954,breast cancer cells,breast cancer,human,['938'],nan,nan,downregulation of irs-1/pi3k pathways via jnk are critical for α-tea and α-tea+mek or mtor inhibitor-induced apoptosis in human mcf-7 and hcc-1954 breast cancer cells.,pmc3039802,1,10,38,1,48
894,pras40,protein,,akt1s1,uniprot,q96b36,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,i,association,rpl11,u2os,osteosarcoma,bone,human,['2286'],nan,nan,"to decrease experimental variation and limit the possibilities of transfection- or selection-related artifacts, we generated u2os cells stably expressing doxycyline (dox)-inducible ns or pras40-targeted shrnas. in agreement with our transient transfection studies, dox-induced pras40 kd results in p53 and p21 upregulation compared to ns control cells (figs. 5e,f). importantly, re-introduction of wt pras40 completely rescues this effect, whereas rpl11 binding-null pras40t246a fails to do so (fig. 5e), indicating that the ability of pras40 to suppress p53 is dependent upon the capacity of pras40 to associate with rpl11. because pras40 is an established negative regulator of mtorc1, we sought to test whether pras40 kd-induced mtorc1 activation contributes to p53 upregulation. although rapamycin treatment robustly blocks mtorc1 activity as indicated by loss of p70s6k t389 phosphorylation, it has no effect on pras40 kd-induced upregulation of p53 (fig. 5f). together, these results reveal that pras40-mediated suppression of p53 is dependent upon pras40’s ability to associate with rpl11, but independent of its ability to inhibit mtorc1. this provides further support for the hypothesis that pras40 negatively regulates p53 through inhibition of the rpl11-hdm2 pathway. to more directly test this, we activated the rpl11-hdm2 pathway by overexpression of rpl11 as previously reported.3–5 rpl11-inducd p53 upregulation is attenuated by co-expression of wt pras40, but not rpl11 binding-null pras40t246a (fig. 6g). interestingly, pras40 overexpression has no effect on p53 induced by the dna damage-causing agent etoposide (fig. 6f), indicating that pras40’s regulatory effect on p53 is at least partially specific to the rpl11-hdm2 pathway.",pmc4216640,1,10,38,1,48
621,kras,protein,,kras,uniprot,p01116,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,t205,,pancreatic,,human,['645'],nan,nan,"kras mutation has been regarded as the most frequent oncogenic event in pdac. overall, oncogenic kras signaling in pdac is through three major pathways: raf/mek/erk, pi3k/pdk1/akt and the ral guanine nucleotide exchange factor pathway25. as the best characterized ras downstream pathway, the mapk signaling axis is of particular importance in pdac development17. the pathway has been reported to play a central role in diverse cellular responses, such as proliferation, differentiation, and survival. briefly, activated ras binds to raf, thereby directly activating mek kinase via phosphorylation. mek1/2 subsequently phosphorylates residues in the activation loops of erk kinase, resulting in their activation. upon activation, erk kinase can phosphorylate and activate both cytosolic and nuclear targets18. previously, minella et al.20 indicated that ras stabilized cyclin e via the activation of the mapk pathway and inhibition of fbw7-dependent cyclin e ubiquitination in vivo. however, the underlying mechanism was not further clarified. inspired by their findings, we speculated that cross-talk may occur between fbw7 and the mapk pathway. as expected, in the current study, we found that fbw7 levels are inversely correlated with erk activation in pdac. on one hand, ectopic expression of erk1 significantly reduced the endogenous fbw7 protein level. on the other hand, inhibition of the mapk pathway dramatically increased endogenous fbw7 abundance. by contrast, inhibition of akt kinase dramatically shortened fbw7 half-life, indicating the pi3k/akt pathway may play a different role in regulating fbw7 stability (supplementary information, figure s3f and s3g). furthermore, we found that erk directly interacts with fbw7 and phosphorylates the t205 site to destabilize fbw7. before our study, a report demonstrated that pin1, the only peptidyl-prolyl cis/trans isomerase, interacts with fbw7 in a phospho-t205-dependent manner and promotes fbw7 self-ubiquitination and protein degradation21. however, the signaling to trigger t205 phosphorylation, which is important for understanding the physiological regulation, was largely left untouched in that study. hence, our research not only filled the missing upstream signaling that controls fbw7 stability via the t205 site but also identified new functions of the kras-mapk kinase pathways in pdac. interestingly, a similar regulation paradigm between other oncogenic kinase and tumor suppressing proteins has also been reported. for example, decreased p27 expression levels in tumor cells mostly occur due to enhanced proteolysis, given that mutation of the p27 gene is a rare event in cancer. this low expression level is well explained by the finding that cylin a/cdk2 phosphorylates the cdk inhibitor p27 and triggers its destruction by the oncoprotein scf-skp2 in many cancer types26, such as oral squamous cell carcinoma27. another example is that the oncoprotein nedd4-1 negatively regulates the stability of the tumor suppressor pten by catalyzing pten polyubiquitination and destruction in lung cancer28,29. thus, in addition to genetic mutations, accelerated protein turnover upon certain post-translational modification is another important means by which oncoproteins inactivate tumor suppressors during tumorigenesis. to dissect a possible role of self-ubiquitination in erk-mediated fbw7 degradation, we generated a fbw7 r465h mutant that could not ubiquitinate substrates based on a previous report21. as shown in supplementary information, figure s7a, r465h is more heavily ubiquitinated than wt fbw7, which is consistent with the previous report. co-transfected erk kinase could still promote poly-ubiquitination of the r465h mutant, which possibly indicates the involvement of other e3 ligases in fbw7 stability control, but the possibility of self-ubiquitination can not be formally excluded. furthermore, we generated t205e fbw7 construct. as shown in supplementary information, figure s7b, t205e mutant failed to form homo-dimer as wt and t205a fbw7 did. we also tested the ubiquitination potential of t205e, and interestingly t205e are less ubiquitinated than wt (supplementary information, figure s7c). although the t→e mutation generated a negative charge at aa205, which is similar to what a phosphor group does after phosphorylation, pin1 isomerase does not interact with ep motif and could not perform the cis-trans conversions. thus, the t205e mutant may not be appropriate to be used to evaluate the regulatory effect involving pin1. overall, our study established an important regulatory function of fbw7 by the activated ras-mapk-erk signaling pathway, although more efforts are required to dissect how fbw7 is ubiquitinated after its phosphorylation.",pmc4423074,1,10,38,1,48
625,kras,protein,,,uniprot,p01116,,,pi3k p110α,protein,,,uniprot,p42336,,,positive,d,binds,,"a549, calu1",epithelial,lung,human,['2650'],nan,nan,"as shown in figure 4a, immunostaining of a549 cells and calu1 cells with kras and pi3k p110α antibodies revealed that kras and the pi3k p110α subunit were well overlapped in these cells. interestingly, when pik3ca e545k plasmid or pten shrna was transfected into these cells, kras and p110α were also well overlapped. to confirm that kras directly interacts with the pi3k p110α subunit in kras mutant cells irrespective of pik3ca and pten statuses, we performed immunoprecipitation assay. as shown in figure 4b, kras directly bound with the pi3k p110α subunit in a549 cells, and transfection with pik3ca e545k plasmid or pten shrna enhanced such interaction corresponded with increased kinetics of the pi3k/akt pathway. consistent results were also obtained in another kras mutant cell line calu1 (figure 4c).",pmc3789171,1,10,38,1,48
1037,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,inactivation,,,cancer cell,colon,human,['967'],nan,nan,"src is known to be overexpressed in more than 80% of colon cancers5 and is closely associated with cancer cell proliferation, survival, angiogenesis, adhesion and metastasis.6, 7, 8 however, the relationship between src and apoptosis is controversial. src has been reported to inhibit apoptosis by activating the phosphatidylinositol 3-kinase/akt pathway, which protects cells against pro-apoptotic stimuli through the phosphorylation and inactivation of death accelerators, such as bad, bax and caspase-9.9, 10, 11 src could downregulate caspase-8 activity either directly12 or through activation of the p38-mitogen-activated protein kinase pathway.13 in addition, src could downregulate pro-apoptotic genes to reduce apoptosis.14, 15 on the other hand, src has also been reported to enhance apoptosis induced by different pro-apoptotic stimuli,16, 17, 18 and this effect is triggered specifically at high src signaling levels.19",pmc4040661,1,10,38,1,48
1036,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,co-localization,,sw480,colorectal,,human,['983'],nan,nan,"sw480 cells (1 × 105) were seeded in a four-chamber polystyrene vessel tissue culture glass slide (bd biosciences) and were treated or not treated with 50 μm 5-fu for 48 h in a 37 °c incubator. cells were fixed with 4% formalin for 15 min at room temperature in the dark. after gentle washing twice for 10 min each with pbs, cells were blocked with pbs, 0.02% tween-20 and 1% bsa in a 37 °c incubator for 1 h. cells were then incubated with a 1 : 100 dilution of a src rabbit antibody and a 1 : 50 dilution of a caspase-7 mouse antibody in pbs and 3% bsa by gently rocking at 4 °c overnight. after washing twice for 5 min each, cells were incubated with a 1 : 200 dilution of alexa fluor 488 goat anti-rabbit antibody and alexa fluor 568 goat anti-mouse antibody (invitrogen) for 1 h in the dark. co-localization of proteins was observed by laser scanning confocal microscopy (nikon c1s1 confocal spectral imaging system, nikon instruments co., melville, ny, usa) using a cfi plan fluor × 40 oil objective and then analyzed using the ez-c1 (v3.20) software program (nikon).",pmc4040661,1,10,38,1,48
1034,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,llc-pk1,epithelial,kidney,unspecified,['2064'],nan,nan,"it is known that ouabain also stimulates pi3k/akt pathways in llc-pk1 and other cells, and that the activation of src is important for the full activation of akt [20, 29]. to further verify the inhibitory effects of yfp-cd2 on ouabain-induced signal transduction, we exposed both control and cd2-2 cells to different concentrations of ouabain and measured akt activation by western blot analysis of cell lysates. as depicted in fig 4c, ouabain-induced akt activation was significantly attenuated by the expression of yfp-cd2. thus, yfp-cd2 appears to work as a dominant negative mutant, capable of blocking ouabain-induced signal transduction including the activation of src, erks and akt.",pmc4638348,1,10,38,1,48
1032,src,protein,,,uniprot,p12931,plasma membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,phosphorylation,y845,,multiple cell types,,multiple organisms,['1424'],nan,nan,"other cellular functions involving y845 phosphorylation include wound-induced activation of the src/egfr pathway in corneal epithelial cells [170], intestinal cell proliferation and tumorigenesis that can be inactivated by the interaction of farnesoid x receptor with src, leading to the inactivation of src and the decrease in y845 phosphorylation [171], and colon cancer proliferation that is stimulated by src-mediated aryl hydrocarbon receptor and egfr interactions, leading to y845 phosphorylation and erk/mapk activation [172]. in primary normal human bronchial epithelial cells, sialyl lewis x modification of egfr involving y845 phosphorylation contributes to wound-induced epithelial repair [173]. another line of evidence shows that reduction of the expression of protein-tyrosine phosphatase-μ results in an increase in tyrosine phosphorylation of egfr, including that on y845, in response to airway epithelial injury [174]. analysis of keratinocytes as a model system for analyzing cutaneous tissue repair also demonstrates the involvement of egfr phosphorylation including y845 [175]. in this case, egfr is trans-activated by the kinin b(1) receptor system; however, the involvement of src in this event is not known. src-dependent y845 phosphorylation also contributes to erk/mapk activation and proliferation of normal keratinocytes, which involves amphiregulin-mediated autocrine signaling of egfr [176]. an alkylating agent, n-methyl-n′-nitro-n-nitrosoguanidine, has been shown to compete with egf in the binding to egfr, thus inhibiting the signaling pathway regulated by egfr phosphorylation, including the basal level of y845 phosphorylation [177]. the sensitization of egf-induced signaling (e.g., intracellular ca2+ release) in primary cultures of rat adrenal chromaffin cells and pc12 cells by bradykinin-dependent g-protein-coupled signal transduction involves src activation and the y845 phosphorylation of egfr [178]. this study also demonstrated that cholesterol-enriched membrane microdomains serve as a platform for the src-egfr functional interaction, and that y845f mutation results in a failure of signal transduction. in an attempt to elucidate the mechanism of nuclear translocation/localization of egfr in cetuximab-resistant nsclc cells (nci-h226), iida et al. [179] have shown that y1101, but not y845, in egfr is a critical tyrosine residue that is phosphorylated by yes and lyn.",pmc3709701,1,10,38,1,48
663,mek1,protein,threonine/tyrosine kinase,map2k1,uniprot,q02750,cytoplasm,go:0005737,raf,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,positive,d,phosphorylation,s217/s221,,,,human,['1273'],nan,nan,"mek1 or mitogen-activated protein kinase kinase 1 is a threonine/tyrosine kinase member of the ras oncogene signaling pathway. ras becomes activated via igf-1r signaling through shc, an alternate intermediate signaling molecule that docks to igf-1rs activation loop via its ptb domain. upon phosphorylation of shc, recruitment of grb2 and sos lead to the activation of ras followed by subsequent activation of raf. it is raf that activates mek1 through phosphorylation of s217/s221. this activation leads to further downstream signaling that regulates cell proliferation, differentiation, and growth 38. our data shows significant increases in phosphorylation when comparing stages i to iv and ii to iii. (fig. 3)",pmc3187934,1,10,38,1,48
1019,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,phosphorylation,multiple tyrosine sites,mouse embryonic fibroblasts,fibroblast,embryonic,mouse,['965'],nan,nan,"although the rate of development of drug resistance remains very high, 5-fluorouracil (5-fu) is still the most common chemotherapeutic drug used for the treatment of colon cancer. a better understanding of the mechanism of why cancers develop resistance to 5-fu could improve its therapeutic effect. sometimes, antioxidants are used simultaneously with 5-fu treatment. however, a recent clinical trial showed no advantage or even a harmful effect of combining antioxidants with 5-fu compared with administration of 5-fu alone. the mechanism explaining this phenomenon is still poorly understood. in this study, we show that 5-fu can induce reactive oxygen species-dependent src activation in colon cancer cells. mouse embryonic fibroblasts that are deficient in src showed a clear resistance to 5-fu, and knocking down src protein expression in colon cancer cells also decreased 5-fu-induced apoptosis. we found that src could interact with and phosphorylate caspase-7 at multiple tyrosine sites. functionally, the tyrosine phosphorylation of caspase-7 increases its activity, thereby enhancing cellular apoptosis. when using 5-fu and antioxidants together, src activation was blocked, resulting in decreased 5-fu-induced apoptosis. our results provide a novel explanation as to why 5-fu is not effective in combination with some antioxidants in colon cancer patients, which is important for clinical chemotherapy.",pmc4040661,1,10,38,1,48
783,p16ink4a,protein,,cdkn2a,uniprot,p42771,cell,go:0005623,rb,protein,,rb1,uniprot,p06400,cell,go:0005623,positive,d,detection,,cancer cell lines,,,human,['2337'],nan,nan,"figure 1. baseline expression of p16/cdk4/rb signaling molecules in 5 cancer cell lines. constitutive basal expression of rb, p-rb, cdk4, cdk6, and p16ink4a were detected by western blotting. actin was used as a loading control.",pmc3742489,1,10,38,1,48
1017,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,effector,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,phosphorylation,,in vitro,,,human,['975'],nan,nan,"to determine whether caspase-7 activity can be influenced by src phosphorylation, an in vitro kinase assay was performed using src and wt-caspase-7 or mut-caspase-7. caspase-7 activity was detected at different time points. caspase-9 is known to be the upstream activator of effector caspases in the intrinsic apoptosis pathway. the presence of caspase-9 protein activated caspase-7 to a higher level than in its absence. our results showed that wt-caspase-7 was first phosphorylated by src, and then adding caspase-9 dramatically increased caspase-7 activity (figure 6a, left panel, supplementary figure 2). in contrast, mut-caspase-7 activity was relatively unaffected in the presence of src and caspase-9 treatment (figure 6a, right panel). 293t cells transfected with wt-myc-caspase-7 exhibited increased caspase-7 activity, whereas little change in caspase-7 activity was observed in cells transfected with mut-myc-caspase-7 (figure 6b). cells co-transfected with src and wt-caspase-7 exhibited a 1.5-fold increase in caspase-7 activity compared with wt-caspase-7 alone. in contrast, no change in caspase-7 activity was observed in cells co-transfected with src and mut-caspase-7 compared with cells transfected with only mut-caspase-7 (figure 6c). overall, these results indicated that src might regulate apoptosis by enhancing caspase-7 activity through phosphorylation.",pmc4040661,1,10,38,1,48
653,mek,protein,,mek,uniprot,p36507,cytoplasm,go:0005737,stat3,protein,y705,stat3,uniprot,p40763,nucleus,go:0005634,negative,d,decrease,,,mesenchymal stem cells (msc),,human,['1896'],nan,nan,"immunoblot analysis of nuclear and cytoplasmic extracts demonstrated that this mek inhibition-induced msc shape change was accompanied by a decrease in nuclear oct4 (2.0 ± 0.2-fold), nanog (2.1 ± 0.3-fold), and stat3 (y705) (1.6 ± 0.2-fold) (fig. 5d, 5f) and reduced the stat3 (y705) nuclear/cytoplasm ratio (2.1 ± 0.4-fold) (fig. 5d). taken together, the results demonstrate that the distinctive pdgfr inhibitor-iv-induced rounded msc shape is jak-stat3 and mek-erk signaling dependent.",pmc3537888,1,10,38,1,48
652,mek,protein,,mek,uniprot,p36507,cytoplasm,go:0005737,ifn,protein,,ifn,uniprot,p01562,extracellular space,go:0005615,positive,i,inhibition,,cancer,,,human,['1627'],nan,nan,restoration of ifn sensitivity by mek inhibition in ifn moderately or completely resistant cancer cell lines,pmc3436881,1,10,38,1,48
650,mek,protein,,map2k,uniprot,p36507,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,,melanoma,,human,['153'],nan,nan,"to study altered signaling responses to mek inhibition in mutant nras melanoma, we utilized reverse phase protein arrays (rppa). in mek-inhibited mutant nras melanoma cells, we detected an increase in akt activation and a decrease in the adaptor protein, mitogen-inducible gene 6 (mig6). mig6 is a non-kinase cytosolic scaffolding protein that binds to erbb family receptors and inhibits their catalytic activity by blocking the formation of an activating dimer (zhang et al, 2007). additionally, mig6 mediates receptor endocytosis (frosi et al, 2010, walsh and lazzara, 2013) and lysosomal degradation (ying et al, 2010). we identified a role for mig6 as a negative regulator of egf-induced akt and erk1/2 signaling and cell migration and invasion in mutant nras melanoma. in the presence of mek inhibition, mig6 did not modulate growth or apoptosis in mutant nras melanoma cells. rather, mig6 expression decreased cell migration and invasion; its further depletion in mek-inhibited cells increased migration and invasion. therefore, the decrease in mig6 in the presence of mek inhibition may be a pro-invasive stimulus in mutant nras melanoma.",pmc4789776,1,10,38,1,48
643,mdm2,protein,,mdm2,uniprot,q00987,,,rb,protein,,rb1,uniprot,p06400,,,positive,d,phosphorylation,,,,,,['1017'],nan,nan,"we then asked if knocking down mdm2 would be sufficient to induce senescence in the non-responder cells. to accomplish this, we generated two independent targeting vectors and transduced ls8107 and ls7785-1 non-responder cells with these or a scrambled control. rb phosphorylation and the amount of cyclin a were reduced in the cells in which mdm2 was knocked down, indicative of growth arrest, even in the absence of pd0332991 (figure 4a). arf and p16 levels did not increase but there was a modest increase in p21, which is consistent with an increase in p53 activity when knocking down mdm2. p53 is wild type and functional in all of these wd/ddls cells as demonstrated by the fact that nutlin-3 induced inhibition of mdm2-p53 interaction triggers apoptosis [35].",pmc4480747,1,10,38,1,48
133,ap-1,protein,transcription factor,jun,uniprot,p05412,nucleus,go:0005634,il-6,protein,cytokine,il6,uniprot,p05231,extracellular space,go:0005615,negative,i,neutralization,,,,,human,['248'],nan,nan,of ap-1. previous studies report that neutralizing antibody therapy against il-6,pmc3084876,1,10,38,1,48
1008,smad4/dpc4,protein,tumor suppressor,smad4,uniprot,q13485,nucleus,go:0005634,wnt,protein,signaling pathway,wnt,uniprot,p04628,extracellular space,go:0005615,positive,d,phosphorylation,linker region,,epithelial,"prostate, colorectal, pancreatic",human,['66'],nan,nan,"the tumor suppressor smad4/dpc4 is an essential transcription factor in the tgf-β pathway and is frequently mutated or deleted in prostate, colorectal, and pancreatic carcinomas. we recently discovered that smad4 activity and stability are regulated by the fgf/egf and wnt signaling pathways through a series of mapk and gsk3 phosphorylation sites located in its linker region. in the present study, we report that loss-of-function associated with 2 point mutations commonly found in colorectal and pancreatic cancers results from enhanced smad4 phosphorylation by gsk3, generating a phosphodegron that leads to subsequent β-trcp–mediated polyubiquitination and proteasomal degradation. using chemical gsk3 inhibitors, we show that smad4 point mutant proteins can be stabilized and tgf-β signaling restored in cancer cells harboring such mutations.",pmc4845174,1,10,38,1,48
131,akt1,protein,,akt1,uniprot,p31749,,,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,sirna knockdown,,t24 cells,epithelial,bladder,human,['379'],nan,nan,"(a) t24 cells and psn1 cells were treated with mk-2206 (5 μm) or dmso for 24 hrs. cells were fixed and stained with dapi and anti-mutant p53 (op29 clone). (b) t24 cells were pre-treated with mk-2206 (5 μm) or dmso for 24 hrs before the addition of fresh media containing cyclohexamide (100 μm) (chx) in combination with mk-2206 (5 μm) or dmso for the times indicated. nuclear extracts were prepared from treated cells and blotted with the indicated antibodies. quantification is relative to initiation of chx treatment for both conditions *, mk-2206 is 40% of dmso control but taken as 1.0 for relative assessment. (c) h1299 cells were transfected with ha-tagged-ubiquitin and mutant p53 (r175h or r248w) as indicated. transfected cells were treated with dmso, mk-2206 (5 μm) or nutlin3a (5 μm) for 16hrs as indicated. p53 immunoprecipitates and whole cell lysates were probed with the indicated antibodies. (d) t24 cells were transfected with non-targeting control or p14arf sirna and treated with dmso, mk-2206 (5 μm) or the npm oligomerisation inhibitor ncs348884 (4 μm) (qi et al., 2008) as indicated. (e) t24 cells were transfected with non-targeting control, akt1, or p14arf sirna. cells were treated with ncs348884 (4 μm), nutlin3a (5 μm) or dmso as indicated. whole cell lysates were probed with the indicated antibodies. (f) kpc mice derived krasg12d p53 floxed (p53fl), krasg12d p53r172h arf+/+ and krasg12d p53r172h arf−/− pancreatic tumor cells were treated with mk-2206 (1μm), nutlin3a (5μm) or dmso as indicated. whole cell lysates were probed with the indicated antibodies.",pmc4171619,1,10,38,1,48
940,ras,protein,,hras,uniprot,p01112,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,d,activation,,,,,,['1923'],nan,nan,activation of the ras/raf/mek/erk and ras/pi3k/pten/akt/mtor pathways by genetic mutations,pmc3660063,1,10,38,1,48
130,akt1,protein,,akt1,uniprot,p31749,,,caspase-3,protein,,casp3,uniprot,p42574,,,positive,d,inhibition,,,tumor,,human,['3662'],nan,nan,"another report investigated the effects of small molecule inhibitors of akt, which target the akt ph domain and have isoform-specific activity [468]. in multiple cellular backgrounds, maximal induction of caspase-3 activity, an indicator of apoptosis, was achieved when both akt1 and akt2 were inhibited [468]. it was also shown that in different tumor cell backgrounds inhibition of mtor was less effective in inducing caspase-3 activity than inhibition of akt1 and akt2 [468].",pmc2652403,1,10,38,1,48
941,ras,protein,,hras,uniprot,p01116,plasma membrane,go:0005886,pten,protein,,pten,uniprot,p60484,nucleus,go:0005634,positive,d,unknown,,,cancer,,human,['1915'],nan,nan,"the concept of a driver mutation is very important in cancer. if the driver mutation can be successfully targeted that may lead to elimination of the cancer. this is a mutation that is statistically enriched in a particular cancer and usually thought to be one of the first events in the malignant transformation of those particular cells to cancer cells [12]. examples of driver mutations in these two pathways include ras, nf1, braf, mek1, pik3ca (pi3k), and pten.",pmc3660063,1,10,38,1,48
128,akt1,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,pten,protein,phosphatase,pten,uniprot,p60484,plasma membrane,go:0005886,negative,d,silencing,,,,,human,['3582'],nan,nan,"akt1 sirna (5′-aaggaggguuggcugcacaaa-3′); foxo3a sirna (5′-aaugugaca-uggaguccauua-3′); bim sirna (5′-aagguagacaauugcagccug-3′); pten si rna (5′-gacuugaaggcguauacagtt-3′) and the control sirna (5′-uucuccgaacguguca-cgutt3′) were chemically synthesized by genepharm (shanghai, china). cells cultured in six-well plates were transfected with 100 pm sirna by lipofectamine 2000 according to the guideline as described above. cells were then subjected to further treatment as demanded.",pmc3734838,1,10,38,1,48
780,p110δ,protein,isoform,pik3cd,uniprot,o00329,endothelial cells,go:0072562,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,,,endothelial,,human,['3657'],nan,nan,"the p110δ isoform was shown to be expressed in endothelial cells [461]. the p110δ specific inhibitor ic486068 abrogated radiation-induced phosphorylation of akt. ic486068 enhanced radiation-induced apoptosis in endothelial cells and reduced cell migration and tubule formation of endothelial cells in matrigel following irradiation [461]. ic486068 enhanced radiation-induced endothelial cytotoxicity, resulting in tumor vascular destruction and tumor control when combined radiotherapy in murine tumor models [461]. these findings suggest that p110δ is a therapeutic target to enhance radiation-induced tumor control [461].",pmc2652403,1,10,38,1,48
156,atm,protein,kinase,atm,uniprot,q13315,nucleus,go:0005634,p53,protein,transcription factor,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,activation,,,,,,['1149'],nan,nan,"it has been shown that the atm-chk2-p53 system is activated with an oscillatory pattern, as a consequence of the equilibrium between activating stimulus (dna damage) and a double feedback system activated by p53 and including mdm2, which induces p53 degradation [22], and wip1, a protein phosphatase that dephosphorylates both atm and chk2 [23]. the oscillations are considered a mechanism to check on the progress of the dna damage and shut down the checkpoint response if the repair has been successful [24]. it has also been proposed that the oscillatory activation of p53 provides a means to fine-tune the cellular response and produce different outcomes according to the severity of the dna damage [25].",pmc3656868,1,10,38,1,48
914,pten,protein,negative regulator,pten,uniprot,p60484,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,induction,,"mouse embryonic fibroblasts, mouse prostate epithelium, mouse hematopoietic stem cells, human endothelial cells, mouse primary keratinocytes",,,"mouse, human",['3341'],nan,nan,"multiple lines of evidence indicate that increased pi3k/akt signalling also induces cell senescence. loss of pten, the major negative regulator of the pi3k/akt pathway, induces senescence in mouse embryonic fibroblasts (chen et al., 2005) and mouse prostate epithelium (chen et al., 2005; alimonti et al., 2010a). pten deletion also induces loss of mouse hematopoietic stem cells by induction of the senescence effectors p53, p21 and p19arf (yilmaz et al., 2006; zhang et al., 2006). expression of constitutively active akt induces senescence in human endothelial cells (miyauchi et al., 2004), mouse embryonic fibroblasts (chen et al., 2005; mavrakis et al., 2008; nogueira et al., 2008) and mouse primary keratinocytes (moral et al., 2009). the mechanisms underlying induction of senescence by akt are poorly defined, although the accumulation of reactive oxygen species has been implicated as playing a role (nogueira et al., 2008). a better understanding of the mechanisms of pi3k/akt-induced senescence will be crucial for understanding the role of dysregulated pi3k/akt signalling in cancer.",pmc3325598,1,10,38,1,48
910,pten,protein,,pten,uniprot,p60484,,,braf,protein,,braf,uniprot,p15056,,,positive,d,mutation,,,melanoma,skin,mouse,['1969'],nan,nan,"in some cancer settings, pten and braf mutations appear to interact. two studies papers have highlighted the hypothesis of mutant braf- and pten-loss-driven carcinogenesis in mouse models [352,353]. in a study by dhomen et al., inducible expression of b-rafv600e was sufficient to induce multiple melanocytic lesions including skin hyperpigmentation, dysplastic nevi and melanoma [352]. tumor cells from these b-rafv600e mice displayed both melanoma growth and melanocyte senescence in this system. approximately 70% of these mice developed melanomas that exhibited histological and molecular characteristics similar to that of human melanoma and were able to colonize the lungs in nude mice [352]. in contrast, another group of researchers generated mice that conditionally-expressed melanocyte-specific braf v600e that were only able to induce benign melanocytic hyperplasias and were unable to progress any further over a 15-20 month period [353]. however, braf v600e expression in a pten gene-silenced background led to the production of melanomas with 100% establishment, short latency and metastasis to lymph nodes and lungs. this development was prevented by the treatment of mice with either the mtor inhibitor rapamycin or the mek1/2 inhibitor (pd0325901). moreover, while combination treatment with rapamycin or pd0325901 led to the reduction of established tumors, upon termination of drug treatment the melanomas reappeared most likely due to the presence of drug resistant melanoma-initiating cells in these mice. overall, these two papers further validated the mutated b-raf/mek/erk and the pi3k/akt/mtor pathways, as promising therapeutic targets in melanoma.",pmc3660063,1,10,38,1,48
16,akt,protein,constitutively active,akt1,uniprot,p31749,cytoplasm,go:0005737,pten,protein,,pten,uniprot,p60484,cytoplasm,go:0005737,negative,d,regulates,,,pancreatic cancer cells,pancreas,human,['2107'],nan,nan,"the constitutively akt has been shown to enhance survival of cancer cells and also to be the cause of drug-resistance [29]. since pten regulates akt activity, we measured the expression of pten and phosphorylation status of akt in pancreatic cancer cells treated with resveratrol (fig. 3a). resveratrol induces pten expression and inhibits akt phosphorylation in panc-1 cells. by comparison, resveratrol has no effect on total akt expression. we next confirmed the inhibition of akt activation by resveratrol with kinase assay (fig. 3b). resveratrol inhibited akt kinase activity in a dose-dependent manner. these data suggest that resveratrol inhibits cell proliferation by regulating pi3k/akt pathway.",pmc3181262,1,10,38,1,48
871,pi3k,protein,,,uniprot,p42336,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,,,leukemia cell lines,,human,['3623'],nan,nan,"another study suggested that pi3k has a major role in the control of proliferation and apoptosis of growth factor-independent multiple myeloma cell lines [324]. constitutive activation of this pathway was shown to be a frequent event in the biology of multiple myeloma in vivo and may be more frequently observed in primary plasma cell leukemia [324]. purified plasmocytes from patients with myeloma or leukemia displayed constitutive phosphorylation of akt, fkhrl-1 and p70(s6k), which was inhibited by ly294002 and enhanced by igf-i [324]. another study demonstrated that akt is activated in aml blasts and that p70(s6k) and 4ebp-1, downstream mediators of akt signaling, also are phosphorylated in aml blasts [325]. in a short-term culture system, most aml patient samples showed a dose-dependent decrease in survival after incubation with ly294002 [325]. incubation of aml blasts with rad001 induced only a small decrease in survival of the cells [325]. however, when combined with ara-c, rad001 enhanced the toxicity of ara-c [325]. these results demonstrated that constitutive activation of the pi3k pathway is necessary for the survival of aml blasts and that targeting of this pathway with pharmacologic inhibitors may be of clinical benefit in treatment of aml [325]. another study demonstrated that the overall survival of patients with the akt phosphoryated on ser473 was significantly shorter than that of patients without [326]. thus, the detection of the akt phosphorylation may provide a new tool for identifying aml patients at high risk of an unfavorable outcome [326].",pmc2652403,1,10,38,1,48
206,c-src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,nox1,protein,,nox1,uniprot,q9y5s8,plasma membrane,go:0005886,positive,d,phosphorylation,"tks4 (phosphorylation), noxa1 (phosphorylation)",dld1,colon cancer,colon,human,['1384'],nan,nan,"we have previously shown that in human dld1 colon cancer cells and other cancer cell lines there is a correlation between the levels of c-src activity and their ability to generate ros (gianni et al., 2008), yet the exact relationships between src activity, ros formation, carcinogenesis, and metastasis remain poorly defined. metastatic cancer cells have the ability to both migrate to and degrade the ecm, and invasiveness has been correlated with the presence of invadopodia (linder, 2007; gimona et al., 2008), as well as ros production (okada et al., 2006). src activity and production of ros via nadph oxidase have been shown to be required for the formation of functional invadopodia in several cancer cells, including human dld1 colon cancer cells. however, the signals and molecular mechanisms by which src induces the redox-dependent generation of invadopodia are still a matter of investigation. in this study, we elucidate the relationship between src phosphorylation of tks4 and noxa1 and the nox1-dependent formation of invadopodia and ecm degradation in dld1 cells. interestingly, we show that the overexpression of tks4 and noxa1 unphoshorylable mutants reduces the ability of dld1 cells to form ecm-degrading invadopodia in presence of active src. on the contrary, the presence of tks4 and noxa1 phosphomimetic mutants is able to partially restore this phenotype even in absence of active src.",pmc2993755,1,10,38,1,48
870,pi3k,protein,kinase,pik3ca,uniprot,p42336,plasma membrane,go:0005886,cyclin d1,protein,cyclin,ccnd1,uniprot,p24385,nucleus,go:0005634,negative,d,blocks,,,,neoplastic,,['2970'],nan,nan,combined mek and pi3k inhibition blocks igf-1 and møcm induced neoplastic proliferation by decreasing cyclin d1 expression,pmc3135566,1,10,38,1,48
801,p53,protein,,tp53,uniprot,p04637,,,akt,protein,,akt1,uniprot,p31749,,,negative,d,repression,,bj-t,fibroblast,skin,human,['3353'],nan,nan,"to determine the contribution of p53 to akt-induced senescence, we examined the induction of senescence markers in bj-t-myr-akt cells stably expressing p53 shrna or a control shrna. myr-akt failed to induce p21 expression in p53 knockdown cells (figure 5a) or increase the cell doubling time and mean cell volume, compared with control cells expressing myr-akt and the control shrna (figures 5b and c). saβgal positivity was significantly reduced in bj-t-myr-akt/p53 stable knockdown cells as compared with control bj-t-myr-akt cells (figure 5d). we also determined that akt could not induce p21 or saβgal activity in bj-t cells expressing sv40 large t antigen (hahn et al., 1999), consistent with the ability of sv40 large t antigen to repress p53 and retinoblastoma activity (data not shown).",pmc3325598,1,10,38,1,48
802,p53,protein,,tp53,uniprot,p04637,,,myr-akt1,protein,,akt1,uniprot,p31749,,,positive,d,knockdown,,bj-t cells,,,human,['3354'],nan,nan,"we also examined the effect of acute p53 knockdown during induction of myr-akt1 expression. bj-t cells co-expressing p53 shrna and myr-akt1 were analysed for proliferation from day 5 post-transduction, and for apoptosis markers and the percentage of cells in the s phase at day 10 post-transduction (supplementary figure 3). acute p53 knockdown, confirmed by immunoblot analysis (supplementary figure 3a), rescued the reduced proliferation of myr-akt1-expressing cells to that of control cells (supplementary figure 3b). the major effect of p53 knockdown was to increase the percentage of cells in the s phase (supplementary figure 3c), with minimal effect on apoptosis observed by annexin v and propidium iodide positivity (supplementary figure 3d).",pmc3325598,1,10,38,1,48
906,pten,protein,,pten,uniprot,p60484,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,inactivation,,,various,,various,['3071'],nan,nan,"in peutz jeghers syndrome, tuberous sclerosis, and other diseases where pten is inactivated, the use of rapamycin as a clinical means to reverse the effect of elevated mtor activity is an attractive option (inoki et al, 2005a). these diseases are distinct from other hamartoma-associated disorders (such as vhl syndrome) since they have an established molecular link to mtor (inoki et al, 2005a). earlier studies demonstrated that pten-inactivated tumour cells exhibit enhanced sensitivity to the rapamycin analog cci-779 (guertin and sabatini, 2005). more recently, several studies have shown that rapamycin treatment, in combination with other chemotherapeutic drugs, can lead to enhanced selective killing of cancer cells. in particular, the protein tyrosine kinase (ptk) inhibitor, imatinib (gleevec, sti571) synergises with rapamycin to inhibit bcr/abl transformed cells (mohi et al, 2004). the effect of rapamycin may be enhanced as a result of imatinib-induced akt/mtor signaling, a complication that is thought to lead to imatinib resistance (burchert et al, 2005). rapamycin can also synergise with paclitaxel, carboplatin, and vinorelbine to induce apoptosis in breast cancer cells (mondesire et al, 2004). cisplatin-induced apoptosis of a549 lung cancer cells is also significantly enhanced when combined with rad001 (beuvink et al, 2005). this could be in part due to reduced translation of p53-activated p21 mrna in a549 and mcf7 cells treated with rad001, thereby allowing the dosage of cisplatin to be reduced (beuvink et al, 2005). also, the use of the egfr/vegfr inhibitor, aee788, in combination with rad001 greatly decreased tumour growth in glioma xenografts (goudar et al, 2005). furthermore, targeting the glycolytic pathway in combination with mtor inhibition may also be useful in cases where dna-damaging agents are less efficient in inhibiting growth and promoting apoptosis of cancer cells (xu et al, 2005).",pmc2361102,1,10,38,1,48
302,chk1,protein,checkpoint kinase,chek1,uniprot,o14757,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,phosphorylation,ser280,,,,human,['20'],nan,nan,"as a key checkpoint kinase, chk1 is activated by a wide range of genotoxic stresses. activated chk1 is essential for g2/m and replication checkpoint proficiency when dna is damaged or replication is incomplete [127–130]. chk1 is directly phosphorylated by akt at ser280, a modification that results in cytoplasmic sequestration [79, 99, 101, 123]. ser280 phosphorylated chk1 covalently associates with ubiquitin, ubiquitination of chk1 does not alter the protein stability; however, it promotes enhanced cytoplasmic localization and inhibition of checkpoint function [101, 123]. the increased cytoplasmic distribution of chk1 is also seen in primary breast carcinomas tissues with elevated akt phosphorylation and reduced pten level [101, 123]. beside regulating the subcellular localization, akt phosphorylation also inhibits the physical interaction between chk1 and claspin, which results in the inhibition of chk1 activity and checkpoint proficiency [124]. by contrast, a recent study by tonic et al. questions the significance of chk1 s280 phosphorylation on the checkpoint function, since overexpression of exogenous chk1 s280e mutant does not override radiation-induced g2 arrest [100]. this apparent discrepancy may be attributable to variable basal levels of active akt in different cell lines.",pmc3317191,1,10,38,1,48
803,p53,protein,,tp53,uniprot,p04637,,,p21,protein,,cdkn1a,uniprot,p38936,,,positive,d,transcriptional regulation,,h1299,epithelial-like,lung,human,['1040'],nan,nan,"h1299 (p53 null) cells stably integrated with the p21-luciferase reporter were grown in rpmi 1640 medium (invitrogen) supplemented with 10% fetal calf serum and g418. twenty four hours before transfection, the cells were subcultured from confluence to a 1 : 6 dilution into 6-well plates. for transfections for luciferase assays, each well received 0.1 µg of pcmv-renilla (promega), 0.2 µg of pcdna-p53 and various amounts of pcdna-14-3-3 plasmids as indicated in the figure legends. the dna amount was normalized using empty pcdna3.1 vector. transfection was performed with lipofectamine 2000 (invitrogen) according to the manufacturer’s instructions. cells were treated with 0.5 µm cpt or dmso immediately after transfection. twenty four hours after drug treatment, cells were washed twice with pbs and lysed using ripa buffer (150 mm nacl, 1% np-40, 0.5% sodium deoxycholate, 0.1% sds and 50 mm tris–hcl at ph 8.0) to which a complete edta-free protease inhibitor tablet (roche) had been added. luciferase assays were performed with the dual-luciferase reporter assay system (promega) in accordance with the manufacturer’s instructions. wells were prepared in triplicate, and error bars represent 1 sd.",pmc2817464,1,10,38,1,48
1111,tsc2,protein,wild-type,tsc2,uniprot,p49815,cytoplasm,go:0005737,irs-1,protein,,irs1,uniprot,p35568,cytoplasm,go:0005737,negative,d,phosphorylation,ser302,mefs,fibroblast,,mouse,['706'],nan,nan,"−/− mefs lines in which wild-type (−/− (+wt)) or a pathogenic mutant tsc2 (−/− (+n1643k)) has been reintroduced; top, ser302-phosphorylated irs-1; bottom, total irs-1. (f) irs-1 ser302 phosphorylation is inhibited by mtor/s6k inhibition with rapamycin in serum-starved tsc2",pmc2172316,1,10,38,1,48
303,chk1,protein,,chek1,uniprot,o14757,nucleus,go:0005634,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,d,activation,,,,breast,human,['3054'],nan,nan,"we could consistently show that dna damage-induced chk1 activation was dependent on mtor in all cell lines studied, suggesting that cells may rely on mtor-chk1 signalling for survival. numerous studies have demonstrated that chk1 inhibition following dna damage potentiates dna damage-induced cell death via multiple mechanisms [48-53]. importantly, this study has revealed an unexpected benefit of mtorc1/2 inhibitors in their ability to inhibit chk1 activity and cell cycle arrest. we show reduced cell survival when mtorc1/2 is inhibited in the presence of genotoxic stress and report that mtorc2 is essential for chk1 activation. our data provides new mechanistic insight into the role of mtor in the dna damage response and support the clinical development of mtorc1/2 inhibitors in combination with dna damage-based therapies for breast cancer.",pmc4381605,1,10,38,1,48
806,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,i,degradation,,bj-t,fibroblast,skin,human,['3356'],nan,nan,"to investigate the mechanism by which p53 accumulates in akt-expressing bj-t cells, p53 stability was assessed by [35s]met/cys pulse-chase analysis. over the 60 min chase period, [35s]met/cys-labelled p53 reduced at a slower rate in myr-akt cells compared to pbabe cells, indicating that myr-akt expression decreased p53 turnover (figure 6a). importantly, a 45% increase in p53 synthesis was observed in the 30 min pulse period in myr-akt-expressing cells compared with control cells (figure 6b), with no change in relative p53 transcript levels detected (supplementary figure 4a). furthermore, rapid lysis of pbabe- or myr-akt-expressing cells plus or minus the proteasome inhibitor mg132 treatment indicated that akt-expressing cells had reduced levels of polyubiquitinated p53 in the steady state (figure 6c). these results indicate that p53 accumulation in akt cells results from both a reduction in mdm2-mediated p53 ubiquitination and degradation, plus enhanced p53 translation.",pmc3325598,1,10,38,1,48
1108,tsc2,protein,,tsc2,uniprot,p49815,,,p70s6k,protein,,rps6kb1,uniprot,p23443,,,negative,d,phosphorylation,,,tumor cells,,human,['2270'],nan,nan,"we next examined if upregulation of tsc2 by rosiglitazone was associated with inhibition of mtor signaling as determined by evaluating the phosphorylation state of p70s6k, a downstream target of mtor. to determine the exact contribution of tsc2, we tested tumor cells transfected with control and tsc2 sirnas. as shown in figure 3(a), the tsc2 sirna blocked tsc2 protein production, while the control sirna had no effect. armed with these tools, we tested the effects of rosiglitazone on p70s6k. as expected, upregulation of tsc2 by rosiglitazone coincided with downregulation of phosphorylated p70s6k (figure 3(b)). silencing of tsc2 by sirna induced phosphorylation of p70s6k at baseline and inhibited p70s6k downregulation in the presence of rosiglitazone demonstrating a direct link between tsc2 induction and inhibition of mtor signaling (figure 3(b)).",pmc1892639,1,10,38,1,48
54,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleolus,go:0005730,positive,d,stabilisation,nucleolus,human fibroblasts,fibroblast,fibroblast,human,['3364'],nan,nan,"activated pi3k/akt signalling results in marked stabilisation of p53 protein. this was unexpected given that akt has been reported to promote the activity of the e3 ubiquitin ligase mdm2, the important negative regulator of p53 (haupt et al., 1997; kubbutat et al., 1997). however, in human fibroblasts, we found that active akt signalling reduces p53 ubiquitination and this corresponds to increased nucleolar sequestration, and hence inactivation of mdm2. our data indicate that this nucleolar sequestration is independent of arf and pml, and thus is likely to involve binding to other proteins, which localise to the nucleolus either constitutively or under conditions of stress such as nucleophosmin (kurki et al., 2004) and multiple ribosomal proteins, including rpl5, rpl11 and rpl23 (lohrum et al., 2003; bhat et al., 2004; dai and lu, 2004; dai et al., 2004). these binding events are invariably associated with p53 stabilisation (zhang and lu, 2009). it is tempting to hypothesise that while transient activation of akt by growth factors can lead to active mdm2, p53 degradation and cell survival, chronic activation of the pathway, such as that following oncogenic mutation within the signalling network, results in nucleolar sequestration and inactivation of mdm2, and accumulation of p53 with a subsequent induction of senescence.",pmc3325598,1,10,38,1,48
863,pi 3-kinase,protein,,,uniprot,p42336,,,p53,protein,,tp53,uniprot,p04637,,,positive,d,phosphorylation,serine 86,,,,human,['510'],nan,nan,"as expected, inhibition of pi 3-kinase led to rapid dephosphorylation of both akt and gsk3 (figure 6a), corresponding to activation of gsk3. phosphorylation of tip60 on serine 86 increased ∼fourfold following inhibition of pi 3-kinase with either pi-103 or gdc-0941 (figure 6b). likewise, inhibition of pi 3-kinase increased the acetylation of p53 lysine 120 by three-to-four-fold (figure 6c). importantly, both tip60 phosphorylation and p53 acetylation were blocked by treatment with the gsk3 inhibitor sb-21676, demonstrating the functional role of gsk3 in p53 activation. inhibition of pi 3-kinase similarly resulted in gsk3-dependent phosphorylation of tip60 (figure 6d) and acetylation of p53 (figure 6e) in pc12 rat pheochromocytoma cells.",pmc3481126,1,10,38,1,48
59,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p53mut,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,inhibitory complex formation,nucleolus,,,,,['394'],nan,nan,"overall the data suggest that an akt/npm/arf pathway contributes to the maintenance of elevated levels of p53mut. thus, we can present a model (fig. s8f) whereby npm and arf are constitutively associated in high molecular weight complexes at the nucleolus. akt phosphorylation on ser48 prevents npm oligomerization, thereby increasing nucleoplasmic npm/arf that forms an inhibitory complex with mdm2 and results in increased p53mut stability.",pmc4171619,1,10,38,1,48
908,pten,protein,,pten,uniprot,p60484,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,,,,,humans,['3632'],nan,nan,"loss of pten protein was reported to correlate with pathological markers of poor prognosis in prostate cancer [361]. a relative reciprocity of mutations in pten and nras was also reported in melanoma, suggesting that the two genetic changes, in a subset of cutaneous melanomas, are functionally overlapping [362]. in multiple myeloma (mm) it was shown that human lines possessing the highest akt activity lost pten expression [363]. sequencing analysis demonstrated that the pten gene contained a deletion. restoration of pten expression suppressed igf-i-induced akt activity, suggesting that loss of pten is responsible for uncontrolled akt activity in mm lines [363]. in lymphoma/leukemia-derived cell lines, an inverse relationship between pten and phosphorylated akt was observed in 63% of cell lines [364]. no cell lines showed absence of pten expression, whereas 50% of cell lines showed low pten expression [364]. another study demonstrated the phosphorylation of akt is accompanied by the loss of pten in clinical specimens of endometrial carcinomas [365]. phosphorylation of akt was accompanied by the loss of pten in clinical specimens of endometrial cancers [366]. the survival rate for pten-positive patients was significantly higher than that for pten-negative or -heterogeneous staining patients, and thus pten-positive staining was proposed to be a significant prognostic indicator of favorable survival for patients with advanced endometrial cancer [366]. in glioma, a strong inverse correlation was described between pten levels and both phosphorylated akt expression and akt activity [367]. a significant association was evident between pten expression level and histology. pten levels were highest in normal brain, lowest in gbm tumors, and intermediate in grade ii oligoastrocytomas [367]. another study demonstrated that loss pten was highly correlated with activation of the main pi3k effector akt in vivo [368]. it was also shown that akt activation is significantly correlated with mtor, the family of forkhead transcription factors (foxo1, foxo3a, and foxo4) and the s6 protein [368]. expression of the mutant egfrviii was also tightly correlated with phosphorylation of these effectors, demonstrating an additional route to pi3k pathway activation in glioblastomas in vivo [368]. pten expression correlated significantly with survival time within the entire cohort and was associated with survival within the subgroup of gbm tumors [367]. thus, reduced pten expression is ubiquitous among gbm tumors and may play a role in the development of low-grade gliomas. pten inactivation in gliomas portends a particularly aggressive clinical behavior [367].",pmc2652403,1,10,38,1,48
55,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,modulates,,,tumor,,,['388'],nan,nan,inhibition of akt modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth,pmc4171619,1,10,38,1,48
907,pten,protein,,pten,uniprot,p60484,,,akt,protein,,akt1,uniprot,p31749,,,negative,d,binds,,,,,,['1218'],nan,nan,"antibodies against pten, phospho-akt, akt, phospho-erk, erk, phospho-p38, p38, p21/cip1, p27/kip1, cyclin d1, and β-actin were purchased from cell signaling technology, inc. (danvers, ma). enhanced chemiluminescence (ecl) western blot detection reagents were from amersham life sciences inc. (arlington heights, il). terminal deoxynucleotidyl transferase biotin-dutp nick end labeling (tunel) assay kit was purchased from emd biosciences/calbiochem (san diego, ca). sulforaphane was purchased from lkt laboratories, inc. (st. paul, mn). kits for terminal deoxynucleotidyl transferase biotin-dutp nick end labeling (tunel) and caspase-3 assays were purchased from emd biosciences/calbiochem (san diego, ca).",pmc2915986,1,10,38,1,48
176,b-raf,protein,,braf,uniprot,o75376,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,d,inhibition,,melanoma,,skin,human,['2445'],nan,nan,"serum-stimulated proliferation of multiple human melanoma cell lines was inhibited by bay43-9006 and by rapamycin. melanoma cells containing the b-raf mutation v599e were more sensitive than cells with wild-type b-raf to 10 nm doses of both bay43-9006 and rapamycin. regardless of b-raf mutational status, the combination of low dose rapamycin and bay43-9006 synergistically inhibited melanoma cell proliferation. as expected, rapamycin inhibited the phosphorylation of mtor substrates, p70s6k and 4ebp1, and bay43-9006 inhibited phosphorylation of erk, which is dependent on b-raf activity. we also observed unexpected rapamycin inhibition of the phosphorylation of erk, as well as bay43-9006 inhibition of the phosphorylation of mtor substrates, p70s6k and 4ebp1.",pmc1289294,1,10,38,1,48
1103,tsc2,protein,,tsc2,uniprot,p49815,,,erk,protein,,mapk1,uniprot,p28482,,,positive,d,phosphorylation,,,,,,['2013'],nan,nan,"akt also phosphorylates the proline-rich akt substrate of 40 kda (pras40), another inhibitor of mtorc1. when pras40 is phosphorylated by akt, it can not suppress mtorc1 signalling [154,154,165,169,183-185]. thus, this is another mechanism by which akt activates mtorc1. to complicate matters, pras40 is a substrate of mtorc1 itself, and mtorc1-mediated phosphorylation of pras40 prevents inhibition of additional mtorc1 signaling. the ras/raf/mek/erk signaling pathway also regulates mtorc1. tsc2 is phosphorylated by both erk and p90rsk-1. when tsc2 is phosphorylated by either erk or p90rsk-1, its inhibitory function is suppressed [183-185]. moreover, inhibition of mtorc1 can result in erk1/2 activation, through p70s6k/pi3k/ras/raf/mek [186].",pmc4102778,1,10,38,1,48
859,phosphatidylinositol 3 kinase (pi3k),protein,,pik3ca,uniprot,p42336,plasma membrane,go:0005886,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,,,,human,['358'],nan,nan,"the phosphatidylinositol 3 kinase (pi3k)-akt signaling cascade is a vital mediator of essential cellular activities including proliferation and survival [1]. mutations, amplification and deletions of the upstream regulators of akt are among the most frequent somatic events in cancer [2, 3]. consequently, deregulation of akt is a major factor enhancing both oncogenesis and resistance to treatment in many human malignancies [4, 5]. alteration of upstream pathway components, such as activating mutations in ras, pi3k or loss of pten, can be the primary oncogenic event leading to therapeutic failure[2, 6]. however, it is the activation of akt that is proposed to modulate cell death responses to therapeutic agents and mediate resistance [3, 7]. not surprisingly, the aim of regaining sensitivity to various therapies has focused attention on targeting the pi3k-akt pathway [8]. pi3k and akt inhibitors, such as pi-103 and mk-2206 have been investigated as single agents, but their potential as combination agents in specific patient cohorts is anticipated to be where the greatest effectiveness of these agents will be identified [9, 10].",pmc4171619,1,10,38,1,48
177,b-raf,protein,,braf,uniprot,p15056,plasma membrane,go:0005886,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,inhibition,,melanoma,cancerous,melanoma,human,['2456'],nan,nan,"we examined the serum-dependent proliferation of multiple human melanoma cell lines and the effects of inhibition of b-raf by bay43-9006 and of mtor by rapamycin. melanoma cell lines were tested for proliferation after treatment with a single dose of bay43-9006 or rapamycin using cell titer-glo (promega corporation, madison, wi), a luminescence-based atp cell viability assay. cells were exposed to different doses of either drug for one hour. then, the media was changed and the cells were cultured for two days in the presence of serum. we found that micromolar concentrations were cytotoxic, because cell numbers decreased after two days, whereas nanomolar concentrations were growth inhibitory. melanoma cells showed dose-dependent inhibition with 0.01 nm to 100 nm of bay43-9006 (figure 2a), or rapamycin (figure 2b). proliferation of the cells was inhibited in either 5% or 0.5% serum.",pmc1289294,1,10,38,1,48
1122,vegf,protein,,,uniprot,p15692,extracellular,go:0005576,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,positive,d,prevents,vp,,neural,cerebral,mouse,['2384'],nan,nan,"in addition to the role of vegf as a mitogen and a vp factor, a functional role for vegf in inducing edema and tissue damage has been identified after cerebral ischemia (van bruggen et al., 1999). direct genetic evidence for the pathophysiological relevance of integrin αvβ5 in the vegf pathway is provided by the observation of a reduction in neuronal damage in β5-deficient mice after cerebral ischemia (fig. 7 c). we have previously shown that src deficiency or blockade of src activity prevents vegf-mediated vp, thereby reducing neuronal damage after stroke (paul et al., 2001). in combination with the reduction in vegf-induced vp (fig. 7) and neuronal damage in β5−/− mice, these results suggest a link between integrin αvβ5 and the src-dependent vegf vascular response in vivo.",pmc2173263,1,10,38,1,48
872,pi3k,protein,,,uniprot,p42336,,,akt,protein,,,uniprot,p31749,,,positive,d,stimulation,,jf32,,,human,['2974'],nan,nan,"we observed reciprocal changes in the erk and akt pathways in response to their respective enzyme inhibitors. in lm2 cells, mek inhibition (by u0126) suppressed early erk1/2 phosphorylation while p-akt levels increased. conversely, pi3k inhibition (by ly294002) increased basal p-erk1/2 levels at the expense of p-akt (4 hrs time point; figure 9c). mek inhibition raised p-erk1/2 and total erk1/2 levels at 24 and 48 hrs, while pi3k inhibition caused a compensatory increase in cellular p-akt levels from 24-48 hrs. jf32 cell growth was also suppressed by each drug; although mek inhibition did not affect p-erk1/2 levels at 4 hrs, p-erk1/2 levels decreased at 48 hrs (figure 9d). pi3k inhibition stimulated erk1/2 phosphorylation from 4-24 hrs, and increased akt phosphorylation throughout the treatment time-course (figure 9g, h).",pmc3135566,1,10,38,1,48
889,pp2a,protein,serine/threonine protein phosphatase,ppp2r,uniprot,p67775,cytoplasm,go:0005737,s6k1,protein,,,uniprot,p23443,cytoplasm,go:0005737,negative,d,dephosphorylation,,,,,human,['3272'],nan,nan,"pp2a, a serine/threonine (ser/thr) protein phosphatase, is a heterotrimeric holoenzyme composed of a catalytic subunit (pp2ac), an a subunit (also termed pr65), and members of the b subunit families, such as b (pr55), b′ (pr61), b″ (pr72), and b′″ (pr93/pr110) [27]. the phosphatase activity of pp2ac is modulated by its association with pp2a-a, and -b regulatory subunits [27]. of interest, pp2a has been identified as the phosphatase responsible for the dephosphorylation of s6k1 and 4e-bp1, and inhibition of mtor with rapamycin has been shown to stimulate these pp2a-mediated events [28], suggesting that pp2a is a novel downstream target of mtor. it has been suggested that α4 protein, the mammalian homolog of yeast tap42 [29], associates with pp2ac [30]. association of α4 with pp2a, pp4, and pp6 has been linked to rapamycin sensitivity [30]–[32]. in yeast tor phosphorylates tap42 and promotes its association with pph21/22 and sit4 (encoding pp2ac and pp6, respectively), inhibiting their activities [29], [33], although there exists disputation [34], [35]. as in yeast, the consequence of α4 dissociation from pp2a or pp6 in mammalian cells is contradictory. for instance, rapamycin has been reported to inhibit cell proliferation by decreasing pp2a activity through dissociation α4 from the pp2ac [36]. however, other studies [31], [34] do not demonstrate rapamycin-induced dissociation of α4 from pp2a or pp6.",pmc2868031,1,10,38,1,48
878,pik3ca,protein,,pik3ca,uniprot,p42336,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,,colorectal cancer cells,,colon,human,['3641'],nan,nan,"to evaluate the consequences of pik3ca alterations, the two most common mutations were inactivated by gene targeting in colorectal cancer cells [405]. biochemical analyses of these cells showed that mutant pik3ca selectively regulated the phosphorylation of akt and of forkhead transcription factors [405]. pik3ca mutations had little effect on growth under standard conditions, but reduced cellular dependence on growth factors [405]. pik3ca mutations resulted in attenuation of apoptosis and facilitated tumor invasion [405]. importantly, treatment with ly294002 abrogated pik3ca signaling and preferentially inhibited growth of pik3ca mutant cells [405]. a recent study also showed that pik3ca mutant colon cancer cell lines have increased metastatic potential in an orthotopic model [406]. two pik3ca mutants observed in breast cancer (e545k and h1047r) were also tested in the mcf-10a immortalized breast epithelial cell line [407]. both variants displayed higher pi3k activity than wild-type p110α yet remained sensitive to pharmacologic pi3k inhibition [407]. in addition, expression of p110α mutants in mammary epithelial cells induced multiple phenotypic alterations characteristic of breast tumor cells, including anchorage-independent proliferation in soft agar, growth factor-independent proliferation, and protection from anoikis [407]. expression of these mutant p110α isoforms also confered increased resistance to paclitaxel and induced abnormal mammary acinar morphogenesis in three-dimensional basement membrane cultures [407].",pmc2652403,1,10,38,1,48
786,p21,protein,,cdkn1a,uniprot,p38936,,,cyclin e,protein,,ccne1,uniprot,p24864,,,positive,d,phosphorylation,s130,,,,,['1129'],nan,nan,"the p21 s130 residue can be phosphorylated by cyclin e-cdk2 [61], [62] and also by cdk6 activated by the viral cyclin k [79]. using 2d gel separations, we show that the in vitro phosphorylation of p21 by cyclin e/a-cdk2 occurs mainly at s130 but also at s98 (a residue reported to be phosphorylated by ask1 and jnk1 but not cdks [82]), and we show for the first time that cyclin d-cdk4/6 also readily phosphorylate s130. like p27 in cyclin e-cdk2 complexes [12], p21 is thus both a potential inhibitor and a substrate of cyclin d-cdk4/6 complexes. interestingly, s130 was more efficiently phosphorylated by the different cdk complexes when p21 was bound to cyclin d-cdk4. this, together with two other observations, suggests that p21 is not phosphorylated merely via an autonomous “intra-complex” mechanism. first, binding to inactive cdk4 complexes similarly increased the s130 phosphorylation of p21 in transfected cho cells (figure 4c). second, s130 phosphorylation did not appear after incubation of p21-cyclin d3-cdk4 complexes with high atp concentrations but no other kinase (figure 3b). p21 as a subunit of the cdk4 complex would thus be phosphorylated, and hence regulated, by other active cdk4 and cdk2 complexes. as for cdk2-dependent phosphorylation of p21 on s130 in vitro",pmc3667761,1,10,38,1,48
58,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p53mut,protein,mutant,tp53,uniprot,p04637,nucleus,go:0005634,negative,i,stability modulation,,,,,human,['377'],nan,nan,inhibition of akt decreases p53mut stability in a npm and arf dependent manner,pmc4171619,1,10,38,1,48
913,pten,protein,,pten,uniprot,p60484,nucleus,go:0005634,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,downregulation,promoter,,hepatocyte,liver,"mouse, human",['1966'],nan,nan,"alterations in pten expression have also been implicated in hcc. the best evidence that strongly supports the connection between pten-suppression and liver carcinogenesis comes from genetic studies. all mice with pten-deficient hepatocytes exhibited liver adenomas and 66% of them developed hcc [334]. in these mice, hepatocytes were hyperproliferative and displayed an abnormal activation of akt [334]. furthermore, although mutations in the pten gene rarely occur in hcc, frequent loss of heterozygosity of pten allele has been identified in 20-30% of hcc patients [335-338]. in addition, down-regulation of pten expression may be partly due to pten promoter methylation [339]. pten expression plays a critical role in hcc progression and patient's outcome. patients with high expression of pten had a significantly better overall survival than patients with low pten expression [340]. hepatitis viruses protect hepatocytes from apoptotic cell death by promoting the activation of ras/pi3k/akt/mtor survival pathway [341,342]. among the four proteins encoded by hbv genome, hbx has been reported to be involved in hepatocarcinogenesis. it has been reported that hbx expression downregulated pten expression in hepatocytes [342]. in contrast, pten expression in liver cells downregulated hbx-induced pi3k and akt activities [343]. therefore, these studies suggest the possible use of pten as a target in therapeutic approaches for the treatment of at least those hcc caused by hbv infection.",pmc3660063,1,10,38,1,48
12,akt,protein,akt1,akt1,uniprot,p31749,cytoplasm,go:0005737,bcl-2,protein,,bbc2,uniprot,p10415,mitochondria,go:0005739,negative,i,phosphorylation,bad,,cd133+ hcc cscs,liver,human,['792'],nan,nan,"in cd133+ hcc cscs, akt inhibition by a akt1-specific inhibitor lowered drug-resistance to both doxorubicin and fluouracil, possibly through a mechanism involving bad phosphorylation and bcl-2 expression [106].",pmc3837323,1,10,38,1,48
838,p70s6k,protein,,,uniprot,p23443,cytoplasm,go:0005737,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,positive,d,inhibition,downstream,nsclc,lung cancer,,human,['3030'],nan,nan,"as shown above, the p70s6k inhibitor pf-4708671 significantly inhibited the activation of p70s6k and its key downstream effector s6, in a concentration dependent manner. furthermore, the protein levels of downstream bad; caspase3 and erk, which affecting apoptosis ability of cells, were increased after treatment with pf-4708671. this proved that pf-4708671 might affect the nsclc cell lines’ survival by regulating relevant factors of apoptosis. in addition, nsclc cell proliferation was time and concentration dependently inhibited by pf-4708671, corroborating previous reports [15–17]. thus, we proposed that p70s6k regulation is associated with cell apoptosis. the differences in minimum effective drug concentrations for the nsclc cell lines assessed may be due to their distinct p70s6k levels and growth rates: we found growth inhibition rate of 30 to 40%.",pmc4714881,1,10,38,1,48
57,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p53mut,protein,mutant,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,represses,in-vivo,,,,unspecified,['385'],nan,nan,inhibition of akt represses p53mut stability in-vivo and sensitizes psn1 xenografts to ir,pmc4171619,1,10,38,1,48
817,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,jnk-1,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,positive,d,activation,,,,,human,['1169'],nan,nan,"indeed, the idea of alteration in activation dynamics as a regulatory strategy has been previously proposed. the atm-chk2-p53 pathway has been shown to be activated in cycles after ir treatment [24]; it has been suggested that the cycles of p53 activation are required to sense the intensity of the dna damage [59] and to modulate the response according to the severity of the damage [70]. moreover, the kinetics of activation of jnk-1 has been proposed to dictate the cellular outcome, with transient activation being pro-inflammatory and pro-survival, while sustained activation inducing cell death [71].",pmc3656868,1,10,38,1,48
816,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,htert,protein,,tert,uniprot,o14727,nucleus,go:0005634,negative,d,repression,,,,,,['2319'],nan,nan,"we identified multiple potential reciprocal repression (toggle switch) and feedback oscillator motifs as in the examples in figure 7a, which may provide substantial scope for dynamic network behaviour. we also identified several types of coherent feed forward motifs. in particular, three distinct sub-networks form candidate activation and repression “modules”. the activation module links all positive regulators of htert via densely overlapping coherent type 1 motifs, while the repression module comprises several coherent type 2 motifs organised by p53 and ar which inhibit htert and its activators. both motif types are reported to reduce noise in gene expression networks [21].",pmc2714081,1,10,38,1,48
224,cdk,protein,inhibitor,cdk,uniprot,p24385,nucleus,go:0005634,il-6,protein,cytokine,il6,uniprot,p05231,extracellular space,go:0005615,negative,d,inhibition,,mouse b cells,b-cell,,mouse,['213'],nan,nan,of il-6 was dramatically reduced in mouse b cells treated with the cdk inhibitor,pmc3084876,1,10,38,1,48
51,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p14arf,protein,,cdkn2a,uniprot,p42771,nucleoplasm,go:0005654,positive,d,association,,,,,,['375'],nan,nan,inhibition of akt promotes enhanced mdm2 activity via the increased association between npm and p14arf,pmc4171619,1,10,38,1,48
52,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p21cip1,protein,,cdkn1a,uniprot,p38936,nucleus,go:0005634,positive,d,phosphorylation,"thr145, ser146",,,,human,['5'],nan,nan,"another important function of akt in g1/s progression is positive regulation of mid- and late-g1-phase cyclin/cdk activity via phosphorylation and inactivation of cdk inhibitors, including p21cip1 and p27kip1. akt phosphorylates p21cip1 at thr145, within its nuclear localization sequence (nls), to recruit p21cip1 from the nucleus to the cytoplasm and suppress its inhibitory effect on cell cycle progression [50]. akt-mediated t145 phosphorylation also prevents p21cip1 forming a complex with pcna to inhibit dna replication and decreases its binding to cdk2/cdk4 and attenuates its cdk2 inhibitory activity [51]. in addition to thr145, ser146 is also phosphorylated by akt, a modification that significantly increases p21cip1 protein stability and protects cells from taxol-induced apoptosis [52]. importantly, p21cip1 protein induced by akt does not inhibit cyclin e-cdk2 but rather promotes the assembly and activation of cyclin d1-cdk4 complex, which controls g1 to s phase progression and enhances cell cycling [52]. p21cip1 elevation in tumors correlates with enhanced survival and chemoresistance [53], indicating that stabilization of p21cip1 by akt would be beneficial for tumor growth.",pmc3317191,1,10,38,1,48
901,pras40,protein,,,uniprot,q96b36,,,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,inhibits,,u2os,,,human,['2289'],nan,nan,"in u2os cells with a functional rpl11-hdm2 nucleolar stress response pathway and inactive p14arf, pras40 kd leads to an rpl11-dependent increase in p53 protein level and transcriptional activity. consistent with a model in which akt- and mtorc1-phosphorylated pras40 inhibits the rpl11-hdm2 pathway, pras40 kd-induced p53 upregulation is achieved through decreased p53 proteasomal degradation. together these data imply that pras40 is a dual-input signal integrator and effector of mtorc1 and akt that suppresses the rpl11-hdm2-p53 pathway in the presence of extracellular growth factors and nutrients (fig. 6). although pict1 has been identified as a regulator of the nucleolar stress response pathway,52 the present findings represent the first known regulatory link between extracellular stimuli, the akt/mtorc1 signaling axis, and the rpl11-hdm2-p53 pathway. the precise mechanism by which pras40 regulates the rpl11-hdm2 pathway remains to be determined. one possibility is that pras40 may block translocation of rpl11 from nucleoli to the nucleoplasm.",pmc4216640,1,10,38,1,48
887,pp2a,protein,,,uniprot,p67775,,,chk1,protein,,chek1,uniprot,o14757,nucleus,go:0005634,negative,d,"dephosphorylation, phosphorylation",s344 (human s345),x. laevis egg extracts,,,x. laevis,['1667'],nan,nan,"in human cells, the inhibition of pp2a induced chk1 phosphorylation in the absence of dna damage and also prevented chk1 dephosphorylation after hydroxyurea removal [118]. the knockdown of pp2a increased chk1 phosphorylation on s317 and s345 and in vitro, pp2a was able to directly dephosphorylate chk1 [118]. in x. laevis egg extracts, the addition of pp2a c reversed chk1 phosphorylation at s344 (human s345) after activation by dsb [119]. the inhibition of pp2a also enhanced chk1 phosphorylation following activation by dsb [119].",pmc2954851,1,10,38,1,48
886,pp2a,protein,,,uniprot,p67775,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,inhibition,,rh1 or rh30,,,human,['3287'],nan,nan,"next, we investigated the role of pp2a in mtor-mediated cell motility. to this end, a monolayer of rh1 or rh30 cells were grown in 6-well plates to 80% confluence, and serum-starved in dmem for 24 h. cell motility was assessed by the wound healing assay, as described previously [23]. following wounding, cells were pretreated with or without oa (100 nm) for 1 h, then treated with or without rapamycin (100 ng/ml) for 2 h, followed by stimulation with or without igf-1 (10 ng/ml) for 22 h. consistent with our previous findings [23], [24], rapamycin inhibited the basal or igf-1-stimulated cell motility by 60–70% in rh1 cells (fig. 3b). igf-1 stimulated the cell motility by ∼3-fold, and this was dramatically attenuated by rapamycin to the basal level (fig. 3b). oa alone did not affect the basal or igf-1 stimulated cell motility significantly, but conferred high resistance to rapamycin inhibition of the basal or igf-1-stimulated cell motility in rh1 cells (fig. 3b). similar results were also observed in rh30 cells (data not shown).",pmc2868031,1,10,38,1,48
897,pras40,protein,,akt1s1,uniprot,q96b36,,,p53,protein,,tp53,uniprot,p04637,,,positive,i,stabilization,,,,nucleoli,,['2284'],nan,nan,"to further explore the possibility that pras40 regulates p53 through inhibition of the rpl11-hdm2 pathway, we employed actinomycin d (actd), a polypeptide antibiotic known to induce nucleolar stress and upregulate p53 exclusively through the rpl11-hdm2 pathway when used at concentrations < 10 nm.6, 8, 46 while pras40 kd and actd have an additive effect at low actd concentrations, there is no combinatorial effect at higher actd concentrations (fig. 5c), suggesting that pras40 kd and actd activate p53 through a similar mechanism, namely the rpl11-hdm2 nucleolar stress response pathway. importantly, we also find the effect of pras40 kd on p53 protein level is abolished by co-kd of rpl11 using two different shrnas (fig. 5d). taken together, these results indicate that pras40 kd induces p53 protein stabilization in an rpl11-dependent manner and imply that pras40 may act as an endogenous regulator of the rpl11-hdm2-p53 pathway.",pmc4216640,1,10,38,1,48
915,pten,protein,phosphatase,pten,uniprot,p60484,nucleus,go:0005634,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,phosphorylation,,pancreatic cancer cell lines,,,human,['1195'],nan,nan,"pten (phosphatase and tensin homolog deleted on chromosome 10, also called mmac1 or tep1) is a tumor suppressor gene [28-30], which is frequently deleted or mutated in a wide range of human cancers, including glioblastoma [31], melanoma [32], and prostate [33], breast [34], and endometrial cancers [35]. while point mutations in pten rarely occur in pancreatic cancer [36,37], functional inactivation of pten through promoter methylation [38], loss of protein expression [39], reduction of mrna levels [40], or loss of heterozygocity (loh) of linked markers [37,41] occur with high frequency. phosphatidylinositol 3,4,5-trisphosphate (pip3) is a substrate of pten [42-44]. akt is a serine-threonine protein kinase regulated by pip3 that is implicated in survival signaling in a wide a variety of cells, including fibroblastic, epithelial, and neuronal cells [45]. pten increases sensitivity to cell death in response to several apoptotic stimuli by negatively regulating the pi3k/akt pathway [43]. in addition to its role in regulating the pi3k/akt cell survival pathway, pten also inhibits growth factor-induced shc phosphorylation and suppresses the map kinase signaling pathway [46], suggesting that pten has roles in independent of pi3k/akt signaling pathway. hyperactivation of akt is associated with resistance to apoptosis, increased cell growth, cell proliferation, metastasis, angiogenesis, and cellular energy metabolism [45,47-54]. overexpression of akt has been reported in a variety of human cancers, including pancreatic cancer, and cells expressing elevated levels of akt are less sensitive to apoptosis stimuli [38,55-57]. antagonizing pi3k activity negatively regulates akt activity. once activated, however, akt exerts antiapoptotic effects through phosphorylation of substrates such as bad [58,59] and caspase-9 [60] that directly regulate the apoptotic machinery, or human telomerase reverse transcriptase subunit [61], forkhead transcription family members [62,63] and ib kinases [64] that indirectly inhibit apoptosis [65]. studies in pancreatic cancer cell lines have demonstrated that pi3k is required for growth and survival of tumor cells [66-68]. furthermore, amplification or activation of akt2 occurs in up to 60% of pancreatic cancer [39,69-71], supporting the participation of an activated pi3k-akt axis in this disease.",pmc2915986,1,10,38,1,48
898,pras40,protein,,akt1s1,uniprot,q96b36,nucleus,go:0005634,p53,protein,,tp53,uniprot,p04637,nucleoplasm,go:0005654,positive,i,couples,nucleolar stress response pathway,,,,human,['2276'],nan,nan,nuclear pras40 couples the akt/mtorc1 signaling axis to the rpl11-hdm2-p53 nucleolar stress response pathway,pmc4216640,1,10,38,1,48
56,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,induces,,,human,,human,['3337'],nan,nan,akt induces senescence in human cells via mtorc1 and p53 in the absence of dna damage: implications for targeting mtor during malignancy,pmc3325598,1,10,38,1,48
822,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,p16,protein,,cdkn2a,uniprot,p42771,nucleus,go:0005634,positive,d,induce,,,,,human,['1001'],nan,nan,"senescence is deemed a clinically favorable response to chemotherapy because of its stability and its capacity to stimulate tumor clearance by the immune system [9-11]. senescence is characterized by gross changes in gene expression and chromatin, changes in cellular metabolism, and changes in the function of the cell. senescence is typically a response to stress [12]. dna damage, telomere attrition, or aberrant oncogene expression can induce p53, p16 and/or arf leading to cell cycle exit and senescence [13-16]. however, senescence can also be triggered in a p53 and ink4 independent manner as well. [17-19].",pmc4480747,1,10,38,1,48
67,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,pten,protein,,pten,uniprot,p60484,nucleus,go:0005634,positive,d,associated with,,mcf7,breast cancer,,human,['3646'],nan,nan,"in breast cancer cell lines, akt activity was constitutive and was associated with either pten mutations or erbb2 over-expression [427]. when combined with therapies commonly used in breast cancer treatment, ly294002 potentiated apoptosis caused by doxorubicin, trastuzumab, paclitaxel, or etoposide [427]. potentiation of apoptosis by ly294002 correlated with induction of akt by doxorubicin or trastuzumab alone that occurred before the onset of apoptosis [427]. to determine a causal relationship between the activity of akt and radioresistance in human breast cancer cells, mcf7 cells, transfected with constitutively active h-ras (radg12v) or constitutively active akt, were chosen for analysis in [428]. the results from this study indicated that the expression of constitutively active ras and the expression of constitutively active akt each increased cellular resistance to radiation [428]. inhibition of pi3k with ly294002 reverted the constitutively active ras-mediated radioresistance, but not the constitutively active akt-mediated radioresistance [428]. these data suggested that akt may be a potential target for enhancing the response to radiotherapy in patients with breast cancer [428]. another study showed the erbb2/p13k/akt pathway plays a role in mediating multi-drug resistance in human breast cancer cells [429]. it was found that cell lines that express both erbb2 and erbb3 appear to have a higher phosphorylation level of akt [429]. transfection of erbb2 in mcf7 breast cancer cells that express erbb3 caused a pi3k-dependent activation of akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin) [429]. selective inhibition of pi3k or akt activity with their respective dominant-negative expression vectors sensitized the cells to the induction of apoptosis by the chemotherapeutic agents [429].",pmc2652403,1,10,38,1,48
900,pras40,protein,,,uniprot,q96b36,cytoplasm,go:0005737,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,i,induces,,,,,,['2282'],nan,nan,pras40 depletion induces p53 protein stability in an rpl11-dependent manner,pmc4216640,1,10,38,1,48
787,p21,protein,,,uniprot,p38936,,,cdk4,protein,,cdk4,uniprot,p11802,,,positive,d,phosphorylation,s130,,,,,"['1102', '1125']","nan,nan","nan,nan","all together, these experiments demonstrate that s130 phosphorylation of p21 is required for phosphorylation of p21-bound cdk4. moreover, they suggest that s130 phosphorylation might modify the interaction of p21 with cyclin d-cdk4 to increase the accessibility of cdk4 t172 to cak (and possibly to other kinases).,involvement of s130 phosphorylation of p21 in cdk4 activation and cell cycle progression","pmc3667761,pmc3667761",2,1,40,1,42
647,mdm2,protein,,mdm2,uniprot,q009873,,,hausp,protein,deubiquitinase,usp7,uniprot,q93009,,,positive,i,turnover,,,,,human,['1030'],nan,nan,"as summarized in figure 9, our data indicate that geroconversion depends on the accelerated rate of mdm2 turnover following the dissociation of the deubiquitinase hausp from mdm2. cdk4 inhibition induces cell cycle exit and this primes cells for mdm2 auto-ubiquitination, however, something in non-responder cells is preventing this. intriguingly, expression of the chromatin-remodeling enzyme atrx is also important for geroconversion. because atrx deficiency prevents the loss of mdm2 we hypothesize that atrx directly regulates a program that impinges on mdm2 regulation. furthermore, because the phosphorylation of atrx at serine 2487 is associated with the inability of cells to undergo geroconversion following cdk4 inhibition, we suspect that this modification affects this activity. more detailed mechanistic studies can examine each part of this model in the future as discussed below.",pmc4480747,1,1,40,1,41
933,raf,protein,,raf1,uniprot,p04049,,,cd24,protein,,cd24,uniprot,p25063,,,negative,d,downregulate,mrna,,,,,['1725'],nan,nan,the raf and pi3k pathways downregulate cd24 mrna expression while the raf pathway is majorly responsible for downregulation of cd24 surface protein expression. (a),pmc4525067,1,1,40,1,41
851,perk,protein,,,uniprot,p27361,nucleus,go:0005634,pelk-1,protein,,elk1,uniprot,p19419,nucleus,go:0005634,positive,d,phosphorylation,nucleus,,fibroblast,serum-starved cells,human,['1241'],nan,nan,"in serum-starved cells weak, punctate pelk-1 staining was seen within the nuclei whereas there was little staining of perk (figure 6a, left panels). following mitogen stimulation, strong, punctate pelk-1 staining was seen, coincident with the appearance of nuclear perk (figure 6a, right panels and figure 6b). no staining was observed with either secondary antibody, either alone or when incubated with unmatched primary antibodies (data not shown). when the pelk-1 and perk images were merged, coincident staining was apparent although not extensive (figure 6b left, see inset in middle quadrant), showing that active erk does not associate predominantly with pelk-1 within the nucleus.",pmc2377423,1,1,40,1,41
91,akt,protein,,akt1,uniprot,p31749,,,npm,protein,,npm1,uniprot,p06748,nucleolus,go:0005730,negative,d,phosphorylation,ser48,,,,,['362'],nan,nan,"in this article we identify that akt regulates both arf stability and localization at the nucleolus. we find that akt phosphorylation of npm-ser48 inhibits npm oligomerisation and localization at the nucleolus. this in turn promotes arf mediated inhibition of mdm2 in the nucleoplasm. importantly, akt mediated promotion of arf localization in the nucleoplasm facilitates oncogenesis by promoting p53mut stability and dominant negative suppression of the dna damage response, thereby contributing to therapeutic resistance. we provide molecular evidence for resensitization of tumors by pi3k-akt inhibitors. most importantly, our findings indicate that akt mediated resistance associates with ink4a/arf status and p53mut, therefore identifying a screening rationale for the patient population in which pi3k-akt inhibitors are most likely to display efficacy.",pmc4171619,1,1,40,1,41
932,raf,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,enac,ionchannel,sodium,scnn1a,uniprot,p37088,plasma membrane,go:0005886,negative,d,inhibition,intracellular c terminus,renal collecting duct cells,epithelial,kidney,human,['1798'],nan,nan,"we demonstrated previously that activation of the raf/mek/erk signaling cascade by exposure to egf results in biphasic inhibition of amiloride-sensitive sodium absorption in renal collecting duct cells. prolonged activation causes a 50–60% reduction in sodium current and a 70–85% decrease in expression of enac subunit mrnas (shen and cotton, 2003); whereas the early inhibitory phase develops within minutes and cannot be attributed to changes in enac expression (falin et al., 2005). the acute, egf-induced inhibition of epithelial sodium channel activity is thought to involve changes in channel gating and/or channel retrieval from the plasma membrane. the results of the present study demonstrate that there are critical sites in the intracellular c terminus of β-enac that are required for erk1/2-dependent inhibition of sodium current and that the inhibitory response is due to sequential effects on channel activity and surface expression.",pmc2151644,1,1,40,1,41
658,mek,protein,,,uniprot,q02750,cytoplasm,go:0005737,cd24,protein,,,uniprot,p25063,plasma membrane,go:0005886,negative,d,inhibition,,,,,human,['1732'],nan,nan,"since we observed that inhibition of mek partially restored cd24 mrna with no significant effect on protein levels we next determined if inhibition of raf directly could restore cd24 expression levels. raf is the major downstream target of ras and can be directly inhibited by sorafenib, which does not inhibit mek or erk (wilhelm et al., 2004). we evaluated the inhibition of raf/mek/erk pathway by sorafenib at different concentrations using western blot analysis of phosphorylated erk (p-erk) and phosphorylated akt (p-akt) as measures of efficacy and specificity (figure 5a). we found that sorafenib reduced erk phosphorylation in rasv12 cells at all concentrations examined. we also found that both phosphorylated and total akt was reduced with 10 and 20 μm sorafenib. sorafenib is known to inhibit additional kinases such as egfr, pdgfr, c-kit and flt-3 (wilhelm et al., 2004; adnane et al., 2006), therefore it is not surprising to observe inhibition of additional pathways with this inhibitor. however, we found that treatment of rasv12 cells with sorafenib had no effect on cd24 mrna expression (figures 5b,c).",pmc4525067,1,1,40,1,41
651,mek,protein,,map2k1,uniprot,q02750,cytoplasm,go:0005737,noxa,protein,,pmaip1,uniprot,q13794,mitochondria,go:0005739,positive,i,upregulation,,human melanoma,epithelial-like,skin,human,['3493'],nan,nan,noxa upregulation by oncogenic activation of mek/erk through creb promotes autophagy in human melanoma cells,pmc4294377,1,1,40,1,41
930,raf,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,cd24,protein,cell surface protein,cd24,uniprot,p25063,plasma membrane,go:0005886,negative,i,inhibition,,,,,,['1731'],nan,nan,inhibition of raf partially restores cd24 cell surface protein expression in cells expressing oncogenic ras but not control cells,pmc4525067,1,1,40,1,41
674,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,4e-bp1,protein,effector,eef2,uniprot,q13541,cytoplasm,go:0005737,negative,i,phosphorylation,,carcinoma cell lines,,colorectal,human,['629'],nan,nan,"in contrast, the second generation of mtor inhibitors targets the mtor kinase activity, thus inhibits both mtorc1 and mtorc2 and are more potent than the first generation of the inhibitors [22]. while the ongoing clinical trials will determine whether these mtor kinase inhibitors are effective in clinical treatment of colorectal carcinomas, preclinical study of the carcinoma cell lines reveals the resistance of many of the cell lines to the treatment of the mtor kinase inhibitor pp242 in part due to mtor-independent 4e-bp1 phosphorylation [48]. consistent with this earlier finding, we show here that pp242 treatment leads to the incomplete inhibition of 4e-bp1 phosphorylation in colorectal cells. 4e-bp1 is a key effector of the pi3k and mtor pathway [57] and the incomplete inhibition by pp242 of the 4e-bp1 phosphorylation contributes to the carcinoma resistance to pp242 treatment [48].",pmc3750018,1,1,40,1,41
673,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,4e binding protein (4ebp),protein,substrate,ensg00000187840,ensembl,q13541,cytoplasm,go:0005737,negative,d,phosphorylation,,,,,,['904'],nan,nan,"growth factor pathways are required for normal development but are often inappropriately activated in many cancers. one growth-factor–sensitive pathway of increasing interest to cancer researchers relies on the mammalian target of rapamycin (mtor), a kinase that (like all kinases) delivers phosphate groups from atp to amino acid residues of downstream proteins. tor proteins were first discovered in yeast as the cellular targets of rapamycin, a small, naturally occurring molecule derived from bacteria that is widely used as an immunosuppressant and more recently in some cancer therapies. the study of tor proteins has relied heavily on the use of rapamycin, but rapamycin does not directly inhibit tor kinase activity; rather, rapamycin influences tor's enzymatic activities by binding to a domain far from the kinase's active site. some mtor functions are resistant to rapamycin, as a result of the kinase activity of one kind of multiprotein complex, the mtor complex 2 (mtorc2), whereas rapamycin-sensitive functions of mtor are due to the mtor complex 1 (mtorc1). we have developed new inhibitors of mtor that bind to the atp-binding site of mtor and inhibit the catalytic activity of both mtorc1 and mtorc2 without inhibiting other kinases. unexpectedly, these inhibitors had profound effects on protein synthesis and cell proliferation due to their inhibition of mtorc1 rather than mtorc2. we found that the phosphorylation of a protein that controls protein synthesis, the mtorc1 substrate 4e binding protein (4ebp) is partially resistant to rapamycin but fully inhibited by our new inhibitors. the finding that 4ebp phosphorylation is resistant to rapamycin suggests that active-site inhibitors may be more effective than rapamycin in the treatment of cancer and may explain why rapamycin is so well tolerated when taken for immunosuppression.",pmc2637922,1,1,40,1,41
911,pten,protein,,pten,uniprot,p60484,,,gsk3β,protein,,gsk3b,uniprot,p49841,,,negative,d,inhibition,,jurkat,t-cell,,human,['2788'],nan,nan,"in jurkat t-cells, deficient in pten expression, basal akt activity is high [15], so we expected gsk3β to be maximally inhibited. consistent with this, licl treatment did not exert any further effect on delta1-induced signalling in jurkat-n2 cells (fig. 3c).",pmc1403772,1,1,40,1,41
86,akt,protein,,akt1,uniprot,p31749,,,mcl-1,protein,,mcl1,uniprot,q07817,,,positive,d,upregulation,,,,,,['2897'],nan,nan,"akt and erk have been shown to upregulate mcl-1 transcription (wang et al., 1999; booy et al., 2011). in addition, both pi3k/akt and mek/erk pathways have also been shown to enhance mcl-1 protein stability (derouet et al., 2004). because akt inhibits gsk3β as described above, akt increases mcl-1 stability, at least in part, by inhibiting gsk3β. indeed, the inhibition of pi3k induces s159 phosphorylation of mcl-1 and subsequent ubiquitination and degradation of mcl-1, which are blocked by gsk3 inhibition (maurer et al., 2006). in addition to gsk3β, it has been show that erk phosphorylates mcl-1 at t92 and t163 (domina et al., 2004; ding et al., 2008). in particular, we showed that erk-phoshorylated mcl-1 can interact with pin1 (ding et al., 2008). pin1 is a peptidyl–prolyl cis/trans isomerase that binds to specific ps/t-p motifs and then isomerizes its substrates, resulting in their conformational changes. interestingly, pin1 stabilizes mcl-1 protein after the phosphorylation by erk, and the expression of mcl-1 correlates with pin1 in multiple human cancer cell lines (ding et al., 2008). thus, erk and pin1 cooperatively regulate mcl-1 stability. regarding ikk, there is no evidence that ikk is directly involved in mcl-1 or gsk3β phosphorylation and/or ubiquitination. however, it has been shown that nf-κb is required for egf-induced mcl-1 induction, suggesting that the ikk–nf-κb pathway plays a role in mcl-1 expression or stability (henson et al., 2003). thus, mcl-1 is a critical apoptosis regulator that is controlled by the three kinases at the post-translational as well as transcriptional level (figure 2a).",pmc3355968,1,1,40,1,41
90,akt,protein,,akt1,uniprot,p31749,,,npm,protein,,npm1,uniprot,p06748,,,positive,d,phosphorylation,ser48,t24 cells,,,human,['363'],nan,nan,"npm was identified by mass spectrometry in akt immunoprecipitates and verified to associate with active akt by western blot (fig. 1a, s1a and s1b). although other groups have reported an interaction between akt and npm [49], a role for this association has not been addressed. in t24 cells with oncogenically active akt, npm is readily detectable using a pan-akt substrate antibody but not in the presence of the pi3-kinase inhibitor pi-103, indicating that npm was a possible akt substrate (fig. s1c). npm contains a single non-consensus (rxxs) akt substrate motif at position ser48 within the n-terminal oligomerisation domain (fig. 1b) and the rxxs motif has previously been reported to function as a bona-fide akt substrate recognition motif in cdk2 [50]. we confirmed that akt specifically phosphorylated npm on ser48 by in-vitro kinase assay (fig. 1c). phosphorylated npm, but not a npm-s48a derivative, can be detected with a specific phospho-peptide antibody (ps48-npm) (fig. 1d and s1d) and furthermore, npm-ser48 could be phosphorylated by akt in response to egf stimulation (fig. s1e).",pmc4171619,1,1,40,1,41
927,rac1,protein,,rac1,uniprot,p63000,nucleus,go:0005634,rhoa,protein,,rhoa,uniprot,p61586,cytosol,go:0005829,positive,d,translocation,nucleus,cos-7,fibroblast-like,,human,['1550'],nan,nan,"it has been shown previously that rac1 pbr (pvkkrkrk), containing a nuclear localization signal (nls), promotes the accumulation of rac1 in the nucleus, whereas rhoa pbr (rrgkkksg), without an nls, sequesters rhoa in the cytosol [42]. we have shown previously that the phosphorylation of rac1 by erk enhanced its nuclear translocation [21]. here, we examined the roles of both the pbr and phosphorylation on the nuclear localization of rhoa and rac1. we replaced the pbr of gfp-rac1 t108e with rhoa pbr to generate the mutant gfp-rac1 t108erhoa-pbr. we also replaced the pbr of gfp-rhoa s88e/t100e with rac1 pbr to generate gfp-rhoa s88e/t100erac1-pbr. these two mutants and two previously generated mutants (gfp-rhoarac1-pbr and gfp-rac1rhoa-pbr) were expressed in cos-7 cells by transient transfection. the localization of these four mutants was examined by fluorescence microscopy. as shown in fig 9, rac1 pbr targets rhoa to the nucleus with or without egf stimulation and rhoa pbr targets rac1 to the cytoplasm, which is consistent with a previous report [42]. interestingly, rhoa pbr was able to target the phosphomimetic mutant rac1 t108e to cytoplasm and rac1 pbr was able to target the phosphomimetic mutants rhoa s88e/100e to the nucleus. these data suggest that pbr is the determining factor for the subcellular localization of rhoa and rac1.",pmc4729484,1,1,40,1,41
931,raf,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,cd24,protein,,cd24,uniprot,p25063,plasma membrane,go:0005886,negative,d,inhibition,,,,,human,['1733'],nan,nan,"we next determined if inhibition of both pi3k and raf together could further restore cd24 expression in rasv12 cells at the mrna and surface protein levels. we evaluated the inhibition of pi3k/akt and raf/mek/erk pathways using western blot analysis of phosphorylated erk (p-erk) and phosphorylated akt (p-akt), respectively, as previously discussed (figure 6a). similar to our previous observations, we found that treatment of rasv12 with ly294002 reduced phosphorylation of akt with no effect on phosphorylation of erk. treatment with both ly294002 and sorafenib inhibited phosphorylation of both erk and akt, as expected. we found that treatment with both ly294002 and sorafenib did not increase cd24 mrna expression (figures 6b,c).",pmc4525067,1,1,40,1,41
61,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,pfkfb3,protein,,,uniprot,q08345,cytoplasm,go:0005737,positive,i,regulation,glycolytic pathway,,,,fungi,['2601'],nan,nan,"rasfonin is a fungal secondary metabolite with demonstrated antitumor effects. however, the underlying mechanism of the regulatory role in autophagy initiated by rasfonin is largely unknown. moreover, the function of akt to positively mediate the induced autophagy remains elusive. in the present study, we observed that rasfonin induced autophagy concomitant with the upregulation of akt phosphorylation. both the inhibition of akt by small molecule inhibitors and genetic modification partially reduced rasfonin-dependent autophagic flux and parp-1 cleavage. the overexpression of myrakts (constant active form) promoted rasfonin-induced apoptosis and autophagy in a cell type- and akt isoform-specific manner. using quantitative pcr and immunoblotting, we observed that rasfonin increased the expression of glycolytic gene pfkfb3, and this increased expression can be suppressed in the presence of akt inhibitor. the inhibition of pfkfb3 suppressed rasfonin-activated autophagy with enhanced parp-1 cleavage. in the case of glucose uptake was disrupted, which mean the glycolytic pathway was fully blocked, the rasfonin-induced autophagy and parp-1 cleavage were downregulated. collectively, these results demonstrated that akt positively regulated rasfonin-enhanced autophagy and caspase-dependent apoptosis primarily through affecting the glycolytic pathway.",pmc4720880,1,1,40,1,41
660,mek,protein,,,uniprot,q02750,,,β-catenin,protein,,ctnnb1,uniprot,p35222,"cytoplasm, nucleus","go:0005737, go:0005634",negative,d,reduction,nucleus,"ht-29, dld-1",colorectal cancer,,human,['2915'],nan,nan,"to elucidate the molecular mechanisms by which mek inhibition reduced β-catenin/tcf transcriptional activity in human crc cells, β-catenin subcellular distribution was verified. as the majority of crc cells exhibit apc mutations,40 it was therefore expected that these cells would exhibit some nuclear β-catenin staining.41 indeed, control ht-29 cells showed β-catenin staining predominantly in the cytoplasm and also in the nucleus. however, the nuclear staining of β-catenin was markedly reduced upon mek inhibition, whereas the membranous signal seemingly accumulated in areas of intercellular contacts (figure 5d). similar results were obtained in dld-1 cells (data not shown). co-immunoprecipitation assays further demonstrated that the β-catenin/tcf4 association was indeed clearly reduced following mek inhibition in these cells (figure 5e). by contrast, we could not detect modified interaction of β-catenin with e-cadherin in u0126-treated cells (figure 5f).",pmc4687460,1,1,40,1,41
659,mek,protein,,,uniprot,q02750,cytoplasm,go:0005737,mmp-2,protein,collagenase,mmp2,uniprot,p08253,extracellular region,go:0005576,positive,i,up-regulation,,a375 or wm266-4,melanoma,,human,['2079'],nan,nan,"our data indicate that mek inhibition induces a ‘mesenchymal’ shape in melanoma cells. for cells to invade with this shape they need to modulate the ecm through protease activities, such as matrix-metalloproteinases (mmps) (10, 11). it is generally accepted that the erk/map kinase pathway regulates mmp expression in cancer cells, although in melanoma only few reports document such a regulation, in particular of mmp-1 or mmp-13 (24, 25). therefore we analysed the effect of mek inhibition on mmp-production in melanoma cells. a zymographic analysis revealed that although low amounts of mmp-9 were present, mmp-2 was by far the most abundant collagenase present in the medium of a375 or wm266-4 cells when cultured on a collagen gel (fig.3a). furthermore, a significant amount of mmp-2 was present in its cleaved and hence active form (fig.3a). most importantly inhibition of mek by either selumetinib or pd184352 did not reduce the amount of pro- and active mmp-2. for a better quantification of mmp activities, we examined the effect of mek inhibition on the mrna expression of mmp-2 and mt1-mmp, a membrane tethered mmp, which apart from being a collagenase itself is essential for the cleavage of pro-mmp-2. this revealed that inhibition of mek by either selumetinib or pd184352 results in a significant up-regulation of mmp-2 and mt1-mmp expression (fig.3b, c), suggesting that this increases the ability of mek inhibited cells to invade in an mmp-dependent fashion. to test this hypothesis, we determined the selumetinib-induced invasiveness of wm266-4 cells in the presence of protease inhibitors. the suppression of proteolytic activities completely abolished the mek inhibitor induced invasiveness (fig.3d), clearly demonstrating that mek inhibition in melanoma cells promotes a protease dependent ‘mesenchymal’ mode of invasion.",pmc3378628,1,1,40,1,41
937,ras,protein,effector,,uniprot,p01116,plasma membrane,go:0005886,cd24,protein,surface,cd24,uniprot,p25063,plasma membrane,go:0005886,negative,d,affects expression,surface,,,,human,['1726'],nan,nan,"we then determined if cd24 surface protein expression was also affected in ras effector mutant cells (figure 3c). we found that there was a significant and substantial reduction in the percentage of cells expressing cd24 surface protein in rasv12 and rasv12s35 cells (figure 3d). rasv12g37 and rasv12c40 expression had an intermediate effect on reducing the percentage of cells expressing cd24, compared to control cells. therefore, activation of the raf kinase pathway, the pi3k pathway, or the ralgds pathway downstream of ras are sufficient to decrease the cd24+ population. however, activation of the raf pathway was sufficient to decrease the cd24+ population to the same low level as rasv12 suggesting that the raf pathway is the major regulator of cd24 expression in these cells. moreover, either raf or pi3k could decrease both cd24 mrna and surface expression while ralgds only partially affected surface expression.",pmc4525067,1,1,40,1,41
656,mek,protein,,,uniprot,p36507,,,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,i,phosphorylation,serine-45,crc,colorectal cancer,,human,['2916'],nan,nan,"as nuclear localization of β-catenin was reduced following mek inhibition in crc cells, we first speculated that this could potentially be associated with changes in β-catenin phosphorylation. indeed, ck1α phosphorylates β-catenin on serine-45, providing a recognition site for gsk3β, allowing gsk3β to phosphorylate threonine-41, serine-37 and serine-3341) leading to β-catenin degradation.42 in addition, phosphorylation of β-catenin at tyrosine-142 has been shown to act as a switch from the transcriptional to the adhesive role of β-catenin.43, 44 src kinases can also phosphorylate tyrosines-86 and 654 on β-catenin; however, only tyrosine-654 phosphorylation regulates its binding to e-cadherin.45 finally, both akt and pka can phosphorylate β-catenin at serine-552, which is associated with its nuclear transcriptional activity.46, 47, 48 however, by using the phospho-specific antibodies, we found that u0126 treatment did not alter β-catenin phosphorylation on these various phosphorylation sites (figure 6a).",pmc4687460,1,1,40,1,41
655,mek,protein,,,uniprot,p36507,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,positive,i,phosphorylation,lrp6,,,colorectal,human,['2932'],nan,nan,"in conclusion, our study demonstrates that the wnt/β-catenin signaling pathway acts as a novel target of mek/erk signaling involved in human colorectal tumorigenesis. whereas further studies are needed to pinpoint the molecular mechanisms by which mek-dependent lrp6 phosphorylation induces β-catenin/tcf4 activity, the present study provides a novel fundamental insight into how oncogenic kras/mapk signaling controls epithelial oncogenesis in the intestine.",pmc4687460,1,1,40,1,41
654,mek,protein,,mek,uniprot,p50750,cytoplasm,go:0005737,mig6,protein,,,uniprot,q9y6q9,cytoplasm,go:0005737,negative,d,decreases expression,,mutant nras melanoma cells,melanoma,skin,human,['154'],nan,nan,mek inhibition decreases mig6 expression in mutant nras melanoma cells,pmc4789776,1,1,40,1,41
905,pten,protein,,pten,uniprot,p60484,cytoplasm,go:0005737,cox-2,enzyme,,ptgs2,uniprot,p35354,cytoplasm,go:0005737,positive,i,signaling,nf-kappab/i-kappab pathway,endometrial cancer cells,epithelial,endometrium,human,['1973'],nan,nan,"when pten is mutated, akt signals via the nf-kappab/i-kappab pathway to induce cox-2 expression in endometrial cancer cells. cox-2 can inhibit apoptosis, increase angiogenesis, and promote invasiveness. cox-2 also promotes inflammation/immunosuppression and conversion of procarcinogens into carcinogens that contribute to tumorigenesis and a malignant phenotype. this study demonstrated that akt signals via the nf-kappab/i-kappab pathway to induce cox2 gene and protein expression in endometrial cancer [370].",pmc3660063,1,1,40,1,41
785,p21,protein,,cdkn1a,uniprot,p38936,,,cdk4,protein,,cdk4,uniprot,p11802,,,positive,i,phosphorylation,,k7as cells,unknown,unknown,unknown,['1091'],nan,nan,"to better understand how p21 could intervene in the regulation of cdk4 activation even before the increase of p21 steady-state level, we evaluated p21 modifications in k7as cells by 2d gel electrophoresis. as shown in figure 3a, one main more negatively charged form appeared in response to serum stimulation in both total p21 and p21 bound to cyclin d1 and cyclin d3 complexes. more modified minor forms in stimulated cells were detected by longer exposure of the western blots (figure s4a). λ-phosphatase treatment showed that all the modified forms resulted from phosphorylation (not shown). the main single phosphorylated p21 form was induced 2–3 h after serum stimulation, coinciding with the appearance of the t172-phosphorylated form of cdk4 (figure s4c). during the reduction of p21 levels associated with late g1 and s-phase progression, this phosphorylated form became the most abundant one. later (16–20 h), coinciding with cyclin a expression (figure s1b), the minor multi-phosphorylated forms of p21 became more abundant (figure s4c). importantly, inhibition of cdk7 by 1-nmpp1 prevented the appearance of the main and minor (multi) phosphorylated forms of p21 (figure 3a; figure s4a). as observed for cdk4 phosphorylation (figure 2b), the phosphorylated forms of p21 already disappeared 1 h after 1-nmpp1 administration (figure s4b).",pmc3667761,1,1,40,1,41
903,procaspase-9,protein,,,uniprot,p55211,cytoplasm,go:0005737,apaf-1,protein,,apaf1,uniprot,o14727,cytoplasm,go:0005737,positive,d,interact,,,,,,['1320'],nan,nan,"caspases are highly regulated by a variety of different inhibitors and activators. the induced proximity or oligomerization model explains that caspases exist as inactive monomers. the effectors of caspases bring the caspases in close proximity, allowing for their intermolecular autoproteolytic activation [66]. for example, activation of procaspase-8 requires association with its cofactor fadd (fas-associated protein with death domain) [67] and procaspase-9 must interact with apaf-1 to become functional [68].",pmc149420,1,1,40,1,41
50,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,oct4,protein,,pou5f1,uniprot,q01860,nucleus,go:0005634,positive,d,phosphorylation,threonine 234,,embryonic stem cell,,human,['858'],nan,nan,"considering the antagonizing effects of satb1 on pluripotency factors and the fact that akt phosphorylates satb1 and protects it from apoptotic cleavage, we predicted that akt-mediated phosphorylation would abolish the functions of oct4 and klf4. our data revealed that akt phosphorylated oct4 and klf4 and increased their degradations. it is thus realized that the pluripotency factors oct4, sox2 and klf4 are regulated through the same phosphorylation-dependent mechanism [30], [31]. the relationship between igf1/akt pathway and klf4 abundance has already been established, but whether akt would directly phosphorylate klf4 was not reported [32]. in agreement with our findings, human oct4 was shown to be phosphorylated at threonine 234 (corresponding to threonine 228 of mouse oct4) in vivo and a phosphorylation-mimetic mutant in place of wild-type oct4 significantly reduced the formation efficiency of ipscs [33]. during ra-induced differentiation of f9 cells, akt activity increases transiently and then decreases gradually, and the landscape of akt substrates is perfectly matched to the profile of akt activity. as examples, phosphorylations of satb1 and oct4 manifest the same trend as the dynamic change of akt activity. on the basis of these observations, it is unlikely that the phosphorylation level of oct4 is continuously increased in the context of decreased akt activity and reduced amount of oct4 [31].",pmc3675137,1,1,40,1,41
47,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,klf4,protein,,klf4,uniprot,q9y4d1,nucleus,go:0005634,positive,d,phosphorylation,threonine 399,,,,,['846'],nan,nan,akt phosphorylates klf4 at threonine 399 and increases its degradation.,pmc3675137,1,1,40,1,41
951,rb,protein,,,uniprot,p06400,nucleus,go:0005634,cdc2,protein,kinase,cdk1,uniprot,p06493,nucleus,go:0005634,negative,d,phosphorylation,tgf-β1,,,,human,['1761'],nan,nan,"rb phosphorylation and the induction of cdc2 in response to tgf-β1 were reduced following survivin depletion (figure 3). this suggests that survivin may regulate the cell cycle and thereby stimulate cells to undergo emt, rather than apoptosis, in response to tgf-β1. increasing evidence indicates that the cell cycle state influences cellular responses to extracellular stimuli. however, the ability of the same stimulus to induce two distinct cellular responses in the same cells, such as the induction of apoptosis or emt by tgf-β1, has not been studied in detail. survivin regulates the g2/m phase of the cell cycle by associating with mitotic spindle microtubules and by directly inhibiting caspase-3 and -7.42 the current study showed that tgf-β1 influences microtubule stability and stabilizes aurora b during emt (figure 6). in figure 6a, we can see multiple mitotic processes, including prophase, metaphase, and telophase with survivin in tgf-β1-treated cells. the ability of survivin to control microtubule dynamics during several phases of the cell cycle may have a dramatic impact on emt. in the present study, we show that survivin has an important role in cell cycle regulation and affects microtubule stability during interphase. as shown in figure 6a, during mitosis, a pool of survivin is localized within the chromosome passenger complex and regulates kinetochore–microtubule interactions; another pool of survivin is associated with spindle microtubules and regulates their stability.",pmc3730417,1,1,40,1,41
93,akt,protein,,akt1,uniprot,p31749,,,oct4,protein,,pou5f1,uniprot,q01860,,,positive,d,phosphorylation,,hek293t,epithelial,,human,['844'],nan,nan,"(a) oct4 phosphorylation by akt is atp-dependent. (b) akt phosphorylates gst-oct4, but not gst, gst-oct4t228a, gst-oct4t228d or gst-oct4t228e. under the same reaction condition, mutation of serine 229 to alanine or aspartic acid significantly reduced the phosphorylation efficiency. (c) the anti-phospho-oct4 antibody (t228) was raised in rabbit and its specificity was tested using in vitro kinase assay. (d) akt phosphorylates wild-type oct4, rather than its mutants at threonine 228. flag-gfp-oct4 or its mutants was ectopically expressed together with myc-akt (myr) in hek293t cells. immunoprecipitates with anti-flag were subjected to immunoblotting with anti-phospho-akt substrate. (e) expression of gfp-tagged oct4 and its mutants in hek293a cells. (f) half-life of oct4 and its mutants in transfected hek293a cells treated with chx (15 µg/ml). (g) hek293a cells were transfected with flag-gfp-oct4 together with myc-akt (wt), myc-akt (myr) or myc-akt (dn) and were treated with dmso or mg132 (20 µm) for 5 h. immunoprecipitates with anti-flag were subjected to immunoblotting with anti-phospho-akt substrate and anti-flag.",pmc3675137,1,1,40,1,41
94,akt,protein,,akt1,uniprot,p31749,,,pfkfb3,protein,,,uniprot,o60825,,,positive,d,regulates,glycolytic pathway,,,,human,['2625'],nan,nan,"a new finding in the present study is that akt positively regulates rasfonin-induced autophagy and apoptosis through the glycolytic pathway. moreover, rasfonin increases the pfkfb3 expression at mrna and protein level, which could be suppressed by akt inhibition. the glycolysis disruption reduces the rasfonin-activated autophagic pathway and parp-1 cleavage. interestingly, the isoform-specific roles of akt in regulating autophagy were revealed in association with cell type and stimulation duration.",pmc4720880,1,1,40,1,41
97,akt,protein,,akt1,uniprot,p31749,,,satb1,protein,,satb1,uniprot,q01826,,,positive,d,phosphorylation,serine 47,hek293t,,,human,['836'],nan,nan,"(a) akt phosphorylates gst-satb1 1–204 and gst-satb1 1-495. purified gst fusion proteins were subjected to in vitro kinase assay in the presence of immunoprecipitated akt. the samples were resolved on 10% sds-page and blotted with anti-phospho-akt substrate, anti-phospho-akt (t308) and anti-myc. (b) the phosphorylation site resides on satb1 within an n-terminal fragment spanning amino acids 1–51. (c) akt phosphorylates gst-satb1, but not gst-satb1 s47a or gst-satb1 s47d. (d) ectopically expressed myc-satb1 is phosphorylated by akt. myc-satb1 was co-expressed with myc-akt (wt), myc-akt (myr) or myc-akt (dn) in hek293t cells. whole-cell lysates were subjected to immunoblotting with anti-phospho-akt substrate, anti-myc and anti-actin. (e) the anti-phospho-satb1 (s47) raised in rabbit specifically recognizes the phosphorylated satb1 at serine 47. (f) hek293t cells were transfected with empty vector or myc-satb1, 24 h post-transfection, cells were rinsed twice with pbs and replenished with fresh dmem with no fbs supplemented. after additional 24 h, cells were treated with ly294002 (20 µm) for 2 h, followed by 20 min stimuli with or without igf-1 (50 ng/ml) or fbs (20%). whole-cell lysates were subjected to western blotting. (g) hek293t cells were treated as indicated. whole cell lysates were subjected to western blotting with antibodies of anti-phospho-satb1 (s47) and anti-myc. hc, heavy chain; wcl, whole cell lysate; myr, myristoylation.",pmc3675137,1,1,40,1,41
952,rb,protein,,rb1,uniprot,p06400,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,q15643,nucleus,go:0005634,positive,d,interaction,,,,,,['318'],nan,nan,"interestingly, the interaction between rb and e2f1 was strongly detected in the absence of galectin-3, although rb did not interact with cyclin d1 and cdk4 (supplementary figure 7a). the interaction between p27kip1, cyclin d1, and cdk4 was enhanced by galectin-3 depletion. in addition, overexpression of galectin-3 reduced the interaction between rb and e2f1 and induced the interaction between rb and the cyclin d1/cdk4 complex (supplementary figure 7b). the interaction between p27kip1, cyclin d1, and cdk4 was also decreased by galectin-3 overexpression.",pmc4211374,1,1,40,1,41
588,igf-1r,protein,receptor,igf1r,uniprot,p08069,plasma membrane,go:0005886,grb-10,protein,adapter,grb10,uniprot,q13322,cytoplasm,go:0005737,positive,d,autophosphorylation,critical tyrosine residues,,,,cancer,['1257'],nan,nan,"igf-1 and igf-ii are two principal ligands of the igf-1r and both have been shown to be upregulated in cancer 10 thus affecting proliferation, differentiation, and metastasis. upon ligand binding, igf-1r undergoes autophosphorylation of three critical tyrosine residues; y1131, 1135, & 1136. these events result in the recruitment and potential tyrosine phosphorylation of irs-1, irs-2, shc, and grb-10 all known to effect oncogenic processes 10. both the pi3k-akt-mtor and raf-mek-mapk pathways are thought to be two important downstream signaling pathways regulating oncogenesis.",pmc3187934,1,1,40,1,41
53,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,p27,protein,,cdkn1b,uniprot,p46527,nucleus,go:0005634,negative,d,depletion,,,,,,['440'],nan,nan,akt/p70s6k pathway was not responsible for hyperphosphorylation of s6 caused by p27 depletion,pmc4260754,1,1,40,1,41
869,pi3k,protein,kinase,pik3ca,uniprot,p42336,plasma membrane,go:0005886,cd24,protein,,cd24,uniprot,p25063,membrane,go:0016020,negative,d,downregulation,mrna,,,,human,['1728'],nan,nan,"since we observed that both cd24 mrna and protein is significantly and substantially downregulated by the raf and pi3k pathways we next determined if inhibition of either or both of these pathways could restore cd24 expression in rasv12 cells at the mrna level. the major downstream effectors of raf are the mek1/2 kinases (gollob et al., 2006), which can be inhibited specifically with the chemical inhibitor u0126 (davies et al., 2000). pi3k can be directly inhibited using ly294002 (davies et al., 2000; xue et al., 2007). we evaluated the inhibition of raf/mek/erk and pi3k/akt pathways using western blot analysis of phosphorylated erk (p-erk) and phosphorylated akt (p-akt), respectively (figure 4a). we found that rasv12 cells treated with u0126 had reduced phosphorylation of erk with no effect on akt phosphorylation. similarly, rasv12 cells treated with ly294002 had reduced phosphorylation of akt with no effect on erk phosphorylation. treatment with both u0126 and ly294002 inhibited phosphorylation of both erk and akt. we found that treatment of rasv12 cells with u0126 had a significant 13-fold increase in cd24 mrna expression (figures 4b,c). surprisingly, treatment with ly294002 alone or in combination with u0126 suppressed cd24 mrna expression to below the levels seen in rasv12 cells (figures 4b,c).",pmc4525067,1,1,40,1,41
581,human chk1,protein,,chek1,uniprot,o14757,,,wip1,protein,,ppm1d,uniprot,o15297,,,negative,d,dephosphorylation,s345 and slightly at s317,,,,human,['1668'],nan,nan,"human chk1 is also regulated by wip1. wip1 could dephosphorylate chk1 primarily at s345 and slightly at s317 in vitro. in vivo, the overexpression of wip1 resulted in the elimination of chk1 phosphorylation at s345 and s317, a decrease of cdc25c phosphorylation at s216, a decrease in cdk1 phosphorylation at y15, and a decrease in the s-phase and g2/m checkpoints, whereas the knockdown of wip1 via sirna caused the reverse effects [106]. breast cancer cell lines overexpressing wip1 (mcf-7, bt474, and mdamb231) showed only a marginal increase in chk1 s345 phosphorylation after uv as compared to the control cells (hek and u2os) [106]. interestingly, wip1-/- mefs in a 129/sv-c57bl6 background showed a greater increase in phosphorylation at s345 in chk1 after ir than wild-type mefs, whereas wip1+/+ and wip1-/- splenocytes expressing eμ-myc did not show any difference in chk1 s345 phosphorylation, possibly indicating a cell type specific or dna damage specific regulation of chk1 via wip1 [105,106]. in summary, chk1 phosphorylation at s317 and s345 and chk1 activity following dna damage are regulated by pp1, pp2a, and wip1. these phosphatases seem to play an important role in recovery from the ddr checkpoints.",pmc2954851,1,1,40,1,41
98,akt,protein,,akt1,uniprot,p31749,,,satb1,protein,,satb1,uniprot,q01826,,,positive,d,"protects, phosphorylation",,,"escs, mouse f9 embryonal carcinoma cells",,,['848'],nan,nan,"the above data indicates that akt protects satb1 from apoptotic cleavage; on the contrary, akt phosphorylates oct4 and klf4, thereby promoting their degradation. it has been reported that satb1 transcriptionally silenced expression of klf4 and nanog in escs [15]. we next intend to understand whether there is an antagonistic effect between satb1 and oct4/sox2/klf4 at protein-protein interaction level. to answer this question, we co-expressed myc-satb1 together with flag-oct4, flag-sox2 or flag-klf4, respectively. co-immunoprecipitation revealed that satb1 interacted solely with sox2 (figure 5a). in addition, satb1 endogenously associated with sox2 in mouse f9 embryonal carcinoma cells (figure 5b). we then mapped the interaction domains that were required for these two molecules. as shown in figure 5c, sox2 did not bind gst, gst-satb1 1–204 or gst-satb1 496–763, but solely bound gst-satb1 52–495, implying that the region required on satb1 was within a fragment spanning amino acids 204–495, which included domains of nmts (nuclear matrix targeting sequence) and md (mar-binding domain). we subsequently made truncated flag-gfp-tagged sox2 constructs to determine which domain was necessary for satb1/sox2 association (figure 5d). except for the fragment of sox2 203–319, satb1 associated with the full-length sox2, subdomains of 1–111, 1–202, 112–202 and 112–319 as well (figure 5e, summarized at the far right of figure 5d). these results suggest that both domains of 1–111 and 112–202 could independently mediate interaction with satb1.",pmc3675137,1,1,40,1,41
953,rb,protein,unphosphorylated,rb1,uniprot,p06400,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,cytoplasm,go:0005737,negative,d,inhibition,,,,,,['1006'],nan,nan,accumulation of unphosphorylated rb has the same effect as cdk4 inhibition or knockdown,pmc4480747,1,1,40,1,41
99,akt,protein,,akt1,uniprot,p31749,nucleus,go:0005634,creb,protein,,creb,uniprot,p16220,nucleus,go:0005634,positive,d,phosphorylation,,,b-cell,,vein,['1944'],nan,nan,"after activation, akt is able to translocate to the nucleus [1-3, 134-138] where it affects the activity of a number of transcriptional regulators. some examples of molecules which regulate gene transcription that are phosphorylated by akt include: creb [149], e2f [150], nuclear factor kappa from b cells (nf-kappab) via inhibitor kappa b protein kinase (i-kappak) [151], the forkhead (foxo) transcription factors [152], and murine double minute 2 (mdm2) which regulates p53 activity [1-3,134-138]. these are all either direct or indirect substrates of akt and each can regulate cellular proliferation, survival and some can modulate emt (e.g., nf-kappab) [135,151-154]. besides transcription factors, akt targets a number of other molecules to affect the survival state of the cell including: the pro-apoptotic molecules bcl-2-associated death promoter (bad) and bcl-2 interacting mediator of cell death (bim) [153], as well as, glycogen-synthase kinase-3beta (gsk-3beta) (see figure 3) [164]. gsk-3beta regulates beta-catenin protein stability, which is important in regulation of emt. when akt phosphorylates gsk-3beta, it is targeted to the proteasome and beta-catenin is active and able to stimulate gene expression. hence the pi3k/pten/akt/mtor pathway is connected to the wnt/beta-catenin, p53 and many additional pathways including ras/raf/mek/erk.",pmc3660063,1,1,40,1,41
46,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,klf4,protein,,klf4,uniprot,o43474,nucleus,go:0005634,positive,d,phosphorylation,,,,,,['859'],nan,nan,"(a) gst-fused proteins were purified and subjected to in vitro kinase assay. in reactions with γ-32p-atp, autoradiography showed that akt phosphorylated mbd3, chd4, twist1, bmi1 and fbxw7. in a parallel experiment using cold atp, anti-phospho-akt substrate recognized twist1 and fbxw7 in the presence of atp, but not in the absence of atp, which was consistent with autoradiogram, a suggestive of specific recognition for phosphorylated proteins. however, regardless the presence or absence of atp, the antibody recognized gst-rnf4, indicating a non-specific recognition. therefore, it is better to combine these two approaches to confirm the phospho-transfer process on a candidate akt substrate. (b) akt phosphorylates satb1 at serine 47 in vitro. (c) oct4 and klf4 are candidate akt substrates. (d) akt phosphorylates oct4 at threonine 228 and klf4 at threonine 399. w/o, without; cbb, coomassie brilliant blue.",pmc3675137,1,1,40,1,41
100,akt,protein,,akt1,uniprot,p31749,nucleus,go:0005634,satb1,protein,,satb1,uniprot,q01826,nucleus,go:0005634,positive,d,phosphorylation,serine 47,,,,,['838'],nan,nan,akt maintains molecular integrity of satb1 through phosphorylation at serine 47,pmc3675137,1,1,40,1,41
101,akt,protein,,akt1,uniprot,p31749,"nucleus, cytoplasm","go:0005634, go:0005737",cdk2,protein,,cdk2,uniprot,p24941,"nucleus, cytoplasm","go:0005634, go:0005737",positive,d,phosphorylation,thr39,,,,human,['11'],nan,nan,"a recent study suggests that akt can also regulate the progression of s to g2 phase via phosphorylation of cdk2. there is a transient nucleocytoplasmic shuttling of akt during late s and g2 phases [87]. nuclear akt phosphorylates cdk2 at thr39 which causes temporary cytoplasmic localization of cyclin a/cdk2 complex. the cytoplasmic redistribution of cdk2 is required for cell cycle progression from s to g2/m phase, as nonphosphorylated cdk2 t39a mutant severely affects cell cycle progression. in addition to its role in cell cycle progression, akt-mediated phosphorylation and cytoplasmic translocation of cdk2 is also important for apoptosis induced by stresses such as methotrexate and docetaxel [87]. phosphorylated cdk2 is sequestered in the cytoplasm and directed to different cytoplasmic substrates including p53, ultimately leading to cell death [87, 88].",pmc3317191,1,1,40,1,41
599,insulin receptor,protein,tyrosine kinase,,uniprot,p06213,plasma membrane,go:0005886,pi3k,enzyme,lipid kinase,pik3ca,uniprot,p42336,plasma membrane,go:0005886,positive,d,recruitment,irs proteins,,,,,['672'],nan,nan,"the signal transduction mechanisms operating downstream of insulin receptor ligation have highlighted the importance both of the receptor tyrosine kinase substrates (insulin receptor substrates, irs-1 and irs-2) and the lipid kinase phosphoinositide 3-oh kinase (pi3k; saltiel, 2001; saltiel and kahn, 2001; cantley, 2002; white, 2002). activation of pi3k occurs via recruitment to irs proteins, and is critical in generating many of the cell's responses to insulin (shepherd et al., 1998). the insulin–pi3k pathway also plays a conserved role in regulating cell and organism size. mice deficient in effectors of pi3k, pdk1 and s6k1, exhibit growth defects (shima et al., 1998; lawlor et al., 2002), whereas activation of pi3k leads to increases in cell and organ growth (leevers et al., 1996; crackower et al., 2002; shioi et al., 2002). the growth response to insulin-like growth factors involves the s6 kinases and leads to increased translation of 5′-terminal oligopyrimidine track mrnas (jefferies et al., 1997), many of which encode ribosomal proteins. by increasing ribosome biogenesis, activation of s6k is thought to lead to an increase in protein synthesis (volarevic and thomas, 2001). two s6k genes, s6k1 and s6k2, together encode four kinase isoforms, three of which are present in the nucleus (reinhard et al., 1992; gout et al., 1998). two signaling pathways have been shown to positively regulate s6k: the insulin–pi3k pathway (reif et al., 1997; martin et al., 2001) and a nutrient pathway involving the mammalian target of rapamycin (mtor; brown et al., 1995; park et al., 2002). a genetic regulator of s6k1 activity has also been identified—the tumor suppressor tuberous sclerosis complex (tsc1-2), a complex of the tsc1 and tsc2 gene products, hamartin and tuberin (van slegtenhorst et al., 1998). inactivation of tsc1-2 leads to constitutive s6k1 activity (jaeschke et al., 2002; kwiatkowski et al., 2002) and growth in drosophila (ito and rubin, 1999; gao and pan, 2001; potter et al., 2001; tapon et al., 2001). an inhibitory target of tsc1-2 action has been identified as rheb, a small gtpase (garami et al., 2003; saucedo et al., 2003; stocker et al., 2003; y. zhang et al., 2003) with rheb overexpression resulting in activation of s6k (for review see li et al., 2004).",pmc2172316,1,1,40,1,41
602,ir,protein,,insr,uniprot,p06213,plasma membrane,go:0005886,shc,protein,,shc1,uniprot,p29353,cytoplasm,go:0005737,positive,d,ligand binding and autophosphorylation,,,,,human,['2673'],nan,nan,"ligand binding and subsequent autophosphorylation of tyrosine residues on the egfr and ir triggers mobilization of multiple adaptors, such as src (src avian sarcoma viral oncogene homolog) homology and collagen domain protein (shc), growth factor receptor binding protein 2 (grb2), insulin receptor substrate family members (irs1–6, gab1–3), and enzymes that contain characteristic domains recognizing receptor phosphotyrosines, such as phosphatidylinositol 3-kinase (pi3k), soluble tyrosine kinase c-src, protein tyrosine phosphatases (e.g., shp2 and ptp1b) and others (white, 1998; sebastian et al, 2006). subsequently, egf and insulin-induced signals propagate through multiple interacting branches, including the mitogen-activated protein kinase (mapk) cascade downstream of the small membrane-anchored gtpase ras and the pi3k/akt cell survival pathway.",pmc2683723,1,1,40,1,41
902,prb,protein,cellcycle/tumor suppressor,rb1,uniprot,p06400,nucleus,go:0005634,cdk4,protein,cyclin-dependent kinase,cdk4,uniprot,p11802,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['1071'],nan,nan,"the cell cycle commitment at the restriction (r) point in g1 phase is initiated by inactivating phosphorylations of the central cell cycle/tumor suppressor prb by cdk4 and cdk6, which are activated by d-type cyclins induced by mitogenic/oncogenic signaling [1]–[3]. prb phosphorylation is then maintained independently of cyclins d, and hence of mitogens, by a positive feedback loop linking prb to e2f-dependent transcription of cyclin e, which leads to cdk2 activation and further phosphorylation of prb [4]. this, together with other positive-feedback circuits, such as e2f inducing its own transcription and the mutual inhibition between cyclin e-cdk2 and p27kip1, has been shown to generate a bistable prb-e2f switch to convert graded mitogen inputs into all-or-none e2f responses and thus cell cycle commitment [5]. the effects of the cip/kip cdk inhibitors p21 and p27 in this process are complex and remain much debated [6], [7]. p21 is the main transcriptional target involved in replicative senescence and p53-dependent cell cycle inhibition in response to dna damage. but in unperturbed cell cycles, it is also transiently induced by mitogenic stimuli during g1, before its required disappearance at the g1/s transition [8]. while p21 inhibits cdk2 [9], it also plays essential positive roles by stabilizing cyclin d-cdk4 complexes and allowing their nuclear import [3], [10]. how can p21 and p27 bind to cdk4 complexes and either inhibit or not inhibit their activity is poorly understood [3], [6], [8]. one debated possibility is related to different stoichiometries of the binding of these proteins to cyclin-cdk complexes [10], [11]. on the other hand, as first exemplified by t187 phosphorylation of p27 [12], phosphorylations of cip/kip proteins, including by oncogenic tyrosine kinases, have also emerged as other potential mechanisms for cdk regulation [13]–[17].",pmc3667761,1,1,40,1,41
628,kras,protein,oncogenic,kras,uniprot,p01116,cytoplasm,go:0005737,lrp6,protein,,lrp6,uniprot,o75581,plasma membrane,go:0005886,positive,d,promotes,wnt/β-catenin pathway,,colorectal cancer,,human,['2903'],nan,nan,oncogenic kras signalling promotes the wnt/β-catenin pathway through lrp6 in colorectal cancer,pmc4687460,1,1,40,1,41
942,ras,protein,,,uniprot,p01112,cytoplasm,go:0005737,cd24,protein,,cd24,uniprot,p25063,plasma membrane,go:0005886,negative,i,downregulation,mrna and protein,nih/3t3,fibroblast,,mouse,['1723'],nan,nan,"since we observed that cd24 mrna and protein expression are downregulated by ras, we next asked which pathways downstream of ras are sufficient to suppress cd24 expression. ras can activate three major pathways, the raf, ralgds, and pi3k pathways, all of which contribute to the fully transformed phenotype of cancer cells (hamad et al., 2002). we made use of nih/3t3 cells expressing the ras effector mutants rasv12g37, rasv12s35, and rasv12c40 (white et al., 1995; khosravi-far et al., 1996; webb et al., 1998), in which only one pathway is activated. specifically, rasv12g37 activates only ralgds but not pi3k or raf. in a similar manner, rasv12s35 selectively activates the raf pathway, and rasv12c40 selectively activates the pi3k pathway.",pmc4525067,1,1,40,1,41
943,ras,protein,,,uniprot,p01112,,,cd24,protein,,cd24,uniprot,p25063,,,negative,d,repression,promoter,,,,,['1720'],nan,nan,ras-mediated repression of cd24 at the level of the promoter,pmc4525067,1,1,40,1,41
944,ras,protein,,,uniprot,p01112,,,shp2,protein,,ptpn11,uniprot,q06124,,,positive,i,phosphorylation,tyrosine,,,,,['2682'],nan,nan,"one group of crosstalk interactions that facilitate the erk response is located upstream of ras. these interactions affect multiple ras activation and deactivation routes involving the adaptor proteins gab1 and irs and the protein phosphatase shp2. in the model, co-stimulation of cells by egf and insulin increases the amount of pip3 produced by pi3k (relative to egf stimulation alone) and further facilitates the gab1 membrane recruitment and its subsequent tyrosine phosphorylation (figure 3d, left and middle panels). an increase in membrane-bound phospho-gab1 is corroborated by our data and it is more appreciable at physiological egf levels (supplementary figure s8b, figure 3d, right panel, and supplementary figure s8a).",pmc2683723,1,1,40,1,41
632,lkb1,protein,serine/threonine kinase,stk11,uniprot,q15831,cytoplasm,go:0005737,4e-bp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,,,,gastrointestinal tract,human,['3069'],nan,nan,"lkb1 is a serine/threonine kinase that phosphorylates and activates ampk. lkb1 is frequently mutated in peutz-jeghers syndrome (pjs), an autosomal dominant inherited cancer predisposing patients to the development of tumours mainly throughout the gastrointestinal tract. disruption of lkb1 in mice causes gastrointestinal and hepatic polyps (bardeesy et al, 2002). in lkb1-deficient cells, phosphorylation ampk is defective and cells resist mtor inactivation in response to aicar (shaw et al, 2004). importantly, 4e-bp1 is less enriched in eif4e-bound cap analogue precipitates from lkb1-deficient cells (shaw et al, 2004). this is indicative of enhanced eif4f formation as a result of increased mtor signaling caused by lkb1-deficiency. lkb1-mediated inhibition of mtor also involves the tsc1/2 complex, thus demonstrating the link between lkb1 and mtor through the regulation of ampk and tsc1/2 activities (shaw et al, 2004).",pmc2361102,1,1,40,1,41
92,akt,protein,,akt1,uniprot,p31749,,,npm,protein,,npm1,uniprot,p49736,nucleolus,go:0005730,negative,d,phosphorylation,ser48,t24,bladder cancer,,human,['369'],nan,nan,"in order to investigate whether akt also regulates arf localization in human tumor cells we examined arf localization in t24 cells, a bladder cancer cell line which has elevated arf expression [35] and constitutive akt activity due to h-rasv12 mutation. in t24 cells, where npm is phosphorylated on ser48 (fig. 1d), inhibition of akt decreases the monomeric fraction of npm (fig. s2b) and increases npm oligomers (fig. s7b). this is also characterized by a change in the localization of phospho-s48-npm, with the untreated cells showing a nuclear (non-nucleolar) and cytoplasmic localization, that is greatly reduced following akt inhibition (fig. s2c and s8d). in tumor cells with constitutive akt activity, arf displays a diffuse nucleoplasmic staining similar to npm−/− mefs or npm−/− mef reconstituted with npm-s48e (fig. 3a and 3b). exogenous expression of npm-s48a promotes arf nucleolar foci and this is not observed with npm-wt (fig. 3a), due to endogenous akt activity. to confirm that akt was responsible for regulating arf localization, we next inhibited akt activity with pi-103 or the pan-akt inhibitor mk-2206. both inhibitors promoted almost complete relocalization of endogenous arf to the nucleoli (fig. 3b).",pmc4171619,1,1,40,1,41
947,ras,protein,oncogene,hras,uniprot,p01112,plasma membrane,go:0005886,cd24,protein,,cd24,uniprot,p25063,plasma membrane,go:0005886,negative,d,suppression,,nih/3t3,fibroblast,mouse,,['1717'],nan,nan,"previous studies have shown that activation of oncogenic ras leads to generation of cd24−/cd44+ stem-like cells from cd24+/cd44low cells (morel et al., 2008). to analyze the regulation of cd24 expression by oncogenic ras we used a model system in which constitutively active h-ras, containing a g12 to v12 mutation (rasv12), was stably expressed in the mouse embryonic fibroblast nih/3t3 cell line (christian et al., 2009). the level of cd24 mrna expression in nih/3t3 cells stably transfected with empty vector (control cells) or containing the constitutively active ras gene was analyzed by rt-pcr and rt-qpcr (figures 1a,b). we observed a clear suppression of cd24 mrna expression (figure 1a) that was over 1000-fold lower in rasv12 cells compared to control cells (figure 1b).",pmc4525067,1,1,40,1,41
948,ras,protein,oncogene,ras,uniprot,p01111,cytoplasm,go:0005737,cd24,protein,,cd24,uniprot,p25063,cell membrane,go:0005886,negative,d,downregulate,mrna and protein levels,,,,human,['1735'],nan,nan,"here, we have demonstrated that expression of oncogenic ras is sufficient to directly downregulate expression of cd24 at the mrna and protein levels as well as repress promoter activity. moreover, activation of either the raf or pi3k pathway is sufficient to downregulate cd24 expression at both the mrna and protein levels (figure 7). surprisingly, inhibition of the raf pathway, at the level of mek or raf, or the pi3k pathway, at the level of pi3k, either separately or together, was not sufficient to fully restore cd24 expression in rasv12 cells. however, inhibition of raf directly was able to partially restore cd24 surface protein expression without affecting mrna levels.",pmc4525067,1,1,40,1,41
626,kras,protein,oncogene,kras,uniprot,p01116,cytoplasm,go:0005737,β-catenin,protein,transcription factor,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,d,activation,,,human crc,colon,human,['2926'],nan,nan,"in keeping with these results, the transcriptional activity of the β-catenin/tcf complex was reduced by mek inhibitors in human crc cell lines, suggesting that mek activation also potentiates wnt signaling in crc. interestingly, these effects were evident despite the presence of apc mutations. this is consistent with the recent observation that wnt signaling components are significantly enriched in kras-dependent crc cells compared with kras-independent cells, despite both classes having comparable apc mutations.64 accordingly, horst et al.65 showed that forced expression of the kras oncogene in the caco-2 crc cell line leads to nuclear accumulation of β-catenin and increases wnt activity, whereas blocking the tyrosine kinase receptor egfr, an activator of mapk signaling, has the converse effect. in addition, the authors observed colocalization of nuclear β-catenin and phosphorylated erk staining in primary colon tumor xenografts. likewise, phelps et al.66 recently reported that kras and raf1 oncogenes promote nuclear accumulation of β-catenin in apc-deficient cells. overall, these studies reveal that the kras/mapk pathway can regulate β-catenin signaling in human crc cells.",pmc4687460,1,1,40,1,41
603,ir,protein,,,uniprot,p06213,plasma membrane,go:0005886,shc,protein,,,uniprot,p29353,plasma membrane,go:0005886,positive,d,phosphorylation,,hek293,epithelial,,human,['2681'],nan,nan,"our data demonstrate weak ras and erk (figure 2a and b) activation by insulin compared with egf. the model provides several arguments to explain these observations, which involve signaling processes both upstream and downstream of ras. first, ir binds and phosphorylates shc with very low efficacy compared with egfr ((paz et al, 1996, 1997; weng et al, 2001) and supplementary figure s2b), whereas in egf signaling, the shc-dependent pathways contribute substantially to the grb2–sos membrane recruitment and subsequent ras activation (kholodenko et al, 1999). second, irs1-6 docking proteins, when phosphorylated by ir, bind preferably pi3k, whereas their binding to grb2–sos is weak. therefore, irs phosphorylation does not lead to significant ras activation in the model (sasaoka et al, 1996; fucini et al, 1999). third, ir is a much weaker stimulator of src activity than egfr (schmelzle et al, 2006), which has the following ramifications in the model: (a) although insulin triggers the pip3-mediated membrane recruitment of gab1, the phospho-gab1 level remains much lower than this level for egf stimulation, when gab1 is phosphorylated by both egfr and src (see figure 2d, left and right panels compare the model simulations and data); (b) the lower level of gab1 phosphorylation by insulin results in less effective grb2–sos recruitment and ras activation (figure 2a); and (c) finally, downstream of ras in the model, full raf activation requires src activity, which is weaker for insulin than for egf. although a higher akt activation by insulin than by egf may contribute to additional raf inhibition, our data suggest that this inhibition is insignificant in hek293 cells (supplementary figure s4). overall, the simulations qualitatively agree with the data (figure 2) for a wide range of parameter values for the proposed regulatory structure of the model.",pmc2683723,1,1,40,1,41
622,kras,protein,,kras,uniprot,p01116,cytoplasm,go:0005737,foxo1,protein,,foxo1,uniprot,o43524,nucleus,go:0005634,positive,d,phosphorylation,,hit-t15,pancreatic beta-cell,pancreatic,human,['1215'],nan,nan,"activation of kras has been shown to activate both pi3k/akt and mapk pathways [24,101,122-124]. oxidative stress and activation of the jnk pathway induce the nucleocytoplasmic translocation of the pancreatic transcription factor pdx-1, which leads to pancreatic β-cell dysfunction [125,126]. furthermore, foxo1/fkhr plays a role as a mediator between the jnk pathway and pdx-1 [127]. under oxidative stress conditions, foxo1 changed its intracellular localization from the cytoplasm to the nucleus in the pancreatic β-cell line hit-t15. the overexpression of jnk also induced the nuclear localization of foxo1, but in contrast, suppression of jnk reduced the oxidative stress-induced nuclear localization of foxo1, suggesting the involvement of the jnk pathway in foxo1 translocation. in addition, oxidative stress or activation of the jnk pathway decreased the activity of akt in hit cells, leading to the decreased phosphorylation of foxo1 following nuclear localization. furthermore, adenovirus-mediated foxo1 overexpression reduced the nuclear expression of pdx-1, whereas repression of foxo1 by foxo1-specific small interfering rna retained the nuclear expression of pdx-1 under oxidative stress conditions. activation of erk has been shown to phosphorylate foxo proteins, resulting in nuclear exclusion and transcriptional repression. in addition to erk, direct phosphorylation of foxo by akt results in cytoplasmic retention and inactivation, inhibiting the expression of foxo-regulated genes, which control the cell cycle, cell death, cell metabolism and oxidative stress [82,128,129]. taken together, these studies demonstrate that dephosphorylation and activation of foxo by inhibition of pi3k/akt and mek/erk pathways has significant implication for pancreatic cancer treatment and prevention, where kras is activated in about 90% patients.",pmc2915986,1,1,40,1,41
949,ras,protein,oncogene,ras,uniprot,p01112,plasma membrane,go:0005886,cd24,protein,,cd24,uniprot,p25063,plasma membrane,go:0005886,negative,d,downregulates,,nih/3t3,fibroblast,,mouse,['1718'],nan,nan,"oncogenic ras downregulates cd24 expression in nih/3t3 cells. cd24 mrna expression in vector control (control) and rasv12 cells was determined by (a) rt-pcr and (b) rt-qpcr. rplp0 was used as the loading and normalization control. cd24 mrna levels shown as mean ± s.e.m. (c) surface cd24 protein was determined by flow cytometry in control and rasv12 cells. one representative histogram of isotype (iso) and cd24-stained cells is shown. (d) quantification of cd24 surface protein expression as mean ± s.e.m percentage of cd24+ cells. significance was determined by student's t-test, n = 3, **p < 0.01; ***p < 0.001.",pmc4525067,1,1,40,1,41
618,jnk,protein,,,uniprot,p45983,,,lc3,protein,,map1lc3a,uniprot,q9h492,,,positive,d,activation,,nci-h460 and a549 cells,,,human,['1844'],nan,nan,"mapk signaling pathways which consist of erk, jnk and p38 mapk signaling pathways are involved in many cellular processes including cell growth, proliferation, autophagy and apoptosis. the jnk, erk1/2 and p38 mapk, which are activated by phosphorylation, are key regulatory proteins in these pathways. we observed that the expression levels of p-p38 mapk and p-jnk were activated by pd in a dose and time-dependent manner, while the expression level of p-erk1/2 was inhibited by pd (fig. 4 a and b ). to further clarify whether pd-induced autophagy was connected with p-p38 mapk and p-jnk activation and p-erk1/2 suppression, cells were pretreated with the pharmacological inhibitors sb203580, sp600125 or u0126 respectively, and then treated with or without pd. notably, we found the conversion of lc3 і to lc3-ii in pd co-treatment with sp600125 or sb203580 group was dramatically increased compared with that in sp600125 or sb203580 treatment group (p<0.01) (fig. 4 c-f). activation of the targeting jnk and p38 mapk has been identified as chemotherapeutic agents for sensitizing cancer cells to autophagy 7, 24, 25. in accordance with these findings, our results demonstrated the activation of jnk and p38 mapk was involved in pd-induced autophagy in nci-h460 and a549 cells. however, we also found the ratio of lc3-ii/lc3-i in pd co-treatment with u0126 group was lower than that treated by pd alone, indicating that p-erk1/2 was not responsible for pd-mediated autophagy (fig. 4 f). and our previous study discovered that the inhibition of erk signaling pathway by pd treatment induced apoptosis in nci-h460 and a549 cells. coordinately, increasing reports elucidate that among mapk families erk pathway is closely related with apoptosis 26, 27.",pmc4466411,1,1,40,1,41
617,jnk,protein,,,uniprot,p45983,cytoplasm,go:0005737,il-2,protein,,,uniprot,p60568,extracellular region,go:0005576,positive,d,mrna stabilization,,,,,human,['3230'],nan,nan,"previous studies highlighted the role of jnk in mrna stability of vegf (pages et al., 2000). in addition, jnk response elements were identified as being required for the stabilization of the il-2 mrna through the binding of nucleolin and yb1 (chen et al., 2000).",pmc2801705,1,1,40,1,41
616,jnk,protein,,mapk8,uniprot,p45983,,,wdr62,protein,,wdr62,uniprot,q9bue7,,,positive,d,binding,,,,skeletal muscles and testes,human,['3226'],nan,nan,"the jnk signaling pathway plays a major role in diverse cellular functions. to do so, the jnk proteins require a protein network that allows an efficient activation platform to identify its specific substrate spatially and temporally. to isolate proteins associated with jnk, we designed a jnk bait protein composed of inactive jnk1 to screen the skeletal muscles and testes cdna expression libraries using the rrs system. one of the clones, wdr62, is a previously uncharacterized protein that displays a specific binding to jnk. interestingly, a high-throughput study using pairwise interaction with the yeast two-hybrid system revealed the association between wdr62 with jnk2 (rual et al., 2005). here, using the rrs as an unbiased approach, we confirmed the interaction between jnk1 and wdr62 in yeast, and jnk1–2 and the upstream regulator mkk7 with wdr62 in tissue culture cells. wdr62 is ubiquitously expressed in all human tissues and cell lines tested, with increased expression in heart, skeletal muscles, and testes. consistently, gene array data available from www.genecards.org confirmed the tissue panel expression pattern (supplemental figure s1b).",pmc2801705,1,1,40,1,41
861,phospho-akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,ciap-2,protein,,birc3,uniprot,o15111,cytoplasm,go:0005737,positive,d,binds,,,,biopsies,human,['420'],nan,nan,"we compared staining intensity of phospho-akt and ciap-2 in biopsies where both stains were performed on serial sections (n = 53). there was a significant correlation between phospho-akt and ciap-2 staining intensities in these biopsies (spearman correlation coefficient, r = 0.484, p = 0.0002). this correlation was seen at all pathology grades.",pmc1325242,1,1,40,1,41
867,pi3k,protein,kinase,pik3ca,uniprot,p42336,cytoplasm,go:0005737,cd24,protein,,cd24,uniprot,p25063,plasma membrane,go:0005886,negative,i,inhibition,,,,,human,['1739'],nan,nan,"unexpectedly, when we performed the complementary loss-of-function experiments using either the mek inhibitor u0126 or the raf inhibitor sorafenib in the presence or absence of the pi3k inhibitor ly294002, we were unable to restore cd24 mrna expression to the level of the control cells. treatment with u0126 caused a 13-fold increase, which is still 100-fold lower than the mrna levels present in control cells, and therefore may be responsible for the modest but not statistically significant increase in cd24 surface expression. in contrast, sorafenib treatment did not alter cd24 mrna levels. inhibition of pi3k alone did not alter cd24 mrna levels but in combination with mek inhibition prevented the u0126-mediated increase in cd24 mrna expression. thus, these data suggest that the inhibition of the pi3k pathway could potentially activate a repressor or inhibit an activator of cd24 mrna expression to block the effects of u0126 treatment. consistent with this hypothesis, significant cross-talk between the pi3k and raf pathways has been shown, including the ability of akt to inhibit raf. as we did not observe an increase in erk phosphorylation, the possible relief of akt-mediated inhibition of raf did not override the u0126-mediated block in mek activation. thus, inhibition of the pi3k pathway may relieve the akt-mediated inhibition of raf and promote raf-mediated suppression of cd24 (figure 7).",pmc4525067,1,1,40,1,41
627,kras,protein,oncogene,kras,uniprot,p01116,cytoplasm,go:0005737,β-catenin,protein,transcription factor,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,d,phosphorylation,serine 552,crc cells,epithelial-like,colon,human,['2927'],nan,nan,"very few studies have explored the molecular mechanisms underlying the enhancement of β-catenin transcriptional activity by oncogenic ras/mapk signaling. oncogenic kras signalling could increase the stability of β-catenin through its phosphorylation at serine 552.47, 48 however, we found in crc cells that mek inhibition reduced β-catenin accumulation into the nucleus and its interaction with tcf4 without affecting its global expression, its phosphorylation on serine 552 (or residues 37, 41, 86, 142 and 654) or its stabilization (data not shown). on the other hand, although the downregulation of e-cadherin on the cell membrane may contribute to nuclear β-catenin accumulation upon oncogenic activation of kras/mapk signaling in normal iecs (the present study;67), additional mechanisms must likely be involved. indeed, data from braf:er cells suggest that e-cadherin downregulation is not necessary for wnt activation by oncogenic mapk signaling. indeed, activation of braf:er fusion protein in iec-6 cells induced lrp6 phosphorylation within 10 min and β-catenin transcriptional activity (topflash) within 16–24 h without inducing concomitant downregulation of e-cadherin during this time period (data not shown). furthermore, in human crc cells, e-cadherin and β-catenin expression and interaction remained unaltered following mek inhibition. interestingly, we observed that the frizzled co-receptor lrp6 was phosphorylated on serine-1490 and threonine-1572 in a mek-dependent manner in human crc cells. furthermore, mek-dependent phosphorylation of lrp6 was also observed upon sustained oncogenic activation of kras, braf and mek1 in iecs, thus providing a mechanism integrating kras/mapk and canonical wnt/β-catenin signalings during intestinal transformation. of note, sustained activation of erk signaling by the brafv600e allele in mice also resulted in increased lrp6 phosphorylation in the colonic epithelium. whether this increased lrp6 phosphorylation was associated with higher wnt/β-catenin signaling in normal colonocytes will require further analyses. indeed, conflicting literature exists with regard to the role of mapk signaling in the activation of the wnt/β-catenin pathway in normal intestinal epithelial cells. on the one hand, data from different groups68, 69 have shown that the activation of the krasg12d or brafv637e alleles in mouse intestinal epithelium induced serrated tumorigenesis without enhancing the wnt signaling. wnt signaling induction was, however, found in a substantial part of brafv637e-induced high-grade tumors.69 on the other hand, carragher et al.70 demonstrated that crypt hyperplasia induced by the brafv600e allele was rapidly associated (within 3 days) with wnt pathway activation as visualized by the accumulation of nuclear β-catenin in crypt cells. moreover, phelps et al.66 reported that kras or braf activation is needed for the nuclear translocation of β-catenin in colonic adenoma. therefore, nuclear translocation of β-catenin might be regarded as a potentially ras/mapk-controlled step in canonical wnt signaling.71, 72",pmc4687460,1,1,40,1,41
62,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,pfkfb3,protein,,pfkfb3,uniprot,o60825,cytoplasm,go:0005737,positive,i,regulation,,,,,,['2618'],nan,nan,"akt augments glycolytic flux through several mechanisms.18, 37 recent studies suggested that pfkfb3 is involved in the regulation of autophagy.24, 38 thus, we speculated that akt might positively regulate rasfonin-induced autophagy by affecting the glycolytic pathway. using qrt-pcr, we revealed that rasfonin increased the mrna expression of pfkfb3 in response to stimulation for up to 8 h (supplementary figure 4a), and either api-2 or sc66 reduced gene expression with or without the agent treatment (supplementary figure 4b). consistently, rasfonin increased the expression of pfkfb3 at protein level (supplementary figure 4c). although activated akt1 have no effect on the expression of pfkfb3 (supplementary figure 4d), akt1 deprivation and api-2 treatment decreased pfkfb3 levels (supplementary figure 4e and f). notably, rasfonin increased the expression of pfkfb3 in vector-transfected, but not in mock-control cells (supplementary figure 4d and e), suggesting that rasfonin affects the glycolytic pathway in a context-dependent manner.",pmc4720880,1,1,40,1,41
675,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,4e-bp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,negative,i,inferred by measuring phosphorylation,,achn,renal,kidney,human,['2612'],nan,nan,"generally, mtor inhibits autophagy, and the kinase activity of mtor is inferred by measuring the phosphorylation of substrates, such as s6k1 and 4e-bp1.6, 8 to determine whether rasfonin-induced autophagy is associated with mtor pathway, the phosphorylation of s6k1 and 4e-bp1 was examined; and the results showed that the phosphorylation of these proteins decreased in a concentration-dependent manner in response to rasfonin in achn cells (figure 3e). in addition, we observed that rasfonin activated autophagy concomitantly with the upregulation of akt activity (figure 3e).",pmc4720880,1,1,40,1,41
805,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,14-3-3 sigma,protein,,sfn,uniprot,p31947,cytoplasm,go:0005737,positive,d,interacts,,,,,,['1044'],nan,nan,"activated p53 interacts with 14-3-3 γ, ε, τ and σ",pmc2817464,1,1,40,1,41
797,p38,protein,map kinase,,uniprot,p53778,cytoplasm,go:0005737,cdc25b,protein,phosphatase,,uniprot,q14004,cytoplasm,go:0005737,negative,d,phosphorylation,y15,,,,human,['2208'],nan,nan,"other dna damage-activated pathways also affect hur localization through cdk1. activation of the map kinase (mapk) p38 by dna damage phosphorylates cdc25b and thus triggers it for degradation. in this manner, p38 affects cdk1 levels through its influence on cdc25b abundance. dna damage induces the cleavage of pkcδ and generates a constitutively active catalytic fragment termed pkcδ-cat. pkcδ-cat can also phosphorylate cdk1 at y15, thereby inactivating cdk1 and inducing g2/m arrest. moreover, pkcδ can phosphorylate directly hur at s221 and s318 (see below), triggering the cytoplasmic translocation of hur [58]. overall, dna damage inactivates cdk1, which increases cytoplasmic hur level and thus enhances mrna stability and translation of dna damage response proteins.",pmc2925474,1,1,40,1,41
84,akt,protein,,akt1,uniprot,p31749,,,ikk,protein,,ikbkb,uniprot,o14920,,,positive,i,activation,,,cancer,,human,['2901'],nan,nan,"in this review, we introduced akt, erk, and ikk as the key survival kinases for cancer progression and survival. we also mentioned that these three pathways have several common targets that are critical for cancer cell proliferation, survival, and emt. because there are many other pathways that are activated in human cancers, we believe that they likely also contribute to the same targets we described here. these three kinase-signaling pathways may have other common targets that are critical for cancer progression. we also introduce some examples of the signaling pathways that are controlled via the ubiquitin–proteasome system, which seems to play an essential role in signaling pathway like phosphorylation. as we described above, inhibition of protein ubiquitination has been demonstrated to be potential drug targets for cancer therapy. moreover, blockade of specific ubiquitination may exhibit less toxicity because inhibition of upstream molecules in key oncogenic signaling pathways may affect numerous signaling pathways and induce unfavorable side effects. clearly, further studies for signaling pathways in cancer including post-translational modifications are required for the development of effective personalized cancer therapies.",pmc3355968,1,1,40,1,41
85,akt,protein,,akt1,uniprot,p31749,,,klf4,protein,,klf4,uniprot,q9hhc0,,,positive,d,phosphorylation,,,,,,['852'],nan,nan,"akt is significantly activated in cycling, rather than in quiescent stem cells [26]. several modulators and effectors that antagonize the functions of akt signaling have been demonstrated to be required for the maintenance of hscs pool [27]. these studies altogether imply that akt probably has a crucial role in the regulation of stem cell homeostasis. using biochemical approaches, we identify three novel substrates of akt that are functionally involved in pluripotency/differentiation regulation. akt phosphorylates satb1, a differentiation regulator for esc, keeps it intact through apoptotic resistance, whereas akt phosphorylates oct4 and klf4, two pluripoptency factors, accelerates their degradation, suggesting that akt is a key upstream molecule that contributes to the differentiation program via inactivation of stemness transcriptional factors and/or activation of differentiation-regulating proteins.",pmc3675137,1,1,40,1,41
798,p38 mapk,protein,mapk,mapk14,uniprot,q16539,cytoplasm,go:0005737,lc3-ii,protein,,,uniprot,o94817,cytoplasm,go:0005737,positive,i,up-regulation,,ht29,epithelial,colon,human,['659'],nan,nan,"we then analyzed the vacuolation response in ht29 cells using further p38 mapk inhibitors (sb203580, birb-796 and vx-745) as well as sb202474, an inactive analogue of the sb compounds, as negative control. while sb202190 and sb203580 induce vacuoles, the two other potent inhibitors of p38 mapk, birb-796 and vx-745, unexpectedly failed to induce vacuoles in ht29 cells (figure 5a, b). vacuole formation in sb202190- and sb203580-treated cells correlated with the late stage up regulation of lc3-ii, which is not up-regulated in response to birb-796 and vx-745 (figure 5c). we monitored fhre-luc reporter activity between sb202190 and birb-796 treated ht29 cells and detected enhanced reporter activity only in response to sb202190 treatment (figure 5d). regardless of the ability to induce vacuoles, all inhibitors tested efficiently blocked p38 mapk α and β activity in these cells as shown by the reduction of phosphorylation of the p38 mapk substrate mk2 at threonine t334 and its downstream targets hsp27 (serine s82) and keratin 20 (serine s13) (figure 5e). we also analyzed the effect of sirna mediated depletion of p38α on vacuole formation. even though the sirna transfection procedure marginally increased the percentage of vacuolated cells, the effect of p38α down regulation was not statistically significant (figure s3),",pmc3154272,1,1,40,1,41
799,p38 mapk,protein,,,uniprot,p28482,cytoplasm,go:0005737,lc3,protein,,map1lc3,uniprot,q9h492,cytoplasm,go:0005737,positive,i,activation,,,,,human,['1840'],nan,nan,"to further clarify whether pd-induced autophagy depended on p-p38 mapk and p-jnk activation and p-erk1/2 suppression, cells were treated with u0126 (an inhibitor of erk1/2), sp600125 (an inhibitor of jnk) or sb203580 (an inhibitor of p38) for 4 h followed by treatment with or without pd for 24h. our date showed that the ratio of lc3-ii/lc3-i was dramatically increased in pd co-treatment with sp600125 or sb203580 group compared with that in sp600125 or sb203580 treatment group (p<0.01) (fig. 4 c-f), suggesting the activation of p-jnk or p-p38 mapk was involved in cell autophagy. though the ratio of lc3-ii/lc3-i in u0126 treatment group was increased, the ratio of lc3-ii/lc3-i in pd co-treatment with u0126 group was lower than that by pd treatment alone (fig. 4 f), suggesting inhibition of p-erk1/2 was not involved in cell autophagy.",pmc4466411,1,1,40,1,41
758,mutant braf,protein,kinase,braf,uniprot,p15056,cytoplasm,go:0005737,mitf,transcriptionfactor,,mitf,uniprot,o75030,nucleus,go:0005634,positive,d,cooperation,,melanoma,melanocyte,skin,human,['1918'],nan,nan,"lineage-specific mutations occur in genes which are abnormally expressed in certain types of cancers. in certain cell types, the cells become addicted to a lineage-specific gene as well as the mutant oncogene(s). an example is observed in melanoma cells which have mutant braf. these cells often have increased expression of the microphthalmia-associated transcription factor (mitf) which is believed to allow the survival of cells of the melanocyte lineage. mitf is sometimes amplified in certain subsets of melanoma cells and cooperates with mutant braf to regulate melanoma proliferation. in normal melanocytes, mitf induces cell cycle arrest, whereas in melanoma cells, mutant b-raf may stimulate mitf transcription while this stimulation of transcription does not occur in normal melanocytes [20].",pmc3660063,1,1,40,1,41
754,mtorc1,protein,,,uniprot,p42345,,,gsk-3β,protein,,gsk3b,uniprot,p49841,,,positive,d,phosphorylation,,,,renal,human,['3384'],nan,nan,"compared with the human renal proximal tubular epithelial cells (hrptepc) and the normal renal parenchymas, the mtorc1 downstream pathway was strongly activated in the rcc cell lines (fig. 2d). these results indicate that gsk-3β, rather than gsk-3α, is required to maintain 4ebp1, s6k, and s6rp phosphorylation in rcc cells.",pmc4936323,1,1,40,1,41
753,mtorc1,protein,,,uniprot,p42345,cytoplasm,go:0005737,srebp1/2,transcriptionfactor,,,uniprot,p36956,nucleus,go:0005634,positive,d,transcription and translation,nucleus,,,,,['1446'],nan,nan,"proliferating cells also require lipids in addition to protein to synthesize plasma membranes and other macromolecules and mtorc1 controls this synthesis of lipids [115] via the transcription factors srebp1/2 (sterol regulatory element binding protein 1/2) that regulate the expression of genes involved in fatty acid biosynthesis. the inhibition of mtorc1 reduces srebp1/2 levels which results in the downregulation of lipogenic genes [116–118]. lipin-1 lowers srebp1/2 levels inside the nucleus and mtorc1 mediated phosphorylation of lipin-1 prevents it from entering the nucleus, thus suppressing this inhibition [119]. the peroxisome proliferator-activated receptor γ (ppar-γ) is the main regulator of adipogenesis which is also activated by mtorc1 [120, 121]. mtorc1 positively regulates cellular metabolism and atp production by activating the transcription and translation of hypoxia inducible factor 1α (hif1α) which is a positive regulator of many glycolytic genes [116, 122].",pmc4258317,1,1,40,1,41
804,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,14-3-3 proteins,protein,,ywha*,uniprot,p63104,cytoplasm,go:0005737,positive,d,binds,c-terminal phosphopeptides,,,,human,['1035'],nan,nan,"p53 maintains genome integrity by initiating the transcription of genes involved in cell-cycle arrest, senescence, apoptosis and dna repair. the activity of p53 is regulated by both post-translational modifications and protein–protein interactions. p53 that has been phosphorylated at s366, s378 and t387 binds 14-3-3 proteins in vitro. here, we show that these sites are potential 14-3-3 binding sites in vivo. epsilon (ε) and gamma (γ) isoforms required phosphorylation at either of these sites for efficient interaction with p53, while for sigma (σ) and tau (τ) these sites are dispensable. further, σ and τ bound more weakly to p53 c-terminal phosphopeptides than did ε and γ. however, the four isoforms bound tightly to di-phosphorylated p53 c-terminal peptides than did the mono-phosphorylated counterparts. interestingly, all the isoforms studied transcriptionally activated wild-type p53. σ and τ stabilized p53 levels in cells, while ε and γ stimulated p53-dna binding activity in vitro. overall, the results suggest that structurally and functionally similar 14-3-3 isoforms may exert their regulatory potential on p53 through different mechanisms. we discuss the isoform-specific roles of 14-3-3 in p53 stabilization and activation of specific-dna binding.",pmc2817464,1,1,40,1,41
751,mtorc1,complex,,mtor,uniprot,p42345,cytosol,go:0005829,4e-bp1,protein,,eif4ebp1,uniprot,q13541,cytosol,go:0005829,positive,d,phosphorylation,,,,,,['778'],nan,nan,"mtorc1 signaling integrates environmental clues (nutrients, oxygen levels, hormones, growth factors, stressors) and information from the cell metabolic status. thus, mtorc1 controls anabolic processes to promote translation and cell growth [30]. mtorc1 regulates protein synthesis in response to nutrients/growth factors by phosphorylating p70s6 kinase (p70s6k) 1 and 2, and 4e-bp1. p70s6k 1/2 phosphorylates the 40s ribosomal protein, s6 (s6rp), leading to active translation of mrnas.",pmc3837323,1,1,40,1,41
740,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,uvrag,protein,,,uniprot,q9p2y5,cytoplasm,go:0005737,positive,i,phosphorylation,s550 and s571,,,,human,['2551'],nan,nan,"to support the in vitro vps34 activity data, we used the px domain staining method to visualise pi(3)p in cells (fig5c–e). to look at pi(3)p levels associated with uvrag phosphorylation, we treated cells with ku and ebss to inhibit mtor. as with the in vitro vps34 assays, inhibition of mtor in cells resulted in a 50% loss of px domain staining, indicating a reduction in cellular vps34 activity (fig5c, top panels, and e). to confirm that the reduction in pi(3)p staining was due to loss of uvrag phosphorylation, we used sirna to deplete endogenous uvrag in cells stably expressing similar levels of either wt or dbla sirna-resistant gfp-uvrag (fig5d). loss of uvrag alone caused a reduction in px domain staining, supporting previous observations that uvrag is important for vps34 activity (liang et al, 2006; sun et al, 2010). this loss was similar to control-depleted cells treated with ku or ebss and was not further reduced upon mtor inhibition (fig5c and e). rescue of the uvrag sirna with expression of resistant wt uvrag restored px domain staining levels to that seen in control cells, ruling out uvrag sirna off-target effects. by contrast, expression of a similar level of dbla uvrag failed to restore px domain staining seen in control cells and displayed similar levels to the uvrag-only depleted cells. taken together with the in vitro data, this suggests that mtor-mediated uvrag phosphorylation at s550 and s571 enhances vps34 activity. consistent with the data presented here, mtor inhibition has previously been shown to inhibit total levels of cellular pi(3)p (byfield et al, 2005; russell et al, 2013; yuan et al, 2013); our data now demonstrate this inhibition is due to uvrag dephosphorylation. it is important to note that mtor inhibition does not reduce all pools of pi(3)p. the autophagy-initiating vps34 complex, which contains atg14l instead of uvrag, is enhanced under these conditions, though the increase in autophagic pi(3)p is small compared to the total pool.",pmc4585463,1,1,40,1,41
750,mtor kinase,protein,kinase,,uniprot,p42345,cytoplasm,go:0005737,4e-bps,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,negative,d,downregulate expression,,,cancer cells,,human,['1457'],nan,nan,"another mechanism that explains the resistance to mtor kinase inhibitors is that cancer cells downregulate the expression of 4e-bps which leads to an increase in the eif4e/4e-bp1 ratio, and it is this change in eif4e/4e-bp1 stoichiometry that limits the sensitivity of cancer cells to catalytic site tor inhibitors suggesting that the eif4e/4e-bp1 ratio might act as a predictive marker for treatments using catalytic tor inhibitors [169].",pmc4258317,1,1,40,1,41
808,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,creb,protein,,creb1,uniprot,p16220,nucleus,go:0005634,positive,d,transcriptional regulation,noxa promoter,igr3 (brafv600e) and mel-rm (brafwt),melanoma,skin,human,['3508'],nan,nan,"(a) a schematic illustration of the luciferase reporter constructs. mutations in the p53, e2f, and creb binding sites are indicated with dotted boxes.(b) mel-rm and me4405 (brafwt) cells were transiently transfected with the indicated pgl3-reporter constructs with or without co-transfection with a construct expressing brafv600e. luciferase activity was measured 24 hours latter. the relative luciferase activity in cells transfected with pgl3-vector was arbitrarily designated as 1 (n=3, mean ± s.e.m.). *p < 0.05, student's t-test. (c) mel-rm and me4405 (brafwt) cells were transiently transfected with the indicated pgl3-reporter constructs. twenty-four hours later, cells were treated with plx4720 (3μm) for a further 12 hours followed by measurement of luciferase activity. the relative luciferase activity in cells transfected with pgl3-vector was arbitrarily designated as 1 (n=3, mean ± s.e.m.). *p < 0.05, ** p < 0.01, student's t-test. (d) igr3 (brafv600e) and mel-rm (brafwt) were transiently transfected with indicated pgl3-reporter constructs. twenty-four hours later, cells were treated with u0126 (20μm) for a further 12 hours followed by measurement of luciferase activity. the relative luciferase activity in cells transfected with pgl3-vector was arbitrarily designated as 1 (n=3, mean ± s.e.m.). *p < 0.05, student's t-test. (e) igr3 and mel-rm (wild-type p53) were transiently transfected with indicated pgl3-reporter constructs. twenty-four hours later, cells were treated with etoposide (50μm) for a further12 hours followed by measurement of luciferase activity. the relative luciferase activity in cells transfected with pgl3-vector was arbitrarily designated as 1 (n=3, mean ± s.e.m.). *p < 0.05, student's t-test. (f) mel-rm (brafwt) cells stably transduced with brafv600e were transfected with the control or creb sirna. twenty-four hours later, whole-cell lysates were subjected to western blot analysis. data shown are representative of three individual experiments. (g) formaldehyde-cross-linked chromatin of igr3 (brafv600e) and mel-rm (brafwt) cells with or without treatment with plx4720 (3μm) for 12 hours was subjected to immunoprecipitation with an antibody against creb. the resultant precipitates were subjected to pcr amplification using primers directed to the noxa promoter. data shown are representative of three individual experiments. (h) whole-cell lysates from igr3 (brafv600e) and mel-rm (brafwt) cells with or without treatment with plx4720 (3μm) for the indicated periods were subjected to western blot analysis. data shown are representative of three individual experiments.",pmc4294377,1,1,40,1,41
747,mtor,protein,serine/threonine kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,eif4e-binding protein 1,protein,translation factor,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['1477'],nan,nan,"the mammalian target of rapamycin (mtor) is a highly conserved serine/threonine kinase that regulates cell growth, cell cycle progression and metabolism. the phosphatidylinositol-3 kinase/akt signaling pathway activates mtor, in turn, directly phosphorylating ribosome protein s6 kinase 1 (s6k1) and eif4e-binding protein 1, both of which are important in the control of protein translation initiation.4, 5, 6 s6k1 phosphorylates s6, which regulates the translation of 5′ terminal oligopyrimidine mrnas that encode ribosomal proteins and translation factors. 4ebp1 binds to and prevents eif4e, initiating cap-dependent translation. mtor is constitutively activated in a variety of human cancers, including ovarian, pancreatic, as well as lung carcinoma.7 thus, mtor signaling networks have emerged as attractive targets in novel therapeutic anticancer strategies.",pmc3388235,1,1,40,1,41
746,mtor,protein,serine/threonine kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,activates,,,,,human,['873'],nan,nan,"in summary, the serine/threonine kinase mtor, a downstream effector of the pi3k/akt pathway, forms two complexes: mtorc1 and mtorc2. the complexes are constituted by different proteins and play distinct functions for cell maintenance. mtorc1 is sensitive to rapamycin, activates s6k1 and 4ebp1, which are involved in mrna translation. mtorc2 is considered resistant to rapamycin, activates pkc-α and akt and regulates the actin cytoskeleton.",pmc3291999,1,1,40,1,41
809,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,esr1,gene,,esr1,hgnc,3467,nucleus,go:0005634,negative,d,binding,,,,,human,['2321'],nan,nan,"to further investigate the network structure, we determined the presence of the myc, rela, and esr1 gene promoters in the p53 chip experiments from figure 5d in which p53 binding to the htert promoter was decreased. we found that 16 h bio treatment also reduced immunoreactive p53 at the myc promoter by 2.2-fold, by 3.6-fold at rela and 5-fold at esr1 (figure 7b). therefore, the early outcome of bio treatment with respect to p53 includes co-ordinate regulation of the htert promoter and the promoters of at least three of its activators also present in the putative repression module sub-network.",pmc2714081,1,1,40,1,41
103,akt,protein,,akt1,uniprot,p31749,plasma membrane,go:0005886,abcg2,protein,,abcg2,uniprot,q9unq0,plasma membrane,go:0005886,positive,d,controls,plasma membrane,,,,human,['793'],nan,nan,"however, another likely mechanism which could explain decreased drug-resistence in response to akt inhibition, is related to the fact that akt controls abcg2 expression on the plasma membrane [107]. intriguingly, doxorubicin is a substrate for abcg2 [108], however, available evidence suggests that fluorouracil is not [109]. the so-called side-population (sp) is thought to be enriched in cscs. sp cells actively extrude the nuclear acid-staing dye hoechst 33342 owing to high expression on their plasma membrane of drug resistance transporters of the abc family such as abcb1 and abcg2, and can be identified by flow cytometry [110,111]. the enrichment of sp in lscs/cscs has been demonstrated in t-all [112], aml [113], lung cancer [114], prostate cancer [115], breast cancer [116], glioblastoma [117], and hcc [118].",pmc3837323,1,1,40,1,41
810,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,h1.2,protein,,h1-2,uniprot,p10412,nucleus,go:0005634,positive,d,promote,,,,,,['3312'],nan,nan,p53 acetylation and h1.2 phosphorylation promote p53-dependent apoptotic cell death,pmc3330162,1,1,40,1,41
745,mtor,protein,,,uniprot,p42345,,,vps34,protein,,,uniprot,q8neb9,,,negative,d,inhibition,,,,,,['2562'],nan,nan,"mtor and vps34 have a complex relationship, and multiple studies have shown that nutrient starvation, and inhibition of mtor, reduce total cellular pi(3)p levels (byfield et al, 2005; russell et al, 2013; yuan et al, 2013). however, this is not so simple as it first seems as there is more than one cellular pool of pi(3)p, such as that present at early endosomes, autophagosomes or as identified here, lysosomes. these pools can be differentially regulated, in part due to the different complexes of vps34. this is most striking upon inhibition of mtor and autophagy induction, where the autophagic pool of pi(3)p is dramatically increased, in part through phosphorylation/dephosphorylation of the vps34–beclin1–atg14l complex by ampk (kim et al, 2013), ulk1 (russell et al, 2013) and mtor (yuan et al, 2013) kinases. this is in contrast to the endocytic and newly identified lysosomal pools that are decreased, which we now show is due to dephosphorylation of the distinct vps34–beclin1–uvrag complex. taken together, this suggests that vps34 and its associated complexes act as signalling nodes to drive and co-ordinate multiple trafficking pathways. we do note that during the submission of this manuscript, a paper was published describing mtor phosphorylation of uvrag at serine 498 (s498) (kim et al, 2015) however, phosphorylation inhibited vps34 activity through enhanced rubicon binding and decreased trafficking of endosomes and autophagosomes to the lysosome. this is somewhat at odds with the data presented here. we did identify s498 of uvrag as being phosphorylated in cells; however, unlike s550 and s571, this was not affected by mtor inhibition and mutation of this site did not reduce endogenous mtorc1 phosphorylation of uvrag in vitro (supplementary fig s3). similarly, mtor inhibition by treatment with ku or ebss did not alter the binding of rubicon to the vps34 complex (fig5g). we also found that mtor inhibition reduced vps34 activity, which is consistent with the previously published work from other groups (byfield et al, 2005; russell et al, 2013; yuan et al, 2013). we cannot fully explain these discrepancies, but an obvious explanation is that in our cellular systems at least, another kinase is responsible for uvrag phosphorylation at s498.",pmc4585463,1,1,40,1,41
744,mtor,protein,,,uniprot,p42345,,,uvrag,protein,,,uniprot,q9p2y5,,,positive,d,phosphorylation,,,,,,['2563'],nan,nan,"mtor activity has previously been shown to regulate lysosomal tubulation, being essential for the process of alr, through an unknown mechanism. our study now provides a further link in showing that mtor is needed not only for tubule initiation, but also for tubule maintenance by phosphorylating uvrag and activating vps34. we do not yet know the exact function of pi(3)p in regulating lysosomal tubules, though given the persistent and extended phenotype upon vps34 inhibition, it is tempting to suggest a role in tubule scission from the donor lysosome. dynamin 2 has been shown to play an important role in tubule scission at lysosomes, and the use of the dynamin inhibitor dynasore rapidly induces a similar lamp1-positive tubular phenotype (schulze et al, 2013). dynamin activity has been shown to be activated by multiple phosphoinositides, including pi(3)p, pi(4)p and pi(4,5)p2, in vitro (yarar et al, 2008). interestingly, this same study showed that the px domain containing protein snx9 synergised with pi(3)p and other phosphoinositides to stimulate dynamin activity further. we are currently investigating whether these proteins are involved in the tubulation observed here.",pmc4585463,1,1,40,1,41
49,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,nf-κb,transcriptionfactor,,rela,uniprot,q04206,"cytoplasm, nucleus","go:0005829, go:0005634",positive,i,phosphorylation,,,,bronchial epithelium,human,['418'],nan,nan,"the transcription factor nf-κb is activated following akt phosphorylation via several mechanisms and is in itself known to play a role in cell survival and protection from apoptosis. we thus characterized the immunohistochemical staining pattern of the nf-κb subunit p65/rela in pre-neoplastic bronchial biopsies. nf-κb subunits are normally held in the cytoplasm, thus preventing them from activating transcription, and are translocated to the nucleus following various activation signals such as oxidative stress or growth factor/cytokine stimulation. we therefore determined the staining pattern of p65/rela in the cytoplasmic or nuclear compartment of airway epithelial cells. faint to moderate cytoplasmic staining for p65 was present in the cytoplasm of epithelial cells in normal biopsies with little staining in the underlying stroma (figure 4a and 4b). however, with the exception of one isolated cluster of cells in a single biopsy, p65/rela staining was not present in the nucleus. with increasing pathology score, nuclear p65/rela staining in the bronchial epithelium was seen in an increasing percentage of biopsies (table 2). there was also a trend towards increased intensity of cytoplasmic staining with increasing pathology grade (figure 4). analysis of variance gave a significant p-value of 0.010 for differences in percent nuclear localization of p65 among the groups. pairwise comparisons indicated that moderate dysplasia and severe dysplasia/cis were significantly different from normal (p = 0.022 and 0.048, respectively). in normal bronchial epithelium, staining of the submucosa was restricted to a few isolated cells, however, many biopsies with moderate to severe dysplasia showed intense staining in submucosal cells in addition to intense epithelial staining (figure 4c and 4d). in nsclc, nuclear localization of p65/rela was seen more frequently in squamous cell carcinomas (figure 4e and 4f) then adenocarcinomas. in all cases, nuclear p65/rela staining was focal within a biopsy.",pmc1325242,1,1,40,1,41
920,pten,protein,tumor suppressor,pten,uniprot,p60484,nucleus,go:0005634,mtor,kinase,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,inhibition,receptor protein fkbp12,,,,,['2449'],nan,nan,"another molecular pathway commonly mutated (30–60%) in melanomas involves loss of the pten tumor suppressor gene, which can lead to constitutive activation of the mtor kinase signaling pathway [11-13]. inhibition of mtor kinase is feasible with the macrolide natural product rapamycin (aka: sirolimus, rapa, rapamune, ay-22989, and nsc-226080). rapamycin is an fda-approved agent used as immunosuppressive therapy post organ transplant [14,15]. more recent clinical application of rapamycin has been with coated stents to suppress the neo-intima formation during restenosis in response to balloon angioplasty [16]. the action of rapamycin is understood to involve binding to the receptor protein fkbp12; this drug-protein complex binds to the mtor protein kinase and interferes with phosphorylation of two well-recognized downstream targets, p70s6k (p70 ribosomal s6 kinase) and 4ebp1 (aka: 4e binding protein 1, eukaryotic translation initiation factor 4e binding protein, and phas-1) [17]. an appreciation of the potent inhibition of cell growth and protein synthesis, as well as cell cycle arrest, imposed by rapamycin led to testing of its derivatives, in particular cci-779, as cytostatic agents, especially for various cancers refractory to other forms of cancer chemotherapy [18-20]. pharmacokinetic analysis revealed that cci-779 was progressively converted into rapamycin, its main metabolite, beginning as early as 15 minutes after infusion of the drug [20], therefore, we used rapamycin in our studies.",pmc1289294,1,1,40,1,41
65,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,phb,protein,,phb,uniprot,p35232,mitochondria,go:0005739,positive,d,phosphorylation,,,,bladder,human,['1859'],nan,nan,"to explore the possibility that akt may directly phosphorylate phb, we analyzed the immunoprecipitated pellet of endogenous phb for the presence of akt. in nmibc or mibc tissues, immunoblot analysis of immunoprecipitated phb detected the presence of akt and activated phospho-akt (figure 6a). we also found phb present following a reciprocal immunoprecipitate using the antibody against phb (figure 6a), further confirming their direct interaction.",pmc4669803,1,1,40,1,41
83,akt,protein,,akt1,uniprot,p31749,,,dna-pkcs,protein,,prkdc,uniprot,p78527,,,positive,d,phosphorylation,t2609 and s2056,,,,,['16'],nan,nan,"as the most hazardous dna lesions, dna double-strand breaks (dsbs) can lead to genome rearrangements and cell death following exposure to genotoxic stresses. two mechanisms are primarily involved in repair of dsbs: nonhomologous end joining (nhej) and homologous recombination repair (hrr) [104, 105]. nhej is evolutionarily conserved in all kingdoms of life and is the predominant dsb repair pathway throughout the cell cycle [106–108]. hrr is a more accurate repair mechanism but restricted to s and g2 phases [109, 110]. numerous studies have shown that inhibition of akt activity impairs dsb repair [111–115]. specific akt inhibitors or akt1 sirna markedly reduce radiation-induced dna-pkcs phosphorylation at t2609 and s2056, modifications required for activation of dna-pkcs [116, 117]. akt1 physically associates with dna-pkcs, indicating that akt1 may function as a signalling kinase relevant for dna-pkcs activation and nhej repair [111–115]. it has been shown in malignant glioblastoma that egfr/erk/akt signalling promotes γh2ax foci resolution and enhances both nhej and hr repair by modulating the localization, expression, and phosphorylation of dna-pkcs, atm, and rad51. inhibition of either akt or mek/erk results in significant reduction of nhej [115]. these results strongly argue that both akt and mek/erk signalling are critical effectors downstream of egfr that modulate dna repair and may contribute to radioresistance in malignant glioblastoma with deregulated egfr/erk/akt signalling. interestingly, recent studies show that dna-pkcs acts as an upstream signal for akt phosphorylation and activation in response to genotoxic stresses [92, 96, 118], suggesting that akt and dna-pkcs are tightly coregulated in both checkpoint response and dna repair.",pmc3317191,1,1,40,1,41
782,p16,protein,,cdkn2a,uniprot,q03164,,,cdk4,protein,,cdk4,uniprot,p11802,,,negative,d,binds,,,,lung,human,['2334'],nan,nan,"the p16/cyclin d1/cdk4/rb signaling pathway is frequently altered in nsclcs. the cdkn2a/p16 gene is a candidate tumor suppressor in wild-type rb malignancies; p16 binds cdk4 and inhibits catalytic activity of the cdk4/cyclin d complex.15 rb and p16ink4a expression in lung cancer are inversely correlated; frequently, rb-positive nsclcs have little or no detectable p16ink4a protein due to homozygous deletions, mutations and methylation of cpg islands.16,17 loss of p16ink4a frees these cdks from inhibition, permitting constitutive phosphorylation of rb and inactivation of its cell growth inhibitory properties. in addition, overexpression of p16 blocks tumor cells in s phase and inhibits ras-induced cell proliferation.18,19",pmc3742489,1,1,40,1,41
781,p16,protein,,cdkn2a,uniprot,p42771,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,negative,d,inactivation,,,lung adenocarcinoma,lung,human,['2348'],nan,nan,"alternative signaling pathways may offer new therapeutic opportunities for treatment of kras mutation-positive lung adenocarcinoma. selective inactivation of the p16/cyclin d1/cdk4/rb signaling pathway is an important strategy for anti-cancer drug development. in this study, we investigated the anti-tumor effects of cdk4 suppression by molecular or pharmacologic inhibition in kras mutant cells. we also examined the impact of cink4, a cdk4/6 inhibitor, in combination with paclitaxel.",pmc3742489,1,1,40,1,41
779,p-p70s6k,protein,,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,p-4e-bp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['2812'],nan,nan,results of univariate and multivariate analyses of clinicopathological variables and the expression levels of p-p70s6k and p-4e-bp1 in relation to recurrence-free survival in 95 patients with lg-urca,pmc4104092,1,1,40,1,41
70,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,satb1,protein,,satb1,uniprot,q01826,nucleus,go:0005634,positive,d,phosphorylation,serine 47,hek293t,epithelial-like,kidney,human,['834'],nan,nan,"satb1 has a sequence motif (r42grlgs47) that is highly conserved across species from fish to human (figure s2a). akt phosphorylated gst-satb1 1–204 and gst-satb1 1–495, rather than gst-satb1 52–204 and gst-satb1 52–495, which suggested the phosphorylation site resided within satb1 1–52 (figure 1a, figures s2b and s2c). a shorter fusion protein gst-satb1 1–51 further corroborated the notion that the phosphorylation site located within this region (figure 1b). we next generated the mutant proteins and examined whether akt phosphorylated satb1 at serine 47 in vitro. gst-satb1 1–204, but not gst, gst-satb1 1-204s47a or gst-satb1 1-204s47d, was efficiently phosphorylated by akt (figure 1c, figures s1b and s2d). we then investigated whether akt could phosphorylate satb1 in vivo. to this purpose, we expressed myc-tagged satb1 together with either myc-tagged wild-type akt, myc-tagged constitutively activated akt or myc-tagged kinase dead akt in hek293t cells (figure 1d, figure s2e). satb1 did exist in a pool of akt substrates reciprocally immunoprecipitated with phosphorylated akt substrate antibody (figures s2f, s2g and s2h). in order to unequivocally define satb1 phosphorylation at serine 47 by akt, we raised a polyclonal antibody g5647 against phosphorylated peptide of n-caaargrlg(ps)tgakm-c in rabbit (figure s3). in the presence of atp, akt phosphorylated gst-satb1 1–204, but not gst, gst-satb1 1-204s47a or gst-satb1 1-204s47d when assayed with the anti-serum of g5647. without atp, gst-satb1 1–204 could not be recognized by g5647, which clearly proved that serine 47 was the phosphorylation site of akt (figure 1e).",pmc3675137,1,1,40,1,41
777,oncogenic ras,protein,,ras,uniprot,p01111,plasma membrane,go:0005886,cd24,protein,,cd24,uniprot,p25063,plasma membrane,go:0005886,negative,i,repression,surface,,,,human,['1712'],nan,nan,repression of cd24 surface protein expression by oncogenic ras is relieved by inhibition of raf but not mek or pi3k,pmc4525067,1,1,40,1,41
71,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,satb1,protein,,satb1,uniprot,q01826,nucleus,go:0005634,positive,d,phosphorylation,serine 47,,,,,['835'],nan,nan,akt phosphorylates satb1 at serine 47 in a pi3k-dependent manner.,pmc3675137,1,1,40,1,41
788,p21,protein,,,uniprot,p38936,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,positive,d,phosphorylation,t172,hct116 k7as,epithelial,colon,human,['1101'],nan,nan,"(a,b) stably infected hct116 k7as cells for tet-on inducible 3×ha-p21 wt or s130a mutant were treated with doxycycline (1 µg/ml) for 16 h prior cell restimulation with fetal bovine serum (fbs) for 16 h in the continuous presence of doxycycline. (a) immunodetection of 3×ha-p21 and endogenous p21 from whole cell extracts (wce) using a p21 antibody. (b) cell lysates were immunoprecipitated (ip) with anti-ha antibody and separated by 2d gel electrophoresis followed by simultaneous immunodetection of ectopic 3×ha-p21 and 3×ha-p21-bound endogenous cdk4 using a mixture of anti-cdk4 and p21 antibodies. black arrows, t172-phosphorylated cdk4. colored arrows indicate phosphorylated forms of p21.",pmc3667761,1,1,40,1,41
789,p21,protein,,,uniprot,p38936,unknown,unknown,cdk4,protein,,cdk4,uniprot,p11802,unknown,unknown,negative,d,inhibition,,cho,unknown,unknown,unknown,['1096'],nan,nan,"to further evaluate the relationship between p21 and cdk4 t172 phosphorylation in intact cells, p21 was co-expressed at two different levels with cyclin d3 and cdk4 by transfection of cho cells (in which no endogenous p21 is detectable) (figure 4). the effect of p21 expression on the assembly and activity of cdk4 complexes was exactly as established [10], [58]–[60]. in the absence of p21, very active cyclin d3-cdk4 complexes were formed [31], and they were largely phosphorylated at t172 (figure 4a, 4c). at the higher level of expression, p21 stabilized cyclin d3-cdk4 complexes but inhibited their prb-kinase activity (figure 4a) and also substantially reduced cdk4 phosphorylation (figure 4c). by contrast, at the lower expression level of p21, p21-bound cyclin d3-cdk4 complexes displayed a weak but readily detected activity (figure 4b) and a much increased phosphorylation of cdk4 (figure 4c).",pmc3667761,1,1,40,1,41
790,p21waf1/cip1,protein,,cdkn1a,uniprot,p38936,,,twist1,protein,,twist1,uniprot,q15672,,,negative,d,binds,,,,lung,human,['1488'],nan,nan,"in view of the earlier finding that increased p21waf1/cip1 expression determines cisplatin resistance in human testicular cancer,22 we analyzed the p21waf1/cip1 mrna and protein levels in nsclc cells treated with cisplatin. as shown in figures 7a and b, cisplatin induced an increase in the p21waf1/cip1 mrna and protein levels in a dose-dependent manner. p21waf1/cip1 upregulation by cisplatin was observed, even in p53-defective h1299 cells, suggesting that cisplatin induces p21 expression in a p53-independent manner. interestingly, p21waf1/cip1 was additionally upregulated by twist1 sirna in both cell types, as shown in figure 7c. we further investigated whether p21waf1/cip1 has a protective role against cisplatin and/or twist1 knockdown-induced cell death by transfecting cells administered with cisplatin and/or twist1 sirna with p21waf1/cip1 sirna. p21waf1/cip1 depletion resulted in enhanced sensitivity of cells to twist1 sirna and cisplatin-mediated apoptosis (figure 7d), suggesting a role of p21waf1/cip1 in preventing cell death by cisplatin or twist1 sirna in nsclc.",pmc3388235,1,1,40,1,41
69,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,satb1,protein,,satb1,uniprot,q01826,nucleus,go:0005634,positive,d,phosphorylation,s47,breast cancer cell lines,epithelial,breast,human,['840'],nan,nan,"in order to analyze the effect of phosphorylation on satb1 stability, we established breast cancer cell lines carrying empty vector, wild-type satb1, satb1s47a or satb1s47d. like mock transduction, the satb1s47a mutant almost could not be detected in stable mcf-7 cells with satb1 antibody (figure 2c). consistently, satb1s47a was expressed at a much lower level in sk-br-3 cells, compared with satb1 and satb1s47d (figure 2d). paradoxically, in cells with the satb1s47a mutant, akt was highly activated through an unknown mechanism (figure 2d). furthermore, the myristoylated akt increased the amount of satb1 over-expressed in sk-br-3 cells, whereas the dominant-negative akt did not (figure 2e). these findings allow us to conclude that akt maintains the molecular integrity of satb1 through phosphorylation.",pmc3675137,1,1,40,1,41
72,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,satb1,protein,,satb1,uniprot,q01826,nucleus,go:0005634,positive,i,phosphorylation,serine 47,hek293t cells,epithelial,,human,['860'],nan,nan,"akt phosphorylates satb1. (a) the putative akt phosphorylation motif on satb1 is highly conserved among multiple species. a consensus akt phosphorylation sequence is denoted for comparison. (b) a schematic representation of gst-fused satb1 constructs is shown. (c) phosphorylation of gst-satb1 1–204 is akt- and atp-dependent in the in vitro kinase assay. (d) a schematic representation for wild-type and mutant satb1 is shown. (e) akt (myr) robustly phosphorylates myc-satb1, compared to wild-type akt or akt (dn). myc-satb1 was co-expressed with myc-akt (wt), myc-akt (myr) or myc-akt (dn) in hek293t cells and immunoprecipitated myc-satb1 was immunobloted with anti-phospho-akt substrate. (f) akt phosphorylates wild-type satb1 other than its mutants at serine 47. myc-satb1 or its mutants was ectopically expressed together with akt (myr) in hek293t cells. the cell lysates were subjected to immunoblotting with anti-phospho-akt substrate and anti-myc. (g) immunoprecipitation with anti-myc followed by immunobloting with anti-phospho-akt substrate reveals satb1 phosphorylation at serine 47 by akt. (h) reciprocal immunoprecipitation indicated that satb1, satb1s557a or satb1s557d, but not satb1s47a or satb1s47d existed in anti-phospho-akt substrate immunoprecipitates.",pmc3675137,1,1,40,1,41
73,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,skp2,protein,,fbxl1,uniprot,o43542,cytoplasm,go:0005737,positive,d,phosphorylation,ser72,,,,human,['7'],nan,nan,"interestingly, recent studies revealed that the protein stability of p27kip1 is controlled by akt-dependent phosphorylation of skp2 [63, 64]. skp2 is a key component of scf (skp1/cul-1/f-box) e3 ubiquitin ligase; it binds to p27kip1 and targets it for ubiquitination and degradation [65–68]. akt interacts with and directly phosphorylates skp2 at ser72, which triggers scf complex formation and e3 ligase activity [63]. in addition, phosphorylation by akt promotes the cytoplasmic localization of skp2 and protects skp2 from apc-cdh1-mediated degradation [64]. high levels of active akt correlates with the cytosolic accumulation of skp2 in aggressive breast and prostate cancer patients, providing a rationale to develop specific akt inhibitors as efficient anticancer drugs [64].",pmc3317191,1,1,40,1,41
74,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,sox2,protein,,sox2,uniprot,p48431,nucleus,go:0005634,positive,i,association,,293a,epithelial-like,,human,['850'],nan,nan,"we then checked whether akt signaling would influence the interaction between satb1 and sox2. myc-tagged satb1 or its phosphorylation-mimetic mutants was co-expressed with flag-gfp-tagged sox2 in 293a cells, respectively. myc-satb1s47a coimmunoprecipitated less sox2 than myc-satb1 and myc-satb1s47d (figure 5e). to confirm this observation, 293a cells were co-transfected with myc-satb1 and flag-sox2, serum starved and treated with dmso, ly294002 or ly294002 plus igf-1. inhibition with ly294002 almost diminished the association between satb1 and sox2, compared to dmso treatment. by contrast, addition of igf-1 to ly294002 treated cells, which would reactivate akt signaling, faithfully recapitulated satb1/sox2 interaction (figure 5f). these results demonstrate that the akt signaling obviously regulates the association between satb1 and sox2, probably contributing to sox2 sequestration by satb1 from an oct4/sox2 core transcription factor complex.",pmc3675137,1,1,40,1,41
78,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,d,phosphorylation,,,,,,['2893'],nan,nan,"regulation of foxo3 and β-catenin by akt, erk, and ikk signaling pathway. (a) akt, erk, and ikk phosphorylates foxo3 at different sites and induces its ubiquitination and subsequent degradation via skp2, mdm2, and β-trcp, respectively. (b) akt and erk phosphorylates gsk3β and inhibit it. gsk3β phosphorylates catenin and induces its ubiquitination and subsequent degradation via β-trcp. both akt and ikkα phosphorylate β-catenin and stabilize it.",pmc3355968,1,1,40,1,41
80,akt,protein,,akt1,uniprot,p31749,cytosol,go:0005829,bad,protein,proapoptotic,bad,uniprot,q92934,mitochondria,go:0005739,positive,d,phosphorylation,ser136,,,,human,['1609'],nan,nan,"bad, a proapoptotic member of the bcl-2 family, has been identified as one of the downstream targets of akt. activated akt increases bad phosphorylation at ser136, which shifts binding of bad from bcl-xl to 14-3-3 protein (zha et al. 1996; datta et al. 1997). based on this observation, it has been proposed that akt inhibits apoptosis mainly through maintaining the prosurvival function of bcl-xl, which regulates cytochrome c release from mitochondria. we tested this model by examining whether active akt can inhibit cytochrome c redistribution in c2-ceramide induced apoptosis. surprisingly, akt did not block cytochrome c release into the cytosol (fig. 6a and fig. b), whereas bcl-2 suppressed cytochrome c release (c and d). this observation is in agreement with the well established role for bcl-2 to inhibit apoptosis by blocking cytochrome c release from mitochondria (kluck et al. 1997; yang et al. 1997). moreover, it suggests that active akt inhibits apoptosis at a step after release of cytochrome c into the cytoplasm.",pmc2185587,1,1,40,1,41
81,akt,protein,,akt1,uniprot,p31749,,,cdk1,protein,,cdk1,uniprot,p06493,,,positive,d,phosphorylation,,,epithelial,,human,['9'],nan,nan,"it has been reported previously that akt activity is high in the g2/m phase of the cell cycle in epithelial cells [79]. akt activity protects cells from apoptosis during the g2/m transition and is necessary for efficient entry to mitosis during unperturbed cell cycles [79, 80]. as shown in figure 1, akt regulates the g2/m transition through direct phosphorylation of both cdk1 activators and inhibitors, suggesting that the pi3k/akt pathway could function to promote mitosis [81, 82].",pmc3317191,1,1,40,1,41
68,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,satb1,protein,,satb1,uniprot,o60841,nucleus,go:0005634,positive,d,phosphorylation,,,t-cell,,human,['841'],nan,nan,"besides lamin b, saf-a/hnrnp-u and numa, satb1 is a fourth nuclear matrix-binding molecule that is cleaved for degradation by caspase upon apoptotic stimuli [23], [24]. we next tested whether akt phosphorylation would protect satb1 from apoptotic cleavage. the satb1s47d mutant was more stable than both satb1 and satb1s47a in response to camptothecin (cpt) treatment. the cpt treatment led to a gradual loss of pan-satb1; however, the phosphorylated satb1 reached a peak 4 h post-treatment and then declined (figure 2f). consistently, endogenous satb1 in jurkat cells manifested the same behavior upon cpt treatment (figure 2g). these results suggest that apoptotic signal may transiently induce an increase of satb1 phosphorylation, which in turn improves its resistance to apoptosis.",pmc3675137,1,1,40,1,41
82,akt,protein,,akt1,uniprot,p31749,,,cytochrome c,protein,,,uniprot,p99999,cytoplasm,go:0005737,negative,d,inhibits,,,,,,['1610'],nan,nan,"akt, but not bcl-2, inhibits caspase activation induced by cytochrome c in a cell-free system",pmc2185587,1,1,40,1,41
66,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,prohibitin 1,protein,,phb,uniprot,p35232,mitochondria,go:0005739,positive,d,phosphorylation,mitochondrial,,bladder cancer,,human,['1846'],nan,nan,akt phosphorylates prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells,pmc4669803,1,1,40,1,41
811,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,h1.2,protein,,hist1h1c,uniprot,p16401,nucleus,go:0005634,negative,d,acetylation and phosphorylation,,"u2os, h1299",epithelial,"osteosarcoma, lung",human,['3311'],nan,nan,"because p53 acetylation and h1.2 phosphorylation decrease p53-h1.2 interaction in vitro (figures 1e and 3c), we next examined to which extent these modifications are involved in regulating h1.2 binding to p53 in u2os cells. cell lysates were prepared from cells treated with etoposide for the indicated times, and p53-h1.2 interaction was examined by western blotting of immunoprecipitated materials. as shown in figure 4e, endogenous p53 efficiently coprecipitated with h1.2 from extracts prepared before etoposide treatment (0 time point), but minimally did so from extracts prepared 15 min and 60 min after etoposide treatment. to further substantiate the role of h1.2 phosphorylation in releasing h1.2 from p53, we repeated immunoprecipitation experiments using h1299 cells transfected with expression vectors for flag-tagged p53 290-393 and xpress-tagged wild type h1.2 or nonphosphorylatable h1.2 harboring alanine substitution at t146. p53 stably interacted with both wild type and mutant h1.2 under normal conditions (0 time point), but there was ~90% reduction in its interaction with h1.2 60 min after etoposide treatment (figure 4f). these results argue that despite the possible positive effects of t146a mutation on p53-h1.2 interaction, p53 acetylation is likely the primary regulator of p53-h1.2 interaction at 60 min time point. in fact, point mutations of the major p53 acetylation sites restored p53-h1.2 interaction at 60 min time point back to that at 0 time point (figure 4g, lanes 1–4). again, these results strongly support earlier indications that h1.2 phosphorylation plays a dominant role in regulating p53-h1.2 interaction 15–30 min after etoposide treatment, whereas p53 acetylation does so 30–60 min after the treatment. no detectable changes in p53-h1.2 interaction when p53 and h1.2 mutants simultaneously replaced their wild type counterparts further indicate that p53 acetylation and h1.2 phosphorylation are essential for their continuous dissociation (lanes 5–8).",pmc3330162,1,1,40,1,41
738,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,tfeb,protein,,,uniprot,q6zmq4,nucleus,go:0005634,negative,d,regulation,,,,,human,['2844'],nan,nan,"tfeb protein levels and subcellular localization are under control of a short-term rheostat, which is highly responsive to negative regulation by mtor, but under conditions of mtor inhibition, restricts tfeb activation in a manner dependent on the proteasome. we further identify a long-term, mtor-independent homeostatic control negatively regulating tfeb upon prolonged mtor inhibition. these findings are of relevance for developing strategies to target tfeb activity in disease treatment. moreover, our quantitative approach to decipher phenotype heterogeneity in imaging datasets is of general interest, as shifts between subpopulations provide a quantitative description of single cell behaviour, indicating novel regulatory behaviors and revealing differences between cell types.",pmc4896000,1,1,40,1,41
678,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,hexokinase ii,enzyme,kinase,hk2,uniprot,p52789,mitochondria,go:0005739,negative,i,inhibition,,tumor cells,epithelial-like,tumor,human,['2237'],nan,nan,tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mtor-mediated hexokinase ii inhibition - a warburg-reversing effect,pmc4373728,1,1,40,1,41
64,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,phb,protein,,phb,uniprot,p22749,mitochondria,go:0005739,positive,d,interacts,,t24,urothelial carcinoma,bladder,human,['1860'],nan,nan,"to confirm that endogenous akt interaction with phb is dependent on akt activity, t24 cells were treated with or without gsk690693, lysed and immunoprecipitated using the antibody against phb or akt. immunoblot analysis affirmed the interaction of phb and activated phospho-akt, and the inhibition of akt completely disrupted the interaction between phb, akt and activated phospho-akt (figure 6b). these data indicate that akt interacts with phb in bc cells and the activation of akt is required for the interaction of phb and akt.",pmc4669803,1,1,40,1,41
829,p53,protein,transcription factor and tumor suppressor protein,tp53,uniprot,p04637,nucleus,go:0005634,hdmx,protein,mdm2-like p53-binding protein,mdm4,uniprot,o15151,nucleus,go:0005634,negative,d,binds,,,,,human,['47'],nan,nan,"cells with irreparable damage activate apoptotic pathways, to avoid propagation of a modified, potentially harmful genome. the induction of apoptosis proceeds through at least two main pathways (extrinsic and intrinsic), each of which can be regulated at multiple levels. a common regulator of both these apoptotic pathways is p53, a transcription factor and tumor suppressor protein that, in response to dna damage, induces the expression of genes involved in checkpoint activation or apoptosis (gomez-lazaro et al., 2004). in unstressed cells, p53 has low activity and a short half-life because it is complexed with two proteins, the e3 ubiquitin protein ligase (mdm2) and the mdm2-like p53-binding protein (hdmx), which cause p53 to be ubiquitinated and degraded by proteasomes; low p53 levels and activity allow normal growth (gomez-lazaro et al., 2004). after dna damage, p53 is phosphorylated by atm, an event that displaces mdm2 and allows p53 to accumulate in the nucleus where it can perform its function as transcription factor (cheng and chen, 2010). this p53 stabilization is also due to the degradation of hdmx, which is induced by phosphorylation by both atm and chk2 (chen et al., 2005b; lebron et al., 2006; pereg et al., 2006). indeed, hdmx normally shuttles between the nucleus and the cytoplasm, but in the presence of dsbs, nuclear hdmx is phosphorylated by atm and chk2 and retained there through binding to 14-3-3 proteins (chen et al., 2005b). this event is an essential step toward hdmx degradation, p53 activation and apoptosis induction (figure 3c).",pmc4296918,1,1,40,1,41
831,p53,protein,tumor suppressor,tp53,uniprot,p04637,nucleus,go:0005634,rpl11,protein,ribosomal,rpl11,uniprot,p62913,nucleoli,go:000573093,positive,d,binds and inhibits,nucleoplasm,,,,human,['2278'],nan,nan,"in order to maintain homeostasis cells must respond efficiently to environmental conditions such as stress, growth factors, and nutrients. the tumor suppressor p53 orchestrates the cellular response to a wide variety of stressors, including dna damage, oncogene expression, and disruption of ribosome biogenesis – a condition known as nucleolar stress.1, 2 recently it has been shown that ribosomal protein l11 (rpl11) plays a key role in coordinating the p53 response to nucleolar stress. specifically, when ribosome production is disturbed, rpl11 translocates from the nucleoli to the nucleoplasm where it binds and inhibits the p53-directed e3 ubiquitin ligase hdm2, resulting in increased p53 protein stability and transcriptional activity.3–6 this enables activation of a transcription program promoting cell cycle arrest, senescence, or apoptosis. although the rp-hdm2-p53 pathway has been shown to play key roles in oncogene-induced apoptosis and senescence,6, 7 the molecular mechanisms responsible for its regulation remain largely unknown.8",pmc4216640,1,1,40,1,41
832,p53,protein,tumour suppressor,tp53,uniprot,p04637,,,4e-bp1,protein,,eif4ebp1,uniprot,q13541,,,negative,i,proteasome mediated specific cleavage,n-terminal,,,,,['1443'],nan,nan,"rapamycin resistant phosphorylation of 4e-bp1 has been reported in regenerating rat livers where rapamycin inhibits activation of s6k1 in response to partial hepatectomy, but 4e-bp1 phosphorylation remains uninhibited, suggesting that the effect of rapamycin on 4e-bp1 function in vivo can be significantly different from its effect in cultured cells [102]. rapamycin has also been reported to differentially regulate s6k1 in comparison with 4e-bp1 in various cell lines including hela, mefs, and hek293, where rapamycin initially decreased 4e-bp1 phosphorylation but this decrease recovered within 6 h while s6k1 phosphorylation continued to be inhibited and by 12 h after treatment since 4e-bp1 was mostly hyperphosphorylated, it dissociated from eif4e leading to a recovery in cap dependent translation even though s6k1 inhibition by rapamycin continued [103]. several mechanisms such as association/dissociation of mtor associated proteins or posttranslational modifications on mtorc1 have been put forward to explain this phenomenon of differential phosphorylation [104]. torin is an atp-competitive inhibitor that inhibits 4e-bp1 phosphorylation more strongly than rapamycin in various human cell lines. it inhibits phosphorylation of t37/t46 as well as s65 but fails to inhibit t70 phosphorylation in mefs. these studies with torin suggest that rapamycin resistance of mtorc1 might be a general feature of a good number of mammalian systems [105]. the activation of the tumour suppressor protein p53 induces a proteasome mediated specific cleavage of 4e-bp1 that gives rise to an n-terminally truncated, completely unphosphorylated and more stable form of 4e-bp1 that interacts with eif4e in preference to full-length 4e-bp1, which results in long-term unavailability of eif4e, thereby contributing to the growth-inhibitory and proapoptotic effects of p53 [106, 107]. 4e-bp1 activity is regulated in apoptosis since treatment of cells with dna damaging drugs such as etoposide and staurosporine results in dephosphorylation of 4e-bp1 due to inhibition of mtor signaling which impairs cap dependent protein translation and drives the ires-mediated cap independent protein synthesis [108]. one mechanism through which dna damage could result in the inhibition of mtor involves p53 [109] while another different link between dna damage and mtor signaling is the tyrosine kinase c-abl, which once activated by dna damage can inactivate mtor [110].",pmc4258317,1,1,40,1,41
692,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,,,melanoma,skin,human,['2453'],nan,nan,"phosphorylation of mtor targets in vmm18 melanoma cells treated with rapamycin, bay43-9006, or u0126. the phosphorylation of p70s6k and 4ebp1 was assayed by migration in sds-page and the proteins detected by immunoblotting. control vmm18 cells grown in pbs without serum were analyzed in lane 1 and vmm18 melanoma cells in lanes 2–6 were grown 24 hours in media that contained 5% serum. cells not treated with drugs (lanes 1 and 2) were compared to cells pre-treated for one hour with rapamycin (lane 3), bay43-9006 (lane 4), a combination of rapamycin and bay43-9006 (lane 5), or u0126 (lane 6). gapdh was immunoblotted as a loading control (bottom panel).",pmc1289294,1,1,40,1,41
691,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,4e-bp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,,,b-cell,,human,['1979'],nan,nan,"mtor regulates translation by phosphorylating components of the protein synthesis machinery, including p70s6k and 4e-bp1 [395, 396]. p70s6k phosphorylates the 40s ribosomal protein, rps6, leading to active translation of mrnas [1-3]. in contrast, 4e-bp1 phosphorylation by mtorc1 on several amino acidic residues (s37; t46; s65; t70) results in the release of the eif4e [2]. mrnas differ in their ability to be translated; the length and sequence of the 5' utr largely dictates the efficiency with which an mrna transcript will be translated. most mrnas contain short, unstructured gc-poor 5' utrs and are efficiently translated. in contrast, long, gc-rich sequences in the 5' utr often hinder the ability of the eif-4e complex to efficiently scan and initiate translation at the start codon. these are called weak mrnas as previously discussed. consequently, under normal circumstances these mrnas are not efficiently translated. however, upon akt-mediated activation of mtor, these latter mrnas are highly and disproportionately translated. interestingly, many of these weak mrnas molecules encode oncogenic proteins involved in cell proliferation or survival (e.g., c-myc, mcl-1, cyclin-d, vegf and survivin). these oncogenic mrnas are therefore tightly regulated at the translation level and their accumulation in cancer cells strongly contributes to the malignant phenotype. these proteins are often subject to the phenomenon of “oncogenic shock” so when an oncogene-addicted cell is treated with a specific inhibitor the expression of these proteins rapidly decays.",pmc3660063,1,1,40,1,41
689,mtor,protein,,frap1,uniprot,p42345,cytoplasm,go:0005737,rictor,protein,,rictor,uniprot,q6r327,cytoplasm,go:0005737,positive,d,forms complex with,,,,,mammalian,['3321'],nan,nan,"the mammalian target of rapamycin (mtor) signalling pathway has a key role in cellular regulation and is involved in multiple diseases. mtor is a central regulator of cell growth, aging, ribosome biogenesis, protein synthesis, actin-cytoskeletal organization, autophagy and metabolism. it also plays a vital role in coupling cell growth via signalling pathways, according to the availability of nutrients and cellular energy supplies and oxygen [1]. mtor forms two distinct heteromeric complexes, mtorc1 and mtorc2. mtorc1 contains mtor, raptor (regulatory associated protein of mtor), mlst8 and pras40 [2-5], whilst mtorc2 contains mtor, rictor (rapamycin-insensitive companion of mtor), mlst8, msin1 and protor [6-9], raptor and rictor being specific components of mtorc1 and mtorc2 respectively.",pmc3549280,1,1,40,1,41
688,mtor,protein,,frap1,uniprot,p42345,cytoplasm,go:0005737,rictor,protein,,rictor,uniprot,q6r327,cytoplasm,go:0005737,negative,d,disrupts assembly,,,cancer,,human,['1581'],nan,nan,"following characterization of these cell lines, we treated them with 10 nm rapamycin for 1 h and then detected assembly of mtorcs via mtor immunoprecipitation (ip) as done previously [24, 25]. to our surprise, we detected reduced levels of not only raptor as expected, but also rictor from ip complexes in all 7 cell lines (fig. 6c), indicating that rapamycin disrupts the assembly of both mtorc1 and mtorc2 in these cell lines. following this study, we further examined the effects of acute rapamycin treatment on phosphorylation of akt, pkcα and sgk1, which are thought to be phosphorylated by mtorc2 at either hydrophobic motif (e.g., akt s473, pkcα s657 and sgk1 s422) or turn motif (akt t450 and pkcα t638) [26]. in agreement with our previous observation [27], acute rapamycin treatment increased akt s473 phosphorylation in every tested cell line; however, we did not see apparent alteration of akt t450 phosphorylation in any of the cell lines. interesting, phosphorylation (s21/9) of gsk3, a putative akt substrate, was only slightly increased by rapamycin in h157 and 686ln cells, but not in other cell lines (fig. 6d). in contrast to akt s473 phosphorylation, rapamycin did not increase the phosphorlation of pkcα and sgk1 in any of the tested cell lines. rather it decreased pkcα t638 phoshorylation in 4 (h157, a549, pc-3 and mb-435) of 7 tested cell lines, pkcα s657 phoshorylation in 3 (h157, pc-3 and mb-435) of 7 tested cell lines and sgk1 s422 phosphorylation in all the tested cell lines (fig. 6d). clearly, acute treatment of cancer cells with rapamycin inhibits mtorc2 assembly accompanied with suppression of sgk1 s422 phosphorylation and increase of akt s473 phosphorylation.",pmc4496196,1,1,40,1,41
687,mtor,protein,,frap1,uniprot,p42345,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,i,phosphorylation,,,unknown,,human,['2153'],nan,nan,"translational control plays an important role in cell physiology, including cell growth, proliferation, differentiation and metabolism. the eukaryotic translation initiation factor 4e (eif4e), an atp-dependent helicase, is a rate limiting component in the regulation of mrna translation1. the eif4e interacts with eif4g, a large scaffold protein for assembly of eif4f complex at mrna 7-mgtp cap structure. formation of eif4f complex is regulated by a tumor suppressor protein called eif4e-binding protein 1 (4ebp1) through its reversible association with eif4e2. mammalian target of rapamycin (mtor) functionally controls this cap-dependent translation machinery through the phosphorylation of its downstream effectors 4ebps and s6ks3. thus, phosphorylation of 4ebp1 by mtor leads to its association with eif4e and hence, eif4f complex formation, whereas inhibition of mtor results in repression of cap-dependent translation.",pmc4700468,1,1,40,1,41
833,p65/rela,protein,,rela,uniprot,q04206,nucleus,go:0005634,ciap-2,protein,,birc3,uniprot,q13489,cytoplasm,go:0005737,positive,i,correlates,,,,,,['422'],nan,nan,"staining for p65/rela, phospho-akt and ciap-2 on serial biopsy sections. serial sections from a moderate dysplasia (a–c) or adenocarcinoma (d–f) underwent immunohistochemical staining with antibodies directed against p65/rela (a and d), phospho-akt (b and e) or ciap-2 (c and f). cells with nuclear localization of p65/rela (arrows in a) correlated with regions of increased staining for phospho-akt and ciap-2 in this moderate dysplasia but the correlation was not consistently observed. high levels of cytoplasmic p65/rela staining in the adenocarcinoma corresponded with faint to moderate staining for phospho-akt and ciap-2 (d–f). there was a statistically significant correlation between ciap-2 and phospho-akt staining intensity at all pathology grades.",pmc1325242,1,1,40,1,41
686,mtor,protein,kinase,,uniprot,p42345,mitochondria,go:0005739,hexokinase ii (hk ii),protein,kinase,hk2,uniprot,p52789,mitochondria,go:0005739,positive,d,co-immunoprecipitated,mitochondrial surface,mcf-7,epithelial-like,breast,human,['2248'],nan,nan,"to elucidate the mechanisms controlling the bioenergetics switch after radiation, we co-immunoprecipitated mtor with another critical mitochondrial protein in glycolysis, hexokinase ii (hk ii), to determine whether mtor mediated mitochondrial bioenergetics is linked with hk ii. hk ii is in the first step of aerobic glycolysis; it is located on the outer membrane of mitochondria and phosphorylates glucose to glucose-6-phosphate. therefore, it is highly possible that the interaction of mtor and hk ii can serve as a switcher on the mitochondrial surface to initiate the bioenergetics reprogramming. a recent study showed that mtorc1 and hk ii formed a complex during glucose starvation in neonatal rat ventricular myocytes [45]. we hypothesized that radiation may trigger an interaction between mtor and hk ii to regulate bioenergetics. co-immunoprecipitation (co-ip) analysis in mcf-7 cells showed that mtor did not interact with hk ii in sham radiation control cells, but indeed, the mtor and hk ii complex was detected 24 h post-irradiation, the same time point where a switch in energy metabolism from aerobic glycolysis to oxphos was detected in mcf-7 cells (fig. 6a). as expected, rapamycin inhibited the translocation of mtor to mitochondria and prevented the interaction of mtor and hk ii.",pmc4373728,1,1,40,1,41
812,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,h1.2,protein,,hist1h1c,uniprot,p16401,nucleus,go:0005634,positive,d,phosphorylation and acetylation,,,,,,['3302'],nan,nan,functional interplay between p53 acetylation and h1.2 phosphorylation in p53-regulated transcription,pmc3330162,1,1,40,1,41
685,mtor,protein,kinase,,uniprot,p42345,cytoplasm,go:0005737,uvrag,protein,,uvrag,uniprot,q9p2y5,cytoplasm,go:0005737,positive,d,phosphorylation,"serine 550, serine 571",mefs,fibroblast,,human,['2542'],nan,nan,"to identify the phosphorylation sites on uvrag, two approaches were undertaken. gst-uvrag was incubated in vitro with endogenous mtor and phosphorylated in a non-radioactive kinase assay in the absence or presence of ku. alternatively, mefs stably expressing flag-uvrag were treated with/without ku and uvrag immunoprecipitated using flag agarose. in each experiment, samples were separated by sds–page and the coomassie-stained uvrag band was excised for phospho-peptide analysis by mass spectrometry. the in vitro kinase assay identified two phosphorylated sites that were abolished upon ku treatment, serine 550 (s550) and serine 571 (s571, fig4a). analysis of uvrag immunoprecipitated from cells also identified s550 and s571 as being phosphorylated in cells and sensitive to ku treatment. from the immunoprecipitated uvrag only, we also identified two additional sites that were phosphorylated at serine 498 and threonine 518. however, unlike s550 and s571, these sites were insensitive to ku treatment and a uvrag mutant with these residues substituted to alanine was still phosphorylated in vitro by mtor, implying that another kinase mediates phosphorylation at these sites (supplementary fig s3). combined, the in vitro and cell data clearly indicate that mtorc1 phosphorylates uvrag at two distinct sites. the domain structure of uvrag is represented in fig4b with an alignment of human uvrag residues 540–582, the region where phosphorylated serines were identified. both s550 and s571 residues are positioned with a +1 leucine that is favourable for mtor-mediated phosphorylation (hsu et al, 2011) and are well conserved across higher eukaryotes, further supporting that these are mtor sites.",pmc4585463,1,1,40,1,41
63,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,phb,protein,,phb,uniprot,p15379,mitochondria,go:0005739,positive,d,phosphorylation,,,bc,breast,human,['1848'],nan,nan,"the purpose of this study was to investigate the role of akt in phb-induced cell proliferation in human bc tissue and cultured cells. this study is the first to show that endogenous akt has the ability to phosphorylate phb, thereby inducing bc cell proliferation, introducing a new molecular mechanism to study and target in bc.",pmc4669803,1,1,40,1,41
684,mtor,protein,kinase,,uniprot,p42345,cytoplasm,go:0005737,uvrag,protein,,,uniprot,q9p2y5,cytoplasm,go:0005737,positive,d,phosphorylation,autophagy-activating ulk1 complex,,,,human,['2556'],nan,nan,"a lysosomal trafficking pathway that is altered by mtor inhibition is that of macroautophagy, being strongly induced at least in part by removal of inhibitory mtor phosphorylation sites on the autophagy-activating ulk1 complex (ganley et al, 2009; hosokawa et al, 2009; jung et al, 2009). the role of uvrag in autophagy is debatable, with studies showing both a positive role (liang et al, 2006) and no role (itakura et al, 2008; knævelsrud et al, 2010; jiang et al, 2014). given the nature of the uvrag-mtor-mediated phosphorylation, it would be expected not to play a role in autophagy induction, though it is possible that it may play a role in fusion and clearance of mature autophagosomes. to analyse this, we used the classical lc3 flux assay to look at the increase in lc3-ii upon lysosomal inhibition (with bafilomycin a1) under normal conditions or autophagy inducing mtor inhibition (with ebss). we found that loss of uvrag in the sirna-resistant gfp-uvrag-expressing cells, either wt or dbla, had no significant effect on lc3 flux under control conditions or short-term autophagy induction with ebss (fig7e and f). thus, as expected, similar to endosome trafficking, autophagy induction and autophagosome trafficking to lysosomes do not require uvrag phosphorylation.",pmc4585463,1,1,40,1,41
683,mtor,protein,kinase,,uniprot,p42345,cytoplasm,go:0005737,tfeb,protein,transcription factor,tfeb,uniprot,o14929,nucleus,go:0005634,negative,d,regulates nuclear localization,,,,,,['2881'],nan,nan,during pharmacological mtor inhibition the proteasome negatively regulates nuclear localization of tfeb,pmc4896000,1,1,40,1,41
784,p21,protein,,cdkn1a,uniprot,p38936,cell nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,cell nucleus,go:0005634,positive,d,phosphorylation,"s130 phosphorylation, t172 phosphorylation",,,,human,['1122'],nan,nan,"in vitro, s130 phosphorylation of p21 was performed not only by cyclin e/a-cdk2 complexes, but also by cdk4 and cdk6 associated with cyclin d1 and cyclin d3. in vivo, both s130 phosphorylation of p21 and t172 phosphorylation of p21-bound cdk4 were inhibited not only in response to cdk7 inhibition, but also in response to increased p21 expression and inhibition of cdk2 (by roscovitine and cr8) and cdk4/6 (by pd0332991). inhibition of cdk4 phosphorylation by roscovitine and pd0332991 depended on p21.",pmc3667761,1,1,40,1,41
837,p70 s6 kinase,protein,,rps6kb1,uniprot,p23443,cell,go:0005623,rictor,protein,,,uniprot,q6r327,cell,go:0005623,positive,d,phosphorylation,t1135,,,,human,['1271'],nan,nan,"to further complicate matters julien et al 37. suggests an even more intriguing role for p70 s6 kinase. they propose that the activation of p70 s6 kinase via mtorc1 results in the phosphorylation of rictor, a component of mtorc2, on t1135 and this in turn signals increased akt and gsk3α/β phosphorylation.",pmc3187934,1,1,40,1,41
681,mtor,protein,kinase,,uniprot,p42345,cytoplasm,go:0005737,fkbp12,protein,enzyme,fkbp1a,uniprot,p62942,cytoplasm,go:0005737,negative,i,inhibition,fkbp12-rapamycin binding,,,,human,['1431'],nan,nan,"mtor belongs to the phosphatidylinositol 3-kinase (pi3k) kinase-related kinase (pikk) superfamily as the catalytic domain of pi3k has strong homology with the c-terminus of mtor [11]. it consists of 2549 amino acids and several conserved domain structures. tandemly repeated heat (for huntingtin, elongation factor 3 (ef3), a subunit of pp 2a, and tor) motifs comprise its first 1200 amino acids [12]. these tandem heat repeats create a superhelical structure with large interfaces that facilitates protein-protein interaction. a fat (frap, atm, and trrap) domain lies downstream the heat repeat region which is followed by an fkpb12-rapamycin binding (frb) domain. rapamycin binds to fk506 binding protein 12 (fkbp12), thereby inhibiting its enzymatic activity as prolylisomerase, and this rapamycin-fkbp12 complex then binds to the frb domain of mtor and inhibits its activity [10]. the frb domain is followed by a catalytic kinase domain (kd), an autoinhibitory or repressor domain (rd domain), and a fat carboxy-terminal (fatc) domain (figure 1). the fatc domain is crucial for the kinase activity of mtor since deletion of even a single amino acid from this domain inhibits mtor kinase activity. the fat domain interacts with the fatc region and this interaction between the two domains might expose the catalytic domain, thus regulating the kinase activity of mtor [13].",pmc4258317,1,1,40,1,41
680,mtor,protein,kinase,mtor,uniprot,p42345,lysosome,go:0005764,uvrag,protein,,uvrag,uniprot,q9p2y5,lysosome,go:0005764,positive,d,phosphorylation,"s550, s571",,,,human,['2534'],nan,nan,"lysosomes are essential organelles that function to degrade and recycle unwanted, damaged and toxic biological components. lysosomes also act as signalling platforms in activating the nutrient-sensing kinase mtor. mtor regulates cellular growth, but it also helps to maintain lysosome identity by initiating lysosomal tubulation through a process termed autophagosome-lysosome reformation (alr). here we identify a lysosomal pool of phosphatidylinositol 3-phosphate that, when depleted by specific inhibition of the class iii phosphoinositide 3-kinase vps34, results in prolonged lysosomal tubulation. this tubulation requires mtor activity, and we identified two direct mtor phosphorylation sites on uvrag (s550 and s571) that activate vps34. loss of these phosphorylation sites reduced vps34 lipid kinase activity and resulted in an increase in number and length of lysosomal tubules. in cells in which phosphorylation at these uvrag sites is disrupted, the result of impaired lysosomal tubulation alongside alr activation is massive cell death. our data imply that alr is critical for cell survival under nutrient stress and that vps34 is an essential regulatory element in this process.",pmc4585463,1,1,40,1,41
679,mtor,protein,kinase,mtor,uniprot,p42345,cytoplasm,go:0005737,hexokinase ii [hk ii],protein,enzyme,hk2,uniprot,p52789,mitochondria,go:0005739,negative,d,inhibition,,,tumor,,human,['2255'],nan,nan,a proposed mechanism switching from glycolysis to mitochondrial oxidative phosphorylation by mtor-mediated hexokinase ii [hk ii] inhibition in tumor cells under genotoxic stress condition created by ionizing radiation (ir).,pmc4373728,1,1,40,1,41
828,p53,protein,transcription factor,tp53,uniprot,p04637,nucleus,go:0005634,pi 3-kinase,enzyme,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,negative,i,phosphorylation,mdm2,rat-1,fibroblast,,,['512'],nan,nan,"the p53 transcription factor, which is a major regulator of cell proliferation and survival, can also be affected by pi 3-kinase signaling. p53 is typically activated in response to dna damage, which results in stabilization of p53 and induction of target genes that induce cell cycle arrest and apoptosis.24, 25, 26, 27 pi 3-kinase/akt signaling can impinge on the regulation of p53 via phosphorylation of mdm2, the ubiquitin ligase that targets p53 for proteasomal degradation.28, 29 in this study, we therefore sought to determine whether p53 had a role in the cellular response to inhibition of pi 3-kinase signaling by comparing the effects of pi 3-kinase inhibition in rat-1 cells (which express wild-type p53) to transfected cell clones stably-expressing a dominant-negative p53 mutant.",pmc3481126,1,1,40,1,41
827,p53,protein,transcription factor,tp53,uniprot,p04637,nucleus,go:0005634,h1.2,protein,linker histone,hist1h1c,uniprot,p16402,nucleus,go:0005634,positive,d,complex formation,promoter region,,,,human,['3305'],nan,nan,"a direct interaction between p53 c-terminal domain and h1.2 c-terminal tail has been well-illustrated for the stable localization and action of the h1.2 complex at p53 target genes (kim et al 2008). thus, a plausible explanation for the transcription/modification results is that p300-mediated acetylation of p53 could perturb p53-h1.2 interaction at the promoter region. this possibilitywas investigated by a series of interaction studies. recombinant h1.2 formed a stable complex with glutathione s-transferase (gst)-p53 fusion proteins pre-bound to glutathione-sepharose beads (figure 1d, lane 3). p53 interaction with h1.2 was dependent upon its c-terminal region, because h1.2 was not precipitated from the reaction by gst-p53 1-363, in which the c-terminal 30 residues were deleted (lane 4). the specificity of these in vitro interactions was confirmed by the failure of h1.2 to bind to gst alone (lane 2). when binding experiments were repeated with or without p300-mediated preacetylation of p53, we detected a remarkable binding preference of h1.2 for the unacetylated p53 over the acetylated p53 (figure 1e). moreover, in similar binding experiments using synthetic peptides derived from the p53 c-terminal domain (amino acids 364-393), the unacetylated peptides showed a distinct binding to h1.2, but the p53 peptides bearing acetylations at k373, k381 and k382 showed a markedly lower affinity to h1.2 (figure 1f).",pmc3330162,1,1,40,1,41
701,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,eif4g,protein,,eif4g1,uniprot,q04637,cytoplasm,go:0005737,negative,d,binds,,,,,,['756'],nan,nan,"since mtor signaling is known to positively regulate cap-dependent translation initiation, we further analyzed the effects of rad001 and bez235 combination on the cap binding of eif4e and eif4g (e.g., eif4f assembly) with the m7gtp-sepharose pull down assay. as presented in fig. 5b, rad0001 and bez235 alone reduced the amounts of eif4g that interacted with eif4e. however, the combination of rad001 and bez235 was much more effective that either agent alone in decreasing the amounts of eif4g binding to eif4e. theses results clearly indicate that the combination of rad001 and bez235 exerts enhanced effects on suppressing the cap binding of eif4e and eif4g or eif4f assembly.",pmc3114848,1,1,40,1,41
702,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,foxo1,protein,,foxo1,uniprot,q12778,nucleus,go:0005634,positive,i,turnover,,,cancer,,human,['581'],nan,nan,"earlier studies have shown that macroautophagy is a constitutively activated process6,7,34,35. it was believed that macroautophagy was activated during the first hours of serum deprivation but then gradually returned to basal levels. if starvation continued beyond that time, the decrease in macroautophagy was concomitant with a progressive increase in chaperone-mediated autophagy (cma), which benefitted cell survival35. in cma-deficient cells, the high rates of sustained protein degradation in response to serum starvation were offset by upregulation of macroautophagy34. it is known that mtor, an important autophagy repressor, is reactivated by the degradation of autolysosomal products in a dynamic manner7. upon mtor reactivation, tubules extend from autolysosomal membranes and give rise to vesicles that ultimately form functional lysosomes7. consistent with previous reports, we also found that autophagy decreased after long-term glutamine starvation treatment (figure 1), which suggests that even in cancer cells autophagy is a dynamic process. furthermore, foxo1 turnover may be an important factor used by cancer cells to control the autophagic process that occurs in response to glutamine starvation.",pmc3616429,1,1,40,1,41
813,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,h1.2,protein,,hist1h1c,uniprot,p16403,nucleus,go:0005634,positive,d,modification,t146,u2os,osteosarcoma,bone,human,['3310'],nan,nan,"given the combinatorial effects of p53 acetylation and h1.2 phosphorylation on p53 transactivation, we investigated a possible alteration of these modifications in u2os cell line after etoposide treatment for 0, 15, 30 or 60 min. as determined by western blotting of extracts, a significant increase in p53 acetylation in response to the etoposide-induced dna damage was observed over 60 min time period (figure 4a, acp53). since etoposide treatment only modestly increased p53 protein levels (p53), p53 acetylation may be an early event in the dna damage response. in western blotting with h1 phospho t146 antibody, a rapid phosphorylation of h1.2 at t146 was detected within 15 min following etoposide treatment and returned to the baseline by 60 min (figure 4b). because the observed changes in p53 and h1.2 modifications were recapitulated with dna damage induced by another dna damage reagent, bleomycin, these modifications may be functional in cellular response to diverse damaging agents (supplementary figure 3). likewise, immunostaining experiments showed that etoposide treatment of u2os cells leads to a progressive increase in the level of acetylated p53 in the nucleus (figure 4c, acp53). in parallel experiments in which changes in h1.2 phosphorylation were analyzed over the same time period, the highest intensity of staining for h1.2 phosphorylation was scored at 15 min time point and gradually decreased thereafter (figure 4d, pt146). these data imply that p53 and h1.2 are modified in a sequential manner upon dna damage, with h1.2 phosphorylation followed by p53 acetylation. in all cases, there were a rather modest increase in p53 protein level (figure 4c, p53) and no detectable change in h1.2 protein level (figure 4d, h1.2) in response to dna damage.",pmc3330162,1,1,40,1,41
733,mtor,protein,,,uniprot,p42345,cytoplasm,go:0005737,p130cas,protein,,bcar1,uniprot,p56945,cytoplasm,go:0005737,negative,d,inhibition,,,tumor,various,human,['3271'],nan,nan,"clinical trials have demonstrated that rapamycin and its analogs (cci-779, rad001 and ap23573) (termed rapalogs) are promising anticancer drugs. they share same mechanism and specifically block the function of mtor, inhibiting growth of numerous solid tumors (renal, breast, prostate, colon and brain cancers) with only mild side effects [20]. intensive studies have focused on the crucial roles of mtor in controlling cell proliferation, growth and survival. recently this laboratory and others have further revealed its pivotal role in regulating cell migration [21]–[26]. we found that rapamycin suppresses igf-1 stimulated f-actin reorganization and migration in various tumor cell lines by inhibiting mtorc1-mediated 4e-bp1 and s6k1 pathways [23]. this is in part associated with rapamycin inhibition of phosphorylation of the focal adhesion proteins (fak, paxillin and p130cas) [24].",pmc2868031,1,1,40,1,41
814,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,h1.2,protein,,hist1h1c,uniprot,p16403,nucleus,go:0005634,positive,d,"phosphorylation, acetylation",,h1299,epithelial,lung,human,['3313'],nan,nan,"based on our findings that p53 acetylation and h1.2 phosphorylation are key events in p53-mediated transactivation, we explored whether these modifications coordinately regulate cell growth and apoptosis. in our clonogenic assays, h1299 cells displayed a reduced ability to form colonies after transfection of wild type p53 or acetylation mimicking mutant p53 (3kq), as compared with empty vector-transfected cells (figure 5a, assays 2 and 3 versus assay 1). by contrast, the observed reduction in colony formation could not be recapitulated by transfection of the h1.2 core complex (assays 4 and 5). consistent with the transcription results indicating h1.2-induced repression of p53 activity, simultaneous expression of wild type p53 and the h1.2 core complex increased the rate of colony formation similar to that observed in the empty vector-transfected cells (assay 6). notably, however, when wild type h1.2 in the core complex was replaced by phosphorylation mimicking mutant h1.2 (t146e), colony numbers were decreased back to those obtained by transfection of p53 alone (assay 7). likewise, transfection of cells with acetylation mimicking mutant p53 (3kq) decreased cell proliferation in all cases, regardless of whether wild type or mutant h1.2 is cotransfected (assays 8 and 9).",pmc3330162,1,1,40,1,41
729,mtor,protein,,mtor,uniprot,p42345,,,tfeb,protein,,tfeb,uniprot,o14976,nucleus,go:0005634,positive,d,activation,,"hela, mcf7",,,human,['2842'],nan,nan,"mtor was activated by renewed addition of fully-supplemented medium, or inhibited by torin1 or nutrient deprivation. single-cell tfeb protein levels and subcellular localization in hela and mcf7 cells were measured over a time course of 15 hours by multispectral imaging cytometry. to extract single-cell level information on heterogeneous tfeb activity phenotypes, we developed a framework for identification of tfeb activity subpopulations. through unsupervised clustering, cells were classified according to their tfeb nuclear concentration, which corresponded with downstream lysosomal responses.",pmc4896000,1,1,40,1,41
727,mtor,protein,,mtor,uniprot,p42345,,,hk ii,protein,,hk2,uniprot,p52732,mitochondria,go:0005739,positive,d,binds,,mcf-7,epithelial-like,breast,human,['2250'],nan,nan,"(a) co-immunoprecipitation of mtor and hk ii of mcf-7 cells treated with sham, ir with or without rapamycin. cells were collected 24 h post-ir and igg replaced anti-mtor as a control. (b) hk ii activity was measured in mcf-7 cells with the same treatment. (c) hk activity and mitochondrial atp were measured in mcf-7 cells treated with sham, 24 h post-ir with dmso and 24 h post-ir with the hk ii inhibitor 3-brpa. (d) co-immunoprecipitation of hk ii and mnsod in mcf-7 cells treated with sham, 24 h post-ir, and 24 h post-ir with rapamycin pre-treatment. mnsod activity was measured in mcf-7 cells at 24 h post-ir and 24 h post-ir with rapamycin. data are mean ± sem, p-values were included in each data.",pmc4373728,1,1,40,1,41
725,mtor,protein,,mtor,uniprot,p42345,mitochondria,go:0005739,hk ii,protein,,hk2,uniprot,p52789,mitochondria,go:0005739,positive,d,inhibition,mitochondria,mouse breast cancer 4t1 cells,epithelial-like,breast,mouse,['2251'],nan,nan,"this interaction, which is important for mitochondrial function enhancement, was also tested in mouse breast cancer 4t1 cells. co-ip showed that the mtor/hk ii complex did not form at 24 h post-irradiation in 4t1 cells (s6 fig.), a finding in accordance with the lack of a radiation-induced switch in bioenergetics for these cells. thus, these result suggest that the mtor/hk ii interaction is required for promoting mitochondrial function in cancer cells and the regulation of mtor on hk ii is a key factor for the switch. to examine this possibility we measured hexokinase activity to determine the regulation of mtor on hk ii after 5 gy (fig. 6b). we found that hexokinase activity decreased at 24 h post-irradiation, when mtor interacted with hk ii, suggesting that mtor-mediated inhibition of hk ii may act as a biochemical switch of bioenergetics. to confirm that the inhibition of hk ii controlled the switch, we treated mcf-7 cells with the hk ii inhibitor, 3-brpa (fig. 6c). 3-brpa can prevent the binding of hk ii to mitochondria and inhibit the ability of hk ii to phosphorylate glucose. we found that hk ii activity was decreased at 24 h post-irradiation and further reduced by 3-brpa treatment. the increase of mitochondrial atp production was in accordance with the results obtained by rapamycin treatment in mcf-7 cells.",pmc4373728,1,1,40,1,41
724,mtor,protein,,mtor,uniprot,p42345,mitochondria,go:0005739,hk ii,protein,,hk2,uniprot,p52789,cytoplasm,go:0005737,negative,d,inhibiting,,,tumor,,human,['2257'],nan,nan,"in summary, this work provides the evidence supporting a unique metabolic mechanism by which tumor cells can quickly shift their major energy metabolism from the aerobic glycolysis to mitochondrial respiration by relocating mtor to mitochondria and inhibiting hk ii activity. the inhibition of hk ii function can slow down the aerobic glycolysis and increase oxphos activity which is required to increase tumor cell survival under genotoxic stress conditions. the dynamics of tumor cell bioenergetics under genotoxic stress conditions, especially the mtor-mediated inhibition of glycolysis in tumor adaptive resistance needs to be further investigated.",pmc4373728,1,1,40,1,41
815,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,histone h1.2,protein,histone,hist1h1c,uniprot,p16402,nucleus,go:0005634,positive,d,translocation,mitochondria,,,,human,['48'],nan,nan,"in cells exposed to ir, p53 and histone h1.2 were also found to translocate to the mitochondria where they directly induced apoptosis. this event was markedly reduced in chk2-deficient cells due to defective p53 stabilization (chen et al., 2005a).",pmc4296918,1,1,40,1,41
723,mtor,protein,,mtor,uniprot,p42345,mitochondria,go:0005739,hexokinase ii [hk ii],protein,,hk2,uniprot,p52789,mitochondria,go:0005739,positive,d,complex formation,mitochondria,,tumor,,human,['2238'],nan,nan,"a unique feature of cancer cells is to convert glucose into lactate to produce cellular energy, even under the presence of oxygen. called aerobic glycolysis [the warburg effect] it has been extensively studied and the concept of aerobic glycolysis in tumor cells is generally accepted. however, it is not clear if aerobic glycolysis in tumor cells is fixed, or can be reversed, especially under therapeutic stress conditions. here, we report that mtor, a critical regulator in cell proliferation, can be relocated to mitochondria, and as a result, enhances oxidative phosphorylation and reduces glycolysis. three tumor cell lines (breast cancer mcf-7, colon cancer hct116 and glioblastoma u87) showed a quick relocation of mtor to mitochondria after irradiation with a single dose 5 gy, which was companied with decreased lactate production, increased mitochondrial atp generation and oxygen consumption. inhibition of mtor by rapamycin blocked radiation-induced mtor mitochondrial relocation and the shift of glycolysis to mitochondrial respiration, and reduced the clonogenic survival. in irradiated cells, mtor formed a complex with hexokinase ii [hk ii], a key mitochondrial protein in regulation of glycolysis, causing reduced hk ii enzymatic activity. these results support a novel mechanism by which tumor cells can quickly adapt to genotoxic conditions via mtor-mediated reprogramming of bioenergetics from predominantly aerobic glycolysis to mitochondrial oxidative phosphorylation. such a “waking-up” pathway for mitochondrial bioenergetics demonstrates a flexible feature in the energy metabolism of cancer cells, and may be required for additional cellular energy consumption for damage repair and survival. thus, the reversible cellular energy metabolisms should be considered in blocking tumor metabolism and may be targeted to sensitize them in anti-cancer therapy.",pmc4373728,1,1,40,1,41
722,mtor,protein,,mtor,uniprot,p42345,lysosome,go:0005766,uvrag,protein,,uvrag,uniprot,q9upq6,lysosome,go:0005766,positive,i,phosphorylation,,,,tubule,,['2565'],nan,nan,"mtor acts at a secondary step via phosphorylation of uvrag to increase formation of lysosomal pi(3)p that appears to be critical for tubule scission, a process regulated by the gtpase dynamin.",pmc4585463,1,1,40,1,41
719,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,tfeb,protein,transcription factor,tfeb,uniprot,q92934,nucleus,go:0005634,negative,i,inhibition,,,,,,['2884'],nan,nan,"actd, actinomycin d; epox, epoxomicin; fm, fresh, fully-supplemented medium; isx, imagestreamx imaging flow cytometer; lamp1, lysosomal-associated membrane protein 1; mtor, mammalian target of rapamycin; nd, nutrient deprivation; nt, non-treated; spade, spanning-tree progression analysis of density-normalized events; tfeb, transcription factor eb; wf, wide field imaging",pmc4896000,1,1,40,1,41
718,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,tfeb,protein,,tfeb,uniprot,q9bxm7,nucleus,go:0005634,positive,i,regulation,,"hela, mcf7",epithelial-like,,human,['2858'],nan,nan,"taken together, isx-based analysis of mean population responses support western blot findings, wherein mtor inhibition by torin1 increases tfeb protein levels in hela (figs. 2e and 3c) as well as in mcf7 cells (fig. 3e). conversely, addition of fresh fm, to mildly increase mtor activity (fig. 1d), led to a slight, but significant, reduction in tfeb levels (figs. 2b and 3c, e). furthermore, these results indicate that changes in tfeb protein levels correlate with significant shifts of tfeb between nuclear and cytoplasmic compartments.",pmc4896000,1,1,40,1,41
717,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,tfeb,protein,,tfeb,uniprot,q92934,nucleus,go:0005634,negative,d,control,,hela and mcf7,epithelial-like,lung,human,['2876'],nan,nan,"here we investigated the relationship between modulations to mtor activity and the consequent changes to localization and concentration of tfeb in hela and mcf7 cells. we report the novel findings that mtor exerts a rapid, time-limited rheostat control on tfeb subcellular localization and protein levels (see fig. 8). during the period of 0.5 to 1.5 hours following perturbation, mtor activation decreased tfeb protein levels and increased tfeb cytoplasmic retention. conversely, in response to mtor inhibition by either torin1 or nutrient deprivation, during this period, tfeb protein levels rapidly increased concurrent to enhanced accumulation of tfeb in the nucleus. surprisingly, this effect was limited in duration to a period of 3 hours, and during the period of 3 to 15 hours, tfeb concentrations and subcellular distributions returned towards basal levels for all conditions, evidencing homeostatic regulatory mechanisms dependent and independent of mtor. while we show that mtor activation maximally inhibits tfeb, mtor inhibition only fractionally activated tfeb. furthermore, our findings indicate that erk signaling exerts a negligible inhibitory effect on tfeb under nutrient deprivation and torin1 conditions, and instead indicate a role for proteasome degradation pathways in the regulation of tfeb subcellular localization (see fig. 8) independent of tfeb levels.",pmc4896000,1,1,40,1,41
716,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,tfeb,protein,,tfeb,uniprot,q6zmq7,nucleus,go:0005634,negative,d,phosphorylation,,hela,epithelial-like,cervix,human,['2852'],nan,nan,"characterization of the effect of torin1 and fresh nutrients on mtor and endogenous tfeb. a schematic representation of the effects of torin1 and fresh fully-supplemented medium (fm) on the regulation of tfeb by mtor. b dose-response of the effect of torin1 on mtor activity. hela cells were treated with fm containing the indicated concentrations of torin1, or kept in culture medium (non-treated, nt), for 1.5 or 3 hours, and phosphorylation of the mtor substrates 4e-bp1 and p70-s6k1 was measured by western blotting. c quantification of the ratio of phosphorylated 4e-bp1 (p-4e-bp1) to total 4e-bp1. graphs display mean values of three independent experiments normalized to nt values. error bars denote mean ± sd of three independent experiments. statistical significance was tested vs. nt conditions (student’s two-tailed t-test; **, p ≤ 0.01; ***, p ≤ 0.001). d immunofluorescence of tfeb and p-4e-bp1, as a read-out for mtor activity, in response to fm and torin1. hela cells were kept in culture medium (non-treated, nt), treated with fresh fm, or with fm supplemented with torin1 (2 μm) for 3 hours and immunostained for tfeb and p-4e-bp1. to reveal varying intensity levels the look-up-table ‘fire’ (imagej) was applied to grey scale images, representing intensity values ranging from low (dark purple) to high (white) as displayed in color scale bar. scale bars, 20 μm",pmc4896000,1,1,40,1,41
715,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,tfeb,protein,,bscl2,uniprot,q9gzv5,nucleus,go:0005634,positive,i,phosphorylation,,hela,epithelial,,human,['2851'],nan,nan,"we first established conditions for suppressing mtor activity with the specific inhibitor torin1 [13], and increasing mtor activity by the renewed addition of fully-supplemented medium (fm) (illustrated in fig. 1a). torin1-mediated tfeb activation has been reported for concentrations ranging from 0.25 μm [5, 6, 9] to 2 μm [7]. thus, we treated hela cells with 0.25 to 2 μm torin1 for 1.5 and 3.0 hours, and determined the phosphorylation state of the mtor substrates 4e-bp1 and p70-s6k1 by western blot. maximal inhibition of 4e-bp1 and p70-s6k1 phosphorylation was achieved in response to 2 μm after 3 hour treatment (fig. 1b, c). high-resolution imaging further demonstrated that at 3 hours of treatment with 2 μm torin1, immunofluorescence detection of phosphorylated 4e-bp1 was fully suppressed, and nuclear accumulation of tfeb was potently induced (fig. 1d). interestingly, total cellular tfeb immunofluorescence appeared strongly increased under torin1 treatment, suggesting that mtor inhibition increased tfeb protein levels. of note, the addition of fresh fm resulted in an increased immunofluorescence signal of phosphorylated 4e-bp1, indicating mtor activation by the replenished metabolic substrates and growth factors present in fresh fm. consistent with increased mtor activity, tfeb was predominantly retained in the cytoplasm under fresh fm conditions.",pmc4896000,1,1,40,1,41
713,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,rictor,protein,,rictor,uniprot,q6r327,cytoplasm,go:0005737,positive,d,forming complex,,,,,,['766'],nan,nan,"mtor exerts its critical roles in promoting cell cycle progression and cell proliferation primarily through interactions with other proteins such as raptor (forming mtorc1) and rictor (forming mtorc2) [18], [20]. mtorc2 is generally thought to be insensitive to rapalogs [18]. however, prolonged treatment with these mtor inhibitors disrupts the assembly of the mtorc2 as demonstrated by us [9] and others [21]. in this study, after a 24 h treatment, rad001, but not bez235, effectively inhibit the assembly or activity of both mtorc1 and mtorc2. the combination of rad001 and bez235 did not further reduce the levels of raptor and rictor in the immunoprecipitates (fig. 6), demonstrating that the combination does not display enhanced effects on inhibiting the assembly of mtorcs. based on these observations, we speculate that the enhanced effects on suppression of the mtor signaling by the combination is likely due to their distinctive effects on inhibiting the mtorc assembly and mtor kinase activity. it is generally believe that a synergy is achieved through a corporation of two drugs functioning via distinct mechanisms. since bez235 effectively inhibits the growth of the rapamycin-resistant cells, it is also possible that the synergy between rad001 and bez235 against the growth of lung cancer cells occurs through an unknown mechanism of bez235, which needs further investigation.",pmc3114848,1,1,40,1,41
712,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,rictor,protein,,,uniprot,q6r327,cytoplasm,go:0005737,negative,d,assembly,,,,,human,['758'],nan,nan,"it is known that the assembly or association of the mtor with its partners (e.g., raptor and rictor) is essential for distinct enzyme activities and biological functions. rad001, like rapamycin, suppresses mtor signaling by inhibiting the assembly of the mtorcs [16]. thus, we further determined whether the combination of rad001 and bez235 exerted enhanced inhibitory effects on the assembly of the mtorcs including mtorc1 (mtor/raptor) and mtorc2 (mtor/rictor). to this end, we did immunoprecipitation (ip) with anti-mtor antibody to pull down both mtorc1 and mtorc2 and then followed with western blotting to detect raptor and rictor in the immunoprecipitates. as presented in fig. 6, bez235 had minimal effects on reducing the levels of raptor and rictor in the immunoprecipitates, whereas rad001 substantially reduced the levels of both raptor and rictor pulled down by mtor antibody. the combination of rad001 and bez235 had similar potency to rad001 alone in reduction of the levels of raptor and rictor in the immunoprecipitates, indicating that the combination does not exhibit enhanced effects on inhibiting the assembly of mtorc1 and mtorc2.",pmc3114848,1,1,40,1,41
711,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,rheb,protein,small gtpase,rheb,uniprot,q15382,cytoplasm,go:0005737,positive,d,modifies localization and nature of interaction,,,unknown,,,['3327'],nan,nan,amino acid starvation modifies the localization and the nature of the direct interaction of mtor with rheb,pmc3549280,1,1,40,1,41
703,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,hexokinase ii,protein,,hk2,uniprot,p52789,mitochondria,go:0005739,negative,d,inhibiting,,,,,,['2249'],nan,nan,mitochondrial adaptive bioenergetics response was blocked by inhibiting the interaction of mtor/hexokinase ii [hk ii].,pmc4373728,1,1,40,1,41
102,akt,protein,,akt1,uniprot,p31749,plasma membrane,go:0005886,abcg2,protein,,abcg2,hgnc,956,plasma membrane,go:0005886,negative,d,inhibition,plasma membrane,,cscs,glioblastomas,human,['794'],nan,nan,"in the sps of both mouse and human glioblastomas (that are enriched in cscs), akt inhibition by the synthetic alkylphosphocholine, perifosine, lowered abcg2 expression on the plasma membrane and decreased efflux of mitoxantrone, another abcg2 substrate [119]. a similar phenomenon has been reported in the sp of a hcc cell line, mhcc97l [120]. akt inhibition by the small molecule a-443654 inhibited the growth of cscs from glioblastoma cell lines [121].",pmc3837323,1,1,40,1,41
122,akt,protein,ser/thr protein kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,foxo1,protein,,foxo1,uniprot,q12778,nucleus,go:0005634,positive,d,phosphorylation,,,,,,['2279'],nan,nan,"in response to growth signals, the ser/thr protein kinase akt phosphorylates a wide array of substrates including bad, tsc2, and foxo1 to inhibit apoptosis and promote survival.9 the main intracellular pathway responsible for nutrient sensing is centered on the mechanistic (formerly referred to as mammalian) target of rapamycin (mtor). mtor is a ser/thr protein kinase that serves as the catalytic subunit of two multi-protein complexes with distinct functions – mtor complexes 1 and 2 (mtorc1/2). mtorc1 is a pro-growth/survival kinase that is activated only when nutrients, such as glucose and amino acids, and growth factors are available in a cell’s microenvironment. once activated, mtorc1 phosphorylates p70s6k and 4ebp1 to promote cap-dependent translation and cell growth. growth factor-stimulated akt promotes mtorc1 activation through two pathways. in the first, akt phosphorylates and inhibits the gtpase-activating protein tsc2, thereby allowing the small gtpase rheb to remain gtp-bound and activate mtorc1 (ref. 10). the second depends upon the proline-rich akt substrate of 40kda (pras40). when in its non-phosphorylated form, pras40 binds the mtorc1 component raptor and is believed to inhibit mtorc1 kinase activity by competing for substrate binding. in response to growth factors, pras40 binds the scaffolding protein 14-3-3 in a phosphorylation-dependent manner and dissociates from raptor, thereby allowing mtorc1 access to its downstream effector substrates. interestingly, both akt- and mtorc1-mediated phosphorylation of pras40 are required for 14-3-3 binding in response to growth factors.11–19 the fate or function, if any, of mtorc1-dissociated, phospho-pras40 remains unknown.",pmc4216640,1,1,40,1,41
43,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,ha-npm,protein,,npm1,uniprot,p06748,nucleus,go:0005634,positive,d,phosphorylation,s48a,t24 cells,,,,['407'],nan,nan,"endogenous akt was immunoprecipitated from t24 cells, glycine eluted and combined with immunoprecipitated ha-npm, ha-npm-s48a or anti ha-ip from non-transfected cells as indicated in 1 × kinase buffer (cell signaling). the reaction was incubated with cold atp (20 μm) and radio-labeled gamma 32p atp (2 μm) at 37°c. the reaction was heat inactivated in the presence of denaturing sds-page sample buffer, separated by sds-page, western blotted and exposed to a phosphor screen. the membrane was additionally probed by standard western blot.",pmc4171619,1,1,40,1,41
395,egfr,protein,,erbb1,uniprot,p00533,plasma membrane,go:0005886,stat5b,protein,,stat5b,uniprot,p51692,nucleus,go:0005634,positive,d,activation,y845 phosphorylation,mcf7,breast cancer,breast,human,['1420'],nan,nan,"in colon carcinoma cells (ht29 and sw480) and breast cancer cells (mcf-7), homophilic ligation of e-cadherin and its interaction with β-catenin are reported to be inhibitory to cell growth by reducing the frequency of cells entering s phase [157]. in this system, inhibition of egfr signaling involving y845 phosphorylation, but not egfr autophosphorylation, and stat5-dependent signal transduction, but not erk/mapk activation, are critical. intracellular interaction between cas and src is also reported to be responsible for the activation of egfr signaling involving y845 phosphorylation and stat5b translocation to the nucleus that contribute to the tamoxifen-resistant proliferation and survival of mcf7 cells [158]. epithelial cell adhesion, migration, and wound healing in hydrogen peroxide-treated rabbit cornea also involve the y845 phosphorylation of egfr [159].",pmc3709701,1,1,40,1,41
383,egfr,protein,,egfr,uniprot,p00533,cell membrane,go:0005886,npm,protein,,npm1,uniprot,p06748,nucleus,go:0005634,positive,d,phosphorylation,s48,,tumor,"lung, pancreas, cervix, colon, breast",human,['391'],nan,nan,"(a) tissue micro array sections (us biomax) of both normal and tumor derived tissue from lung, pancreas, cervix, colon and breast were stained with ps48-npm. all images are 5 x magnifications and scale bars represent 200 μm. total numbers of samples analysed by automated aperio scanning and those with low, medium or high degrees of staining are shown in table 2. (b) (left) data from the breast tumor microarray demonstrating the degree of phospho-s48-npm staining in those cores annotated as egfr/her2 positive (low and high) or estrogen receptor (er) +ve. (right) phospho-s48-npm staining in cores scored low, medium or high for p53. (c) scatter plots demonstrating bivariate correlation of automated total ps48-npm and nuclear phospho-s473-akt staining in human pancreatic ductal adenocarcinomas (n=122, left), or cytoplasmic ps48-npm in samples with p53 positivity (n=81, right). below, representative images for comparison of variation in ps48-npmcyto scoring of pancreatic ductal adenocarcinoma tumor micro array sections.",pmc4171619,1,1,40,1,41
381,egf,protein,,,uniprot,p01133,,,enac,protein,,scnn1a,uniprot,p37088,,,negative,d,downregulation,py motif,,,,,['1769'],nan,nan,acute downregulation of enac by egf involves the py motif and putative erk phosphorylation site,pmc2151644,1,1,40,1,41
379,egf,protein,,,uniprot,p01133,extracellular region,go:0005576,rhoa,protein,,rhoa,uniprot,p61586,cytoplasm,go:0005737,positive,d,translocation,plasma membrane,,,,human,['1549'],nan,nan,"we also examined the effects of egf stimulation on the subcellular localization of endogenous rhoa. as shown in fig 8d & 8e, rhoa was mostly distributed in the cytoplasm without egf stimulation. following egf stimulation for 15 min, a significant amount of rhoa was translocated to the plasma membrane, but not to the nucleus.",pmc4729484,1,1,40,1,41
378,egf,protein,,,uniprot,p01133,extracellular,go:0005576,rhoa,protein,,rhoa,uniprot,p61586,plasma membrane,go:0005886,positive,d,phosphorylation,"serine, threonine",cos-7,fibroblast-like,kidney,monkey,['1535'],nan,nan,"(a) egf-induced serine and threonine phosphorylation of rhoa and mutants. cos-7 cells were transfected with expression constructs encoding gfp-rhoa and various gfp-rhoa mutants. the cells were stimulated with egf (50 ng/ml). gfp-rhoa/rhoa mutant proteins were immunoprecipitated with anti-gfp antibodies and the serine or threonine phosphorylation of gfp-rhoa was detected by immunoblotting with anti-p-ser or anti-p-thr antibodies. to confirm the gfp antibody captured protein is gfp-rhoa, the membranes with p-ser (shown in the panel) and p-thr blots were reprobed with anti-rhoa antibody. the expression level of gfp-tagged rhoa proteins was determined by immunoblotting of the total lysates with antibody to gfp (bottom panel). (b) the effects of mek inhibitor u0126 on egf-induced phosphorylation of erk. (c) the effects of mek inhibitor u0126 on egf-induced phosphorylation of rhoa proteins. the cos-7 cells were treated similar to the method described in (a), but with the addition of u0126. following ip of cell lysates with anti-gfp antibodies, the phosphorylation of gfp-rhoa and its various mutants was determined by immunoblotting with antibodies to p-ser and p-thr.",pmc4729484,1,1,40,1,41
376,egf,protein,,egf,uniprot,p01133,extracellular space,go:0005615,rhoa,protein,,rhoa,uniprot,p61586,plasma membrane,go:0005886,positive,d,phosphorylation,"ser, thr",cos-7,fibroblast-like,,human,['1536'],nan,nan,"we next examined whether egf-induced rhoa phosphorylation is mediated by erk in vivo. as a positive control, we verified that u0126, a mek inhibitor, blocked egf-induced erk phosphorylation in cos-7 cells (fig 3b). we then expressed gfp-rhoa and various mutants in cos-7 and stimulated the cells with egf in the presence of u0126. following ip of these expressed gfp-tagged proteins, the phosphorylation of these proteins was examined by immunoblotting with antibodies to p-ser and p-thr. as shown in fig 3c, inhibition of erk by u0126 blocked egf-induced phosphorylation of wild type and mutant rhoa, which suggested that egf-induced rhoa phosphorylation of both 88s and 100t is most likely mediated by erk.",pmc4729484,1,1,40,1,41
375,egf,protein,,egf,uniprot,p01133,extracellular,go:0005576,erlotinib,compound,,,pubchem,176870,cytoplasm,go:0005737,negative,d,treatment,,"dld-1, ht29",epithelial-like,colon,human,['622'],nan,nan,"(a) dld-1 cells grown in egf (50 ng/ml) containing medium were treated with erlotinib (2 μm) and pp242 (1 μm), alone or in combination, for the indicated hours and analyzed by western blotting for the indicated proteins (left). (b) dld-1 and ht29 cells were treated with pp242 (1 μm) and erlotinib (2 μm), alone or in combination, and then subjected to cell viability assay. the data were presented as mean + sd. **, p < 0.01. (c) colony formation assay of dld-1 cells, treated or untreated with pp242 (1 μm) and/or erlotinib (2 μm), shows the colony densities in culture wells. (d) the colony numbers from the colony formation assay as described above in c were accounted and presented as mean + sd. ns, no significance; **, p < 0.01.",pmc3750018,1,1,40,1,41
158,atm,protein,,atm,uniprot,q13315,nucleus,go:0005634,cdc25c,protein,,cdc25c,uniprot,p30307,nucleus,go:0005634,negative,d,inactivation,,,,,human,['3238'],nan,nan,"it is well recognized that ddr is intimately linked to cell division. one of the major tasks of atm and atr activation is to initiate checkpoint controls to halt cell cycle progression in order to coordinate the repair of dna lesions [1]. activation of checkpoints leads to the up-regulation of p21cip1 and the inactivation of cdc25c via activation of chk1 and chk2 [48, 1]. these events collectively inhibit the kinase activity of cdk1 and cdk2, leading to cell cycle arrest. therefore, inhibition of cdk activity or arrest of cell division is a downstream event of atm and atr. recent developments, however, demonstrated that cell division contributes more to ddr than only being a downstream event. cdk activity promotes the proper activation of atm and atr in response to dna damage [49, 50]. this may explain, at least in part, a long-term observation that malignant cells are more sensitive to genotoxic agents than cells in normal tissues [51]. direct evidence supporting this concept was the recent demonstration that directly blocking cell division via loss of cdc25 protected intestinal mucosa from damage induced by irinotecan, a commonly used chemotherapeutic/genotoxic agent in treating patients with colon cancer [52]. consistent with the theme that the mechanism regulating cell proliferation actively engages ddr, erk1 and erk2 kinases, also contributes to ddr via mechanisms that are dependent or independent on p53 as well as lying downstream of atm and atr or facilitates the activation of atm and atr.",pmc3330700,1,1,40,1,41
159,atm,protein,,atm,uniprot,q13315,nucleus,go:0005634,trf2,protein,,terf2,uniprot,q15554,telomere,go:0005694,negative,d,phosphorylation,,,,,human,['50'],nan,nan,"in the presence of dna damage, atm and chk2 phosphorylate trf2, reducing its affinity for telomeres (figure 3d; tanaka et al., 2005; buscemi et al., 2009), but whereas atm promotes trf2 relocalization from telomeres to the dna lesion, probably to enhance the protection and repair of the dsb, the functional significance of chk2 phosphorylation of trf2 is unclear.",pmc4296918,1,1,40,1,41
161,atm,proteinkinase,,atm,uniprot,q13315,,,chk2,proteinkinase,,chek2,uniprot,o96017,,,positive,i,phosphorylation,ser-gln (sq) and thr-gln (tq) motifs,,eukaryotic cell,,human,['2183'],nan,nan,"in response to genotoxic stress, eukaryotic cells activate conserved pathways that increase expression of many genes involved in cellular functions such as dna repair, cell-cycle arrest and cell death (12–14). protein kinases atm (ataxia-telangiectasia, mutated) and atr (atm and rad3-related) are emerging as potential sensors of dna damage. activated atm and atr phosphorylate downstream effector kinases including chk1 (checkpoint kinase 1) and chk2 (checkpoint kinase 2) for the damage-signaling cascade (15,16). atm and atr share consensus sites, the ser-gln (sq) and thr-gln (tq) motifs, and chk1/chk2 recognize the r–x–x–s/t motif. moreover, cabin1 is reported to have a putative atm-/atr-mediated phosphorylation site in response to uv irradiation (17). this fact prompted us to examine the possibility of cabin1 phosphorylation upon dna damage.",pmc3575827,1,1,40,1,41
22,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,klf4,protein,transcription factor,,uniprot,q8wuw1,nucleus,go:0005634,positive,d,phosphorylation,threonine 399,hek293a,epithelial,kidney,human,['845'],nan,nan,"like oct4 and sox2, klf4 also possesses a consensus akt phosphorylation site within a motif of r394krtat399. the finding that akt phosphorylates oct4 prompts us to check whether klf4 is also an akt substrate. to this aim, we co-expressed flag-gfp-oct4, flag-sox2 or flag-klf4 together with myc-akt in hek293a cells. co-immunoprecipitation showed that oct4 and klf4, but not sox2, associated with akt. akt phosphorylated oct4 and klf4, but not sox2, as detected with anti-phospho-akt substrate (figure 4a). we then mutated threonine 399 to alanine and carried out in vitro kinase assay. autoradiography indicated akt phosphorylated gst-klf4; however, under the same condition, akt failed to modify gst or gst-klf4t399a (figure 4b). to exclude the possibility that threonine 397 was phosphorylated by akt, using gst as a negative control and gst-satb1 1–204 a positive control, we found that akt phosphorylated threonine 399, rather than threonine 397 on klf4 (figure 4c). immunoprecipitation with anti-flag followed by immunoblotting with anti-phospho-akt substrate revealed that akt phosphorylated klf4, and that activated akt increased the phosphorylation signal, whereas dominant-negative akt decreased the signal (figure 4d). although wwp2 and trim24, two e3 ubiquitin ligases, seemed to promote degradation of oct4 and sox2, both of them did not affect the level of klf4 (figure s4c). using flag-wwp2 as a transfection control, we found that the expression level of the mutant t399a was higher than that of klf4 without mutation; whereas the expression level of the mutant t399e was much lower (figure 4e). like oct4, in comparison with wild-type and the t399a mutant, the mutation t399e significantly shortened the half-life of klf4 in response to chx treatment (figure 4f). hek293a cells were transfected with flag-tagged klf4 and his-tagged ubiquitin, serum starved and treated with or without ly294002 and/or mg132. ly294002 treatment reduced the amount of ubiquitinated klf4 (lane 1 versus lane 2), whereas mg132 treatment significantly increased ubiquitinated klf4 (lane 1 versus lane 3), which suggested that pi3k/akt signaling was required for ubiquitination and degradation of klf4 (figure 4g). in agreement to this observation, combined treatment with ly294002 and mg132 indicated that ly294002 compromised the effect of mg132 compared to treatment with mg132 alone (lane 3 versus lane 4) (figure 4g). taken together, these results reveal that akt phosphorylates klf4 at threonine 399, promoting klf4 ubiquitination and degradation.",pmc3675137,1,1,40,1,41
358,cyclin d1,protein,,ccnd1,uniprot,p24385,,,insulin,hormone,,ins,uniprot,p01308,,,positive,d,infected,,,,vein,mice,['1305'],nan,nan,"hyperinsulinemic euglycemic clamps were performed as previously reported with minor modifications35. mice were operated to implant an indwelling catheter in the right jugular vein seven days prior to study. four days before study, mice were infected with gfp or cyclin d1 t286a adenovirus by tail vein injection. following overnight fasting, mice were infused with a fixed amount of insulin (40 mu/kg/min) and a variable amount of 20% dextrose to maintain euglycemia. 3-[3h] glucose was included in the infusates in order to trace whole-body rates of glucose metabolism. whole-body glucose uptake was determined under steady-state conditions during the final 40 minutes of the clamp when exogenous glucose infusion and endogenous glucose production are in equilibrium with whole-body disposal. whole-body glucose disposal was calculated as the ratio of the 3-[3h]-glucose infusion rate and the specific activity of plasma glucose and hepatic glucose production represents the difference between the glucose infusion rate and whole-body uptake calculation.",pmc4076706,1,1,40,1,41
357,cyclin d1,protein,,ccnd1,uniprot,p24385,,,gsk3,protein,,gsk3a,uniprot,p49841,,,negative,d,protein degradation,,nsclc,,,human,['1573'],nan,nan,"in addition to translation regulation, cyclin d1 is known to be regulated at the posttranslational level through gsk3-dependent protein degradation [17, 18]. hence, we examined other two proteins, c-myc and mcl-1, known to be regulated by both cap-dependent translation and gsk3-dependent protein degradation mechanisms [5, 19, 20]. like cyclin d1, rapamycin reduced the levels of both c-myc and mcl-1 in 3 tested nsclc cell lines even early at 4 h post treatment (fig. 4c). the presence of sb216763 rescued the reduction of both c-myc and mcl-1 induced by rapamycin (fig. 4d). moreover, we tested the effects of another gsk3 inhibitor, chir99021, and gsk3 knockdown on rapamycin-induced reduction of cyclin d1, c-myc and mcl-1. in agreement with the findings using sb216763, both chir99021 (fig. 4e) and gsk3 knockdown (fig. 4f) rescued reduction of these proteins induced by rapamycin. thus, it is clear that rapamycin induces a gsk3-dependent reduction of cyclin d1, c-myc and mcl-1, likely independent of translation regulation.",pmc4496196,1,1,40,1,41
21,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,klf4,protein,transcription factor,klf4,uniprot,o43474,nucleus,go:0005634,positive,d,phosphorylation,,,embryonic stem cell,,human,['828'],nan,nan,"in the present study, we focused on a number of pluripotency/differentiation-regulating factors that have potential and conserved akt phosphorylation motifs. we identified several novel substrates of akt by using in vitro kinase assay, including oct4, klf4, bmi-1, mbd3, twist1, fbxw7 and satb1. based on preliminary data, considering the opponent effects of satb1 on the expression of nanog and klf4, we proposed that akt may phosphorylate the differentiation factor satb1 and the pluripotency factors oct4 and klf4 simultaneously or sequentially to change their abundance or conformation, thereby dictating stem cells to maintain the pluripotency status or enter the differentiation program. our data favors a model that akt facilitates the differentiation process through coordinated regulation of satb1 versus oct4/klf4, i.e. by boosting satb1 function yet attenuating oct4/klf4 activity. this conclusion is consistent to the fundamental function of akt as a survival kinase, whereby that activated akt gives rise to more progenies of stem cells would result in a partial loss of stemness in a population level.",pmc3675137,1,1,40,1,41
347,chk2 kinase,protein,kinase,chek2,uniprot,o96017,nucleus,go:0005634,sirt1,protein,deacetylase,sirt1,uniprot,q96eb6,nucleus,go:0005634,negative,d,inhibition,,,,,human,['2428'],nan,nan,"collectively, besides atm/atr, the activity of chk2 kinase is also required for dbc1-mediated sirt1 inhibition, ensuing acetylation/activation of p53, and finally apoptosis.",pmc4245943,1,1,40,1,41
346,chk2,protein,transducer kinase,chek2,uniprot,o96017,nucleus,go:0005634,atr,protein,,atr,uniprot,q13535,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['29'],nan,nan,"the other class of proteins, the transducer kinases, is involved in spreading of the dna damage signal through a phosphorylation cascade. two transducer kinases are known: chk2 for atm (matsuoka et al., 2000) and chk1 for atr (kumagai et al., 2004). they phosphorylate effector proteins, which are the executors of ddr functions and may also be phosphorylated by atm and atr and by other kinases. in this way, the transducer kinases enhance or redirect the atm-atr response.",pmc4296918,1,1,40,1,41
345,chk2,protein,,chk2,uniprot,o96017,nucleus,go:0005634,parp1,protein,,parp1,uniprot,p09874,nucleus,go:0005634,positive,i,repair,dna,,,,human,['43'],nan,nan,"these findings indicate that chk2, like other proteins (e.g. parp1, atm, atr, p53, blm, and brca2), is involved in different repair processes and underline the strong connection among repair pathways, which cooperate in the restoration of dna integrity.",pmc4296918,1,1,40,1,41
343,chk2,protein,,chk2,uniprot,o96017,nucleus,go:0005634,cdc25a,protein,,cdc25a,uniprot,p30307,nucleus,go:0005634,negative,d,degradation,,,es cells,embryo,human,['56'],nan,nan,"chk2 and other ddr proteins were found to be highly expressed in both human embryonic stem (es) and ips cells (momcilovic et al., 2010). this is coherent with the high repair efficiency detected in these cells and obtained essentially by hdr. overexpression of ddr proteins could also explain why cancer stem cells are resistant to radiation, an event that can be reversed by chk1 and chk2 inhibition (bao et al., 2006). indeed, in es cells, the g1 checkpoint is absent; accordingly, in these cells, chk2 was unable to induce cdc25a degradation (hong et al., 2007). on the other hand, apoptosis occurs more frequently in es than in somatic differentiated cells, perhaps as a safety mechanism to prevent the replication of a mutated genome (hong and stambrook, 2004).",pmc4296918,1,1,40,1,41
342,chk2,protein,,chk2,uniprot,o96017,cell nucleus,go:0005634,cdc25a,protein,,cdc25a,uniprot,p30307,cytoplasm,go:0005737,negative,d,phosphorylation,s79,mia paca-2,epithelial-like,pancreas,human,['3536'],nan,nan,"to exclude potential off-target effect of nsc109555, we further tested the effect of chk2 knockdown on gem-induced cell death in mia paca-2 cells. knockdown of chk2 by chk2-specific sirna completely reduced the level of chk2 in mia paca-2 cells (fig. 5a). under this condition, gem-induced accumulation of the chk2 phosphorylation (t68) and autophosphorylation (s516) was also abolished by chk2-sirna. consistent with nsc109555 treatment (fig. 3b), knockdown of chk2 suppressed the phosphorylation level of cdc25a (s79). the cytotoxic effect of gem was also assessed in mia paca-2 cells with chk2 knockdown. mia paca-2 cells, pre-treated with chk2-sirna or control-sirna for 48 hrs, were further incubated with a various concentrations of gem for 72 hrs and cell viability was determined by mtt assay. as shown in figure 5b, knockdown of chk2 by sirna sensitized the cells to gem. in addition, gem-induced parp cleavage and caspase-3/7 activity were enhanced in mia paca-2 cells treated with chk2-sirna than in mia paca-2 cells treated with control-sirna (fig. 5c and d). furthermore, analysis of annexin v/pi staining revealed an increase in early apoptotic cells (annexin v+/pi−) in mia paca-2 cells treated with chk2-sirna plus gem than in mia paca-2 cells treated with control-sirna plus gem (fig. 5e).",pmc4159025,1,1,40,1,41
341,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,trf2,protein,,terf2,uniprot,q15554,telomere,go:0000781,positive,d,phosphorylation,,in vitro,human,,human,['529'],nan,nan,"several studies have previously addressed the role of chk2 in the response to dysfunctional telomeres in vitro cultured human cells (thanasoula et al., 2012; cesare et al., 2013). thus, cesare et al. (2013) showed that telomere deprotection resuting from trf2 downregulation to levels that do not induce telomere–telomere fusions, results in p53-mediated g1 cell cycle arrest independently of chk2 phosphorylation. only when trf2 was fully abrogated leading to chromosome fusions, the authors observed chk2 phosphorylation (cesare et al., 2013). the authors concluded that very few trf2 molecules at telomeres are sufficient to prevent the nonhomologous end joining pathway (nhej) and to inhibit chk2 activation, thereby allowing the cells to continue through mitosis avoiding the g2/m arrest (cesare et al., 2013). in contrast, thanasoula et al. (2012) showed that trf2 depletion leads to chk2 phosphorylation and to g2/m arrest, preventing fusions and genome instability.",pmc4331747,1,1,40,1,41
340,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,trf1,protein,,terf1,uniprot,q15554,nucleus,go:0005634,negative,d,dna damage,,,skin,,mouse,['540'],nan,nan,"k5cre chk2−/− mice showed extensive dysplasia in the skin, suggesting an increased preneoplastic growth associated to massive trf1-induced dna damage in the absence of chk2 (fig. 1d; see also fig. 2).",pmc4331747,1,1,40,1,41
339,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,trf1,protein,,terf1,uniprot,q15554,nucleus,go:0005634,negative,d,deficiency,,,,,mice,['545'],nan,nan,"k5cre chk2−/− doubly deficient mice compared to that of single trf1 knockouts (fig. 2a,c–d). this was also paralleled by a higher proliferation in trf1δ/δ",pmc4331747,1,1,40,1,41
384,egfr,protein,,egfr,uniprot,p00533,cell membrane,go:0005886,pai-1,protein,,serpine1,uniprot,p05121,extracellular region,go:0005576,positive,d,phosphorylation,y845,,endothelial,microvessel,human,['1416'],nan,nan,"the anti-apoptotic mechanism of cell proliferation often involves y845 phosphorylation. in microvessel endothelial t2 cells, serum-deprivation-induced apoptosis can be prevented by tgfβ1, which promotes such egfr signaling [145]. knockdown of egfr results in the decrease in tgfβ1-induced expression of pai-1, a major tgfβ1 target that is required for the anti-apoptotic mechanism. tgfβ1-induced expression of pai-1 in vascular smooth muscle cells, r22, has also been shown to require the src phosphorylation of y845 of egfr [146].",pmc3709701,1,1,40,1,41
397,egfr,protein,,,uniprot,p00533,plasma membrane,go:0005886,met,protein,,met,uniprot,p08581,plasma membrane,go:0005886,positive,d,phosphorylation,y1003,,,breast cancer,human,['1402'],nan,nan,"in breast cancers that are not responsive to egfr inhibitor therapy, not only src but also met, the hepatocyte growth factor (hgf) receptor that is itself a tyrosine kinase, is implicated in cancer cell malignancy [88]. for example, in sum229 breast cancer cells, src activation and y845 phosphorylation of egfr depend upon the activity of met, as judged by the effects of the met-specific activator (hgf) and inhibitors (su11274). crosstalk of met with the src/egfr signaling pathway has also been demonstrated in bladder carcinoma cells, in which serum-independent growth of the cells requires the activation of egfr and src, which leads to the phosphorylation of met on y1003 [89]. in this case, the phosphorylated y1003 of met, rather than the kinase activity of met, seems to be responsible for the anti-apoptosis and proliferation under serum-starved culture conditions [89,90]. whether or not y845 phosphorylation takes place under serum-deprived conditions is unknown. in glioma cells, it has been shown that hgf stimulates the transcription of egfr ligands such as transforming growth factor α (tgf α) and heparin-binding egf-like growth factor (hb-egf), whose inhibitions result in the failure of egfr activation involving y845 phosphorylation [91]. thus, crosstalk between egfr and met is, at least in some cases, transcription-dependent.",pmc3709701,1,1,40,1,41
337,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,smrt,protein,,ncor2,uniprot,q9y618,nucleus,go:0005634,negative,d,regulates,,,,,,['1154'],nan,nan,"chk2 interacts with smrt and regulates different transcription factors, acting as a repressor",pmc3656868,1,1,40,1,41
400,egfr,protein,receptor,egfr,uniprot,p00533,plasma membrane,go:0005886,met oncogene,protein,oncogene,met,uniprot,p08581,plasma membrane,go:0005886,positive,i,bypass,signal transduction component,,,,cell,['1920'],nan,nan,"oncogene bypass occurs when a cell bypasses the signal transduction component it normally depended upon for survival [4]. this has been observed in certain cells which were normally dependent upon egfr for survival, however, when upon exposure to an egfr inhibitor, cells emerged which displayed amplification of another oncogene, the met oncogene (mnng-hos transforming gene) which allowed the growth of the cells in the presence of the egfr inhibitor [22].",pmc3660063,1,1,40,1,41
434,erk,protein,,mapk1,uniprot,p28482,,,rhoa,protein,,rhod,uniprot,p61586,,,positive,d,phosphorylation,d-site,,,,,['1521'],nan,nan,"in the present study, we have investigated whether rhoa and cdc42 can be phosphorylated by erk. the results have demonstrated that 88s and 100t of rhoa are phosphorylated by erk. there is a direct physical interaction between rhoa and erk which is dependent on the d-site of rhoa. we also showed that phosphorylation of rhoa by erk increased its activity and its function in mediating stress fiber formation.",pmc4729484,1,1,40,1,41
432,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,rhoa,protein,,rhoa,uniprot,p61586,plasma membrane,go:0005886,positive,d,binds,erk d-site (185kkksgclll193),,,,,['1529'],nan,nan,"it has been well established that the substrate selectivity of erk is dependent on erk-docking sites (d-sites) [22,23]. the amino acid sequence analysis indicates that rhoa contains a putative erk d-site 185kkksgclll193 in its c-terminus. we examined whether the interaction between rhoa and erk is mediated by this putative rhoa d-site. we constructed a gst fusion rhoa mutant with the deletion of its putative d-site (gst-rhoaδd) and examined its interaction with erk by gst pull-down assay (fig 1e). our results showed that gst-rhoaδd pulled down substantially less p-erk and total erk compared with wild type gst-rhoa, indicating that the d-site is required for the interaction between rhoa and erk.",pmc4729484,1,1,40,1,41
431,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,elk-1,protein,,elk1,uniprot,p19419,nucleus,go:0005634,positive,d,phosphorylation,cooh terminus,,fibroblast,,human,['2760'],nan,nan,"upon mitogenic stimulation, erk translocates from the cytoplasm to the nucleus, where it phosphorylates the ternary complex factors elk-1 and sap-1a (chen et al. 1992; gille et al. 1992; lenormand et al. 1993). phosphorylation of elk-1 increases its affinity for the serum response factor and in concert enhances transcription of growth-related proteins, such as c-fos (marais et al. 1993; whitmarsh et al. 1995). several sites in the cooh terminus of elk-1 are phosphorylated by erk, the most critical of which appears to be serine 383 (marais et al. 1993). erk-mediated transcriptional events ultimately impinge on cell cycle elements, such as the induction of cyclin d1 (albanese et al. 1995; lavoie et al. 1996), although it is becoming evident that activation of additional pathways, such as the phosphatidyl-inositol-3-kinase pathway, are often required for cell cycle progression (marshall 1999).",pmc2169466,1,1,40,1,41
428,erk,protein,,mapk1,uniprot,p27361,,,rhoa,protein,,rhoa,uniprot,p61586,,,positive,d,phosphorylation,88s and 100t,,,,,['1542'],nan,nan,"we also examined whether erk activation is required for egf-induced activation of endogenous rhoa. we stimulated the cells with egf with or without u0126. the activated gtp-bound rhoa was pulled down with gst-rbd of rhotekin. we showed that egf stimulated rhoa activation and this activation was inhibited by u0126 (fig 5c & 5d). as controls, we showed that egf stimulated erk activation and this erk activation is abolished in the presence of u0126 (fig 5c). together our results indicate that phosphorylation of rhoa 88s and 100t by erk in response to egf enhances rhoa activity.",pmc4729484,1,1,40,1,41
427,erk,protein,,mapk1,uniprot,p27361,cytoplasm,go:0005737,rhoa,protein,,rhoa,uniprot,p61586,plasma membrane,go:0005886,positive,d,phosphorylation,88s and 100t,,,,,['1534'],nan,nan,phosphorylation of rhoa on 88s and 100t by erk in response to egf in vivo.,pmc4729484,1,1,40,1,41
425,erk,protein,,erk,uniprot,p27361,cytoplasm,go:0005737,elk-1,protein,transcription factor,elk1,uniprot,p19419,nucleus,go:0005634,positive,d,phosphorylation,elk-1,,,,,['2761'],nan,nan,"as erk translocation is a critical determinant in the transcriptional and biological responses to activation of this pathway, we addressed whether erk activity, in the absence of integrin engagement, was able to impinge on nuclear events. we demonstrate that under conditions of equivalent erk activity, erk-mediated phosphorylation of the transcription factor elk-1 is diminished in the absence of integrin engagement or upon disruption of the actin cytoskeleton. additionally, elk-1–driven gene transcription is low in nonadherent cells despite erk being activated. both during nonadherent conditions and in the absence of an intact cytoskeleton in adherent cells, erk predominantly accumulated in the cytoplasm rather than translocating to the nucleus. thus, integrin-mediated adhesion permits erk to efficiently localize in the nucleus and phosphorylate a key downstream nuclear substrate.",pmc2169466,1,1,40,1,41
424,erk,protein,kinase,,uniprot,p27361,cytoplasm,go:0005737,rhoa,protein,gtpase,rh,uniprot,p61586,plasma membrane,go:0005886,positive,d,phosphorylation,,,epithelial,skin,human,['1517'],nan,nan,phosphorylation and activation of rhoa by erk in response to epidermal growth factor stimulation,pmc4729484,1,1,40,1,41
423,erk,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,rhoa,protein,gtpase,rhoc,uniprot,p08134,cytoplasm,go:0005737,negative,d,phosphorylation,,,,,human,['1556'],nan,nan,"since we have shown that rac1 phosphorylation on t108 by erk plays important role in targeting rac1 to the nucleus [21], in the present study we examined whether erk-induced rhoa phosphorylation is important in determining the subcellular localization of rhoa. we showed that treatment with egf for 15 min, which activates erk and induces rhoa phosphorylation, increased the plasma membrane localization of endogenous rhoa, but had no effects on the nuclear localization of rhoa (fig 8a & 8b). we also showed that the phosphomimetic mutant gfp-rhoa s88e/t100e has a similar level of nuclear localization with or without egf stimulation, as does the non-phosphorylated mutant gfp-rhoa s88a/t100a (fig 8c–8e). these data indicate that rhoa phosphorylation by erk does not target rhoa to the nucleus, in contrast to rac1 phosphorylation by erk.",pmc4729484,1,1,40,1,41
422,erk,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,rhoa,protein,gtpase,rh0a,uniprot,p61586,plasma membrane,go:0005886,positive,d,phosphorylation,,,,,,['1530'],nan,nan,phosphorylation of rhoa by erk in response to egf treatment,pmc4729484,1,1,40,1,41
421,erk,protein,kinase,mapk1,uniprot,p28482,cytoplasm,go:0005737,bad,protein,,bad,uniprot,q92934,cytoplasm,go:0005737,negative,d,phosphorylation,,,,,,['292'],nan,nan,test compounds inhibit erk-mediated phosphorylation of p90 rsk-1 and bad proteins,pmc3025971,1,1,40,1,41
415,epidermal growth factor receptor,protein,,,uniprot,p00533,plasma membrane,go:0005886,ki-67,protein,,mki67,uniprot,p46013,nucleus,go:0005634,positive,d,staining,nucleus,,,,human,['487'],nan,nan,"the epidermal growth factor receptor and ki-67 primary antibodies were from novocastra (newcatle, uk) and were used at 1 : 20 and 1 : 100 dilutions, respectively. they both were used according to the manufacturer's recommendations, including the use of appropriate positive and negative controls for each antibody. for the egfr staining, three of the authors (gt, cgc and lmm) scored the specimens as positive, when any intensity and extension of staining was apparent, or negative when no signs of staining at all were seen, as described by other authors (albanell et al, 2001). a positive score for the ki-67 staining was considered when more than 5% of the tumour nuclei were stained as described before (xu et al, 2002).",pmc2409626,1,1,40,1,41
1063,src,protein,tyrosine kinase,src,uniprot,p12931,cytoplasm,go:0005737,noxa1,protein,,noxo1,uniprot,q96rr8,cytoplasm,go:0005737,positive,d,phosphorylation,tyr110,hek293,epithelial,kidney,human,['1365'],nan,nan,"to identify the tyr residue(s) on noxa1 targeted by src, we used bioinformatics tools available online (www.cbs.dtu.dk) and scanned human noxa1 protein (accession number nm_006647) for predicted phosphorylation sites. as illustrated in figure 2d, several threonine (thr) and serine (ser) phosphorylation sites are predicted with high score. of note, among those are included the ser172 and ser461, which our group has shown to be the sites for pka phosphorylation (kim et al., 2007). however, only tyr110 on noxa1 was recognized as a high-score phosphorylation site for tyrosine kinases. to verify whether tyr110 was the site for c-src phosphorylation on noxa1, we generated noxa1 phosphomimetic and unphosphorylable mutants (noxa1-y110e and noxa1-y110a, respectively), and used them to transfect hek293 cells along with srcyf. as indicated in the western blot analysis in figure 2e, (as expected) srcyf phosphorylates wild-type noxa1, while the disruption of y110 residue on noxa1 blocked its srcyf-induced tyr-phosphorylation. these results confirm that c-src phosphorylates noxa1 on its tyr110 residue.",pmc2993755,1,1,40,1,41
1064,src,protein,tyrosine kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,negative,i,mislocalization,,"hela, sfy",,,human,['806'],nan,nan,"runx3 is mislocalized from the nucleus to the cytoplasm by the overexpression of src. hela cells (a) and sfy cells (b) were transfected with myc-runx3 in the presence or absence of ha-src or ha-src-kd. after 48 h, the subcellular localizations of runx3 and src were analyzed by immunofluorescence using a monoclonal anti-myc antibody and a polyclonal anti-ha antibody. a mouse igg coupled to green fluorescence and a rabbit igg coupled to red fluorescence were used to detect the myc-runx3 and ha-src immune complexes, respectively. nuclei are visualized by 4,6-diamidino-2-phenylindole staining. in the cells expressing myc-runx3 alone, runx3 was almost exclusively localized to the nucleus (top panel). in the cells cotransfected with myc-runx3 and ha-src, runx3 displayed cytoplasmic mislocalization in virtually all of ha-src coexpressing cells (middle panel). in the cells coexpressing myc-runx3 and ha-src-kd, runx3 was mainly localized in the nucleus (bottom panel), indicating that the cytoplasmic mislocalization of runx3 is dependent on the tyrosine kinase activity of src.",pmc2843174,1,1,40,1,41
1065,src,protein,tyrosine kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,positive,d,phosphorylation,multiple tyrosine residues,hek293,epithelial-like,kidney,human,['807'],nan,nan,"because the tyrosine kinase activity of src was required for the cytoplasmic localization of runx3, we examined whether runx3 is phosphorylated by src. the coexpression of a fixed amount of myc-runx3 and increasing amounts of ha-src in hek293 cells, followed by immunoprecipitation (ip) with anti-myc (runx3) antibody and immunoblotting (ib) with anti-phosphotyrosine antibody (4g10; tyr(p)), revealed that runx3 is phosphorylated at multiple tyrosine residues in an src concentration-dependent manner (fig. 2a).",pmc2843174,1,1,40,1,41
1066,src,proteinkinase,nonreceptor,src,uniprot,p12931,cytoplasm,go:0005737,p27kip1,protein,,cdkn1b,uniprot,p46527,nucleus,go:0005634,positive,d,phosphorylation,tyrosine residues,,,,human,['800'],nan,nan,"the src family of kinases (sfks)3 includes the largest family of nonreceptor protein kinases. the sfk family is composed of nine members as follows: blk, fgr, fyn, hck, lck, lyn, src, yes, and yrk. src, fyn, and yes are ubiquitously expressed in most tissues, whereas the others are selectively expressed in particular cell lineages (30–33). sfks are critical components of the signaling cascades initiated by various membrane receptors, including growth factor receptors, integrins, other adhesion receptors, g protein-coupled receptors, cytokine receptors, immunoglobulin-like domain receptors, and ion channels. sfks are essential for many cellular activities, including proliferation, differentiation, motility, and adhesion. src is the most extensively studied of the sfks, and it has been closely associated with tumor development, tumor progression, and distant metastasis by promoting cell proliferation, invasion, and motility (31). it has been found that src is overexpressed or highly activated in a large number of human cancers (34). it phosphorylates p27kip1 on tyrosine residues and accelerates p27kip1 proteolysis (35).",pmc2843174,1,1,40,1,41
1068,src kinase,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,positive,d,phosphorylation,tyrosine,,,,,['798'],nan,nan,src kinase phosphorylates runx3 at tyrosine residues and localizes the protein in the cytoplasm *,pmc2843174,1,1,40,1,41
105,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,cytochrome c,protein,,cycs,uniprot,p99999,mitochondria,go:0005739,negative,i,inhibits,,hmn1,neuronal,,human,['1597'],nan,nan,"in this report, we examine the cellular mechanism by which akt inhibits apoptosis in hybrid motor neuron 1 (hmn1) cells, a neuronal cell line that requires pi 3-kinase but not map kinase for survival. by generating stable hmn1 lines overexpressing constitutively active akt, subcellular fractionation, cell-free assays of apoptosis, and microinjection, we investigated the effects of akt on several critical apoptotic events, with particular focus on its effect on cytochrome c redistribution. our data indicate that akt inhibits apoptosis downstream of cytochrome c release based on the following observations: (a) akt inhibits cell death but does not block release of cytochrome c, (b) akt inhibits cytochrome c–induced caspase activation in a cell free assay, and (c) hmn1 cells expressing active akt are resistant to apoptosis induced by microinjection of cytochrome c. in sum, our study indicates that akt plays an important role in suppressing neural apoptosis at a postmitochondrial stage, downstream of cytochrome c release and before activating caspase-9.",pmc2185587,1,1,40,1,41
1070,src kinase,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3 protein,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,negative,i,mislocalized,,,,,,['804'],nan,nan,runx3 protein is mislocalized from the nucleus to the cytoplasm by overexpression of src kinase,pmc2843174,1,1,40,1,41
1071,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,skp2,protein,,,uniprot,o43602,nucleus,go:0005634,positive,d,increased expression,,pancreatic β cell line,pancreatic,pancreas,human,['2587'],nan,nan,stat3 increased the expression of skp2 in a pancreatic β cell line,pmc4923948,1,1,40,1,41
1072,stat3,protein,,stat3,uniprot,p40763,nucleus,go:0005634,skp2,protein,,,uniprot,o43663,nucleus,go:0005634,positive,d,transcriptional regulation,enhancer region of the skp2 gene,,pancreatic β-cells,pancreas,human,['2596'],nan,nan,"meanwhile, several studies indicated that the transcript level of skp2 depends on stat3. stat3 is the most well characterized signalling pathway for increasing the nuclear localization and transactivation of genes, and is thought to promote cell growth and survival through multiple mechanisms, including increased expression of oncogenes, such as c-myc, skp2 and cyclin d1. stat3 can regulate the transcription of skp2 by recruiting p300 and then binding to the enhancer region of the skp2 gene. our studies indicated that stat3 controlled skp2 gene expression as an important regulator in pancreatic β-cells, in which stat3 overexpression can reverse the decrease in the skp2 protein levels elicited by rig-i (fig. 7).",pmc4923948,1,1,40,1,41
402,egfrviii,protein,mutant,egfr,uniprot,p00533,mitochondria,go:0005739,upar,protein,,plau,uniprot,q03405,,,positive,d,phosphorylation,y845,u373mg,glioblastoma,brain,human,['1400'],nan,nan,"there is a specific type of egfr mutation, called de2-7egfr or egfrviii, whose expression is often found in glioma or glioblastoma multiforme (gbm). in this case, src-dependent phosphorylation of y845 seems to be important for the survival and proliferation of glioma cells through its involvement in the stimulation of mitochondrial oxidative metabolism under low-glucose conditions [67]. actually, mitochondrial localization of this egfr mutant was shown to depend upon y845 phosphorylation. in another study using u373mg cells, another type of gbm cells, urokinase-type plasminogen activator receptor (upar) was shown to interact with egfrviii and to be important for y845 phosphorylation and sustained erk activation in this cell system [76]. huang et al. [77] showed that, by mutating y845 or two other tyrosine phosphorylation sites (y1148 and y1173), these specific tyrosine residues in egfrviii are required for suppressing the erk activity, which acts against the cell proliferation of egfrviii-expressing u87mg glioblastoma cells.",pmc3709701,1,1,40,1,41
338,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,smrt,protein,,ncor2,uniprot,q9y618,nucleus,go:0005634,positive,d,required for activation,,,,,human,['1159'],nan,nan,wip1 and chk2 are required for activation of caspase by smrt knock-down after dna damage.,pmc3656868,1,1,40,1,41
335,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,pp1,protein,,ppp1ca,uniprot,p62136,nucleus,go:0005634,negative,i,inactivation by,serine/threonine phosphorylation sites,,,,human,['35'],nan,nan,"while much is known about chk2 activation, many aspects of its inactivation remain to be elucidated. in the absence of dna damage, chk2 is maintained in an inactive state by serine/threonine protein phosphatase 2a (pp2a; freeman et al., 2010) protein phosphatase 1d (wip1; fujimoto et al., 2006) and serine/threonine protein phosphatase 1 (pp1; carlessi et al., 2010). after the ddr has run its course, chk2 must be deactivated but it is not known to what extent this happens by degradation, dephosphorylation or phosphorylation at inactivating sites (figure 2c).",pmc4296918,1,1,40,1,41
436,erk,protein,,mapk1,uniprot,p28482,nucleus,go:0005634,foxo1,protein,,foxo1,uniprot,q12778,nucleus,go:0005634,negative,i,degradation,,h1299,,,,['574'],nan,nan,"to determine whether erk directly phosphorylates foxo1 to induce foxo1 degradation, a plasmid encoding a mutated foxo1 (9a) in which the nine putative erk phosphorylation sites in foxo1 were mutated to alanine, or a plasmid encoding wild-type foxo1 (wt), were separately transfected into h1299 cells. both foxo1 (wt) and foxo1 (9a) were degraded after glutamine starvation (figure 4c), indicating that erk-mediated foxo1 degradation does not result from direct phosphorylation of foxo1 by erk.",pmc3616429,1,1,40,1,41
18,akt,protein,isoform,akt1,uniprot,p31749,cytoplasm,go:0005737,il-8,protein,,il8,uniprot,p10145,extracellular,go:0005576,positive,d,upregulated,,,,,human,['3351'],nan,nan,"as all three akt isoforms potently induced senescence, continuing analyses focused on the most widely expressed akt1 isoform. real-time pcr (rt–pcr) of known sasp factors confirmed that expression of il-1α and il-1β was upregulated in cells expressing myr-akt1 (figure 4a). expression of h-rasv12 also induced il-1α and il-1β as described previously (coppé et al., 2008), although to different levels than that observed with akt. surprisingly, il-6 mrna was reduced in cells expressing myr-akt1 or h-rasv12, whereas il-8 was only significantly upregulated in h-rasv12-expressing cells. to further investigate this lack of il-6 induction, we determined the levels of secreted il-1α, il-1β, il-6 and il-8 released into the media from cells expressing myr-akt1 or h-rasv12 at day 10 post-transduction. the relative levels of secreted il-1α, il-1β and il-8 induced by myr-akt1 and h-rasv12 (figure 4b) reflected the mrna expression data (figure 4a). furthermore, despite the paradoxically decreased il-6 mrna levels detected following myr-akt1 or h-rasv12 expression, il-6 protein levels secreted into the media were elevated fourfold, consistent with published data showing that secreted il-6 is a major contributor to sasp (coppé et al., 2008). although the basis of this discrepancy is unclear, il-6 expression has been reported to be subjected to post-transcriptional regulation, including via mir-365- and mtor-dependent regulation of il-6 translation (narita et al., 2011; xu et al., 2011). thus, akt-induced senescence is characterised by an sasp, with increased secretion of il-1α, il-1β, il-6 and il-8.",pmc3325598,1,1,40,1,41
1097,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,negative,i,phosphorylation,,,prostate cancer,,human,['1178'],nan,nan,"to understand the mechanism of 5–10-fold higher translational efficiency of the reporters in pc3 in comparison to pc3bm and hela, the status of mtor, its regulators and the target translation factors in these three cell lines was examined. as shown in figure 2a, while the levels of mtor and tsc2 were similar in the three cell lines, that of the phosphorylated tsc2 (s1254 phosphorylated by p38-activated kinase mk2 (mapkapk-2) [29] was less in pc3 than in the other cells. the activity of eif4e, the limiting factor in translation initiation, is controlled in part by 4ebps, [30]–[36], and by phosphorylation by mnk1 [45], [46]. as shown in figure 2b, though the levels of phosphorylated forms of eif4e were similar in pc3 and pc3bm but were relatively less in hela, 4ebp1 was hyperphosphorylated at all the four residues t37/46, t70 and s65 in pc3 than in the other cell lines, which is necessary to inhibit its interaction with eif4e (figure 2c). further, the ribosomal protein s6 was hyper-phosphorylated at s240 and s235 in pc3 in comparison to pc3bm and hela. though the level of the elongation factor eef2 was similar in pc3 and pc3bm but higher than in hela (figure 2e), the phosphorylated forms of the protein were not detectable in any of the cell lines using the available antibody (data not shown). however, eef2k was significantly highly phosphorylated in pc3 than in the other two cell lines (figure 2e).",pmc3010991,1,1,40,1,41
1104,tsc2,protein,,tsc2,uniprot,p49815,,,gsk3α/β,protein,,gsk3b,uniprot,p49841,,,positive,i,phosphorylation,,mefs,,,mouse,['675'],nan,nan,"−/− mefs in which a pathogenic tsc2 mutant is reintroduced, pkb is activated strongly only by egf. similarly, a downstream effector of pkb, gsk3α/β, is robustly phosphorylated in response to stimulation by all three growth factors in control mefs, but only strongly by egf in tsc2",pmc2172316,1,1,40,1,41
17,akt,protein,downstream effector,akt1,uniprot,p31749,cytoplasm,go:0005737,satb1,protein,,satb1,uniprot,q01826,nucleus,go:0005634,positive,d,phosphorylation,serine 47,,,,human,['837'],nan,nan,"as akt is a potent downstream effector of pi3k signaling pathway, we then ask whether satb1 phosphorylation by akt would rely on pi3k activation. treatment with ly294002, a pi3k inhibitor, suppressed akt activation, thereby abrogating satb1 phosphorylation. addition of igf-1 or fbs (fetal bovine serum) following ly294002 treatment reactivated pi3k/akt signaling, which in turn resulted in satb1 phosphorylation (figure 1f). as a control, satb1 phosphorylation was increased by constitutively activated akt compared with wild-type akt, whereas it was significantly decreased in the presence of an epitopically expressed kinase dead akt, a dominant-negative form lacking kinase activity (figure 1f). we then confirmed that satb1 phosphorylation at serine 47 relied on igf1/pi3k/akt signaling with the anti-phospho-satb1 (s47) (figure 1g). collectively, the data supports the idea that pi3k/akt pathway is required for satb1 phosphorylation at serine 47.",pmc3675137,1,1,40,1,41
15,akt,protein,constitutively active,akt1,uniprot,p31749,cytoplasm,go:0005737,cytochrome c,protein,,,uniprot,p99999,mitochondria,go:0005739,negative,d,inhibits,,,,,,['1612'],nan,nan,constitutively active akt inhibits apoptosis after microinjection of cytochrome c,pmc2185587,1,1,40,1,41
14,akt,protein,constitutively active,akt,uniprot,p31749,cytoplasm,go:0005737,il-1α,cytokine,,il1a,uniprot,p01583,extracellular region,go:0005576,positive,i,upregulation,,,fibroblast,,human,['3350'],nan,nan,"to further characterise the akt-induced senescence phenotype, we examined whether, like h-rasv12 (acosta et al., 2008; coppé et al., 2008), constitutively active akt could initiate a ‘senescence-associated secretory phenotype' or ‘sasp', where cells markedly increase the secretion of a number of proinflammatory cytokines. the role of this sasp has not been well delineated; however, it may function in an autocrine manner to reinforce growth arrest and also promote immune system-mediated clearance of senescent cells (freund et al., 2010). most commonly associated with the sasp is the upregulation of interleukin-6 (il-6), il-8 (acosta et al., 2008; coppé et al., 2008; rodier et al., 2009), and importantly il-1α, which can mediate a positive feedback loop, resulting in the induction of itself, il-6 and il-8 (orjalo et al., 2009).",pmc3325598,1,1,40,1,41
13,akt,protein,constitutively activated,akt1,uniprot,q15831,cytoplasm,go:0005737,runx2,mrnaandprotein,,runx2,uniprot,p43351,nucleus,go:0005634,positive,d,induces expression,,"prostate cancer cells, vascular smooth muscle cells (vsmcs), colorectal cancer cells",,"prostate, vascular smooth muscle, colon",human,['3253'],nan,nan,"in prostate cancer cells, stable expression of constitutively activated akt (myr-akt) induces the expression of runx2 mrna and its target genes, such as pip, pgc, mmp9 and mmp13 [43]. in a model of oxidative stress-induced vascular smooth muscle cell (vsmc) calcification, h2o2 induces runx2 mrna and protein expression, resulting in vsmc calcification [44]. h2o2 also increases phosphorylated akt levels. the h2o2-mediated runx2 expression is prevented in the presence of an akt inhibitor, suggesting that akt-mediated induction of runx2 plays a critical role in oxidative stress-induced vsmc calcification [44]. interestingly, treatment of colorectal cancer cells with h2o2 results in a dramatic increase in total akt and phosphorylated akt (pakts473) levels [45]. considering that runx2 immunoreactivity in colon carcinoma cells is associated with their aggressive clinical behavior in colon carcinoma patients [22], we propose that in a way similar to vsmc calcification, prevalent oxidative stress in cancer [46] could participate in maintaining high levels of runx2 through stimulation of the pi3k/akt pathway.",pmc4513933,1,1,40,1,41
1121,vegf,protein,growth factor,,uniprot,p15692,extracellular space,go:0005615,fak,protein,kinase,ptk2,uniprot,q05397,plasma membrane,go:0005886,positive,d,phosphorylation,tyrosine 861 (y861),,endothelial,vascular,mouse,['2363'],nan,nan,"evidence is provided that vegf and other growth factors activate src kinase, which induces the phosphorylation of tyrosine 861 (y861) within the fak cooh terminus, facilitating the association of fak with integrin αvβ5 both in vivo and in vitro. src deficiency or blockade of src activity inhibits the formation of a vegf-induced fak/αvβ5 complex. in contrast, both β1 and β3 integrins were found to couple to fak in the absence of growth factor stimulation. the physiological relevance of this pathway is underscored by the finding that mice lacking the integrin β5 subunit, or mice deficient in src, have reduced vegf-induced vp, suggesting a critical role for integrin αvβ5, together with src kinase activity, in regulating vegf-induced vascular responses in vivo.",pmc2173263,1,1,40,1,41
1123,vegf,protein,,,uniprot,p15692,extracellular region,go:0005576,fak,protein,,,uniprot,q05397,focal adhesion,go:0005925,positive,d,phosphorylation and translocation,focal adhesions,huvec,endothelial,brain and lung,human,['2365'],nan,nan,"vegf promotes fak phosphorylation and translocation in endothelial cells. (a) lysates of vegf-stimulated primary huvecs (20 ng/ml; 5 min), mouse brain and lung brain (2 μg/animal, 5 min) were prepared as described in materials and methods and subjected to immunoblotting with anti-phosphotyrosine antibodies specific for aa 397, 407, 576, 577, 861, or 925 within fak. the sensitivity and specificity of the phosphospecific antibodies were characterized in various tissues as described in the materials and methods. these immunoblots are representative of three different experiments. (b) translocation of endogenous fak in vegf-stimulated huvecs (20 ng/ml; 5–60 min) to focal adhesions was determined by indirect immunofluorescence with an anti-fak antibody in representative micrographs, as described in materials and methods. bar, 5 μm. (c) representative fak activity in lysates of vegf-stimulated huvecs (20 ng/ml; 5–60 min) was measured by immune complex in triplicate in vitro kinase assays as described in materials and methods (p < 0.05). (d) lysates of vegf-stimulated huvecs (20 ng/ml; 2–60 min) were subjected to immunoblotting with an anti-phosphotyrosine antibody specific for aa 397, 861, an anti-phospho erk antibody, or an anti-fak antibody. each of these panels are representative of triplicate experiments.",pmc2173263,1,1,40,1,41
1124,vegf,protein,vascular endothelial growth factor,vegfa,uniprot,p15692,extracellular,go:0005576,pp62c-yes,protein,nonreceptor tyrosine kinase,yes1,uniprot,p07947,cytoplasm,go:0005737,positive,d,kinase activity,,,endothelial,,mouse,['2360'],nan,nan,"vascular endothelial growth factor (vegf)* was originally described as a vascular permeability (vp) factor secreted by tumor cells, expressed in hypoxic tissues (senger et al., 1983; connolly et al., 1989; marti et al., 2000), mitogenic for endothelial cells (ferrara and davis-smyth, 1997), and essential for development (carmeliet et al., 1996; ferrara et al., 1996). recent evidence demonstrates that mice lacking the nonreceptor tyrosine kinase, pp60c-src, have defects in vegf-mediated vascular responses (eliceiri et al., 1999; paul et al., 2001). specifically, in pp60c-src- or pp62c-yes-deficient mice, the vp-promoting functions of vegf were distinguished from the mitogenic functions of vegf because their blood vessels were resistant to vegf-mediated vp, even though these animals showed normal vegf-mediated angiogenesis (eliceiri et al., 1999). however, chick embryos or mice transduced with kinase-deleted src, which suppresses multiple src family kinases (sfks), fail to undergo vegf-mediated angiogenesis (eliceiri et al., 1999). together these findings demonstrate that, in general, sfks are compensatory during embryogenesis and angiogenesis, but that vegf-induced vp is dependent on a subset of sfks, such as src or yes (eliceiri et al., 1999).",pmc2173263,1,1,40,1,41
11,akt,protein,active,akt1,uniprot,p31749,cytoplasm,go:0005737,cytochrome c,protein,,,uniprot,p99999,cytoplasm,go:0005737,negative,d,inhibits,,hmn1,,,,['1613'],nan,nan,"to determine whether akt inhibits cytochrome c–induced apoptosis in vivo, purified cytochrome c was microinjected into the cytoplasm of akt-expressing and vector-transfected cells. control injections did not induce apoptosis, whereas microinjection of cytochrome c was sufficient to induce rapid apoptosis in hmn1 cells. cytochrome c but not control-injected cells exhibited condensed and/or fragmented nuclei (fig. 8 a). moreover, constitutively active akt inhibited and delayed cytochrome c–induced apoptosis (fig. 8 b), which is consistent with results obtained from the cell-free system in which expressing active akt-inhibited apoptotic events such as parp cleavage and activation of caspase-9 and caspase-3 in response to cytochrome c (fig. 7a, fig. c, and fig. d).",pmc2185587,1,1,40,1,41
10,akt,protein,active,akt1,uniprot,p31749,cytoplasm,go:0005737,bax,protein,,bax,uniprot,q07817,mitochondria,go:0005739,positive,d,increase expression level,,baf/3,unknown,unknown,not specified,['1606'],nan,nan,"one mechanism by which active akt protects baf/3 cells from interleukin-3 withdrawal–induced apoptosis is to increase the expression level of bcl-2 (ahmed et al. 1997). we previously showed that transiently overexpressing constitutively active akt in hmn1 cells inhibits c2-ceramide–induced apoptosis; however, the expression levels of bcl-2, bcl-x, or bax were not changed (zhou et al. 1998; data not shown). the lack of an effect in hmn1 cells may have been due to the low transfection efficiency in our transiently transfected cells or possibly that active akt may protect neurons from apoptosis via a mechanism different from that in baf/3 cells. to elucidate the cellular mechanisms by which akt inhibits apoptosis, stable hmn1 lines overexpressing constitutively active akt were generated. the expression of constitutively active myr-aktδ4-129 in these clones was confirmed using anti–akt antibody (fig. 3 a) and antiphosphospecific akt (ser473) antibody (b). note that myr-aktδ4-129 has a much higher degree of ser473 phosphorylation than endogenous akt despite its relative lower expression level. hmn1 lines overexpressing human bcl-2 were also generated to help dissect the role of akt in regulating apoptosis (fig. 3 c).",pmc2185587,1,1,40,1,41
1130,wild-type src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,ing1,protein,,ing1,uniprot,q15375,nucleus,go:0005634,positive,d,co-immunoprecipitation,,hek293,epithelial,kidney,human,['3546'],nan,nan,"a) wild-type src and the mutants indicated were ectopically expressed in hek293 cells. expression levels of src and ing1 are shown in immunoblots of whole cell extracts (upper two panels). src immunoprecipitates from these cells were probed with antibodies against ing1 or src (lower two panels). bands at 55 and 23 kda represent heavy and light chains of α−src used in immunoprecipitation. the top two and bottom panels are data from the same experiment. the third panel showing ing1 co-immunoprecipitated with src is from a separate experiment performed under the same conditions; however, a larger amount of total protein in the lysate was used for immunoprecipitation than in the bottom panel in order to aid in the visualization of endogenous ing1. note: the level of activated y530f src (lanes 3 and 7, top and bottom panels) is less than that of wt or kinase-dead k298m src because of its shorter half life. this effect is also seen in fig. 3. b) a431 cell extracts were immunoprecipitated using either antibody against src (lane 1) or ing1 (lane 2), using control mouse igg antibody (lane 3), or in the absence of antibody (lane 4), followed by immunoblotting of the immunoprecipitates for ing1. untreated whole cell extract (approx. 8% of cell extract protein used in the immunoprecipitations for lanes 1–4) (lane 5) was also blotted for ing1.",pmc3621671,1,1,40,1,41
184,bcl-2,protein,,bcl2,uniprot,p10415,mitochondria,go:0005739,bax,protein,,bax,uniprot,q07812,mitochondria,go:0005739,positive,d,displacement,mitochondrion,,melanoma,,human,['3496'],nan,nan,"bcl-2 family proteins play a central role in regulation of apoptosis [8, 9]. according to their biochemical structures and biological functions, they are largely divided into pro-survival proteins including bcl-2, mcl-1, bcl-xl, and a1, bh3-only anti-survival proteins such as bid, bad, bim, puma, and noxa, and their effectors, the multidomain anti-survival proteins bax and bak [8, 9]. activation of bh3-only proteins are essential in induction of apoptosis as they act as intracellular “death ligands” to activate bax and bak leading to mitochondrion damage by displacing them from pro-survival bcl-2 family members [8, 9]. deregulated expression of bcl-2 family proteins either as consequences of genetic alterations or resulting from environmental stimulations contributes to the pathogenesis of various types of cancers including melanoma [10, 11]. for example, the expression of mcl-1 increases with melanoma progression and is associated with poor patient prognosis [10]. in contrast, the bh3-only proteins puma and bim are frequently reduced in melanomas, which is also associated with poor survival of patients [12, 13].",pmc4294377,1,1,40,1,41
1136,wnt ligand,protein,,,uniprot,p56705,extracellular region,go:0005576,fz,protein,,,uniprot,q9npg1,plasma membrane,go:0005886,positive,d,binds,,,,,human,['2025'],nan,nan,"when wnt ligand is present, it binds fz, which signals through dvl to suppress beta-catenin phosphorylation. beta-catenin is then able to complex with lef/tcf and induces the transcription of genes. when beta-catenin is mutated at certain nucleotides it can act as an oncogene, as the beta-catenin proteins can not be phosphorylated by gsk-3 or cki (depending on the residue). other regulatory proteins are also involved in controlling the activity of the wnt/beta-catenin complex. in many cases, they may be either oncogenes or tumor suppressor genes. gsk-3-binding protein (gbp), also known as, frequently rearranged in advanced t-cell lymphomas (frat), may regulate the binding of gsk-3 to axin. diversin (div) is an ankyrin rich protein that interacts with both dvl and axin to promote wnt signaling. the beta-catenin destruction complex consists of: beta-catenin, axin/conductin, adenomatous polyposis coli (apc), ck1, gsk-3 and gbp. apc is a tumor-suppressor gene and an essential component of the beta-catenin complex which controls cytoplasmic beta-catenin levels. mutations at apc are detected in certain cancers such as colo-rectal cancer (crc). mutations at apc occur early in crc and result in increased beta-catenin levels which lead to the expression of wnt/beta-catenin responsive genes. the axin and related conductin (axil) proteins contain multiple protein:protein interaction domains. the axin/axil proteins interact with apc and form key components of the beta-catenin destruction complex. axin and apc are both phosphorylated by gsk-3. phosphorylation of axin by gsk-3 increases it stability as well as its ability to bind to beta-catenin [222-225]. cki is a priming kinase by phosphorylating axin, dvl and apc. once these proteins are phosphorylated by ck1, gsk-3 then phosphorylates them. the div protein can recruit cki to the beta-catenin destruction complex [226].",pmc4102778,1,1,40,1,41
198,c-flip,protein,inhibitor,cflar,uniprot,q13158,cytoplasm,go:0005737,apoptosis sensitivity,process,,,go,go:0006915,,,negative,d,knockdown,,,tumor,various,human,['2155'],nan,nan,"on the other hand, cellular flice (fadd-like il-1β converting enzyme)-inhibitory protein (c-flip), a highly ubiquitous protein with a very short half life period, contributes an important role in the cap metastasis through multi-target effects11. deregulated expression of c-flip has been reported in various cancer types and its knock down restores the apoptosis sensitivity of tumor cells11. upregulation of c-flip has been evidenced in various tumor types and its (c-flip) amplification is closely associated with the development of chemotherapeutic resistance. nonetheless, knockdown of c-flip restores the proapoptotic signaling cascades efficiently (extrinsic as well as intrinsic apoptotic pathways) to enhance chemo-sensitivity12.",pmc4700468,1,1,40,1,41
200,c-jun,protein,,jun,uniprot,p05412,nucleus,go:0005634,cdk,protein,,,uniprot,p06493,nucleus,go:0005634,positive,d,regulation,,,b-cell,,,['203'],nan,nan,involved in the sustained phosphorylation of c-jun. positive regulation of cdk,pmc3084876,1,1,40,1,41
202,c-jun n-terminal kinase (jnk),protein,enzyme,jnk,uniprot,p45983,cytoplasm,go:0005737,wdr62,protein,binding protein,wdr62,uniprot,q8naz1,stress granules,go:0010494,positive,i,recruited,stress granules,,unspecified,,human,['3202'],nan,nan,a novel c-jun n-terminal kinase (jnk)-binding protein wdr62 is recruited to stress granules and mediates a nonclassical jnk activation,pmc2801705,1,1,40,1,41
203,c-myc,protein,,myc,uniprot,p01106,nucleus,go:0005634,gsk3β,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,negative,d,phosphorylation,,,,,,['2737'],nan,nan,"whole cell lysates were prepared in m-per buffer (thermo, waltham, ma), resolved by sds-page and blotted with indicated antibodies. the following antibodies were used in this study: anti-ha, anti-flag, anti-phospho-β-catenin (ser33/37/thr41), anti-β-catenin, anti-gsk3α, anti-β-trcp, anti-α-tubulin, anti-gsk3β, anti-fak, anti-phospho-fak (tyr397), anti-pyk2 and anti-phospho-pyk2 (tyr402) (cell signaling); anti-flag m2 (sigma); anti-ubiquitin and anti-β-catenin (bd bioscience, san jose, ca); anti-gsk3, anti-c-myc, anti-pyk2, anti-β-trcp, anti-phospho-gsk3β (tyr216) and anti-β-actin (santa cruz biotechnology, dallas, tx); anti-phospho-gsk3 (tyr279/tyr216) (millipore). anti-gsk3β for ip was purchased from abcam (cambridge, ma) and bethyl laboratories (montgomery, tx). supersignal west pico chemiluminescent substrate and supersignal western blot enhancer (thermo) were used to enhance western signal when needed. pf-562271 was purchase from medkoo biosciences (chapel hill, nc) and selleck chemicals (houston, tx). gelucire is a gift from gattefosse (paramus, nj). mg-132 was obtained from sigma.",pmc4558782,1,1,40,1,41
204,c-src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,noxa1,protein,activator protein,duox1,uniprot,q9hd67,cytoplasm,go:0005737,positive,d,phosphorylation,tyrosine,hek293,epithelial-like,kidney,human,['1362'],nan,nan,"it was previously established by our group that the activation of the kinase c-src leads to increased nox1-dependent ros generation through the tyrosine phosphorylation-mediated activation of rac1 exchange factor vav2 (gianni et al., 2008). however, it cannot be excluded that c-src might directly target other regulatory components of nox1 pathway such as the activator protein noxa1. to test this hypothesis, hek293 cells were transfected with flag-tagged noxa1 in presence of srcyf or srckm and protein extracts were analyzed by sds-page using a specific noxa1 antibody. as shown in figure 2a, we observed the presence of a doublet corresponding to noxa1 only when this was coexpressed with srcyf, suggesting that noxa1 might be phosphorylated by src under these conditions. to confirm this, cell extracts from hek293 cells cotransfected with noxa1 and srcyf were treated with or without calf intestinal phosphatase (cip). figure 1b shows that the phosphorylation doublet was not detected when cell extracts were pre-treated with cip, indicating that noxa1 can be phosphorylated.",pmc2993755,1,1,40,1,41
205,c-src,protein,kinase,src,uniprot,p12931,cytosol,go:0005829,vav2,protein,exchange factor,vav2,uniprot,p52735,cytosol,go:0005829,positive,d,phosphorylation,tyrosine residues,,,,human,['1354'],nan,nan,"despite much investigation, very little is known about the signaling events regulating the formation of ros by nox proteins under normal, much less pathological, conditions. increasing evidence suggests that phosphorylation of various nox proteins or their regulatory cofactors or both may play important roles in regulating the activity of these enzymes (bokoch et al., 2009). for instance, it has been shown that during neutrophil activation, the phosphorylation by protein kinase c (pkc) on serine (ser) and threonine (thr) residues of p47phox is critical to nox2 priming and activation (el-benna et al., 2008). this phosphorylation event induces the translocation of p47phox/p67phox complex to the plasma membrane, where it primes the oxidase for activation. on the other hand, our group has shown that protein kinase a (pka) inhibits nox1 activity in colon epithelial cells by phosphorylating noxa1 at two distinct sites, ser172 and ser461 (kim et al., 2007). on this phosphorylation event, noxa1 is sequestered in the cytosol, thus resulting in inhibition of nox1-dependent ros generation. finally, we have also described a signaling axis linking the activation of the kinase c-src to increased nox1-dependent ros generation through the tyrosine phosphorylation-mediated activation of rac1 exchange factor vav2 (gianni et al., 2008).",pmc2993755,1,1,40,1,41
225,cdk,protein,kinase,cdk,uniprot,p06493,nucleus,go:0005634,il-6,cytokine,,il6,uniprot,p05231,extracellular space,go:0005615,negative,i,inhibition,il-6 production,,,,,['211'],nan,nan,effects of cdk inhibition first by monitoring il-6 production as a biologically,pmc3084876,1,1,40,1,41
1096,tsc2,protein,gtpase activating protein,tsc2,uniprot,p49815,cytoplasm,go:0005737,rheb,protein,small gtp-binding protein,rheb,uniprot,p62491,cytoplasm,go:0005737,negative,d,gap activity,,,,,mammalian,['1177'],nan,nan,"mtor, a serine-threonine kinase, is the central controller of translation in mammalian cells [14]–[16]. mtor exists in two structurally and functionally distinct multi-protein complexes called mtorc1 and mtorc2 [17]–[19]. two upstream elements that regulate mtor-signaling pathway include the ras homolog enriched in brain (rheb), a small gtp-binding protein, and the heterodimeric tuberous sclerosis complex 1 and 2 (tsc1/tsc2) [17]–[23]. tsc2, a gtpase activating protein (gap) for rheb, functions as a negative regulator of mtor and facilitates the formation of the inactive gdp bound form of rheb from the active gtp-bound form which activates mtor kinase activity [22], [23]. phosphorylation of tsc2-tsc1 by several signaling cascades leads to its inactivation, leading to mtorc1 activation [24]–[29]. activated mtorc1 phosphorylates its two best-known downstream effectors, the 4e-binding proteins (4ebps) and the ribosomal p70 s6 kinase (s6k1) [30]–[33]. phosphorylation of these two translational regulators is frequently used as an in vivo readout for mtor activation. 4ebp1 binds to the translation initiation factor eif4e and prevents the formation of the eif4f complex at the cap structure. phosphorylated 4ebp1 fails to bind 4e, leading to recruitment of ribosomes to the mrna and translational activation [34]–[36]. on the other hand, activated p70s6k1 phosphorylates the ribosomal protein s6 and eukaryotic elongation factor 2 kinase (eef2k) leading to increased translational efficiency. eukaryotic elongation factor 2 (eef2) binds gtp and mediates the translocation step of translation elongation. phosphorylation of eef2 at t56 by eef2k, within the gtp-binding domain, interferes with its ability to bind the ribosome [37]–[40]. further, phosphorylation of eef2k at s366 by activated s6k1 inhibits its kinase activity, leading to efficient translation [41], [42]. while the effects of mtorc1 are rapamycin sensitive, those of mtorc2 are rapamycin-insensitive which primarily regulates actin cytoskeletal polarization and reorganization [43],[44].",pmc3010991,1,1,40,1,41
19,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,ciap-2/birc3,protein,inhibitor of apoptosis,birc3,uniprot,o15519,cytoplasm,go:0005737,positive,d,activation,,,lung,bronchial epithelium,human,['423'],nan,nan,"the pathways utilized by lung tumors to evade apoptosis, allowing the tumors continued survival and growth, are incompletely characterized. equally important are the pathways that become activated in ien lesions before they become invasive cancer. in this study, we examined the presence and cellular localization of the phosphorylated form of akt kinase, the transcription factor p65/rela and the cellular inhibitor of apoptosis protein ciap-2/birc3 in human bronchial ien lesions. in normal human bronchial epithelium, staining for phosphorylated akt was present as a faint cytoplasmic stain. staining intensity increased with increasing pathology grade and was present in a nuclear, perinuclear or plasma membrane pattern. the intensity of p65/rela staining also increased with increasing pathology grade. furthermore, more biopsies had nuclear localization of p65/rela with advancing pathology grade, indicating nuclear translocation of the protein and the potential for transcriptional activation. the apoptosis inhibitor ciap-2/birc3 also had increased staining intensity with increasing pathology grade. these results indicate that akt, p65/rela and ciap-2/birc3, components of an anti-apoptotic pathway, are elevated in pre-neoplastic lung lesions.",pmc1325242,1,1,40,1,41
328,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,mdmx,protein,,mdm4,uniprot,o15151,nucleus,go:0005634,negative,d,ubiquitin-mediated proteosomal degradation,,,,,human,['1653'],nan,nan,"p53 is stabilized after dna damage which allows it to activate the transcription of genes whose products participate in cell cycle arrest, dna repair, senescence, or apoptosis, depending upon the stimulus [69]. mdm2 negatively regulates p53 through ubiquitin-mediated proteosomal degradation [70-72]. mdmx also negatively regulates p53 by binding to mdm2 and enhancing mdm2 binding to and ubiquitination of p53 [73-75]. atm, atr, and dna-pk phosphorylate p53 on s15, while chk1 and chk2 phosphorylate p53 on s20 which stabilize p53 by preventing binding to mdm2 [76-78]. atm and atr also directly inhibit mdm2 by phosphorylating it on s395 and s407, respectively [79,80]. atm phosphorylates mdmx on s403 which leads to its ubiquitination and degradation [81] whereas chk2 phosphorylates mdmx on s367 and s342 which promotes 14-3-3 binding and degradation of mdmx [82,83]. therefore, multiple ddr proteins coordinate to stabilize and activate p53 through phosphorylation of p53 and its negative regulators mdm2 and mdmx.",pmc2954851,1,1,40,1,41
1087,tgf-β1,protein,,tgfb1,uniprot,p01137,,,survivin,protein,,birc5,uniprot,q13241,,,positive,d,upregulating,,,,,,['1765'],nan,nan,"an important conclusion of this study is that tgf-β1-induced emt is influenced by the cell cycle, and tgf-β1 regulates cell cycle progression by upregulating survivin (figure 8). upregulated survivin by tgf-β1 should act as a mitotic regulator and also activate aurora b for cell cycle progression, so tgf-β1 leads to multiple mitotic defects and cell apoptosis when survivin is absent.",pmc3730417,1,1,40,1,41
327,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,ku70/80,protein,,,uniprot,p12004,nucleus,go:0005634,positive,i,phosphorylation,"centrosomes, kinetochores, midbodies",hela,epithelial-like,cervix,human,['52'],nan,nan,"when dna damage occurs in g2 phase, chk2 normally arrests the cell cycle at the g2/m boundary (matsuoka et al., 1998). when chk2 was repressed by expression of an inactive dominant-negative chk2 mutant or by exposure to specific chemical inhibitors, hct116 colon cancer cells with dna lesions entered mitosis and, in metaphase, underwent apoptosis (castedo et al., 2004), a phenomenon called mitotic catastrophe (castedo and kroemer, 2004). in hela cells, upon dna damage, ku70/80 drives dna-pkcs to phosphorylate scd of chk2 on centrosomes, kinetochores, and midbodies, stabilizing centrosomes and spindle formation in an unknown way and preventing mitotic catastrophe (shang et al., 2010). these observations underline a role for chk2 in monitoring mitotic structures, an activity further confirmed by studies in the absence of exogenous damage.",pmc4296918,1,1,40,1,41
326,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,kap1,protein,,trim28,uniprot,q13263,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['3102'],nan,nan,"curiously we found that, although the priming phosphorylation of chk2 on t68 by atm is not affected by ccar2, the dimerization and the autophosphorylation on t387 of chk2, essential for a full activity of chk2 on its substrates [8], are reduced in ccar2 ablated cells. this reduction of chk2 activation finally leads to defective phosphorylation of kap1 on s473 that can prevent chromatin relaxation and dna repair. of note, we found as previously reported [21] that kap1 phosphorylated on s473 does not accumulate in dna damage induced foci (data not shown), as expected because of its role in the induction of global chromatin relaxation upon dna damage. beside this, our results suggest that ccar2 could be involved in the regulation of the interaction between chk2 and its substrates. indeed, in ccar2-wt cells, chk2-kap1 association decreases in response to dna damage, whereas it is induced in ccar2 negative cells. this phenomenon could be explained with the fact that chk2 releases its substrates after phosphorylation [8, 29, 30], but maintains the interactions in the case of defective catalytic activity.",pmc4627348,1,1,40,1,41
325,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,kap1,protein,,trim28,uniprot,p78317,nucleus,go:0005634,negative,d,phosphorylation,,,,,human,['3077'],nan,nan,"we also report that the impairment in heterochromatic dna repair is caused by defective chk2 activation, detectable in ccar2 ablated cells, which finally impacts on the phosphorylation of the chk2 substrate kap1 that is required for the induction of heterochromatin relaxation and dna repair.",pmc4627348,1,1,40,1,41
324,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,kap-1,protein,transcriptional repressor,trim28,uniprot,q13263,nucleus,go:0005634,positive,i,phosphorylation,"ser824, ser473",,,,human,['44'],nan,nan,"the successful rejoining of dna ends requires that ddr proteins can access the lesion within the complex chromatin ‘landscape’. dsbs occurring nearby or within heterochromatin are difficult to repair because the chromatin is more compact (goodarzi and jeggo, 2012). therefore, ddr proteins modify histones and remodel the nucleosome to facilitate lesion processing. in this context, chk2 ‘collaborates’ with atm by phosphorylating a common substrate, the transcriptional repressor krab-associated protein 1 (kap-1). to relax chromatin atm phosphorylates kap-1 at ser824, disrupting the complex between kap-1 and the nucleosome remodeler protein (chd3) and allowing chd3 to be removed or to dissociate from heterochromatin (goodarzi et al., 2011). then, chk2 phosphorylates kap-1 on ser473, which compromises the kap-1/hp1-β interaction on chromatin, leading to hp1-β mobilization (bolderson et al., 2012; hu et al., 2012). since hp1-β is a heterochromatin packaging factor, the release of this protein from chromatin relaxes the dna structure, further favoring the access of repair factors to lesion sites.",pmc4296918,1,1,40,1,41
323,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,il-8,protein,cytokine,cxcl8,uniprot,p10145,extracellular region,go:0005576,positive,d,regulation,,,fibroblast,,human,['51'],nan,nan,"chk2 has also been described to be an essential player in a process named senescence-associated secretory phenotype (sasp), in which senescent cells express and secrete numerous proteins that alter the local tissue environment (figure 3d; coppe et al., 2010). the expression of several sasp proteins, particularly the inflammatory cytokines il-6 and il-8, is regulated by a pathway involving chk2, atm, and the nijmegen breakage syndrome protein nbs1, another ddr component (rodier et al., 2009). senescence is also associated with persistent nuclear foci containing ddr proteins, called dna segments with chromatin alterations reinforcing senescence (dna-scars). these structures, in which active chk2, pml, and p53 coexist, regulate senescence-associated growth arrest (rodier et al., 2011), il-6 secretion, and sustainment of senescence after dna damage.",pmc4296918,1,1,40,1,41
322,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,foxm1,protein,transcription factor,foxm1,uniprot,q08050,nucleus,go:0005634,positive,d,phosphorylation,,,,,,['42'],nan,nan,"chk2 has also been implicated in base excision repair (ber), a mechanism by which damaged nucleobases are recovered. indeed chk2 phosphorylates, and activates, the transcription factor forkhead box protein m1 (foxm1, figure 3a) which in turn induces the transcription of the base excision repair factor xrcc1 (tan et al., 2007).",pmc4296918,1,1,40,1,41
321,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,dna-pkcs,protein,,prkdc,uniprot,p78527,nucleus,go:0005634,positive,i,phosphorylation,,bj-htert immortalized human fibroblast cells,fibroblast,,human,['34'],nan,nan,"chk2 may also be activated by dna-dependent protein kinase (dna-pkcs; li and stern, 2005), another member of the pi3k family. dna-pkcs was shown to phosphorylate exogenous chk2 in undamaged bj-htert immortalized human fibroblast cells (buscemi et al., 2009). after dna damage, it phosphorylates a subfraction of chk2 molecules bound to chromatin or centrosomes (shang et al., 2010), preventing mitotic catastrophe. these findings suggest that dna-pkcs participates in the activation of chk2, at least when damage occurs during mitosis. in addition, upon dna damage, polo-like kinase-3 (plk3), which phosphorylates chk2 at s62 (in the scd) and at s73 (bahassi el et al., 2006), and the dna mismatch repair protein msh2, which interacts with chk2 at sites of damage (adamson et al., 2005), facilitate atm-mediated phosphorylation of t68 and promote chk2 activation. chk2 autophosphorylation seems to also be regulated by pml protein (yang et al., 2006), a tumor suppressor implicated in acute promyelocytic leukemia and a main component of pml-nuclear bodies (pml-nbs), which are nuclear matrix-associated structures. pml-nbs appear to be storage sites for inactive chk2, which leaves the structures when activated (yang et al., 2002). nonetheless, a fraction of active chk2 is retained in pml-nbs, where it phosphorylates pml protein itself or associates with p53 to regulate pml-nb number and pml-induced apoptosis (yang et al., 2002; zannini et al., 2009).",pmc4296918,1,1,40,1,41
320,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,cdc25a,protein,phosphatase,cdc25a,uniprot,p30307,nucleus,go:0005634,negative,d,phosphorylation and subsequent degradation,,,,,,['45'],nan,nan,"in the presence of dsbs, chk2 arrests the cell cycle at g1/s and g2/m by several mechanisms (figure 3b). about g1/s arrest, one mechanism involves the phosphorylation and subsequent degradation of cdc25a phosphatase by the proteasome; this event prevents the dephosphorylation and activation of cyclin-dependent kinase 2 (cdk2), needed for g1/s and s phase progression (falck et al., 2001). another mechanism involves the phosphorylation of p53 by atm and chk2, which stabilizes and activates p53 (chehab et al., 2000; hirao et al., 2000). activated p53 upregulates the expression of p21, an inhibitor of cyclin-dependent kinases, leading to g1/s transition arrest (chehab et al., 2000). however, because this pathway requires transcription of p21 gene, it is assumed to sustain, more than start, g1/s arrest (bartek and lukas, 2001).",pmc4296918,1,1,40,1,41
319,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,cdc25a,protein,,cdc25a,uniprot,p30304,nucleus,go:0005634,positive,d,phosphorylation,s79,,,,human,['3527'],nan,nan,"cells were grown to ∼70% confluency and reagents were added as indicated concentrations. cells were lysed in lysis buffer containing 20 mm tris-hcl, 0.5 m nacl, 0.25% triton x-100, 1 mm edta, 1 mm egta, 10 mm β-glycophosphate, 10 mm naf, 300 μm na3vo4, 1 mm benzamidine, 2 μm pmsf and 1 mm dtt. the protein concentration was determined by the bca protein assay (thermo scientific, rockford, il, usa). proteins were separated on sds-page, transferred on to pvdf membrane, blocked in 1× blocking buffer (sigma-aldrich) and probed with the following antibodies: phospho-chk2 (t68), phospho-chk2 (s516), phospho-atm (s1981), phospho-atr (s428), phospho-chk1 (s296), phospho-histone h2a.x (s139) and poly-adp-ribose-polymerase (parp; cell signaling technology, boston, ma, usa), phospho-cdc25a (s79) and chk2 (santa cruz biotechnology, santa cruz, ca, usa), and α-tubulin (sigma-aldrich). then, the membranes were incubated with horseradish peroxidase (hrp)-conjugated secondary antibodies (sigma-aldrich), incubated with a chemiluminescence reagent (santa cruz biotechnology) according to the manufacturer's recommendation and exposed with x-ray film (american x-ray & medical supply, jackson, ca, usa) [9].",pmc4159025,1,1,40,1,41
318,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,cabin1,protein,,cep250,uniprot,o75914,nucleus,go:0005634,positive,d,phosphorylation,dna-damage mediated,hek293,epithelial-like,,human,['2193'],nan,nan,"to verify that the activity of atm and chk2 affected cabin1 ubiquitination, we transfected hek293 cells with the myc-cabin1 expression vector in combination with ha-ubiquitin and flag-atm or the flag-chk2 expression vectors. overexpression of atm or chk2 increased the ubiquitination of cabin1 protein (figure 4a and b). we also observed that the ubiquitination of cabin1 in response to uv irradiation was attenuated in the presence of caffeine (figure 4c). thus, these results indicate that the dna-damage kinase-mediated phosphorylation of cabin1 is prone to ubiquitination upon dna damage.",pmc3575827,1,1,40,1,41
317,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,brca2,protein,,brca2,uniprot,p51587,nucleus,go:0005634,positive,d,phosphorylation,,,,,,['41'],nan,nan,"multiple roles of chk2 in nuclear dna damage response. (a) chk2 in the repair of damaged dna. chk2 phosphorylates brca1 and brca2 to regulate hdr and nhej, and phosphorylates foxm1 to promote foxm1 accumulation and subsequently ber. n,m,r is the nbs1/mre11/rad50 complex. (b) chk2 in cell cycle checkpoint activation upon dna damage. chk2 phosphorylates p53, cdc25a, lats2, and rb to promote g1/s arrest and phosphorylates p53, cdc25c, che-1, strap, and ttk to induce g2/m checkpoint activation. (c) chk2 in apoptosis. upon dna damage, chk2 phosphorylates p53 and mdmx to promote p53 accumulation and p53-dependent apoptosis. chk2 targets e2f1 to induce both p53-dependent and independent apoptosis, and phosphorylates hur to modulate apoptosis and survival. (d) chk2 in senescence. chk2 regulates senescence by targeting trf2 and possibly acting on p53, p21, and il-6 and il-8.",pmc4296918,1,1,40,1,41
314,chk2,protein,,chek2,uniprot,o96017,,,smrt,protein,,ncor1,uniprot,q9y618,,,positive,d,monitoring,dna repair,u2os,osteosarcoma,,human,['1163'],nan,nan,"it has been argued that the cycles of oscillation in checkpoint proteins allow cells to monitor dna repair and re-activate the checkpoint response if the damage is still present at the end of each cycle [24], [63]. to assess the applicability of this model to chk2, we treated u2os cells with doxorubicin with or without co-treatment with the antioxidant n-acetyl-cysteine (nac), which reduces the amount of dna damage by scavenging free radicals. as expected, treatment with the antioxidant reduced caspase activation in response to doxorubicin. however, if the cells were transfected with sirna specific for smrt, the ability of the antioxidant to rescue the dna damage-induced apoptosis was lost (figure 5a), suggesting that smrt is involved in monitoring repair and shutting down the response if the dna damage is repaired. interestingly, co-treatment with the wip1 inhibitor partially restored the ability of the smrt-deficient cells to block apoptosis in the presence of nac (figure 5a, lane 5), suggesting a role of wip1 de-repression in the observed phenomenon.",pmc3656868,1,1,40,1,41
313,chk2,protein,,chek2,uniprot,o96017,,,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,negative,d,inhibition,,u2os,osteosarcoma,bone,human,['2425'],nan,nan,chk2 is required for dbc1-dependent sirt1 inhibition and induction of p53-mediated apoptosis after dna damage in u2os cells. western blot analysis of total cell extracts from cells transfected with control or chk2 sirna and then with mock- or dbc1-encoding vectors. in (a) cells were incubated with 20 μm mg132 for 20 min prior to treatment with etoposide for 1 h and analyzed for p53 acetylation. densitometric analyses (relative fold) show the ratios of acetylated p53-k382/total p53 normalized to the value of mock-transfected cells. in (b) and (c) cells were respectively treated with etoposide for 6 and 30 h and puma levels and apoptotic markers were analyzed. the same cells of experiment c were used to evaluate the percentage of dead cells by trypan blue staining. values are mean ± sd from three independent experiments. significant p-value is indicated (d).,pmc4245943,1,1,40,1,41
310,chk2,protein,,chek2,uniprot,o96017,,,kap1,protein,,trim28,uniprot,o75626,,,positive,d,phosphorylation,s473,u2os,osteosarcoma,,human,['3092'],nan,nan,"chk2 immunoprecipitates from ccar2+/+ and ccar2−/− u2os cells a., or from ccar2wt and ccar2t454a overexpressing cells b. were analyzed for chk2-t387 autophosphorylation before and after etoposide exposure. c. time course analysis of kap1-s473 phosphorylation in ccar2+/+ and ccar2−/− cells exposed to etoposide. d. kap1-s473 phosphorylation in ccar2−/− cells transfected with wt or kd chk2 or ccar2wt and ccar2t454a encoding vectors and treated with etoposide for 6h. e. time course analysis of kap1-s473 phosphorylation in etoposide treated ccar2-overexpressing cells. arrow indicates ccar2 specific band. f. phosphorylation of kap1-s473 in ccar2-overexpressing cells treated or not with etoposide and vrx0466617. accumulation of chk2-pt68 demonstrates vrx0466617 efficacy [28]. g. association of kap1 and hp1α in ccar2+/+ and ccar2−/− cells before and 24h after etoposide treatment for 1h (left). pc: pre-cleared negative control. right panel: input.",pmc4627348,1,1,40,1,41
309,chk2,protein,,chek2,uniprot,o96017,,,hur,protein,,elavl1,uniprot,q15717,cytoplasm,go:0005737,positive,d,phosphorylation,"hur residues s88, s100, t118",human diploid fibroblasts,fibroblast,,human,['2209'],nan,nan,"exposure of human diploid fibroblasts to genotoxic doses of hydrogen peroxide (h2o2) activated chk2, which in turn phosphorylated hur [27]. hur phosphorylation by chk2 triggered the dissociation of the mrna encoding the longevity and stress-response protein sirt1 from hur ribonucleoprotein (rnp) complexes; this dissociation rendered the sirt1 mrna unstable and triggered a decrease in the abundance of sirt1 mrna and protein. three putative chk2 phosphorylation sites were identified: hur residues s88, s100, and t118. in human diploid fibroblasts, mutating s100 to a nonphosphorylatable residue (s100a) promoted the continued association of sirt1 mrna with hur after oxidative damage, indicating that phosphorylation at residue s100 (located between rrm1 and rrm2) was critical for dissociation of the mrna [27]. a more stable target transcript, the prothymosin α (ptma) mrna, also showed increased binding to hur(s100a) compared to wild-type hur following h2o2 treatment. interestingly, mutation of t118 (located within rrm2) to a nonphosphorylatable site (t118a) generally showed reduced binding to all target mrnas, suggesting that phosphorylation at t118 enhanced hur binding to target mrnas. additional studies are needed to elucidate if other dna-damaging agents also act upon chk2 to phosphorylate hur and how these modifications affect hur function following genotoxic stress. further work is also necessary to investigate how other hur target mrnas are regulated following hur phosphorylation by chk2.",pmc2925474,1,1,40,1,41
308,chk2,protein,,chek2,uniprot,o96017,,,brca2,protein,,,uniprot,p51587,,,positive,d,phosphorylation,,,,,,['40'],nan,nan,"chk2 directly participates in the early steps of dsb repair by phosphorylating the two breast cancer susceptibility proteins, brca1 (lee et al., 2000) and brca2 (bahassi et al., 2008), with the final outcome of promoting hdr over nhej (figure 3a). on one hand, after dna damage, chk2 phosphorylation of brca1 facilitates recruitment of the recombinase rad51 to the lesion and repression of the nhej functions of the exonuclease mre11 (zhang et al., 2004). rad51 then promotes dna strand invasion and the exchange steps (ciccia and elledge, 2010), which are the main events of hdr. on the other hand, chk2 phosphorylation of brca2 leads to disruption of the rad51-brca2 complex, also allowing rad51 to bind lesioned sites (bahassi et al., 2008). because rad51 is a key component of the hdr, these phosphorylation events favor this repair pathway.",pmc4296918,1,1,40,1,41
307,chk2,protein,,chek2,uniprot,o96017,cytoplasm,go:0005737,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,positive,d,physically interacts,,u2os,osteosarcoma,,human,['2430'],nan,nan,"we next carried out co-ip experiments to determine whether chk2 physically interacts with dbc1 and sirt1 in human cells and to what extent dna damage regulates this interaction. for this, chk2 was immunoprecipitated from u2os cells treated or untreated with neocarzinostatin or etoposide and immunoblotted for dbc1 and sirt1, and, as shown in figure 3a, chk2 immunoprecipitates, but not negative controls, showed an interaction with both dbc1 and sirt1 that weakly increased after dna damage. additional co-ip experiments confirmed the presence of chk2 in dbc1 immunocomplexes from u2os cells (figure 3b), and in sirt1 immunoprecipitates prepared from other two cell lines (figure 3c).",pmc4245943,1,1,40,1,41
306,chk2,protein,,chek2,uniprot,o96017,cytoplasm,go:0005737,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,negative,d,deacetylation,,,,,human,['2433'],nan,nan,"we previously demonstrated that chk2 interacts with the proteasome activator regγ (12), while, more recently, it was shown that sirt1 deacetylates regγ and reduces its activity (10), and that the interaction of these proteins promotes sirt1 degradation and inhibition by substrates displacement (11). these observations raise the possibility of interplay between regγ, chk2, sirt1 and dbc1. to test this, we initially verified whether dbc1 and regγ associate in human cells and found, in co-ip assays, that endogenous regγ and dbc1 reciprocally immunoprecipitate each other (figure 4a and b) both before and after dna damage (figure 4b).",pmc4245943,1,1,40,1,41
305,chk2,protein,kinase,chek2,uniprot,o96017,nucleus,go:0005634,hur,protein,rna-binding,elavl1,uniprot,q15717,cytoplasm,go:0005737,positive,d,phosphorylation,hur residue k182,,,,human,['2210'],nan,nan,"unexpectedly, hur phosphorylation by chk2 in response to heat shock helped to prevent its degradation in this stress paradigm [38]. following heat shock, the nonphoshorylatable hur mutants (s88a, s100a, and t118a) were more labile while hur phosphomimic mutants (s88d, s100d, and t118d) were more resistant to degradation [38]. although details of this process await further analysis, chk2 phosphorylation of hur appeared to block hur proteolysis mediated by ubiquitination at hur residue k182 [38]. whether dna damage also helps to increase hur stability via chk2-mediated phosphorylation also warrants careful consideration.",pmc2925474,1,1,40,1,41
20,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,gsk-3,protein,kinase,gsk3b,uniprot,p49841,cytoplasm,go:0005737,positive,i,phosphorylation,gsk-3,not specified,not specified,not specified,not specified,['3584'],nan,nan,"the in vitro kinase activity of akt kinase in cells treated with or without selenite was determined using the akt kinase assay kit (cell signaling technology). briefly, cells were harvested, and cell lysates were prepared in cell lysis buffer provided by the manufacturer. subsequently, immobilized akt antibody was used to immunoprecipitate p-akt from cell lysates followed by in vitro detection of akt kinase activity using gsk-3 fusion protein and cold atp in the kinase buffer. finally, the activity of akt kinase in each sample was determined according to gsk-3α/β phosphorylation by western blotting.",pmc3734838,1,1,40,1,41
1086,tgf-β,protein,cytokine,tgfb1,uniprot,p01137,extracellular space,go:0005615,smad4,transcriptionfactor,,smad4,uniprot,q13485,nucleus,go:0005634,positive,d,phosphorylation,c-terminal serine residues,,,,human,['67'],nan,nan,"the transforming growth factor-β (tgf-β) family of cytokines constitutes the largest group of growth factors in humans and regulates many aspects of cell behavior such as differentiation, migration, and apoptosis.1 the tgf-β pathway exerts potent antitumor effects and its misregulation often results in cancer progression.2 in the canonical tgf-β signaling pathway, activated tgf-β receptors phosphorylate c-terminal serine residues of the transcription factors smad1/5/8 for bone morphogenetic proteins (bmps) or smad2/3 for the tgf-β/activin branch of the pathway.3 the transcription factor smad4, also called deleted in pancreatic carcinoma 4 (dpc4), functions as a co-smad that binds to receptor-phosphorylated smads (r-smads) and is an essential downstream determinant in tgf-β signaling that was, until recently, considered a constitutive component of the pathway.3",pmc4845174,1,1,40,1,41
435,erk,protein,,mapk1,uniprot,p28482,nucleus,go:0005634,elk-1,protein,transcription factor,elk1,uniprot,p19419,nucleus,go:0005634,positive,d,recruitment,d-domain/kinase interaction motif (kim) of elk-1,,,,human,['1222'],nan,nan,"we studied pre-initiation complexes (pics) on immobilized, mitogen-responsive sre promoters and found that both erk and msk were recruited to sre-dependent pics in a mitogen- and elk-1-dependent manner. reconstitution experiments with recombinant proteins indicated that the d-domain/kinase interaction motif (kim) of elk-1 was essential for erk recruitment. chromatin immunoprecipitation (chip) assays confirmed the mitogen-dependent phosphorylation of elk-1 and recruitment of erks and msk1 to the c-fos and egr1 promoters in cells. however, co-localization of phospho-erk (perk) with phospho-elk-1 (pelk-1) in mitogen-stimulated cells was low and exceeded significantly by co-localization of perk with rnapii in which the ctd was phosphorylated on s5 (ps5-ctd). this implies that the interaction between elk-1 and erk is transient and that erk may subsequently associate with and phosphorylate other targets within pics, thereby contributing directly to the transcriptional activation of mitogen-responsive genes.",pmc2377423,1,1,40,1,41
1069,src kinase,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,positive,d,phosphorylation,tyrosine residues,hek293,epithelial,,human,['808'],nan,nan,"src kinase phosphorylates runx3 on tyrosine residues in vitro and in vivo. a, hek293 cells were transiently transfected with a fixed amount of myc-runx3 (0.5 μg) and increasing amounts of ha-src (0, 0.03, and 0.3 μg), and tyrosine phosphorylation of runx3 was examined by ip with anti-myc (runx3) antibody and ib with anti-phosphotyrosine antibody (py; 4g10). b, hek293 cells were transiently transfected with myc-runx3 and/or ha-src. physical interactions between runx3 (rx3) and src were examined by ip and ib using the indicated antibodies (top and 2nd panels). tyrosine phosphorylation of runx3 was analyzed by ip with the anti-myc antibody and ib with the antibody against phosphotyrosine (4g10; py) (3rd panel). the levels of myc-runx3 and ha-src in the transfected cells were measured by ib with the anti-myc and anti-ha antibodies. c, cells were transfected with myc-runx3 in the presence or absence of ha-src (wild type) or ha-src-kd (kinase-dead mutant). cell lysates were analyzed by ip with the anti-myc antibody and ib with anti-phosphotyrosine antibody (py). d, cells were transfected with myc-runx3 in the presence or absence of ha-src. cell lysates were treated with λ-phosphatase for 1 h at 30 °c and analyzed by ip and ib with the indicated antibodies. e, gst-src and his-runx3 obtained from e. coli were mixed as indicated, and ni-nta pulldown experiments were performed to determine the physical interaction between these two proteins. the interaction was analyzed by ib with the indicated antibodies. f, same proteins were subjected to an in vitro phosphorylation analysis. a fixed amount of his-runx3 (500 ng) and increasing amounts of gst-src (50, 150, and 300 ng) were incubated and analyzed by ib with the anti-runx3 (5g4), anti-src, and anti-phosphotyrosine antibodies. the amount of tyrosine-phosphorylated runx3 increased with increasing amounts of src.",pmc2843174,1,1,40,1,41
437,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,bad,protein,,bcl2l1,uniprot,q92934,cytoplasm,go:0005737,negative,d,phosphorylation,"ser112, ser136",hela cells,epithelial,cervical cancer,human,['293'],nan,nan,"test compounds inhibit erk-mediated phosphorylation of p90rsk-1 and bad. (a) hela cells were pre-treated for one hour in the presence or absence of 50 um of the indicated test compounds and then stimulated with egf (25 ng/ml) for 10 minutes. immunoblots of phosphorylated p90rsk-1 (prsk), total rsk (rsk), phosphorylated erk1/2 (pperk), and total erk2 (erk2). α-tubulin was used as a loading control. graph shows densitometry quantification of prsk-1 to total rsk or pperk2 to erk2 ratios. data represents the mean ± sem from three independent experiments. (b) in vitro kinase assays examining 32p incorporation into p90rsk-1 following incubation with active erk2 and γ-32p-atp for 60 min. in the absence or presence of 1-25 μm of test compounds. relative phosphate incorporation was quantified by phosphoimager analysis. (c) hela cells were serum starved overnight and pre-treated for 1 hr with 50 um indicated test compounds, 10 mm u0126 (u), or 25 mm ly294002 (l) prior to stimulation with or without egf (25 ng/ml). immunoblot analysis of bad phosphorylated on ser112 (ps112) or ser136 (ps136) and total bad. α-tubulin was used as a loading control. data represents the mean ± sem from three independent experiments. * and # indicates statistical significance compared to egf-only treatment (a and c) or untreated controls (b), p ≤ 0.05 and p ≤ 0.01, respectively. c, untreated control; (-) egf treated control.",pmc3025971,1,1,40,1,41
989,s6k1,protein,,rps6kb1,uniprot,p23443,,,eif4b,protein,cap binding complex component,eif4b,uniprot,q13541,,,positive,d,phosphorylation,s422,,,,,['1439'],nan,nan,"s6k1 targets a number of proteins that control protein translation (figure 3). s6k1 regulates translation initiation by phosphorylating the cap binding complex component eif4b at s422 [70]. it also controls initiation of translation by phosphorylating pdcd4, a tumor suppressor that is a negative regulator of eif4a [71], and targets it for degradation by the ubiquitin ligase, βtrcp [72]. s6k1 inactivates eukaryotic elongation factor-2 kinase (eef2k) which is a negative regulator of eukaryotic elongation factor 2 (eef2), by phosphorylating it at s366, and thus regulates the elongation step of translation [73]. eukaryotic translation initiation factor 4b (eif4b) is also phosphorylated by s6k1 and this phosphorylation promotes the recruitment of eif4b to eukaryotic initiation factor 4a (eif4a) at the translation initiation complex where it functions as a cofactor of eif4a and increases its processivity [74]. s6k1 controls transcription by phosphorylating the camp response element binding protein (creb) isoform, cremt, and also regulates ribosome biogenesis by phosphorylating the transcription factor ubf-1 which results in the activation of rna pol1 mediated transcription of genes that encode rrna [75, 76]. s6k1 directly phosphorylates estrogen receptor (erα) to stimulate its transcriptional activity in breast cancer cell lines [77]. s6k1 also phosphorylates the p53 ubiquitin ligase, mdm2, on s166 [78] and proapoptotic protein bad, thus regulating cell survival [79]. s6k1 regulates mrna processing since it phosphorylates skar (s6k1 aly/ref-like target) which is involved in mrna splicing [80].",pmc4258317,1,1,40,1,41
123,akt,protein,serine/threonine kinase,akt,uniprot,p31749,plasma membrane,go:0005886,bad,protein,,bad,uniprot,q92934,cytoplasm,go:0005737,positive,d,phosphorylation,plasma membrane,,,,human,['2889'],nan,nan,"the serine/threonine kinase akt is one of the major downstream kinases activated by growth factor signaling such as egfr, platelet-derived growth factor receptor (pdgfr), and insulin-like growth factor receptor (igfr). akt has three isoforms, akt1, akt2, and akt3, and their activities are frequently elevated in multiple human cancers, which contribute to cancer cell survival and growth (altomare and testa, 2005). akt is activated by phosphatidylinositol-3 kinase (pi3k) that converts phosphatidylinositol (3,4)-bisphosphate (pip2) to phosphatidylinositol (3,4,5)-trisphosphate (pip3) in plasma membrane through lipid phosphorylation (altomare and testa, 2005; yuan and cantley, 2008). akt and phosphoinositide dependent kinase 1 (pdk1) are then recruited to the plasma membrane where akt is directly phosphorylated and activated by pdk1 (chan et al., 1999). activated akt phosphorylates various substrates involved in cell metabolism (gsk3, tsc2), survival (bad, foxo), and cell cycles (p21, p27, mdm2; cross et al., 1995; datta et al., 1997; brunet et al., 1999; zhou et al., 2001a,b; liang et al., 2002; manning et al., 2002), and then inhibits apoptosis and promotes cell growth. therefore, the pi3k–akt pathway is a potential drug target, and several pi3k or akt inhibitors have been actively tested in numerous clinical trials (garcia-echeverria and sellers, 2008; wong et al., 2010; chappell et al., 2011).",pmc3355968,1,1,40,1,41
126,akt,protein,serine/threonine-protein kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,phb,protein,,phb,uniprot,p04792,mitochondria,go:0005739,positive,d,phosphorylation,thr 258,miapaca-2 clones and hek-293t cells,,,human,['1847'],nan,nan,"rac-alpha serine/threonine-protein kinase (akt) is responsible for mediating a variety of biological responses.22, 23, 24 dysregulation of akt activity has been implicated in the pathogenesis of a growing number of disorders.24 recently, phb has been identified as a substrate for akt in miapaca-2 clones and hek-293t cells expressing constitutively active akt.25 in these cells, akt-induced phosphorylation of phb occured at thr 258. this phosphorylation of phb by akt could lead to alteration in the localization of phb, transcriptional regulation of e2f and also activation of the ras-raf pathway.26 considering these possibilities, it would be both interesting and clinically relevant to study the potential phosphorylation of phb by endogenous akt.",pmc4669803,1,1,40,1,41
25,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,oct4,protein,transcription factor,pou5f1,uniprot,q01860,nucleus,go:0005634,positive,d,phosphorylation,threonine 228,hek293a,epithelial-like,kidney,human,['843'],nan,nan,"the putative akt phosphorylation site on oct4 resides within a motif of (r223krkrt228). in vitro kinase assay indicated that akt phosphorylated oct4 in an atp-dependent manner (figure 3a). a series of truncated gst-oct4 constructs was made and gst fusion proteins were subjected to in vitro kinase assay (figure s4a). only gst fusion proteins that carried the putative akt phosphorylation motif could be phosphorylated by akt (figure s4b). oct4 has been shown to be phosphorylated at serine 229 by pka [25]. the serine 229 is adjacent to the akt phosphorylation motif, mutation of which may influence the phosphorylation efficiency of akt. we therefore generated gst-oct4 proteins with threonine 228 or serine 229 being mutated. akt phosphorylated gst-oct4, but not gst, gst-oct4t228a, gst-oct4t228d or gst-oct4t228e (figure 3b). as expected, the serine 229 mutations significantly decreased the reaction efficiency (figure 3b). an antibody against phosphorylated oct4 at threonine 228 was raised and purified. using this antibody, we further confirmed akt phsophorylated gst-oct4 in vitro (figure 3c). to examine whether akt phosphorylated oct4 in vivo, hek293a cells were transfected with myc-akt (myr) together with flag-gfp-oct4, flag-gfp-oct4t228a or flag-gfp-oct4t228e. immunoprecipitation with anti-flag followed by immunoblotting with anti-phospho-akt substrate indicated that mutation of threonine 228 abolished phosphorylation-specific antibody recognition (figure 3d). the gfp-tagged phosphorylation-mimetic mutants of t228d and t228e always manifested low gfp intensity and low gfp-positive cell number, which implied that phosphorylation might confer oct4 unstable (figure 3e). we therefore evaluated the effects of t228 mutations on oct4 half-life. as illustrated in figure 3f, compared with wild-type oct4, t228a mutation extended the half-life of oct4, whereas t228e mutation significantly shortened in transfected 293a cells treated with cycloheximide (chx). to confirm that phosphorylated oct4 was prone to be ubiquitinated and degraded, we treated cells with mg132, an inhibitor of 26s proteasome, and found that the amount of phosphorylated oct4 was dramatically increased (figure 3g, figure s4d). we subsequently asked whether akt associated with oct4. to this purpose, a reciprocal co-immunoprecipitation indicated akt interacted with oct4 in an ectopically expressed system (figure s4e and s4f). a reciprocal gst pull-down assay showed gst-oct4 interacted with akt, and gst-akt interacted with oct4 (figure s4g and s4h). importantly, endogenous akt associated with oct4 in mouse es cells (figure s4i and s4j). collectively, these data indicate that akt phosphorylates oct4 and accelerates its degradation.",pmc3675137,1,1,40,1,41
439,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,elk-1,protein,,elk1,uniprot,p19419,nucleus,go:0005634,positive,d,phosphorylation,serine 383,,fibroblast,,human,['2767'],nan,nan,"to examine whether active erk was able to phosphorylate elk-1 at serine 383 in the absence of integrin engagement, we cotransfected cells with elk-1 and either 22w raf or empty vector. as before, control transfected cells exhibited little phosphorylation of elk-1 when either held in suspension or readhered to fibronectin for 3 h in the absence of growth factors (fig. 3 a). expression of 22w raf stimulated erk phosphorylation of elk-1 at serine 383 in adherent cells, but this effect was markedly reduced under suspension conditions (fig. 3 a). the levels of elk-1 and 22w raf were comparable between the suspension and fibronectin conditions (fig. 3 a, and latter data not shown). similarly, expression of mek1-δed resulted in efficient phosphorylation of serine 383 in elk-1 when cells were adherent to fibronectin but not under suspension conditions (fig. 3 b). in both the 22w raf and mek1-δed experiments, there remained a small but noticeable increase in the phosphorylation of elk-1 above control conditions in suspended cells. thus, the adhesion effect on erk-mediated phosphorylation of elk-1 is potent but not complete.",pmc2169466,1,1,40,1,41
1002,smad4,protein,,smad4,uniprot,q13485,nucleus,go:0005634,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,negative,d,phosphorylation,gsk3 phosphorylation sites (phospho-thr 273 and 269),hek-293,embryonic kidney,,human,['73'],nan,nan,"when these smad4 constructs were transfected into human embryonic kidney cells (hek-293) we found that all 3 mutants were less stable than the smad4 wild-type (wt) protein (fig. 2a and a', compare lanes 2, 4, 6, and 8).25,26 to determine the level of gsk3 phosphorylation of smad4 mutant proteins, the western blot was also immunostained with an affinity-purified phospho-specific antibody raised against the 2 first smad4 linker gsk3 phosphorylation sites (phospho-thr 273 and 269, referred to as ps4gsk3 ab in fig. 2a).19 because the expression levels of smad4wt and its mutants were different, the intensity of the ps4gsk3 bands was quantitated using the li-cor infrared imaging system and normalized over the total level of flag-tagged smad4 in each lane (ps4gsk3/s4-flag, fig. 2a”). this normalization showed that smad4m130 and smadm351 were more highly phosphorylated by gsk3 compared to the wild-type protein (fig. 2a”, compare lane 2 to lanes 4 and 6, brackets). the phosphorylations were inhibited by the gsk3 inhibit or lithium chloride (licl) and therefore required gsk3 activity (fig. 2a). phosphorylation of smad4m383 (used here as a control) was not significantly different from that of the wild-type protein (fig. 2a”, bars 2 and 8).",pmc4845174,1,1,40,1,41
1003,smad4,protein,,smad4,uniprot,q13485,nucleus,go:0005634,p300,protein,,ep300,uniprot,q09472,nucleus,go:0005634,positive,d,binding,smad-activating domain (sad),,,,human,['88'],nan,nan,"until recently, smad4 was believed to function as an unregulated constitutive co-smad that bound to r-smads after their activation by c-terminal phosphorylations, causing nuclear translocation of the complex.1 however, our recent work has shown that smad4 is a transcription factor regulated both by fgf/egf and canonical wnt signaling.19 in the presence of thr277 phosphorylation by mapk/erk, the transcriptional activity of smad4 is maximal provided that gsk3 activity is inhibited by wnt. maximal activity is mediated by the binding of a co-activator, probably p300, to a growth factor-regulated smad-activating domain (sad) that includes thr277.19,20 in the absence of wnt, thr277 phosphorylation primes 3 gsk3 phosphorylations that generate a phosphodegron recognized by β-trcp, inhibiting transcription and triggering smad4 degradation (fig. 6).",pmc4845174,1,1,40,1,41
1004,smad4,protein,,smad4,uniprot,q13485,nucleus,go:0005634,β-trcp,protein,e3 ligase,btrc,uniprot,q9y297,cytoplasm,go:0005737,negative,d,binding,gsk3 phosphorylation,,,,human,['71'],nan,nan,"we previously showed that smad4 stability is controlled by wnt-regulated gsk3 phosphorylations that generate a docking site for the ubiquitin e3 ligase β-trcp.19 others had observed that point mutations commonly found in colorectal and pancreatic cancers enhance the interaction between smad4 and β-trcp.25 our discovery that the binding of smad4 to β-trcp requires gsk3 phosphorylation suggested that smad4 containing point mutations may have an increased susceptibility to gsk3 phosphorylation. this, in turn, would generate a phosphodegron recognized by β-trcp, triggering polyubiquitination and degradation in the proteasome (fig. 1a).",pmc4845174,1,1,40,1,41
1005,smad4,protein,transcription factor,smad4,uniprot,q13485,nucleus,go:0005634,gsk3,kinase,,gsk3,uniprot,p49841,cytoplasm,go:0005737,positive,d,phosphorylation,serine and threonine residues,"hek293, smad−/− mammary cancer cell line, caco-2",epithelial,"prostate, colon, pancreatic","human, mouse",['87'],nan,nan,"smad4 is a critical transcription factor in the tgf-β pathway and loss of smad4 is associated with malignant progression in prostate, colon, and pancreatic carcinomas.4,5 in the present work, we provide evidence that 2 smad4 missense point mutations found in human cancers (pro130ser and asn351his) increase smad4 phosphorylation by the gsk3 kinase, thus triggering its degradation (fig. 6). chemical inhibition of gsk3 blocked the increased phosphorylation caused by these smad4 mutations and stabilized protein levels in hek293 cells. replacing smad4 with various mutations in a smad−/− mammary cancer cell line showed that tgf-β signaling is greatly impaired by point mutations that naturally occur in cancer, and that in 2 of these cases signaling via a synthetic tgf-β reporter gene can be reactivated by simply inhibiting gsk3 activity. in caco-2 cells, which express smad4n351h protein, the gsk3 inhibitor licl was sufficient to restore tgf-β responsiveness in a cell line that was previously impervious to tgf-β signaling. these findings suggest that the tgf-β intracellular cascade is intact and that the low level of smad4n351h is the rate-limiting factor in caco-2 cells. tgf-β signaling can be reactivated provided that smad4 rapid degradation is blocked by a gsk3 chemical inhibitor in cells that would otherwise behave as tgf-β loss-of-function mutants.",pmc4845174,1,1,40,1,41
129,akt1,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,satb1,protein,,satb1,uniprot,q01826,nucleus,go:0005634,positive,d,co-transfection,,hek293a,epithelial-like,,human,['832'],nan,nan,"hek293a cells grown on glass coverslips were transfected with either plasmids encoding gfp-satb1 together with myc-akt1 wt, myc-akt1 myr or myc-akt1 dn, or plasmids of gfp alone, gfp-satb1, gfp-satb1s47a or gfp-satb1s47d using lipofectamine 2000 (invitrogen). transfected cells were cultured for 24 h. fluorescent cells were viewed using fluorescence microscopy, and images were aquired with a ccd camera.",pmc3675137,1,1,40,1,41
1006,smad4-wt,protein,,smad4,uniprot,q13485,cytoplasm,go:0005737,tgf-beta,cytokine,,tgfb1,uniprot,p01137,extracellular space,go:0005615,positive,i,potentiation,gsk3 phosphorylation sites of smad4,,,,human,['79'],nan,nan,"co-transfection of smad4-wt into these smad4−/− cells restored tgf-β responsiveness, which was moderately increased by licl (fig. 3, bars 1–6). in contrast, cells expressing smad4m130 and smad4m351 transduced the tgf-β signal very poorly but their signaling levels were dramatically increased by the addition of licl (fig. 3, compare bars 11 to 12 and 17 to 18). importantly, when cells were transfected with their counterpart gsk3-resistant forms (smad4m130-gm and smad4m351-gm, respectively), tgf-β caused a strong response but the potentiation by licl was lost (fig. 3, bars 13–15 and 19–21). since replacing smad4m130 and smad4m351with their gsk3-insensitive mutants eliminated licl potentiation, we conclude that the observed potentiation of tgf-β by licl is mediated by the gsk3 phosphorylation sites of smad4 and not by other components of the signal transduction pathway. in contrast, the low activity of smad4m383 was not reactivated by licl or by mutation of its gsk3 sites (fig. 4, bars 22–27) indicating that the ile383lys mutation has some functional defect in transducing the tgf-β signal that cannot be reversed by gsk3 inhibition.",pmc4845174,1,1,40,1,41
1007,smad4/dpc4,protein,tumor suppressor,smad4,uniprot,q13485,nucleus,go:0005634,tgf-β,cytokine,,tgfb1,uniprot,p01137,extracellular space,go:0005615,negative,d,phosphorylation,gsk3,,,,,['65'],nan,nan,point mutations in the tumor suppressor smad4/dpc4 enhance its phosphorylation by gsk3 and reversibly inactivate tgf-β signaling,pmc4845174,1,1,40,1,41
132,amp-activated protein kinase (ampk),protein,,ampk,uniprot,q13131,cytoplasm,go:0005737,hur,protein,,elavl1,uniprot,q15717,nucleus,go:0005634,positive,i,phosphorylation,s242,,,,,['2213'],nan,nan,"the amp-activated protein kinase (ampk) does not phosphorylate hur directly, but it phosphorylates and enhances the acetylation of importin α1 [42]; in turn, importin α1 favors the nuclear import of hur. stress conditions that reduce ampk activity can suppress this import pathway, thus allowing cytoplasmic hur to accumulate [73]. how dna damage affects importin 1α-mediated localization of hur remains to be tested directly. finally, an as-yet unidentified kinase was reported to phosphorylate hur at s242, promoting its nuclear retention [40, 74] (figure 1).",pmc2925474,1,1,40,1,41
24,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,npm,protein,chaperone,npm1,uniprot,p06748,nucleolus,go:0005730,positive,d,phosphorylation,serine 48,,,,,['364'],nan,nan,akt phosphorylates npm on serine 48 and regulates npm quaternary structure,pmc4171619,1,1,40,1,41
1020,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,cofilin,protein,,cfl1,uniprot,p23528,cytosol,go:0005829,positive,i,dephosphorylation,,mcf-10a v-src:er,epithelial-like,mammary gland,human,['2398'],nan,nan,"src has been shown to elicit cofilin-mediated disruption of the actin cytoskeleton through the mek/erk pathway [5]. the function of cofilin is activated via its dephosphorylation [32]. thus, we examined whether src can disrupt the actin cytoskeleton through dephosphorylation of cofilin in mcf-10a v-src:er cells. indeed, phalloidin staining and western blot analysis demonstrated that src can depolymerize the actin cytoskeleton and dephosphorylate cofilin (fig. 2). we further examined the involvement of the mek/erk pathway in src-mediated modulation of the actin cytoskeleton. treatment of mcf-10a v-src:er cells with the mek inhibitor u0126 completely inhibited src-mediated phosphorylation of erk1/2, a major target of mek1/2 (fig. 3a). under this condition, u0126 significantly inhibited both src-induced actin dynamics (fig. 3b) and the dephosphorylation of cofilin (fig. 3c). therefore, these results indicate that src induces cofilin-mediated actin depolymerization through the mek/erk pathway in mcf-10a cells.",pmc4334522,1,1,40,1,41
1021,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,ing1,protein,,,uniprot,o95365,nucleus,go:0005634,positive,d,cotransfection,,hek293,epithelial,kidney,human,['3549'],nan,nan,"hek293 cells were untransfected (lane 1), transfected with src constructs alone (lanes 2–4) ing1 alone (lane 5) or cotransfected with ing1 plus wt src (lane 6), activated src (lane 7) or kinase dead src (lane 8). lysates (top panels) or ing1 immunoprecipitates (bottom panels) were blotted with the indicated antibodies.",pmc3621671,1,1,40,1,41
1022,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,noxa1,protein,,cyba,uniprot,p13498,plasma membrane,go:0005886,positive,d,phosphorylation,tyr110,hek293,epithelial,,human,['1368'],nan,nan,"to verify whether src-mediated phosphorylation of noxa1 on its tyr110 had an effect on its binding to tks4, hek293 cells were cotransfected with flag-tagged tks4 and either with noxa1 wt, noxa1 y110e, and noxa1 y110a mutant. as clearly indicated in the coimmunoprecipitation experiments in figure 3a, noxa1 wt bound tks4 as expected, whereas the presence of noxa1 y110a unphosphorylable mutant completely abolished its binding to tks4. conversely, noxa1 y110e phosphomimetic mutant restored this interaction. to validate this finding, we pursued an alternative biochemical approach, performing a pulldown using recombinant gst-tagged tks4 protein to probe hek293 cell extracts expressing either noxa1 wt, noxa1 y110e and noxa1 y110a mutants. figure 3b confirms that gst-tks4 bound noxa1 wt and noxa1 y110e but not noxa1 y110a.",pmc2993755,1,1,40,1,41
1023,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,noxa1,protein,,cyba,uniprot,q15080,cytoplasm,go:0005737,positive,d,phosphorylation,tyrosine,ht29,epithelial,colon,human,['1364'],nan,nan,"human ht29 colon cancer cells were also reported to endogenously express noxa1 and high level of active src. to test whether noxa1 is targeted by src under more physiological conditions, ht29 cells were treated with src inhibitor pp2 or pp3, endogenous or ectopically-expressed noxa1 was immunoprecipitated and the levels of tyrosine (tyr)-phosphorylated noxa1 were analyzed using p-tyr antibody. as shown in figure 2c, pp2 treatment strongly diminished the levels of tyr-phosphorylation of both endogenous and ectopically-expressed noxa1 compared with pp3 treatment.",pmc2993755,1,1,40,1,41
119,akt,protein,,,uniprot,p31749,,,satb1,protein,,satb1,uniprot,q01826,,,positive,d,phosphorylation,,,breast cancer,,human,['857'],nan,nan,"we provide several lines of evidence revealing that satb1 is a novel substrate of akt. moreover, satb1 phosphorylation is perfectly dependent on igf-1/pi3k signaling and igf-1/pi3k/akt/satb1 presumably constitutes a novel signal relay axis. it is reported that satb1 partially co-localizes with pml, and when apoptosis occurs is targeted for the pml body where satb1 is sumoylated and cleaved by caspase 6 [23]. our data reveals that akt-mediated phosphorylation shields satb1 from apoptotic cleavage, but it remains unknown whether satb1 cleavage is a cause or a result of apoptosis. consistently, the phosphorylation-mimetic mutant satb1s47d is reluctant to be localized to pml body, whereas the mutant satb1s47a is unstable in several breast cancer cell lines. the unstable mutant satb1s47a reversibly stimulates akt activation by a yet-to-be identified mechanism, suggesting that a feedback loop exists between akt and satb1 in terms of kinase catalytic activity. a number of molecules including pdk1, mtorc2, pp2a, pten and phlpp may serve as candidates to modulate akt activation, which could be indirectly regulated by satb1.",pmc3675137,1,1,40,1,41
26,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,phb,protein,,phb,uniprot,p35232,mitochondria,go:0005739,negative,d,inhibition,mitochondria,bc cell lines,epithelial-like,breast cancer,human,['1856'],nan,nan,"to examine whether the activity of akt is responsible for localization of phb, bc cell lines were treated with the akt inhibitor gsk690693, a potent and selective, atp-competitive, pan-akt kinase inhibitor currently in clinical development for patients with various malignancies.34, 35 treatment with gsk690693 resulted in reduction in phosphorylation of akt sustrate gsk3β (ser9) and an increase in akt phosphorylation at ser473 site (figure 4c), consistent with the feedback mechanism observed previously with this akt kinase inhibitor.36 furthermore, inhibition of akt activation by gsk690693 effectively reduced the localization of phb in mitochondria (figure 4d), without influencing the total protein level of phb (figure 4c).",pmc4669803,1,1,40,1,41
1025,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,positive,d,overexpression,cytoplasm,hela,epithelial,cervical cancer cells,human,['805'],nan,nan,"because src is frequently activated in various cancers where runx3 is mislocalized in the cytoplasm, we hypothesized that the cytoplasmic localization of runx3 might be associated with the activation of src kinase. to investigate this possibility, we examined whether the subcellular localization of runx3 is affected by the overexpression of src. hela cells were transiently transfected with an expression plasmid encoding myc-tagged runx3 (myc-runx3) with or without a plasmid encoding ha-tagged wild-type src (ha-src). the subcellular localizations of runx3 and src were analyzed by immunocytochemical analysis using corresponding antibodies. in the absence of src, runx3 protein was localized in the nucleus of transfected cells (fig. 1a, top panel). in contrast, when runx3 was coexpressed with wild-type src, runx3 was localized in the cytoplasm (fig. 1a, 2nd panel). these results suggested that the overexpression of src is associated with the cytoplasmic localization of runx3. we also tried coexpression with a plasmid encoding an ha-tagged kinase-dead mutant of src (ha-src-kd). this mutant protein has a k298a substitution in its atp-binding site that was previously shown to inactivate the tyrosine kinase activity of src (47). coexpression with ha-src-kd failed to induce the cytoplasmic localization of runx3 (fig. 1a, 3rd panel), suggesting that the src-mediated cytoplasmic localization of runx3 is dependent on the tyrosine kinase activity of src. essentially the same results were obtained when hela cells were replaced by syf cells (fig. 1b). although biochemical interaction experiments were done with hek293 cells, we have not used hek293 cells in immunocytochemical analysis, because these cells are easily detached from the plate when staining with antibodies.",pmc2843174,1,1,40,1,41
27,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,satb1,protein,transcription factor,satb1,uniprot,q01826,nucleus,go:0005634,negative,d,phosphorylation,unknown,f9,embryonic,unknown,mouse,['851'],nan,nan,akt-mediated phosphorylation is crucial for the role of satb1 to down-regulate the nanog expression during ra-induced f9 cell differentiation,pmc3675137,1,1,40,1,41
42,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,gsk3β,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,negative,d,phosphorylation,s9,,,,human,['2895'],nan,nan,"akt has been shown to directly phosphorylate gsk3β and inhibits it (cross et al., 1995), and therefore, akt seems to indirectly inhibit β-catenin degradation and inactivation through inhibition of gsk3β (monick et al., 2001). in addition to the indirect mechanism, akt directly mediates the β-catenin stability by phosphorylating β-catenin at s552. once phosphorylated by akt, β-catenin binds to 14-3-3ζ and is stabilized (tian et al., 2004; fang et al., 2007). in addition to akt, we also demonstrated that erk upregulates β-catenin via inhibition of gsk3β (ding et al., 2005). activated erk directly interacts with gsk3β and phosphorylates it at t43. after the phosphorylation by erk, gsk3 is primed for subsequent phosphorylation by p90rsk at s9, which inactivates it. furthermore, ikk has been shown to be directly involved in the β-catenin regulation, and ikkα but not ikkβ phosphorylates β-catenin and prevent its ubiquitination and degradation (lamberti et al., 2001; albanese et al., 2003; carayol and wang, 2006). collectively, β-catenin is another common target of akt, erk, and ikk, demonstrating that the ubiquitin–proteasome system plays a critical role in these signaling pathways (figure 1b).",pmc3355968,1,1,40,1,41
41,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,gsk-3,protein,kinase,gsk3b,uniprot,p49841,cytoplasm,go:0005737,positive,d,phosphorylation,gsk-3 peptide,,,,human,['2131'],nan,nan,"cells were lysed in 1 ml of lysis buffer (50 mm tris-hcl, ph 7.5, 150 mm nacl, 1% (w/v) triton x-100, 10% glycerol, 1 mm edta, 1 mm dithiothreitol, 1 mm benzamidine, 1 mm phenylmethylsulfonyl fluoride, 1 mg/ml bacitracin, 1 mm na3vo4, 30 mm nappi, 10 mm naf, 100 nm okadaic acid). following centrifugation, the supernatants were incubated for 2 h at 4 °c with protein a-sepharose beads coated with 2.5 µl of anti-akt antibody. immunoprecipitates were washed three times with the lysis buffer and twice with the kinase assay buffer (50 mm tris-hcl, ph 7.5, 10 mm mgcl2, 1 mm dithiothreitol) and assayed using gsk-3 peptide (grprtssfaeg) as substrate as described [43].",pmc3181262,1,1,40,1,41
40,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,foxo3a,protein,,foxo3,uniprot,o43524,nucleus,go:0005634,negative,i,correlated with,,crc,colorectal cancer,,human,['3568'],nan,nan,akt/foxo3a signaling is correlated with selenite-induced apoptosis in crc cells,pmc3734838,1,1,40,1,41
106,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,foxo3a,protein,,foxo3,uniprot,o43524,nucleus,go:0005634,positive,i,phosphorylation,ser253,,crc,colorectal,human,['3569'],nan,nan,"having discovered that selenite treatment inhibited src/pi3k/pdk1/akt signaling and activated foxo proteins, we conducted a series of experiments to investigate the relationship between akt and foxo3a in selenite-induced apoptosis in crc cells. on one hand, as revealed in figures 2a and b, when akt was inhibited in selenite-treated crc cells with either the pi3k inhibitor ly294002 or akt sirna, we found that both treatments further decreased the p-akt level. as expected, inhibiting akt further suppressed the phosphorylation of foxo3a at ser253 even with selenite treatment. conversely, when we activated akt in crc cells using constitutively activated akt constructs prior to selenite treatment, we found that, consistent with our hypothesis, constitutively activated akt increased phosphorylation of akt and foxo3a and selenite could no longer reduce phosphorylation of akt and consequently phosphorylation of foxo3a (figure 2c). these results collectively showed that selenite-elicited inhibition of akt was associated with the activation of foxo3a. subsequently, we attempted to determine the role of akt/foxo3a in selenite-induced apoptosis of crc cells. first, from western blot results of the above-mentioned samples, we observed that reactivation of akt resulted in less cleavage of apoptosis-related markers such as caspase 9 and parp, whereas further inhibition of akt led to additional cleavage of these apoptosis-related markers. analysis of the apoptotic rate by facs using cells treated as indicated in the panels of figures 2d and e and supplementary figures s2a and b demonstrated that akt reactivation or inhibition could blunt or enhance, respectively, the apoptosis of crc cells treated with selenite. complementary to the above results, silencing foxo3a with sirna specifically decreased the level of apoptosis in selenite-treated crc cells, as revealed by western blotting and facs (figures 2f and g; supplementary figure s2c). thus, these findings clearly demonstrate that selenite induced apoptosis in crc cells through regulation of the akt/foxo3a pathway.",pmc3734838,1,1,40,1,41
107,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,insulin,hormone,,ins,uniprot,p01308,extracellular space,go:0005615,positive,d,stimulation,,,,,,['930'],nan,nan,"except where indicated otherwise, cells were serum starved overnight and incubated with inhibitors or 0.1% dmso for 30 min prior to stimulation with 100 nm insulin for 10 min. all inhibitors were either synthesized as previously described [21,24,55] or were from calbiochem (rapamycin and akti-1/2). cells were lysed by scraping into ice cold lysis buffer followed by brief sonication. lysates were cleared by centrifugation, resolved by sds-page, transferred to nitrocellulose, and immunoblotted with antibodies from cell signaling technology. unless otherwise indicated, cells were lysed in 300 mm nacl, 50 mm tris ph 7.5, 5 mm edta, 1% triton x-100, 0.02% nan3, 20 nm microcystin (calbiochem), sigma phosphatase inhibitor cocktails 1 and 2, roche protease inhibitor cocktail, and 2 mm pmsf. for figures 6a and 7a, and figure s2a, cells were lysed in cap lysis buffer (140 mm kcl, 10 mm tris ph 7.5, 1 mm edta, 4 mm mgcl2, 1 mm dtt, 1% np-40, 20 nm microcystin, sigma phosphatase inhibitor cocktails 1 and 2, roche protease inhibitor cocktail without edta and 2 mm pmsf).",pmc2637922,1,1,40,1,41
39,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,foxo3,protein,transcription factor,foxo3,uniprot,o43524,nucleus,go:0005634,negative,d,inhibits,,,cancer cells,,human,['2900'],nan,nan,"recent advances in signal transduction studies have identified many key oncogenic kinases and their substrates in cancer progression, and the signaling pathways associated with these kinases have been recognized as promising drug targets. indeed, several kinase inhibitors have been developed and used in clinic that show high efficacy and low toxicity (sharma and settleman, 2010). however, several clinical studies have emerged showing that some patients exhibit little or no response to these targeted drugs, and those who originally responded the drugs eventually developed resistance. although the detailed mechanisms underlying drug resistance are not fully understood, there is evidence to support that alternative pathways are being activated in resistant cells to compensate for the survival signal blocked by targeting agents. for example, egfr tyrosine kinase inhibitors (tkis) are effective drugs for egfr mutant lung cancer, but c-met amplification or k-ras mutation causes the resistance to tkis by bypassing the inhibition of survival signaling (bean et al., 2007; linardou et al., 2008). we also showed that cancer cells with high akt signaling pathway exhibit resistance to erk inhibitors by inhibiting foxo3 (yang et al., 2010). therefore, in order to develop effective personalized cancer therapy, it would be essential that we understand the cross-talk among the multiple oncogenic signaling pathways.",pmc3355968,1,1,40,1,41
38,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,foxo1,protein,,foxo1,uniprot,o43524,nucleus,go:0005634,negative,d,inhibition,,"panc-1, aspc-1",pancreatic cancer,epithelial,human,['2115'],nan,nan,"(a), panc-1 and aspc-1 cells were transiently transfected with 6× dbe-luciferase construct for 24 h. after transfection, cells were pretreated with akt inhibitor iv (1 µm) and/or mek1/2 inhibitor pd98059 (10 µm) for 2 h, followed by treatment with or without resveratrol (10 µm) for 24 h. cells were harvested for firefly/renilla luciferase assays using the dual-luciferase reporter assay system (promega). luciferase counts were normalized using renilla luciferase transfection control (prl-tk; promega). data represent the mean ± s.d. *, # and ** = significantly different from respective controls, p<0.05. (b), resveratrol induces translocation of wild type and triple mutant foxo1 to nucleus. pancreatic cancer panc-1 cells were transfected with either gfp-foxo1 or gfp-foxo-tm and treated with resveratrol (10 µm) for 24 h. cells were visualized by fluorescence microscopy. (c), phosphorylation deficient mutants of foxo (triple mutants) enhance resveratrol-induced foxo transcriptional activity in pancreatic cancer. panc-1 and aspc-1 cells were transiently transfected with empty vector or constructs encoding foxo1-tm, foxo3a-tm, or foxo4-tm together with 6× dbe-luciferase for 24 h. after transfection, culture medium was replaced with complete rpmi, treated with resveratrol (10 µm) for 24 h, and harvested for firefly/renilla luciferase assays using the dual-luciferase reporter assay system (promega). luciferase counts were normalized using renilla luciferase transfection control (prl-tk; promega). data represent the mean ± s.d. *, % and # = significantly different from control, p<0.05. (d) left panel, resveratrol inhibits cytoplasmic phosphorylation of foxo1 and foxo3a. panc-1 cells were treated with resveratrol (0, 10 and 20 µm) for 36 h, and cytoplasmic fractions were prepared. the expressions of p-foxo1 and p-foxo3a were measured by the western blot analysis. right panel, foxo-dna binding. panc-1 cells were treated with or without resveratrol (10 µm) for various time points (0–32 h). nuclear extracts were prepared. gelshift assay was performed as we described in material and methods. lane 1 = probe only, lane 2 = 50× cold probe, lane 3 = control, lane 4 = cell lysates from control samples treated with sp1 probe, lanes 5–11 = cell lysate from resveratrol treated samples at 4, 8, 12, 16, 20, 24 and 32 h.",pmc3181262,1,1,40,1,41
37,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,erα,protein,,esr1,uniprot,p03372,nucleus,go:0005634,negative,i,disrupts,,5637/t24,bladder cancer,bladder,human,['1863'],nan,nan,"to further confirm whether akt-induced phb phosphorylation could mediate the translocation of phb, we analyzed the interaction between phb and erα. in 5637 or t24 cell lines, immunoblot analysis of immunoprecipitated phb detected neither the presence of erα nor erβ (figure 7b, data not shown). also, phb was not present following a reciprocal immunoprecipitate using the antibody against erα (figure 7b). furthermore, we found that phb interacted with erα upon akt inhibitor treatment (figure 7b). furthermore, following akt inhibitor treatment, phb levels were elevated in the nuclear fractions and decreased in the mitochondrial fractions as compared with untreated bc cells (figure 7c). these results indicate that phosphorylation of phb could disrupt the interaction between erα and phb and mediate the mitochondrial localization of phb.",pmc4669803,1,1,40,1,41
108,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,npm,protein,,npm1,uniprot,p06748,cytoplasm,go:0005737,negative,d,inhibition,,psn1,pancreatic,,human,['387'],nan,nan,"we confirmed that the regulation of npm oligomerisation and p53mut levels in psn1 cells were affected by akt inhibition with mk-2206 in-vitro (fig. 5a, s5b and 7b). psn1 cells were injected into athymic nude mice which were subsequently treated with mk-2206 or carrier as indicated (fig. 7a). tumors were excised and reduced levels of phospho-s473-akt and phospho-s48-npm are apparent in the tumor lysates of mk-2206 treated mice, correlating with the enhanced oligomerization of npm and induction of p21 expression (fig. 7a). additionally, we verified that increased p21 expression in mk-2206 treated psn1 xenografts was linked to inhibition of akt, decreased phospho-s48-npm, arf nucleolar re-localization and decreased p53mut expression by ex-vivo staining of tumor sections by immunofluorescence and immunohistochemical staining (ihc) (fig. 7b, 7c and 7d). in agreement with previous reports [9], pi-3k and akt inhibitors have little effect on tumor growth as single agents (fig. s7c). however, our data demonstrates that reduction of p53mut levels reinstates tumor suppressor and dna damage responses (fig. 6a, s6a and s6b). we therefore selected the minimal dose that reduced akt activity (60 mg/kg) for xenograft studies in combination with a single dose of ir (6 gy, xrt) to determine whether synergy can be achieved in-vivo. mk-2006 induced a tumor growth delay of 3.3 days compared to control animals, however, overall survival (time to sacrifice) was not affected. in contrast, the combination of mk-2206 with a single dose of xrt resulted in a growth delay of 12.5 and 9.2 days compared to either xrt or mk-2206 alone (fig. 7e and s7d). moreover, this resulted in a significant increase in survival of the treated animals (represented here by the surrogate measure of 4 times tumor volume from time of randomization and initiation of treatment) compared to controls (p<0.0001 mantel cox log-rank; p<0.0001 gehan-breslow-wilcoxon).",pmc4171619,1,1,40,1,41
31,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,4ebp-1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,,,aml blasts,bone marrow,human,['1974'],nan,nan,"elevated akt activity can also result in increased phosphorylation of mtor. mtor was found to be phosphorylated in aml blasts, along with its two downstream substrates, p70s6k and 4ebp-1, in a pi3k/akt-dependent fashion [384]. nevertheless, others failed to detect any relationship between pi3k/akt signalling upregulation and p70s6k phosphorylation in aml primary cells [385]. this might occur via the ras/raf/mek/erk pathway activating mtor via erk phosphorylation [385]. the ras/raf/mek/erk pathway is frequently activated in aml [386-388].",pmc3660063,1,1,40,1,41
30,akt,protein,,akt,uniprot,p31749,cytosol,go:0005829,bad,protein,,bcl2l8,uniprot,q92934,cytosol,go:0005829,positive,d,phosphorylation,,,,,mammalian,['1618'],nan,nan,"in mammalian cells, the release of cytochrome c from mitochondria has been proposed as the critical event for cells to initiate the apoptotic cascade. in the cytosol, cytochrome c binds to apaf-1 and triggers apaf-1–mediated caspase-9 activation. activated caspase-9 propagates the death signal by activating caspase-3 and other caspases (slee et al. 1999; zou et al. 1999). in cell-free assays of apoptosis, exogenously added cytochrome c initiates rapid apoptotic events, including caspase-3 activation and dna fragmentation (liu et al. 1996; li et al. 1997a; slee et al. 1999). data from our cell fractionation study and cell-free assay are consistent with bcl-2 acting to inhibit apoptosis mainly at the mitochondrial level to suppress cytochrome c release, since bcl-2 inhibits the release of cytochrome c but fails to inhibit caspase activation induced by added cytochrome c in the cell-free assay. akt phosphorylates and inactivates bad, which may maintain bcl-2 and bcl-xl function, and it has been suggested that akt inhibits cell death by preventing cytochrome c release from mitochondria (kennedy et al. 1999). in contrast, our data indicate that akt protects neural cells from apoptosis at a postmitochondrial stage to inhibit caspase activation. first, active akt protects cells from apoptosis without blocking cytochrome c release into the cytosol. second, addition of cytochrome c failed to induce caspase-9 activation, caspase-3 processing, or parp cleavage in extracts from cells expressing active akt. third, addition of active akt to lysates from control cells blocked cytochrome c–induced caspase activation. fourth, cells expressing active akt are resistant to apoptosis induced by microinjection of cytochrome c.",pmc2185587,1,1,40,1,41
111,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,rps3,protein,,rps3,uniprot,p23396,nucleus,go:0005634,positive,d,phosphorylation,,,,,,['19'],nan,nan,"akt is thought to phosphorylate up to 100 substrates, some of which have been implicated in dna damage checkpoint response and dna repair. for instance, direct phosphorylation of cell cycle checkpoint kinase chk1, topbp1, brca1, and rps3 by akt is important for the activation of dna damage signalling cascade [101, 123–125] (figure 3). in addition, akt activity is pivotal for the focal accumulation of key factors regulating dsb resection and dna repair, including rad51, brca1, ctip, and rpa [100, 121, 122, 126].",pmc3317191,1,1,40,1,41
112,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,runx2,protein,,runx2,uniprot,q13950,nucleus,go:0005634,positive,i,phosphorylation,,,osteoblastic,bone,human,['3257'],nan,nan,"additional studies demonstrate that akt also positively regulates runx2 activity through indirect mechanisms, involving foxo1, foxo4 and glycogen synthase kinase 3β (gsk3β). the transcription factor foxo1 physically interacts with runx2 in osteoblastic cells and in cos-7 cells and inhibits runx2 binding to its cognate site within the osteocalcin promoter. upon igf1/insulin binding to their receptors, activation of the pi3k/akt pathway leads to phosphorylation and nuclear exclusion of foxo1 and reactivation of runx2 [54]. this indirect mechanism of runx2 activation by the pi3k/akt pathway is also described in human tumor cells. foxo1 interacts with runx2 in vitro and in prostate cancer cells, and inhibits runx2 transcriptional activity on the op, il8, vegf and mmp13 genes. foxo1 also inhibits runx2-mediated migration and invasion of prostate cancer cells [55]. the loss of pten in prostate cancer cells leads to activation of akt and phosphorylation and retention of foxo1 in the cytoplasm. the foxo1 phosphorylation by akt therefore abolishes foxo1-mediated inhibition of runx2 and favors runx2-mediated gene expression, migration and invasion [55]. interestingly, expression of pten and the level of foxo1 in the nucleus inversely correlate with runx2 expression in prostate cancer specimens from patients with lymph nodes or bone metastasis [55]. as demonstrated in prostate cancer, foxo4 antagonizes runx2 activity by physically interacting with and preventing runx2 to induce the expression of pro-metastatic genes, such as pip and pgc [43]. as for foxo1, akt phosphorylation of foxo4 results in its retention in the cytosol [56]. therefore, in the case of hyperactive akt signaling, the retention of foxo4 in the cytoplasm prevents this antagonism, thereby reactivating runx2 and favoring expression of runx2-dependent metastasis genes [43]. phosphorylation of runx2 at s369-s373-s377 by glycogen synthase kinase 3β (gsk3β) attenuates the transcriptional activity of runx2, explaining the suppression of bone formation by overexpression of wild-type gsk3β or constitutively active form of gsk3β (ca-gsk3β) [57]. since akt phosphorylates gsk3β at s9 causing its inactivation [58], we postulate that akt activation will result in gsk3β inactivation and restoration of runx2 transcriptional activity. therefore, in tumor cells exhibiting constitutive activation of the pi3k/akt pathway, by various mechanisms such as ras mutation, pten deletion, pi3k mutation, or receptor tyrosine kinase overexpression, it is conceivable that gsk3β inactivation will prevent the repression of runx2 transcriptional activity.",pmc4513933,1,1,40,1,41
29,akt,protein,,akt,uniprot,p31749,cell membrane,go:0005886,satb1,protein,,satb1,uniprot,q01826,nucleus,go:0005634,positive,d,phosphorylation,,f9,embryonal carcinoma,,mouse,['853'],nan,nan,akt-mediated phosphorylation is critical for the regulatory role of satb1 in f9 cell differentiation and nanog expression.,pmc3675137,1,1,40,1,41
117,akt,protein,,,uniprot,p31749,,,phb,protein,,,uniprot,p35232,,,positive,d,phosphorylation,,,bc cells,,human,['1858'],nan,nan,"increased cell proliferation during phb overexpression is eliminated with akt inhibitor treatment (figure 4e), which indicates that akt may promote cell proliferation in a phb-dependent manner. previous work and our study have also established that akt is activated and has a crucial role in the localization of phb and cell proliferation in bc,31 prompting us to ask whether phb is an akt substrate in bc cells. phospho-(ser/thr) akt substrate (pas) antibody recognizes the rxrxxp(s/t) peptide motif and has been used in studies of akt substrates. when phb immunoprecipitates of normal bladder, nmibc or mibc tissues were probed with pas antibody, we showed that the phosphorylation of phb in nmibc or mibc tissues controlled to normal bladder tissues were remarkably upregulated (figure 5a). furthermore, pas antibody also detected phosphorylated phb in phb immunoprecipitates of bc cells, while gsk690693 inhibited the phosphorylation of phb (figure 5b). the level of phb phosphorylation correlates well with that of akt activity in bc tissues and cells. another akt inhibitor mk-2206 (mk-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain and inhibits auto-phosphorylation of both akt thr308 and ser473),37 which inhibit akt activation and did not perturb the expression of phb (figure 5c), also inhibited the phosphorylation of phb effectively (figure 5b). our data confirm that phb is a downstream effector of the pi3k/akt pathway in bc cells and are consistent with the earlier finding of the breast cancer cell line, mcf-7.",pmc4669803,1,1,40,1,41
118,akt,protein,,,uniprot,p31749,,,runx2,protein,,,uniprot,q13950,,,positive,d,up regulation,mrna,,cancer,,,['3252'],nan,nan,"model of runx2 and pi3k/akt reciprocal interaction as a driving force for tumor progression. a. akt activity results in up regulation of runx2 mrna, stabilization of runx2 protein or activation of runx2 transcriptional activity. b. runx2 transcriptional activity leads to higher expression of the pi3k subunits p110β and p85, akt or mtor and rictor, two major components of the mtorc2 complex. c. mutual activation of akt and runx2 in the context of cancer cells might favor tumor progression. a pioneering study [47] shows that runx2 and the pi3k/akt axis are mutually dependent on each other in the regulation of osteoblast and chondrocyte differentiation and their migration. we propose that a similar feed-forward loop could operate in tumor cells to potentiate runx2 and pi3k/akt activities and generate the pro-migratory and pro-invasive behavior of tumor cells. studies described in paragraphs 1 and 2 support this hypothesis",pmc4513933,1,1,40,1,41
28,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,satb1,protein,transcription factor,satb1,uniprot,q01826,nucleus,go:0005634,positive,d,phosphorylation,,,stem cell,,adult,['833'],nan,nan,"the observation that akt is activated during the stage switch from quiescent to active adult stem cells raises the question of whether akt regulates self-renewal through control of its downstream stemness/differentiation substrates. we chose a number of candidate akt substrates according to the following criteria: (1) they modulate stemness/differentiation; (2) they have the conserved akt phosphorylation motif rxrxxs/t. we carried out an in vitro kinase assay to address whether akt could directly phosphorylate these candidate substrates (figure s1). we checked the phosphorylation by akt using phospho-akt substrate antibody and autoradiography. positive signals from both antibody detection and the autoradiography were set up as golden standard for further characterization. an autoradiographic signal alone was a less stringent standard if anti-phospho-akt substrate antibody failed to recognize the candidate motifs. we regarded antibody detection reliable when a positive signal was detected in the presence of atp and no band presented with a mutant gst fusion protein as a substrate. we identified several novel substrates of akt, including satb1, oct4 and klf4 (table s1). it is known that satb1 transcriptionally represses the expression of klf4 and nanog, we therefore hypothesized that akt signaling is probably involved in regulation of stemness through phosphorylation of satb1, oct4 and klf4 and by enhancing the antagonistic role of satb1 on nanog and klf4.",pmc3675137,1,1,40,1,41
1024,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,cytoplasm,go:0005737,negative,d,phosphorylation,tyrosine,,cancer cell lines,,human,['801'],nan,nan,"in this study, we provide evidence that src phosphorylates runx3 at multiple tyrosine residues. this src-mediated tyrosine phosphorylation results in the cytoplasmic mislocalization of runx3. notably, runx3 is localized in the cytoplasm in various cancer cell lines where the src kinase is highly activated. the knockdown of src by sirna facilitates the nuclear localization of runx3. our results suggest that the tyrosine phosphorylation and mislocalization of runx3 by the activation of src could be one of the mechanisms for runx3 inactivation in cancer cells.",pmc2843174,1,1,40,1,41
1001,smad4,protein,,smad4,uniprot,o15198,,,β-trcp,protein,,btrc,uniprot,q9y297,,,negative,d,binding,,,,,human,['72'],nan,nan,"to test this hypothesis, we constructed a series of smad4 mutants harboring 3 point mutations in the mh1 or mh2 domain that are commonly found in human cancers (fig. 1b).4 two of these, pro130ser and asn351his (referred to herein as smad4m130 and smad4m351), had been reported to be rapidly degraded as a consequence of increased binding to β-trcp.25 on the other hand, binding between smad4 ile383lys (smad4m383) and β-trcp was not found to be significantly enhanced,25 and was used as a control. to test the role of the newly discovered gsk3 linker phosphorylation sites in the degradation of smad4 mutants, we generated these point mutations with either intact linker gsk3 phosphorylation sites or mutated (thr to val) gsk3 phosphorylation sites (designated as smad4m130-gm; smad4m351-gm and smad4m383-gm) (fig. 1b).",pmc4845174,1,1,40,1,41
1052,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,abl,protein,,abl1,uniprot,p00519,plasma membrane,go:0005886,positive,i,inhibition,,,,,human,['803'],nan,nan,"cells grown on microscope coverslips were transfected with sirna-src or treated with the abl-src inhibitor (thiadiazole). cells were fixed with 4% paraformaldehyde for 15 min, treated with a serum-free blocking solution (dako, denmark), and incubated with a primary antibody at 4 °c overnight and a secondary antibody at room temperature for 1 h in a diluent solution (dako) (28). to visualize the nuclei, cells were counterstained with 4,6-diamidino-2-phenylindole. after mounting, cells were observed with a laser-scanning confocal microscope (leica, wetzlar, germany).",pmc2843174,1,1,40,1,41
1048,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,,runx3,uniprot,q13761,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['810'],nan,nan,"to investigate whether src directly interacts with runx3, bacterially expressed his-runx3 and gst-src were analyzed by ni-nta pulldown assays followed by ib. the results revealed that his-runx3 interacts with gst-src (fig. 2e). in vitro kinase assays performed with gst-src and his-runx3 proteins showed tyrosine phosphorylation of runx3 by src in an src concentration-dependent manner (fig. 2f). together, these results demonstrate that runx3 is a direct target of src.",pmc2843174,1,1,40,1,41
1035,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,c-src,protein,,csk,uniprot,p00519,plasma membrane,go:0005886,negative,d,disrupted,,syf cells,fibroblast-like,,human,['802'],nan,nan,"the hek293, bosc23, hela, and syf cells were maintained in dulbecco's modified eagle's medium. we used bosc23 cells and syf cells because src is not activated in bosc23, and c-src/yes/fyn are disrupted in syf cells. human gastric cancer cell lines mkn45, snu16, and human breast cancer cell lines bt549, bt20, and mda-mb-468 were maintained in rpmi 1640 medium, minimum essential media, or leibovitz's l-15 medium, respectively, with 10% fetal bovine serum and 100 units/ml penicillin/streptomycin in a humidified atmosphere with 5% co2 at 37 °c. transient transfections were carried out using lipofectamine plus reagent, and cells were harvested 24–48 h after transfection. immunoprecipitations, immunoblotting, and immunostaining were performed as reported previously (46).",pmc2843174,1,1,40,1,41
445,erk,protein,,,uniprot,p27361,,,enac,protein,,scnn1a,uniprot,q8wz42,apical membrane,go:0016324,negative,d,enhanced removal,apical membrane,,kidney,,human,['1805'],nan,nan,"in summary, our results are consistent with an erk-mediated decrease in channel po and enhanced removal of enac from the apical membrane. the importance of the examination of erk-mediated control of sodium absorption is twofold. first, in autosomal recessive polycystic kidney disease, mislocalization of the egf receptor to the apical membrane results in chronic activation of erk1/2 (veizis and cotton, 2005). the resulting inhibition in sodium absorption is believed to contribute to disease progression (omori et al., 2006). second, although this study deals with the egf-induced inhibition in enac activity, other agonists, including extracellular atp and pma (falin et al., 2005), inhibit sodium absorption partially via an erk-mediated mechanism and these results may aid in our understanding of those processes.",pmc2151644,1,1,40,1,41
1038,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,cofilin,protein,,cfl1,uniprot,p23528,cytoplasm,go:0005737,negative,d,actin depolymerization,,,,,,['2399'],nan,nan,the mek/erk pathway is indispensable for both fat4 gene repression and cofilin-mediated actin depolymerization by src.,pmc4334522,1,1,40,1,41
1039,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,cofilin,protein,,cfl1,uniprot,p23528,cytoplasm,go:0005737,negative,i,repression,fat4 gene,,,,,['2397'],nan,nan,src activation induces both fat4 gene repression and cofilin-mediated actin depolymerization through the mek/erk pathway,pmc4334522,1,1,40,1,41
1042,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,gab1,protein,,gab1,uniprot,q13480,plasma membrane,go:0005886,positive,d,phosphorylation,gab1,hek293,epithelial,,human,['2691'],nan,nan,"the phospho-erk levels measured in src-depleted cells (supplementary figure s13a) agree reasonably well with the corresponding model predictions (supplementary figure s13c). neither egfr nor ir autophosphorylation levels were affected by src downregulation (data not shown). moreover, we found that rnai-mediated suppression of src in hek293 cells led to a decrease in gab1 phosphorylation that was more pronounced for egf than for insulin. considering a substantial src contribution to gab1 phosphorylation under various conditions (nishida et al, 1999; bisotto and fixman, 2001; chan et al, 2003; jin et al, 2005), the model explains this observation by the fact that src is preferably activated by egfr and not by ir.",pmc2683723,1,1,40,1,41
1043,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,ing1,protein,,ing1,uniprot,o15278,nucleus,go:0005634,positive,d,phosphorylation,tyrosine,hek 293,epithelial,,human,['3548'],nan,nan,"to address whether the src-ing1 interaction promoted ing1 phosphorylation by src, an in vitro kinase assay was performed. bacterial recombinant ing1 protein was resuspended in kinase buffer, and incubated in the presence of atp, purified src, or both atp and src. only in the presence of both atp and src, an intense band corresponding to the size of ing1 was seen when the reaction was blotted with anti-phosphotyrosine (α-py) antibody (figure 2). in order to determine if ing1 was phosphorylated by src in vivo, hek 293 cells were transfected with plasmids to express ing1 alone or in the presence of ectopically-expressed wt src, activated src (y530f), or kinase-dead src (k298m). cell extracts were immunoprecipitated with α-ing1 antibody, and blotted with α-py antibody. as shown in figure 3, a band corresponding to the size of phosphorylated ing1 was detected in cells expressing ing1 together with wt src or activated src (lanes 6 and 7, lower panel). this result confirmed that ing1b can be phosphorylated by src in vivo. a decrease in total ing1 and in ing1 recovered in src immunoprecipitates was also observed in cells expressing elevated levels of src (figure 3, lanes 6–8), which was consistent with results previously described in figure 1.",pmc3621671,1,1,40,1,41
1044,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,ing1,protein,,,uniprot,q9uk53,nucleus,go:0005634,negative,d,destabilization,nucleus,,,,human,['3551'],nan,nan,"since it was observed in the in vivo experiments that ing1 levels were decreased in the presence of wt, activated, or kinase-dead src, we next asked if the various forms of src were involved in regulating the stability of ing1. cycloheximide (chx) was used to block protein synthesis, and ing1 levels were analyzed at 0 time and after 8 hrs of chx treatment by western blotting. in the absence of elevated src 80% of ing1 protein remained at 8hrs (figure 6) which agrees well with a previous study [39]. in the presence of wt or activated src, the level of ing1 decreased to 45% or 42%, respectively, after 8 hours, whereas very little decrease was observed in the presence of kinase-dead src. this indicated that src reduced the stability of ing1 significantly and suggested that src-induced ing1 destabilization was largely kinase-dependent. this was further supported by the results of cell fractionation experiments in which the activated and wt forms of src eliminated ing1 from the nucleus to a greater degree than kinase-dead src (figures 4b and 5).",pmc3621671,1,1,40,1,41
1046,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,noxa1,protein,,cyba,uniprot,q15513,plasma membrane,go:0005886,positive,d,phosphorylation,tyr110,hek293,kidney,,human,['1370'],nan,nan,"to test the functional relevance of noxa1 tyr-phosphorylation by src on nox1-dependent ros generation, hek293 cells were cotransfected with nox1, tks4, and either noxa1 wt, noxa1 y110e, or noxa1 y110a constructs and ros formation was monitored using luminol-based chemiluminescence (cl) assay. as shown in figure 3c, we observed a consistent 30% decrease of ros formation when noxa1 y110a mutant was expressed, but the presence of noxa1 y110e construct did not change the levels of ros production compared with noxa1 wt used as a positive control. these experiments strengthen the findings illustrated in figure 3, a and b and support the hypothesis that src-mediated phosphorylation of noxa1 on tyr110 affects its binding to tks4 and nox1-dependent ros generation.",pmc2993755,1,1,40,1,41
1060,src,protein,non-receptor tyrosine kinase,src,uniprot,p12931,plasma membrane,go:0005886,vhl,protein,tumor suppressor,vhl,uniprot,p40337,nucleus,go:0005634,positive,d,phosphorylation,,,cancer cell line,breast and other cancers,human,['3543'],nan,nan,"the proto-oncogene, src, is a non-receptor tyrosine kinase that plays an important role in transducing signals received through growth factor membrane receptors [27]. increased expression and activation of src has been observed in breast cancers [28], [29] as well as other cancers [30]–[33]. recently, we reported that src is able to trigger the degradation of the von hippel-lindau (vhl) tumor suppressor through direct phosphorylation of vhl [34]. the reduction of vhl levels resulted in increased hif1-α levels and angiogenesis. in another study, overexpression of src resulted in the mislocalization of runx3, a transcription factor that has tumor suppressor function [35]. furthermore, in tumor cell lines where src was activated, tyrosine phosphorylated runx3 was mainly detected in the cytoplasm [35].",pmc3621671,1,1,40,1,41
448,erk kinase,protein,kinase,mapk1,uniprot,p27361,cytoplasm,go:0005737,fbw7,protein,e3 ubiquitin ligase,fbxw7,uniprot,q969h4,nucleus,go:0005634,positive,d,phosphorylation,thr205,,pancreatic cancer cell,pancreas,human,['635'],nan,nan,"herein, we report that fbw7 is rarely mutated and the protein level is significantly downregulated in pdac, through a mechanism involving an activated ras-raf-mek-erk signaling pathway. we demonstrate that erk kinase directly interacts with and phosphorylates fbw7 at thr205, which leads to the ubiquitination and proteosomal degradation of fbw7 itself and the elevation of multiple fbw7 substrates, such as c-myc, thus facilitating the proliferation and survival of pancreatic cancer cells. furthermore, overexpression of a phospho-deficient mutant of fbw7 (thr205ala) significantly reduced the tumorigenesis potential of pdac cells both in vitro and in vivo. through our experiments, we established a novel link between the oncogenic kras-mutant/mapk/erk signaling axis and the tumor suppressor fbw7 and revealed the mechanism underlying the impairment of fbw7 function in pdac. these findings may help develop new therapeutic strategies to treat pancreatic cancer.",pmc4423074,1,1,40,1,41
1031,src,protein,,,uniprot,p12931,,,runx3,protein,,,uniprot,q13761,nucleus,go:0005634,positive,d,phosphorylation,tyrosine,bosc23,fibroblast-like,,human,['816'],nan,nan,"tyrosine phosphorylation of endogenous runx3 in cancer cell lines. a, immunoblotting analysis of whole cell lysates from the indicated cell lines using two different anti-runx3 (rx3) antibodies (5g4 and 6e9) and an antibody against phosphorylated-src (p-src). an anti-tubulin (tub) antibody was used as a loading control. both the anti-runx3 antibodies detected a 58-kda protein (indicated by arrows) in src-activated cells and in cells with mislocalized runx3 (see text for further details). this phosphorylated runx3 is larger than the normally detected bands (46 and 50 kda). activated src was detected by the anti-p-src antibody. b, bt20 cells were grown for 48 h after treatment with scrambled si-rna (sc-si-rna) or src specific sirna (si-src-1, 5′-gccucucagugucugacuucgacaa-3′; si-src-2, 5′-gccucucagugucugacuucgacaa-3′). cell lysates were immunoblotted with the indicated antibodies. c, bosc23 cells were transiently transfected with or without ha-src, and the cell lysates were immunoblotted with the indicated antibodies. cell lysates were also obtained from bosc23 cells transfected with runx3 (without tag), and small amounts (1:20 compared with other samples) were loaded as molecular weight markers (con-rx3, 50 kda). d, snu16 and bt20 cell lysates were treated with or without λ-phosphatase (λ-ppase) for 1 h at 30 °c, then immunoprecipitated with the anti-runx3 antibody (6e9; rx3) or igg as a control, and immunoblotted with the anti-phosphotyrosine antibody (py). e, nuclear (n) and cytoplasmic (c) fractions were obtained separately from each of the src-activated cell lines and analyzed by immunoblotting with the anti-runx3 antibody (6e9; rx3). laminin (lam) and tubulin (tub) were used as fractionation controls. the 58-kda protein (tyrosine-phosphorylated runx3) was detected mainly in the cytoplasmic fractions.",pmc2843174,1,1,40,1,41
1049,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,,runx3,uniprot,q13761,nucleus,go:0005634,positive,d,physical interaction,runt domain,hek293,epithelial-like,kidney,human,['811'],nan,nan,"to identify the src-interacting region within runx3, the full-length myc-runx3 construct (which encodes a protein containing 11 tyrosine residues) or truncated versions of myc-runx3 were transiently coexpressed with ha-src in hek293 cells (fig. 3, a and b). both the full-length runx3 protein and the runt domain alone physically interacted with src (fig. 3b). however, the runt domain deletion mutant (δrunt; deleted between amino acids 54 and 187), the n-terminal region of the protein (amino acids 1–53), and the c-terminal region (amino acids 188–415) failed to interact with src (fig. 3b). these results suggest that src interacts with runx3 at the runt domain. interestingly, however, multiple shifted runx3 bands were observed in cells transfected not only with full-length runx3 but also with the mutant encoding the runx3 c-terminal region (188–415) and the δrunt mutant (δrunt). this result suggests that the amino acids 188–415 region of runx3 may also interact with src weakly. although we have evidence that runx3 is a target of src (fig. 2), our results do not rule out the possibility that another tyrosine kinase, activated by src, could also phosphorylate runx3.",pmc2843174,1,1,40,1,41
1051,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,tks4,protein,,bcar1,uniprot,o75815,cytoplasm,go:0005737,positive,d,phosphorylation,tyr110,human dld1 colon cancer cells,epithelial-like,colon,human,['1377'],nan,nan,src induces the formation of functional invadopodia in human dld1 colon cancer cells by phosphorylating noxa1 on tyr110 and tks4 on tyr508,pmc2993755,1,1,40,1,41
1057,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,na/k-atpase,other,,atp1a1,uniprot,p05023,plasma membrane,go:0005886,negative,d,co-precipitation,,cd2-2,b-cell,,human,['2065'],nan,nan,"to probe the molecular mechanism of the observed inhibition, we immunoprecipitated src using a monoclonal anti-src antibody from cd2-2 cell lysates and measured co-precipitated α1 subunit of na/k-atpase. cell lysates from control yfp-1 cells were subjected to the same measurements and used as a control. as depicted in fig 4d, expression of yfp-cd2 significantly reduced the co-precipitated α1 subunit of na/k-atpase from cd2-2 cell lysates in comparison to that in yfp-1 cell lysates, which is in accordance with the finding that yfp-cd2, not yfp, co-precipitated with src as depicted in fig 3a. thus, while the expression of cd2 increased surface expression of na/k-atpase, it actually reduced the formation of receptor complex (na/k-atpase/src), leading to the inhibition of ouabain-induced signal transduction in cd2-2 cells.",pmc4638348,1,1,40,1,41
1058,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,noxa1,protein,,noxo1,uniprot,q15067,plasma membrane,go:0005886,positive,d,phosphorylation,tyr110,dld1,epithelial,colon,human,['1379'],nan,nan,"the formation of functional invadopodia relates to the ability of cells to degrade the ecm (baldassarre et al., 2003; weaver, 2006). to further confirm that src induces the formation of functional invadopodia in dld1 cells by phosphorylating noxa1 on tyr110 and tks4 on tyr508, we tested the effect of these tks4 and noxa1 unphosphorylable mutants on srcyf-induced ecm degradation in dld1 cells. dld1 cells were transfected as indicated in figure 7a, plated on fitc-labeled gelatin-coated coverslips, and stained with phalloidin. the analysis of the ability of cells (in red) to degrade the matrix (in green) revealed that, as expected, srcyf overexpression induced the ecm degradation in dld1 cells. interestingly, we also observed that the presence of tks4 and noxa1 unphosphorylable mutants blocked this effect. again, the overexpression of tks4 and noxa1 phosphomimetic mutants was able to partially restore the ability of these cells to degrade the ecm. the quantification of three independent experiments is shown in figure 7b. these results support the idea that src induces the formation of functional invadopodia in human dld1 colon cancer cells by phosphorylating noxa1 on tyr110 and tks4 on tyr508.",pmc2993755,1,1,40,1,41
455,erk2,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,atr,protein,,atr,uniprot,q13535,nucleus,go:0005634,positive,i,activation,,,,,,['3234'],nan,nan,"consistent with erk kinases being a major player in promoting cell cycle progression [5], erk1 and erk2 also contribute to ddr [6]. a variety of genotoxic agents have been shown to activate the erk kinases and erk activity modulates ddr [7]. consistent with the apical roles of atm and atr in ddr, dna damage-induced erk activation has been reported to be a downstream event of atm and atr [8, 9]. on the other hand, erk activation also facilitates the activation of atm and atr [10, 11]. the impact of the mek-erk pathway on checkpoint activation in ddr is cell type dependent [6]. while erk activity facilitates dna damage-induced cell cycle arrest and apoptosis in a several mammalian cell lines and drosophila [12, 7, 13, 9, 14, 15], erk activation also prevents dna damage-induced apoptosis in myeloma and leukemia [16, 17]. in this review, we will briefly discuss the erk system, atm/atr-initiated ddr, and experimental evidence showing the interplay between erk and ddr. finally, we will briefly discuss strategies of using mek inhibitors in cancer therapy.",pmc3330700,1,1,40,1,41
454,erk2,protein,,erk2,uniprot,p28482,nucleus,go:0005634,snail1,protein,,snai1,uniprot,o95863,nucleus,go:0005634,positive,d,activity,,,mesenchymal,,human,['986'],nan,nan,"upregulated expression snail1 gene has been detected in several experimental conditions in which cells are forced to adopt a mesenchymal phenotype (20–26). in order to study the elements controlling snail1 gene expression, we have recently cloned and characterized a dna fragment corresponding to the human promoter (26). the activity of this promoter (−869/+59, respect to the transcription start) mimics the expression of snail1 during emt and is greatly dependent on erk2 and gsk-3β/nfκb pathways activity (26,27). other researchers have demonstrated that pi3 kinase (pi3k) activity also controls snail1 transcription and promoter activity (24), probably acting on the same pathway than gsk-3β/nfκb. however, these pathways are also active in epithelial cells and do not enterely explain the specificity of expression of snail1 in mesenchymal cells. in this article we describe the existence in this snail1 promoter of a functional 5′-cacctg-3′ e-box that acts as a negative element. we also demonstrate that snail1 binds to this element and therefore creates a negative loop controlling its own expression.",pmc1440880,1,1,40,1,41
1059,src,protein,non-receptor tyrosine kinase,src,uniprot,p12931,cell membrane,go:0005886,p27,protein,,cdkn1b,uniprot,q13309,cell,go:0005623,positive,d,phosphorylation,,,pancreatic β cells,,human,['2575'],nan,nan,"src, a non-receptor tyrosine kinase, is activated by many factors, such as high glucose, palmitate, leptin, tnf-α and ifn-γ56789. activation of src might result in the promotion of survival and proliferation pathways, and even induce malignant tumours (v-src)10. many cell-cycle regulatory proteins involved in cell proliferation are induced by src, such as cyclin a, e, d1, a/cdk2 complex, p27 and p5311121314. active src induces phosphorylation of p27, and then downregulates its protein level15. protooncogene src was suggested to counteract the reduction of skp2 protein effectively, which involves the negative regulation of p27 and plays a proto-oncogenic role in vitro and in vivo1617. in addition, the transcription factor stat3 can be activated by src to regulate skp2 expression positively18. however, the effects of tyrosine kinases on cell-cycle regulatory proteins in pancreatic β cells remain unclear.",pmc4923948,1,1,40,1,41
452,erk1/2,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,p90rsk,protein,,rps6ka1,uniprot,q15418,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['1284'],nan,nan,"as a downstream effector of the ras/erk/mapk signaling cascade, p90rsk is a direct substrate of erk1/2 44. as shown previously, erk1/2 also significantly decreased in phosphorylation level from stage iii to iv and this is reflected here with p90rsk phosphorylation level.",pmc3187934,1,1,40,1,41
453,erk2,protein,active,mapk1,uniprot,p28482,cytoplasm,go:0005737,p90rsk-1,protein,,rps6ka1,uniprot,q15418,cytoplasm,go:0005737,positive,d,incubated with,,,,,human,['285'],nan,nan,"active erk2 (2 ng, new england biolabs, ipswich, ma) was incubated with 0.5 μg his6-tagged caspase 9 (c287a) or p90rsk-1 for 60 minutes at 30°c in 50 mm tris-hcl, 10 mm mgcl2, 1 mm egta, 2 mm dtt, 0.01% brij 35 (ph 7.5) containing 20 μm atp and 2 μci γ-32p-atp. reactions were stopped with an equal volume of 2× sds-page sample buffer and the proteins were resolved by sds-page. the gels were stained with coomassie blue, dried, and 32p incorporation into substrate was determined by phosphoimager analysis.",pmc3025971,1,1,40,1,41
1033,src,protein,,,uniprot,p12931,plasma membrane,go:0005886,runx3,protein,,,uniprot,q13761,cytoplasm,go:0005737,negative,i,knockdown,,"mkn45, snu16, bt20, mb468",,"stomach, breast",human,['819'],nan,nan,"relocalization of endogenous runx3 by the knockdown of src or the inhibition of src activity in src-activated cancer cell lines. a, two gastric cancer cell lines (mkn45 and snu16) and two breast cancer cell lines (bt20 and mb468) were grown on coverslips for 24 h and then treated with src sirna (si-src-1) or src inhibitor (thiadiazole). forty eight hours after sirna transfection or 24 h later after src inhibitor, the cells were fixed, permeabilized, and analyzed by immunofluorescence using the anti-runx3 monoclonal antibody (6e9) and a mouse igg coupled to green fluorescence to detect the subcellular localization of endogenous runx3. nuclei are visualized by 4,6-diamidino-2-phenylindole staining. for each cell line, runx3 was detected mainly in the cytoplasm when cells were treated with a control sirna construct. treatment with si-src-1 or the src inhibitor resulted in an increase in nuclear localization and a decrease in cytoplasmic localization of runx3 in all four cell lines. b, cell lines were treated with src sirnas (si-src-1 or si-src-2) for 48 h, and the expression level of src was analyzed by immunoblotting with the anti-src antibody. the results show that both sirnas effectively knock down src expression. tub, tubulin. c, mkn45 cells, which show cytoplasmic localization of runx3, were treated with or without leptomycin b (lmb) for 24 h, and then the subcellular localization of runx3 was analyzed by immunocytochemical staining. treatment with leptomycin b resulted in the nuclear localization of runx3.",pmc2843174,1,1,40,1,41
444,erk,protein,,,uniprot,p27361,,,elk-1,protein,,,uniprot,p19419,nucleus,go:0005634,positive,d,association,promoter,,,,,['1249'],nan,nan,"our data provide the first demonstration of an association between active erk and elk-1 bound in a promoter complex. in this scenario, the d domain/kim was the dominant motif and the fxfp made a lesser contribution to erk recruitment. the severity of the fxfp mutation was confirmed by the virtual loss of s383 phosphorylation. extrapolating from the model proposed by zhang et al. (77) to the context of a pic, it is conceivable that while erk is associated with elk-1 via d domain/kim-cd interactions, fxfp motifs present on neighbouring proteins might engage erk to promote trans-phosphorylation events. however, the paucity of elk-1/erk co-localization indicates that during active transcription, associations between elk-1 and erk are likely to be transient.",pmc2377423,1,1,40,1,41
443,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,rhoa,protein,,rhod,uniprot,p61586,plasma membrane,go:0005886,positive,d,interaction,,cos-7 and skbr3 cells,epithelial-like,breast cancer,human,['1527'],nan,nan,"(a) co-immunoprecipitation of erk and p-erk with rhoa. cos-7 cells expressing gfp-rhoa were stimulated with egf as indicated. gfp-rhoa was iped from cell lysates with antibodies to gfp, and the co-iped erk and phosphor erk (p-erk) were analyzed by immunoblotting with antibodies to erk and p-erk. (b) interaction between erk and gst-rhoa. lysates of cos-7 cells, with or without egf stimulation, were incubated with gst-rhoa or gst bound to glutathione sepharose beads. the sepharose beads were collected, washed and analyzed by immunoblotting with antibodies against p-erk and erk. gst/gst-rhoa fusion protein loading was verified by amido black staining of the nitrocellulose membrane. (c) the expression levels of endogenous rhoa in cos-7 cells and various breast cancer cell lines. cells were lysed and the expression levels of rhoa were determined by immunoblotting with anti-rhoa antibody. α-tubulin was used as a loading control. (d) interaction between endogenous rhoa and erk in cos-7 and skbr3 cells. endogenous rhoa was iped from lysates of cos-7 and skbr3 cells by anti-rhoa antibody, and the co-ip of endogenous erk was determined by immunoblotting with antibodies to erk. α-tubulin was used as a loading control. (e) the effect of the rhoa d-site on the interaction between rhoa and erk. lysates of cos-7 cells (with or without egf stimulation) were incubated with gst-rhoa or mutant gst-rhoa with its d-site deleted (gst-rhoaδd) bound to glutathione agarose beads. the sepharose beads were then collected, washed and analyzed by immunoblotting with antibodies against p-erk and erk. gst/gst fusion protein loading was verified by amido black stain of the nitrocellulose membrane.",pmc4729484,1,1,40,1,41
441,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,rhoa,protein,,rhoa,uniprot,p61586,cytoplasm,go:0005737,positive,d,physical association,,"cos-7, skbr3",breast,,human,['1558'],nan,nan,"erk plays a pivotal role in the mitogenic signal transduction pathway. erk cascades are critical in regulating cell proliferation, survival and differentiation. the aberrant regulation of erk cascades contributes to cancer and other human diseases [61]. constitutive activation of erk has been observed in many tumor cell lines in a tissue-specific manner [62]. like many other members in rho gtpases family, increased rhoa expression has often been correlated with human cancer progression through its regulation of cell migration and is linked to poor prognosis [63–67]. moreover, rhoa is both overexpressed and spontaneously active in the invasive breast cancer cell line mda-mb-231 [68]. the ectopic expression of rhoa can induce the paraneoplastic transformation of mammary epithelial cells [69]. in our present study, it is noteworthy that a direct physical association between rhoa and erk can be found both in the cos-7 cell line and in skbr3, a breast cell line. in addition, this association is stronger in skbr3 cells than in cos-7 cells (fig 1c & 1d). the physiological significance of this interaction requires further research.",pmc4729484,1,1,40,1,41
1030,src,protein,kinase,src,uniprot,p12931,plasma membrane,go:0005886,syf,protein,kinase,,uniprot,p06241,plasma membrane,go:0005886,positive,i,cell spreading,,,fibroblast,,mouse,['2053'],nan,nan,"cell spreading assay was performed as described by richardson et al [24]. cells were harvested by trypsinization and 200,000 cells were plated in 60 mm dish containing 4 ml of dmem with 10% fbs. cells were then allowed to spread at 37°c for the indicated time points. images of cell spreading were recorded by phase contrast microscope and for each experiment 5 random fields were photographed. at least 300 cells per experimental condition were counted. spread cells are defined as those which had extended processes, lacked a rounded morphology and were not phase bright. in order to analyze the spreading of transfected syf and syf+ src cells, 400,000 cells were seeded in 60 mm dishes and cell spreading was recorded using a fluorescent microscope at indicated time points. spreading of untransfected syf and syf+src cells were measured using a phase contrast microscope.",pmc4638348,1,1,40,1,41
1027,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,positive,d,phosphorylation,tyrosine,,cancer,,human,['817'],nan,nan,"to determine whether the shifted runx3 band found in lysates from the cancer cell lines might represent tyrosine phosphorylation of runx3 by src kinase, we analyzed cell lysates after the sirna-mediated knockdown of src or the overexpression of src. interestingly, the knockdown of src in bt20 cells (src activated) resulted in a significant decrease in the intensity of the shifted (58 kda) runx3 band (fig. 4b; si-src). consistent with this, the overexpression of src in bosc23 cells (src-nonactivated) resulted in the appearance of the 58-kda runx3 band (fig. 4c; ha-src).",pmc2843174,1,1,40,1,41
1029,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,positive,i,kinase inhibition,,,unspecified,unspecified,unspecified,['820'],nan,nan,"we then asked whether the localization of endogenous runx3 in src-activated cell lines could be counteracted by the sirna-mediated knockdown of src. by using two kinds of src-specific sirnas (si-src-1 and si-src-2), we confirmed that these sirnas efficiently knocked down src (fig. 5b). in all four lines, treatment with si-src-1 resulted in an increase in the nuclear localization of the runx3 protein (fig. 5a). similar results were obtained with si-src-2 (data not shown). furthermore, treatment with the src kinase inhibitor thiadiazole also resulted in the relocalization of runx3 to the nucleus (fig. 5a).",pmc2843174,1,1,40,1,41
1028,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,positive,d,phosphorylation,tyrosine residues,unknown,unknown,gastric cancer and breast cancer,human,['822'],nan,nan,"runx3 is a transcription factor that functions as a tumor suppressor regulating cell proliferation, apoptosis, and differentiation. in various cancers, runx3 is frequently inactivated by promoter methylation. recently, it has been shown that runx3 is inactivated not only by promoter methylation, but also by mislocalization of the protein to the cytoplasm in gastric cancer and breast cancer cells. however, the molecular mechanisms controlling this mislocalization have been poorly understood. to address this question, we investigated the possibility that the oncogenic protein src kinase might be responsible for the cytoplasmic localization of runx3, because src is frequently activated in various cancers where runx3 is mislocalized in the cytoplasm. in this study, we found the following. 1) overexpression of src results in cytoplasmic localization of runx3. 2) src phosphorylates runx3 at multiple tyrosine residues, both in vitro and in vivo. 3) tyrosine residues of endogenous runx3 are phosphorylated in src-activated cell lines. 4) tyrosine-phosphorylated runx3 is localized in the cytoplasm. 5) sirna-mediated knockdown of src, or inhibition of src by an src inhibitor, results in the relocalization of runx3 to the nucleus. collectively, our results demonstrate that runx3 is a target of the src kinase and that the tyrosine phosphorylation of runx3 by src is associated with the cytoplasmic localization of runx3.",pmc2843174,1,1,40,1,41
1026,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,runx3,protein,transcription factor,runx3,uniprot,q13761,nucleus,go:0005634,positive,d,phosphorylation,,"bosc23, syf, bt549",,,human,['815'],nan,nan,"to address the question of whether tyrosine phosphorylation of endogenous runx3 occurs in tumor cell lines with cytoplasmic mislocalization of runx3 (mkn45 and snu16 gastric cancer cell lines) or lines with activated src (bt20 and mb468 breast cancer cell lines (14, 48)), we performed ib experiments with the anti-runx3 antibody (5g4). among the cell lines with cytoplasmic mislocalization of runx3, snu16 also bears activated src (49). the antibody detected not only two normal runx3 bands (46 and 50 kda) but also a shifted band (58 kda) in the src-activated cell lines (fig. 4a, top panel, shifted bands are indicated by arrows). ib with another anti-runx3 antibody (6e9) showed essentially the same result except for an enhanced sensitivity to the 58-kda protein (fig. 4a, 2nd panel). in this case, the 58-kda band was also detected in the mkn45 cell line. these results indicated that the anti-runx3 antibodies detect a shifted band in src-activated cell lines and in lines with cytoplasmic mislocalization of runx3. on the other hand, the shifted band was not detected in the bosc23 cells (src-nonactivated), syf cells (c-src/yes/fyn triple knock-out), or bt549 cells (runx3 down-regulated) (29) (fig. 4a).",pmc2843174,1,1,40,1,41
442,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,rhoa,protein,,rhoc,uniprot,p08134,cytoplasm,go:0005737,positive,d,phosphorylation,serine 188,,,,human,['1555'],nan,nan,"in the present study, we have further shown that erk-induced rhoa phosphorylation enhances the formation of actin stress fibers (fig 6), which is consistent with the increased rhoa activity induced by erk-mediated rhoa phosphorylation. it is interesting to note that rhoa phosphorylation on serine 188 induces the collapse of actin stress fibers [6,13]. to gain insight into the mechanisms underlying the regulation of actin stress fiber formation by erk-induced rhoa phosphorylation, we examined the effects of rhoa phosphorylation on its interaction with downstream substrates. several rhoa substrates, including rock1 and mdia, have been implicated in mediating the rhoa regulation of actin remodeling [33,35]. here, we have shown that rhoa phosphorylation enhances its interaction with rock1, but does not affect its interaction with mdia (fig 7). we further showed that rhoa phosphorylation on 88s and 100t increase rock1 activity and the phosphorylation of rock1 substrate nypt1 (fig 7). thus, it is likely that rock1 is responsible for the enhanced actin stress fiber formation induced by rhoa phosphorylation on 88s and 100t. consistent with our results, it has been found that the phosphorylation of serine 188 on rhoa by pka induced by nerve growth factor (ngf) blocks rhoa association with rock1 without affecting its ability to interact with other effectors including rhotekin, mdia, and pkn [53].",pmc4729484,1,1,40,1,41
520,gsk-3β,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,,rcc,renal cell carcinoma,,human,"['3370', '3394']","nan,nan","nan,nan","gsk-3β could directly phosphorylate 4ebp1 and activate the mtorc1 downstream signaling cascades to enhance protein biosynthesis and cell proliferation in rcc cell lines independent of rapamycin sensitivity. the direct gsk-3β/4ebp1 pathway might be an important subcellular mechanism as an inherent equipment for rcc cells to acquire clinical chemoresistance to mtorc1 inhibitors.,gsk-3β could directly phosphorylate 4ebp1 and activate the mtorc1 downstream signaling cascades to enhance protein biosynthesis and cell proliferation in rcc cell lines independent of rapamycin sensitivity. the direct gsk-3β/4ebp1 pathway, not associated with the pi3k/akt/mtorc1 pathway, would be an important subcellular intrinsic mechanism for rcc cells to resist mtorc1 inhibition, possibly leading to potential therapeutic limitations in systemic treatment for mrcc patients with rapalogues.","pmc4936323,pmc4936323",2,0.1,39,1,39.2
1151,β-catenin,protein,,,uniprot,p35222,,,tcf3,protein,,,uniprot,p15923,,,positive,d,binding,β-catenin binding domain of tcf3,,,,,['120'],nan,nan,"structure-function analysis of β-catenin (von kries et al., 2000) and the x-ray crystal structure of its complex with the β-catenin binding domain of tcf3 (graham et al., 2000) indicate that the tcf/lef1 binding site of β-catenin forms a positively charged groove. this interacts with the β-catenin binding domain of tcf3 consisting of an extended structure that can be divided into three sites. a comparison of this structure to β-cateninδc2 indicates that this mutant is missing one of the flanking regions and part of the central region involved in tcf–β-catenin interaction.",pmc2196183,1,0.1,39,1,39.1
1150,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,tcf4,protein,,tcf4,uniprot,p15884,nucleus,go:0005634,positive,d,transactivation,,,iecs,,human,['2925'],nan,nan,"the cadherin/catenin-based adhesion system is the major means by which epithelial cells adhere to one another.34 β-catenin, a central structural component of this adhesion complex, also acts as a transcriptional co-activator in the wnt signaling pathway in epithelial cells.34, 35, 36 despite this finding, there has been much speculation over whether the cadherin-bound and signal transduction pools of β-catenin are functionally interchangeable.58, 59, 60, 61, 62, 63 in the present study, we show that the nuclear transcriptional activity of β-catenin was enhanced upon sustained oncogenic stimulation of normal iecs by kras, braf or mek. importantly, expression of a dominant-negative tcf4 mutant that inhibits β-catenin/tcf4 transactivation severely attenuated morphological transformation and tumorigenic potential induced by oncogenic mek1. thus, these data suggest that kras/mapk signaling may utilize the wnt/β-catenin pathway to induce transformation in iecs.",pmc4687460,1,0.1,39,1,39.1
8,akt,enzyme,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,phb,protein,,phb,uniprot,p04792,mitochondria,go:0005739,positive,d,phosphorylation,thr258,,b-cell,breast cancer (bc),human,['1869'],nan,nan,"in conclusion, this study has identified phb as a bona fide target of akt kinase for the first time. our findings demonstrate that akt phosphorylates phb at thr258 and promotes phb mitochondrial translocation to induce bc proliferation and highlights phb as an important regulator during bc tumorigenesis.",pmc4669803,1,0.1,39,1,39.1
1152,β-catenin,protein,transcriptional coactivator,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,casein kinase (ck) 1ε,protein,kinase,csnk1e,uniprot,p48730,cytoplasm,go:0005737,negative,d,inhibition,β-catenin degradation,,,,,['96'],nan,nan,"the wnt pathway regulates the steady state level of β-catenin, a transcriptional coactivator for the tcf3/lef1 family of dna binding proteins. we demonstrate that tcf3 can inhibit β-catenin turnover via its competition with axin and adenomatous polyposis for β-catenin binding. a mutant of β-catenin that cannot bind tcf3 is degraded faster than the wild-type protein in xenopus embryos and extracts. a fragment of β-catenin and a peptide encoding the nh2 terminus of tcf4 that block the interaction between β-catenin and tcf3 stimulate β-catenin degradation, indicating this interaction normally plays an important role in regulating β-catenin turnover. tcf3 is a substrate for both glycogen synthase kinase (gsk) 3 and casein kinase (ck) 1ε, and phosphorylation of tcf3 by ckiε stimulates its binding to β-catenin, an effect reversed by gsk3. tcf3 synergizes with ck1ε to inhibit β-catenin degradation, whereas cki-7, an inhibitor of ck1ε, reduces the inhibitory effect of tcf3. finally, we provide evidence that ck1ε stimulates the binding of dishevelled (dsh) to gsk3 binding protein (gbp) in extracts. along with evidence that a significant amount of tcf protein is nonnuclear, these findings suggest that ck1ε can modulate wnt signaling in vivo by regulating both the β-catenin-tcf3 and the gbp-dsh interfaces.",pmc2196183,1,0.1,39,1,39.1
9,akt,kinase,,akt1,uniprot,p31749,cytoplasm,go:0005737,ikkα,kinase,,ikbka,uniprot,o15111,cytoplasm,go:0005737,positive,d,associates,,,,,human,['877'],nan,nan,"cytokines, such as tnfα (tumour necrosis factor α), can also activate mtorc1 [86,87]. it has been described that ikkβ (inhibitor of nuclear factor κb (nfκb) kinase β), a major downstream kinase in the tnfα signalling pathway, phosphorylates tsc1 at ser487 and ser511, leading to the inhibition of tsc1/tsc2 complex formation and mtorc1 activation [88]. moreover, tnfα also signals to akt [89]. activated akt induces ikkα, another major downstream kinase in the tnfα signalling pathway [90]. it has been described that ikkα associates with mtorc1 in an akt dependent manner. importantly, ikkα is required for the efficient induction of mtorc1 activity by akt in cell lines [91].",pmc3291999,1,0.1,39,1,39.1
1148,β-catenin,protein,,ctnnb1,uniprot,p35222,,,lrp6,protein,,lrp6,uniprot,o75581,,,positive,d,phosphorylation,ser33/ser37/thr41,,,,,['3131'],nan,nan,"we attempted to address this question via a β-catenin phosphorylation assay reconstituted in vitro using recombinant β-catenin, gsk3, ck1, and axin. this in vitro system recapitulated key features of β-catenin phosphorylation in vivo, such that gsk3 phosphorylation of β-catenin at ser33/ser37/thr41 is greatly enhanced by the presence of axin and by priming phosphoryaltion of β-catenin at ser45 by ck1 (figure 1). given that a single pppspxs motif upon phosphorylation is sufficient to activate β-catenin signaling in both mammalian cells and xenopus embryos [34], [35], [37], we tested whether phosphorylated pppspxs motifs from lrp6 had any effect on β-catenin phosphorylation in this in vitro assay. we found that each of four dually phosphorylated pppspxs peptides we examined, motifs a, c, d and e (figure 2), exhibits inhibition of β-catenin phosphorylation at ser33/ser37/thr41 by gsk3 in a dose-dependent manner (figure 3). we speculate that motif b may exhibit the same property, although we have not synthesized and tested a motif b peptide in our assay. several aspects of this inhibition appear to correlate well with the properties of wnt/lrp6 regulation of β-catenin phosphorylation in vivo: (i) a corresponding mutant peptide, pppapxa (figure 2), has little, if any, inhibitory effect on β-catenin phosphorylation by gsk3 under the identical experimental condition (figure 3). this correlates well with the fact that the dually phosphorylated pppspxs motif upon transferred to a heterologous receptor is sufficient to activate β-catenin signaling in vivo, whereas the pppapxa mutant is completely inactive [34], [35], [37]. in addition, other control peptides including ha and 14-3-3bp (a dually phosphorylated peptide) do not have any inhibitory activity in the β-catenin phosphorylation assay (figure 3); (ii) the ability of dually phosphorylated pppspxs peptides to inhibit β-catenin phosphorylation by gsk3 correlates well with their differential ability to activate β-catenin signaling tested in vivo [37]. thus the phos-d peptide, which has an atypical cppspxs motif (figure 2), has the weakest ability to inhibit β-catenin phosphorylation by gsk3 in vitro (figure 3) and also the least ability to activate β-catenin signaling in vivo when it is transferred to a heterologous receptor [37]. further, this result is also in line with that from scanning mutagenesis of the pppspxs motif, which has demonstrated a critical role of the first proline in the pppspxs motif such that its replacement by alanine or cysteine drastically diminished the signaling activity of the motif in vivo [37]; (iii) the dually phosphorylated pppspxs motif inhibits β-catenin phosphorylation at ser33/ser37/thr41 by gsk3 but not ser45 phosphorylation by ck1 in vitro (figure 4). this correlates with the fact that wnt signaling primarily inhibits β-catenin phosphorylation at ser33/ser37/thr41 by gsk3 but not ser45 phosphorylation by ck1 [5], [50]; (iv) finally we found that injection of a phosphorylated pppspxs peptide, but not the mutant pppapxa peptide, into xenopus embryos is able to induce axis duplication and the expression of xnr3, a wnt/β-catenin target gene (figure 6), consistent with the notion that phosphorylated pppspxs inhibits gsk3 in vivo. these results together suggest that our in vitro observations with the pppspxs peptides likely reflect, at least in part, the function of these motifs in activated lrp6 in vivo.",pmc2654145,1,0.1,39,1,39.1
1153,β-cateniny142e,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,gsk3,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,positive,d,phosphorylation,,xenograft,,,human,['2754'],nan,nan,"we have conducted a cell line xenograft study to address this important question, and the answer is yes. our new data (figure 4f) showed that although overexpression of β-cateniny142e partially jeopardized the anti-tumor effect of pf562271, pf562271 treatment significantly inhibited in vivo growth of sw480 cells ectopically expressing flag-β-cateniny142e. while this result further proved the importance of fak/pyk2-mediated gsk3 phosphorylation, it also suggested that phosphorylation of β-cateniny142e plays a role in fak-targeted therapy for crc.",pmc4558782,1,0.1,39,1,39.1
1154,β-enac,protein,,,uniprot,p37088,unknown,,nedd4,protein,,nedd4,uniprot,p46934,unknown,,negative,i,endocytosis,py motif,mdck,epithelial,kidney,human,['1800'],nan,nan,"deletion of the intracellular β-enac c terminus eliminates several consensus phosphorylation sites as well as two internalization motifs (py and yxxφ) important for nedd4- and dynamin/clathrin-dependent endocytosis. to test the importance of individual sites, point mutations were evaluated. disruption of the py motif by mutation of β-enac p616l (a human liddle's disease causing mutation) was as effective as the r564st β-enac truncation mutation for preventing the egf-induced inhibition of sodium absorption in mdck cell monolayers (fig. 6). a similar result was obtained from studies of oocytes in which point mutations in the py motif of either β- or γ-enac (y618a or y628a, respectively) were found to completely prevent progesterone-induced inhibition of sodium current (michlig et al., 2005). whereas, mutation of the putative erk phosphorylation sites in either β-enac (t613a) or γ-enac (t623a) reduced the progesterone-induced inhibition of sodium current by only 20–25% (michlig et al., 2005). in contrast, mutation of the putative erk phosphorylation site in β-enac stably expressed in mdck cells (t613a) was as effective as the r564st β-enac truncation (fig. 6). furthermore, the small inhibitory effect of egf on sodium transport in mdck cells expressing the r564st, p616l, and t613a mutations was completely abolished by an erk kinase inhibitor (fig. 7), consistent with a role for the corresponding py motif and putative erk phosphorylation site in the c terminus of the γ-enac subunit.",pmc2151644,1,0.1,39,1,39.1
1156,βcat,protein,,ctnnb1,uniprot,p35222,puncta,go:000881,axin,protein,,axin1,uniprot,o15169,puncta,go:000881,positive,i,stabilizing,,,,,human,['3415'],nan,nan,"one potential caveat to the increased accumulation of βcat in puncta of cells expressing axin alone vs those expressing apc2 plus axin is that the former cells may simply have higher overall levels of βcat, thus resulting in higher accumulation in puncta. to address this, we inhibited βcat destruction using the proteasome inhibitor mg132. as others have previously observed (sadot et al., 2002), proteasome inhibition elevates βcat levels. proteasome inhibition elevates βcat levels both in cells expressing axin alone and in those expressing apc2 plus axin (figure 3—figure supplement 1c). strikingly, this allows it to accumulate in puncta even in cells expressing axin + apc2 (figure 3—figure supplement 1a vs b). however, cells expressing axin still accumulate significantly higher levels of βcat than those expressing axin plus apc2 (figure 3—figure supplement 1c). together, these data are consistent with a model in which apc increases βcat throughput of the destruction complex by stabilizing axin assembly.",pmc4568445,1,0.1,39,1,39.1
965,rhoa,protein,small gtpase,rhoa,uniprot,p61586,cytoplasm,go:0005737,erk,proteinkinase,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,serine 188 (188s) and threonine 100 (100t),cos-7,fibroblast-like,kidney,human,['1518'],nan,nan,"the small gtpase rhoa has been implicated in various cellular activities, including the formation of stress fibers, cell motility, and cytokinesis. in addition to the canonical gtpase cycle, recent findings have suggested that phosphorylation further contributes to the tight regulation of rho gtpases. indeed, rhoa is phosphorylated on serine 188 (188s) by a number of protein kinases. we have recently reported that rac1 is phosphorylated on threonine 108 (108t) by extracellular signal-regulated kinases (erk) in response to epidermal growth factor (egf) stimulation. here, we provide evidence that rhoa is phosphorylated by erk on 88s and 100t in response to egf stimulation. we show that erk interacts with rhoa and that this interaction is dependent on the erk docking site (d-site) at the c-terminus of rhoa. egf stimulation enhanced the activation of the endogenous rhoa. the phosphomimetic mutant, gfp-rhoa s88e/t100e, when transiently expressed in cos-7 cells, displayed higher gtp-binding than wild type rhoa. moreover, the expression of gfp-rhoa s88e/t100e increased actin stress fiber formation in cos-7 cells, which is consistent with its higher activity. in contrast to rac1, phosphorylation of rhoa by erk does not target rhoa to the nucleus. finally, we show that regardless of the phosphorylation status of rhoa and rac1, substitution of the rhoa pbr with the rac1 pbr targets rhoa to the nucleus and substitution of rac1 pbr with rhoa pbr significantly reduces the nuclear localization of rac1. in conclusion, erk phosphorylates rhoa on 88s and 100t in response to egf, which upregulates rhoa activity.",pmc4729484,1,0.1,39,1,39.1
1149,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,tcf,protein,transcription factor,tcf7,uniprot,p36402,nucleus,go:0005634,positive,d,transcriptional activity,,,iec,,human,['2909'],nan,nan,induction of β-catenin/tcf complex transcriptional activity in iecs transformed by oncogenic kras or mek1,pmc4687460,1,0.1,39,1,39.1
1146,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,tcf3,protein,,tf7l1,uniprot,p15923,nucleus,go:0005634,negative,d,binding,,,,,human,['106'],nan,nan,"to explore further the possibility that β-catenin degradation is normally inhibited by its interaction with tcf3, we asked if perturbing this interaction would affect β-catenin degradation in vivo and in extracts. we first developed an inhibitor of this interaction. based on our deletion analysis, a fragment of β-catenin (amino acids 449–645, cat449/645) between the cooh termini of β-cateninδc1 and β-cateninδc2 was expressed as a maltose-binding protein (mbp) fusion and tested for its ability to block the binding of β-catenin to tcf3 beads. excess cold β-catenin and cat449/645 (2 μm each) compete equally well with radiolabeled β-catenin for binding to tcf3-beads (fig. 3 d). in contrast to full-length β-catenin, cat449/645 does not compete for binding of axin to β-catenin beads, indicating that the fragment selectively interferes with the β-catenin–tcf3 interaction. lower than 2-μm levels of cat449/645 do not affect binding of β-catenin to apc (fig. 2 h); however, higher cat449/645 concentrations can significantly inhibit binding to apc, suggesting some overlap between the tcf3 and the apc binding sites on β-catenin.",pmc2196183,1,0.1,39,1,39.1
1134,wip1,protein,,ppm1d,uniprot,o15355,chromatin,go:0000785,h2ax,protein,,h2afx,uniprot,p16104,chromatin,go:0000785,positive,d,bind,chromatin,,,spleen,mouse,['1659'],nan,nan,"finally, wip1 (wild-type p53-induced phosphatase 1, also known as ppm1 d or pp2cδ) was found to bind to h2ax, associate with the chromatin throughout the cell cycle, and co-localize with γ-h2ax in ir-induced foci [96]. overexpression of wip1 resulted in a significantly impaired induction of γ-h2ax after ir and uv and decreased γ-h2ax foci staining in an atm-independent manner [96,97]. the spleen tissue of wip1-/- mice had higher basal levels of γ-h2ax than wip1+/+ mice in the absence of dna damage as well as higher levels of γ-h2ax after ir [97]. interestingly, overexpression of wip1 inhibited the formation of mdc1 and 53bp1 foci [96,97]. silencing of wip1 also resulted in more efficient repair of the break since wip1 inhibited both homology-directed recombination and non-homologous end joining [97].",pmc2954851,1,0.1,39,1,39.1
1147,β-catenin,protein,,ctnnb1,uniprot,p35222,,,gsk3,protein,,gsk3,uniprot,p49841,,,negative,d,phosphorylation,ser33/ser37/thr41,,,,,['3124'],nan,nan,"since the dually phosphorylated pppspxs peptide directly inhibited β-catenin phosphorylation at ser33/ser37/thr41 by gsk3 independent of axin, we tested whether this inhibition was specific for β-catenin or was broad for other gsk3 substrates, such as glycogen synthase (gs) and the tau protein [44]. we expressed the mouse glycogen synthase carboxyl terminal domain (mgs-ctd, amino acid 585–738) as a gst-fusion protein in e. coli, and purified mgs-ctd by gst column affinity chromatography (figure 5a). we reconstituted in vitro phosphorylation for mgs-ctd by incubating it together with gsk3 and the priming casein kinase 2 (ck2) [44] in the presence of atp and mgcl2. when ck2 and gsk3 were both present, mgs-ctd was strongly phosphorylated at ser641 (figure 5b, lanes 1 and 6). when ck2 was absent from the reaction, the phosphorylation of mgs-ctd at ser641 by gsk3 was significantly reduced (figure 5b, lane 3), recapitulating ck2 priming phosphorylation-dependent gs phosphorylation by gsk3. we found that the phos-a peptide, but not the a-mutant peptide, inhibited mgs-ctd phosphorylation by gsk3 at ser641 (figure 5c). gsk3 also phosphorylated purified tau protein in vitro, which does not require priming phosphorylation (figure 5d), as detected by the anti-phospho-tau antibody phf1 (specific for tau phosphorylated at ser396 and ser404) [45]. when the phos-a peptide was added to the in vitro assay, tau phosphorylation was greatly reduced, whereas the a-mut peptide had little effect (figure 5e). in addition, when phos-a peptide was titrated in the phosphorylation assay performed side-by-side for tau and β-catenin (without axin but with ck1 priming phosphorylation), indistinguishable dose-dependent inhibition of gsk3 by phos-a was reproducibly observed (figure 5f and 5g). these results suggest that the phosphorylated pppspxs motif inhibits gsk3 kinase activity towards multiple substrates.",pmc2654145,1,0.1,39,1,39.1
1145,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,tcf3,protein,,tcf3,uniprot,p15923,nucleus,go:0005634,negative,d,binding,,,,,,['104'],nan,nan,"phosphorylation and subsequent degradation of β-catenin requires its association with both apc and axin. since binding of tcf3 to β-catenin blocks its degradation, we tested if this is due to blocking binding of β-catenin to axin and/or apc. as shown in fig. 2",pmc2196183,1,0.1,39,1,39.1
1144,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,negative,d,inhibition,pppspxs peptides,,,,,['3119'],nan,nan,the inhibition of β-catenin phosphorylation by phosphorylated pppspxs peptides is specific for gsk3 and independent of axin function.,pmc2654145,1,0.1,39,1,39.1
1137,xbp-1,protein,,xbp1,uniprot,p17861,,,foxo1,protein,,foxo1,uniprot,q12778,,,positive,d,knockdown-induced,,hct116,colorectal,,human,['579'],nan,nan,"it is well known that autophagic death is a non-apoptotic form of programmed cell death. to investigate whether autophagy induced by xbp-1 knockdown has an effect on the overall survival of cancer cells, we tested the viability of hct116 cells with or without xbp-1 knockdown under conditions of glutamine starvation. as expected, following glutamine starvation for 72 h, cell viability was significantly decreased in xbp-1-knockdown hct116 cells compared with wild-type hct116 cells (figure 7a). interestingly, cell death was inhibited in hct116 cell lines that were stably transfected with the xbp-1- and foxo1-rnai plasmids, suggesting that xbp-1 knockdown-induced cell death upon glutamine starvation is dependent on foxo1 (figure 7a). to determine which type of cell death was occurring after xbp-1 knockdown, the autophagy inhibitor 3-ma or the apoptosis inhibitor z-vad-fmk were used. the cell death was greatly suppressed by 3-ma, verifying the role of autophagy in cell death caused by xbp-1 knockdown upon glutamine starvation (figure 7b). these data suggest that persistent induction of autophagy induces cell death, which likely results from excessive degradation of cell components essential for survival.",pmc3616429,1,0.1,39,1,39.1
1138,xbp-1u,protein,,,uniprot,q9uh73,er,go:0005783,foxo1,protein,,foxo1,uniprot,o43524,nucleus,go:0005634,negative,d,binds,,,,,human,['580'],nan,nan,"in this study, we provide evidence that autophagy induced by glutamine starvation is a dynamic process that is highly associated with the turnover of foxo1 protein. xbp-1u binds to foxo1 and recruits foxo1 to the 20s proteasome for degradation. this interaction between xbp-1u and foxo1 is greatly enhanced by erk1/2, which specifically catalyzes the phosphorylation of xbp-1u at ser61 and ser176; this suggests that cellular signaling pathways regulate the autophagic process by influencing foxo1 levels (figure 7e).",pmc3616429,1,0.1,39,1,39.1
958,rhoa,protein,gtpase,rhoa,uniprot,p61586,cytoplasm,go:0005737,egf,ligand,,egf,fplx,egf,extracellular region,go:0005576,positive,d,binding,rho-binding domain,cos-7,fibroblast-like,kidney,human,['1541'],nan,nan,"(a) the activity of wild type and various mutant rhoa proteins in response to egf. cos-7 cells were transfected with expression constructs encoding wild type and mutant gfp-tagged rhoa proteins. after serum starvation, cells were stimulated with egf for 15 min. cell lysates were incubated with a gst fusion rhotekin rho-binding domain (gst-rbd). the active rhoa proteins that bound to gst-rbd were determined by immunoblotting with antibodies to gfp. (b) quantification of the data from (a). the gtp-gfp-rhoa protein intensity was normalized to the intensity of the expressed gfp proteins (input) as detected by anti-gfp antibodies. (c) the effects of u0126 on the activation of endogenous rhoa in response to egf. cos-7 cells were stimulated with egf for the indicated time with or without u0126. the amount of active rhoa was determined by gst-rbd pull down assay as described in (a), except that antibodies to rhoa were used to detect the endogenous rhoa. (d) quantification of the data from (c). the gtp-rhoa protein intensity was normalized to the intensity of the total endogenous rhoa protein (input) as detected by anti-rhoa antibodies. each value is the average of at least three experiments and the error bar is standard error. * indicates p<0.05.",pmc4729484,1,0.1,39,1,39.1
1139,yap,protein,,,uniprot,p46937,cytoplasm,go:0005737,mst1,protein,,mst1,uniprot,q13043,cytoplasm,go:0005737,positive,d,phosphorylation,ser127,mcf-10a,epithelial,breast,human,['2419'],nan,nan,"western blotting for phosphorylated yap (ser127) (#4911; cell signaling technology), mst1 (#3682; cell signaling technology), and α-tubulin in mcf-10a cells. the cells were treated with control or fat4 sirna (sicontrol and sifat4).",pmc4334522,1,0.1,39,1,39.1
5,4e-bp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,eif4g,protein,eukaryotic initiation factor 4g,eif4g1,uniprot,p60842,cytoplasm,go:0005737,negative,d,competes for binding,,,,,,['1957'],nan,nan,"unphosphorylated 4e-bp1 interacts with the cap-binding protein eif4e and prevents the formation of the 4f translational initiation complex (eif4f); by competing for the binding of eukaryotic initiation factor 4g (eif4g) to eif4e. 4e-bp1 phosphorylation by mtorc1 results in the release of the eif4e, which then associates with eif4g to stimulate translation initiation [1-3,135-138].",pmc3660063,1,0.1,39,1,39.1
1126,vps34,protein,,,uniprot,q8neb9,lysosome,go:0005764,pikfyve,protein,lipid kinase,pikfyve,uniprot,q9ubf8,lysosome,go:0005764,negative,d,inhibition,,u2os,bone osteosarcoma,,human,['2537'],nan,nan,"given the dynamic nature of lysosomes and to preserve tubular elements that can be disrupted by fixation (sridhar et al, 2013), we analysed lysosomal structures in live u2os cells stably expressing low levels of lamp1-mcherry (fig2). inhibition of vps34 had a clear effect on lysosomal morphology, both at 1 and at 5 μm vps34-in1 (fig2a) with lysosomes appearing larger in general. larger lysosomes are seen upon pikfyve inhibition, the lipid kinase that uses pi(3)p to generate pi(3,5)p2, a phospholipid involved in regulating endosomal and lysosomal size (jefferies et al, 2008). it is therefore possible that this larger lysosomal size is due to reduced pi(3,5)p2 levels upon vps34-in1 treatment. remarkably at 1 μm vps34-in1, which inhibits lysosomal pi(3)p levels, a large increase in lysosomal tubulation occurred (fig2a, right panels, and b). these tubules are reminiscent of alr where lysosomes regenerate following starvation and reactivation of mtor signalling (yu et al, 2010). to determine whether the vps34-in1-induced tubules occur through a related process, cells were treated in combination with the specific mtor inhibitor ku0063794 (shortened to ku here; garcía-martínez et al, 2009; fig2a, left panels, and b). mtor inhibition is known to increase lysosomal size, and this had no effect on the large lysosomes seen upon vps34-in1 treatment. however, mtor inhibition completely abolished the tubules formed upon 1 μm vps34-in1 treatment, implying these tubules are linked to alr. we also used gfp-lamtor as an additional lysosomal marker and found this behaved in a very similar fashion to lamp1-mcherry with respect to tubule formation (supplementary fig s2).",pmc4585463,1,0.1,39,1,39.1
1141,zap-70,protein,,zap70,uniprot,p43403,cytoplasm,go:0005737,nfat,protein,,nfatc1,uniprot,q13469,nucleus,go:0005634,positive,i,phosphorylation,,,,,mammalian,['3270'],nan,nan,"the mammalian target of rapamycin (mtor), a member of the phosphoinositide-3′ kinase-related kinase family, is a central controller of cell proliferation, growth and survival [1]. rapamycin can form a complex with fk506 binding protein 12 (fkbp-12) and then bind mtor, selectively inhibiting its kinase activity and function [1]. recently, two mtor complexes (mtorc1 and mtorc2) have been identified in mammalian cells [1]. mtorc1 is composed of mtor, mlst8 (also termed g-protein β-subunit-like protein, gβl, a yeast homolog of lst8), pras40 (proline-rich akt substrate 40 kda) and raptor (regulatory-associated protein of mtor), and is rapamycin-sensitive [2]–[8]. in response to growth factors and nutrients, mtorc1 regulates cell proliferation and growth by modulating many processes, including protein synthesis and ribosome biogenesis through downstream effectors like 4e-bp1 (eukaryotic initiation factor 4e binding protein 1) and s6k1 (ribosomal p70 s6 kinase 1) [1]. mtorc2 consists of mtor, mlst8, msin1 (mammalian stress-activated protein kinase-interacting protein 1), rictor (rapamycin insensitive companion of mtor), and prr5 (proline-rich protein 5), and is rapamycin-insensitive [9]–[15]. mtorc2 phosphorylates akt [12], [14], [16], and controls cytoskeleton organization and cell survival [10], [11]. most recently, mtorc2 has been reported to phosphorylate sgk1 (serum and glucocorticoid-inducible kinase 1) [17], although this remains controversial [18]. both mtorc1 and mtorc2 interact with a negative regulator deptor [19].",pmc2868031,1,0.1,39,1,39.1
959,rhoa,protein,mutant,rhac,uniprot,p61586,cytoplasm,go:0005737,rock1,protein,,,fplx,rock1,cytoplasm,go:0005737,positive,d,binding,,cos-7,fibroblast-like,,monkey,['1546'],nan,nan,"(a) co-ip of wild type and mutant rhoa with rock1/mdia. cos-7 cells were transfected with constructs encoding wild type or mutant gfp-tagged rhoa and stimulated with egf (50 ng/ml). gfp-tagged wild type and mutant rhoa proteins were immunoprecipitated from cell lysates with anti-gfp antibodies and the co-iped rock1 and mdia were detected with anti-rock1 and anti-mdia antibodies. the input gfp was determined by immunoblotting the whole lysate with anti-gfp antibodies (bottom panel). (b&c) quantification of the co-iped rock1 (b) and mdia (c). the binding between rock1/mdia and the rhoa proteins was measured as the ratio of the rock1/mdia band intensity relative to the rhoa band intensity. each value is the mean of at least three experiments. the error bar is standard error. * indicates p<0.05. (d) the effects of rhoa phosphorylation on rock1 activity. cos-7 cells were transfected with wild type or mutant gfp tagged rhoa. after pretreatment with y-27632 (5um) for 60 min, cells were stimulated with egf (50 ng/ml) for 15min. (e&f) quantification of the phosphorylation level of mypt1 (e) and rock1protein (f) measured by the ratio between p-mypt1 and rock1band intensity relative to gfp band intensity. each value is the mean of at least three experiments. the error bar is standard error. * indicates p<0.05.",pmc4729484,1,0.1,39,1,39.1
1127,vps34,protein,,pik3c3,uniprot,q8neb9,lysosome,go:0005764,uvrag,protein,,uvrag,uniprot,q9p2y5,lysosome,go:0005764,positive,d,phosphorylation,uvrag,,,,human,['2536'],nan,nan,"here, we uncover a role for vps34 and pi(3)p at the lysosome and identify mtor phosphorylation sites on the vps34 binding partner uvrag. loss of these sites reduces vps34 activity, leading to persistent lysosomal tubulation and a failure to regenerate normal lysosomes that results in increased cell death following starvation.",pmc4585463,1,0.1,39,1,39.1
1079,tfeb,protein,,,uniprot,q6nzi2,nucleus,go:0005634,lamp1,protein,,lamp1,uniprot,p11279,lysosome,go:0005764,positive,d,tfeb-mediated,,,,,human,['2867'],nan,nan,"we subsequently sought to gain insight into functional relevance of tfeb activity subpopulations during the response to nutrient deprivation. therefore, we simultaneously monitored responses of endogenous tfeb and tfeb-controlled lysosomal marker lamp1 [1, 2] by multispectral imaging cytometry (fig. 6a). nutrient deprivation significantly increased the cellular concentration of lamp1 for all time points up to 5 hours, peaking at 3 hours with an increase of 30 % and decreasing thereafter (fig. 6b). the delay in the peak in lamp1 concentration relative to tfeb is consistent with tfeb-mediated lysosomal biogenesis. notably, although at 15 hours tfeb accumulated in the nucleus again (fig. 5a, c), no increase in tfeb (fig. 5a) or lamp1 (fig. 6b) levels was observed at this time point. importantly, lamp1 concentration was significantly higher for the “active” cluster (~17 % increase relative to “medium” and “inactive” clusters), demonstrating enhanced lysosomal content and thus higher tfeb downstream signaling for the phenotype classified as “active” (fig. 6c).",pmc4896000,1,0.1,39,1,39.1
1125,vhl,protein,,,uniprot,p40337,cytoplasm,go:0005737,gsk-3,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,negative,i,inhibition,,,renal,kidney,human,['3375'],nan,nan,"the rcc cell lines achn, caki1, and a498 were obtained from american type culture collection (manassas, va, usa). achn is derived from pleural effusion in metastatic rcc having wild type of vhl [23, 24]. caki1 and a498 cells come from clear cell rcc with vhl wild type [23, 25], and clear cell rcc with vhl mutation (426_429deltgac) [25], respectively. cells were cultured in rpmi medium supplemented with 50 μg/ml of kanamycin and 10 % fetal bovine serum in an incubator at 5 % co2 and 37 °c. human renal proximal tubular epithelial cell (hrptepc) was obtained from cell applications inc (san diego, ca, usa). cells were cultured in renaepi cell growth medium with growth supplements in an incubator at 5 % co2 and 37 °c. ar-a014418 was purchased from calbiochem (san diego, ca, usa). two other gsk-3 inhibitors, sb-216763 and tdzd8, were obtained from cayman chemicals (ann arbor, mi, usa) and sigma-aldrich japan (tokyo, japan), respectively. rapamycin and everolimus were obtained from selleck chemicals (houston, tx, usa), ly294002 was from wako pure chemical industries (tokyo, japan), recombinant gsk-3β was purchased from new england biolabs (neb) japan (tokyo, japan), and recombinant gst-4ebp1 was obtained from sigma-aldrich japan.",pmc4936323,1,0.1,39,1,39.1
1016,src,kinase,,src,uniprot,p12931,cytoplasm,go:0005737,fak,protein,,ptk2,uniprot,q05397,plasma membrane,go:0005886,negative,d,inhibition,,melanoma cells,epithelial-like,skin,human,['2083'],nan,nan,"treatment of melanoma cells with the src kinase inhibitor saracatinib resulted in efficient suppression of src auto-phosphorylation activity at y416 (fig.5a) and led to a strong decrease in fak y861 phosphorylation (fig.5b), which is required for efficient integrin-mediated focal adhesion formation. in line with this, treatment with saracatinib resulted in the reduction of vinculin containing focal adhesions (fig.5c) and eventually in the complete detachment of cells from the collagen substrate (fig.5d), which was even more noticeable in cells cultured on a thick collagen gel (fig.5d, right panel). most importantly, src inhibition by saracatinib prevented the increase in adhesion to collagen observed in selumetinib treated cells (fig.5e and f).",pmc3378628,1,0.1,39,1,39.1
1010,snail,protein,transcription repressor,snai1,uniprot,o95863,nucleus,go:0005634,e-cadherin,protein,,cdh1,uniprot,p12830,plasma membrane,go:0005886,negative,d,binds,promoter,,epithelial,,human,['2899'],nan,nan,"epithelial–mesenchymal transition (emt) is an important physiological process that converts epithelial cells to mesenchymal cells which plays an essential role in embryonic development and tissue repair (nieto, 2009). in addition, accumulating evidence shows that emt is also critical for cancer metastasis. epithelial cells lose cell–cell contacts and gain migratory properties during emt. during cancer progression, cancer cells undergo emt, resulting in increased motility, invasiveness, and aggressive behavior (kalluri and weinberg, 2009). snail is a zinc-finger transcription repressor that is one of the emt regulators. snail family contains snail1 (snail), snail2 (slug), and snail3 (smuc; de herreros et al., 2010). like other emt regulators, snail suppresses e-cadherin expression by binding to its promoter. in addition to emt, snail is also involved in cell death, survival, stem cell, and immune regulation by controlling multiple target genes (wu and zhou, 2010). downregulation of snail reduces tumor growth and invasiveness in xenograft animal model (olmeda et al., 2007). moreover, snail is overexpressed in multiple human cancers, and expression of snail is associated with poor cancer prognosis (peinado et al., 2007). therefore, snail is a critical oncogenic factor.",pmc3355968,1,0.1,39,1,39.1
921,pyk2,protein,,,uniprot,q14289,cytoplasm,go:0005737,gsk3β,protein,,gsk3b,uniprot,p49841,nucleus,go:0005634,positive,i,ubiquitination,,r454/pyk2 kd mefs,fibroblast-like,,,['2750'],nan,nan,"as suggested, we now included results from the experiments using the kkkk15/27/32/36 rrrr mutant (s4) and the s4-ubiquitin fusion mutant (ub-s4, mimicking ubiquitinated form of s4 mutant). as shown in figure 4c (lanes 7-10), in r454/pyk2 kd mefs with deficient fak and pyk2 activity, ectopic expression of ub-s4 mutant protein, but not s4, restored wnt-induced β-catenin, confirming the role of gsk3β ubiquitination in the activation of wnt signaling.",pmc4558782,1,0.1,39,1,39.1
1011,snail1,protein,,snai1,uniprot,o95863,nucleus,go:0005634,cdh1 (e-cadherin),protein,,cdh1,uniprot,p12830,plasma membrane,go:0005886,negative,d,binds,,"nih-3t3, sw-480, ht-29 m6","fibroblast, epithelial","skin, colon","mouse, human",['989'],nan,nan,"nih-3t3, sw-480 and sw-480-snail1 or ht-29 m6 and ht-29 m6-snail1 (4 × 106 cells) were cross-linked with 1% formaldehyde. cell lysates were prepared in ip buffer [16.7 mm tris (ph 8), 167 mn nacl, 1.2 mm edta, 1.1% triton x-100, 0.01% sds] for sw-480 cells and ht-29 m6 cells or in lysis buffer [50 mm tris (ph 8), 10 mm edta and 1% sds] for 10 min at room temperature. cell lysates were sonicated to generate 200–1500 bp dna. immunoprecipitation of ectopic snail1-ha (sw-480 and ht-29 m6 transfectants) was carried out with antibodies against ha epitope (roche) in ip buffer 1. nih3t3 endogenous snail1 was immunoprecipitated with a specific monoclonal antibody (mab) rose against the snail1 protein (29) in ip buffer. precipitates were then re-extracted with lysis buffer and re-immunoprecipitated for 3 h at 4°c; then, the samples where treated with elution buffer (100 mm na2co3, 1% sds) and incubated at 65°c overnight to reverse formaldehyde cross-linking. samples were treated with proteinase k and rnase and dna purified using the gfx pcr dna and gel band purification kit (amersham). promoter regions were detected by pcr amplification with the following specific primers: snail1 human promoter (gi: 9 650 757) 5′-ggcgcacctgctcggggagtg-3′ and 5′-gccgattcgcgcagca-3′, corresponding to sequences 20 603–20 623 and 20 811–20 796, respectively; snail1 mouse promoter (gi: 2 105 424) 5′-cgcacctgctccggtctcag-3′ and 5′-ctacgatcccctagcagcag-3′, corresponding to sequences 683–703 and 802–822, respectively cdh1 (e-cadherin) promoter (gi: 29 568 028) 5′-actccaggctagagggtcac-3′ and 5′-ccgcaagctcacaggtgctttgcagttcc-3′ (80 636–80 655 and 80 853–80 825, respectively); human negative control (cyclophilin a, gi: 5 882 164): 5′-atggtcaaccccaccgtg-3′ and 5′-tgcaatccagctaggcatg-3′ (137–154 and 800–782, respectively) and murine negative control (rna pol ii, gi: 45 501 362) 5′-actccaggctagagggtcac-3′ and 5′-taggtgctcagacctcgtca-3′.",pmc1440880,1,0.1,39,1,39.1
1013,snail1,protein,transcription factor,snai1,uniprot,o95863,nucleus,go:0005634,e-cadherin,protein,cell adhesion molecule,cdh1,uniprot,p12830,plasma membrane,go:0005886,negative,d,repression,,,epithelial,,cells,['985'],nan,nan,"effects of snail1 expression on epithelial cells are not limited to repress e-cadherin, since it induces a complete emt (3,7), accordingly, some other epithelial genes are directly repressed by snail1 as muc1 (7), and the tight junction proteins claudins and occludin (8). other snail1 targets are vitamin d3 receptor (9), the β-subunit of the na+, k+ atpase (10), and p53 (11) and cycd2 (12), two genes presumably responsible for the resistance to apoptosis and decreased proliferation observed in cells transfected with snail1. moreover, snail1 stimulates the expression of matrix proteases (13), wnt5a factor (14), transcriptional factors zeb1 and lef-1 (7,14), and the mesenchymal markers vimentin and fibronectin (fn) (3,7).",pmc1440880,1,0.1,39,1,39.1
1014,snail2,protein,dna-binding,snai2,uniprot,o43623,nucleus,go:0005634,e-cadherin,protein,cell adhesion molecule,cdh1,uniprot,p12830,plasma membrane,go:0005886,negative,d,transcriptional repression,promoter,,epithelial cells,,mammal,['984'],nan,nan,"the snail1 family members snail1 (snail) and snail2 (slug) are essential for triggering epithelial-to-mesenchymal transitions (emts) during embryonic development and tumour progression (1). both genes codify for dna-binding proteins with activity as transcriptional repressors. in mammals, snail1 blocks e-cadherin expression by binding to specific 5′-cacctg-3′ boxes in its promoter (2,3). snail1-induced e-cadherin downregulation is necessary for early phases of embryonic development, since mice deficient in snail1 expression fail to downregulate e-cadherin levels and to complete gastrulation (4). repression of e-cadherin transcription is also particularly relevant in the transition from adenoma to carcinoma, since a causal relationship between loss of expression of this protein and the invasive properties of some tumours has been established (5,6).",pmc1440880,1,0.1,39,1,39.1
1015,sqstm1,protein,,sqstm1,uniprot,q13501,cytoplasm,go:0005737,sqstm1,protein,,optn,uniprot,q96cv9,cytoplasm,go:0005737,positive,i,phosphorylation,ser177,,,,human,['2992'],nan,nan,little is known about the mechanisms regulating selective autophagy and the protein aggregation process. phosphorylation of sqstm1 by csnk2/ck2 (casein kinase 2) has recently been shown to increase the affinity of sqstm1 for polyubiquitin chains resulting in increased autophagic degradation of ubiquitinated proteins.12 phosphorylation of the autophagy receptor optn/optineurin at ser177 by tbk1 (tank-binding kinase 1) enhances map1lc3/lc3 binding affinity and autophagic clearance of salmonella.17,pmc4091167,1,0.1,39,1,39.1
1074,tcf3,protein,,,uniprot,p15923,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,d,inhibition,,xenopus embryos,,,xenopus,['118'],nan,nan,"we have demonstrated both in vivo in xenopus embryos and in vitro in xenopus egg extracts that tcf3 inhibits the rate of β-catenin degradation in a dose-dependent manner. we show that the inhibition of β-catenin degradation by tcf3 protein has physiological relevance, since a significant fraction of the total tcf protein resides in the cytoplasm in xenopus eggs and early embryos and in cultured 293 cells. thus, tcf can effectively compete with the degradation machinery (axin/apc/gsk3 complex) for β-catenin binding.",pmc2196183,1,0.1,39,1,39.1
924,pyk2,protein,,ptk2b,uniprot,q14289,plasma membrane,go:0005886,gsk3β,protein,,gsk3b,uniprot,p49841,,,negative,i,inhibition of phosphorylation,,sw480,epithelial-like,colon,human,['2722'],nan,nan,"(a) time courses of pf-562271 treatment-induced inhibition of phosphorylation of pyk2, gsk3β and β-catenin in sw480 cells. the whole cell lysates were used for the ib analysis using indicated antibodies. (b) the whole cell lysates from indicated cells were used for ib analysis. (c) the wt mefs, fakr454/r454/pyk2 kd mefs transfected with empty vector or vector expressing indicated gsk3β mutants were treated with wnt-3a cm or control-cm for 6 hr before harvesting for ib analysis. (d) the wt mefs and fakr454/r454/pyk2 kd mefs transfected with empty vector or vector expressing ha-gsk3βy216e were treated with wnt3a-cm and proteasome inhibitor mg132 for 4 hr and then harvested for ip and ib analyses. ki/kd: fakr454/r454/pyk2 kd mefs expressing empty vector. ki/kd/y216e: fakr454/r454/pyk2 kd mefs expressing ha-gsk3βy216e. (e) parental sw480 cells and sw480 cell lines expressing vector control, ha-gsk3β or its mutants were treated with 2 µm pf-562271 for 4 days. cell viability was determined by cck-8 assay, using sw480 parental cell treated with dmso as control. data are presented as mean ±sd. * denotes a statistically significant difference (p < 0.01) between pf-562271-treated parental sw480 cells and cells overexpressing ha-gsk3βy216e. (f) upper left panel: indicated ht-29 cell lines were injected into both flanks of nude mice (5 mice in each cell group). animals were treated with either vehicle (5% gelucire) or pf-562271 (33 mg/kg in vehicle) as indicated by oral gavage twice daily for 3 weeks. tumor sizes were measured at indicated time points. tumor volumes were calculated and plotted. * denotes a statistically significant difference (p < 0.01) comparing with vehicle-treated group. upper right panel, tumor weighs from different groups at the end of the experiment. values are means ±sd (n = 10). bottom panel, representative tumors from different groups.",pmc4558782,1,0.1,39,1,39.1
1084,tgf-α,other,,,uniprot,p01135,,,bcl-xl,protein,,bcl2l1,uniprot,q07817,,,positive,i,overexpression,,,,liver and pancreas,mice and pancreatic cancer cells,['1332'],nan,nan,"tgf-α is structurally and functionally related to members of the egf family [130]. numerous human solid tumors express high levels of tgf-α [131]. recent work has shown that overexpression of tgf-α in liver has a dramatic protective effect on fas-mediated apoptosis in tgf-α transformed mice. mice with tgf-α overexpression in the pancreas develop ductal pancreatic cancer [132]. interestingly, expression of bcl-xl, an anti-apoptotic protein, was greatly increased in these transgenic mice and may participate in protective role of tgf-α [133]. this may contribute to apoptosis resistance in pancreatic cancer cells.",pmc149420,1,0.1,39,1,39.1
1075,tcf3,protein,,,uniprot,q9nqb0,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,negative,d,inhibits degradation,,xenopus,,,,['101'],nan,nan,"a) or added purified recombinant tcf3 to the extracts (fig. 1 b). in both cases, tcf3 inhibited β-catenin degradation. an ic50 of 30 nm was determined by careful titration of tcf3 (1 nm to 1 μm) into xenopus extracts (unpublished data). as a test for the specificity of this interaction, we used an nh2-terminal deletion mutant of tcf3, δntcf3, which cannot bind β-catenin in vitro (molenaar et al., 1996). when δntcf3 mrna was translated in extracts, it had no effect on β-catenin degradation (fig. 1 a); similarly, δntcf3 purified protein (fig. 1 b) had no effect. thus, the inhibitory effect of tcf3 on β-catenin degradation is dependent on its ability to interact with β-catenin through the nh2-terminal domain. 1 μm of purified gsk3 (fig. 1 b) did not reverse the inhibitory effect of tcf3 (1 μm) on β-catenin degradation, suggesting that the effect of tcf3 was not due to titration of gsk3. a more careful examination showed that excess gsk3 could partially rescue the inhibition of β-catenin degradation by lower levels of tcf3 (100 nm); however, even a large excess of gsk3 did not reverse the effect of 300 nm added tcf3 (fig. 1c).",pmc2196183,1,0.1,39,1,39.1
1082,tfeb,protein,,tfeb,uniprot,q6zne5,nucleus,go:0005634,lamp1,protein,,lamp1,uniprot,p11279,lysosome,go:0005764,positive,d,transcriptional activation,nucleus,hela,epithelial-like,cervix,human,['2868'],nan,nan,"single cell correlation of nutrient deprivation-induced tfeb activity and downstream lysosomal response by multispectral imaging cytometry. hela cells were kept in culture medium (nt, non-treated) or subjected to nutrient deprivation. at the indicated time points, cells were immunostained for tfeb and lamp1, and nuclei labelled with hoechst 33342. following, cells were analyzed by isx multispectral imaging cytometry. a bright field and fluorescence images of representative cells for the indicated treatments. b time course of the mean population response of lamp1 protein levels, shown relative to time point ‘0’. reported values represent the mean among three independent experiments ± sd. statistical significance was tested vs. time point ‘0’, which corresponds to the nt control (student’s two-tailed t-test; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001). c mean lamp1 concentration for the three tfeb activation phenotypes. bars represent the mean among all cells in each cluster ± sd (from all repetitions and time points). statistical significance was tested between clusters on 1000 randomly selected cells (student’s two-tailed t-test; ***, p ≤ 0.001; n.s. p > 0.05). d representative fluorescence images for different ranges of the feature “lamp1 max contour position” to assess lysosomal positioning. e time course of the mean population response of “lamp1 max contour position”, shown relative to time point ‘0’. reported values represent the mean among three independent experiments ± sd. statistical significance was tested vs. time point ‘0’, which corresponds to the nt control (student’s two-tailed t-test; *, p ≤ 0.05; **, p ≤ 0.01). f mean “lamp1 max contour position” for the three tfeb activation phenotypes. bars represent the mean among all cells in each cluster ± sd (from all repetitions and time points). statistical significance was tested between clusters on 1000 randomly selected cells (two-sided wilcoxon-rank-sum test; ***, p ≤ 0.001). g percentage of cells with values of “lamp1 max contour position” within the ranges specified in (d), presented separately for each tfeb activation phenotype",pmc4896000,1,0.1,39,1,39.1
1081,tfeb,protein,,tfeb,uniprot,p19484,cytoplasm,go:0005737,lamp1,protein,,lamp1,uniprot,p11279,lysosome,go:0005764,positive,d,immunostained,,,,,human,['2849'],nan,nan,"two hundred fifty thousand cells per well of a 12-well plate were plated on the day before drug treatments. following drug treatments, cells were trypsinized, harvested by centrifugation at 800 g for 5 minutes at 4 °c and fixed with 4 % paraformaldehyde for 15 minutes at room temperature. for detection of endogenous tfeb, cells were immunostained as stated above. nuclei were labeled with 1 μg/ml hoechst 33342 in pbs for 10 minutes. compensation controls were generated from single-color control cells. endogenous tfeb was immunostained with an antibody against tfeb and alexa fluor 594. lysosomes were immunostained with an antibody against lamp1 and alexa fluor 647. for measurements cells were resuspended in pbs. fluorescence signal of hoechst 33342 was excited using the 405 nm laser and detected in channel 1 (420–480 nm). alexa fluor 594 was excited using the 561 nm laser and the fluorescence signal was detected in channel 4 (595–642 nm).",pmc4896000,1,0.1,39,1,39.1
1080,tfeb,protein,,,uniprot,q6zne3,cytoplasm/nucleus,go:0005737/go:0005634,lamp1,protein,,,uniprot,p11279,lysosome,go:0005764,positive,d,immunostained,,hela,epithelial-like,cervix,human,['2864'],nan,nan,"mean population and subpopulation response of tfeb to nutrient deprivation. hela cells were kept in culture medium (nt, non-treated) or subjected to nutrient deprivation. at the indicated time points, cells were immunostained for tfeb and lamp1, and nuclei were labelled with hoechst 33342. following, cells were analyzed by isx multispectral imaging cytometry. a time course of the mean population response of tfeb subcellular localization and protein levels. concentrations are shown relative to time point ‘0’. reported values represent the mean among three independent experiments ± sd. unless specified by horizontal lines, statistical significance was tested vs. time point ‘0’, which corresponds to the nt control (student’s two-tailed t-test; *, p ≤ 0.05; **, p ≤ 0.01). b mean tfeb subcellular localization and protein levels for the three activation phenotypes in a cell population subjected to nutrient deprivation. bars represent the mean among all cells in each cluster ± sd (from all repetitions and time points). statistical significance was tested between clusters on 1000 randomly selected cells (two-sided wilcoxon-rank-sum test; ***, p ≤ 0.001). c dynamics of the distribution of cells among the three activation phenotypes in a cell population subjected to nutrient deprivation. reported values represent the mean among three independent experiments ± sd. shaded regions highlight different stages in tfeb dynamic response. r1: first activation wave, r2: re-inactivation, r3: second activation wave",pmc4896000,1,0.1,39,1,39.1
1076,tcf3,protein,,tcf7l1,uniprot,p15923,nucleus,go:0005634,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,negative,d,blocks degradation,,,,,human,['102'],nan,nan,"tcf3 blocks β-catenin degradation in extracts and phosphorylation in vitro. (a) translated tcf3 but not δntcf3 mrna inhibits β-catenin degradation in extracts. (b) purified tcf3 protein (1 μm) blocks β-catenin degradation. this effect was not reversed by 1 μm gsk3. purified δntcf3 (1 μm) does not block β-catenin degradation. (c) inhibition of β-catenin degradation by lower (100 nm) tcf3 levels can be partially rescued by gsk3; higher tcf3 (300 nm) levels cannot be rescued by even a large gsk3 excess. (d) tcf3 inhibits the phosphorylation of β-catenin by gsk3 and axin in a purified system. in the same reaction, axin phosphorylation by gsk3 is not affected by tcf3.",pmc2196183,1,0.1,39,1,39.1
1009,smrt,protein,,ncor2,uniprot,q9y618,nucleus,go:0005634,wip1,protein,phosphatase,ppm1d,uniprot,o15297,nucleus,go:0005634,negative,d,repression,,u2os,osteosarcoma,,human,['1158'],nan,nan,"interestingly, smrt was required for cddp-induced repression of the wip1 phosphatase (ppm1d gene, figure 2a), a major down-regulator of the chk2 pathway, as well as of other phosphorylated proteins such as p53 and p38 [55]. to confirm the repressive action of smrt on ppm1d, u2os cells were transfected with sirna against smrt and treated with another genotoxic drug, doxorubicin, which inhibits topoisomerase ii and causes double strand breaks. as expected, wip1 protein levels were augmented by doxorubicin treatment and increased by sirna against smrt, even in the absence of dna damage, indicating basal repression of ppm1d by smrt (figure 4a).",pmc3656868,1,0.1,39,1,39.1
923,pyk2,protein,,ptk2b,uniprot,o60674,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,positive,i,phosphorylation,y216,,,,,['2746'],nan,nan,"the authors report a fak/pyk2/gsk3βy216/β-catenin signaling axis, through which fak and pyk2 converge on gsk3βy216 and gsk3αy279, with phosphorylated gsk3βy216 recruiting β-trcp, which monoubituitinates gsk3β, blocking wnt-induced degradation of β-catenin. all experiments were done in cell lines only, and a single fak/pyk dual inhibitor was tested (although experiments were done in genetic and knockdown systems to verify signaling).",pmc4558782,1,0.1,39,1,39.1
970,rock,protein,,,uniprot,q13464,cytoplasm,go:0005737,oct4,protein,transcription factor,pou5f1,uniprot,q01860,nucleus,go:0005634,positive,d,increase,,,mesenchymal stem cell,,human,['1899'],nan,nan,"we then examined the effects of gradually inhibiting rock activity. immunofluorescence analysis showed that rock inhibition also affected msc shape and actin organization (fig. 6d, 6e). immunoblot analysis demonstrated that oct4 expression was h-1152 dose-dependent, with exposure to 2.5 nm inducing enhanced oct4 expression; however, in contrast to pdgfr inhibitor iv effects, nanog expression was not increased (fig. 6f). exposure to 2.5 nm h-1152 was also shown to produce an increase in stat3 (y705) (fig. 6f). similar results were also obtained using the rock inhibitor y27632 (data not shown). thus, while a rock-mediated decrease in actomyosin tension produced an increase in oct4 expression and stat3 (y705), it was not sufficient to increase nanog expression.",pmc3537888,1,0.1,39,1,39.1
1089,tlr7,receptor,,,uniprot,q9nyk8,cell membrane,go:0005886,cd40,costimulator,adaptive immune,cd40,uniprot,p25942,cell membrane,go:0005886,positive,d,activation,,,immune,,,['185'],nan,nan,receptor (tlr) 7 or the adaptive immune costimulator cd40 activates multiple,pmc3084876,1,0.1,39,1,39.1
971,rock1,protein,kinase,rock1,uniprot,q13464,cytoplasm,go:0005737,mypt1,protein,substrate,ppp1r12a,uniprot,q13332,cytoplasm,go:0005737,positive,d,phosphorylation,853,cos-7,fibroblast-like,,human,['1547'],nan,nan,"to determine if rock1 activity has changed, we investigated the phosphorylation level of mypt1, a substrate of rock1 [39]. as shown in fig 7d–7f, egf treatment did not affect rock1 protein expression level; however, it increased mypt1 phosphorylation on site 853, which was blocked by pretreatment with rock1 inhibitor y-27632. cos-7 cells transfected with rhoa 88e/100e increased mypt1 phosphorylation level compared to wild type rhoa and rhoa 88a/100a, suggesting the increased interaction of rhoa and rock1 enhanced rock1 activity (fig 7d–7f).",pmc4729484,1,0.1,39,1,39.1
973,runx2,protein,,runx2,uniprot,q13950,,,mmp13,protein,,mmp13,uniprot,p50281,,,negative,d,reduces,mrna levels,breast cancer,cancer cell,breast,human,['3254'],nan,nan,"in addition to inducing the expression of runx2, earlier experiments show that activation of the pi3k/akt signaling pathway enhances dna binding of runx2 and runx2-dependent transcription in a mouse osteoblastic cell line [47]. the promoter activity of osteocalcin in mouse runx2-overexpressing osteoblastic cells is enhanced by a constitutively active form of akt1 (akt1ca) and suppressed by akt1 sirna. chromatin immunoprecipitation (chip) assay shows that the complex between runx2 and the osteocalcin promoter present in wild-type osteoblasts disappears in akt1-/- osteoblasts [48]. in these studies, no mechanism is proposed for the pi3k/akt-mediated increase in runx2 dna binding and transcriptional activity. more recently, it was shown in cell-free assays that akt phosphorylation of runx2 runt homology domain enhances its dna binding potential on a runx2 consensus oligonucleotide. in addition, mutation in akt phosphorylation sites (generated by substitution of s203/t205 (double mutant) or s203/t205/s207 (triple mutant) by alanines) produces runx2 forms that have a reduced ability to bind the runx2 consensus oligonucleotide. expression of the double or triple mutants of runx2 in breast cancer cells reduces the mrna levels of two metastasis-related target genes, mmp9 and mmp13, and reduces the runx2-dependent invasive potential of breast cancer cells. this study establishes runx2 as an akt substrate and an important mediator of pi3k/akt signaling in breast cancer [49].",pmc4513933,1,0.1,39,1,39.1
1117,uvrag,protein,,,uniprot,q9p2y5,golgi,go:0005794,lamp1,protein,,,uniprot,p11279,lysosome,go:0005765,negative,d,depletion,,,,,human,['2552'],nan,nan,"to determine whether uvrag phosphorylation had any major effects on multiple membrane compartments, we utilised sirna and our gfp-uvrag rescue cells to look at cis-golgi (gm130 staining), early endosomes (early endosomal antigen 1—eea1) and late endosomes (cation-independent mannose-6 phosphate receptor—ci-mpr) (supplementary fig s4a). in fixed cells, depletion of uvrag resulted in a dispersed and fragmented staining pattern of gm130. this is consistent with an earlier publication implicating uvrag in golgi-er transport, disruption of which causes golgi fragmentation (he et al, 2013). however, expression of sirna-resistant wt or dbla gfp-uvrag rescued this phenotype suggesting uvrag phosphorylation does not affect golgi integrity. little change in eea1 or ci-mpr staining was observed upon depletion of uvrag or rescue with the dbla mutant, implying uvrag phosphorylation does not play an important role in maintenance of these compartments, although we cannot rule out subtle changes at this resolution. uvrag depletion, however, had a clear effect on lamp1 staining (fig6a–c). loss of uvrag resulted in a small decrease in lamp1 puncta that were larger in size, similar to the effect seen with high doses of vps34-in1 treatment (see fig2a), a phenotype that was rescued by expression of wt gfp-uvrag. in contrast, rescue of the uvrag depletion with dbla gfp-uvrag expression resulted in a large increase in smaller dispersed lamp1 structures (fig6a and c). to confirm that reduction of vps34 activity upon loss of the mtor-uvrag phosphorylation sites altered lysosomal pi(3)p levels, we carried out lamp1-px domain staining in the gfp-uvrag rescue cells (fig6d and e). in very good agreement with the inhibitor data shown in fig1b and c, we found that loss of uvrag resulted in a decrease in lamp1-px colocalisation, which was rescued by expression of wt gfp-uvrag, but not the dbla mutant. we do not think that that the reduction in px domain staining is due to mislocalisation of the dbla gfp-uvrag mutant. both wt and dbla gfp-uvrag show a similar localisation with a large proportion co-localising with lamp1-mcherry (supplementary fig s4b). this therefore provides additional support for the vps34–uvrag complex in regulating lysosomal function.",pmc4585463,1,0.1,39,1,39.1
1113,twist1,protein,,twist1,uniprot,q15672,nucleus,go:0005634,mcl-1,protein,,mcl1,uniprot,q07820,mitochondria,go:0005739,negative,d,downregulation,,,,,,['1481'],nan,nan,knockdown of twist1 enhances cell sensitivity to cisplatin through mcl-1 downregulation,pmc3388235,1,0.1,39,1,39.1
1077,tcf3,protein,,tcf7l1,uniprot,p36402,nucleus,go:0005634,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,negative,d,inhibits,,xenopus embryos and cultured cells,,,not specified,['100'],nan,nan,"components of the wnt pathway upstream of tcf3 regulate β-catenin stability. however, a clear role for tcf3 itself in the stabilization of β-catenin has not been demonstrated. in the present study, we show that tcf3 inhibits the interaction between β-catenin and axin/apc and that tcf3 and β-catenin interact significantly even in the absence of wnt signaling to modulate β-catenin turnover. we show that gsk3 and casein kinase (ck) 1ε both have direct but opposite effects in regulating the β-catenin–tcf3 interaction. we also find that a significant fraction of tcf3 is cytoplasmic in both xenopus embryos and cultured cells, indicating that tcf3 can act outside the nucleus to regulate β-catenin degradation. additionally, we provide evidence that ckiε stimulates the interaction between dsh and gbp. these results suggest two possible mechanisms for the role of ck1ε in wnt signaling and provide further evidence that regulated formation of the β-catenin–tcf3 complex and the dsh–gbp complex play a crucial role in wnt signaling.",pmc2196183,1,0.1,39,1,39.1
1093,transcription factor eb (tfeb),protein,transcription factor,tfeb,uniprot,q6uuv9,"cytoplasm, nucleus","go:0005737, go:0005634",14-3-3 protein family members,protein,adaptor protein,,uniprot,p31947,cytoplasm,go:0005737,negative,d,phosphorylation,serine s211,,,,human,['2846'],nan,nan,"autophagy, a process of lysosomal degradation essential for cellular homeostasis, is transcriptionally regulated by transcription factor eb (tfeb) [1–3], which coordinates the expression of genes involved in lysosome biogenesis, autophagy and endocytosis [1, 2, 4]. under normal growth conditions tfeb is transiently recruited to the lysosomes through its interaction with active rag gtpases at the lysosomal membrane [5]. active rag gtpases also recruit the anabolic kinase complex mtor, which phosphorylates tfeb at serine s211 to promote its dissociation from the lysosome and binding with 14-3-3 protein family members, which retain tfeb in the cytoplasm and inhibit its transcriptional activity [5–7]. upon amino acid starvation, rag gtpases are inactivated [8] resulting in the loss of lysosomal recruitment of tfeb and mtor. consequently, the cytoplasmic pool of tfeb becomes dephosphorylated, leading to the dissociation from 14-3-3 proteins and ultimately to nuclear accumulation of tfeb. besides amino acid starvation, pharmacological inhibition of mtor and lysosomal stresses result in tfeb dephosphorylation and nuclear accumulation [7, 9]. in the nucleus, tfeb activates the transcription of the clear network (coordinated lysosomal expression and regulation), which is composed of at least 471 direct targets, including a battery of lysosomal and autophagy genes [1].",pmc4896000,1,0.1,39,1,39.1
978,runx3,protein,,runx3,uniprot,q13761,,,lck,protein,,lck,uniprot,p06239,,,positive,d,interact with and phosphorylate,kinase domain,,,,,['814'],nan,nan,"because runx3 interacts with the kinase domain of src, we investigated whether other tyrosine kinases also interact with runx3. the results revealed that fyn and lck also interact with and phosphorylate runx3 as shown by the coimmunoprecipitation and the induced band shift of runx3 (fig. 3d), suggesting that runx3 could be a target of other tyrosine kinases.",pmc2843174,1,0.1,39,1,39.1
1000,skp2,protein,,skp2,uniprot,q13309,,,p27,protein,,cdkn1b,uniprot,p46527,,,positive,d,ubiquitination,,,pancreatic β cell,pancreas,human,['2595'],nan,nan,"mounting evidence suggests that the s-phase kinase-associated protein 1 (skp1)/cul1/f-box protein skp2 acts as an e3 ubiquitin ligase and is involved in the ubiquitination and proteasome-dependent degradation of p2744454647. our analyses suggested the participation of skp2 in rig-i-mediated p27 stability. correspondingly, skp2 was downregulated by elevated rig-i and glucolipotoxicity-stimulated p27 stability was abrogated when skp2 was overexpressed (fig. 6). skp2 has been suggested to play a critical and specific role in regulating the cellular abundance of p27, and acts as an essential determinant of β cell proliferation. for example, diminished β cell mass, hypoinsulinaemia and glucose intolerance occurred in skp2(−/−) mice48.",pmc4923948,1,0.1,39,1,39.1
993,satb1,protein,,satb1,uniprot,o60844,nucleus,go:0005634,nanog,protein,,nanog,uniprot,q92586,nucleus,go:0005634,positive,d,phosphorylation,s47a,f9,embryocarcinoma,,mouse,['855'],nan,nan,"in order to ascertain the regulatory role of satb1 phosphorylation in f9 cell differentiation and nanog expression, we established f9 stable cells carrying vector control, flag-ha-satb1, flag-ha-satb1s47a or flag-ha-satb1s47d, respectively (figure s5a). under normal growth culture, expression of nanog, oct4, sox2 or klf4 mainfested no significant difference among these stable cell lines (figure s5a, s5b and s5c). in the presence of ra, the phosphorylated satb1 was more stable as shown with anti-phospho-satb1, and the ability of satb1s47a to repress nanog expression was dramatically lower than that of satb1 or satb1s47d, which agreed to an idea that phosphorylation was critical for the function and stability of satb1 (figure 6c and 6d). in addition, the rna level of nanog was the highest in the f9 cells integrated with the mutant of satb1s47a in the late stage of differentiation (figure 6e). therefore, it was quite possible that satb1s47a was functionally inert with respect to wild-type satb1. such inability could account for the phenomenon that this mutant was enriched to the nanog locus more than satb1 or satb1s47d (figure 6f). consistently, wortmannin and akti-1/2, inhibitors of pi3k and akt, delayed the attenuation of nanog and oct4 during ra-induced differentiation of eccs (figure s5d). on the other hand, the satb1s47a mutant failed to efficiently activate expression of two differentiation genes, bcl2 and nestin, in the ra-induced differentiation process (figure 6g and 6h). however, we detected neither a striking difference in klf4 at transcriptional and translational levels upon exogenous expression of satb1, nor any satb1 binding on the klf4 locus using a chip assay, which could be caused by a possible genomic structure change within the klf4 locus in the f9 cell, a carcinoma cell line (figure s5e). taken together, the results indicate that akt is involved in the differentiation of mouse f9 embryocarcinoma cells through coordinated phosphorylations of pluripotency/differentiation factors.",pmc3675137,1,0.1,39,1,39.1
994,satb1,protein,,satb1,uniprot,q01826,nucleus,go:0005634,sox2,protein,,sox2,uniprot,o60315,nucleus,go:0005634,positive,d,associates,,f9,embryonic,,human,['849'],nan,nan,"(a) satb1 associates with sox2, but not oct4 or klf4. (b) endogenous interaction between satb1 and sox2. satb1 was immuprecipitated from f9 cell lysates, immuprecipitations were subjected to immunblotting with anti-satb1 and anti-sox2. (c) mapping of satb1 domain required for sox2 binding using gst pull-down assay. (d) a schematic representation of flag-gfp-tagged sox2 constructs is shown. (e) mapping of sox2 domains that are necessary for satb1 binding. (f) satb1s47a sequesters much less sox2 than wild-type satb1 and satb1s47d. (g) inhibition of akt signaling disrupts satb1/sox2 interaction. hek293t cells were co-transfected with myc-satb1 and flag-sox2, serum-starved and treated as indicated.",pmc3675137,1,0.1,39,1,39.1
996,sirt1,protein,,sirt1,uniprot,q96eb6,cytoplasm,go:0005737,sirt3,protein,,sirt3,uniprot,q9ntg7,mitochondria,go:0005739,positive,d,expression,,"pancreatic cancer panc-1, mia paca-2, aspc-1",epithelial,pancreas,human,['2121'],nan,nan,"(a–c) pancreatic cancer panc-1, mia paca-2 and aspc-1 cells were treated with resveratrol (0–30 µm) for 24 h, and the expression of sirt1, sirt2 and sirt3 was measured by qrt-pcr. data represent mean ± sd. * = significantly different from respective control, p<0.05.",pmc3181262,1,0.1,39,1,39.1
997,skp2,protein,,,uniprot,q13309,,,p27kip1,protein,,cdkn1b,uniprot,p46527,,,negative,d,overexpression,,snu-638,,,,['312'],nan,nan,"we also prepared an skp2 overexpression vector and transiently transfected it into the snu-638 cells. increased p27kip1 expression resulting from galectin-3 depletion was significantly diminished by skp2 overexpression (figure 4a). although cell proliferation increased by skp2 overexpression, it was not significantly affected by galectin-3 depletion (figure 4b). an increase in the g1 cell cycle population induced by galectin-3 depletion was also compensated for by skp2 overexpression (figure 4c). these data suggest that overexpression of both galectin-3 and skp2 results in reduced p27kip1 expression and cell cycle progression.",pmc4211374,1,0.1,39,1,39.1
998,skp2,protein,,skp2,uniprot,o43318,cytoplasm,go:0005737,p27kip1,protein,,cdkn1b,uniprot,p46527,nucleus,go:0005634,negative,d,increase in protein levels,,,,,human,['313'],nan,nan,depletion of skp2 induces premature senescence through an increase in p27kip1 protein levels,pmc4211374,1,0.1,39,1,39.1
999,skp2,protein,,skp2,uniprot,o43663,nucleus,go:0005634,p27kip1,protein,,cdkn1b,uniprot,p46527,cytoplasm,go:0005737,negative,d,decrease in expression,,,,,,['310'],nan,nan,overexpression of galectin-3 or skp2 induces a decrease in p27kip1 protein expression,pmc4211374,1,0.1,39,1,39.1
221,cd40,protein,,cd40,uniprot,p25942,plasma membrane,go:0005886,tlr7,protein,,tlr7,uniprot,q9nyk1,endosome,go:0005769,positive,i,dual stimulation,,,,,human,['195'],nan,nan,response to dual stimulation via cd40 and tlr7 were similar to those of jnk,pmc3084876,1,0.1,39,1,39.1
666,men1,gene,tumor suppressor,men1,hgnc,6835,nucleus,go:0005634,cdk4,protein,cyclin-dependent kinase,cdk4,uniprot,p11802,nucleus,go:0005634,negative,i,downstream target,specific sites,ins-1,insulinoma,pancreatic islet,mouse,['3141'],nan,nan,"recent studies suggest that physiological and tumorigenic proliferation of mammalian cells is controlled by multiple cyclin-dependent kinases (cdks) largely in tissue-specific manners. we and others previously demonstrated that adult mice deficient for the d-cyclin-dependent kinase cdk4 (cdk4−/− mice) exhibit hypoplasia in the pituitary and pancreatic islet due to primary postnatal defects in proliferation. intriguingly, those neuroendocrine tissues affected in cdk4−/− mice are the primary targets of tumorigenesis in the syndrome of multiple endocrine neoplasia type-1 (men1). mice with heterozygous disruption of the tumor suppressor men1 gene (men1+/−) develop tumors in the pituitary, pancreatic islets and other neuroendocrine tissues, which is analogous to humans with men1 mutations. to explore the genetic interactions between loss of men1 and activation of cdks, we examined the impact of cdk4 or cdk2 disruption on tumorigenesis in men1+/− mice. a majority of men1+/− mice with wild-type cdks developed pituitary and islet tumors by 15 months of age. strikingly, men1+/−; cdk4−/− mice did not develop any tumors, and their islets and pituitaries remained hypoplastic with decreased proliferation. in contrast, men1+/−; cdk2−/− mice showed pituitary and islet tumorigenesis comparable to those in men1+/− mice. pituitaries of men1+/−; cdk4−/− mice showed no signs of loss of heterozygosity (loh) in the men1 locus, while tumors in men1+/− mice and men1+/−; cdk2−/− mice exhibited loh. consistently, cdk4 knockdown in ins-1 insulinoma cells inhibited glucose-stimulated cell cycle progression with a significant decrease in phosphorylation of retinoblastoma protein (rb) at specific sites including ser780. cdk2 knockdown had minimum effects on rb phosphorylation and cell cycle progression. these data suggest that cdk4 is a critical downstream target of men1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas cdk2 is dispensable for tumorigenesis in these neuroendocrine cell types.",pmc4135037,1,0.1,39,1,39.1
885,pp1,protein,phosphatase,ppp1ca,uniprot,p62136,nucleus,go:0005634,brca1,protein,tumor suppressor,brca1,uniprot,p38398,nucleus,go:0005634,negative,d,dephosphorylation,"chk2 target site s988, atm target site s1524, atr site s1423",,,breast,human,['1675'],nan,nan,"pp1 could dephosphorylate brca1 at the chk2 target site s988, the atm target site s1524, and the atr site s1423 [133,134]. the overexpression of pp1 partially inhibited the hyperphosphorylation of brca1 after ir [134]. since pp1 was shown to dephosphorylate brca1 at sites that have been shown to be important for brca1 function, it was intriguing to find that pp1 may actually act to enhance brca1 function. pp1 specifically binds to brca1 amino acids 898-901 (kvtf) [133,135]. mutation of this site negatively affected homology-directed recombination and the localization of the hr factor rad51 to the break site, which are functions of brca1 [133]. interestingly, in human tissues, pp1 mrna levels were significantly higher in normal tissue as compared to sporadic breast tumors [135]. this implicates pp1 in the regulation of brca1 function.",pmc2954851,1,0.1,39,1,39.1
366,cytochrome c,protein,,cycs,uniprot,p99999,mitochondria,go:0005739,parp,protein,,,uniprot,p09874,nucleus,go:0005634,positive,d,cleavage,,hmn1,neural,,human,['1599'],nan,nan,"cell-free extracts were generated from hmn1 cells as described by slee et al. 1999 with some modifications. cells were pelleted and washed twice with pbs, ph 7.2, followed by washing once with 5 ml of ice-cold cell extract buffer (ceb; 20 mm hepes-koh, ph 7.5, 10 mm kcl, 1.5 mm mgcl2, 1 mm edta, 1 mm egta, 1 mm na3vo4, 1 μm okadaic acid, 1 mm dithiothreitol, 100 μm pmsf, 10 μg/ml leupeptin, 2 μg/ml aprotinin). the cell pellet was resuspended in 2 vol of ice-cold ceb and incubated on ice for 15 min. cells in ceb were then transferred to a 2-ml dounce homogenizer and disrupted with 20 strokes of a b-type pestle. lysates were transferred to eppendorf tubes and centrifuged at 15,000 g for 15 min at 4°c. the resulting supernatants were obtained as postnuclear extracts and frozen in aliquots at −80°c until required. cell-free reactions were set up in a 120-μl reaction volume. cell extracts were brought to a final volume of 120 μl in ceb with protein concentration of 2.5 mg/ml. apoptosis was induced by addition of bovine heart cytochrome c and datp to extracts at a final concentration of 50 μg/ml and 1 mm, respectively. the reactions were then incubated at 37°c. at the indicated time points, 20 μl of reactions were removed and boiled with 10 μl 3× sample buffer for 5 min at 95°c. samples were frozen at −20°c for subsequent sds-page/western blot analysis. addition of cytochrome c and datp to nonapoptotic hmn1 cell extracts induces rapid cleavage of poly (adp-ribose) polymerase (parp) by activated caspase-3. on the other hand, addition of bsa and datp does not lead to parp cleavage (data not shown). these observations suggest that, in this cell free system, caspase activation is strictly dependent on the presence of cytochrome c.",pmc2185587,1,0.1,39,1,39.1
144,apc,protein,truncated,,uniprot,o96028,cytoplasm,go:0005737,βcat,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,i,facilitate,destruction complex,sw480 cells,colorectal cancer cells,colon,human,['3434'],nan,nan,"based on our model apc mediated βcat transfer is only possible when r2 and b are maintained in the truncated apc (figure 10). r2 and b are essential for function in the absence of endogenous apc function in vivo in drosophila (roberts et al., 2011). in sw480 cells our data suggest they are essential for apc2 to further simulate the rate of βcat destruction mediated by axin transfection. consistent with this, tumor cells that retain r2/b in the truncated apc have low levels of phospho-βcat (yang et al., 2006), suggesting apc is still able to facilitate βcat transfer out of the destruction complex due to the presence of the arm rpts, r2 and b (although the transfer would be less efficient due to loss of the samps, the axin binding sites). in contrast, truncated apc mutants that disrupt r2 and b function can associate with the axin complex via the arm rpts, but would not be able to assist in βcat transfer out of the destruction complex. the development of crispr knockout technology will allow future examination of the importance of truncated apc1, as well as the endogenous apc2 and axin expressed in colon cancer cells in destruction complex assembly and function.",pmc4568445,1,0.1,39,1,39.1
145,apc2,protein,,apc2,uniprot,o95996,cytoplasm,go:0005737,axin,protein,,axin1,uniprot,o15169,cytoplasm,go:0005737,positive,d,interactions,,,,,,['3435'],nan,nan,destruction complex function requires dynamic apc2:axin interactions regulated by r2/b,pmc4568445,1,0.1,39,1,39.1
146,apc2,protein,,apc2,uniprot,q9upn3,cytoplasm,go:0005737,axin,protein,,axin1,uniprot,o15169,cytoplasm,go:0005737,positive,d,stabilize,arm rpts and samps,,,,,['3418'],nan,nan,apc2’s arm rpts and samps each are required to stabilize apc2:axin complexes.,pmc4568445,1,0.1,39,1,39.1
147,apc2,protein,,,uniprot,o95996,,,axin,protein,,,uniprot,o15169,,,positive,d,enhances,,,,,,['3458'],nan,nan,that apc2 enhances axin's ability to downregulate beta-catenin isn't informative: apc2 alone is as good as apc2 + axin. this undercuts the utility of the,pmc4568445,1,0.1,39,1,39.1
148,apc2,protein,,,uniprot,q9np62,,,ßcat,protein,,ctnnb1,uniprot,p35222,puncta,,positive,d,exit,puncta,,epithelial,colon,human,['3477'],nan,nan,"we have addressed this in two ways. first, our data showed that expression of either “apc2 alone” or apc2 plus axin similarly stimulated ßcat exit out of the puncta to destruction. in our initial manuscript, we had suggested this was “presumably due to the presence of endogenous human axin”. we now have tested whether fly apc2 can and does interact with human axin. we found that fly gfp-apc2 colocalizes in puncta with exogenous haxin1-rfp (present in new figure 3j), and more importantly, that endogenous haxin1 coips with flag-apc2 expressed in sw480 cells (new figure 3k). thus this is at least a reasonable possibility.",pmc4568445,1,0.1,39,1,39.1
409,enac,protein,,,uniprot,p37088,plasma membrane,go:0005886,nedd4,protein,,nedd4,uniprot,p46934,,,negative,d,binding,,,epithelial,kidney,,['1802'],nan,nan,"liddle's syndrome is caused by mutations in enac that disrupt or eliminate the py motifs found in the intracellular c termini of the β and γ subunits, thereby interfering with nedd4 binding and promoting channel retention in the plasma membrane (schild et al., 1996; staub et al., 1996). garty and coworkers reported erk-dependent phosphorylation of amino acids near py motifs in β- and γ-enac subunit, namely βt613 and γt623 and enhanced binding to nedd4 (shi et al., 2002a). we showed that egf-induced inhibition of sodium absorption is significantly attenuated by deletion or mutation of the py motif and mutation of the putative erk phosphorylation site (figs. 1 and 6). these results point to enhanced channel retrieval as the mechanism for erk-mediated inhibition of enac activity. a relatively small fraction of enac is present at the plasma membrane so it was necessary to evaluate changes in surface expression by apical membrane biotinylation followed by immunoprecipitation of flag-tagged β-enac. unexpectedly, we found that surface expression of enac was not decreased 30 min after egf treatment, a time at which egf-induced inhibition of isc was fully developed (figs. 8 and 2). we cannot rule out the possibility that the individual enac subunits are differentially retrieved (mohan et al., 2004). a large pool of inactive channels in the plasma membrane could also mask selective retrieval of a small subpopulation of functional channels. as described in the preceding section, it is unlikely that under the conditions of our experiments, there exist a significant number of inactive channels in the apical membrane. thus, the failure to detect a decrease in surface expression of enac after 30 min exposure to egf despite the ∼30% decrease in isc cannot be explained by a large pool of silent channels that obscures selective retrieval of a small number of active channels. furthermore, we did observe a time-dependent decrease in enac surface expression at later time points (60, 90, and 120 min). despite the fact that egf-induced inhibition of sodium absorption is sensitive to mutations at sites associated with channel retrieval, our results demonstrate that inhibition occurs without concurrent channel internalization.",pmc2151644,1,0.1,39,1,39.1
152,atm,kinase,,atm,uniprot,q13315,nucleus,go:0005634,chk2,kinase,,chek2,uniprot,o96017,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['32'],nan,nan,"during normal growth, chk2 is present in the nucleus in an inactive monomeric form (ahn et al., 2000). after dna damage, chk2 is phosphorylated by atm on the priming site t68 and on other residues in the scd (figure 2b). these phosphorylations lead to a conformational change which induces chk2 dimerization through binding of the phosphorylated scd of one monomer with the fha domain of another (ahn et al., 2002; xu et al., 2002). dimerization promotes chk2 autophosphorylation of the kinase domain at residues s260 and t432, the t-loop residues t383 and t387, and s516 (lee and chung, 2001; schwarz et al., 2003; wu and chen, 2003), triggering an additional conformational change and dissociation of the dimers into fully active monomers. although phosphorylation of the scd is the initial, essential step of chk2 activation, this domain is rapidly dephosphorylated, perhaps because after dimer dissociation it is exposed to phosphatases (ahn et al., 2002). therefore, scd phosphorylation is detectable only at early time points after damage.",pmc4296918,1,0.1,39,1,39.1
404,eif4e,protein,,eif4e,uniprot,q04637,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,negative,i,binds,,,,,human,['3395'],nan,nan,"4ebp1, eukaryotic translation initiation factor 4e (eif4e) -binding protein 1; ci, combination index; eif4e, eukaryotic translation initiation factor 4e; gs, glycogen synthase; gsk-3, glycogen synthase kinase-3; gst, glutathione s-transferase; mrcc, metastatic renal cell carcinoma; mtor, mammalian target of rapamycin; mtorc, mammalian target of rapamycin (mtor) complex; pi3k, phosphoinositide 3-kinase; rcc, renal cell carcinoma; s6k, ribosomal protein s6 kinase; s6rp, ribosomal protein s6; tki, tyrosine kinase inhibitor; vhl, von hippel lindau; xiap, x-linked inhibitor of apoptosis protein",pmc4936323,1,0.1,39,1,39.1
403,eif3b,protein,,eif3b,uniprot,o00303,,,4ebp1,protein,,eif4ebp1,uniprot,q13541,,,positive,d,binds,,,,,,['133'],nan,nan,"sodium arsenite, sodium selenite, emetine, cycloheximide and rapamycin were purchased from sigma-aldrich. mntmpyp (manganese (iii) tetrakis (1-methyl-4-pyridyl) porphyrin) was obtained from enzo life sciences. the following antibodies were used for western blotting and immunofluorescence: anti-eif3b (goat polyclonal, n-20), eif3e (goat polyclonal, c-20), eif4e (mouse monoclonal, p-2), eif4g1 (rabbit polyclonal, h-300), g3bp1 (mouse monoclonal, tt-y), fmr1 (mouse monoclonal, 148.1), hedls (mouse monoclonal, originally intended to react with s6k1 (18), h-9), hdac6 (rabbit polyclonal, h-300), hur (mouse monoclonal, 3a2), pabp (mouse monoclonal, 10e10), rack1 (mouse monoclonal, b-3) and tiar (goat polyclonal, c-18) from santa cruz biotechnology; anti-eif4e-binding protein1 (4ebp1) (rabbit polyclonal), phospho-4ebp1 (thr37/46, rabbit monoclonal), eif4a1 (rabbit monoclonal), ribosomal s6 (mouse monoclonal), phospho-ribosomal s6 (rabbit polyclonal) and rsk2 (rabbit monoclonal) from cell signaling technology; anti-β-actin (mouse monoclonal) from chemicon; anti-eif5a (mouse monoclonal) from bd biosciences; anti-g3bp1 (rabbit polyclonal) from bethyl; anti-phospho-eif2α (rabbit polyclonal) from assay designs; anti-ago2 (mouse monoclonal) from wako bioproducts; anti-pcbp2 (mouse monoclonal) from abnova; anti-o-glcnac (mouse igm, ctd110.6) from covance; anti-importin β1 (mouse monoclonal) from pierce; anti-small ribosomal s14 (rabbit polyclonal) from proteintech group. anti-rch1/importin α1 (mouse monoclonal) antibody was kindly provided by dr. jun katahira (osaka university). secondary antibodies used for immunofluorescence (cy2-, cy3- and cy5-conjugated) and western blotting (horseradish peroxidase-conjugated) were from jackson immunoresearch laboratories. biotinylated oligo-dt18 probe was purchased from idt. non-targeting, control small interfering rna (sirna) (u0) was as described previously (19). sirna targeting human 4ebp1 was purchased from qiagen; the target sequence was 5′-tcggaactcacctgtgaccaa-3′.",pmc3439927,1,0.1,39,1,39.1
370,ddb1,protein,,ddb1,uniprot,q16531,nucleus,go:0005634,xpc,protein,,xpc,uniprot,q01831,nucleus,go:0005634,positive,d,ubiquitination,,,,,,['2184'],nan,nan,"dna-damage-binding proteins (ddb1 and ddb2) are subunits of a heteromeric complex, which is known as the primary detection device for uv-induced lesions in the genome and mediates global genome nucleotide excision repair (gg-ner) (18–20). the crl4ddb2 ubiquitin ligase complex participates in diverse cellular and physiological processes including dna repair, dna replication and chromatin remodeling. more specifically, the ligase complex facilitates ner by targeting xpc and histones h2a, h3 and h4 for ubiquitination (21–24). the complex also targets the replication licensing factor, cdt1, for degradation which in turn results in delayed cell-cycle progression, finally permitting time for dna repair (25).",pmc3575827,1,0.1,39,1,39.1
369,dbc1,protein,,dbc1,uniprot,o60563,,,sirt1,protein,deacetylase,sirt1,uniprot,q96eb6,,,negative,d,interacts with,,,,,human,['2423'],nan,nan,"it is now well established that dbc1 interacts with and negatively regulates sirt1 (24,25), a nad+-dependent deacetylase able to deacetylate histone and non-histones protein, such as the tumor suppressor p53 (26,27). dbc1-mediated repression of sirt1 results in increased levels of p53 acetylation and upregulation of p53-mediated apoptosis after dna damage (24,25). previously, we and others reported that, in response to dna damage, dbc1 phosphorylation of thr454 by atm and atr enhances dbc1 binding to and inhibition of sirt1, promoting p53 activation and induction of apoptosis (28,29). furthermore, recent studies show that, after dna damage, kinase suppressor of ras-i (ksr1) plays a role in decreasing dbc1 phosphorylation of thr454, leading to a reduced dbc1-sirt1 interaction and a lower transcriptional activity of p53 (30). moreover, dbc1-sirt1 binding is negatively regulated by hmof acetylation (a member of the myst family of histone acetyltransferases) of specific dbc1 residues, a process inhibited by atm upon dna damage (31). collectively these results indicate that dbc1 and sirt1 form, in human cells, a dynamic and regulated complex.",pmc4245943,1,0.1,39,1,39.1
364,cyclin d3,protein,,ccnd3,uniprot,p30291,,,cdk4,protein,,cdk4,uniprot,p11802,,,positive,d,phosphorylation,,cho,,,,['1110'],nan,nan,"in asynchronously proliferating cho cells transfected to overexpress cyclin d3 and cdk4 in the presence of a limiting amount of ectopic p21 (performed as in figure 4), roscovitine treatment was insufficient to reduce the phosphorylations of cdk4 and p21. this intriguing observation is at variance with the situation observed in re-stimulated k7as cells. so we re-investigated the effect of roscovitine in the presence of cdk4/6 inhibition by pd0332991 in such transfected cho cells (figure 7c). whereas pd0332991 partly inhibited p21 phosphorylation, roscovitine alone was inactive. only the combination of both inhibitors abrogated both p21 and cdk4 phosphorylations (figure 7c), suggesting that they depended on both cdk4/6 and cdk2 (and/or cdk7) activities in this experimental setting.",pmc3667761,1,0.1,39,1,39.1
884,pp1,protein,,,uniprot,p62136,,,dna-pk,protein,,prkdc,uniprot,p78527,,,positive,d,influence,,,,,,['1664'],nan,nan,"pp1, pp2a, and pp6 have all been shown to positively influence dna-pk activity. when pp1 was added to dna-pk complexes that were induced to autophosphorylate, the reduction in activity and disruption of the dna-pk-dna binding due to the autophosphorylation were reversed [110]. pp2a dephosphorylated dna-pkcs as well as ku70 and ku80 leading to increased dna-pk activity [111]. this opposes the autophosphorylation of dna-pk that results in decreased activity of dna-pk [112]. camptothecin-induced dsb increased the association between pp2a and ku proteins. pp2a dephosphorylation of dna-pkcs and ku increased the association between the dna-pk proteins and this promoted dna repair [113].",pmc2954851,1,0.1,39,1,39.1
163,atr,protein,,atr,uniprot,q13535,nucleus,go:0005634,atrip,protein,,atrip,uniprot,o00227,nucleus,go:0005634,positive,d,binds,rpa-coated ssdna,,,,human,['3237'],nan,nan,"while atr is activated by multiple types of dna lesions, including dsbs, base adducts, crosslinks, and replication stress [18]; its activation is primarily mediated by the structure containing single-stranded dna (ssdna) [29, 30]. association of atr with replication protein a (rpa)-coated ssdna is required for atr activation. atr binds directly to the atr interacting protein (atrip). this association does not depend on dna damage but is required for the stabilization of both atr and atrip, as knockdown of one causes the reduction of the other [31]. atr function depends on atrip in human cells and its homologues in yeast, rad26 in schizosaccharomyces prombe and ddc2/lcd1/pie1 in saccharomyces cerevisiae. loss of atrip in yeast and human cells recapitulate the same phenotypes as loss of atr [31, 32, 33, 34, 35, 36]. atrip binds to rpa-coated ssdna and thereby results in the recruitment of atr to the dna lesion [30, 37, 38]. although the association of the atr-atrip complex with rpa-coated ssdna is required, it is insufficient to increase atr-derived kinase activity. biochemical analysis revealed that topbp1 (topoisomerase-binding protein 1), the mammalian homologue of yeast cut5/dbp11, significantly enhanced the kinase activity of the atr-atrip complex in vitro [39]. in line with the rpa-coated ssdna being the primary structure leading to atr activation; topbp1 is recruited to rpa-coated ssdna independent of the atr-atrip complex, and requires the rad17/rfc (replication factor c) and the rad9-rad1-hus1 (9-1-1) complex. rad17/rfc binds to rpa-ssdna (fig. 1) [40, 20], which loads the 9-1-1 complex [41, 42] and subsequently recruits topbp1 [43, 44]. this recruitment allows topbp1 to activate atr via binding to both atr and atrip subunits (fig. 1) [39, 45]. atr activation coordinates a global cellular response to prevent cell cycle progression into mitotic phase (s phase arrest or induction of apoptosis) and to initiate dna damage repair [18]. atr accomplishes these multiple functions by phosphorylation of a variety of down-stream targets, including the serine 139 (s139) in the sqe motif located on the tail of histone h2ax (γh2ax), the s15 of p53, and the s345 of chk1 [1, 46, 47].",pmc3330700,1,0.1,39,1,39.1
361,cyclin d3,protein,d-type cyclin,ccnd3,uniprot,p30281,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,positive,d,assembly,,,thyrocyte,thyroid,dog,['1499'],nan,nan,"the dog thyrocyte system has provided the first evidence for a critical regulation of d-type cyclin-cdk4 assembly by a physiological mitogenic stimulus [70]. in these cells, cyclin d3 is abundantly expressed depending in part on the presence of comitogenic factors (insulin and carbachol), whereas cdk4 is constitutively expressed. tsh and camp trigger the entry into s-phase at least in part by promoting the assembly of required cyclin d3-cdk4 complexes [70,83-85]. other examples of regulation of the formation of d-type cyclin-cdk4/6 complexes unexplained by modulations of cyclin d or cdk4/6 presence were found in b lymphocytes [86], or fsh-stimulated granulosa cells of hamster preantral follicles [87].",pmc1647274,1,0.1,39,1,39.1
360,cyclin d2,protein,,ccnd2,uniprot,p30279,,,cdk4,protein,kinase,cdk4,uniprot,p11802,,,positive,i,activity,,,,,,['204'],nan,nan,"the presence of cyclin d2 indicates cdk4 activity, the role of its activity in",pmc3084876,1,0.1,39,1,39.1
352,cki,protein,,,uniprot,p48729,,,beta-catenin,protein,,ctnnb1,uniprot,p35222,,,negative,d,phosphorylation,s45,,,,,['2028'],nan,nan,"cki phosphorylates beta-catenin on s45 when wnt signaling is extinguished. gsk-3beta can then phosphorylate beta-catenin on s33, s37 and t41. the axin/gsk-3/ck1/apc complex induces the degradation of beta-catenin. this occurs via ubiquitination by the skp1/cullin1-f-box e3 ligase (beta-trcp) complex in the 26s proteasome. the tumor suppressor apc interacts with both gsk-3 and beta-catenin. axin serves as the scaffold of the destruction complex. apc binds directly to axin. axin is phosphorylated by cki and then gsk-3 [291]. the affinity of beta-trcp for beta-catenin is normally low. the wilms tumor suppressor (wtx) protein increases the affinity of beta-trcp for beta-catenin [237]. a complex is formed consisting of and apc, axin, beta-catenin, beta-trcp and wtx, which promotes beta-catenin ubiquitination and subsequent proteasomal degradation.",pmc4102778,1,0.1,39,1,39.1
351,ck1ε,protein,,csnk1e,uniprot,p49674,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,positive,d,synergistically,,xenopus extracts,,,,['115'],nan,nan,"effect of ck1ε on tcf3– β-catenin interaction. (a) tcf3 and ck1ε act synergistically to inhibit β-catenin degradation. his6-tcf3 (3 nm) and mbp-ck1ε (200 nm) were added to xenopus extracts either alone or together. inhibition of β-catenin degradation is dramatically enhanced by addition of both tcf3 and ck1ε (nearly 80% remaining after 3 h) compared with addition of either tcf3 or ck1ε alone (35% remaining after 3 h). (b) the ck1ε inhibitor cki-7 inhibits the effect of tcf3 or β-catenin stabilization. cki-7 inhibits the effects of 10 and 30 nm tcf3 in a dose-dependent manner. at high cki-7 concentrations (100 μm), the effect of tcf3 is abolished and β-catenin degradation is actually stimulated when compared with the buffer control. (c) ck1ε stimulates the binding of tcf3 to β-catenin. preincubation of tcf3 beads with 1 μm ck1ε in kinase buffer stimulates its binding to β-catenin (compared with preincubation in buffer alone). this effect of ck1ε was decreased by addition of 1 μm gsk3 to the kinase reaction. gsk3 by itself had no effect on the binding of tcf3 to β-catenin. a nearly fivefold increase in the binding of tcf3 to β-catenin is seen when tcf3 beads were preincubated with ck1ε. (d) ck1ε acts synergistically with gbp to inhibit β-catenin degradation. 50 nm gbp or 200 nm ck1ε has no effect on β-catenin degradation; however, together they dramatically inhibit β-catenin degradation in extracts.",pmc2196183,1,0.1,39,1,39.1
350,ck1ε,protein,,csnk1e,uniprot,p48730,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,positive,d,bind and phosphorylate,,,,,,['113'],nan,nan,"these experiments establish that both gsk3 and ck1ε can bind and phosphorylate tcf3 and suggest a possible role for both gsk3 and ck1ε in modulating tcf3 activity. we therefore tested if these kinases affect the interaction of tcf3 with β-catenin. tcf3 can inhibit the degradation of β-catenin (fig. 1, a and b). ck1ε and tcf3 act synergistically to inhibit β-catenin degradation: as shown in fig. 7",pmc2196183,1,0.1,39,1,39.1
349,ck1 ε,protein,,csnk1e,uniprot,p49674,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,negative,i,regulates stability,,,,,unspecified,['95'],nan,nan,physiological regulation of  β -catenin stability by tcf3 and ck1 ε ,pmc2196183,1,0.1,39,1,39.1
348,ck1,protein,,ck1,uniprot,p78368,cytoplasm,go:0005737,beta-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,negative,d,phosphorylation,s45,,,,,['2024'],nan,nan,"in the absence of stimulation, ck1 phosphorylates beta-catenin at s45 which primes beta-catenin for subsequent phosphorylation by gsk-3 at s41, s37 and s33 [29,143,217-221]. these phosphorylation events target beta-catenin for ubiquitination and proteasomal degradation [29]. a blow up of the wnt/beta-catenin and beta catenin destruction complex is presented in figure 5.",pmc4102778,1,0.1,39,1,39.1
304,chk2,kinase,,chek2,uniprot,o96017,cytoplasm,go:0005737,kap1,protein,,trim28,uniprot,q13263,nucleus,go:0005634,positive,d,phosphorylation,s473,,,,human,['3099'],nan,nan,"in unstressed cells chk2 kinase exists as inactive monomer. upon dna damage, ccar2 contributes to chk2 homodimerization and activation by autophosphorylation, which induces kap1 phosphorylation on s473, thus increasing dsbs repair, possibly by induction of chromatin relaxation.",pmc4627348,1,0.1,39,1,39.1
301,cdk9,protein,,cdk9,uniprot,p50750,nucleus,go:0005634,rna polymerase ii,enzyme,,polr2a,uniprot,p24928,nucleus,go:0005634,positive,d,bind,hiv tat,,,,hiv,['2476'],nan,nan,"cdk9 associates with cyclin t1 and plays a role in transcription regulation through regulation of rna polymerase ii [72]. cdk9/cyclin t1 was in fact identified as the ptefb transcription factor and further found to bind hiv tat and promote its transactivation from the integrated provirus through activation of rna polii. as such, cdk9 has emerged as a novel target for anti-retroviral strategies.",pmc4381256,1,0.1,39,1,39.1
300,cdk8,protein,kinase,cdk8,uniprot,p49336,nucleus,go:0005634,β-catenin,protein,transcriptional regulator,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,i,transcriptional regulation,,,,"colon, gastric, melanoma, breast",human,['2492'],nan,nan,"cdk8 has been reported as an oncoprotein in colorectal and gastric cancers and further evidence points to its role in promoting cell proliferation in melanoma and breast cancer [52,261,262,263]. cdk8 kinase activity is required for β-catenin-driven transformation and expression of several β-catenin transcriptional targets. colorectal cancers with cdk8 expression have distinct clinical, prognostic and molecular attributes and both cdk8 and β-catenin levels have been reported to correlate with carcinogenesis, tumor progression and increased colon cancer-specific mortality [193,194]. however suppression of cdk8 expression inhibits proliferation in colon cancer cells characterized by high levels of cdk8 and β-catenin hyperactivity [52]. likewise, cdk8 was found to be overexpressed in gastric adenocarcinomas and cdk8 expression and the delocalization of β-catenin expression showed a significant positive correlation with carcinogenesis and tumor progression [195]. upregulation of cdk8 expression was also described in melanoma following loss of the histone variant macroh2a [196]. a role for cdk8 in breast cancer has been suggested through sirna silencing in breast cancer cell lines which leads to a significant decrease in proliferation [197]. cdk8 is further required for tumor growth and maintenance of tumor dedifferentiation in vivo and has been reported to play a role in control of cancer and stem cell function. cdk8 expression correlates with embryonic stem cell pluripotency and loss of cdk8 causes embryonic stem cells to differentiate through regulation of myc target gene expression. likewise, increased expression of a cdk8-regulated, embryonic stem cell myc target gene signature was associated with loss of differentiation and poor outcome in primary human colon cancers [192].",pmc4381256,1,0.1,39,1,39.1
419,erk,enzyme,protein kinase,mapk1,uniprot,p27361,cytoplasm,go:0005737,β-enac subunit,protein,,scnn1b,uniprot,p51168,plasma membrane,go:0005886,negative,i,inhibition,erk phosphorylation site,mdck,epithelial,kidney,mouse,['1788'],nan,nan,"three types of mutations were introduced into the β-enac subunit in order to evaluate the importance of specific sites in erk-dependent inhibition of sodium transport. a truncation mutation (r564st) to mimic the liddle's mouse model, a py motif mutation (p616l), and a mutation in the putative erk phosphorylation site located adjacent to the py motif (t613a). mdck cells were transduced with the β-enac subunit containing the flag tag, the g525c mutation, and one of the three additional mutations (fig. 4 a). stable mdck cell lines were created by facs-positive selection, and expression of the mutant β-enac subunit was confirmed (fig. 4 b). mdck cells from each of the cell lines were seeded onto permeable supports, grown to confluence, and wild-type enac expression was induced for 48 h before electrophysiological characterization. the amiloride-sensitive isc and transepithelial resistance for each cell line are summarized in fig. 4 (c and d). the values for amiloride-sensitive isc and transepithelial resistance were not significantly different among the cell lines that carried the mutant β-enac subunit or compared with the parental line (fig. 4, c and d).",pmc2151644,1,0.1,39,1,39.1
446,erk,proteinkinase,,mapk1,uniprot,p28482,cytoplasm,go:0005737,rhoa,protein,,rhod,uniprot,p61586,plasma membrane,go:0005886,positive,d,phosphorylation,serine 188,,,,human,['1554'],nan,nan,"rhoa phosphorylation by erk on 88s and 100t increased rhoa activity (fig 5), which is opposite to the effects of rhoa s188 phosphorylation, as reported previously (5, 6, 11). rhoa has been reported as a target for several protein kinases. pkapkg are two main kinases that phosphorylate rhoa on serine 188 [6,11–14]. rhoa is also phosphorylated by ampkα1 mst3 kinase [15,16]. rhoa phosphorylation on serine 188 by pka and pkg did not modify its gtpase activity and its interaction with gefs and gaps; however, it deactivates rhoa by increasing its interaction with rhogdi and translocation of rhoa from the membrane to the cytosol [5,6,11,12]. our data indicate that rhoa phosphorylation at different sites regulates rhoa differently.",pmc4729484,1,0.1,39,1,39.1
447,erk,proteinkinase,,,uniprot,p28482,nucleus,go:0005634,med1,protein,,,uniprot,q15648,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['1251'],nan,nan,"the recruitment of erk by elk-1 and the progesterone receptor (27) as well as the observation of other mapks at promoters (22–28) implies that there may be other erk targets within promoter complexes. in fact med1 appears to be phosphorylated by erk, influencing its stability and transactivation potential (29,31). however, several other protein kinases are associated with pics, including the ctd kinase cdk7/cyclin h (present with mat1 in tfiih), cdk8/cyclin c (present in the negative regulatory arc/mediator-like complex with med230/240) and cdk9/cyclin t/k, part of the p-tefb complex (positive transcription elongation factor) responsible for the phosphorylation of the rnapii ctd on s2, promoting elongation (82). hence, the identification of bona fide erk substrates in promoter complexes may not be straightforward. for example, we observed promoter-specific differences in ps5-ctd levels and confirmed that recombinant ctd can be phosphorylated by erk2 in vitro (82,83), but phosphorylation of s5-ctd in pics was not blocked by erk inhibitors (84,85). further analysis of proteins undergoing modification in sre pics is currently underway.",pmc2377423,1,0.1,39,1,39.1
449,erk1,kinase,,mapk3,uniprot,p27361,,,fbw7,protein,,,uniprot,q969h0,,,negative,d,regulation,,pancreatic cancer cell lines,epithelial,pancreas,human,['638'],nan,nan,"to test the hypothesis that the activation of mapk signaling negatively regulates fbw7, we examined the expression of fbw7 at both the mrna and protein levels by q-pcr and immunoblotting, respectively, upon overexpression of erk1 kinase in two pancreatic cancer cell lines. notably, the fbw7 mrna level was barely affected (figure 3a and 3b). besides, dna methylation of fbw7 promoter region was also analyzed. there were 16 cpg sites at the promoter region of fbw7/hcdc4-α (supplementary information, figure s3a). bisulfate sequencing results demonstrated that cpg sites were seldom methylated. moreover, overexpression of erk had no detectable influence on the methylation status of cpg sites in the promoter region (supplementary information, figure s3b), which is consistent with the transcriptional analysis of fbw7 upon erk1 overexpression, indicating that fbw7 was regulated mostly via post-transcriptional modifications. as expected, the fbw7 protein level was significantly decreased upon overexpression of wild-type erk1 but not the kinase-dead mutant (figure 3c and supplementary information, figure s3c). as constitutive activation of erk is observed in almost all pancreatic cell lines, we pretreated the pancreatic cancer cell lines with the mek/erk inhibitors (uo126, azd6244, trametinib and sch772984) to suppress erk activity before harvesting and then determined fbw7 protein level. fbw7 protein levels significantly increased in response to inhibition of mapk-erk signaling in pancreatic cells (figure 3d and supplementary information, figure s3d). similarly, downregulation of endogenous erk1 by shrna constructs significantly increased the abundance of fbw7 in sw1990 cells (supplementary information, figure s3e). furthermore, we performed the cycloheximide (chx) chase experiment to determine the fbw7 half-life with or without uo126 treatment in panc-1 cell lines. as expected, inhibition of the mapk/erk pathway dramatically extended the fbw7 half-life (figure 3e and 3f). these results suggest that activation of the ras/raf/mek/erk pathway negatively regulates fbw7 stability in pancreatic cancer cells.",pmc4423074,1,0.1,39,1,39.1
479,foxo1,protein,,foxo1,uniprot,q12778,nucleus,go:0005634,xbp-1u,protein,,,uniprot,p17861,,,negative,d,degradation,,hct116,epithelial,colon,human,['577'],nan,nan,"as foxo1 is essential for the induction of autophagy in response to serum starvation or oxidative stress10, we tested whether xbp-1u suppresses autophagy via induction of foxo1 degradation. as shown in figure 6a and supplementary information, figure s5a, overexpression of xbp-1u significantly decreased foxo1 protein levels, and blocked the accumulation of lc3-ii and degradation of p62 induced by glutamine starvation. similarly, the number of lc3 puncta significantly decreased when glutamine-starved hct116 cells were transfected with xbp-1u, but not with xbp-1s (figure 6b). to further clarify the role that endogenous xbp-1u plays in the induction of autophagy, an xbp-1 rnai plasmid was transfected into hct116 cells to establish stable xbp-1-knockdown cell lines; a non-specific rnai plasmid was used as a negative control. these cell lines were separately cultured in glutamine-free medium for up to 48 h. cell lysates were extracted for western blotting to detect changes in p62 degradation and lc3-ii accumulation. lc3-ii levels dropped by 36 h after glutamine starvation in cells containing normal xbp-1 levels (figure 1a), whereas in xbp-1-knockdown cells, lc3-ii levels did not drop until 72 h after glutamine starvation (figure 6c and supplementary information, figure s5b, statistical data shown in supplementary information, figure s8). additionally, glutamine starvation-induced p62 degradation was markedly reduced in xbp-1-knockdown hct116 cells compared with control cells (figure 6c, statistical data shown in supplementary information, figure s8). consistently, even at 48 h after glutamine starvation, the number of autophagic cells did not drop in the xbp-1-knockdown cell lines as observed by fluorescent or electron microscopy (figure 6d and 6e). we also performed the long-lived protein degradation assay in xbp-1-knockdown hct116 cells. the 3-ma-sensitive degradation was persistently increased after glutamine removal (figure 6f). in contrast, in foxo1/xbp-1 double knockdown hct116 cells, glutamine starvation did not induce p62 degradation or lc3-ii accumulation (figure 6g). these data indicate that downregulation of xbp-1 promotes autophagy and that this function requires foxo1.",pmc3616429,1,0.1,39,1,39.1
478,foxo1,protein,,foxo1,uniprot,o43551,nucleus,go:0005634,xbp-1u,protein,,xbp1,uniprot,p17861,nucleus,go:0005634,positive,d,binding,20s proteasome,,cancer,colorectal,human,['566'],nan,nan,"in this study, our results demonstrate that foxo1 turnover is highly associated with the dynamic autophagy process. phosphorylation of xbp-1u by erk is required for xbp-1u binding to foxo1, which leads to localization of foxo1 to the 20s proteasome for degradation. interestingly, we also identified an inverse correlation between xbp-1u and foxo1 expression in 229 cases of human colorectal cancer tissues. the relationship between xbp-1u and foxo1 expression was also found to be highly correlated with p62 status in these cancer tissues, which suggests that xbp-1 is a critical protein for the promotion of tumor development.",pmc3616429,1,0.1,39,1,39.1
477,foxo1,protein,,foxo1,uniprot,o43524,nucleus,go:0005634,xbp-1u,protein,,xbp1,uniprot,p17861,endoplasmic reticulum,go:0005783,positive,d,phosphorylation,,hct116,colon,,human,['575'],nan,nan,"as foxo1 interacted with xbp-1u during glutamine starvation, we could not rule out the possibility that erk might directly phosphorylate xbp-1u, and that in turn, phosphorylated xbp-1u might play a role in foxo1 degradation. indeed, we found that glutamine starvation induced phosphorylation of both endogenous and overexpressed xbp-1u in hct116 cells, as shown by a co-immunoprecipitation assay (figure 4d and supplementary information, figure s3b). using the software program gps2.1, we identified two residues in xbp-1u, ser61 and ser176, as putative erk target sites. therefore, we generated a plasmid encoding a mutated xbp-1u (s61/176a) in which the two serine residues were changed to alanine. after transfection into hct116 cells, we confirmed that glutamine starvation did not induce xbp-1u (s61/176a) phosphorylation (figure 4e and supplementary information, figure s3c). the purified xbp-1u and erk1 were then incubated in vitro to investigate whether erk is responsible for xbp-1u phosphorylation. as shown in figure 4f, xbp-1u was significantly phosphorylated by erk1. these data suggest that erk activity may be required for xbp-1u to modulate degradation of foxo1.",pmc3616429,1,0.1,39,1,39.1
139,apc,protein,,apc,uniprot,p25054,,,axin,protein,,axin1,uniprot,o15169,,,positive,d,multimerization,known and novel,,,,,['3468'],nan,nan,"“our data suggest apc plays two roles: (1) apc promotes efficient axin multimerization through one known and one novel apc:axin interaction site, and (2) gsk3 acts through apc motifs r2 and b to regulate apc:axin interactions, promoting high-throughput of βcatenin to destruction.”",pmc4568445,1,0.1,39,1,39.1
140,apc,protein,,apc,uniprot,p25054,,,axin,protein,,,uniprot,o15169,,,positive,d,stabilizes assembly,puncta,,,,,['3412'],nan,nan,"to test the hypothesis that apc stabilizes assembly of axin monomers into the multimeric destruction complex, we compared axin dynamics in puncta containing axin alone with those containing axin plus apc2. interestingly, axin expressed alone was quite dynamic, with a recovery plateau of almost 90% and a t1/2 = 150 s (figure 3c,e). however, when axin was coexpressed with apc2, axin dynamics were significantly reduced (recovery plateau = 40% and t1/2 = 300 s; figure 3d,e), suggesting apc stabilizes axin assembly within puncta.",pmc4568445,1,0.1,39,1,39.1
474,fat4,protein,,fat4,uniprot,q6u841,,,ctgf,protein,,ctgf,uniprot,p29279,,,negative,d,sirna transfection,,mcf-10a,epithelial,breast,human,['2404'],nan,nan,"a. rt-qpcr analyses of fat4 and ctgf mrna levels in mcf-10a cells transfected with control or fat4 sirna (sicontrol and sifat4, respectively, 30 nm) for 48 h (mean ± sd, n = 3). b. immunofluorescence images of yap/taz in mcf-10a cells transfected with sifat4 for 48 h. the nuclei were stained with dapi. white bars, 50 μm. c. rt-qpcr analysis of ctgf mrna expression levels in 24 h tam-treated mcf-10a v-src:er cells (mean ± sd, n = 3, ** indicates p < 0.01). d. immunofluorescence images of yap/taz in tam-treated cells (24 h). the nuclei were stained with dapi. white bars, 50 μm. e. staining for f-actin (phalloidin) and nuclei (dapi) in cells transfected with sifat4 for 48 h. white bars, 50 μm. f. western blotting for the indicated proteins in 48 h sifat4-treated cells.",pmc4334522,1,0.1,39,1,39.1
473,fat4,protein,,fat4,uniprot,q68da7,,,yap,protein,phosphorylated,yap1,uniprot,p46937,,,positive,d,expression,yap,mcf-10a,epithelial,breast,human,['2418'],nan,nan,fat4 knockdown in mcf-10a cells does not alter phosphorylated yap expression but reduces mst1 expression.,pmc4334522,1,0.1,39,1,39.1
472,fastk,protein,serine-threonine phosphoprotein,fastk,uniprot,q9y4l2,stress granules,go:0022421,tia,protein,,tial1,uniprot,q01085,stress granules,go:0022421,positive,d,interaction,,,unspecified,unspecified,unspecified,['3229'],nan,nan,"so far no one has been able to purify isolated sgs and pbs; nevertheless, the granules are morphologically defined by using immunostaining. stress granules are composed mainly of mrna, mrna binding proteins with a known function in translational control, mrna stability and metabolism, preinitiation and translation-related factors and signaling proteins with no known direct link to rna metabolism. interestingly, only very few kinases were described to be recruited to sgs and pbs. fas-activated serine-threonine phosphoprotein (fastk) is recruited to sgs via its direct interaction with tia. traf-2, which is a tnf-α receptor adaptor protein, is localized to sgs. traf-2 recruitment to sgs correlates with its inactivation upon stress. a recent study (arimoto et al., 2008) identified the scaffold protein, receptor-activated protein kinase c (rack1), which is localized to sgs after type 1 stresses (arsenite, heat-shock). rack1 binds the stress responsive map 3k of the jnk pathway, mekk4/mtk1. interestingly, rack1 is also composed of seven wd40 repeats. rack1 recruitment to sgs results in reduced mtk1 activity in the cytoplasm, and it is suggested that this is part of the mechanism whereby cancer cells escape from apoptosis after chemotherapy (arimoto et al., 2008).",pmc2801705,1,0.1,39,1,39.1
141,apc,protein,,apc,uniprot,p25054,,,beta-catenin,protein,,ctnnb1,uniprot,p35222,,,negative,d,down-regulating,,,,,,['3444'],nan,nan,"1) all of the cell biology analysis is done on punctae that are only observed when axin or axin/apc are overexpressed. there are a couple of general sentences stating that the field is comfortable with using these punctae as surrogates for the endogenous dc that are not very compelling. the super-resolution microscopy is cool and the images are gorgeous, though the fact remains they are large protein complexes caused by overexpression. they are probably are functional in regard to down-regulating beta-catenin, but are all their characteristics relevant to endogenous dc function? this is an inherent limitation of the manuscript. it would be helpful for readers to know what level of overexpression is being employed (compare to endogenous proteins) and what is variability of expression among individual cells transfected with apc or axin constructs.",pmc4568445,1,0.1,39,1,39.1
142,apc,protein,,,uniprot,p25054,nucleus,go:0005634,βcat,protein,,ctnnb1,uniprot,p35222,plasma membrane,go:0005886,negative,d,binding,,,,,human,['3402'],nan,nan,"in exploring apc's mechanism of action when wnt signaling is inactive, we recently focused on two conserved binding sites in apc, 20r2 (r2) and motif b (b; this is also known as the catenin interaction domain = cid; kohler et al., 2009; roberts et al., 2011; schneikert et al., 2014; choi et al., 2013; figure 1a). r2 is related to the 20r βcat binding sites, but lacks a key interacting residue and cannot bind βcat (liu et al., 2006). b is immediately adjacent to r2—its function was initially unknown, though it was recently shown to bind α-catenin, and thus play a role in wnt regulation (choi et al., 2013). strikingly, although other 20rs are individually dispensable, both r2 and b are essential for the destruction complex to target βcat for destruction (kohler et al., 2009; roberts et al., 2011; schneikert et al., 2014). our data further suggested that r2/b negatively regulates apc/axin interaction, a somewhat surprising role for an essential part of the destruction complex.",pmc4568445,1,0.1,39,1,39.1
469,fak,protein,,ptk2,uniprot,q05397,nucleus,go:0005634,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,d,increase,nucleus,,,,,['2744'],nan,nan,1) the kkkk mutant should be used to confirm that nuclear β-catenin is increased regardless of fak and pyk2 activity.,pmc4558782,1,0.1,39,1,39.1
468,fak,protein,,ptk2,uniprot,q05397,,,pyk2,protein,,ptk2b,uniprot,o60674,,,positive,d,correlate,,,,colorectal cancer,human,['2730'],nan,nan,"fak, pyk2, p-gsk3βy216 and β-catenin positively correlate in human colorectal cancer tissues.",pmc4558782,1,0.1,39,1,39.1
467,fak,protein,,ptk2,uniprot,q05397,,,pyk2,protein,,ptk2b,uniprot,o60674,,,negative,i,compound inhibition,,mouse,,colon,mouse,['2711'],nan,nan,"during the early stages of colon cancer, cells first develop into polyps, which subsequently become cancerous. gao, chen et al. treated mice that had genetic mutations that made them susceptible to colon cancer with a chemical compound that inhibits both fak and pyk2. these mice grew fewer polyps than untreated mice, and the polyps that did grow tended to be smaller.",pmc4558782,1,0.1,39,1,39.1
466,fak,protein,,ptk2,uniprot,q05397,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,d,unknown,,,,colorectal cancer,human,['2728'],nan,nan,"positive correlation between the levels of fak, pyk2, gsk3β, p-gsk3βy216 and β-catenin in human colorectal cancer tissues",pmc4558782,1,0.1,39,1,39.1
465,fak,protein,,ptk2,uniprot,q05397,cytoplasm,go:0005737,integrin β5,protein,,itgb5,uniprot,p18084,plasma membrane,go:0005886,positive,d,phosphorylation,,,,,,['2379'],nan,nan,"phosphorylation of the cooh-terminal fak tyrosine 861 regulates assembly with integrin β5 in vitro. (a) alignment of the cytoplasmic tails of β integrin subunit for integrins β1, β3, and β5. full-length fusion proteins of β3 and β5 cytoplasmic tails (dashed line), truncated β3 and β5 cytoplasmic tails lacking the membrane-proximal domain (solid line) used in this study, and previously mapped conserved peptide region of β1 integrin (schaller et al., 1995; circles). boxed regions represent conserved domains. (b) associations between src-phosphorylated fak cooh terminus (fak ct*) or mock-phosphorylated fak ct (fak ct) with gst fusions of full length β3 or β5 integrin cytoplasmic tails, or truncated β3 or β5 integrin cytoplasmic tails (5 min) were identified by immunoblotting glutathione-sepharose pulldowns with an anti-fak antibody, as described in materials and methods. these blots were representative of at least three different experiments. (c) (upper) phosphorylated fak ct or a mutant of tyrosine 861 within the fak ct (fak ct y861f) was incubated with the truncated β5 integrin cytoplasmic tail. (lower) src-mediated phosphorylation of the fak ct was determined by immunoblotting with phosphotyrosine specific anti-fak antibodies recognizing aa 861 or 925.",pmc2173263,1,0.1,39,1,39.1
464,fak,protein,,ptk2,uniprot,q05397,cytoplasm,go:0005737,gsk3,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,positive,i,activates,,,,colon,human,['2743'],nan,nan,"from the significance point of view, the authors introduce the paper by saying that 85% of crcs have mutant apc yet only 50% have increased nuclear β-catenin, implying that apc mutation is not sufficient to up-regulate nuclear β-catenin. their paper provides data in support of a mechanism in which increased fak/pyk2 activity in crcs leads to increased gsk3βy216, increases gsk3 ubiquitination, inhibits β-catenin turnover by btrcp, and raises nuclear β-catenin levels. this predicts that nuclear β-catenin would be detected in crcs that lack apc mutations, rather than the converse. it isn't clear how many human crcs have increased nuclear β-catenin but lack apc mutations. putting that aside, the tumor growth studies with 216f mutant gsk3 support the importance of this site, and the cancer studies with the pf inhibitor and the pathology supports the importance of fak/pyk2 in crc. however, the inhibition of tumors by pf does not exclude gsk3-independent effects of fak.",pmc4558782,1,0.1,39,1,39.1
463,fak,protein,,,uniprot,q05397,plasma membrane,go:0005886,apc,protein,,apc,uniprot,p25054,plasma membrane,go:0005886,positive,d,kinase activity,,,intestinal,colorectal,mouse,['2725'],nan,nan,"intestine-specific deletion of fak almost completely suppressed intestinal adenoma formation in apc-mutant mouse model for colorectal cancer (ashton et al., 2010), proving that fak is required for the oncogenicity of apc mutation in intestinal tumorigenesis. but the underlying mechanisms remain unclear. to determine whether fak is involved in apc-driven tumorigenesis through its catalytic activity, we examined the anti-tumorigenic effects of dual fak/pyk2 kinase inhibitor pf-562271 in apcmin/+ mice, a genetic model predisposed to the formation of intestinal adenomas due to aberrant activation of the wnt/β-catenin signaling. we found that pf-562271 treatment significantly inhibited both polyp formation (number) and polyp expansion (size) (figure 5a,b). the results of ib confirmed that loss of functional apc upregulated intestinal expression of c-myc (β-catenin target gene) and fak (c-myc target) (figure 5c, left panel). pf-562271 treatment inhibited intestinal fak kinase activity, evidenced by reduced level of p-faky397 (avraham et al., 2000), and remarkably reduced β-catenin level, accompanied by reduced expressions of c-myc and fak, consistent with the notion that fak functions as both ‘effector’ and ‘regulator’ of β-catenin. in line with the previous report (carothers et al., 2006), we also found that intestinal pyk2 expression was substantially increased in tumors of apcmin/+ mice (figure 5c, right panel), pf-562271 treatment abrogated the induction (figure 5c, left panel).",pmc4558782,1,0.1,39,1,39.1
462,fak,protein,,,uniprot,q05397,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,positive,d,phosphorylation,tyrosine 142,,,,,['2723'],nan,nan,"fak can directly phosphorylate β-catenin at tyrosine 142 (chen et al., 2012). we next examined whether pf-562271 treatment inhibits tumor growth when y142 in β-catenin is mutated. the results from xenograft experiments showed that although overexpression of β-cateniny142e partially jeopardized the anti-tumor effect of pf562271, pf562271 treatment significantly inhibited in vivo growth of sw480 cells ectopically expressing flag-β-cateniny142e (figure 4f). while this result further proved the importance of fak/pyk2-mediated gsk3 phosphorylation, it also suggested that phosphorylation of β-cateniny142 plays a role in fak-targeted therapy for crc.",pmc4558782,1,0.1,39,1,39.1
461,fak,protein,,,uniprot,q05397,,,pyk2,protein,,ptk2b,uniprot,q14289,,,positive,i,elevated,colon tumors,,,colon,humans,['2757'],nan,nan,"regardless of the exact mechanisms mediating in vivo pyk2 regulation during intestinal tumorigenesis, both fak and pyk2 are elevated in already established colon tumors in crc patients (figure 6). the current study indicates that effective inhibition of the wnt/β-catenin pathway in crc cells expressing fak and pyk2 will only be achieved by simultaneously targeting both kinases, which provides a solid mechanistic justification for clinical use of fak/pyk2 dual inhibitor instead of fak-specific inhibitor for better clinical outcomes in crc patients.",pmc4558782,1,0.1,39,1,39.1
460,fak,protein,,,uniprot,q05397,,,integrin β5,protein,,,uniprot,p18084,plasma membrane,go:0005886,positive,d,association,cooh-terminal fak aa 861,"hek-293 cells, huvecs","epithelial, endothelial",,human,['2376'],nan,nan,"a role for the growth factor–induced tyrosine phosphorylation of the cooh-terminal fak aa 861 for assembly with integrin β5 in vivo. (a) various epitope-tagged (ha) fak constructs (ha wild-type, y397f, or y861f) were expressed in hek-293 cells, as previously described (sieg et al., 2000). (b) lysates of egf-stimulated cells (20 ng/ml; 5 min) expressing these various fak constructs were subjected to immunoprecipitation with an anti-αvβ5 antibody and immunoblotted with an anti-ha antibody to detect fak/αvβ5 complexes. expression levels of each ha-tagged construct was confirmed by ha immunoblotting. (c) association of ha-wt fak or ha-y861 mutant fak with integrin αvβ5 in vegf-stimulated huvecs. parallel blotting of huvec lysates with anti-ha antibody reveals transient expression levels of ha-tagged fak constructs. (d) lysates of vegf or mock-treated huvecs were analyzed for the vegf-induced association of fak with αvβ5, αvβ3, or β1 integrins by immunoprecipitation with anti-αvβ5, αvβ3, or β1 antibodies and immunoblotting with an anti-fak antibody. these immunoblots were representative from at least three different experiments.",pmc2173263,1,0.1,39,1,39.1
459,fak,protein,,,uniprot,q05397,,,gsk3β,protein,,gsk3b,uniprot,p49841,,,positive,i,regulation,,,,colon,human,['2729'],nan,nan,"most colorectal carcinomas develop from adenomas via adenoma-carcinoma-sequence driven by the accumulation of genetic and epigenetic mutations (fearon and vogelstein, 1990); our results (figure 5) imply that fak/pyk2/gsk3βy216/β-catenin regulation axis is an early participant and driving force for intestinal tumorigenesis in apcmin/+ mice. if this is also true in the development of human crc, dysregulation of fak/pyk2 expression, gsk3βy216 phosphorylation and β-catenin accumulation should occur at the adenoma stage of the adenoma–carcinoma-sequence. in a proof-of-concept experiment, we analyzed serial sections of colon specimen from the same tissue block. we found that the ihc staining intensities of fak, pyk2, gsk3β, p-gsk3α/βy279/y216 and β-catenin were increased during the course of the normal-adenoma–carcinoma progression (figure 6a), demonstrating that induction of fak/pyk2 expression, gsk3α/βy279/y216 phosphorylation and β-catenin accumulation did occur at the early stage (the adenoma stage) of colon cancer development. the positive correlation between these elevated expressions also suggested that these inductions were related events.",pmc4558782,1,0.1,39,1,39.1
458,fak,kinase,,ptk2,uniprot,q05397,cytoplasm,go:0005737,gsk3β,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,positive,d,phosphorylation,,,mixed,,"human, mice",['2710'],nan,nan,"gao, chen et al. analyzed cells taken from human and mice and observed that two kinases called pyk2 and fak phosphorylate one form of gsk3, known as gsk3β. furthermore, both kinases are required to inactivate gsk3β completely, and so turn on the wnt signaling pathway.",pmc4558782,1,0.1,39,1,39.1
143,apc,protein,,,uniprot,q13006,destruction complex,,axin,protein,,,uniprot,o15169,destruction complex,,negative,d,regulates,,,,,human,['3411'],nan,nan,"the effect of apc on destruction complex structure might suggest apc helps regulate axin turnover within the destruction complex. previous analyses suggested that axin dynamics within the destruction complex puncta correlate with function. axin puncta are dynamic protein assemblies, and the wnt effector dishevelled significantly increases axin dynamics in puncta, suggesting it negatively regulates axin self-association (schwarz-romond et al., 2007), consistent with its known negative regulatory role in destruction complex function. to directly assess apc2 and axin dynamics in the destruction complex and their influence on one another, we used fluorescent recovery after photobleaching (frap) to measure dynamics of both apc2-gfp and axin-rfp (figure 3a–d). we assessed both recovery (mobile) fraction and t1/2, using unbleached puncta as controls. recovery fraction assesses what percentage of molecules in a complex turnover in the experimental time frame, and t1/2 reflects the rate at which the dynamic fraction is exchanged—they are not necessarily dependent on one another. we found apc2 is also a dynamic component of destruction complex puncta, reaching a recovery plateau of 40% and a t1/2 of 150 s (figure 3b); however, apc2 is not as dynamic as axin (figure 3c).",pmc4568445,1,0.1,39,1,39.1
299,cdk7,protein,,,uniprot,p50613,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,,,positive,i,phosphorylation,t172,"hct116, t98g",epithelial,"colon, brain",human,['1123'],nan,nan,"together with a parallel study by fisher lab [72], our data extend to cdk4 and cdk6 the concept that cdk7 activity is critically required for the activating phosphorylation of all the cdks that orchestrate cell cycle progression [53], [73], [74]. as also found in the parallel study [72], cdk4 complexes are much more rapidly deactivated than cdk2 complexes in response to cdk7 inhibition, showing that the t172 phosphorylation of cdk4 is exceptionally labile and thus potentially regulated by phosphatases. indeed, for cdk4, unlike cdk2, cyclin binding does not block the accessibility of the phosphorylated t-loop to phosphatases [33], [75]. because of this unique responsiveness of t172 phosphorylation and its initializing role at r point, cdk4 might well be the physiologically most significant target of cdk7 in g1/s transition. on the other hand, in hct116 k7as cells and other human cell lines including t98g cells, t-loop (t170) phosphorylation of cdk7 and its activity on cdk4 [35]–[37] were essentially constitutive (figure s10 and unpublished results). perhaps due to slight differences in the used cells and/or methodology, we were thus unable to confirm an important stimulation by serum of cdk7 t170 phosphorylation [72].",pmc3667761,1,0.1,39,1,39.1
166,axin,protein,,axin1,uniprot,o15169,cytoplasm,go:0005737,ck1,protein,,csnk1a1,uniprot,p48729,cytoplasm,go:0005737,positive,d,binds,,,,,human,['3448'],nan,nan,"10) it would be helpful if figure 1a showed that domain b is also called the catenin interaction domain (cid, choi et al., 2013), and clearly define this since cid was not adequately described in the introduction. also, since all reviews cite that axin binds ck1 in addition to gsk3, it would be helpful to have this interaction mapped for completeness (if precisely known)?",pmc4568445,1,0.1,39,1,39.1
167,axin,protein,,axin1,uniprot,o15169,cytoplasm,go:0005737,ck1,protein,,csnk1a1,uniprot,p48730,cytoplasm,go:0005737,positive,d,binds,,,,,human,['3476'],nan,nan,"choi et al., 2013), and clearly define this since cid was not adequately described in the introduction. also, since all reviews cite that axin binds ck1 in addition to gsk3, it would be helpful to have this interaction mapped for completeness (if precisely known)?",pmc4568445,1,0.1,39,1,39.1
182,bax,protein,,bax,uniprot,q07817,cytoplasm,go:0005737,parp,protein,,parp1,uniprot,p09874,nucleus,go:0005634,positive,d,cleavage,,"h23, h358, pc14, a549, sklu-1",lung cancer cells,lung,human,['2353'],nan,nan,"key molecules in the cell cycle could serve as targets for anticancer agents to halt uncontrolled proliferation of tumor cells and to initiate apoptosis.35 our study demonstrated that apoptotic induction with increased bax, cleaved parp, and cleaved caspase3 occurred after cink4 treatment (72 h, 10 μm) in h23, h358, and pc14, but not in a549 and sklu-1. however, we found significantly increased cleaved parp in a549 cells treated with cink4 (72 h, 20 μm) (data not shown). cink4 inhibits cdk4 in similar fashion of p16, an endogenous inhibitor of cdk4.30 in present study, when treated with same concentration of cink4, tumor cells had dissimilar apoptotic induction by cink4. a previous study reported that p16ink4 mediated apoptosis was induced when p16-deficient lung cancer cells was infected with an adenovirus vector (adv/p16).36 our result suggested that apoptosis be positively correlated with expression level of endogenous p16ink4. and our results are consistent with a previous report that low-concentration cink4 also induced senescence, which was “bypassed” when cells were treated with either a higher dose or prolonged exposure to cink4, both of which caused apoptotic induction.30 katsuda et al. reported that rb was cleaved after activation of caspase-3; when rb expression was significantly diminished, apoptosis began.36 our experiment showed that higher doses of cink4 remarkably reduced rb in a549 and h23 cells, suggesting that apoptosis induced by cink4 treatment is also associated with rb activation.",pmc3742489,1,0.1,39,1,39.1
187,bcl-xl,protein,,bcl2l1,uniprot,q07817,mitochondria,go:0005739,apaf-1,protein,,apaf1,uniprot,o14727,mitochondria,go:0005739,negative,d,binds,,hek 293t,epithelial-like,kidney,human,['3464'],nan,nan,"b) we significantly revised this section of the results to more clearly state the caveats. putting these changes together, this section of the results now reads:",pmc4568445,1,0.1,39,1,39.1
262,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,ap-1,transcriptionfactor,,jun,uniprot,p05412,nucleus,go:0005634,positive,d,regulation,,,,,human,['218'],nan,nan,effects of cellular proliferative status on cdk4 regulation of ap-1,pmc3084876,1,0.1,39,1,39.1
188,bcl-xs,protein,isoform,bcl2l1,uniprot,q07817,,,apaf-1,protein,,apaf1,uniprot,o14727,mitochondria,go:0005739,positive,i,overexpression,,pancreatic cancer,epithelial,pancreas,human,['1315'],nan,nan,"bcl-x exists in two distinct isoforms in humans. bcl-xl, the longer form, functions in an anti-apoptotic manner. bcl-xs, the shorter form, in contrast, functions as an apoptosis promoter. like bcl-2, bcl-xl also prevents cytochrome c release from mitochondria [reviewed in [47]]. different studies showed that most likely every cell type is protected by at least one member of anti-apoptotic bcl-2-like proteins. in pancreatic carcinoma cells bcl-xl plays the most important role in protecting from fas and trail-mediated apoptosis [32]. furthermore, bcl-xl is believed to bind to apaf-1 and may therefore inhibit the association of apaf-1 with procaspase-9 and thereby prevent caspase-9 activation [48]. unlike bcl-2, bcl-xl is constitutively overexpressed in pancreatic cancer cell lines highly resistant to fas and trail-mediated apoptosis [32]. therefore bcl-xl may be an ideal target for pancreatic cancer therapy. overexpression of bcl-xl in cell lines with low bcl-xl expression like colo357, showed complete suppression of apoptosis. on the other hand, inhibition of bcl-xl function by overexpression of bax or administration of antisense oligonucleotides against bcl-xl mrna resulted in sensitization of cells expressing high levels of bcl-xl like panc-1 or panctui [32]. additionally, another study revealed that bcl-xl antisense oligonucleotide inhibited pancreatic cancer cell growth and caused apoptosis by reducing bcl-xl protein levels in different pancreatic cancer cell lines [49]. bcl-xl antisense nucleotides also increased the sensitivity to chemotherapeutics like gemcitabine. this was confirmed by another study [50]. activation of bcl-2 family member bcl-xl after repeated exposure to the chemotherapeutic drugs 5-fu and gemcitabine contribute to chemo-resistance of pancreatic cancer cells [50]. correlation of the molecular data with clinical patient parameters revealed that patients whose tumors exhibited no, faint, or weak bcl-xl expression lived significantly longer after tumor resection than patients whose tumors exhibited moderate bcl-xl mrna expression [51].",pmc149420,1,0.1,39,1,39.1
189,bcr-abl,protein,fusion protein,,uniprot,p00519,plasma membrane,go:0005886,p27(kip1),protein,,cdkn1b,uniprot,p46527,nucleus,go:0005634,positive,d,phosphorylation,,,hematopoietic,,human,['3615'],nan,nan,"pi3k and some of its downstream targets, such as akt and p70(s6k) are crucial effectors in oncogenic protein-tyrosine kinase signaling [289]. the ability of the bcr-abl tyrosine kinase fusion protein to transform hematopoietic cells required pi3k/akt [290, 291]. bcr/abl suppresses p27(kip1) protein levels through pi3k/akt, leading to accelerated entry into s phase [292]. this activity is likely to explain in part previous studies showing that activation of pi3k was required for optimum transformation of hematopoietic cells by bcr/abl in vitro and in vivo [292]. it was also shown that inhibition of p27(kip1) transcription through pi3k/akt involves phosphorylation of the forkhead transcription factor fkhr-l1 [293]. in addition, an ubiquitin e3 ligase, the scf(skp2) complex, mediates p27(kip1) ubiquitin-dependent proteolysis. it was shown that skp2 functions as a critical component in the pten/pi3k pathway for the regulation of p27(kip1) and cell proliferation [294]. bcr-abl was shown to regulate the cell cycle in cml cells at least in part by inducing proteasome-mediated degradation of the cell cycle inhibitor p27(kip1), which depends on skp2 [295]. further work showed that activation of class ia pi3k and downstream inactivation of foxo transcription factors are essential for survival of murine pro/pre-b cells transformed by v-abl or bcr-abl [296]. in addition, analysis of mice lacking individual pi3k genes indicates that products of the pik3r1 gene contribute to transformation efficiency by bcr-abl [296]. these findings established a role for pi3k signaling in b-lineage transformation by abl oncogenes.",pmc2652403,1,0.1,39,1,39.1
258,cdk4,protein,,cdk4,uniprot,p11802,,,rb,other,,rb1,uniprot,p06400,,,negative,d,inhibition,cdk4,,,,,['2509'],nan,nan,"pd-0183812 and pd-0332991-screening of a chemical compound library lead to identification of [2,3-d]pyridopyrimidines as inhibitors of cdk4. the pyrido[2,3-d]pyrimidin-7-one template provided an effective platform for the inhibition of a broad cross-section of kinases, including cdks [395] and further modification to include a 2-aminopyridine side chain at the c2-position yielded pd-0183812, a potent and highly selective atp competitive inhibitor of cdk4 and cdk6 kinase activity, which arrested rb positive cell lines in g1 [336]. on the basis of its selectivity profile and pharmacokinetic profile, pd-0332991 was further identified as a drug candidate for the treatment of cancer [338]. indeed, pd-0332991, also called palbociclib is a highly selective inhibitor of cdk4-6/cyclin d that blocks retinoblastoma (rb) phosphorylation in the low nanomolar range, but does not exhibit any activity against a panel of 36 additional protein kinases. oral administration of pd-0332991 to mice bearing the colo-205 human colon carcinoma produces marked tumor regression and a net reduction in tumor burden, associated with downregulation of phospho-rb and ki-67 as well as of genes under the transcriptional control of e2f [339]. pd-0332991 has proven efficient in advanced cancer and mantle cell lymphoma, in multiple myeloma in combination with other drugs (bortezomib and dexamethasone) and in estrogen receptor-positive advanced breast cancer in combination with letrozole. pd-0332991 also acts synergistically with tamoxifen and trastuzumab in er+ and her2 cell lines, respectively. pd-0332991 is one of three oral atp-competitive selective inhibitors of cdk4 in clinical trials [343]. pd-0332991 is currently tested for liposarcoma, breast cancer and mantle cell lymphoma in phase ii or iii. lee011 [344], and ly2835219 [345] are in phase i for melanoma and breast cancer, respectively.",pmc4381256,1,0.1,39,1,39.1
192,bim,protein,,bcl2l11,uniprot,q92843,mitochondria,go:0005739,bcl-xl,protein,,bcl2l1,uniprot,q07817,mitochondria,go:0005739,positive,d,interacting,mitochondria,,,,,['3578'],nan,nan,"bim is widely known for its pro-apoptotic functions in mitochondria, and it induces apoptosis by interacting with proteins harboring anti-apoptotic function such as bcl-xl and bcl-2. such interactions release proteins, including bax and bak, at the mitochondria to initiate apoptosis.37, 38 bim was also shown to be a direct target of foxo3a.39 in the present study, we found that activated foxo3a could bind more intensely to the promoter of bim, thereby facilitating bim transcription. in parallel, an increased bim level was correlated with translocation from the cytoplasm to the mitochondria, and knockdown experiments showed that selenite-induced bim expression was involved in selenite-induced apoptosis.",pmc3734838,1,0.1,39,1,39.1
252,cdk4,protein,,cdk4,uniprot,p11802,,,cyclin a,protein,,ccna2,uniprot,p20248,nucleus,go:0005634,negative,d,inactivation,large pocket,"ls8817, ls0082, ls7785-1",,,,['1007'],nan,nan,"multiple cdk4 substrates have been identified and proposed to play roles in cell cycle exit [27, 28]. we wanted to determine if the accumulation of unphosphorylated rb alone was sufficient to recapitulate the growth arrest phenotype of cdk4 inhibition or loss. to accomplish this we expressed the non-phosphorylatable large pocket mutant of rb (psm-rb) [29] in two of the responder cell lines, ls8817 and ls0082, and one of the non-responder cell lines, ls7785-1. as a control we also expressed the wild type large pocket (lp), which could be inactivated by endogenous cyclin-dependent kinases. as expected brdu incorporation was significantly curtailed by expression of psm-rb in all three cell lines, but not by lp (figure 2a). sa-β-gal staining (figure 2b) increased significantly only in the psm-rb expressing responder cell lines and not the non-responder. arf and p16 were not increased and cyclin a was reduced in the senescent and growth arrested cells (figure 2c). phosphorylation of the endogenous rb protein, while diminished relative to control cells was still detectable (figure 2d), indicating that these growth arrested cells still had higher levels of cdk4 activity than the pd0332991 treated control cells. we did not perform this experiment in the other cell lines. thus, the accumulation of unphosphorylated rb, even in cells with active cdk4, could mimic the effect of cdk4i or cdk4 knockdown with respect to the choice of cells to become quiescent or senescent.",pmc4480747,1,0.1,39,1,39.1
250,cdk4,protein,,cdk4,uniprot,p11802,cytoplasm,go:0005737,cyclin d2,protein,,ccnd2,uniprot,p30279,nucleus,go:0005634,positive,d,association,,,,,,['239'],nan,nan,"consistent with early cdk4 activation events, the level of cyclin d2 association",pmc3084876,1,0.1,39,1,39.1
208,cak (cdk7),protein,,cdk7,uniprot,p50613,,,cdk4,protein,,cdk4,uniprot,p11802,,,positive,d,phosphorylation,,,,,,['1513'],nan,nan,"although cak (cdk7) can unambiguously phosphorylate and activate cyclin d3-bound cdk4 in vitro, other regulated cdk4-activating kinase(s) might thus remain to be discovered. they might even be different in distinct mitogenic stimulations and selectively target cdk4 complexed to cyclin d3 or cyclin d1. some observations cannot be easily explained by only one kinase activating the different d-type cyclin-cdk4 complexes. indeed, how could tgfβ selectively inhibit the activating phosphorylation of cdk4 bound to cyclin d3 in dog thyrocytes stimulated by tsh, without affecting the activity and phosphorylation of cdk4 stimulated by egf [91]? how could egf stimulate the phosphorylation and activity of cdk4 bound to cyclin d1 in human thyrocytes, but not the activity of abundant cyclin d3-cdk4 complexes, which were specifically activated by tsh [100]?",pmc1647274,1,0.1,39,1,39.1
242,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,gsk3β,protein,kinase,gsk3b,uniprot,p49841,cytoplasm,go:0005737,negative,d,inhibition,,,hepatocytes,liver,mouse,['1301'],nan,nan,"primary hepatocytes were isolated from 8-10 weeks old male balb/c mice by perfusion with liver digest medium (invitrogen, 17703-034) followed by 70μm mesh filtration. percoll (sigma, p7828) gradient centrifugation allowed primary hepatocytes isolation from other cell types and debris. on 6 well plates, 4x105 cells per well were seeded in plating medium (dmem with 10% fbs, 2mm sodium pyruvate, 1% penicillin/streptomycin, 1μm dexamethasone, and 100nm insulin). after 3hr of seeding, medium was changed and incubated overnight in maintenance medium (dmem, 0.2% bsa, 2mm sodium pyruvate, 1% penicillin/streptomycin, 0.1μm dexamethasone, and 1nm insulin). to infect cells with adenovirus, 3-8x106 infectious particles per well were added to cells for 4hr. cells were harvested within 48hr after infection and medium was changed everyday as well as 3hr prior to harvest. 1μm cdk4 inhibitors and gsk3β inhibitors were added overnight whereas 200nm insulin was added 1.5hr prior to the harvest. when necessary, medium was changed to starvation medium (dmem, 0.2% bsa, 2mm sodium pyruvate, and 1% penicillin/streptomycin) for 3hr and cells were stimulated with 10μm forskolin for additional 1.5hr. when glucose production was measured, cells were incubated in starvation medium for 2hr followed by 3hr incubation in glucose free medium (phenol-red/glucose free dmem, 0.2% bsa, 2mm sodium pyruvate and 20mm sodium lactate). glucose level in medium was measured by glucose assay kit from bioassay system (ebgl-100) following the manufacturer’s instruction. for amino acids addition, primary hepatocytes were incubated overnight with amino acids free medium (earl’s balanced salt solution, 25mm glucose, 2mm sodium pyruvate, 1% penicillin/streptomycin, bme vitamin mix and 0.2% fatty acids free bsa). cells were harvested after 4hr incubation with 4mm hepes-koh ph 7.4 buffer, mem (minimum essential medium) amino acids or nonessential amino acids.",pmc4076706,1,0.1,39,1,39.1
209,calpain,protein,,,uniprot,p07384,cytoplasm,go:0005737,cdk5,protein,,cdk5,uniprot,q00535,nucleus,go:0005634,positive,d,proteolytic cleavage,,,,,,['2479'],nan,nan,"cdk5 activation occurs following ca2+-stimulated calpain-dependent proteolytic cleavage of p35 or p39 proteins to yield a p25 protein responsible for complete activation of cdk5 [87,88,89] (figure 2b). p25 does not share any primary sequence similarity with cyclins but adopt a cyclin-box fold and binds cdk5 at the interface through which cdks interact with cyclins, and in a similar fashion to cyclin a binding to cdk2 [90,91].",pmc4381256,1,0.1,39,1,39.1
210,ccar2,protein,,ccar2,uniprot,q86xe7,nucleus,go:0005634,hdac3,protein,,hdac3,uniprot,o15379,nucleus,go:0005634,negative,d,inhibits,,,,,,['3080'],nan,nan,"besides sirt1, ccar2 inhibits the activity of the histone-modifying enzymes suv39h1 and hdac3 [9, 10], thus playing an important role in chromatin structure regulation.",pmc4627348,1,0.1,39,1,39.1
211,ccar2,protein,,ccar2,uniprot,q8wu40,nucleus,go:0005634,kap1,protein,,trim28,uniprot,q13263,nucleus,go:0005634,negative,d,reduced kinase activity,heterochromatin,,human cells,,human,['3082'],nan,nan,"here we report that, in human cells, ccar2 loss markedly impairs the repair of dna lesions in heterochromatin as consequence of a reduced kinase activity of chk2 towards kap1.",pmc4627348,1,0.1,39,1,39.1
238,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,ap-1,transcriptionfactor,,jun,uniprot,p05412,nucleus,go:0005634,positive,d,activity,,non-dividing bmdcs,dendritic,,mouse,['244'],nan,nan,"presented here using non-dividing bmdcs, indicate that cdk4 activity and ap-1",pmc3084876,1,0.1,39,1,39.1
237,cdk4,protein,kinase,cdk4,uniprot,p11802,,,pgc-1α,protein,,ppargc1a,uniprot,q9ubk2,,,positive,d,phosphorylation,,,,,,['1290'],nan,nan,"because cdk4 inhibitor-induced pgc-1α deacetylation was not affected when sirtuin 1 or hdac class i/ii were inhibited (extended data fig. 2d), we tested whether cyclin d1-cdk4 regulates pgc-1α acetylation through gcn5, the principal pgc-1α acetyltransferase. indeed, knockdown of gcn5 significantly blunted fascaplysin-induced pgc-1α deacetylation (fig. 1e). in contrast, pcaf-mediated acetylation was not affected by fascaplysin, further suggesting that cdk4 inhibition modulates pgc-1α acetylation through gcn5 (extended data fig. 2e). in vitro catalytic activity of gcn5 immunoprecipitated from cells treated with fascaplysin was reduced by 50% relative to vehicle control (fig. 1f). we observed physical interaction between ectopically expressed or endogenous cdk4 and gcn5, suggesting that cdk4 could regulate gcn5 activity by direct phosphorylation (fig. 1g, extended data fig. 2f). cyclin d1-cdk4 kinase directly phosphorylated gcn5 in vitro and its phosphorylation was inhibited by fascaplysin (fig. 1h, extended data 2g). systematic mutagenesis revealed two phosphorylation sites, t272 and s372, located within the gcn5’s conserved pcaf domain. alanine substitutions of these two sites (“gcn5 aa”) ablated gcn5 phosphorylation by cyclin d1-cdk4 in vitro, and reduced pgc-1α acetylation (fig. 1i, 1j, extended data fig. 2h, 2i). compared to gcn5 wild-type, in vitro catalytic activity of gcn5 aa was decreased, but remained insensitive to fascaplysin (fig. 1k). cdk4 phosphorylation on gcn5 augmented acetyltransferase catalytic activity by increasing vmax, while km for acetyl-coa binding was unaffected (fig. 1k). because gcn5 functions as a complex with subunits important for its activity16, its phosphorylation by cdk4 could modulate interaction between gcn5 and subunits. we found one subunit, paf65β, interacting less with gcn5 aa compared to gcn5 wild-type, when tested with modestly overexpressed gcn5, where pgc-1α acetylation was not saturated (extended data fig. 2j, 2k). taken together, these results indicate that cyclin d1-cdk4 regulates pgc-1α acetylation through the direct phosphorylation and activation of gcn5 acetyltransferase activity.",pmc4076706,1,0.1,39,1,39.1
212,ccar2,protein,,ccar2,uniprot,q8wwq1,chromatin,go:0000785,kap1,protein,,trim28,uniprot,q13263,chromatin,go:0000785,positive,d,functionality,,,,,human,['3095'],nan,nan,"these findings further confirm the importance of ccar2 in chromatin dynamics following dna damage and that the dna repair defect of ccar2 knock-out cells can be ascribed to a defective chk2 functionality on kap1. given however that ccar2 silencing does not affect the proapoptotic function of chk2 [7], a finding further substantiated here in ccar2−/− cells (supplementary figure 9a), nor the phosphorylation of p53 on s20 [8] (supplementary figure 9b), it is likely that ccar2 might differentially regulate the activity of chk2 towards distinct targets.",pmc4627348,1,0.1,39,1,39.1
235,cdk4,protein,g1-regulatory,cdk4,uniprot,p11802,,,menin,protein,,men1,uniprot,o00255,,,positive,d,tumorigenesis,pituitary,,,,mouse,['3144'],nan,nan,"to determine whether the requirement for cdk4 in menin-associated tumorigenesis is unique among the g1-regulatory cdks or there is functional overlap, we next examined the impact of cdk2-deficiency on tumorigenesis of men1+/− mice, by generating men1+/−; cdk2−/− and men1+/−; cdk2+/+ (cdk wild-type) littermates. in sharp contrast to men1+/−; cdk4−/− mice, 51% of examined men1+/−; cdk2−/− mice (n=29) showed macroscopic pituitary tumors comparable to those in men1+/−; cdk wild-type mice (fig. 1a, 1b). interestingly, we observed tumors in 4 (24%) of 17 men1+/−; cdk2−/− male mice and 11 (92%) of 12 men1+/−; cdk2−/− female mice. this may imply that cdk2 deficiency modestly promoted pituitary tumorigenesis under the conditions of the study, although examinations of a larger cohort will be necessary to be conclusive. regardless, these data indicate that the absence of cdk2 can be compensated, and has no impact on restraining the process of pituitary tumorigenesis induced by menin deficiency.",pmc4135037,1,0.1,39,1,39.1
213,ccar2,protein,,,uniprot,q8n163,nucleus,go:0005634,sirt1,protein,,sirt1,uniprot,q96eb6,nucleus,go:0005634,positive,d,phosphorylation,t454,,,,human,['3078'],nan,nan,"human ccar2 (cell cycle and apoptosis regulator 2, also known as dbc1 or kiaa1967) is a nuclear protein involved in several biological processes, such as dna damage response (ddr) and apoptosis, cellular metabolism, epigenetics, cell proliferation and tumorigenesis, nuclear receptor function, circadian cycle and mrna splicing [1]. upon dna damage, the apical checkpoint kinases atm and atr phosphorylate ccar2 on t454, enhancing its inhibitory binding to the histone deacetylase sirt1, promoting p53 acetylation and p53-dependent apoptosis [2, 3]. besides phosphorylation, other ccar2 post-translational modifications like acetylation and sumoylation finely regulate sirt1 activity [4-6]. additionally, the checkpoint kinase chk2 and the proteasome activator regγ do also play a role in the regulation of sirt1 by ccar2, as we recently reported [7].",pmc4627348,1,0.1,39,1,39.1
214,cd11c,protein,,itgax,uniprot,p20702,plasma membrane,go:0005886,cd86,protein,,cd86,uniprot,p42081,plasma membrane,go:0005886,positive,d,expression,,,b-cell,,unspecified,['225'],nan,nan,"activation, as determined by cd11c and cd86 expression respectively (fig. s1),",pmc3084876,1,0.1,39,1,39.1
232,cdk2,protein,,cdk2,uniprot,p24941,nucleus,go:0005634,cyclin a,protein,,ccna2,uniprot,p20248,nucleus,go:0005634,negative,d,disrupts complex,pstaire/alpha5 helix,,cancer,,human,['2513'],nan,nan,"a peptide that targets the primary interface between cdk2 and cyclin a (pstaire/alpha5 helix) was reported to interfere specifically with cdk2 activity in vitro and in cultured cancer cells, although it did not to disrupt cdk2/cyclin a complex [356]. another peptide, nbi1, was identified in a screen as binding the surface pocket in cyclin a and inhibiting catalytic activity of cdk2/cyclin a with high selectivity compared to other protein kinases [357].this peptide binds a structurally conserved domain comprising alpha helices 3, 4 and 5 of cyclin a (involved in the interaction between cdk2 and cyclin a) and competes with cyclin a in disrupting the complex with cdk2 (figure 6a).",pmc4381256,1,0.1,39,1,39.1
217,cd24,protein,,cd24,uniprot,p25063,cell membrane,go:0005886,h-ras,protein,,hras,uniprot,p01112,cytosol,go:0005829,negative,d,repression,promoter,mouse embryonic fibroblasts,fibroblast,embryonic,mouse,['1740'],nan,nan,"cd24 expression is dynamically regulated throughout the development of b and t lymphocytes, dendritic cells, neurons, and adipocytes (nathan et al., 1986; smith et al., 2015; tan et al., 2015). moreover, cd24 expression in some normal cell types is associated with proliferation or differentiation (li et al., 2004; smith et al., 2015), while in others it is associated with apoptosis (suzuki et al., 2001). therefore, transformation of a particular cell type at a particular cell stage may dictate if cd24 promotes or inhibits proliferation. previously, it was found that overexpression of oncogenic h-ras as the last step in the sequential transformation of primary human mammary epithelial cells or in immortalized mcf10a cells resulted in an epithelial to mesenchymal transition (emt) concomitant with the downregulation of cd24 surface expression (morel et al., 2008). here we have found that expression of oncogenic ras in mouse embryonic fibroblasts, which are already mesenchymal, represses cd24 mrna and protein expression, and promoter activity. therefore, it may be the mesenchymal phenotype that predisposes a cell to lose cd24 expression in response to ras transformation while other cell types will gain or retain cd24 expression dependent on their epithelial vs. mesenchymal status.",pmc4525067,1,0.1,39,1,39.1
228,cdk1,protein,,,uniprot,p06493,,,cdk2,protein,,,uniprot,p24941,,,negative,d,inhibition,,,,,,['2499'],nan,nan,"6-dimethyl aminopurine was the first cdk1 inhibitor identified with an ic50 120 um [396] further derivatives lead to discovery of olomoucine ic50 7 um, a purine analog with selectivity for cdk1, cdk2, cdk5 and mapk but not cdk4 or 6 [321,397] purvalanol b is 1000-fold more efficient than olomoucine for cdk2/cyclin a, which owes its overall efficacy to its membrane permeability (ic50 70 nm) for cdk2/cyclin a [318].",pmc4381256,1,0.1,39,1,39.1
227,cdk1,protein,,cdk1,uniprot,p06493,nucleus,go:0005634,cyclin b1,protein,,ccnb1,uniprot,p14635,nucleus,go:0005634,positive,d,association,,mouse models,,,mammalian,['2482'],nan,nan,"despite a high level of coordination and specificity underlying formation and activation of cdk/cyclin complexes, functional redundancy has been observed between cdks and cyclin partners. indeed, knockout studies in mice reveal that the only indispensable cdk is cdk1, capable of compensating for the lack of interphase cdks and recapitulating all cell cycle transitions and driving progression through the cycle in mammalian cells through sequential association with different cyclins, the absence of other cell cycle cdks or cyclins, except for cyclins b1 and a2, is completely bypassed and compensated in mammalian cells through formation of “illegitimate” complexes which do not normally occur in physiological conditions [15,36,97,98,99]. studies in mouse models have revealed that although each phase of the cell cycle is driven by a specific cdk, all interphase cdks including cdk2, cdk4 and cdk6 are dispensable for cell cycle progression in most cell types [36,97]. these cdks are however essential for development and differentiation of highly specialized cell types.",pmc4381256,1,0.1,39,1,39.1
265,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,positive,i,phosphorylation,t/s-p motifs,,,,animal,['1076'],nan,nan,"we thus hypothesized that unlike cdk2 and cdk1 [53], cdk4 is not activated in cells by cyclin h-cdk7, but by one or several proline-directed kinase(s). the hypothesis that animal cells have multiple caks like yeasts and plant cells [44], [54] is not novel [44], [55], [56] and it could help to resolve the complex issue of the divergent constrains of the dual roles of cdk7 in cell cycle and mrna transcription [50]. alternatively, cdk7 could still be the catalytic subunit of the proline-directed cdk4-activating kinase that we postulated. indeed, cyclin h-cdk7-mat1 associated with tfiih phosphorylates non-cdk substrates at t/s-p motifs [49].",pmc3667761,1,0.1,39,1,39.1
268,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,p27,protein,,cdkn1b,uniprot,p46527,cytoplasm,go:0005737,negative,d,binds,nucleus,,,nervous system,,['2481'],nan,nan,"functions of cdk4/cyclin d and cdk5/p25. (a) function and regulation of cdk4/cyclin d: the expression of cyclin d (orange) via mitogenic signals leads to its association with cdk4 (blue) and formation of the complex. the binding with cip/kip proteins (light purple) is required for complex assembly and its nuclear localization. the activity of cdk4/cyclin d activity is negatively regulated by interaction with the ink4 protein family (pink). once activated, cdk4/cyclin d regulates the progression through g1 phase and the transition into s phase. cdk4/cyclin d phosphorylates the retinoblastoma protein (rb) (dark purple) inducing the derepression of e2f transcription factors (green) which allows the transcription of genes which are required for g1/s transition; (b) different functions of cdk5 in the nervous system and schematic representation of cdk5 regulation through cleavage of p35 to p25 at the cellular membrane; when cdk5/p35 binds p27 and e2f1 and dp1 in the nucleus, the cell cycle is inactivated. when p27 is degraded cdk5/p35 returns to the cytoplasm and the cell death pathway is inactivated.",pmc4381256,1,0.1,39,1,39.1
168,axin,protein,,axin1,uniprot,o15169,cytoplasm,go:0005737,ßcat,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,i,transfer,,,,,human,['3475'],nan,nan,"this is a good point. the photoconversion experiment would ultimately help to clarify this, and we now mention this in the discussion as a useful future direction. we also clarify in the discussion that, as noted, many of the mutants can stimulate ßcat degradation (at least when expressed together with axin), and thus we must be looking at a rate difference. the relevant text in the discussion now reads: “thus while axin can template βcat phosphorylation and can, at least in the presence of the truncated apc1 present in tumor cells, send it on to destruction, our data suggest apc promotes the rate at which ßcat is transferred out of the destruction complex and sent to the proteasome. future use of photoactivatible ßcat constructs will further clarify this.” and “based on our model apc mediated βcat transfer is only possible when r2 and b are maintained in the truncated apc (figure 10). r2 and b are essential for function in the absence of endogenous apc function in vivo in drosophila (roberts et al., 2011). in sw480 cells our data suggest they are essential for apc2 to further simulate the rate of ßcat destruction mediated by axin transfection.”",pmc4568445,1,0.1,39,1,39.1
181,bak,protein,pro-apoptotic,bak1,uniprot,q16611,cytoplasm,go:0005737,bcl-xl,protein,anti-apoptotic,bcl2l1,uniprot,q07817,mitochondria,go:0005739,negative,d,inhibition,bh3 domain,,pancreatic cancer,regions of chronic inflammation surrounding cancer cells,human,['1317'],nan,nan,"another member of pro-apoptotic proteins of bcl-2 family is bak. in pancreatic cancer, bak expression and apoptosis occur in regions of chronic inflammation surrounding the cancer cells but not in the tumor cells themselves [57]. this may facilitate tumor growth and spread. recent studies have demonstrated that bad, a typical pro-apoptotic protein of bcl-2 family, binds with its bh3 domain to both bcl-2 and bcl-xl but mediates its pro-apoptotic functions through inhibition of bcl-xl, but not bcl-2 [58].",pmc149420,1,0.1,39,1,39.1
295,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,cdk6,protein,,cdk6,uniprot,q00534,nucleus,go:0005634,positive,i,phosphorylation,,hct116,colon carcinoma,colon,human,['1077'],nan,nan,"rnai-mediated (partial) depletion of cdk7 is generally insufficient to affect cell cycle progression and thus cdk activity. moreover, approaches based on inhibition of cdks or their knockout (or knockdown) have generated divergent conclusions [57]. as no specific inhibitor of cdk7 has been developed, robert fisher's group has replaced in hct116 human colon carcinoma cells the two cdk7 alleles by a mutated cdk7 (f91g) that can be specifically inhibited by “bulky” adenine analogs (k7as hct116 cells) [53]. these cells enabled us to (i) demonstrate crucial –but unexpectedly complex and partly indirect– involvements of cdk7 in cdk4 and cdk6 activation, (ii) uncover novel positive feedback pathways mediated by p21 phosphorylation and involving cdk7-dependent activities of cdk4 and cdk2 in cdk4 activation, and (iii) demonstrate the existence of non-cdk7 cdk4-activating kinase(s).",pmc3667761,1,0.1,39,1,39.1
294,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,cdk6,protein,,cdk6,uniprot,q00534,nucleus,go:0005634,negative,i,inhibition,serum,k7as,epithelial-like,,,['1081'],nan,nan,"in the same experiments, we analyzed in k7as cells the effect of cdk7 inhibition on the prb-kinase activity of cdk4 and cdk6, both of which were immunoprecipitated using antibodies against cyclin d1, d3, p21 or cdk6. the protein composition of these complexes was also analyzed by western blotting (figure 1c; figure s2c). cdk7 inhibition by 1-nmpp1 largely or totally inhibited the serum-stimulated activity of cdk4 and cdk6 without reducing their association with cyclin d1 or cyclin d3. as generally observed in unperturbed cell cycles [3], [10], [58], p21-bound cdk4/6 was largely active in response to serum stimulation, and here again its activity was inhibited by 1-nmpp1 treatment (figure 1c).",pmc3667761,1,0.1,39,1,39.1
293,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,positive,d,phosphorylation,t172,hct116 k7as,colon,colonic,human,['1113'],nan,nan,"we next wanted to verify the effect of cdk7 inhibition under the experimental conditions that permitted us to propose the existence of non-cdk7 proline-directed cdk4-activating kinases, i.e. using ectopic cyclin d3-cdk4 overexpressed by cell transfection as previously [33]. hct116 k7as cells were co-transfected using expression plasmids encoding cyclin d3 and ha-tagged cdk4 in the continuous presence or absence of 1-nmpp1. the ha-tag allowed us to distinguish endogenous and ectopic cdk4 after 2d gel separation from the same co-immunoprecipitations. as shown in figure 8a, cyclin d3-bound cdk4-ha was more phosphorylated than endogenous cdk4, and unlike endogenous cdk4, its phosphorylation was largely resistant to cdk7 inhibition. however, in the minor fraction of cdk4-ha that could be co-immunoprecipitated through its binding to endogenous p21 (using a p21 antibody), we observed a partial but marked reduction of cdk4 phosphorylation after cdk7 inhibition by 1-nmpp1 (figure 8a). therefore, we reasoned that the higher t172 phosphorylation level and its resistance to cdk7 inhibition seen in most ectopic cyclin d3-cdk4 complexes might have been due to their overexpression, which allows them to assemble without being stabilized by the endogenous p21, which was not present in sufficient amounts.",pmc3667761,1,0.1,39,1,39.1
292,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,positive,d,phosphorylation,t-loop,,,,human,['1139'],nan,nan,"[32]. as t-loop phosphorylation of cdk7 might be more important for its recognition of s/t-p motifs (as found in cdk4 and most non-cdk substrates of cdk7) [92], we also verified that the recombinant cdk7 was largely phosphorylated at t170 using 2d-gel electrophoresis combined with a t170-phosphospecific antibody (data not shown).",pmc3667761,1,0.1,39,1,39.1
291,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,positive,d,phosphorylation,,,,,,['1085'],nan,nan,"these results show that the activation of cdk4 and cdk6 in vivo depends critically on cdk7 activity. moreover, cdk4 phosphorylation is labile and thus more prone to rapid regulation, potentially making cdk4 the most influential target of cdk7 in g1/s transition.",pmc3667761,1,0.1,39,1,39.1
290,cdk7,protein,,cdk7,uniprot,p50613,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,nucleus,go:0005634,negative,d,inhibition,t160,hct116,epithelial,colon,human,['1084'],nan,nan,"effect of acute inhibition of cdk7 by 1-nmpp1 on cdk4 activity (a) and phosphorylation (b). (a,b) hct116 k7as cells were stimulated with fbs for 5 h and 1-nmpp1 was then added for 1 or 3 h. cell lysates were immunoprecipitated (ip) with anti-cyclin d1 (d1), or anti-p21 antibodies, assayed for their prb-kinase activity, separated by sds-page and immunoblotted with the indicated antibodies (a), or separated by 2d gel electrophoresis followed by cdk4 immunodetection (b). in (b), t160 phosphorylation of cdk2 immunodetected from whole cell extracts is shown for comparison.",pmc3667761,1,0.1,39,1,39.1
169,axin,protein,,axin1,uniprot,o15169,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,,['3110'],nan,nan,in vitro reconstitution of axin-dependent and ck1 priming-dependent β-catenin phosphorylation by gsk3.,pmc2654145,1,0.1,39,1,39.1
170,axin,protein,,axin1,uniprot,q9y294,cytoplasm,go:0005737,βcat,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,negative,i,target for destruction,,sw480 cells,colorectal adenocarcinoma,colon,human,['3413'],nan,nan,"axin cannot target βcat for destruction in apc's complete absence, even when axin is overexpressed (mendoza-topaz et al., 2011). however, in sw480 cells, which express both truncated hapc1 and endogenous hapc2 (maher et al., 2009), axin overexpression can increase βcat destruction (nakamura et al., 1998). if apc's role in the active destruction complex is to stabilize axin assembly and thus the destruction complex scaffold, then apc should enhance axin's ability to target βcat for destruction. we thus examined whether axin alone fully restores βcat destruction, or whether adding apc2, either to endogenous wild-type axin or co-expressed with fly axin, further facilitates this. we began by measuring βcat fluorescence intensity in z-projections of cells transfected with either apc2 + axin or axin alone, using untransfected cells as internal controls (figure 3f–h). interestingly, while axin reduced total βcat levels (figure 3f,g), βcat was further reduced in cells expressing both apc2 and axin (figure 3f,i) suggesting that apc2 promotes more effective destruction complex activity.",pmc4568445,1,0.1,39,1,39.1
171,axin,protein,,,uniprot,o15169,cytoplasm,go:0005737,ßcat,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,i,stabilizing,,,,,human,['3460'],nan,nan,"strikingly, this allows it to accumulate in puncta even in cells expressing axin + apc2 (figure 3–figure supplement 1a vs b). however, cells expressing axin still accumulate significantly higher levels of ßcat than those expressing axin plus apc2 (figure 3–figure supplement 1c). together, these data are consistent with a model in which apc increases βcat throughput of the destruction complex by stabilizing axin assembly.”",pmc4568445,1,0.1,39,1,39.1
286,cdk7,protein,,cdk7,uniprot,p50613,,,cdk4,protein,,cdk4,uniprot,p11802,,,positive,d,phosphorylation,t172,hct116,,,,['1117'],nan,nan,"to definitively establish the involvement of p21-binding in the requirement for cdk7 activity in the activation of endogenous cdk4, we compared the effect of the inhibition of both cdk2 and cdk7 by roscovitine in p21-null hct116 cells and wt hct116 cells. as p21-null hct116 cells did not survive serum deprivation, both wt and p21-null cells were treated for 16 h with roscovitine when cycling asynchronously (figure 8c). phosphorylation of cdk4 bound to cyclin d1 or cyclin d3 was much more abundant in p21-null cells (figure 8c) (as observed for overexpressed cyclin d3-cdk4 in figure 8a). importantly, t172 phosphorylation of cdk4 was completely inhibited by roscovitine in wt cells but not in p21-null cells (figure 8c).",pmc3667761,1,0.1,39,1,39.1
285,cdk7,protein,kinase,cdk7,uniprot,p50613,nucleus,go:0005634,cdk6,protein,kinase,cdk6,uniprot,q00534,nucleus,go:0005634,positive,d,activation,,hct116,epithelial-like,colon,human,['1078'],nan,nan,acute requirement for cdk7 activity in cdk4 and cdk6 activation in hct116 cells,pmc3667761,1,0.1,39,1,39.1
284,cdk7,protein,kinase,cdk7,uniprot,p50613,nucleus,go:0005634,cdk6,protein,kinase,cdk6,uniprot,q00534,cytoplasm,go:0005737,positive,d,phosphorylation,s178p,,,,,['1114'],nan,nan,cdk7 inhibition does not prevent activating phosphorylations of p21-unbound cdk4 and s178p cdk6.,pmc3667761,1,0.1,39,1,39.1
283,cdk7,protein,kinase,cdk7,uniprot,p50613,nucleus,go:0005634,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,positive,d,phosphorylation,t172,hct116,epithelial,colon,human,['1079'],nan,nan,"to test whether cdk7 inhibition affects the activation of cdk4 through t172-phosphorylation, serum-deprived wild-type (wt) and k7as hct116 cells were re-stimulated by serum in the continuous presence or absence of the bulky adenine analog 1-nmpp1 (10 µm) to specifically inhibit cdk7 activity. as previously shown [53], 1-nmpp1 prevented the induction of dna synthesis in k7as but not in wt hct116 cells (figure 1a). this was associated with a similar inhibition of the stimulated t826 phosphorylation of prb in k7as but not in wt cells, without any inhibition of the accumulation of cyclin d1, cyclin d3 or cdk4 (figure 1b; figure s2a). instead, cyclin d1 accumulation increased further at 8 and 16 h in response to cdk7 inhibition in k7as cells (figure s2a), likely due to impairment of the degradation it undergoes during s-phase progression. serum-stimulated t160 phosphorylation of cdk2 was also inhibited only in k7as cells, as previously demonstrated [53]. interestingly, a marked accumulation of p21 in response to cdk7 inhibition was observed at 8 h and even more at 16 h (figure 1b; figure s2a).",pmc3667761,1,0.1,39,1,39.1
282,cdk7,protein,kinase,cdk7,uniprot,p50613,nucleus,go:0005634,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,positive,d,activation,,,,,,['1120'],nan,nan,"cdk7 is required for cdk4 activation in vivo, but this requirement is conditioned by cdk4 binding to p21, and other cdk4-activating kinases must exist to phosphorylate p21-unbound cdk4 during cdk7 inhibition.",pmc3667761,1,0.1,39,1,39.1
281,cdk7,protein,kinase,cdk7,uniprot,p50613,nucleus,go:0005634,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,negative,d,phosphorylation,t-loop,,,,human,['1124'],nan,nan,"how could the rapid responsiveness of cdk4 activation to cdk7 inhibition be reconciled with the observations that raised doubts about cak being the sole cdk4 activating kinase (as summarized in the introduction; [35])? first, the unaffected phosphorylation of ectopic cyclin d3-cdk4 and s178p cdk6 during cdk7 inhibition, as well as the unaltered phosphorylation of endogenous p21-free cdk4 complexes, demonstrate that cdk7 cannot be the sole cdk4-activating kinase as previously postulated [33], [35]. while completing our study, it was reported that inactivation of rb family proteins by a sv40 large t fragment restores t-loop phosphorylation of cdk2 and cdk1 despite genetic inactivation of cdk7 [74]. that observation too shows the existence of non-cdk7 caks in mammalian cells. second, in our experiments, the requirement for cdk7 activity appears to be restricted to p21-bound cdk4 (or s178p cdk6). one possible explanation is that p21 binding might be required to co-localize cdk4 in the nucleus with cdk7, the cak activity of which depends on its nuclear targeting [76]. outside the nucleus, ectopic cyclin d3-cdk4 and s178p cdk6 (which are mostly cytoplasmic [33]) might be phosphorylated by other proline-directed kinase(s). third, the requirement for cdk7 activity is complex and at least in part indirect. for example, it might be mediated by cdk2 and cdk4 activation and thus by s130 phosphorylation of cyclin d/cdk4-bound p21, as discussed below. though the rapid effect of cdk7 inhibition on cdk4 phosphorylation indicates a direct involvement, it does not formally demonstrate it because cdk7 might conceivably act on other cdk4 kinases (or phosphatases). fourth, cdk7 could still be the catalytic subunit of the regulated proline-directed cdk4-activating kinase that we postulated [33]. in vitro, cyclin h-cdk7-mat1 phosphorylates cdk4 independently of its +1 proline [33], and when coimmunoprecipitated from various cell lysates, it is constitutively active (even when assayed on cdk4) [35]–[37] (figure s10). nevertheless, cdk7 might act differently in cells due to interaction with unknown accessory proteins that might not be preserved in cdk7 immunoprecipitations. such regulated accessory proteins might mediate the complex regulations of cdk4 phosphorylation, including its differential regulation in cyclin d1 and cyclin d3 complexes [36], [47]. even the possibility that cdk7 would not utilize cyclin h to activate cdk4 in cells cannot be excluded.",pmc3667761,1,0.1,39,1,39.1
280,cdk7,protein,kinase,cdk7,uniprot,p50613,nucleus,go:0005634,cdk4,protein,kinase,cdk4,uniprot,p11802,nucleus,go:0005634,negative,d,inhibition,t160,k7as cells,fibroblast-like,unspecified,unspecified,['1083'],nan,nan,"application of cdk7 inhibition after mitogenic stimulation has been reported to have only a delayed effect on cdk2 activity because t160 phosphorylation of cdk2 is stabilized by cyclin binding [53]. we thus wanted to compare the stability of the activating phosphorylations of cdk2 and cdk4, and of cdk4 activity, in response to shorter treatments with 1-nmpp1 in k7as cells. serum-deprived k7as cells were stimulated for 5 h before treating them for 1 or 3 h with 1-nmpp1. both the cdk4/6 prb kinase activity (figure 2a) and cdk4 phosphorylation (figure 2b) completely disappeared after 1 h of cdk7 inhibition. by contrast, t160 phosphorylation of cdk2 was only partially reduced 3 h after 1-nmpp1 administration (figure 2b).",pmc3667761,1,0.1,39,1,39.1
172,axin,protein,,,uniprot,o15169,cytoplasm,go:0005737,βcat,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,d,facilitate,,sw480,colon cancer,colon,human,['3414'],nan,nan,"interestingly, in axin-alone transfected cells, much of the excess βcat that accumulated (figure 3f) was in axin puncta (figure 3g′, inset, arrow). in contrast, puncta in cells co-expressing apc2 and axin had almost undetectable βcat levels (figure 3i′, inset). we thus hypothesized that apc enhances axin's ability to promote βcat exit from the destruction complex, and thus the destruction complex's βcat throughput. to further explore this, we examined phospho-βcat levels. sw480 cells, like other colon cancer cell lines with hapc1 truncated before the mutation cluster region (mcr; figure 1b), have high phospho-βcat levels (yang et al., 2006). this suggests that while axin can facilitate βcat phosphorylation in these cells, axin is less efficient at targeting βcat for destruction in the absence of wild-type apc1, and thus phosphorylated βcat accumulates. strikingly, expressing apc2 alone or apc2 + axin dramatically decreased phospho-serine 33/37 βcat (to ∼20% that in untransfected cells), while axin alone reduced phospho-βcat to only 60% (figure 3l,m). these data further support the hypothesis that apc2 enhances axin's ability to promote βcat destruction.",pmc4568445,1,0.1,39,1,39.1
173,axin,protein,scaffolding,axin1,uniprot,o15169,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,negative,d,binds,pppspxs motif,,,,,['3118'],nan,nan,"since axin is a scaffolding protein critical for gsk3 phosphorylation of β-catenin and binds to the phosphorylated pppspxs motif [34], [35], [37], we considered the possibility whether inhibition of β-catenin phosphorylation by the phosphorylated pppspxp motif involves the binding between axin and the phosphorylated pppspxs motif. to this end we first employed an axin mutant, axinδdix (figure 4a and 4b), which lacks the so-called dix domain required for axin-binding to lrp5/6 [36] and therefore does not associate with phosphorylated lrp6 or the pppspxp motif (h. h and x. h., unpublished results). β-catenin phosphorylation by gsk3 in vitro was promoted by axinδdix as effectively as the wild type axin; but unexpectedly, this reaction was inhibited by phos-a in a similar dose-dependent manner in the presence of either the wild type axin or axinδdix (figure 4c). this result implies that phos-a inhibition of β-catenin phosphorylation by gsk3 may not involve its binding to axin. to address this issue further, we tested another axin fragment, axin(351-701) (figure 4a and 4b), which contains only the β-catenin- and gsk3-binding domains of axin and promote β-catenin phosphorylation by gsk3 [42]. indeed β-catenin phosphorylation by gsk3 was promoted by axin(351-701) similarly to that by the wild type axin, and importantly, was inhibited by phos-a in a dose-dependent manner regardless of the presence of axin or axin(351-701) (figure 4d). these results suggest that phosphorylated pppspxs peptide inhibited β-catenin phosphorylation by gsk3 via a manner that is independent of pppspxs-binding to axin, perhaps by inhibiting gsk3 directly.",pmc2654145,1,0.1,39,1,39.1
174,axin,protein,tagged,axin1,uniprot,o15169,cytoplasm,go:0005737,ßcat,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,i,co-ip,,,epithelial,,human,['3472'],nan,nan,"this is an interesting question. we attempted the experiment the reviewer suggested, iping tagged axin co-expressed with wild-type apc2, apc2∆r2 or apc2∆b, and looking for ßcat co-ip. there was a trend toward increased ßcat in the ips but due to the variability between ips (likely due to, as suggested, to variability in solubility and in preservation of the complex upon lysis), we cannot make an air-tight statement about this. these data are now included as author response image 1. we would be happy to add them to the manuscript if the reviewers and editor think it appropriate.",pmc4568445,1,0.1,39,1,39.1
276,cdk4,protein,,,uniprot,p11802,nucleus,go:0005634,cdk6,protein,,,uniprot,q00534,nucleus,go:0005634,positive,d,phosphorylation,,,,,,['1075'],nan,nan,"pvvvt in cdk4 vs qmaltsvvvt in cdk6) [30], [33]. p173 mutations of cdk4 abrogated its t172 phosphorylation in cells, while s178p mutation of cdk6 led to its complete t177 phosphorylation [33]. however, cdk2 and cdk6 are much better in vitro substrates of cak/cdk7 than cdk4 [31]–[33], [49]. moreover, p173s mutation of cdk4 did not impair its in vitro activation by cak [33], which is consistent with the concept that cdk recognition by cak does not depend on a consensus sequence around the phosphoacceptor site [49]–[52].",pmc3667761,1,0.1,39,1,39.1
275,cdk4,protein,,,uniprot,p11802,,,men1,gene,,men1,hgnc,6975,,,positive,i,,,,,endocrine,mice,['3150'],nan,nan,"the requirement for cdk4 in tumorigenesis of men1+/− mice expands upon its physiologic role previously demonstrated in the pituitary and pancreatic islets in cdk4−/− mice 14, 15. it is important that this phenotype is restricted to adult mice, while embryonic development of these organs is completely intact 18-20. regarding murine pancreatic islets, it is possible that cdk4 activity is essential for proliferation of differentiated β cells, which is thought to be a major mechanism for the adaptive regulation of islet mass in response to homeostatic requirement for insulin secretion 35. a similar scenario might apply to the regulation of adult pituicyte proliferation. a recent study proposed that downregulation of menin promotes β cell proliferation during pregnancy 36. thus, menin could be a limiting factor for not only tumorigenesis but also physiological proliferation in adult endocrine tissues, presumably via cdk4 inhibition. pancreatic islets and pituitaries in cdkn2c−/−; cdk4−/− double mutant mice are as hypoplastic as cdk4−/− mice 37, indicating a linear functional relationship between p18 and cdk4. while cdk6 is another target of p18 and this kinase has also been implicated in the control of human islet proliferation 38, genetic evidence suggests that murine islet cells depend solely on cdk4 for proliferation and tumorigenesis. moreover, cdk4 expression was robust in islet tumors of men1+/− mice, suggesting that upregulation of cdk4 protein may cooperate with downregulation of the cdk inhibitors in men1+/− neuroendocrine cells. this notion is consistent with a recent report that a number of human pancreatic neuroendocrine tumors expressed high levels of cdk4 39. we hypothesize that cdk4 activation not only accelerates proliferation but also generates a selective pressure for cells with loh at the men1 locus. to further delineate the role of cdk4 in pituitary tumorigenesis triggered by the loss of menin, we recently generated mice with pituitary-specific disruption of men1, using cre transgenic mice under the growth hormone promoter (rghp-cretg+) crossed with mice with a floxed men1 allele (men1lox/lox). while rghp-cretg+; men1 lox/lox; cdk4+/+ mice displayed large pituitary tumors by 7 months of age with complete penetrance, no tumor was detected in rghp-cretg+; men lox/lox; cdk4−/− mice autopsied at 9 months (gillam et al., unpublished observations). since the gh promoter becomes active during late embryogenesis, homozygous loss of menin in this model occurs earlier than any detectable impact of cdk4 deficiency on pituitary proliferation or differentiation. thus, the abrogation of tumorigenesis observed in men1+/−; cdk4−/− mice results from the requirement for cdk4 in neuroendocrine tumor initiation, and is unlikely to reflect other functional defects in hypoplastic pituitary or islets in cdk4−/− mice before loh occurs in the men1 locus.",pmc4135037,1,0.1,39,1,39.1
274,cdk4,protein,,,uniprot,p11802,,,cdk2,protein,,,uniprot,p97377,,,positive,d,phosphorylation,,,,neuroendocrine,mouse,['3151'],nan,nan,"unlike cdk4 deficiency, cdk2 deficiency does not affect the homeostasis and function of the neuroendocrine tissues, and does not inhibit menin-associated tumorigenesis. these results are congruent with our previous observation that cdk2 deficiency does not prevent p27-deficient mice from developing pituitary tumors 40. in sharp contrast, cdk2 deficiency and cdk4 deficiency are both inhibitory on her2/neu- induced murine mammary tumorigenesis 41, 42. the embryonic lethality of cdk4−/−; cdk2−/− double mutant mice 43 implies that these two kinases have overlapping function in embryonic tissues as well as in most non-endocrine organs. cdk4 abundantly expressed in islet cells of men1+/−; cdk2−/− mice may be sufficient to compensate for the absence of cdk2 during tumorigenesis. it is thought that cdk4 and cdk2 collaborate in phosphorylating the critical substrate rb, sharing different phosphorylation sites on the protein 44. in the present study using the islet cell lines, cdk4 depletion inhibited glucose-stimulated hyperphosphorylation of rb, including ser780 phosphorylation, and g1-s progression, whereas cdk2 depletion had no effect. collectively, these data underscore the significance of the cdk4-rb pathway in the control of neuroendocrine cell proliferation. further investigations are necessary to understand how multiple cdk complexes control phosphorylation of rb at the 16 cdk-consensus sites 44 in neuroendocrine-specific manners, and whether non-rb substrates of cdk4 are involved in men1 tumorigenesis.",pmc4135037,1,0.1,39,1,39.1
180,bad,protein,proapoptotic,bcl2l1,uniprot,q92934,mitochondrial outer membrane,go:0005741,bcl-xl,protein,prosurvival,bcl2l1,uniprot,q07817,mitochondrial outer membrane,go:0005741,negative,d,heterodimerizes,bax,,cancer,,human,['961'],nan,nan,"bad is a proapoptotic member of the bcl-2 family, which belongs to the bh3-only protein family comprising bad, bik, bmf, hrk, noxa, tbid, bim, and puma (kim et al, 2006). bcl-2 associated death (bad) promoter, bcl-2 antagonist of cell death) is a proapoptotic factor that promotes apoptosis via forming heterodimers with prosurvival proteins bcl-2 and bcl-xl, preventing them from binding with bax (yang et al, 1995). phosphorylation of bad at ser-112 and ser-136 disrupts its association with bcl-2 or bcl-xl, promoting cell survival (datta et al, 2000; hayakawa et al, 2000). phosphorylation of bad at ser-112 and ser-136 has been proposed to be mediated by erk/p90rsk1 and pi3k/akt pathways, respectively (hayakawa et al, 2000). thus, the phosphorylation status of bad at these critical serine residues serves as a determinant of either cell death or survival (downward, 1999). data showing that α-tea reduces phosphorylation of bad at both ser-112 and ser-136 sites suggest that the ability of α-tea to reduce akt and erk activities contributes to restoration of bad's proapoptotic function. furthermore, data showing that inhibition of pi3k with wortmannin suppressed phosphorylation of bad at both ser-112 and ser-136 supports a role for pi3k in regulating both akt and erk/p90rsk1 in these cells. previous data from our lab showed that α-tea induces mitochondria-dependent apoptosis via activation of bax, a critical step in triggering mitochondria-dependent apoptosis (yu et al, 2006; jia et al, 2008b; yu et al, 2010). two other bh3-only proapoptotic bcl-2 members, caspase-8-mediated tbid (active form of bid) and p73-mediated noxa, have been shown to be upregulated by α-tea (yu et al, 2006; jia et al, 2008b; wang et al, 2008; yu et al, 2010). in this study, for the first time, we report that α-tea induces bad activation via inhibiting akt and erk. these data demonstrate that α-tea triggers mitochondria-dependent apoptosis via targeting different bcl-2-associated death promoters, namely, bid, noxa, and bad, in cancer cell types.",pmc3039802,1,0.1,39,1,39.1
480,foxo1,protein,transcription factor,foxo1,uniprot,q12778,nucleus,go:0005634,xbp-1u,protein,transcription factor,xbp1,uniprot,p17861,cytoplasm,go:0005737,positive,d,recruitment,20s proteasome,,,,human,['563'],nan,nan,"autophagy is activated to maintain cellular energy homeostasis in response to nutrient starvation. however, autophagy is not persistently activated, which is poorly understood at a mechanistic level. here, we report that turnover of foxo1 is involved in the dynamic autophagic process caused by glutamine starvation. x-box-binding protein-1u (xbp-1u) has a critical role in foxo1 degradation by recruiting foxo1 to the 20s proteasome. in addition, the phosphorylation of xbp-1u by extracellular regulated protein kinases1/2 (erk1/2) on ser61 and ser176 was found to be critical for the increased interaction between xbp-1u and foxo1 upon glutamine starvation. furthermore, knockdown of xbp-1u caused the sustained level of foxo1 and the persistent activation of autophagy, leading to a significant decrease in cell viability. finally, the inverse correlation between xbp-1u and foxo1 expression agrees well with the expression profiles observed in many human cancer tissues. thus, our findings link the dynamic process of autophagy to xbp-1u-induced foxo1 degradation.",pmc3616429,1,0.1,39,1,39.1
481,foxo3,protein,,foxo3,uniprot,o43524,nucleus,go:0005634,runx2,protein,,runx2,uniprot,q13950,nucleus,go:0005634,negative,d,ubiquitination,,vascular smooth muscle cells (vsmc),,vascular smooth muscle,human,['3256'],nan,nan,"a novel function of foxo1 and foxo3 in negatively regulating runx2 stability has been delineated in vascular smooth muscle cells (vsmc). foxo1/foxo3 knockdown inhibits runx2 ubiquitination, increasing runx2 abundance. activation of akt, either by pten deficiency or by overexpression of constitutively activated akt, leads to nuclear exclusion of foxo1 and foxo3 in vsmc [53]. in the context of cancer cells, constitutive akt activation would favor foxo1/o3 nuclear exclusion, thereby decreasing runx2 ubiquitination and degradation and increasing runx2 stability. these studies altogether show that akt activity positively regulates runx2 stability through ubiquitin/proteasome-mediated degradation of smurf2 or nuclear exclusion of foxo1 and foxo3, depending on the cellular system.",pmc4513933,1,0.1,39,1,39.1
138,apc,protein,,apc,uniprot,p25054,destruction complex,go:1990387,βcat,protein,,ctnnb1,uniprot,p35222,destruction complex,go:1990387,positive,i,phosphorylation,,,,,human,['3431'],nan,nan,"mutations in apc disrupt embryonic development from its onset, and are the first step in most colon cancers. although we know apc functions in the destruction complex to help target βcat for degradation, its mechanism of action remains unknown. our study offers novel insights into apc's function in the destruction complex, providing the first glimpses of the internal structure of the apc:axin complex, and leading to a novel dynamic and testable model of a regulated catalytic cycle of destruction complex function. based on our data we propose an explicit mechanistic model for apc2 function inside the destruction complex (figure 10). in step 1, apc2 stabilizes destruction complex assembly via its arm rpts and samps motifs. the assembled destruction complex then facilitates βcat phosphorylation (step 2) and protects it from dephosphorylation. gsk3, which phosphorylates βcat, axin and other sites on apc, also phosphorylates apc2's r2 and b (step 3; ck1 may also be involved, as it is in the other phosphorylation events in the complex). we hypothesize this induces a conformational change in apc2 that releases the arm rpts from association with axin (step 4); since only a subset of apc2 molecules in the destruction complex would release the arm rpts at any given time, the overall destruction complex would remain stable. we propose this conformational change allows transfer of phospho-βcat to the e3-ligase (step 5). alternately, gsk3 may regulate the release of a complex of apc and phospho-βcat, allowing apc to shield phospho-βcat from dephosphorylation (su et al., 2008) and guide it to the e3-ligase. the catalytic cycle of apc would then be reset by dephosphorylation (step 6). this provides a testable model for the mechanisms regulating a key signaling pathway. it also may provide insights into the assembly and dynamics of other large multiprotein complexes that assemble via dynamic multivalent interactions involving motifs within intrinsically disordered regions, leading to phase transitions (li et al., 2012a; toretsky and wright, 2014).",pmc4568445,1,0.1,39,1,39.1
638,lrp6,protein,,,uniprot,o75581,cell membrane,go:0005886,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,i,inhibition,β-catenin,,,,,['3135'],nan,nan,a working model for lrp6 inhibition of β-catenin phosphorylation by the axin-gsk3 complex.,pmc2654145,1,0.1,39,1,39.1
636,lrp6,protein,,lrp6,uniprot,o75581,plasma membrane,go:0005886,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,d,inhibition,pppspxs motif,,,,human,['3130'],nan,nan,"although it is known that the activated wnt/frizzled/lrp6 receptor complex results in inhibition of β-catenin degradation, the underlying molecular mechanism has remained unclear. one critical initiating event is wnt-induced lrp6 phosphorylation at multiple pppspxs motifs [34], [35]. the phosphorylation of the pppspxs motif is sequentially carried out by gsk3 and ck1 [35], [38], and is under the control of the frizzled receptor and its downstream partner dishevelled protein [39], [40]. the dually phosphorylated pppspxs motif in turn provides a docking site for axin [34], [35], thereby recruiting axin and likely associated proteins to the frizzled-lrp6 receptor complex [36]. but how these events lead to inhibition of β-catenin phosphorylation by the axin-gsk3 complex has been poorly understood.",pmc2654145,1,0.1,39,1,39.1
635,lrp6,protein,,lrp6,uniprot,o75581,plasma membrane,go:0005886,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,d,inhibition,,,,,human,['3134'],nan,nan,"in summary, we propose a working model to link lrp6 activation and the inhibition of β-catenin phosphorylation. when activated by wnt, pppspxs motifs in lrp6 intracellular domain are phosphorylated by gsk3 and ck1, and they act together to recruit axin-gsk3 into the wnt receptor complex. when axin is bound to one of the phosphorylated pppspxs motifs, other phosphorylated pppspxs motifs in the vicinity of the axin-gsk3 complex directly inhibit gsk3 phosphorylation of β-catenin (figure 7). several considerations suggest the feasibility of this model. first, although each phosphorylated pppspxs motif can bind to axin [34], [37], it is unlikely that these five pppspxs motifs clustered within a 120-residue region of lrp6 intracellular domain bind simultaneously to five molecules of axin, which has 863 amino acids. rather, these five pppspxs motifs together may provide a high local concentration of docking sites for a single axin molecule, thereby ensuring a tight association between lrp6 and axin. in this scenario multiple phosphorylated pppspxs motifs in each lrp6 are available for direct inhibition of gsk3. this model implies that the five pppspxs motifs when fully phosphorylated may have two major functions, i.e., to ensure the binding of axin to lrp6 and to carry out inhibition of gsk3 phosphorylation of β-catenin. this notion is consistent with the finding by others and us that the coorperativity of the five pppspxs motifs are critical for lrp6 signaling function [37], [43]. secondly, this model explains lrp6 signaling specificity in the inhibition of β-catenin phosphorylation, since gsk3 phosphorylation of other substrates such as gs and tau occurs outside the axin complex and is not in the proximity to lrp6 upon wnt stimulation, and therefore will not be affected by the phosphorylated pppspxs motif under the physiological condition. thirdly, direct inhibition of gsk3 by phospho-pppspxs motifs within lrp6 is consistent with a recent observation that upon wnt stimulation dephosphorylated β-catenin is observed at the plasma membrane together with the activated lrp6 [52].",pmc2654145,1,0.1,39,1,39.1
634,lrp6,protein,,lrp6,uniprot,o75581,plasma membrane,go:0005886,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,d,inhibit phosphorylation,motif c,,,,,['3136'],nan,nan,"while one of the five phosphorylated pppspxs motifs of lrp6 physically interacts with axin, other phosphorylated pppspxs motifs may directly inhibit gsk3 phosphorylation of β-catenin in the axin complex. axin-binding to motif c is drawn arbitrarily. see discussion for details.",pmc2654145,1,0.1,39,1,39.1
633,lrp6,protein,,lrp6,uniprot,o75581,,,lrp5,protein,,lrp5,uniprot,o75197,,,positive,i,phosphorylation,,,,,human,['3113'],nan,nan,"a. sequence alignment of the five pppspxs motifs in human lrp6 and lrp5 by the cluster v program. the pppspxs motifs are highlighted in color and boxed. b. the sequences of synthetic peptides are shown. the pppspxs motifs in the peptides are underlined, and phosphorylated ser/thr residues are shown in italics. the c or k residue in the parenthesis at the amino terminus of peptides a, c, d, and e was introduced for protein conjugation purposes (during immunization for antibody production) [34], [37].",pmc2654145,1,0.1,39,1,39.1
630,lamp1,protein,,,uniprot,p11279,lysosome,,tfeb,protein,,tfeb,uniprot,o75385,nucleus,go:0005634,negative,i,redistribution,nuclear region,,,,human,['2869'],nan,nan,"in addition, we analyzed the subcellular positioning of lysosomes, which is intricately linked to the cellular nutrient state [18]. to that end, we employed the “lamp1 max contour position” feature, defined as the location of the contour in the cell with the highest lamp1 intensity concentration [16]. as shown in fig. 6d and additional file 8: figure s8, values close to 0 indicate a centered (perinuclear) lysosomal distribution, while values close to 1 indicate a peripheral (cytoplasmic) lysosomal distribution. the mean population response (fig. 6e) demonstrates that within 0.5 hours, as expected [18], nutrient deprivation significantly redistributed lysosomes to the nuclear region. this perinuclear lysosomal distribution was maintained up to 5 hours, and after 15 hours lysosomes re-localized towards the cell periphery. notably, the three clusters displayed statistically different mean “lamp1 max contour position” values (fig. 6f) and clear differences between lysosomal positioning distributions (fig. 6g), indicating that cells in the “inactive” cluster contain the most peripheral lysosomes and cells in the “active” cluster contain the most perinuclear lysosomes. consistent with the inter-cluster differences, “lamp1 max contour position” negatively correlated with tfeb nuclear/cytoplasmic ratio in single cells, with a correlation coefficient of −0.25 (see additional file 1: figure s1, panel iii). overall, lamp1 concentration dynamics and spatial distribution within subpopulations indicate that the tfeb-defined subpopulations are of physiological relevance for the cellular lysosomal state.",pmc4896000,1,0.1,39,1,39.1
629,lamp1,protein,,lamp1,uniprot,p11279,lysosome,go:0005764,lc3,protein,,map1lc3a,uniprot,q9h492,cytoplasm,go:0005737,positive,d,co-localisation,,,,,,['2538'],nan,nan,quantitation of co-localisation of lamp1 tubules with lc3 from (c). mean ± sem for n = 3 independent experiments.,pmc4585463,1,0.1,39,1,39.1
619,kap1,protein,transcriptional co-repressor,trim28,uniprot,q13263,nucleus,go:0005634,hp1β,protein,heterochromatin protein,cbx1,uniprot,p83916,nucleus,go:0005634,positive,d,phosphorylation,s473,,,,human,['3081'],nan,nan,"chromatin relaxation is a key event in ddr as it favors the recruitment of repair factors at damaged sites. it is now well established that dna lesions located in the tightly packaged heterochromatin are repaired with a slower kinetics compared to those occurring in the less compact and transcriptionally active euchromatin [11, 12]. many proteins are involved in the regulation of chromatin structure; among them, the transcriptional co-repressor kap1 (krab domain-associated protein 1) recruits histone deacetylases and methyltransferases to promote the transcriptionally inactive state of chromatin [13, 14]. moreover, kap1, which is also known to associate with ccar2 [15], is involved in the recruitment of the heterochromatin protein 1 family (hp1α, hp1β e hp1γ) that binds methylated histones, preserving their methylation and promoting gene silencing [14, 16]. however, upon dna damage kap1 is phosphorylated by atm on s824 [17] and by chk2 on s473 [18, 19] inducing chromatin relaxation and dna repair in the heterochromatic regions of the genome. of note, phosphorylation of s473 by chk2 decreases the interaction between kap1 and hp1 proteins and is necessary for hp1β mobilization, a key event for dna repair in the heterochromatin [18-21].",pmc4627348,1,0.1,39,1,39.1
596,insulin,hormone,,ins,uniprot,p01308,,,sp-a,protein,,sftpa1,uniprot,p35247,,,negative,d,inhibition,,cultured human fetal lung explants,fetal lung,lung,human,['1817'],nan,nan,"we also treated cultured human fetal lung explants with wortmannin, rapamycin or pd98059 in the presence or absence of insulin. fig. 2 shows that wortmannin (100 nm) and rapamycin (50 nm) both abolished the insulin-mediated inhibition of sp-a gene expression. in agreement with the h441 cells results, pd98059 (2.5–10 μm) had no effect on the insulin inhibition of sp-a mrna while decreasing basal sp-a mrna levels in a dose-dependent manner when added alone.",pmc150512,1,0.1,39,1,39.1
595,insulin,hormone,,ins,uniprot,p01308,extracellular,go:0005576,sp-a,protein,,,uniprot,p35247,extracellular,go:0005576,positive,d,exposure,,h441,epithelial,lung,human,['1813'],nan,nan,"nuclear isolation, transcription elongation reactions and hybridizations were performed as described previously with minor modifications [7]. subconfluent h441 cells were incubated in serum-free media for 24 hours and then exposed to media plus either vehicle or insulin (2.5 μg/ml) for an additional 1, 4, 8 and 24 hours. the cells were then rinsed and trypsinized, and nuclei from control and treated cells were harvested. the transcription elongation reaction was performed with 20 × 106 nuclei. labeled, newly synthesized rna was then isolated and purified from the nuclei. nytran membranes with immobilized cdnas for the bluescript vector, human sp-a and human α-actin were prehybridized in 1 ml of buffer (50% formamide, 5 x ssc, 5 x denhardt's solution, 100 μg/ml denatured herring sperm, 0.1% sds) for 4 hours at 45°c and then hybridized to the labeled rnas (6 × 106 cpm in the presence of 500 units of rnasin) in duplicate for an additional 60 hours. afterwards, the hybridized membranes were washed twice in 0.2 x ssc with 0.1% sds at 55°c for 1 hour, once in 2 x ssc at 55°c for 15 min, once in 2 x ssc with 10 μg/ml rnase a at 37°c for 30 min and then rinsed twice in 2 x ssc at room temperature for 15 min. membranes were exposed to a storage phosphor screen (molecular dynamics, san francisco, ca, usa) for 3–5 days, scanned using a phosphorimager (molecular dynamics) and data quantitated using quantity one software (bio-rad laboratories, hercules, ca, usa).",pmc150512,1,0.1,39,1,39.1
590,igf-1r,receptor,,igf1r,uniprot,p08069,plasma membrane,go:0005886,akt,kinase,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,i,activation,,,neoplastic lung,lung,human,['2981'],nan,nan,"igf-1r signals through numerous downstream pathways in which the intracellular kinases erk1/2 and akt are frequently activated [12,48]. we have previously determined that mek inhibition induces a potent g1 phase arrest in neoplastic lung cell cycle progression in vitro [51], and others have determined that blocking both mek and pi3k slows lung tumor growth in vivo [25]. we show herein that møcm-stimulated neoplastic proliferation significantly increases cyclin d1 expression, which is abrogated by the combined inhibition of both mek and pi3k. sole inhibition of either mek or pi3k partially limits macrophage stimulation of lm2 and jf32 growth to slightly different extents. while møcm modestly increases erk1/2 and akt activity, long-term mek and pi3k inhibition strikingly stimulates both kinases in an additive manner with conditioned media treatment. this increased kinase activity resulting from mek and pi3k inhibition, however, is no longer associated with changes in cyclin d1, as combined inhibition resulted in the highest levels of akt activity, but lowest levels of cyclin d1 expression (""u + l""; figure 9e and 9h). compensatory akt or erk activation in response to upstream kinase inhibition is consistent with the extensive cross-talk that exists among mapk pathways, where inhibition of any single mediator results in exaggerated and/or sustained signaling through an alternate pathway [32,34,52,53]. indeed, when the mek pathway was inhibited in lm2 cells, early p-akt activity increased, while pi3k inhibition increased p-erk1/2 (4 hrs: figure 9c). akt is hyper-phosphorylated with 24 hrs of treatment with either mek or pi3k inhibitor, and this hyper-activated akt sustains 5-10 higher levels of p-gsk-3β and p-craf for at least 48 hrs. erk1/2 phosphorylation is also stimulated by drug treatment, which peaks at 24 hrs and rapidly declines by 48 hrs. consistent with our observations, continuous hyper-activation of akt or erk1/2 induces cytostasis or even apoptosis in some tissues, while more modest erk1/2 activation drives kras mutant tumor cell proliferation [34,40,51]. while our studies demonstrate that møcm and igf-1 stimulated neoplastic growth is affected similarly by mek and pi3k inhibition, further studies in genetically-silenced or kinase-mutant cell lines are required to determine the discrete cellular mechanisms necessary for growth factor-stimulated neoplastic proliferation.",pmc3135566,1,0.1,39,1,39.1
579,hk ii,protein,,hk2,uniprot,p52789,cytoplasm,go:0005737,mnsod,protein,,sod2,uniprot,p04179,mitochondria,go:0005739,negative,d,interacts with,,mcf-7,epithelial,breast,human,['2252'],nan,nan,"our previous study showed that after low dose radiation, hk ii can move into the mitochondrial matrix and interact with mnsod [46]. we co-immunoprecipitated hk ii and mnsod in mcf-7 cells treated with rapamycin and/or radiation (fig. 6d) and found that at 24 h post-irradiation, relocation of mtor to mitochondria can prevent the influx of hk ii into the mitochondrial matrix to form a complex with mnsod. however, rapamycin treatment can rescue the hk ii influx. hk ii interaction with mnsod results in reduced mnsod activity (fig. 6d) which may lead to higher ros production and cell death. by blocking the interaction between hk ii and mnsod, mtor enables the proper activation of mnsod, which is required to scavenge elevated ros resulting from enhanced oxphos. these results support the conclusion that the inhibitory function of mtor on hk ii can be induced by radiation and serves as a switch to turn mitochondrial functions on or off. thus blocking this interaction may result in the inhibition of the acute adaptive response and cell survival under genotoxic stress condition caused by 5 gy of radiation.",pmc4373728,1,0.1,39,1,39.1
577,h1.2,protein,,,uniprot,p16403,nucleus,go:0005634,dna-pk,protein,,,uniprot,p78527,nucleus,go:0005634,positive,d,phosphorylation,c-terminal tail domain of h1.2,u2os,osteosarcoma,,human,['3307'],nan,nan,"the n- and c-terminal tail domains of h1 have been known as prominent substrates for various posttranslational modifications. intrigued by our observation that dna-pk is co-purified with h1.2 (kim et al 2008), we explored whether dna-pk can catalyze h1.2 phosphorylation and, if so, h1.2 phosphorylation is functionally connected to p53 acetylation in regulating p53-h1.2 interaction. as shown in figure 2b, in vitro kinase assays demonstrated that dna-pk can phosphorylate full length gst-h1.2, but not gst alone (lanes 1 and 2). to locate possible phosphorylation sites, we repeated the kinase assays using three distinct domains of h1.2: the n-terminal tail domain (amino acids 1-34), the central globular domain (amino acids 35-109) and the c-terminal tail domain (amino acids 110-213) (figure 2a). unlike the n-terminal tail and globular domains, the c-terminal tail domain of h1.2 was efficiently phosphorylated by dna-pk at a level similar to that of full length h1.2 (figure 2b, lanes 3–5). in similar experiments with two subregions of the c-terminal tail domain, namely amino acids 110-138 and 139-213, we found that dna-pk can phosphorylate amino acids 139-213, but not amino acids 110-138, of h1.2 (lanes 7 and 8). potential phosphorylation sites in amino acids 139-213 include four threonine residues (t146, t154, t165 and t167) and three serine residues (s150, s173 and s188). to determine which of these residues are phosphorylated by dna-pk, kinase assays were repeated with full length mutant proteins in which the seven potential sites were individually substituted with alanine. substitution of each of t150, t154, t165, t167, s173 and s188 did not change the level of h1.2 phosphorylation (figure 2c, compare lanes 3–8 with lane 1). meanwhile, mutation of t146 completely abrogated h1.2 phosphorylation (lane 2), indicating that t146 is the predominant site in h1.2 c-terminal tail that is phosphorylated by dna-pk. western blot analysis using h1 phospho t146 antibody further confirmed that t146 serves as a major substrate for dna-pk (figure 2d). in agreement with these in vitro results, when human osteosarcoma u2os cells were treated with etoposide, h1.2 phosphorylation at t146 was rapidly increased within 15 min following etoposide-induced dna damage and decreased to the base line after 60 min of etoposide treatment (figure 2e, dmso, pt146). however, no such increase in h1.2 phosphorylation at the 15 min point was observed in cells pretreated with a dna-pk specific inhibitor, nu7026 (nu7026, pt146). as a control of equivalent amounts of protein loaded in each lane, the western blot was probed with anti-h1.2 antibody. there were equal amounts of h1.2 in all samples (h1.2). in conclusion, h1.2 is phosphorylated at t146 in response to dna damage, and dna-pk is mainly responsible for the observed phosphorylation.",pmc3330162,1,0.1,39,1,39.1
572,gsk3β,protein,,gsk3b,uniprot,p49841,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,positive,d,phosphorylation,,,intestinal cells,intestine,human,['2732'],nan,nan,"the current study has revealed a novel fak/pyk2/gsk3βy216/β-catenin regulatory circuit in intestinal tumorigenesis. our findings indicate that: loss of functional apc induces the expression of fak and pyk2, elevated fak/pyk2 phosphorylates gsk3βy216 to stabilize β-catenin, which initiates and supports intestinal tumorigenesis (figure 6e). phosphorylation of gsk3βy216 was discovered about two decades ago (hughes et al., 1993), but until now, its role in wnt/β-catenin signaling remains mysterious. our results has uncovered a previously unrealized role of gsk3βy216 phosphorylation: it triggers gsk3β recruitment of β-trcp and subsequent gsk3β monoubiquitination by β-trcp, an event required for wnt-induced inhibition of β-catenin degradation, thus identifying phosphorylation of gsk3βy216 as an ‘activator’ of the wnt/β-catenin pathway.",pmc4558782,1,0.1,39,1,39.1
570,gsk3β,protein,,gsk3b,uniprot,p49841,cytosol,go:0005829,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,d,phosphorylation,,hek293t,epithelial-like,kidney,human,['2714'],nan,nan,"(a) the whole cells lysates from hek293t cells transfected with empty vector or constructs expressing ha-tagged gsk3β or its phosphorylation mutants were used for immunoprecipitation (ip) and immunoblotting (ib) analysis with indicated antibodies. (b) ubiquitination of ha-gsk3β was evaluated by ip with anti-flag using whole cell lysates derived from hek293t cells transfected with indicated constructs followed by ib analysis with anti-ha. (c) in vitro synthesized wild type (wt) and mutant ha-gsk3β proteins were immunoprecipitated with anti-ha affinity gel. left panel: in vitro ubiquitination assay was performed by incubating immunoprecipitated ha-gsk3β with e1, e2, ub and scfβ-trcp1 in the presence of atp at 37°c for 2 hr. the reaction mixtures were analyzed by ib. right panel: the immunoprecipitated ha-gsk3β was incubated with atp at 37°c for 2 hr before subjecting to ib using antibody recognizing phosphorylated gsk3βy216. (d) hek293t cells were treated with wnt3a-conditioned medium (cm) for the indicated time before harvesting for ib analysis. (e) hek293t cells were transfected with indicated plasmids and treated with control-cm or wnt3a-cm for 6 hr. ubiquitination of ha-gsk3β wt and y216f mutant protein were evaluated by ip with anti-flag followed by ib with anti-ha. (f) hek293t cells were transfected with constructs expressing ha-gsk3β or its mutant. 24 hr post-transfection, the cells were harvested for ip with anti-ha followed by ib with anti-axin1. (g) upper panel: ha-tagged gsk3β or its mutants were ectopically expressed in hek293t cells and immunoprecipitated with anti-ha. the precipitated proteins were incubated with purified ck1 and β-catenin in the presence of atp at 37°c for 1 hr. kinase activity was evaluated by ib with antibody recognizing phosphorylation of β-catenins33/s37/t41 catalyzed by gsk3β. lower panel: the whole cell lysates from wt mefs, gsk3β knockout (ko) and gsk3α knockdown (kd) mefs reconstituted with empty vector or indicated ha-gsk3β mutants were used for ib. antibody recognizing both gsk3α and gsk3β was used for detecting endogenous gsk3 and ha-tagged gsk3β. this antibody recognized ha-gsk3βy216f but not ha-gsk3βy216e mutant protein.",pmc4558782,1,0.1,39,1,39.1
569,gsk3β,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,pyk2,protein,,ptk2b,uniprot,o60674,plasma membrane,go:0005886,positive,d,phosphorylation,,"hek293t, ht-29, sw480, dld-1",various,various,human,['2719'],nan,nan,"to identify the kinases responsible for gsk3βy216 phosphorylation, we performed a pilot screening experiment using various kinase inhibitors. in line with a prior report that gsk3βy216 can be phosphorylated by pyk2 (sayas et al., 2006), we found that treatment of hek293t cells with pf-562271, a dual inhibitor of fak/pyk2, inhibited gsk3βy216 and gsk3αy279 phosphorylation in the presence and absence of wnt3a (figure 3a). fak and pyk2 are closely related non-receptor tyrosine kinases, participating in diverse signaling pathways and control a number of cellular processes (mitra et al., 2005; schaller, 2010). unlike ubiquitously expressed fak, pyk2 has a more restricted tissue expression and is highly enriched in the brain and hematopoietic cells (avraham et al., 2000). our ib results (figure 3b) showed that while hek293t and ht-29 cells predominantly expressed fak, sw480 cells primarily expressed pyk2. both fak and pyk2 were expressed in dld-1 cells. in hek293t cells, kd of fak abrogated gsk3αy279 and gsk3βy216 phosphorylation and wnt-induced β-catenin accumulation (figure 3c). in crc cells predominantly expressing either fak (ht-29 cells) or pyk2 (sw480 cells), kd of fak or pyk2 alone was sufficient to reduce the levels of phosphorylated gsk3αy279 and gsk3βy216 and total β-catenin (figure 3d,e). however, in dld-1 cells expressing fak and pyk2, simultaneous kd of both kinases were required to inhibit gsk3y279/y216 phosphorylation and to reduce the level of β-catenin (figure 3f), strongly suggesting that fak and pyk2 function redundantly to phosphorylate gsk3y279/y216 to promote wnt/β-catenin signaling. to further confirm that gsk3 is a phosphorylation substrate of fak/pyk2, we examined whether fak/pyk2 binds to gsk3β and fak/pyk2's ability to phosphorylate gsk3βy216 in vitro. in line with prior findings that gsk3β interacts with fak and pyk2 in vivo (huang et al., 2002; sayas et al., 2006), our co-ip results showed that gsk3β interacted with pyk2 in sw480 cells and with fak in ht-29 cells (figure 3g). however, whether they bind directly or indirectly is not known. the result of in vitro kinase assay confirmed that fak and pyk2 were able to directly phosphorylate gsk3βy216 in vitro (figure 3h). together, these results reveal that fak and pyk2 mediate gsk3y279/y216 phosphorylation in crc cells.",pmc4558782,1,0.1,39,1,39.1
568,gsk3β,protein,gsk3βy216e/s4 mutant,gsk3b,uniprot,p49841,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,d,inhibition,y216 phosphorylation,gsk3β ko/gsk3α kd mefs,fibroblast,connective,mouse,['2751'],nan,nan,"as predicted by the reviewer, our new data (figure 2a, lanes 13 and 14) showed that reconstitution of gsk3β ko/gsk3α kd mefs with gsk3βy216e/s4 mutant (y216 phosphorylation mimetic lacking ubiquitination) inhibited wnt-induced β-catenin accumulation.",pmc4558782,1,0.1,39,1,39.1
567,gsk3α,protein,,,uniprot,p49841,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,positive,d,accumulation,,sw480,crc,,human,['2755'],nan,nan,"we have performed new experiments to address the role of gsk3αy279; (1) in the activation of wnt/β-catenin pathway and (2) in vivo growth of sw480 cells. our new results showed that wnt-induced β-catenin accumulation was inhibited in gsk3β ko/gsk3α kd mefs reconstituted with gsk3αy279f but not with gsk3αy279e (figure 2e, comparing lanes 9-10 with 11-12), hence validating the role of gsk3αy279 phosphorylation in the activation of wnt signaling. our new data also showed that in gsk3α/β kd sw480 cells, reconstitution of the cells with wt ha-gsk3α or ha-gsk3αy279e but not ha-gsk3αy279f restored cell growth in a xenograft assay (figure 2f), implying the functional importance of gsk3αy279 phosphorylation in crc cells.",pmc4558782,1,0.1,39,1,39.1
566,gsk3a,protein,,,uniprot,p49840,,,nbr1,protein,,,uniprot,q14596,,,positive,d,phosphorylation,,293t,,embryonic,mouse,['2995'],nan,nan,"in the context of a systematic protein-protein interaction network mapping effort for components of the pi3k-akt-mtor pathway, we screened a cdna library from e10.5 mouse embryo and the horfeome1.1 library with human gsk3a and gsk3b as baits.29 we identified nbr1 as the most represented gsk3a and gsk3b interacting protein. these interactions were confirmed by co-affinity purification experiments in 293t cells (fig. s1a). nbr1 bound to wild-type gsk3a and gsk3b and to constitutively active gsk3 mutants in which inhibitory phosphorylation sites ser21 (gsk3a s21a) of gsk3a or ser9 of gsk3b (gsk3b s9a) had been mutated to nonphosphorylable alanines. similar to several gsk3a and gsk3b interaction partners,29 nbr1 binding was lost with inactive gsk3 mutated in the active site (gsk3a k148a or gsk3b k85a). nbr1 possesses a n-terminal pb1 (phox and bemp1) domain, a zz-type zinc finger, 2 coiled-coil domains, 2 lir, a j (juxta-uba) domain and a c-terminal uba domain (fig. 1a). because gsk3 is a kinase, we tested if nbr1 was a substrate. in vitro radioactive 32p kinase assays showed that wild-type and constitutively active gsk3a and gsk3b efficiently phosphorylated nbr1 (fig. 1b). as expected, this phosphorylation was lost with inactive gsk3 mutants or upon gsk3 inhibition by 1-azakenpaullone, an inhibitor of gsk3 kinase activity (fig. 1b; fig. s1b).30 altogether, our results show that gsk3a and gsk3b phosphorylate nbr1 in vitro.",pmc4091167,1,0.1,39,1,39.1
563,gsk3,protein,,,uniprot,p49841,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,negative,d,destruction,,,,,,['3396'],nan,nan,a novel gsk3-regulated apc:axin interaction regulates wnt signaling by driving a catalytic cycle of efficient βcatenin destruction,pmc4568445,1,0.1,39,1,39.1
562,gsk3,protein,,,uniprot,p49841,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,d,inhibition,,xenopus embryos,,,xenopus,['3127'],nan,nan,"as the dually phosphorylated phos-a peptide inhibits gsk3 phosphorylation of β-catenin in vitro, we examined whether phos-a could inhibit gsk3 and activate β-catenin signaling in vivo. it has been well established that inhibition of gsk3, such as via a dominant-negative gsk3 mutant, activates wnt/β-catenin signaling and induces axis duplication in xenopus embryos [46], [47], [48]. we found that injection of the phos-a peptide, but not the a-mut peptide, in xenopus embryos induced partial axis duplication and the expression of xnr3, a direct downstream target gene for β-catenin signaling [49] (figure 6). although the activity of the injected phos-a peptide was significantly weaker compared to that of injected xwnt8 mrna (figure 6), this was not unexpected since the phospho-peptide was likely subjected to dilution, proteolysis and/or dephosphorylation by proteases and/or phosphatases in the embryo in the absence of de novo synthesis. importantly the a-mut peptide had no axis- or xnr3-inducing activity in xenopus embryos. these experiments demonstrate that the dually phosphorylated pppspxs peptide is able to activate wnt/β-catenin signaling in embryos, presumably via inhibition of gsk3 phosphorylation of β-catenin in vivo.",pmc2654145,1,0.1,39,1,39.1
561,gsk3,protein,,,uniprot,p49841,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,cell junction,go:0030054,negative,d,phosphorylation,ser33/ser37/thr41,,epithelial,,human,['3121'],nan,nan,"as demonstrated in figure 1, β-catenin phosphorylation by gsk3 in vitro was greatly enhanced by the presence of axin [9], [42]. however, gsk3 can nonetheless phosphorylate β-catenin in vitro, although less efficiently, in the absence of axin [5], [9], [42]. taking advantage of this property, we found that β-catenin phosphorylation at ser33/ser37/thr41 by gsk3 in the absence of axin was also inhibited by the phos-a peptide in a dose-dependent manner (figure 4e). as in the presence of axin (figure 3b), the a-mut peptide had little or no effect on β-catenin phosphorylation by gsk3 in the absence of axin (figure 4e). these results suggest that phosphorylated pppspxs motif directly inhibits gsk3 phosphorylation of β-catenin.",pmc2654145,1,0.1,39,1,39.1
559,gsk3,protein,,,uniprot,p49841,cytoplasm,go:0005737,nbr1,protein,,,uniprot,q14596,cytoplasm,go:0005737,positive,d,phosphorylation,,293t,fibroblast-like,kidney,human,['2996'],nan,nan,"figure 1. nbr1 is phosphorylated by gsk3. (a) schematic representation of nbr1 functional protein domains. amino acid positions of phosphorylated threonine and serine residues (letter p in circle) on the human protein are shown. pb1, phox, and bemp1 domain; zz, zz-type zinc finger; cc1 and 2, coiled-coil domains; lir1 and 2, lc3-interacting regions; j, juxta-uba domain (membrane-interacting amphipathic α-helix), uba, ubiquitin-associated domain. alignment of nbr1 amino acids flanking gsk3 putative phosphorylation consensus site shows conservation of threonine and serine residues (indicated by stars) in different species. gray color shows amino acids conserved in all depicted species, and numbers above stars indicate threonine and serine residue positions in the human nbr1 protein. h. sapiens, homo sapiens; m. musculus, mus musculus; g. gallus, gallus gallus; x. tropicalis, xenopus tropicalis; d. rerio, danio rerio. (b) gsk3 in vitro kinase assays. gst-tagged gsk3a or gsk3b forms (wt, wild-type; inactive, gsk3a k148a or gsk3b k85a; active, gsk3a s21a or gsk3b s9a) and wild-type gst-tagged nbr1 proteins were purified from 293t cells and mixed with radioactive γ−32p atp. the upper panel shows radioactive 32p signal and the lower panels show gst-tagged protein amounts revealed with an anti-gst antibody. arrows indicate the bands corresponding to phosphorylation of nbr1 by gsk3, gsk3 autophosphorylation, and total proteins. (c) gsk3 in vitro kinase assays performed with purified active (s9a) or inactive (k85a) gst-gsk3b mutants mixed with wild-type or mutant gst-nbr1. thr581, thr586, and ser590 were mutated to nonphosphorylable alanine (3mut., t581a t586a s590a). lower panel: adjusted phosphorylation signal calculated as the ratio of the relative amount of phosphorylated nbr1 (32p signal) to total gst-nbr1. (d) western blot showing the specificity of an antibody generated against human nbr1 phosphorylated at threonine 586. human hela cells and murine c2c12 cells were transfected with a control sirna targeting luciferase or human or mouse nbr1-specific sirna. (e) western blot showing the level of phospho-nbr1t586 signal in gsk3a−/− mefs cotransfected with plasmids encoding gst or gst-gsk3a forms (wt, wild-type; inactive, k148a; active, s21a) and dsred-nbr1 forms (wt, wild-type; nonphosphorylable, t586a). phosphorylation of nbr1 by endogenous gsk3b is detectable in the absence of wild-type and active gst-gsk3a. the phosphorylation status of this signal was confirmed through treatment of gsk3a−/− mef protein extracts with lambda-phosphatase. (f) confocal pictures showing the immunofluorescence staining of anti-phospho-nbr1t586 in c2c12 myoblasts transfected with wild-type dsred-nbr1 or the nonphosphorylable dsred-nbr1 t586a s590a double mutant. inserts correspond to a magnification of the dotted frame in each picture. right panels are merged pictures showing the presence or absence of colocalization. scale bar: 15 μm. data in this figure are representative of at least 2 independent experiments.",pmc4091167,1,0.1,39,1,39.1
558,gsk3,protein,,,uniprot,p49841,cytoplasm,go:0005737,nbr1,protein,,,uniprot,q14596,cytoplasm,go:0005737,negative,d,phosphorylation,thr586,,muscle,sibm,human,['2994'],nan,nan,"in this work, we show that nbr1 is a substrate of gsk3. nbr1 phosphorylation by gsk3 at thr586 inhibits its adaptor function during the formation of pathological protein aggregates and the selective autophagy of ubiquitinated proteins. interestingly, our work has established a link between nbr1 phosphorylation and protein aggregation in sibm muscle pathology. indeed, we have shown that nbr1 phosphorylation is strongly decreased in muscles of sibm patients and directly correlates with the severity of protein aggregation in these patients. our work thus connects selective autophagy defects and a human muscle pathology.",pmc4091167,1,0.1,39,1,39.1
637,lrp6,protein,,lrp6,uniprot,o75581,plasma membrane,go:0005886,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,i,inhibit,,,colorectal cancer,,human,['2931'],nan,nan,"in the future, it will be quite relevant to verify whether inhibiting lrp6 function can interfere with β-catenin signaling and tumoral properties of human crc cells exhibiting apc mutation with or without kras or braf mutations. this would be a very important finding due to the frequency of such mutations in human crc and the difficulty to target β-catenin, kras and braf.81 in this respect, the potential utility of lrp6 blocking antibodies to inhibit wnt signaling in tumorigenesis was recently demonstrated.82",pmc4687460,1,0.1,39,1,39.1
639,lrp6,protein,,,uniprot,o75581,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,positive,d,phosphorylation,ppps/tp motifs,,iecs,,,['2930'],nan,nan,"in presence of wnt, lrp6 is phosphorylated within the ppps/tp motifs by gsk3β and multiple ck1 members, providing docking sites to bind axin1 and gsk3, thereby sequestering both proteins away from the β-catenin destruction complex.73, 74 however, in our cell models, blockade of mek reduced lrp6 phosphorylation and decreased β-catenin nuclear localization and transcriptional activity without affecting β-catenin expression. one could speculate that phosphorylation of lrp6 by erk triggers a signaling cascade controlling β-catenin nuclear localization and activity, independently of axin or the degradation complex. such signaling cascade operating in parallel with β-catenin stabilization has recently been documented in other biological systems.75 indeed, activation of lrp6/rac1/jnk2 signaling has been suggested to mediate nuclear accumulation of β-catenin independently of its stabilization during canonical wnt signaling in stromal cells from the bone marrow.75 intriguingly, in our cell models such as kras-transformed iecs, jnk activity seems to control especially lrp6 expression and not phosphorylation suggesting that lrp6 can be regulated at multiple levels. hence, the question of how mek-dependent phosphorylation of lrp6 promotes β-catenin transcriptional activity remains unresolved and will need to be addressed in the future.",pmc4687460,1,0.1,39,1,39.1
556,gsk3,protein,,gsk3b,uniprot,p49841,nucleus,go:0005634,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,negative,d,phosphorylation,ser33/ser37/thr41,hek293t,,,human,['3120'],nan,nan,"a. different axin constructs used in this study, the full length axin (amino acid 1–863), axinδdix (1-773), and axin(351-701) are shown. b. purification of the full length axin, axinδdix, and axin(351-701) proteins. these flagged tagged axin and axin fragments were expressed in hek293t cells, purified via m2 agarose (sigma) resin, and eluted by 0.2 mg/ml flag peptides. c and d. the phos-a peptide inhibited gsk3 phosphorylation of β-catenin in the presence of the full length axin, or axinδdix (c), or axin(351-701) (d). four-fold serial dilutions of the phos-a peptide were tested as in figure 3. the a-mut peptide was added at the concentration equivalent to that of phos-a without dilution (10 µm). the phosphorylation reaction products were analyzed using an anti-phospho-ser33/ser37/thr41 β-catenin antibody. e. inhibition of gsk3 phosphorylation of β-catenin by phos-a was independent of axin. four-fold serial dilutions of the phos-a peptide (10 µm, 2.5 µm, and 0.63 µm) were included in the β-catenin phosphorylation assay in the absence or presence of axin. the a-mut peptide was added at the concentration equivalent to that of phos-a without dilution (10 µm). the phosphorylation reaction products were analyzed using an anti-phospho-ser33/ser37/thr41 β-catenin antibody. note that in order to achieve and visualize β-catenin phosphorylation by gsk3 in the absence of axin (lanes 1–5), 5-fold excess amount of gsk3 (2.2 µm) was employed compared to that in the presence of axin (lanes 6–10), and the film was overexposed. f. β-catenin ser45 phosphorylation by ck1 was not affected by phos-a, used at 10 µm and 2.5 µm. a-mut was at 10 µm. the phosphorylation reaction products were analyzed using an anti-phospho-ser33/ser37/thr41 β-catenin antibody and an anti-phospho-ser45 β-catenin antibody.",pmc2654145,1,0.1,39,1,39.1
640,lrp6 intracellular domain,protein,,,uniprot,o75581,nucleus,go:0005634,β-catenin,protein,,ctnnb1,uniprot,p35222,cell membrane,go:0005886,negative,d,inhibits,,xenopus egg extracts,,egg,xenopus,['3132'],nan,nan,"cselenyi et al recently reported that the recombinant lrp6 intracellular domain directly inhibits gsk3 phosphorylation of β-catenin in xenopus egg extracts and in a reconstituted in vitro kinase assay similar to the one employed in this study [41]. they found that the inhibition of gsk3 by the lrp6 intracellular domain is direct and axin-independent, and requires the intact pppspxs motifs [41]. while cselenyi et al tested the lrp6 intracellular domain at a single concentration, our experiments examined each individual phosphorylated pppspxs motif, which represents the minimal signaling module as our previous studies have suggested [34], [35], [37], and we demonstrated dose-dependent inhibition of gsk3 by these phospho-pppspxs peptides at multiple concentrations. overall our results are in good agreement with the main conclusions by cselenyi et al. however, one noticeable difference exists between the results by cselenyi et al and ours regarding the inherent (or the lack of) specificity of phospho-lrp6 inhibition of gsk3 phosphorylation. cselenyi et al reported that the lrp6 intracellular domain specifically inhibits gsk3 phosphorylation of β-catenin, but not of tau [41]. by contrast, we found that the phosphorylated pppspxs peptide also inhibits gsk3 phosphorylation of tau and glycogen synthase (gs, with priming phosphorylation by ck2), and indeed gsk3 phosphorylation of β-catenin and tau appears to be similarly inhibited by different concentrations of the phospho-pppspxs peptide (figure 5). our results suggest a general inhibition of gsk3 activity by the phosphorylated pppspxs peptide, and are consistent with an earlier study demonstrating that the lrp6 intracellular domain can inhibit gsk3 phosphorylation of both β-catenin and tau [51]. we note that our findings are fully compatible with specific inhibition of β-catenin phosphorylation by wnt signaling (see below).",pmc2654145,1,0.1,39,1,39.1
882,platelet-derived growth factor receptor,protein,,pdgfra,uniprot,p16234,cell membrane,go:0005886,nanog,protein,transcription factor,nanog,uniprot,q9h9s0,nucleus,go:0005634,negative,d,regulates,,,mesenchymal stem cell,,human,['1873'],nan,nan,"inhibition of platelet-derived growth factor receptor signaling regulates oct4 and nanog expression, cell shape, and mesenchymal stem cell potency",pmc3537888,1,0.1,39,1,39.1
881,pkcδ,protein,,,uniprot,q05655,cytoplasm,go:0005737,hur,protein,,elavl1,uniprot,q15717,cytoplasm,go:0005737,positive,d,phosphorylation,"s221, s318",,mesangial,human mesangial cells,human,['2211'],nan,nan,"protein kinase c (pkc)α was reported to phosphorylate hur at s158 and s221 while pkcδ was phosphorylated hur at s221 and s318 [41, 58, 65, 66]. pkcα and pkcδ were implicated in the cytoplasmic export of hur, its enhanced association with target transcripts (e.g., cox-2, cyclin d1, and cyclin a mrnas), and their stabilization [41, 58, 65, 66]. doller and coworkers primarily examined the effect of angiotensin ii (angii) in human mesangial cells, uncovering a complex set of regulatory features. however, pkc is a bona fide dna damage response kinase [39, 67]. the influence of pkc on hur-modulated gene expression is a promising area for future study.",pmc2925474,1,0.1,39,1,39.1
858,phlpp2,protein,,,uniprot,q96jb8,cytoplasm,go:0005737,akt3,protein,,akt3,uniprot,q9y243,cytoplasm,go:0005737,negative,d,dephosphorylation,ser473,,,,,['4'],nan,nan,"recently, a family of novel protein phosphatases, namely, phlpp (ph domain and leucine-rich repeat protein phosphatase), have been identified as important regulators of akt kinases and protein kinase c (pkc) [33–35]. two isoforms, phlpp1 and phlpp2, directly dephosphorylate ser473 and therefore inactivate akt. it has been shown that phlpp differentially terminates akt signaling by regulating distinct akt isoforms. phlpp2 dephosphorylates akt1 and akt3, whereas phlpp1 is specific for akt2 and akt3 [35]. several lines of evidence suggest that phlpp functions as a tumor suppressor. phlpp expression is commonly lost in cancer, including colon, breast, ovarian, wilms tumors, and prostate cancer [33, 36, 37]. overexpression of phlpp1 in a glioblastoma cell line inhibits tumor growth in xenografted nude mice [34], and decreased expression of phlpp has been linked to the metastatic potential of 21t breast cancer cells [38]. codeletion of phlpp1 and pten is strongly associated with metastatic prostate cancer and tightly correlated to deletion of p53 and phlpp1, suggesting the role of phlpp as a prostate tumor suppressor [37].",pmc3317191,1,0.1,39,1,39.1
854,pgc-1α,protein,,ppargc1a,uniprot,q9ubk2,nucleus,go:0005634,cdk4,protein,,cdk4,uniprot,p11802,cytoplasm,go:0005737,positive,d,inhibitor,,u-2os,osteosarcoma,,human,['1288'],nan,nan,"to discover new factors that can regulate pgc-1α activity through its acetylation status, a high throughput enzyme-linked immunoassay was designed to specifically and quantitatively monitor the level of pgc-1α acetylation in u-2os cells (extended data fig. 1a). a library of 1600 compounds, including bioactive and natural compounds, was screened (fig. 1a). interestingly, the compound with the highest z score for pgc-1α deacetylation was fascaplysin, a known cdk4 inhibitor12 (extended data fig. 1b). cdk4 regulates g1 to s phase transition and its kinase activity is dependent on its binding to one of the three d-type cyclins including cyclin d113. we, therefore, investigated the effect of this cell cycle complex on pgc-1α acetylation and function, in connection to nutrient and insulin metabolic actions.",pmc4076706,1,0.1,39,1,39.1
853,pgc-1α,protein,,ppargc1a,uniprot,q9ubk2,,,gcn5,protein,,,uniprot,q92830,,,negative,d,acetylation,,,,,,['1287'],nan,nan,"insulin constitutes a major evolutionarily conserved hormonal axis for maintaining glucose homeostasis1-3; dysregulation of this axis causes diabetes2,4. pgc-1α links insulin signaling to the expression of glucose and lipid metabolic genes5-7. gcn5 acetylates pgc-1α and suppresses its transcriptional activity, whereas sirt1 deacetylates and activates pgc-1α8,9. although insulin is a mitogenic signal in proliferative cells10,11, whether components of the cell cycle machinery contribute to insulin’s metabolic action is poorly understood. herein, we report that insulin activates cyclin d1-cdk4, which, in turn, increases gcn5 acetyltransferase activity and suppresses hepatic glucose production independently of cell cycle progression. through a cell-based high throughput chemical screen, we identified a cdk4 inhibitor that potently decreases pgc-1α acetylation. insulin/gsk3β signaling induces cyclin d1 protein stability via sequestering cyclin d1 in the nucleus. in parallel, dietary amino acids increase hepatic cyclin d1 mrna transcripts. activated cyclin d1-cdk4 kinase phosphorylates and activates gcn5, which then acetylates and inhibits pgc-1α activity on gluconeogenic genes. loss of hepatic cyclin d1 results in increased gluconeogenesis and hyperglycemia. in diabetic models, cyclin d1-cdk4 is chronically elevated and refractory to fasting/feeding transitions; nevertheless further activation of this kinase normalizes glycemia. our findings show that insulin uses components of the cell cycle machinery in post-mitotic cells to control glucose homeostasis independently of cell division.",pmc4076706,1,0.1,39,1,39.1
852,pgc-1α,protein,,ppargc1a,uniprot,q9ubk2,,,cdk4,protein,kinase,cdk4,uniprot,p11802,,,negative,d,deacetylation,,,,,,['1289'],nan,nan,"first, we calculated an ic50 of 0.7μm for fascaplysin-induced pgc-1α deaceylation, which is similar to its ic50 for cdk4 inhibition (extended data fig. 2a). fascaplysin-induced pgc-1α deacetylation overlapped with rb dephosphorylation, a well-characterized cdk4 substrate14 (fig. 1b). pd 0332991, the most specific cdk4 inhibitor available15, led to a similar decrease of pgc-1α acetylation (fig. 1c, extended data fig. 2b). furthermore, cdk4 depletion through transient shrna transfection had the same effect as chemical inhibitors, confirming that cdk4 activity controls pgc-1α acetylation levels (fig. 1d, extended data fig. 2c).",pmc4076706,1,0.1,39,1,39.1
850,pdgfrβ,protein,,,uniprot,p09619,plasma membrane,go:0005886,cabl,protein,,,uniprot,p00519,nucleus,go:0005634,negative,d,inhibition,nucleus,,,,human,['1883'],nan,nan,"we confirmed that phosphorylation levels of pdgfrα and pdgfrβ were suppressed by both pdgfr inhibitor-iv (supporting information fig. s1a, s1c) and pdgfr inhibitor-v (supporting information fig. s1b). an important distinction between the two compounds is that pdgfr inhibitor-iv also inhibits cabl activity (ic50 = 22 nm), while pdgfr inhibitor-v has little or no effect on cabl (ic50 > 1 μm) (supporting information table 1). these differential effects on cabl phosphorylation were also confirmed (supporting information fig. s1d), including the efficiency of pdgfr inhibitor-iv in suppressing nuclear cabl phosphorylation (supporting information fig. s1e). these results demonstrated that the combined inhibitory effects of pdgfr inhibitor-iv on pdgfr and cabl signaling upregulated oct4 and nanog expression.",pmc3537888,1,0.1,39,1,39.1
848,pdgfrα,receptor,,pdgfra,uniprot,p16234,plasma membrane,go:0005886,nanog,protein,,nanog,uniprot,q9h9s0,nucleus,go:0005634,positive,d,knockdown,,,stem cell,,mouse,['1887'],nan,nan,"rt-pcr (fig. 3b) and quantitative rt-pcr (fig. 3c) demonstrated that while pdgfrα knockdown increased oct4a (2.7 ± 0.4-fold) and nanog (1.4 ± 0.2-fold), pdgfrβ or cabl knockdown produced a higher level of oct4a (3.6 ± 0.6-fold and 3.0 ± 0.3-fold, respectively) and nanog (2.5 ± 0.3-fold and 1.8 ± 0.2-fold respectively). pdgfrα or pdgfrβ knockdowns also increased oct4b, but cabl knockdown had less effect on oct4b expression (fig. 3b), suggesting that cabl knockdown preferentially increased the oct4a isoform.",pmc3537888,1,0.1,39,1,39.1
847,pdgfr,receptor,,pdgfra,uniprot,p16234,cell membrane,go:0005886,nanog,transcriptionfactor,,nanog,uniprot,q9h9s0,nucleus,go:0005634,negative,i,inhibition,,,mesenchymal stem cell,,,['1905'],nan,nan,"taken together, these results demonstrate that mscs pretreated with pdgfr inhibitor-iv can be induced to differentiate toward all three germline lineages, demonstrating their increased multipotency. this study therefore identifies inhibition of pdgfr signaling as a primary regulator of oct4 and nanog expression and of msc potency.",pmc3537888,1,0.1,39,1,39.1
845,pdgfr,protein,,,uniprot,p09619,plasma membrane,go:0005886,cabl,protein,,abl1,uniprot,p00519,cytoplasm,go:0005737,negative,d,block,,,mesenchymal stem cell (msc),,human,['1877'],nan,nan,"based on the premise that selective inhibition of signaling pathways involved in msc differentiation may enhance multipotency, we used a small molecular inhibitor [20] to block pdgfr and downstream cabl signaling, which induced a more rounded msc shape. this inhibition produced a pronounced increase in oct4 and nanog levels, which was regulated by janus kinase (jak)-signal transducer and activator of transcription 3 (stat3) signaling and actomyosin contractility. these mscs were induced to express definitive markers for ectoderm, endoderm, and mesoderm lineages, demonstrating their increased multipotency. this study demonstrates that inhibition of pdgfr signaling is an important regulator of oct4 and nanog expression and of msc potency.",pmc3537888,1,0.1,39,1,39.1
844,pdgf,protein,,pdgfa,uniprot,p04085,cytoplasm,go:0005737,cabl,protein,,abl1,uniprot,p00519,cytoplasm/nucleus,go:0005737/go:0005634,positive,i,activation,,,neuron,,human,['1909'],nan,nan,"pdgf-induced activation of cytoplasmic cabl plays an important role in mediating actin assembly and regulation of cell shape [13]. in neurons, inhibition of cabl signaling can reduce rhoa-rock activity and actomyosin contraction [43]. however, the resulting effect is dependent on the cellular context; therefore, the outcome will likely be determined by the balance between rac and rho and the effects of other signaling molecules regulated by the rho-rock pathway. in this study, we demonstrated cabl (y412) in nuclear extracts, which suppressed pdgfr inhibition. thus inhibiting cabl signaling may not only increase oct4 expression indirectly by decreasing actomyosin tension but may also regulate cellular differentiation due to reduced nuclear cabl activity.",pmc3537888,1,0.1,39,1,39.1
843,pabp,protein,,pabpc1,uniprot,p11940,cytoplasm,go:0005737,eif3b,protein,,eif3b,uniprot,o00303,cytoplasm,go:0005737,positive,d,immunostaining,sgs,u2os,osteosarcoma,,human,['137'],nan,nan,"accumulation of major translation initiation factors in selenite-induced sgs. the localization of pabp, eif4g (top row, red and blue, respectively), eif4e (second row, red), eif4a1 (third row, red) and eif3b (bottom row, red) was probed by immunostaining of selenite-treated u2os cells. arrows indicate sg localization, whereas arrowheads indicate the lack of enrichment in sgs. bar = 10 µm.",pmc3439927,1,0.1,39,1,39.1
841,p70s6k,proteinkinase,serine/threonine,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,pdcd4,protein,,pdcd4,uniprot,q53el6,cytoplasm,go:0005737,positive,d,phosphorylation,,,cancer,lung,human,['3018'],nan,nan,"as a serine/threonine protein kinase of the agc kinase family, p70s6k is phosphorylated by different growth factors and insulin-like factors through the pi3k/mtor pathway, and interacts with s6, eif4b, eef2k, pdcd4 and many other substrates; this is important for mitogen-induced cell proliferation, survival, motility and chemotherapy drug resistance in cancer cells [3]. recent studies demonstrated that overexpression of p70s6k and p-p70s6k in various tumor tissues is important in predicting poor prognosis, and contributes to chemotherapy resistance [4–14]. in vitro overexpression of p70s6k promotes cell proliferation, angiogenesis, and apoptosis suppression [15, 16]. meanwhile, s6k1 knockdown inhibits p70s6k expression and significantly reduces cell proliferation, decreasing tumor formation in nude mice [17]. moreover, p70s6k and p-p70s6k levels are significantly higher in tumors than in normal tissues from nsclc patients [18, 19]. our previous study showed that p-p70s6k is closely related to long-term survival in nsclc [20]. therefore, p70s6k plays an important role in nsclc, and assessment of high specificity p70s6k inhibitors could help further define this new therapeutic target for clinical application.",pmc4714881,1,0.1,39,1,39.1
792,p27,protein,,cdkn1b,uniprot,p46527,nucleus,go:0005634,d-type cyclin-cdk4 complexes,complex,cdk4,cdk4,uniprot,p11802,nucleus,go:0005634,positive,d,nuclear import,,,variety of cell systems,,,['1510'],nan,nan,"to conclude, the instrumental role of the up-regulation by mitogenic treatments of either p21 or p27 in the required nuclear import of d-type cyclin-cdk4 complexes is well demonstrated in a variety of cell systems. it appears to be dominant over mechanisms that promote nucleus export of cdk4 and d-type cyclins, including the gsk3β-dependent phosphorylation of cyclin d1. a significant role for posttranslational modifications of p21 and p27 in the regulation of this process has yet to be firmly demonstrated.",pmc1647274,1,0.1,39,1,39.1
769,noxa1,protein,,,uniprot,q96d21,cytoplasm,go:0005737,tks4,protein,,sh3pxd2a,uniprot,o14976,cytoplasm,go:0005737,negative,d,binding,tyr110,,,,,['1367'],nan,nan,the abolishment of noxa1 phosphorylation on tyr110 blocks its binding to tks4 and decreases nox1-dependent ros generation,pmc2993755,1,0.1,39,1,39.1
765,nic1,protein,,,uniprot,p46531,nucleus,go:0005634,maml1,protein,,maml1,uniprot,q92585,nucleus,go:0005634,positive,d,association,,,,,human,['600'],nan,nan,"we established that the egta-induced hes1 expression required transcriptional events (figure 1c) supporting a model whereby the released nic1 translocates towards the nucleus to impact (hes1) gene expression. inherent to this, the association of nic1 with its dna-binding partner csl and the co-activator maml1, hence forming a functional transcriptional unit, is certainly a prerequisite to gene modulation [1,2]. therefore, to begin delineating the mechanisms that account for the positive impact of the mek/erk pathway on notch signalling, we investigated whether activation of the mek/erk pathway could promote the association of nic1 with either csl or maml1. as opposed to nic1, csl and maml1 expression levels were not modulated upon egta treatment (figure 5a). consequently, we immunoprecipitated csl and maml1 and tested nic1 association. following a pulse of notch1 activation, higher levels of nic1 were found associated with either csl or maml1 (figure 5b) again reinforcing our model whereby, upon egta-mediated notch1 activation, the released nic1 assembles into an active transcriptional complex to modulate gene expression. interestingly, as compared to dmso-treated cells, treatment with pma promoted by nearly 2-fold the association of nic1 with either csl (figure 5c) or maml1 (figure 5d). the addition of u0126 prevented both the pma-induced nic1/csl and nic1/maml1 association (figure 5c-d) supporting mek-dependent mechanisms.",pmc3877363,1,0.1,39,1,39.1
764,nbr1,protein,,,uniprot,o60749,cytoplasm,go:0005737,gsk3,protein,,,uniprot,p49841,cytoplasm,go:0005737,negative,d,phosphorylation,,c2c12 myoblasts,muscle,,human,['3000'],nan,nan,"two hypotheses could explain the decrease of protein aggregation resulting from nbr1 phosphorylation by gsk3. nbr1 phosphorylation could either prevent protein aggregate formation or stimulate their degradation through autophagy. using an inhibitor of lysosomal degradation, bafilomycin a1, we thus tested if the decrease in aggregates observed with gsk3 activation in muscle cells was due to aggregate degradation via autophagy. after transfection of c2c12 myoblasts with wild-type gsk3a and gsk3a activity mutants, cells were treated with puromycin, in the presence or absence of bafilomycin a1. we then performed a detergent separation of puromycin-induced aggregates (fig. 3a). in the presence of bafilomycin a1, nbr1, sqstm1, and ubiquitinated proteins were still less accumulated in the detergent-insoluble fraction of cells expressing wild-type and active gsk3 as compared with cells expressing inactive gsk3, and control cells. therefore, the decrease of protein aggregation in muscle cells caused by gsk3 activation is not due to their degradation in lysosomes.",pmc4091167,1,0.1,39,1,39.1
763,nbr1,protein,autophagy receptor,nbr1,uniprot,q14596,cytoplasm,go:0005737,map1lc3/lc3,protein,microtubule-associated protein 1 light chain 3,map1lc3/lc3,uniprot,q9gzq8,cytoplasm,go:0005737,positive,d,binds,,,,,human,['2989'],nan,nan,"the autophagy receptor nbr1 (neighbor of brca1 gene 1) binds ub/ubiquitin and the autophagosome-conjugated map1lc3/lc3 (microtubule-associated protein 1 light chain 3) proteins, thereby ensuring ubiquitinated protein degradation. numerous neurodegenerative and neuromuscular diseases are associated with inappropriate aggregation of ubiquitinated proteins and gsk3 (glycogen synthase kinase 3) activity is involved in several of these proteinopathies. here we show that nbr1 is a substrate of gsk3. nbr1 phosphorylation by gsk3 at thr586 prevents the aggregation of ubiquitinated proteins and their selective autophagic degradation. indeed, nbr1 phosphorylation decreases protein aggregation induced by puromycin or by the des/desmin n342d mutant found in desminopathy patients and stabilizes ubiquitinated proteins. importantly, decrease of protein aggregates is due to an inhibition of their formation and not to their autophagic degradation as confirmed by data on atg7 knockout mice. the relevance of nbr1 phosphorylation in human pathology was investigated. analysis of muscle biopsies of sporadic inclusion body myositis (sibm) patients revealed a strong decrease of nbr1 phosphorylation in muscles of sibm patients that directly correlated with the severity of protein aggregation. we propose that phosphorylation of nbr1 by gsk3 modulates the formation of protein aggregates and that this regulation mechanism is defective in a human muscle proteinopathy.",pmc4091167,1,0.1,39,1,39.1
670,mst1,protein,,mst1,uniprot,q13043,cytoplasm,go:0005737,yap,protein,,yap1,uniprot,p46937,nucleus,go:0005634,negative,d,phosphorylation,,,,,mammal,['2391'],nan,nan,"the hippo pathway is involved in tumor suppressor signaling and regulates organ size, cell proliferation, apoptosis and stemness [9,10,15,16]. in mammals, the core components of the hippo pathway are primarily composed of mst1/2 and lats1/2, which inactivate the hippo effector yap/taz via phosphorylation [17–22]. yap/taz acts as a transcriptional co-activator by binding the transcription factors tead1–4 to induce the expression of genes such as the connective tissue growth factor ctgf [18,23,24]. fat4 has been shown to repress yap activity and thereby negatively regulates neural progenitor cell proliferation during mammalian neurogenesis [25,26]. thus, the fat4-hippo axis is believed to be functionally conserved in humans; however, the functional significance and the molecular mechanisms that confer this axis are poorly understood.",pmc4334522,1,0.1,39,1,39.1
667,men1,protein,,men1,uniprot,o00255,,,cdk4,protein,,cdk4,uniprot,p11802,,,positive,i,driving force,,,,pituitary,mouse,['3143'],nan,nan,"previous studies demonstrated that men1+/− mice develop tumors in the anterior pituitary with a latency of 9-13 months 3, 4. cdk4−/− mice exhibit hypoplasia of the anterior pituitary and pancreatic islets during postnatal periods, while embryonic development of these endocrine tissues occurs normally 21-23. to determine whether cdk4 activity is required for tumorigenesis initiated by the loss of menin, men1+/−; cdk4−/− mice were generated by crossbreeding and characterized in comparison with men1+/−; cdk4+/+ (cdk wild-type) littermates. mice were euthanized at 15 months of age for pathological examinations. none of 12 wild-type (men1+/+) mice generated from the breeding displayed pituitary tumors, while 45% of men1+/− mice (n=31) showed pituitary tumors (fig. 1a, b). it is noteworthy that no men1+/− males exhibited macroscopic pituitary tumors at 15 months of age (n=11), whereas 14 (70%) of 20 men1+/− female mice had developed pituitary tumors. this gender-specific effect on pituitary tumorigenesis is consistent with a previous study, which showed 79% of men1+/− mice that developed pituitary tumors were females 4. strikingly, none of 30 men1+/−; cdk4−/− mice (11 males and 19 females) displayed pituitary tumors. these observations indicate that pituitary tumorigenesis induced by menin deficiency depends on cdk4 activity. furthermore, the pituitaries from the entire cohort of men1+/−; cdk4−/− mice remained hypoplastic, in a manner similar to the single cdk4−/− mice throughout their 15-month lifespan (fig. 1a). our previous study demonstrated that cdk4 is an essential driving force for estrogen- or ghrh-induced proliferation in murine pituicytes 23. thus, these data indicate that cdk4 is required for both physiological and tumorigenic control of cell cycle progression in this particular endocrine tissue.",pmc4135037,1,0.1,39,1,39.1
222,cd40,protein,,,uniprot,p25942,cell membrane,go:0016020,tlr7,protein,,,uniprot,q9nyk8,endosome,go:0005768,positive,d,stimulation,,purified b lymphocytes,b-cell,,,['197'],nan,nan,purified b lymphocytes were stimulated through both cd40 and tlr7 for,pmc3084876,1,0.1,39,1,39.1
665,men1,gene,,men1,hgnc,681,,,cdk2,protein,,cdk2,uniprot,p24941,,,negative,d,deficiency,,,,,human,['3147'],nan,nan,"it is well established that endocrine tumors that arise in men1+/− humans and men1+/− mice exhibit loh 3, 4, which is consistent with the classical “two-hit” model of tumorigenesis operative with inactivation of tumor suppressor genes 26. in order to determine whether cdk2 or cdk4 deficiency had a differential impact on men1 loh, we examined whether loh had occurred at the men1 locus in pituitary tissues and tumors from men1+/− mice with cdk4−/−, cdk2−/− and cdk-wild type backgrounds. genomic pcr analyses unambiguously indicated that pituicytes in men1+/−; cdk wild-type mice and men1+/−; cdk2−/− mice underwent loh, i.e., the loss of the wild-type men1 allele in genomic dna, while livers from those mice as non-tumorigenic control tissues retained both wild-type and mutant alleles (fig. 4, compare lanes 4, 8 to lanes 3, 7). in contrast, pituitary tissues from men1+/−; cdk4−/− mice showed no sign of loh (fig. 4, lane 6). these results suggest that cdk4 deficiency impedes early tumorigenic changes in men1+/− pituicytes that normally occur in prior to the complete loss of menin expression. in contrast, cdk2 deficiency does not alter loh that occurs as part of the multi-step tumorigenic process.",pmc4135037,1,0.1,39,1,39.1
664,membrane-bound gab1,protein,,gab1,uniprot,q13480,plasma membrane,go:0005886,shp2,protein,phosphatase,ptpn11,uniprot,q06124,plasma membrane,go:0005886,positive,d,binding,plasma membrane,,,,human,['2683'],nan,nan,"an increase in the phosphorylation level of membrane-bound gab1 promotes grb2–sos binding, increasing the sos concentration in close proximity to ras (kholodenko et al, 2000). at the same time, this gain in phospho-gab1 also increases the amount of rasgap (ras deactivator) and the phosphatase shp2 bound to gab1. in the model, this phosphatase negatively regulates the level of phosphorylated receptors, irs, and gab1; yet it has the pronounced positive effect on ras activation, as we showed using a specific shp2 inhbitor, nsc-87877 (supplementary figure s9a). this positive effect is related to the formation of the gab1–shp2 and irs–shp2 complexes in close proximity to the plasma membrane and subsequent dephosphorylation of the docking sites on egfr, ir, gab1, and irs, which are involved in rasgap binding. thus, shp2 has an essential role in inhibiting rasgap-catalyzed ras deactivation, only if there is a strong activatory signal to ras arising from egf co-stimulation, whereas the irs–shp2 complexes cannot effectively activate ras on their own. simulations predict that the net result of these insulin plus egf-induced interactions is an increase in positive signaling and decrease in negative signaling to ras. this amplifies the ras-gtp level, which is corroborated by the experimental data (figure 3a).",pmc2683723,1,0.1,39,1,39.1
557,gsk3,protein,,,uniprot,p49841,cytoplasm,go:0005737,nbr1,protein,,,uniprot,o60563,cytoplasm,go:0005737,positive,i,phosphorylation,t586,,muscle,skeletal,mouse,['3001'],nan,nan,"to further exclude the role of autophagy in gsk3-nbr1-mediated clearance of protein aggregates, we used atg7 muscle-specific knockout mice. atg7 belongs to the autophagy conjugation system and is crucial for lc3 lipidation and autophagosome formation. atg7 deletion in skeletal muscles results in severe muscle atrophy and accumulation of protein aggregates containing ubiquitinated proteins and sqstm1.38 immunostaining with anti-nbr1 revealed that sqstm1-positive aggregates also contained nbr1 (fig. s2a). interestingly, muscle fibers of atg7 muscle-specific knockout mice, which were highly positive for phospho-nbr1t586 immunostaining, systematically contained smaller sqstm1 aggregates compared with neighboring fibers (fig. s2b). this is consistent with a role of phospho-nbr1t586 in aggregation inhibition. adult muscles of autophagy-deficient mice were electroporated with inactive and active gsk3 mutants and the percentages of transfected fibers containing no aggregate or sqstm1-positive aggregates were quantified (fig. 3b). despite the context of autophagy inhibition, active gsk3 still decreased the proportion of fibers containing aggregates. expression of the 3 different forms of nbr1 (wild type, nonphosphorylable, or phosphomimetic) by electroporation in atg7 knockout mice induced the formation of nbr1, ub, and sqstm1-positive speckles in a similar proportion, showing that ectopic nbr1 destabilized aggregates (size > 1-μm diameter) independently of its phosphorylation status to favor speckles (size < 1-μm diameter) (fig. 3c; fig. s2d). in addition, phosphorylation of nbr1 by gsk3 had an impact on remaining aggregates. indeed, wild-type and phosphomimetic nbr1 mutants decreased the proportion of fibers containing protein aggregates as compared with muscles transfected with nonphosphorylable nbr1. the phosphorylation status of ectopic wild-type nbr1 was confirmed by immunostaining of muscle sections performed with anti-phospho-nbr1t586 antibody (fig. s2c). importantly, large sqstm1-positive aggregates almost disappeared when phosphomimetic nbr1 was expressed in adult autophagy-deficient fibers suggesting that nbr1 is able to affect pre-existing sqstm1-positive aggregates. in conclusion, phosphorylation of nbr1 by gsk3 decreases protein aggregation both in cultured cells and in vivo in mice in an autophagy-independent manner, strongly suggesting that gsk3-mediated nbr1 phosphorylation affects the process of protein aggregation.",pmc4091167,1,0.1,39,1,39.1
555,gsk3,protein,,gsk3a,uniprot,p49841,,,nbr1,protein,,nbr1,uniprot,q14596,,,negative,d,inhibits,adaptor function,hela,epithelial,cervical,human,['3003'],nan,nan,"figure 4. gsk3-mediated phosphorylation inhibits nbr1 adaptor function and this prevents the selective autophagy of ubiquitinated proteins. (a) western blot of detergent-soluble (supernatant) and detergent-insoluble (pellet) fractions of hela cells treated with puromycin. endogenous phospho-nbr1t586, total nbr1, sqstm1, and tuba1a/α-tub (tubulin, α) (loading control) were analyzed by western blot. arrows show bands that have been found to be specific in nbr1-specific sirna experiments. the proportion of total nbr1 and phospho-nbr1t586 present in the insoluble fraction was calculated as the ratio of (signal of x in pellet fraction * 100)/(signal of x in supernatant fraction + signal of x in pellet). 24% of phospho-nbr1t586 is present in the detergent-insoluble fraction whereas 74% of total nbr1 is contained in this fraction. (b) western blot of extracts from c2c12 myoblasts transfected with gst or gst-gsk3a forms (wt, wild-type; inactive, k148a; active, s21a). cells were treated with chx and proteins were extracted at different time points to determine nbr1 stability. ectopic nbr1 was detected with anti-nbr1 antibody and the same patterns were observed with anti-gfp antibody (not shown). lower panel: quantification of the percentage of nbr1 (left) and of ubiquitinated proteins (right) degradation after 6 h of chx treatment compared with their initial amounts. half-life time extrapolations calculated from the quantifications of western blot are shown in rectangles. data are mean of 3 independent experiments. error bars represent standard deviations. *p < 0.05, student t test. (c) western blot of extracts from c2c12 myoblasts transfected with wild-type or mutant egfp-nbr1 and treated with chx. lower panel: quantification of the percentage of egfp-nbr1 (left) and of ubiquitinated proteins (right) degradation after 6 h of chx treatment compared with their initial amounts. half-life time extrapolations calculated from quantifications of western blot are shown in rectangles. data are mean of 3 independent experiments. error bars represent standard deviations. *p < 0.05, student t test.",pmc4091167,1,0.1,39,1,39.1
483,foxo3a,protein,transcription factor,foxo3,uniprot,o43524,nucleus,go:0005634,ccng2,protein,cyclin,ccng2,uniprot,q16576,nucleus,go:0005634,positive,d,binds,upstream,,,,human,['505'],nan,nan,"computational predictions of foxo and e-box binding sites were verified by chip assays. binding of foxo3a, and to a lesser extent foxo1, was detected to predicted sites upstream of 10 genes that were induced in response to inhibition of pi 3-kinase, including atrogin-1, ccng2 and txnip18 (figure 3a). these foxo target genes included one gene whose induction was independent of p53 (pdk4), as well as nine genes whose induction was inhibited by expression of dominant-negative p53 (aspn, atrogin-1,ccng2, gadd45a, flcn, hbp1, hoxc5, tp53inp1 and txnip). similarly, binding of mitf was detected to predicted e-box sites upstream of six of the genes induced by inhibition of pi 3-kinase (figure 3b). usf1 bound to the predicted e-box sequences upstream of the same six genes targeted by mitf, as well as to sequences upstream of nr1d1 (figure 3c). as in the case of foxo, the genes targeted by mitf and usf1 included both genes whose induction was inhibited (atrogin-1, ccng2, gadd45a, hbp1, hoxc5 and txnip) and whose induction was unaffected by dominant-negative p53 (nr1d1).",pmc3481126,1,0.1,39,1,39.1
511,gsk-3beta,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,sirt2,protein,,sirt2,uniprot,q8ixj6,nucleus,go:0005634,positive,d,deacetylation,,,liver,hcc,human,['2033'],nan,nan,"gsk-3beta/beta-catenin signaling plays roles in the sirtuin 2 (sirt2)-mediated transformation in hcc [246]. sirt2 is a member of sirtuin family, which is upregulated in about 50% of hcc patients. increased sirt2 expression is correlated with shorter overall survival [246]. the sirtuins have been associated with oxidative stress and aging [247]. the authors demonstrated that sirt2 regulated activation of akt by its deacetylation [246]. subsequently akt phosphorylated and inactivated gsk-3beta. the beta-catenin-signaling cascade is enhanced and promoted emt and cell migration of hcc cells. together these results suggested that gsk-3beta is probably a tumor suppressor gene in hcc, and the loss of gsk-3beta expression and/or activity may contribute to development of hcc.",pmc4102778,1,0.1,39,1,39.1
508,gsk-3beta,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,beta-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,i,regulation,cytoplasm,,,,,['1995'],nan,nan,"bcl-2-associated x protein (bax) can be phosphorylated by gsk-3beta in neuronal cells. bax phosphorylation by gsk-3beta stimulated the mitochondrial localization of bax. this localization of bax had pro-apoptotic consequences [107]. tp53 activity in colorectal cancer cells (crcs) can be in part regulated by gsk-3beta. these effects of gsk-3beta on tp53 lead to increased levels of bax [108]. gsk-3 can activate the v-maf musculoaponeurotic fibrosarcoma oncogene homolog (maf) transcription factor which enhanced its transforming activity [109]. gsk-3 also serves to regulate the levels of beta-catenin, a key molecule involved in normal development as well as cancer progression [110-119].",pmc4102778,1,0.1,39,1,39.1
507,gsk-3beta,protein,kinase,gsk3b,uniprot,p49841,cytoplasm,go:0005737,noxa,protein,,pmaip1,uniprot,o14788,cytoplasm,go:0005737,positive,i,induction,,melanoma cells,melanoma,,human,['2048'],nan,nan,"certain small molecule inhibitors synergized with gsk-3beta inhibition to result in cell death [299]. the multi-kinase inhibitor sorafenib induced gsk-3beta which actually provides a survival signal in melanoma cells. when a constitutively-active form of gsk3b was introduced into the melanoma cells, elevated levels of anti-apoptotic bcl-2, bcl-xl and survivin were detected while decreased levels of pro-apoptotic noxa were observed. elimination of gsk-3beta activity increased the activity of sorafenib.",pmc4102778,1,0.1,39,1,39.1
506,gsk-3beta,protein,ki mutant,gsk3b,uniprot,p49841,nucleus,go:0005634,beta-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,d,stabilization,,,mammary glands,mammary,mouse,['1999'],nan,nan,"expression of ki gsk-3beta in murine mammary glands can function as dn mutation and promote breast cancer development by stabilizing beta-catenin protein expression [126]. the gsk-3beta ki construct stabilized beta-catenin expression and increased its nuclear localization and upregulated the expression of beta-catenin target genes such as cyclin d1. the gsk-3beta ki gene was driven by a mouse mammary tumor virus long terminal repeat (ltr) which contains sequences that promoted high level expression of the introduced gene in the mammary tissue. expression of the gsk-3beta ki mutant resulted in stabilized beta-catenin expression, beta-catenin nuclear localization, activation of a tcf/lef-dependent reporter construct and increased cyclin-d mrna and protein levels.",pmc4102778,1,0.1,39,1,39.1
503,gsk-3,protein,,,uniprot,p49841,,,ppar-delta,protein,,,uniprot,q03181,,,positive,d,phosphorylation,,,,,,['2017'],nan,nan,"the promyelocytic leukemia (pml)–peroxisome proliferator-activated receptor-delta (ppar-delta)–fatty-acid oxidation (fao) pathway is another pathway which is important in hsc maintenance [201]. gsk-3 regulates this pathway. ppars are regulated by gsk-3 phosphorylation [202]. loss of hsc maintenance can occur after suppression of ppar-delta or inhibition of mitochondria fao. improved hsc maintenance was observed after treatment with ppar-delta agonists. pml regulates ppar signaling and fao which have important roles in hsc maintenance [201]. the asymmetric division of hscs is controlled by this pathway. thus the ppar-fao pathway is a metabolic regulatory switch for the control of hsc fate. ppars are important transcription factors that regulate nutrient sensing and metabolic pathways including fao and fatty acid transport. these studies have important therapeutic implications as small molecule ppar activators and inhibitors have been developed and evaluated for the treatment of obesity and metabolic disorders [203,204].",pmc4102778,1,0.1,39,1,39.1
502,gsk-3,protein,,gsk3b,uniprot,p49841,,,beta-catenin,protein,,ctnnb1,uniprot,p35222,,,negative,d,phosphorylation,,,,,,['1998'],nan,nan,"gsk-3 also functions as a tumor suppressor. gsk-3 can suppress the wnt/beta-catenin pathway by phosphorylating beta-catenin which results in the ubiquitin/proteasome-dependent degradation of beta-catenin. introduction of kinase-inactive (ki), gsk-3beta mutants which presumably functioned as inhibitors of the endogenous wild-type (wt) gsk-3beta protein stimulated wnt signaling and mammary tumorigenesis [126]. enforced expression of kinase-dead (kd) gsk-3beta, which presumably functioned as inhibitors of the wt gsk-3beta protein, promoted tumorigenesis of breast and skin tumors [127]. overexpression of constitutively-active gsk-3beta mutants, in some studies, increased chemosensitivity, cell cycle arrest, and reduced tumorigenicity of breast cancers [128-130]. pharmacological inhibition of gsk-3 induced emt and invasion in breast cancer [89]. in these studies suppression of gsk-3 lead to stabilization of beta-catenin which resulted in elevated c-myc, cyclin-b1 and survivin expression and promoted proliferation and tumorigenesis. there is perhaps a fine balance with gsk-3 whether it functions a tumor suppressor or tumor inducer.",pmc4102778,1,0.1,39,1,39.1
501,gsk-3,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,nanog,protein,transcription factor,nanog,uniprot,q9h9s0,nucleus,go:0005634,negative,d,phosphorylation,,,esc,,human,['2045'],nan,nan,"1i is a selective atp competitive inhibitor of gsk-3. 6-bromoindirubin-3-oxime (bio) and tws119 are also gsk-3 inhibitors. bio inhibited gsk-3 and activated wnt/beta catenin signaling, thereby maintaining the pluripotency of human and mouse escs [208]. continued gsk-3 inhibition or wnt pathway activation promoted esc differentiation into multipotent mesendodermal progenitors or their differential progenitors [293-295]. as stated previously, gsk-3 interacts with the wnt, hh and notch pathways. these interactions can under the appropriate conditions regulate cell fate determination and maintenance of stem cells. gsk-3 can phosphorylate the gli2 transcription factor, which can effect differentiation [296]. the self-renewal of escs was enhanced when they were cultured with leukemia inhibitory factor (lif) and bmp3 and gsk-3 were suppressed. the mechanism responsible for the enhanced self-renewal is not clear. it was proposed that the expression of pluripotency factors such as oct-4 and nanog was prevented in these conditions [295]. gsk-3 may phosphorylate and inactivate other transcription factors associated with pluripotency, such as c-myc and c-jun. 48 derivatives of the gsk-3 inhibitor 1i were synthesized by bone and colleagues. the abilities of these gsk-3 inhibitors to maintain undifferentiated escs were determined. the effectiveness of these compounds on maintaining undifferentiated escs was linked with inhibition of gsk-3 [297]. thus gsk-3 inhibitors may be used to both maintain stem cell pluripotency as well as to expand these cells. these inhibitors may also be effective with induced pluripotent stem cell generation (ipsc) [295].",pmc4102778,1,0.1,39,1,39.1
500,gsk-3,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,beta-catenin,protein,,ctnnb1,uniprot,p35222,"cytoplasm, nucleus","go:0005737, go:0005634",negative,d,phosphorylation,amino terminals domain,,,,human,['2023'],nan,nan,"gsk-3 normally inhibits this pathway as in the absence of wnt ligands; gsk-3 phosphorylates the amino terminals domain of beta-catenin which targets it for ubiquitination and proteasomal degradation. however, when wnt ligands are present, gsk-3 is inactivated. the disheveled (dvl) phosphoprotein is required to transduce a signal from wnt that results in the inactivation of gsk-3beta [216]. as a result, beta-catenin is dephosphorylated and accumulates in the cytoplasm and translocates to the nucleus where it associates with tcf/lefs to become a transcriptional co-activator [29].",pmc4102778,1,0.1,39,1,39.1
499,gsk-3,protein,,gsk3a,uniprot,p49841,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,thr37/46,,mixed,,human,['3392'],nan,nan,"approximately 100 substrates of gsk-3 have been identified to date [17, 19]. recently, several researchers reported about relationships between gsk-3β and akt/mtorc1/4ebp1 pathway [31, 36–38]. however, to our knowledge, only two papers have referred to direct interaction of gsk-3β and 4ebp1 currently [31, 38]. according to shin et al. [31], gsk-3β directly phosphorylates 4ebp1 at thr37/46 and inactivates 4ebp1 activity in breast cancer and normal cell lines, thereby increasing eif4e-dependent protein synthesis and regulating cell proliferation. in addition, they showed that gsk-3β significantly reduced in vivo the size of tumor injected subcutaneously in a mouse xenograft model [31].",pmc4936323,1,0.1,39,1,39.1
498,gsk-3,protein,,gsk3,uniprot,p49841,nucleus,go:0005634,nf-kappab,transcriptionfactor,,nfkb1,uniprot,p19838,nucleus,go:0005634,negative,d,phosphorylation,s468,,epithelial cells,,human,['1992'],nan,nan,"gsk-3 regulates the activity of other transcription factors including nf-kappab [69,71,72], snail [73,74], notch [75,76], forkhead [77], caat-enhancer binding protein (c/ebp) [78]. gsk-3 modifies the activity of other transcription factors frequently implicated in cancer including: activation protein 1 (ap1) [79] and c-myc [70]. gsk-3beta can phosphorylate nf-kappab at s468 which promoted its proteasomal degradation [80]. gsk-3beta also interacted with i-kappabalpha in epithelial cells [81]. other studies have indicated that gsk-3beta suppressed nf-kappab activity by preventing the degradation of ikapabalpha [82]. thus gsk-3beta can regulate nf-kappab activity by multiple mechanisms.",pmc4102778,1,0.1,39,1,39.1
497,gsk-3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,,achn,renal cell carcinoma,kidney,human,['3388'],nan,nan,"to confirm that gsk-3 regulates cell proliferation and 4ebp1 phosphorylation independently of pi3k/akt/mtorc1 pathway, we furthermore investigated inhibitory effects of ar-a014418 in rapamycin-resistant achn (achn/rr) cells that were generated through culturing achn parental (achn/p) cells in progressively higher concentrations of rapamycin from 1nm finally to 1 μm. as shown in fig. 6a, achn/p cells were sensitive to rapamycin in proliferation, but achn/rr cells presented with rapamycin-resistance. in contrast, ar-a014418 suppressed greatly achn/p and achn/rr proliferation in concentration-dependent manner. notably, the concentration-response relation for ar-a014418 did not differ from achn/p and achn/rr cells (fig. 6b). in achn/rr cells, ar-a014418 remarkably inhibited p4ebp1 and ps6rp rapidly and the inhibition had continued constantly even at 48 h. however, phosphorylations of 4ebp1 and s6rp in achn/rr cells were suppressed only mildly and transiently by rapamycin. the phosphorylations almost recovered to the baseline in 24 h (fig. 6c). the findings indicate that gsk-3 inhibition can sufficiently decrease the activities of mtorc1 downstream cascades and overcome rapamycin-resistance in rcc cells.",pmc4936323,1,0.1,39,1,39.1
134,apc,protein,arm domain,apc,uniprot,p25054,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,d,binding,intrinsically disordered region,,,,,['3449'],nan,nan,"11) in the fourth paragraph of the introduction it sounds like the arm domain of apc behaves as an intrinsically disordered domain, but it seems more appropriate to use this description for the 15 and 20r downstream (especially since many β-cat binding ligands are id in the region of binding. please clarify or specify the regions in figure 1a as “intrinsically disordered region, or ird.”",pmc4568445,1,0.1,39,1,39.1
495,gsk-3,protein,beta,gsk3b,uniprot,p49841,cytoplasm,go:0005737,notch1,protein,,notch1,uniprot,p46531,plasma membrane,go:0005886,positive,d,phosphorylation,s/t-p-s/t domains,,,,,['2041'],nan,nan,"notch signaling pathway is regulated by gsk-3. gsk-3beta phosphorylates the nicd. this phosphorylation event up-regulates nicd transcriptional activity by preventing its proteasomal degradation [75]. in contrast to the effects of gsk-3, akt negatively regulates nicd activity [270]. gsk-3beta phosphorylates domains in the nicd of notch1 (s/t-p-s/t) which are important for the nuclear localization of nicd [271]. phosphorylation of these domains by gsk-3beta increased the transcriptional activity of nicd. in contrast, other studies have shown that gsk-3 phosphorylation can decrease notch1 protein levels and its transcriptional activity [272]. beta-catenin could also modulate the transcriptional activity of notch1/nicd [273]. beta-catenin levels are usually increased when gsk-3 is suppressed. other studies have indicated that gsk-3beta phosphorylation of notch downregulates notch activity [274]. some of these differences in the effects of gsk-3 on the phosphorylation of notch observed in the different studies may be related to the different cell lines utilized or culture conditions. different culture conditions or cell lines containing different mutated activated oncogenes activated and tumor suppressor genes inactivatedmay affect notch activity. these studies and others indicate the complex interactions between the gsk-3, wnt/beta-catenin and notch signaling pathways.",pmc4102778,1,0.1,39,1,39.1
494,gsk-3,kinase,,,uniprot,p49841,,,beta-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,negative,d,phosphorylation,s45 of beta-catenin,,,,,['2003'],nan,nan,"since gsk-3 is a kinase with a specific recognition motif present in substrate proteins that it phosphorylates, mutations can occur in certain genes which prevent gsk-3-mediated phosphorylation of the proteins they encode. the mutant proteins may have altered half-lifes as compared to the wt proteins as they may not be subject to proteasomal degradation. for example, mutations changing t58 of c-myc prevented the ability of gsk-3 to phosphorylate c-myc and thus suppressed its proteasomal degradation [138-141]. genetic mutations changing the gsk-3 phosphorylation sites s33, s37, s45 or t41 present in beta-catenin prevented the ability of gsk-3beta to phosphorylate beta-catenin and thus inhibited its proteasomal degradation. likewise mutations at s45 of beta-catenin prevented cki from performing the priming phosphorylation, thus gsk-3 was unable to phosphorylate the other residues of beta-catenin. thus mutations at gsk-3 or cki phosphorylation sites which prevent the ability of gsk-3 or cki to phosphorylate target proteins which can under certain circumstances be oncogenic [142-145].",pmc4102778,1,0.1,39,1,39.1
493,gs,enzyme,glycogen synthase,,uniprot,p13807,cytoplasm,go:0005737,tau,protein,,mapt,uniprot,p10636,cytoplasm,go:0005737,negative,d,phosphorylation,ser641,,,,mouse,['3125'],nan,nan,"a. recombinant gst-tagged mouse glycogen synthase carboxyl-terminal domain (mgs-ctd) was expressed in bacteria, and purified by glutathione agarose resin. b. in vitro reconstitution of gs phosphorylation by ck2 and gsk3. the phosphorylation reaction products were analyzed using an anti-phospho-ser641 gs antibody. c. gs phosphorylation at ser641 was inhibited by phos-a, but not by a-mut. the phosphorylation reaction products were analyzed using an anti-phospho-ser641 gs antibody. d. in vitro reconstitution of tau phosphorylation by gsk3. the phosphorylation reaction products were analyzed using an anti-phospho-tau antibody (phf1). e. tau phosphorylation was inhibited by phos-a, but not a-mut. the phosphorylation reaction products were analyzed using an anti-phospho-tau antibody (phf1). f and g. different concentrations of phos-a inhibited β-catenin and tau phosphorylation by gsk3 in a similar manner. a four-fold dilution of phos-a was employed. the graph represents the average of three independent experiments.",pmc2654145,1,0.1,39,1,39.1
135,apc,protein,,apc,uniprot,p25054,cytoplasm,go:0005737,beta-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,d,promotes,,,,,drosophila,['3451'],nan,nan,"the reviewers felt that this manuscript provided important new information about apc protein function, and that the super-resolution and frap studies provided new insight into the destruction complex. the reviewers appreciated the use of both drosophila and tissue culture models to probe the system, and felt the drosophila rescue experiments were elegant. however, there were many places where the reviewers felt that there were additional experiments and important controls needed to support the conclusions of the manuscript. in particular, providing more information about the levels of overexpression in tissue culture cell lines would be helpful. more support is also needed for the conclusion that apc dynamics promotes beta-catenin flux through the dc (alternative approaches are suggested by the reviewers, such as the use of proteasome inhibitors). more explanation is needed for the selection of the sites focused on, and more mutational analysis should be considered in order to strengthen their conclusions.",pmc4568445,1,0.1,39,1,39.1
491,galectin-3,protein,,,uniprot,p17931,cytoplasm,go:0005737,p27kip1,protein,decreased expression,,uniprot,p46527,nucleus,go:0005634,positive,d,regulation,,,,,,['316'],nan,nan,"furthermore, the overexpression of galectin-3 increased the levels of phosphorylated rb (ser 780, ser 807/811) and skp2, and decreased p27kip1 expression (figure 5b and supplementary figure 5b). the expression of cyclin d1, cdk4, k-ras, and c-myc increased, whereas that of pten was decreased by galectin-3 overexpression. we also detected the cellular localization of these proteins during galectin-3 overexpression using the nuclear isolation assay (supplementary figure 6b). taken together, depletion and overexpression of galectin-3 induce a contrasting pattern of expression of these proteins in the nucleus and cytosol (supplementary figures 6a and b).",pmc4211374,1,0.1,39,1,39.1
490,galectin-3,protein,,,uniprot,p17931,cell,go:0005623,p27kip1,protein,,cdkn1b,uniprot,p46527,nucleus,go:0005634,positive,d,overexpression,,snu-638,,,human,['311'],nan,nan,"when galectin-3 was overexpressed in the galectin-3-null snu-638 cells, the expression of skp2 and p27kip1 was found to increase and decrease, respectively; additional skp2 depletion enhanced the p27kip1 expression (figure 3e). although cell proliferation was increased by galectin-3 overexpression, additional skp2 depletion restored it to the control levels (figure 3f). increase in the g1 cell cycle population induced by skp2 depletion was also rescued by galectin-3 overexpression (figure 3g).",pmc4211374,1,0.1,39,1,39.1
489,galectin-3,protein,,lgals3,uniprot,p17931,cytoplasm,go:0005737,p27kip1,protein,,cdkn1b,uniprot,p46527,nucleus,go:0005634,negative,d,inhibition,,,,,,['309'],nan,nan,"increased premature senescence by inhibition of galectin-3 without oncogenic stress is p27kip1 dependent, but p53 independent",pmc4211374,1,0.1,39,1,39.1
488,galectin-3,protein,,lgals3,uniprot,p17931,cytoplasm,go:0005737,p27kip1,protein,,cdkn1b,uniprot,p46527,cytoplasm,go:0005737,positive,i,correlates,,,,gastric cancer,human,['324'],nan,nan,positive correlation between the expression of galectin-3 and skp2 and the significantly decreased probability of survival of gastric cancer patients with tumors showing high galectin-3 and low p27kip1 expression,pmc4211374,1,0.1,39,1,39.1
487,galectin-3,protein,,lgals3,uniprot,p17931,cytoplasm,go:0005737,p27 kip1,protein,,cdkn1b,uniprot,p46527,nucleus,go:0005634,negative,d,induces,,,,,human,['301'],nan,nan,ablation of galectin-3 induces p27 kip1 -dependent premature senescence without oncogenic stress,pmc4211374,1,0.1,39,1,39.1
136,apc,protein,,apc,uniprot,p25054,cytoplasm,go:0005737,beta-catenin,protein,,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,i,promotes throughput,dc,,,,,['3457'],nan,nan,2) a key part of the authors' model is that apc dynamics promotes beta-catenin throughput through the dc. but the data supporting this in,pmc4568445,1,0.1,39,1,39.1
485,free β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,lef1,protein,,lef1,uniprot,p15897,nucleus,go:0005634,positive,d,binds,nh2 terminus of tcf3,,,,,['99'],nan,nan,"free β-catenin interacts with the dna binding proteins tcf3 and lef1 (behrens et al., 1996; huber et al., 1996; molenaar et al., 1996) to form a bipartite transactivator that stimulates the transcription (van de wetering et al., 1997) of immediate gene targets (for example, siamois [brannon et al., 1997] and xnr3 [mckendry et al., 1997] in xenopus). in the absence of β-catenin, tcf3/lef1 proteins mediate repression when bound to the groucho family of transcription factor, creb binding protein (cbp), and ctbp. interaction between tcf3 and β-catenin occurs at the nh2 terminus of tcf3 and is separate from the groucho and ctbp binding regions (for review see barker et al., 2000).",pmc2196183,1,0.1,39,1,39.1
137,apc,protein,,apc,uniprot,p25054,cytoplasm,go:0005737,beta-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,i,promotion,dc,,,,human,['3445'],nan,nan,"2) a key part of the authors' model is that apc dynamics promotes beta-catenin throughput through the dc. but the data supporting this in figure 3 are unconvincing. the results in figure 3f that apc2 enhances axin's ability to downregulate beta-catenin isn't informative: apc2 alone is as good as apc2 + axin. this undercuts the utility of the figure 3g, i comparison, maybe there is undetectable levels of beta-catenin in axin/apc2 punctae because there is less overall beta-catenin. the data with phospho-beta-catenin has the same fatal flaw. perhaps using proteosome inhibitors would allow the authors to make more compelling conclusions, if conditions could be found where overexpression of apc and axin did not affect beta-catenin levels.",pmc4568445,1,0.1,39,1,39.1
509,gsk-3beta,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,beta-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,positive,i,stabilization,,,hcc,liver,human,['2030'],nan,nan,"in a different study, it was reported that some hcc cells expressed high basal levels of s9-phosphorylated gsk-3beta [242]. as a result of the sustained phosphorylation of gsk-3beta, beta-catenin was stabilized and contributed to hepatic transformation.",pmc4102778,1,0.1,39,1,39.1
515,gsk-3beta,protein,,gsk3b,uniprot,p49841,,,pyk2,protein,,,uniprot,q14289,,,positive,d,phosphorylation,y216/y270,,,,,['1989'],nan,nan,"phosphorylation of gsk-3beta at tyrosine (y) 216 also regulates it activity and may activate gsk-3beta. this may be due to autophosphorylation [45] but it may also be mediated by kinases such as src. y279 is the corresponding residue present in gsk-3alpha. phosphorylation of gsk-3beta at y216 may be constitutive in resting cells [45,46]. apoptotic stimuli can increase y216 phosphorylation of gsk-3beta indicating roles for gsk-3beta in cell death [47-52]. the proline-rich tyrosine kinase 2 (pyk2) may phosphorylate gsk-3alpha and gsk-3beta at y216 and y270 respectively [53]. pyk2 controls lysophosphatidic acid-induced activation of gsk-3 which regulates the phosphorylation of microtubule-associated proteins. pyk2-mediated activation of gsk-3 destabilized microtubules during actinomyosin-driven neurite retraction [54,55]. the fyn tyrosine kinase also phosphorylates gsks [45,56]. the mapk family also regulates the activity of gsk-3s. p38mapk phosphorylates gsk-3beta at s389/t390 [57]. erk phosphorylation of gsk-3beta at t43 has been proposed to induce a conformational change in gsk-3 which alters its activity [30]. finally protein phosphatases (e.g., pp2a, pp1) have important roles in regulation of gsk-3 activity by removing the phosphate on s9 as well as other regulatory residues [58,59]. in addition, gsk-3s likely have protein phosphatases as substrates (e.g., pp1g) [30].",pmc4102778,1,0.1,39,1,39.1
554,gsk3,protein,,gsk3,uniprot,p49841,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,positive,d,phosphorylation,,,,,,['3139'],nan,nan,"the phosphorylation assays were performed in buffer containing: 25 mm hepes ph 7.5, 20 mm β-glycerophosphate, 25 mm mgcl2, 2 mm dtt, and 10 mm atp (ph 7.0), in a total volume of 15 µl at 37°c for 3 hours. for axin-dependent phosphorylation of β-catenin, 0.43 µm of gsk3, 0.54 µm of ck1α, 0.21 µm of axin, and 0.73 µm of β-catenin were used in each assay. for axin-independent phosphorylation of β-catenin, the condition was the same except that 2.2 µm of gsk3 (and no axin) were used in each assay. for phospho-peptide (or control peptide) inhibition experiments, 1 µl of the dialyzed peptide (final concentration: 10 µm) or four-fold serially diluted peptide (final concentrations: 2.5 µm, 0.63 µm, and 0.16 µm) was used in each assay. for gs phosphorylation, 0.50 µm of ck2 proteins, 0.43 µm of gsk3, and 0.8 µm of gst-mgs-ctd were used in each reaction. for tau phosphorylation, 0.43 µm of gsk3 and 0.8 µm of tau protein were used in each reaction. each in vitro assay was repeated three or more times.",pmc2654145,1,0.1,39,1,39.1
127,akt,proteinkinase,,akt1,uniprot,p31749,cytoplasm,go:0005737,gsk3,proteinkinase,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['500'],nan,nan,"downstream targets of pi 3-kinase/akt signaling include the protein kinases mtor, which is a key regulator of translation and autophagy,3, 4 and glycogen synthase kinase (gsk) 3, which is a proapoptotic protein kinase inhibited by akt phosphorylation.5, 6 akt and gsk3 act to phosphorylate several direct regulators of cell survival and proliferation, including mcl1, bad and cyclin d.7, 8, 9, 10 gsk3 also regulates translation via phosphorylation of eif2b,11, 12 and both akt and gsk3 regulate gene expression by phosphorylating a variety of transcription factors.13, 14, 15",pmc3481126,1,0.1,39,1,39.1
553,gsk3,protein,,gsk3,uniprot,p49841,,,β-catenin,protein,,ctnnb1,uniprot,p35222,,,negative,d,destabilised,,,,,,['2305'],nan,nan,"bio treatment strongly induced β-catenin (30.9-fold), cyclin d1 (8.2-fold) and glycogen synthase (gs) (6.3-fold), which are all destabilised by gsk3 [14]–[16]. expression of cyclins b1 and e2, p90-rsk, stat3, c-jun and iκb were also increased by around 2–3 fold each. it has previously been reported that c-jun and ikb stability are also regulated by gsk3 [17], [18]. roscovitine also mildly induced cyclin d1 (2.7-fold) but, in contrast with bio, decreased β-catenin (49% of control) and cyclin e2 (34%). as previously reported, roscovitine induced mapk phosphorylation [19], while bio blocked phosphorylation on akt s473 (29% of control), p90-rsk s380 (12%), stat3 s727 (26%), and gs (56%) and induced pp1α t320 phosphorylation (4.9-fold). thus, the effects of bio are consistent with gsk3 inhibition and largely non-overlapping with those of a pan-cdk inhibitor.",pmc2714081,1,0.1,39,1,39.1
550,gsk3,protein,,gsk3,uniprot,p49841,,,nbr1,protein,,,uniprot,q14596,,,positive,d,phosphorylation,,,,,,['3009'],nan,nan,"gsk3 activity is inhibited by the pi3k-akt pathway, a well-known regulator of nonselective autophagy. akt activates mtor by a cascade of phosphorylations, and mtor inhibits autophagy through the inhibitory phosphorylation of ulk1 (unc-51 like autophagy activating kinase 1) and atg13, proteins required for autophagy induction.43 gsk3 has recently been shown to be part of this regulatory cascade. in conditions of serum deprivation, gsk3 activates autophagy through the phosphorylation and activation of the acetyltransferase kat5/tip60(k[lysine] acetyltransferase 5), which in turn acetylates and stimulates ulk1.44 we observed that gsk3-mediated nbr1 phosphorylation was increased in serum-deprived cells and that nbr1 phosphorylation inhibited selective autophagy of ubiquitinated proteins. during starvation periods, we can speculate that gsk3 might influence a balance between activation of nonselective and inhibition of selective autophagy. this would favor random bulk autophagy that will provide the nutrients necessary for cell survival. in addition to its role in nonselective autophagy, our work opens the door to a new function for the pi3k-akt pathway that will need to be further investigated. through gsk3, this pathway could also modulate selective autophagy.",pmc4091167,1,0.1,39,1,39.1
549,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,i,degradation,,mefs,fibroblasts,,mouse,['2717'],nan,nan,"(a) ib analysis using whole cell lysates from indicated mefs treated with control-cm or wnt3a-cm for 6 hr. anti-gsk3 was used to detect endogenous gsk3 and ha-gsk3β. this antibody recognized ha-gsk3βy216f but not ha-gsk3βy216e or gsk3βy216e/s4 mutant proteins. (b) the gsk3β ko/gsk3α kd mefs were transfected with vectors expressing indicated proteins, treated with wnt3a-cm and proteasome inhibitor mg132 (10 µm) for 4 hr as indicated, and then harvested for ip and ib analyses using indicated antibodies. (c) left panel, sw480 cells and gsk3α/β kd sw480 cell lines expressing vector control, shrna-resistant wt ha-gsk3β or its mutants were used for soft agar assays. pictures were taken 16 days after plating at 40×. right panel, quantification of soft agar assays. data are presented as mean ±sd. expressions of gsk3α/β (endogenous or mutants) and β-catenin were evaluated by ib at the time of plating. (d) upper left panel, sw480 cell lines used in (c) were injected into both flanks of nude mice (5 mice in each cell group). tumor sizes were measured at indicated time points. tumor volumes were calculated and plotted. * denotes a statistically significant difference (p < 0.01) comparing with shrna control group. bottom left panel, tumor weighs from different groups at the end of the experiment. values are means ±sd (n = 10). right panel, representative tumors from different groups. (e) ib analysis using whole cell lysates from indicated mefs treated with control-cm or wnt3a-cm for 6 hr. anti-gsk3 was used to detect endogenous gsk3 and flag-gsk3α. this antibody recognized flag-gsk3αy279f but not flag-gsk3αy279e mutant protein. (f) left panel: ib characterization of the sw480 cell lines. middle panel: indicated sw480 cell lines were injected into both flanks of nude mice (5 mice in each cell group). tumors from different groups were weighed at the end of the experiment. values are means ±sd (n = 10). * denotes a statistically significant difference (p < 0.01) comparing with shrna control group. right panel, representative tumors from different groups.",pmc4558782,1,0.1,39,1,39.1
548,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,d,phosphorylation,,,,,human,['103'],nan,nan,"phosphorylation of β-catenin by gsk3 is required for β-catenin degradation (yost et al., 1996). β-catenin and axin are phosphorylated by gsk3 in vitro, and β-catenin phosphorylation is stimulated greatly by axin (hart et al., 1998; ikeda et al., 1998). we reconstituted this reaction in vitro using purified proteins and examined the effects of recombinant tcf3 on the kinase reaction. 5 μm tcf3 strongly inhibited β-catenin phosphorylation by gsk3 but had no effect on the phosphorylation of axin (fig. 1 d). this result demonstrates that the effect of tcf3 on β-catenin phosphorylation is not due to titration or inhibition of gsk3 but rather to the sequestration of β-catenin, preventing its interaction with axin/gsk3.",pmc2196183,1,0.1,39,1,39.1
547,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,cell junction,go:0030054,positive,i,phosphorylation,py216,,,,,['2752'],nan,nan,"should be measured with gsk3 yf, ye and kkkk mutants to confirm the inference that py216 is not needed for phosphorylation of β-catenin.",pmc4558782,1,0.1,39,1,39.1
541,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,nbr1,protein,,nbr1,uniprot,q14596,cytoplasm,go:0005737,positive,d,phosphorylation,nbr1,c2c12 myoblasts,myoblasts,skeletal muscle,mouse,['2999'],nan,nan,"figure 2. gsk3 reduces protein aggregation through nbr1 phosphorylation. (a) confocal pictures of c2c12 myoblasts left untreated or treated with 7.5 μg/ml puromycin for 2 h and stained for endogenous ubiquitin (ub, green), nbr1 (red), and sqstm1 (violet). scale bar: 20 μm. (b) proportion of c2c12 myoblasts harboring protein aggregates under puromycin treatment. cells were nontransfected or transfected with egfp empty vector or egfp-gsk3a forms (wt, wild-type; inactive, k148a; active, s21a). cells were left untreated (control) or treated with puromycin. immunostainings performed with anti-sqstm1 and anti-ub antibodies revealed protein aggregates. since all sqstm1-positive aggregates were found ub-positive, transfected cells with and without sqstm1-positive aggregates were counted. at least 200 transfected cells were counted for each condition. error bar represent the 95% confidence interval. ***p < 0.001; pearson chi-square test with yates continuity correction. five independent experiments were performed. (c) upper panel: confocal pictures of gsk3b+/+ and gsk3b−/− mefs left untreated or treated with 7.5 μg/ml puromycin for 4 h and stained with dapi (blue) and anti-sqstm1 (gray) to reveal protein aggregates. scale bar: 50 μm. lower panel: proportion of cells harboring protein aggregates. at least 200 cells were counted for each condition. error bar represent the 95% confidence interval. **p < 0.01; ***p < 0.001; pearson chi-square test with yates continuity correction. the experiment was reproduced 2 times independently. (d) confocal pictures of c2c12 myoblasts transfected with wild-type or n342d mutant myc-tagged des. des was revealed by either an anti-myc antibody (upper panel, green) or an anti-des antibody (lower panel, green). endogenous ub (upper panel, red), sqstm1 (upper panel, violet), and nbr1 (lower panel, red) stainings were also performed. right panels are enlargements of the corresponding dotted frame. scale bar: 20 μm. (e) proportion of c2c12 myoblasts harboring des n342d-myc aggregates. cells were cotransfected with des n342d-myc and egfp or egfp-gsk3a mutants (inactive, k148a; active, s21a) together with dsred, wild-type or mutant dsred-nbr1 (t586a s590a, nonphosphorylable; t586e s590e, phosphomimetic). cells were immunostained with anti-myc antibody to reveal des n342d-myc. proportions of myc-, gfp-, and dsred-positive cells with and without des-myc aggregates were quantified. at least 200 transfected cells were counted for each condition. error bar represent the 95% confidence interval. *p < 0.05; ***p < 0.001; pearson chi-square test with yates continuity correction. three independent experiments were performed.",pmc4091167,1,0.1,39,1,39.1
538,gsk3,protein,,gsk3,uniprot,p49841,cytoplasm,go:0005737,apc2,protein,,apc2,uniprot,q99996,cytoplasm,go:0005737,positive,i,phosphorylation,r2 and b,,epithelial,,human,['3467'],nan,nan,"we also softened this conclusion substantially in the discussion. for example, one of the relevant sections now reads: “motifs r2 and b include highly conserved serine/threonines matching the gsk3 and ck1 consensuses, and this region is phosphorylated by gsk3 in vitro. gsk3 increases apc2 dynamics, destabilizing the arm rpts:axin association via a mechanism that requires r2 and b. strikingly, mutating two conserved serines in b to alanine blocked apc2's ability to reduce βcat levels, while a parallel phosphomimetic mutant did not disrupt apc2 function. we saw a similar reduction in apc2 function after mutating a conserved serine residue in r2. consistent with our data, ck1epsilon phosphorylation of hapc1 r2 occurs in an axin-dependent fashion, and site directed mutagenesis blocking phosphorylation of two conserved serines in r2 (hapc1 s1389 and s1392; distinct from and just c-terminal to the residue we mutated in apc2 r2) reduced the ability of a human apc1 fragment to down regulate wnt signaling (rubinfeld et al., 2001), further suggesting r2 phosphorylation also is important for apc function. our data are consistent with a model in which gsk3 phosphorylation of r2 and b could be one major regulatory step in apc2's dynamic cycle in the destruction complex, triggering release of the arm rpts from the axin complex, and thus allowing apc2 to promote βcat release for destruction (figure 10). however, our data also show that mutating two residues in motif b to prevent their phosphorylation had only a subtle effect on apc2 dynamics. this may suggest additive roles for multiple phosphorylated residues, or may suggest the connection between phosphorylation, dynamics and function is more complex. further, gsk3 can phosphorylate most of the other proteins in the destruction complex, and thus it clearly plays multiple roles in its function.”",pmc4568445,1,0.1,39,1,39.1
537,gsk3,protein,kinase,,uniprot,p49841,cytoplasm,go:0005737,nbr1,protein,,,uniprot,q14596,cytoplasm,go:0005737,positive,i,phosphorylation,lir2 domain,human hela cells,myoblasts,any,human,['2997'],nan,nan,"gsk3 preferentially phosphorylates substrates on serine and threonine residues followed by proline in a relay fashion.31 the gsk3 consensus phosphorylation site is s/t-x-x-x-s/t-(p): a priming phosphorylation on a ser/thr residue is catalyzed by gsk3 or another kinase. this increases the rate of phosphorylation by gsk3 of another ser/thr residue located 4 amino acids upstream of the primed phosphorylation site. however, the phosphorylation of “unprimed” substrates by gsk3, such as axin and ctnnb1 (catenin [cadherin-associated protein]), β 1, 88 kda), has also been described.32 a bioinformatics search for gsk3 consensus phosphorylation sites on the nbr1 sequence with the netphosk 1.0 server (http://www.cbs.dtu.dk/services/netphosk/) indicated human nbr1 thr581, thr586, and ser590 as putative phosphorylated residues (fig. 1a). these 3 amino acids are followed by proline residues and are located in the lir2 domain. thr581 is not conserved in zebrafish, but thr586 and ser590 are widely conserved among animal species. thr586 and ser590 were confirmed to be essential amino acids for gsk3-dependent phosphorylation of nbr1, as mutations of these residues to nonphosphorylable alanines led to the loss of nbr1 phosphorylation by gsk3 in kinase assays (fig. 1c). thr581 is probably not a phosphorylation site but co-affinity purification experiments showed that it was essential for gsk3 binding (fig. s1c). to determine if nbr1 needs to be primed for gsk3 phosphorylation, we performed kinase assays with the gsk3b r96a mutant, a mutant that is unable to phosphorylate primed substrates but remains capable of phosphorylation of unprimed substrates.32 nbr1 phosphorylation was reduced by 70% when nbr1 was incubated with gsk3b r96a (fig. s1d). this strongly suggests that nbr1 is a gsk3 substrate that requires phosphorylation priming by gsk3 or another kinase at ser590. to confirm and investigate the phosphorylation of nbr1 on thr586 by gsk3 in vivo, we generated an antibody against human nbr1 phosphorylated on thr586 (phospho-nbr1t586). specificity of the antibody was verified in human hela cells and mouse immortalized c2c12 myoblasts using a specific sirna (small interfering rna) against nbr1 (fig. 1d). anti-phospho-nbr1t586 detected several bands by western blot suggesting that phosphorylated nbr1 is subjected to other posttranscriptional modifications. commercial antibody targeted against total nbr1 mostly recognized bands around 150 kda despite a theoretical size of 108 kda for the longest isoform of nbr1; this antibody might have less affinity for phosphorylated nbr1 forms migrating at others sizes, or these phosphorylated forms might be present in lower quantity. the level of phosphorylation of nbr1t586 detected by anti-phospho-nbr1t586 was consistent with gsk3 activity as shown with gsk3a−/− mouse embryonic fibroblasts (mefs) expressing ectopic nbr1 and gsk3 activity mutants (fig. 1e). moreover, anti-phospho-nbr1t586 did not recognize nbr1 when thr586 was mutated to a nonphosphorylable alanine (t586a mutant, fig. 1e). this confirms the specificity of our antibody for phosphorylated thr586 and demonstrates that gsk3 phosphorylates nbr1t586 in cells. finally, treatment of gsk3a−/− mef protein extract with lambda-phosphatase confirmed that anti-phospho-nbr1t586 detected a residue phosphorylated by endogenous gsk3b (fig. 1e). consistent with western blot results, immunofluorescence experiments performed in basal conditions in c2c12 transfected cells showed that anti-phospho-nbr1t586 recognized ectopic wild-type dsred-nbr1 present as dots, but not the nonphosphorylable dsred-nbr1 t586a s590a double mutant (fig. 1f). we also tested the level of nbr1 phosphorylation in response to stimuli that modulate gsk3 activity. cell starvation inhibits the pi3k-akt pathway, which leads to a decreased inhibitory phosphorylation of gsk3a at ser21 by akt. accordingly, phosphorylation of nbr1t586 was increased in starved cells (fig. s1e). altogether, these findings show that gsk3 phosphorylates primed nbr1 at thr586 in cells.",pmc4091167,1,0.1,39,1,39.1
536,gsk3,protein,kinase,gsk3b,uniprot,p49841,cytoplasm,go:0005737,nbr1,protein,,nbr1,uniprot,q14596,cytoplasm,go:0005737,positive,d,phosphorylation,t586,,muscle,,human,['3010'],nan,nan,"our findings reveal a novel mechanism of selective autophagy regulation by gsk3 and highlight the role of the posttranslational modification of nbr1 in controlling intracellular pathological protein aggregation and selective autophagy of ubiquitinated proteins. consistently, we have observed a strong reduction of nbr1 phosphorylation in muscles of sibm patients, and residual levels of phospho-nbr1t586 in sibm patients directly correlated with the severity of protein aggregation. this is the second observation that reports nbr1 defects in a human muscle proteinopathy. indeed, a human mutation in ttn that disrupts the binding to nbr1 causes hmerf.22 hmerf patients have features similar to myofibrillar myopathies including myofibrillar lesions and intracellular protein aggregates positive for actin, myot and sqstm1.22,45,46 importantly, experiments performed with atg7 muscle-specific knockout mice indicated that phosphomimetic nbr1 is able to eliminate pre-existing protein aggregates in vivo. our finding that nbr1 phosphorylation is regulated by gsk3, a druggable kinase with known inhibitors already in pre-clinical trials for diabetes and alzheimer disease,47 offers a great way to test the functional impact of protein aggregates in various proteinopathies and might potentially represent promising therapeutic strategies that would aim at modifying pathological protein aggregates. we propose that nbr1 dysregulation has a key role in the pathogenesis of proteinopathies and that modulation of nbr1 phosphorylation may provide novel opportunities for therapeutic approaches.",pmc4091167,1,0.1,39,1,39.1
535,gsk3,protein,kinase,gsk3a,uniprot,p49841,cytoplasm,go:0005737,β-catenin,protein,onco-protein,ctnnb1,uniprot,p35222,cytoplasm,go:0005737,positive,i,phosphorylation,"ser33, ser37",,,gastrointestinal tract,human,['3107'],nan,nan,"the wnt/β-catenin signal transduction pathway plays central roles in many aspects of cell proliferation and differentiation, such as segment polarity determination in drosophila, dorsal-ventral axis formation in xenopus, and homeostasis of the mammalian gastrointestinal tract [1]–[3]. the onco-protein β-catenin is a central component of the wnt signaling pathway. its protein level inside the cell is tightly regulated by phosphorylation-dependent and ubiquitin-mediated degradation, and deregulated β-catenin protein level leads to many types of human cancers, such as colorectal carcinoma and melanoma [4]. in the absence of secreted wnt ligands, cytosolic β-catenin is phosphorylated at ser45 by the priming kinase casein kinase 1 (ck1). consequently, glycogen synthase kinase 3 (gsk3), in complex with axin and adenomatous polyposis coli (apc), phosphorylates β-catenin at thr41, ser37, and ser33 [5]–[15]. ser33 and ser37 doubly-phosphorylated β-catenin is specifically recognized by β-trcp [16]–[22], a subunit of the scfβ-trcp e3 ubiquitin ligase complex. the scfβ-trcp ubiquitin ligase poly-ubiquitinates β-catenin, leading to β-catenin degradation via the proteosome pathway [23], [24]. in the presence of wnt ligands, the activation of the wnt pathway results in inhibition of β-catenin phosphorylation at ser33 and ser37 (and thr41) by gsk3, thereby preventing β-catenin ubiquitination and degradation. stabilized β-catenin translocates into the nucleus and complexes with members of the t cell factor (tcf)/lymphoid enhancer factor (lef) family of transcription factors [25]–[27], leading to the activation of wnt/β-catenin responsive genes such as c-myc and cyclin d1 [28], [29]. therefore, inhibition of amino-terminal phosphorylation of β-catenin by gsk3 is a central step in wnt/β-catenin signaling.",pmc2654145,1,0.1,39,1,39.1
534,gsk3,protein,kinase,gsk3,uniprot,p49841,cytoplasm,go:0005737,β-catenin,protein,transcription co-activator,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,d,phosphorylation,"serine 33, serine 37, threonine 41",,,,human,['2712'],nan,nan,"a key feature of the wnt/β-catenin pathway is the tight control of the abundance of transcription co-activator β-catenin by the β-catenin destruction complex, consisting of gsk3, casein kinase 1 (ck1), apc, scaffold protein axin and β-catenin. in wnt-off state, the cytosolic level of β-catenin is kept low by its continuous degradation: β-catenin is phosphorylated by gsk3 on serine 33 and 37 and threonine 41, phosphorylation then triggers β-catenin recruitment of ubiquitin e3 β-trcp (β-transducin repeats-containing proteins), causing its ubiquitination and proteasomal degradation (wu and pan, 2010). in wnt-on state, wnt ligand forms a complex with the cell-surface receptor frizzled and low-density lipoprotein receptor-related protein (lrp) 5/6 (wu and pan, 2010), and initiates a series of molecular events ultimately causing stabilization of β-catenin by suppressing phosphorylation of β-catenin (hernandez et al., 2012; kim et al., 2013) as well as β-trcp-mediated ubiquitination and proteasomal degradation of β-catenin (li et al., 2012). newly synthesized β-catenin then accumulates and enters the nucleus to interact with transcription factors tcf (t-cell factor)/lef (lymphoid enhancing factor) to activate transcription of the wnt target genes (li et al., 2012).",pmc4558782,1,0.1,39,1,39.1
533,gsk3,protein,kinase,gsk3,uniprot,p49841,cytoplasm,go:0005737,β-catenin,protein,,ctnnb1,uniprot,p35222,nucleus,go:0005634,negative,d,phosphorylation,ser33/ser37/thr41,,,,human,['3114'],nan,nan,"when the phosphorylated pppspxs peptides were added to the in vitro β-catenin phosphorylation assay, the phos-a, phos-c, as well as phos-e peptide each inhibited, interestingly, β-catenin phosphorylation at ser33/ser37/thr41 by gsk3 (figure 3a, left panel). the phos-d peptide, which is atypical and has a cppspxs motif (figure 2b), inhibited β-catenin phosphorylation by gsk3 to a less degree (figure 3a, left panel). we note that in cultured cells motif d also exhibits significant less activity than a, c and e motifs [37]. the a-mut peptide failed to inhibit β-catenin phosphorylation (figure 3a, right panel). as additional controls, neither the ha peptide nor the unrelated and dually phosphorylated peptide, 14-3-3bp, affected β-catenin phosphorylation by gsk3 (figure 3b and 3c). furthermore, when the amount of peptides used in the phosphorylation assay was titrated, phos-a, phos-c and phos-e peptides inhibited β-catenin phosphorylation in a dose-dependent manner (figure 3b, 3d, 3e), whereas phos-d was significantly less active (figure 3d, 3e). the ha and a-mut peptides did not inhibit β-catenin phosphorylation at all concentrations tested (figure 3b, 3d, 3e). we note that the molar concentrations of phospho-pppspxs peptides employed in these titration assays were 0.4×, 1.5×, 6×, and 24× of that of gsk3 (see methods).",pmc2654145,1,0.1,39,1,39.1
530,gsk3,protein,kinase,gsk3,uniprot,p49841,cytoplasm,go:0005737,telomerase,enzyme,,tert,uniprot,o14727,nucleus,go:0005634,negative,d,inhibition,,"5637, hct116, a2780",cancer,various,human,['2306'],nan,nan,"to determine whether gsk3 inhibition suppresses endogenous telomerase, 5637, hct116 and a2780 cells were cultured continuously in log phase with bio or dmso given twice-weekly for five weeks. drug was not removed between treatments. cells were counted weekly and at each time point individual cell pellets were taken from both control and treated cells for telomere length analysis, htert expression analysis by rt-qpcr, microarray analysis, western blotting of gsk3 inhibition markers, and for trap analysis of telomerase activity (figure 3c). at the time of sampling, drug had not been replenished for 3 days. bio concentrations used in these experiments were 2.5 µm (a2780), 1 µm (hct116) and 500 nm (5637).",pmc2714081,1,0.1,39,1,39.1
529,gsk3,protein,kinase,gsk3,uniprot,p49841,cytoplasm,go:0005737,tau,protein,,mapt,uniprot,p10636,cytoplasm,go:0005737,negative,d,inhibits phosphorylation,,,,,,['3123'],nan,nan,the dually phosphorylated pppspxs peptide inhibits the phosphorylation of glycogen synthase and tau by gsk3,pmc2654145,1,0.1,39,1,39.1
526,gsk3,enzyme,protein kinase,gsk3,uniprot,p49841,cytoplasm,go:0005737,apc,protein,,apc,uniprot,p25054,cytoplasm,go:0005737,positive,d,phosphorylation,r2 and b,,,,,['3491'],nan,nan,"“gsk3, which phosphorylates βcat, axin and other sites on apc, also phosphorylates apc2's r2 and b (step 3; ck1 may also be involved, as it is in the other phosphorylation events in the complex).”",pmc4568445,1,0.1,39,1,39.1
525,gsk-3β,protein,,,uniprot,p49841,,,4ebp1,protein,,,uniprot,q13541,,,positive,d,phosphorylation,"thr70, thr37/46, and ser65",,,,,['3386'],nan,nan,"we performed an in vitro kinase assay using recombinant proteins of gsk-3β and 4ebp1 (fig. 4). recombinant gsk-3β phosphorylated recombinant 4ebp1 at thr70, thr37/46, and ser65. ar-a014418 and sb-216763 blocked the recombinant gsk-3β mediated phosphorylation of recombinant 4ebp1. these results suggest that gsk-3β could participate in the direct phosphorylation of 4ebp1 at thr70, thr37/46, and ser65, as reported for s6k [30].",pmc4936323,1,0.1,39,1,39.1
524,gsk-3β,protein,,,uniprot,p49841,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,phosphorylation,,rcc cell lines,renal cell carcinoma,,human,['3390'],nan,nan,"consistent with previous reports [30, 31], in the present study, we demonstrate that gsk-3β directly phosphorylates 4ebp1 independent of rapamycin sensitivity to mtorc1 and continuously activates 4ebp1 and s6k, the mtorc1 downstream substrates to drive cell proliferation in rcc cell lines. the present findings would also indicate that the direct gsk-3β/4ebp1 pathway is an important subcellular mechanism as an inherent equipment for rcc cells to acquire clinical chemoresistance to mtorc1 inhibitors. although rapamycin increased the g0/g1 phase in cell cycle and suppressed cell proliferation, the inhibitory effects of rapamycin on the mtorc1 downstream pathway were only transient leading to gradual return of p4ebp1 and ps6rp to the baseline level. when the present results extrapolated into clinical setting, it could be easy for us to understand limited efficacy of mtorc1 inhibition on size reduction and progression of rcc [2, 3]. our data suggest that gsk-3 inhibition could be a promising strategy for the treatment of mrcc.",pmc4936323,1,0.1,39,1,39.1
523,gsk-3β,protein,,gsk3b,uniprot,p49841,,,4ebp1,protein,,eif4ebp1,uniprot,p62075,,,positive,d,phosphorylation,,,,,human,['3393'],nan,nan,"many gsk-3β substrates have the motif ser/thr-pro-x-x-pser/thr [39]. the binding affinity of gsk-3β to a substrate is enhanced if the substrate receives prior phosphorylation at the second ser/thr [19]. 4ebp1 reportedly has seven phosphorylation sites (thr37/46, ser65, thr70, ser83, ser101, and ser112) [14, 39]. comparison of the 4ebp1 sequence with those of known gsk-3β substrates showed that the best-matched sequences in 4ebp1 for phosphorylation by gsk-3β are thr-pro-gly-gly-thr for both thr37 and thr46 as the first ser/thr residues [40]. phosphorylation of 4ebp1 at thr37/46 by gsk-3β requires pre-phoshorylation at priming sites (thr41/50) [31]. however, gsk-3 does not necessarily require a primed substrate [17, 19, 41]. the residues other than thr37/46, thr70, and ser65 in 4ebp1 might be also targeted by gsk-3β. in the present study, we demonstrated that recombinant gsk-3β phosphorylated an unprimed recombinant 4ebp1 at thr37/46. it is possible that phosphorylation of thr41/50 also is regulated by gsk-3β itself. there are no priming phosphorylation sites at thr70 and ser65 of 4ebp1 (thr70-pro-pro-arg-asp, ser65-pro-val-thr-lys). the phosphorylation of 4ebp1 appears to occur in a hierarchical manner, as follows [13, 14]: thr37/46 are phosphorylated at baseline, and this is further enhanced by insulin production [13, 14]. thr37/46 phosphorylation is followed by phosphorylation of thr70, followed by phosphorylation of ser65 as the last step [13]. phosphorylation of thr70 seems to play the most important role in releasing 4ebp1 from eif4e [14]. the fact that the phosphorylation levels of recombinant unprimed 4ebp1 increased in the order of thr37/46, thr70, and ser65 likely reflects this hierarchical phosphorylation process (fig. 4). as shown in fig. 3, ly294002 and rapamycin exhibited apparently no and slightly inhibitory action on thr37/46 phosphorylation in 4ebp1, respectively, leading to the notion that thr37/46 residue may be the main target of gsk-3 in case of 4ebp1 phosphorylation [31]. abnormal overexpression of gsk-3 is observed in cancers which are resistant to chemo-, radio- and targeted therapy [32]. targeting gsk-3 could improve cancer therapy and overcome therapeutic resistance [32].",pmc4936323,1,0.1,39,1,39.1
522,gsk-3β,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,fbxw7,protein,,fbxw7,uniprot,q969h0,cytoplasm,go:0005737,negative,d,knockdown,,,,,,['1590'],nan,nan,"the non-silencing control, gsk-3α, gsk-3β and gsk3α/β sirnas were described previously [16]. fbxw7 sirna was the same as described previously [47]. transfection of these sirna duplexes was conducted in 6-well plates using the hiperfect transfection reagent (qiagen) following the manufacturer's manual. the knockdown effects of fbxw7 sirna were evaluated with rt-pcr as described previously [47] due to lack of a specific antibody for western blotting.",pmc4496196,1,0.1,39,1,39.1
521,gsk-3β,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,unknown,,"rcc cell lines, normal renal tubular epithelial cell line",b-cell,normal renal tissues,human,['3374'],nan,nan,"in the present study, we investigated direct relationships between gsk-3β and 4ebp1 using human rcc cell lines and a normal renal tubular epithelial cell line, and normal renal tissues obtained from rcc patients who had surgical resection, in order to study the role of gsk-3 in the akt/mtorc1/4ebp1 pathway in rcc.",pmc4936323,1,0.1,39,1,39.1
519,gsk-3β,protein,,gsk3b,uniprot,p49841,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,positive,d,interaction,,"achn, caki1, a498, hrptepc","renal proximal tubular epithelial cell, rcc",kidney,human,['3369'],nan,nan,"we used human rcc cell lines (achn, caki1, and a498) and, as normal controls, human renal proximal tubular epithelial cell (hrptepc) and non-tumorous kidney tissues that were obtained surgically for treatment of rcc patients. rapamycin-resistant achn (achn/rr) cells were generated with chronic exposure of achn to rapamycin ranging from 1nm finally to 1 μm. cell viability, cell cycling and direct interaction between gsk-3β and 4ebp1 were evaluated with mts assay, flowcytometry and in vitro kinase assay with recombinant gsk-3β and 4ebp1products, respectively. protein expression and phosphorylation of molecules associated with the pi3k/akt/mtorc1 pathway were examined by immunoblotting. effects of drug combination were determined as the combination index with compusyn software.",pmc4936323,1,0.1,39,1,39.1
518,gsk-3β,protein,kinase,gsk3b,uniprot,p49841,cytoplasm,go:0005737,4ebp1,protein,transcription factor,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,negative,d,inhibition,,,,,human,['3387'],nan,nan,in vitro kinase assays. in vitro kinase assays were performed using recombinant gsk-3β and recombinant 4ebp1 as described in the materials and methods. either ar-a014418 (25 μm) or sb-216763 (25 μm) was applied in vitro to inhibit recombinant gsk-3β. p4ebp1 levels were measured with immunoblot analysis. data are representative of three separate immunoblot analysis,pmc4936323,1,0.1,39,1,39.1
517,gsk-3β,protein,isoform,gsk3b,uniprot,p49841,cytoplasm,go:0005737,4ebp1,protein,,eif4ebp1,uniprot,q13541,cytoplasm,go:0005737,negative,d,phosphorylation,"thr70, thr37/46, ser65",achn cells,renal,kidney,human,['3383'],nan,nan,"next, to determine which of two gsk-3 isoforms, gsk-3α and gsk-3β, phosphorylates 4ebp1, we examined p4ebp1 status in stable gsk-3α and gsk-3β knockdown cells with sirnas, respectively (fig. 2c). as expected, 4ebp1 phosphorylation at thr70, thr37/46 and ser65 in sigsk-3β-transfected achn cells decreased than negative controls. however, sigsk-3α knockdown presented with inconsistent outcome, no changes and reduction in p4ebp1 for each of two specific sigsk-3α transfected, respectively (fig. 2c).",pmc4936323,1,0.1,39,1,39.1
1157,βcat,protein,,,uniprot,p35222,cytosol,go:0005829,apc,proteincomplex,,,fplx,apc,cytosol,go:0005829,positive,i,mediates destruction,,sw480,colon cancer cells,,human,['3478'],nan,nan,"second, we significantly expanded our description of the status and potential roles of endogenous proteins in sw480 cells. we now begin the results section with a more complete description of this, as follows: “here we sought to define the mechanism by which these motifs and apc itself act, using as a model sw480 colon cancer cells. these cells have high βcat levels, as they lack wildtype human apc1 (hapc1) and instead express a truncated apc1 protein ending before the mutation cluster region (mcr; figure 1b). sw480 cells also express human apc2 (maher et al., 2009), but this is not sufficient to help mediate βcat destruction.” we note the potential importance of truncated apc1 and apc2 in the residual function of axin over-expression in these cells when we initiate examination of axin vs axin + apc2 function, as follows: “axin cannot target βcat for destruction in apc's complete absence, even when axin is overexpressed (mendoza-topaz et al., 2011). however, in sw480 cells, which express both truncated hapc1 and endogenous hapc2 (maher et al., 2009), axin overexpression can increase βcat destruction (nakamura et al., 1998).” finally, we now end the relevant section of the discussion by pointing toward the importance of further resolving these issues in the future, as follows: “the development of crispr knockout technology will allow future examination of the importance of truncated apc1, as well as the endogenous apc2 and axin expressed in colon cancer cells in destruction complex assembly and function.”",pmc4568445,1,0.1,39,1,39.1
